{
  "drugs": [
    {
      "heading": "Epratuzumab\u2013SN-38",
      "names": [
        "Epratuzumab\u2013SN-38"
      ],
      "phases": [],
      "conditions": [
        "Lymphoma and Leukemia"
      ],
      "targets": [
        "CD22"
      ],
      "payload": [
        "Irinotecan metabolite (SN38)"
      ],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Immunomedics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMGN-242",
      "names": [
        "- C-242 DM4",
        "Cantuzumab Ravtansine",
        "HUC242-DM4",
        "- C242 DM4 immuno",
        "- Maytasinoid DM4-d humanised monoclonal  huC242",
        "CANTUZUMAB RAVTANSINE",
        "IMGN242",
        "- IMGN-242",
        "- C242 maytansinoid-4",
        "- huC242-DM4",
        "IMGN-242"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Gastric (stomach) cancers",
        "Gastric cancer (metastatic or locally advanced) ; Solid Tumors; Neoplasms (Stomach); GE Junction Cancer (metastatic or locally advanced)"
      ],
      "targets": [
        "CanAg",
        "CanAg-expressing cancers, including gastric cancer; MUC1 sialylated carbohydrate tumour-associated (CA242, cancer antigen 242)"
      ],
      "payload": [
        "maytansinoid DM4",
        "Maytansinoid (DM4)  ravtansine (DM4)."
      ],
      "linker": [
        "A reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "huC242"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1742998",
        "Name": "CANTUZUMAB RAVTANSINE",
        "Synonyms": "CANTUZUMAB RAVTANSINE|HUC242-DM4|IMGN-242|IMGN242",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMGN 289",
      "names": [
        "IMGN 289"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "EGFRviii"
      ],
      "payload": [
        "DM1"
      ],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "IMMUNOGEN"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "RG-7636 | Anti-ETBR",
      "names": [
        "RG-7636",
        "Anti-ETBR",
        "RG7636",
        "DEDN6526A",
        "DEDN-6526A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Unresectable, malignant melanoma; melanoma, cutaneous, mucosal and ocular",
        "Melanoma"
      ],
      "targets": [
        "Endothelin receptor ETB"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Peptide linker (using Seattle Genetics ADC technology)",
        "Peptide linker (Seattle Genetics)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109282",
        "Name": "RG-7636",
        "Synonyms": "DEDN-6526A|RG-7636",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "SC16LD6.5",
      "names": [
        "ROVALPITUZUMAB TESIRINE",
        "SC-16LD6.5",
        "Rova-T",
        "SC 002",
        "SC-002",
        "SC16LD6.5 SC0001-SCX",
        "SC0002",
        "SC16LD6.5",
        "Rovalpituzumab tesirine",
        "sc0001-SCX",
        "SC0001"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma",
        "Advanced Solid Tumors",
        "Cancer",
        "Cancers, small cell lung (SCLC)",
        "Recurrent Small Cell Lung Cancer",
        "Small Cell Lung Cancer"
      ],
      "targets": [
        "DLL3 (delta-like 3) | delta like canonical Notch ligand 3",
        "SC-16 (anti-Fyn3)"
      ],
      "payload": [
        "D6.5 (DNA damaging agent)",
        "pyrrolobenzodiazepine (PDB) dimer SCX"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8).   An average of 2 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa SC16"
      ],
      "Max Phase": "3",
      "developers": [
        "Stemcentrx"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3990011",
        "Name": "ROVALPITUZUMAB TESIRINE",
        "Synonyms": "ROVALPITUZUMAB TESIRINE|SC 002|SC-002|SC-16LD6.5|SC0002",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "trials": [
        "NCT03543358",
        "NCT02674568",
        "NCT02874664",
        "NCT01901653",
        "NCT03061812",
        "NCT03086239",
        "NCT03000257"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Turkey",
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Serbia",
        "Belarus",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "Latvia",
        "Spain",
        "Germany",
        "Croatia",
        "Finland"
      ]
    },
    {
      "heading": "AGS-16C3F | AGS-16M8F | AGS 16C3F",
      "names": [
        "AGS-16C3F",
        "AGS-16M8F",
        "AGS 16C3F"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Renal Cell Carcinoma; Liver Carcinoma; Prostate Cancer",
        "Renal Cell Carcinoma / Liver carcinoma / Prostate Cancer"
      ],
      "targets": [
        "AGS-16/ENPP3  (Ectonucleotide pyrophosphatase/phosphodiesterase family member 3)"
      ],
      "payload": [
        "Monomethyl auristatin\u00a0F (MMAF)"
      ],
      "linker": [
        "Non-cleavable maleimido-caproyl linker"
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Agensys",
        "Astellas"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17551",
        "Name": "AGS-16C3F",
        "Description": "AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 conjugate. ... 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "MDX-060 | iratumumab",
      "names": [
        "MDX-060",
        "iratumumab"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma"
      ],
      "targets": [
        "CD30"
      ],
      "payload": [
        "-"
      ],
      "linker": [
        "-"
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Bristol Myers Squibb",
        "Medarex"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "KTN0182A",
      "names": [
        "KTN0182A"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Broad Range of Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Pyrrolobenzodiazepine (PBD)"
      ],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Kolltan"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "RG7986",
      "names": [
        "RG7986"
      ],
      "phases": [],
      "conditions": [
        "Non-Hodgkin lymphoma"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Genentech",
        "Roche"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "EDO-772P/B776",
      "names": [
        "EDO-772P/B776"
      ],
      "phases": [],
      "conditions": [
        "Ovarian cancer"
      ],
      "targets": [
        "A fragment of the cancer antigen 125 (CA125)"
      ],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Mundipharma EDO"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "EDO-B278",
      "names": [
        "EDO-B278"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "Human tissue factor"
      ],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Mundipharma EDO"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CD22-4AP",
      "names": [
        "CD22-4AP",
        "TRPH-222",
        "Anti-CD22 -  TRPH-222 ANTI-CD22 ADC TRPH-222 TRPH222"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, Large B-Cell, Diffuse",
        "Non-Hodgkin\u2019s lymphoma Acute lymphoid leukemia B-cell Lymphoma",
        "Non-Hodgkin Lymphoma, Acute Lymphoid Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Marginal Zone",
        "Lymphoma"
      ],
      "targets": [
        "CD22",
        "CD22, a B-cell-restricted sialogycoprotein that is an important modulator of B-cell signaling and survival. CD22 is expressed on nearly all B-cell malignancies and is a validated ADC target."
      ],
      "payload": [
        "Site-specific conjugation of a maytansine payload."
      ],
      "linker": [
        "A 4AP non-cleavable linker."
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "Site-specific modified humanized antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Catalent",
        "Triphase Accelerator Corporation"
      ],
      "ttd": "DQC80I",
      "trials": [
        "NCT03682796"
      ],
      "locations": [
        "Canada",
        "United States"
      ]
    },
    {
      "heading": "KTN0125",
      "names": [
        "KTN0125"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [],
      "payload": [
        "a thienoindole cytotoxic agent (TEI)"
      ],
      "linker": [],
      "domain": [],
      "antibody": [
        "An anti-ALK monoclonal antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Kolltan"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-Ly6E | RG-7841 | Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | DLYE5953A",
      "names": [
        "Anti-Ly6E",
        "RG-7841",
        "Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841",
        "DLYE5953A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors Breast Non Small Lung Cancer"
      ],
      "targets": [
        "Lymphocyte antigen 6 complex locus E (LY6E)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche",
        "Seagen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CDX014 | CDX-014 | CR 014-vcMMAE | CR014-vcMMAE",
      "names": [
        "CDX014",
        "CDX-014",
        "CR 014-vcMMAE",
        "CR014-vcMMAE"
      ],
      "phases": [
        "Preclinical",
        "Phase 1/2"
      ],
      "conditions": [
        "Kidney cancer, Clear Cell Renal Cell Carcinoma, Papillary Cell Renal Cell Carcinoma, Renal cell carcinoma (RCC)"
      ],
      "targets": [
        "Transmembrane protein T-cell immunoglobulin mucin-1 (TIM-1); HAVCR1 (hepatitis A virus cellular receptor 1; KIM-1"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Celldex"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Hertuzumab-vcMMAE | Hertuzumab Vedotin",
      "names": [
        "Hertuzumab-vcMMAE",
        "Hertuzumab Vedotin"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Breast Cancer and HER2 positive human gastric cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor-2 (HER2)"
      ],
      "payload": [
        "monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "MC-Val-Cit-PAB"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Hertuzumab"
      ],
      "Max Phase": "2",
      "developers": [
        "MabPlex",
        "Rongchang"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "DS-7300 | B7-H3 ADC",
      "names": [
        "DS-7300",
        "B7-H3 ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer",
        "Solid Tumors"
      ],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "ttd": "DT8R1L",
      "trials": [
        "NCT05280470"
      ],
      "locations": [
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "Japan",
        "Spain",
        "Germany"
      ]
    },
    {
      "heading": "ADCT-502",
      "names": [
        "ADCT-502"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Epidermal growth factor receptor 2 (HER2)-expressing solid tumors"
      ],
      "targets": [
        "HER2 (Human epidermal growth factor receptor 2)"
      ],
      "payload": [
        "Tesirine, a clinically-validated, potent pyrrolobenzodiazepine (PBD-based) dimer toxin (SG3249).   Drug-to-antibody ratio is 1.7"
      ],
      "linker": [
        "A cathepsin B-cleavable valine-alanine linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A engineered version of the humanized anti-HER2 IgG1 trastuzuma"
      ],
      "Max Phase": "1",
      "developers": [
        "ADC Therapeutics"
      ],
      "ttd": "D05CRY",
      "locations": [],
      "trials": []
    },
    {
      "heading": "SGN-CD19B",
      "names": [
        "SGN-CD19B"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma, Diffuse large B-cell lymphoma, Follicular lymphoma (high grade)"
      ],
      "targets": [
        "CD19; a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, expressed on B-cell-derived cancers."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer, SGD-1882"
      ],
      "linker": [
        "A maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker"
      ],
      "domain": [
        "Hematology"
      ],
      "antibody": [
        "hBU12ec"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SC-006 | SC006",
      "names": [
        "SC-006",
        "SC006"
      ],
      "phases": [],
      "conditions": [
        "Colorectal Cancer"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "AbbVie",
        "Stemcentrx"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AMG172",
      "names": [
        "AMG172",
        "AMG 172"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Clear Cell Renal Carcinoma",
        "Renal Cell Carcinoma (RCC) | Kidney Cancer",
        "Renal Cell Adenocarcinoma"
      ],
      "targets": [
        "CD70 (CD27L); A Type II transmembrane protein and member of the Tumor Necrosis Factor (TNF) family"
      ],
      "payload": [
        "Maytansine DM1"
      ],
      "linker": [
        "Non-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Amgen"
      ],
      "trials": [
        "NCT01497821"
      ],
      "locations": [
        "Germany",
        "United States",
        "France"
      ]
    },
    {
      "heading": "BIIB-015 | BIIB015",
      "names": [
        "BIIB-015",
        "BIIB015"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "CFC1B (Cripto)"
      ],
      "payload": [
        "Maytansinoid derivative, DM4"
      ],
      "linker": [
        "MCC"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Biogen"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109575",
        "Name": "BIIB-015",
        "Synonyms": "BIIB-015",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "trials": [
        "NCT00674947"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "IMGN388 | CNTO 365 | IMGN-388 | CNTO 95-DM4",
      "names": [
        "IMGN388",
        "CNTO 365",
        "IMGN-388",
        "CNTO 95-DM4"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors/endothelial cells"
      ],
      "targets": [
        "alpha-V (?v) integrin"
      ],
      "payload": [
        "DM4"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109633",
        "Name": "IMGN-388",
        "Synonyms": "IMGN-388",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "hLL1 | IMMU-110 | Milatuzumab doxorubicin | MEDI-115 | CD74-DOX | hLL1-DOX",
      "names": [
        "hLL1",
        "IMMU-110",
        "Milatuzumab doxorubicin",
        "MEDI-115",
        "CD74-DOX",
        "hLL1-DOX"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Lymphoma, T-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Breast Neoplasms",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "HER2-positive Early Breast Cancer",
        "T-Cell Lymphoma",
        "DLBCL",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Locally Advanced or Early Breast Cancer",
        "Refractory B Acute Lymphoblastic Leukemia",
        "HER2-Positive Metastatic Breast Cancer",
        "Refractory B Lymphoblastic Lymphoma",
        "Large B-Cell Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Chronic lymphocytic leukemia; Multiple myeloma; Non-Hodgkin\u2019s lymphoma",
        "Lymphoma, NK-cell",
        "Stage II Childhood Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Hodgkin Disease",
        "Recurrent B Lymphoblastic Lymphoma",
        "Breast Cancer",
        "Stage III Childhood Hodgkin Lymphoma",
        "B-Cell Lymphoma"
      ],
      "targets": [
        "CD74 (major histocompatibility class II invariant chain, MH2)"
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [
        "Hydrazone"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Immunomedics"
      ],
      "trials": [
        "NCT04914741",
        "NCT03755804",
        "NCT06377566",
        "NCT01712490",
        "NCT01309789",
        "NCT06047080",
        "NCT04594798",
        "NCT02734771",
        "NCT01534078",
        "NCT02292979",
        "NCT05404945",
        "NCT06132958",
        "NCT06112379",
        "NCT04884035",
        "NCT01920932",
        "NCT03726879",
        "NCT02605915",
        "NCT04203641",
        "NCT05600686",
        "NCT02505269",
        "NCT03467373",
        "NCT01992653",
        "NCT01060904",
        "NCT06340568",
        "NCT03646123",
        "NCT01777152",
        "NCT04790903",
        "NCT05673785",
        "NCT01966471",
        "NCT02979522",
        "NCT03274492",
        "NCT03991884",
        "NCT06486441",
        "NCT05113251",
        "NCT04569032",
        "NCT03677141",
        "NCT04685616"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "DSTP-3086S | DSTP3086S | Anti-STEAP1 ADC | RG7450 | RG-7450 | MSTP2109A | Vandortuzumab vedotin",
      "names": [
        "DSTP-3086S",
        "VANDORTUZUMAB VEDOTIN",
        "DSTP3086S",
        "Anti-STEAP1 ADC",
        "RG7450",
        "RG-7450",
        "MSTP2109A",
        "Vandortuzumab vedotin"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Metastatic castration-resistant Prostate Cancer"
      ],
      "targets": [
        "Anti-six transmembrane epithelial antigen of the prostate 1 (STEAP1); a membrane protein overexpressed in prostate cancer (PRSS24)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3833306",
        "Name": "VANDORTUZUMAB VEDOTIN",
        "Synonyms": "DSTP3086S|MSTP2109A|RG-7450|RG7450|VANDORTUZUMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "DFRF 4539A | RG-7598 | RG 7598 | RG7598",
      "names": [
        "DFRF4539A",
        "DFRF 4539A",
        "RG7598",
        "RG-7598",
        "RG 7598"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma"
      ],
      "targets": [],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109279",
        "Name": "RG-7598",
        "Synonyms": "DFRF4539A|RG-7598",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Vorsetuzumab mafodotin | SGN-75",
      "names": [
        "Vorsetuzumab mafodotin",
        "VORSETUZUMAB MAFODOTIN",
        "SGN-75"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/1",
        "Phase 1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Glioblastoma Multiforme",
        "Malignant Glioma",
        "Non-Hodgkin\u2019s lymphoma (NHL);  renal cell carcinoma (RCC); CD70-positive hematologic malignancies",
        "Carcinoma, Renal Cell"
      ],
      "targets": [
        "CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L)"
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)"
      ],
      "linker": [
        "Maleimidocaproyl\u00a0 Phenylalanine\u00a0(a non-cleavable maleimidocaproyl (mc) linker).   An average of 3-5 cysteinyl"
      ],
      "domain": [
        "Oncology | Hematology | Immunology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Seagen"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108672",
        "Name": "VORSETUZUMAB MAFODOTIN",
        "Synonyms": "SGN-75|VORSETUZUMAB MAFODOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT02590263",
        "NCT01015911"
      ],
      "locations": [
        "United States",
        "Japan"
      ]
    },
    {
      "heading": "PF06688992 | GD3 ADC | PF-06688992",
      "names": [
        "PF06688992",
        "GD3 ADC",
        "PF-06688992"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Melanoma",
        "Multiple myeloma"
      ],
      "targets": [
        "Ganglioside GD3; a surface antigen expressed on many malignant melanoma cells"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Pfizer"
      ],
      "trials": [
        "NCT03159117"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "SGN-CD352a",
      "names": [
        "SGN-CD352a"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma (MM)"
      ],
      "targets": [
        "CD352; SLAMF6 (Signaling Lymphocyte Activation Molecule family member 6), a type 1 membrane protein in the SLAM family of immunoreceptors."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "Protease Cleavable Linker"
      ],
      "domain": [
        "Oncology, Hematology"
      ],
      "antibody": [
        "An anti-CD352 engineered cysteine (EC-mAb) h20F3ec"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AbGn-110",
      "names": [
        "AbGn-110"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Breast cancer Gastric (stomach) cancer"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Biobetter cytotoxic payload"
      ],
      "linker": [
        "Proprietary linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "AbGenomics BV"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AbGn-108",
      "names": [
        "AbGn-108"
      ],
      "phases": [],
      "conditions": [
        "Lung cancer Ovarian cancer"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "AbGenomics BV"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AB-3A4-ADC | AB-3A4 | AB-3A4 ADC | AB-3A4-vcMMAE",
      "names": [
        "AB-3A4-ADC",
        "AB-3A4",
        "AB-3A4 ADC",
        "AB-3A4-vcMMAE"
      ],
      "phases": [],
      "conditions": [
        "Ovarian cancer; Triple Negative Breast Cancer (TNBC); Prostate"
      ],
      "targets": [
        "KAAG-1 (kidney-associated antigen-1); KAAG1-positive cell lines including, SKOV-3 (ovarian), MDA-MB-231 (TNBC) and PC-3 (prostate)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Alethia"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Q5-",
      "names": [
        "Q5-"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Alteogen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "RG 7600 | DMOT-4039A | DMOT4039A | RG7600",
      "names": [
        "RG 7600",
        "RG-7600",
        "RG7600",
        "DMOT-4039A",
        "DMOT4039A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Unresectable pancreatic or platinum-resistant cancer Ovarian tumor; pancreatic tumor"
      ],
      "targets": [
        "mesothelin (MSLN); Unnamed antigen"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease-cleavable peptide linker."
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109281",
        "Name": "RG-7600",
        "Synonyms": "DMOT4039A|RG-7600",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-5T4 monoclonal | PF-06263507 | A1-mafodotin | PF06263507 | PF 06263507 | A1-mcMMAF",
      "names": [
        "Anti-5T4 monoclonal",
        "PF-06263507",
        "A1-mafodotin",
        "PF06263507",
        "PF 06263507",
        "A1-mcMMAF"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma Multiforme",
        "Solid tumors"
      ],
      "targets": [
        "5T4"
      ],
      "payload": [
        "Monomethyl auristatin\u00a0F (MMAF)"
      ],
      "linker": [
        "A non-cleavable maleimidocaproyl linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Oxford BioMedica",
        "Pfizer",
        "WYETH"
      ],
      "trials": [
        "NCT02590263"
      ],
      "locations": [
        "Japan"
      ]
    },
    {
      "heading": "RN927C | PF06664178 | PF 06664178 | PF-06664178",
      "names": [
        "RN927C",
        "PF06664178",
        "PF 06664178",
        "PF-06664178"
      ],
      "phases": [],
      "conditions": [
        "Solid tumors; Non Small Cell Lung Cancer ovarian cancer, and breast cancer",
        "Pancreatic, lung, ovarian, and triple-negative breast tumor types"
      ],
      "targets": [
        "Trop-2, also known as TACSTD2, EGP-1, GA733-1, and M1S1",
        "TROP2; a cell-surface glycoprotein overexpressed in a variety of late stage epithelial carcinomas with low to no expression in normal tissues."
      ],
      "payload": [
        "PF-06380101, a novel cytotoxic Dolastatin 10 analogue.",
        "A proprietary microtubule inhibitor (MTI) linker-payload, PF-06380101 (a Dolastatin 10 analogue) linked at the C-terminus of the antibody heavy chain via an enzymatic process."
      ],
      "linker": [
        "AcLys-VC-PABC; site-specific transglutaminase-mediated conjugation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-Trop-2 hIgG1 antibody."
      ],
      "Max Phase": null,
      "developers": [
        "Pfizer",
        "WYETH"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SGN CD70 A | superseding SGN-75 | SGN-CD70A",
      "names": [
        "SGN CD70 A",
        "superseding SGN-75",
        "SGN-CD70A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Renal Cell Carcinoma",
        "Renal cell carcinoma/RCC;  hematologic malignancies",
        "Follicular Lymphoma, Grade 3",
        "Mantle-Cell Lymphoma",
        "Carcinoma, Renal Cell",
        "Diffuse, Large B-Cell, Lymphoma"
      ],
      "targets": [
        "CD70; the ligand for the co-stimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, found on the surfaces of various types of cancer cells."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "A stable, protease-cleavable, peptide-based linker"
      ],
      "domain": [
        "Oncology; Hematology."
      ],
      "antibody": [
        "An engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "trials": [
        "NCT02216890",
        "NCT01015911"
      ],
      "locations": [
        "United States",
        "Japan"
      ]
    },
    {
      "heading": "RG7861 | Anti-S. aureus TAC | DSTA4637S",
      "names": [
        "RG7861",
        "Anti-S. aureus TAC",
        "DSTA4637S"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Healthy Volunteers Staphylococcus aureus infections"
      ],
      "targets": [
        "S. Aureus"
      ],
      "payload": [
        "dmDNA31"
      ],
      "linker": [],
      "domain": [
        "Infectious diseases"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "MLN2704 | MLN-2704",
      "names": [
        "MLN2704",
        "MLN-2704",
        "MLN-591DM1"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Prostatic Neoplasms",
        "Prostate Cancer"
      ],
      "targets": [
        "PSMA  (Prostate-specific membrane antigen)"
      ],
      "payload": [
        "Maytansine analog drug maytansinoid-1 (DM1)"
      ],
      "linker": [
        "Disulfide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MLN591"
      ],
      "Max Phase": "2",
      "developers": [
        "Millennium",
        "Takeda"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109556",
        "Name": "MLN-2704",
        "Synonyms": "MLN-2704|MLN-591DM1",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "trials": [
        "NCT00052000",
        "NCT00070837"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "BAY 794620 | BAY 79-4620 | BAY79-4620 | 3ee9",
      "names": [
        "BAY 794620",
        "BAY 79-4620",
        "BAY79-4620",
        "3ee9"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Various solid tumors"
      ],
      "targets": [
        "CA9 (carbonic anhydrase IX, CAIX, MN, G250)"
      ],
      "payload": [
        "Monomethyl  Auristatin E (MMAE)"
      ],
      "linker": [
        "Valine\u2013citrulline (vc)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-proto-oncogene protein c-kit IgG1/kappa -maitansine | LOP-628 | LOP628 | LOP 628 | Anti-c-kit humanised IgG1/\u03ba -maitansine",
      "names": [
        "Anti-proto-oncogene protein c-kit IgG1/kappa -maitansine",
        "LOP-628",
        "LOP628",
        "LOP 628",
        "Anti-c-kit humanised IgG1/\u03ba -maitansine"
      ],
      "phases": [
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia",
        "Papillary thyroid carcinoma",
        "Gastric Cancer",
        "HER2 Overexpressing Gastric Carcinoma"
      ],
      "targets": [
        "CD117; Mast/stem cell growth factor receptor (SCFR); proto-oncogene c-Kit or tyrosine-protein kinase Kit"
      ],
      "payload": [
        "A maytansine payload"
      ],
      "linker": [
        "Non-cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Novartis"
      ],
      "trials": [
        "ChiCTR-DND-17012404",
        "NCT04714190"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "SGN-CD123A",
      "names": [
        "SGN-CD123A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Acute Myelogenous / Myeloid Leukemia (AML)"
      ],
      "targets": [
        "CD123; also known as IL-3RA (alpha-chain of the interleukin-3 receptor)  This target is frequently observed in leukemic disorders and may contribute to the proliferative advantage of leukemic cells. CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "Protease Cleavable Linker"
      ],
      "domain": [],
      "antibody": [
        "Humanized"
      ],
      "Max Phase": "1",
      "locations": [],
      "trials": []
    },
    {
      "heading": "SAR428926 SAR 428926 | SAR428926",
      "names": [
        "SAR428926 SAR 428926",
        "SAR428926"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors; Advanced triple negative breast cancer (TNBC)"
      ],
      "targets": [
        "LAMP1; Lysosome-associated membrane protein 1.  This target plays a key role in cell-cell adhesion and migration."
      ],
      "payload": [
        "Maytansinoid DM4; DM4"
      ],
      "linker": [
        "A disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-cMET ADC | CBT-161",
      "names": [
        "Anti-cMET ADC",
        "CBT-161"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "cMET; Also called tyrosine-protein kinase Met and hepatocyte growth factor receptor (HGFR)"
      ],
      "payload": [
        "Proprietary tubulin-binding, DNA alkylation and other cytotoxic agents"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Sorrento Therapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "PF-6650808 | PF06650808 | Anti-NOTCH3-ADC | Anti-NOTCH3 ADC | PF-06650808",
      "names": [
        "PF-6650808",
        "PF06650808",
        "Anti-NOTCH3-ADC",
        "Anti-NOTCH3 ADC",
        "PF-06650808"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors; Triple negative breast cancer (TNBC); Ovarian cancer; Non-small  cell  lung  cancer (NSCLC)"
      ],
      "targets": [
        "Notch3 (Neurogenic locus notch homolog protein 3)"
      ],
      "payload": [
        "Auristatin-based cytotoxic agent"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Pfizer",
        "WYETH"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AGS62P1 | AGS 62P1",
      "names": [
        "AGS62P1",
        "AGS 62P1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Acute Myelogenous / Myeloid Leukemia (AML)"
      ],
      "targets": [
        "FLT3 (FMS-like tyrosine kinase 3) a member of the class III receptor tyrosine kinase family, which is highly expressed in the blasts of both AML and ALL patients."
      ],
      "payload": [
        "Amberstatin269 | Aurixime"
      ],
      "linker": [
        "Oxime bond to pAF sites"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-FLT3 monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Agensys",
        "Astellas"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADCM-E7974 | NC-6201",
      "names": [
        "ADCM-E7974",
        "NC-6201"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Cetuximab-insensitive KRAS-mutated tumors; Pancreatic Cancer; Triple Negative Breast cancer (TNBC)"
      ],
      "targets": [
        "EGFR; Epidermal growth factor receptor (EGFR),  a transmembrane tyrosine kinase receptor involved in the proliferation and survival of cancer cells."
      ],
      "payload": [
        "E7974, a synthetic analog of  hemiasterlin (tubulin inhibitor"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "NCAB001 (Same sequence with  Cetuximab)"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Eisai",
        "NanoCarrier (Japan)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Doxorubicin-anti-CD99 | NV101",
      "names": [
        "Doxorubicin-anti-CD99",
        "NV101"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Large-Cell, Anaplastic",
        "Ewing Sarcoma",
        "Pancreas Cancer",
        "Lymphoma, T-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Breast Neoplasms",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "HER2-positive Early Breast Cancer",
        "T-Cell Lymphoma",
        "DLBCL",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Locally Advanced or Early Breast Cancer",
        "Refractory B Acute Lymphoblastic Leukemia",
        "HER2-Positive Metastatic Breast Cancer",
        "Refractory B Lymphoblastic Lymphoma",
        "Large B-Cell Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage II Childhood Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Hodgkin Disease",
        "Recurrent B Lymphoblastic Lymphoma",
        "Breast Cancer",
        "Stage III Childhood Hodgkin Lymphoma",
        "B-Cell Lymphoma"
      ],
      "targets": [
        "CD99; also known as MIC2 or Single-chain type-1 glycoprotein, is a heavily O-glycosylated transmembrane protein. CD99 is xpressed on all leukocytes but highest on thymocytes; found on the cell surface of Ewing's sarcoma and positive in granulosa cell tumors. It is more expressed in malignant gliomas than in the brain. Overexpression results in higher levels of invasiveness and lower rates of survival."
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "NanoValent"
      ],
      "trials": [
        "NCT04914741",
        "NCT03755804",
        "NCT06377566",
        "NCT01712490",
        "NCT01309789",
        "NCT06047080",
        "NCT04594798",
        "NCT02734771",
        "NCT01534078",
        "NCT02292979",
        "NCT05404945",
        "NCT06132958",
        "NCT06112379",
        "NCT04884035",
        "NCT01920932",
        "NCT03726879",
        "NCT02605915",
        "NCT04203641",
        "NCT05600686",
        "NCT02505269",
        "NCT03467373",
        "NCT01992653",
        "NCT01060904",
        "NCT06340568",
        "NCT03646123",
        "NCT01777152",
        "NCT04790903",
        "NCT05673785",
        "NCT01966471",
        "NCT02979522",
        "NCT03274492",
        "NCT03991884",
        "NCT06486441",
        "NCT05113251",
        "NCT04569032",
        "NCT03677141",
        "NCT04685616"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "Irinotecan-anti-CD99 | NV103",
      "names": [
        "Irinotecan-anti-CD99",
        "NV103"
      ],
      "phases": [
        "Preclinical",
        "Phase 2"
      ],
      "conditions": [
        "Gastric Cancer",
        "Pancreatic Adenocarcinoma",
        "Gastroesophageal Junction Cancer",
        "Ewing Sarcoma; Neuroendocrine tumors"
      ],
      "targets": [
        "CD99; also known as MIC2 or Single-chain type-1 glycoprotein, is a heavily O-glycosylated transmembrane protein. CD99 is xpressed on all leukocytes but highest on thymocytes; found on the cell surface of Ewing's sarcoma and positive in granulosa cell tumors. It is more expressed in malignant gliomas than in the brain. Overexpression results in higher levels of invasiveness and lower rates of survival."
      ],
      "payload": [
        "Irinotecan"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "NanoValent"
      ],
      "trials": [
        "NCT06219941"
      ],
      "locations": [
        "Moldova, Republic of",
        "Canada",
        "United Kingdom",
        "Republic of Korea",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Republic of Moldova",
        "Japan",
        "Spain",
        "Singapore",
        "United States",
        "Poland",
        "United States of America",
        "Georgia",
        "Taiwan"
      ]
    },
    {
      "heading": "NV102 | Doxorubicin-anti-CD19",
      "names": [
        "NV102",
        "Doxorubicin-anti-CD19"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Lymphoma, T-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Acute myeloid leukemia (AML); And acute lymphoblastic leukemia (ALL)",
        "Double-Expressor Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Breast Neoplasms",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "HER2-positive Early Breast Cancer",
        "T-Cell Lymphoma",
        "DLBCL",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Locally Advanced or Early Breast Cancer",
        "Refractory B Acute Lymphoblastic Leukemia",
        "HER2-Positive Metastatic Breast Cancer",
        "Refractory B Lymphoblastic Lymphoma",
        "Large B-Cell Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage II Childhood Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Hodgkin Disease",
        "Recurrent B Lymphoblastic Lymphoma",
        "Breast Cancer",
        "Stage III Childhood Hodgkin Lymphoma",
        "B-Cell Lymphoma"
      ],
      "targets": [
        "CD19; a cell surface molecule expressed only by B lymphocytes and follicular dendritic cells of the hematopoietic system. CD19 is the earliest of the B-lineage-restricted antigens to be expressed and is present on most pre-B cells and most non-T-cell acute lymphocytic leukemia cells and B-cell type chronic lymphocytic leukemia cells."
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "NanoValent"
      ],
      "trials": [
        "NCT04914741",
        "NCT03755804",
        "NCT06377566",
        "NCT01712490",
        "NCT01309789",
        "NCT06047080",
        "NCT04594798",
        "NCT02734771",
        "NCT01534078",
        "NCT02292979",
        "NCT05404945",
        "NCT06132958",
        "NCT06112379",
        "NCT04884035",
        "NCT01920932",
        "NCT03726879",
        "NCT02605915",
        "NCT04203641",
        "NCT05600686",
        "NCT02505269",
        "NCT03467373",
        "NCT01992653",
        "NCT01060904",
        "NCT06340568",
        "NCT03646123",
        "NCT01777152",
        "NCT04790903",
        "NCT05673785",
        "NCT01966471",
        "NCT02979522",
        "NCT03274492",
        "NCT03991884",
        "NCT06486441",
        "NCT05113251",
        "NCT04569032",
        "NCT03677141",
        "NCT04685616"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "EDC-CD20 | EDC9",
      "names": [
        "EDC-CD20",
        "EDC9"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Diffuse large B cell lymphoma."
      ],
      "targets": [
        "CD20 and sodium-potassium ATPase."
      ],
      "payload": [
        "Rituximab is conjugated to a steroidal glycoside"
      ],
      "linker": [
        "A proprietary long non-cleavable, fexible, stable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Centrose",
        "Wisconsin Alumni Research Foundation - WARF"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "DYS-ADC | DYS-EDC | EDC1 | EDC-1",
      "names": [
        "DYS-ADC",
        "DYS-EDC",
        "EDC1",
        "EDC-1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Thyroid Carcinoma; Pancreatic Cancer; Lymphoma;"
      ],
      "targets": [
        "Dysadherin (also known as  FXYD5); a cancer cell membrane-associated glycoprotein that has been recognized as a prognostic indicator of metastasis and/or poor survival in many different cancer types. The presence of dysadherin expression contributes causally to cancer metastasis in a number of ways, including downregulation of E-cadherin-mediated cell adhesion, upregulation of tumor-promoting chemokine production and enhancement of cancer stem-cell properties."
      ],
      "payload": [
        "CEN-106, a novel Na,K-ATPase inhibitor known to induce necrosis in human cancer cell types."
      ],
      "linker": [
        "A proprietary long non-cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-dysadherin antibody (NCC-M53)"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Centrose",
        "Wisconsin Alumni Research Foundation - WARF"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ASN 004 | ASN-004 | ASN-004 ASN004 ASN 004",
      "names": [
        "ASN 004",
        "ASN-004",
        "ASN-004 ASN004 ASN 004"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid Tumors (Breast, Lung, Stomach)"
      ],
      "targets": [
        "5T4 (Oncofoetal glycoprotein); TPBG and trophoblast glycoprotein, a 72 kDa glycoprotein member of the LRR family of proteins expressed on trophoblasts, tumor cells, ovarian cuboidal epithelium and embryonic stem cells, and impacts cell adhesion and motility."
      ],
      "payload": [
        "Dolaflexin (auristatin) analog, a microtubule disruptor capable of bystander-effect tumor cell killing.  Drug-to-antibody ratio (DAR): ~15"
      ],
      "linker": [
        "Single-chain homo-dimer  antibody,  Fleximer\u00ae linker  technology; 3 Fleximer chains per antibody."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "scFvFc antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Asana BioSciences"
      ],
      "trials": [
        "NCT04410224"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "MEN 1309 MEN1309 OBT076 | OBT076 | MEN1309",
      "names": [
        "OBT076",
        "MEN 1309 MEN1309 OBT076",
        "MEN1309"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor",
        "Diffuse large B-cell lymphoma (DLBCL) | a type of non-Hodgkin lymphoma - NHL); Triple Negative Breast Cancer (TNBC)"
      ],
      "targets": [
        "Ly75/CD205 (a type I transmembrane glycoprotein and a C-type lectin receptor; over-expressed in several solid tumors and non-Hodgking lymphomas (NHL)"
      ],
      "payload": [
        "Maytansinoid toxin (DM4)"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Hematology; Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Menarini Ricerche",
        "Oxford BioTherapeutics"
      ],
      "ttd": "D8DJX0",
      "trials": [
        "NCT04064359"
      ],
      "locations": [
        "Greece",
        "Belgium",
        "Spain",
        "United States",
        "France"
      ]
    },
    {
      "heading": "anti-HER-3 ADC | Anti-HER-3 -",
      "names": [
        "anti-HER-3 ADC",
        "Anti-HER-3 -"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Stomach Cancer; Breast cancer; Prostate cancer,  Ovarian cancer,  Lung cancer,  Head & neck,  Pancreatic Cancer; Colon cancer; Melanoma;  Neuroblastoma."
      ],
      "targets": [
        "HER3"
      ],
      "payload": [
        "A duocarmycin derivative"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "EV20, an anti-HER3 monoclonal antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "MediaPharma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "EC145/MK 8109 | VYNFINIT\u00ae | MK 8109 | Vintafolide | MK8109 | EC145",
      "names": [
        "EC145/MK 8109",
        "VYNFINIT\u00ae",
        "MK 8109",
        "Vintafolide",
        "MK8109",
        "EC145"
      ],
      "phases": [],
      "conditions": [
        "Ovarian Cancer;  Platinum-resistant ovarian cancer; Non-Small Cell Lung Cancer;"
      ],
      "targets": [
        "Folate Receptor"
      ],
      "payload": [
        "Vinblastine"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Endocyte",
        "Merck Sharp & Dohme"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "EC2629",
      "names": [
        "EC2629"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Triple negative breast cancer (TNBC); Drug-resistant ovarian cancer"
      ],
      "targets": [
        "Folate receptor positive cancer cells; Tumor-associated macrophages (TAMs)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Endocyte"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "PF-06647263 | PF-06647263 EFNA4-ADC | anti-EFNA4-ADC",
      "names": [
        "PF-06647263",
        "PF-06647263 EFNA4-ADC",
        "anti-EFNA4-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic Triple Negative Breast Cancer (mTNBC)"
      ],
      "targets": [
        "Ephrin-A4 (EFNA4)"
      ],
      "payload": [
        "Calicheamicin"
      ],
      "linker": [
        "Hydrazone cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hE22"
      ],
      "Max Phase": "1",
      "developers": [
        "Pfizer"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "MEDI-547 | MEDI547",
      "names": [
        "MEDI-547",
        "MEDI547"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "EphA2"
      ],
      "payload": [
        "Auristatin MMAF"
      ],
      "linker": [
        "Stable linker maleimidocaproyl (mc)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "MedImmune"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "EC1169",
      "names": [
        "EC1169"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic Castrate-resistant Prostate Cancer (mCRPC)."
      ],
      "targets": [
        "PSMA; Prostate-Specific Membrane Antigen"
      ],
      "payload": [
        "Tubulysin B hydrazide (TubBH)"
      ],
      "linker": [
        "A stable, enzyme-cleavable, bioreleasable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Endocyte"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV 176 | ABBV-176 | ABV176 | ABBV176",
      "names": [
        "ABBV 176",
        "ABV176",
        "ABBV-176",
        "ABBV176",
        "ABBV-176 DC-1630993 h16f",
        "Rolinsatamab talirine"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced solid tumors",
        "Sold tumors"
      ],
      "targets": [
        "PRLR (prolactin receptor);  a tumor-associated antigen (TAA) overexpressed by a variety of tumor cell types",
        "PRLR (prolactin receptor); a tumor-associated antigen (TAA) overexpressed by a variety of tumor cell types"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PDB) dimers SGD-1882",
        "Auristatin-0101, an auristatin microtubule inhibitor"
      ],
      "linker": [
        "Cleavable maleimidocaproyl type linker  On an average of 2 site-specific drug attachment engineered cysteines (C242, C242')"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-PRLR (prolactin receptor)], monoclonal antibody,",
        "anti-PTK7 monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "anti-CD70 ADC | Anti-CD70-ADC | CD70 ADC | CD70-ADC",
      "names": [
        "anti-CD70 ADC",
        "Anti-CD70-ADC",
        "CD70 ADC",
        "CD70-ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Cancer; Renal cell carcinoma (RCC); nasopharyngeal cancers"
      ],
      "targets": [
        "CD70"
      ],
      "payload": [
        "Ambrx's proprietary drug payloads"
      ],
      "linker": [
        "Site-specific"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CD184-Dasatinib-ADC | CD184-Dasatinib",
      "names": [
        "CD184-Dasatinib-ADC",
        "CD184-Dasatinib"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Chronic diseases"
      ],
      "targets": [
        "CXCR4; Chemokine receptor type 4 (CXCR-4) also known as fusin or CD184; CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12)"
      ],
      "payload": [
        "Dasatinib;  an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity.  Drug-to-antibody ratio (DAR) ~3"
      ],
      "linker": [],
      "domain": [
        "Non-Oncology; Non-Hematology;"
      ],
      "antibody": [
        "anti-CXCR4 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Cymac-001 | anti-CD163-dexamethasone | CD163-dexamethasone ADC | anti-CD163-dexamethasone ADC",
      "names": [
        "Cymac-001",
        "anti-CD163-dexamethasone",
        "CD163-dexamethasone ADC",
        "anti-CD163-dexamethasone ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "ALL",
        "Severe and/or chronic inflammatory diseases",
        "Refractory Multiple Myeloma",
        "Diffuse Large B-cell Lymphoma",
        "B-Cell Lymphoma",
        "B-cell Non Hodgkin Lymphoma",
        "Multiple Myeloma",
        "B-cell Acute Lymphoblastic Leukemia",
        "Solid Tumor",
        "Relapsed Cancer",
        "Small Cell Lung Cancer"
      ],
      "targets": [
        "CD-163; a high affinity scavenger receptor for the hemoglobin-haptoglobin complex (in the absence of haptoglobin, with lower affinity, for hemoglobin alone. CD163 has also been shown to mark cells of monocyte/macrophage lineage."
      ],
      "payload": [
        "Synthetic glucocorticoids (GCs) | Dexamethasone  Drug-to-antibody ratio: 4"
      ],
      "linker": [],
      "domain": [
        "Non-Oncology; Non-Hematology; Inflammation;"
      ],
      "antibody": [
        "Anti-CD163"
      ],
      "Max Phase": "3",
      "developers": [
        "Affinicon"
      ],
      "trials": [
        "NCT04484623",
        "NCT03544281",
        "NCT04300556",
        "NCT05498220",
        "NCT05016947",
        "NCT03828292",
        "NCT04246047",
        "NCT03061812",
        "NCT05180097",
        "NCT05922501",
        "NCT05991388"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Czechia",
        "Turkey",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Serbia",
        "Belarus",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "New Zealand",
        "Japan",
        "Latvia",
        "Spain",
        "Germany",
        "Croatia",
        "Israel"
      ]
    },
    {
      "heading": "CD70-glucocorticoid ADC",
      "names": [
        "CD70-glucocorticoid ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Anti-inflammatory diseases."
      ],
      "targets": [
        "CD70 (also referred to as CD27L), a tumor necrosis factor-related cell-surface ligand, and its receptor, CD27, is expressed on different immune cell populations."
      ],
      "payload": [
        "Glucocorticoids"
      ],
      "linker": [
        "A novel phosphate bridged Cathepsin B sensitive linker designed to enable the targeted delivery of glucocorticoids. This linker expands the scope of potential ADC payloads by allowing an aliphatic alcohol to be a stable, yet cleavable attachment site."
      ],
      "domain": [
        "Non-Oncology; Non-Hematology; Inflammation"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CD184-FK506",
      "names": [
        "CD184-FK506"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Rheumatoid arthritis; Inflammatory  bowel disease; Psoriasis."
      ],
      "targets": [
        "CXCR4; Chemokine receptor type 4 (CXCR-4) also known as fusin or CD184; CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12)"
      ],
      "payload": [
        "FK506,  also known as tacrolimus or fujimycin, an antibiotic with immunosuppressive properties."
      ],
      "linker": [],
      "domain": [
        "Non-Oncology; Non-hematology; Inflammation"
      ],
      "antibody": [
        "anti-CXCR4 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CDH6-ADC | HKT288 | HKT-288 | Maytansine-based ADC HKT-288",
      "names": [
        "CDH6-ADC",
        "HKT288",
        "HKT-288",
        "Maytansine-based ADC HKT-288"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumors; Epithelial Ovarian cancer; Renal Cell Carcinoma (RCC)"
      ],
      "targets": [
        "Tumor-associated antigen (TAA) CDH6 (CDH-6); Cadherin-6 (cell-cell adhesion molecule)."
      ],
      "payload": [
        "Tubulin-binding maytansinoid DM4 payload. (N2'-Deacetyl-N2'-(4-mercapto-4- methyl-1-oxopentyl)maytansine)"
      ],
      "linker": [
        "sulfo-SPDB (N-succinimidyl-4-(2-pyridyldithio)-2-sulfo butanoate)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-CDH6 IgG1"
      ],
      "Max Phase": "1",
      "developers": [
        "Novartis"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "PCA-062 | PCA062 PCA-062 | PCA062",
      "names": [
        "PCA-062",
        "PCA062 PCA-062",
        "PCA062"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "P-cadherin-positive cancers; Triple negative breast cancer (TNBC); Head & neck cancer; Esophageal cancer."
      ],
      "targets": [
        "P-cadherin; a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN",
        "Novartis"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ZV203",
      "names": [
        "ZV203"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Breast cancer; Gastric/Stomach cancer"
      ],
      "targets": [
        "HER2; Human epidermal growth factor receptor 2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Concortis"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "c-MET ADC",
      "names": [
        "c-MET ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Non-small cell lung cancer (NSCLC)"
      ],
      "targets": [
        "c-MET; Tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR); involved in cell proliferation, invasion, and angiogenesis."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-c-Met antibody STI-0602"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Concortis"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "EP-400",
      "names": [
        "EP-400"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Esperance"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMAB362-vcMMAE",
      "names": [
        "IMAB362-vcMMAE"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Pancreatic Cancer; Gastric Cancer"
      ],
      "targets": [
        "CLDN18.2; Tight junction protein Claudin 18.2"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Valine\u2013citrulline linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Astellas",
        "Ganymed"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-endosialin-MC-VC-PABC-MMAE",
      "names": [
        "Anti-endosialin-MC-VC-PABC-MMAE"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Neuroblastoma;  Ewing sarcoma"
      ],
      "targets": [
        "CD248; also known as Endosialin, a member of a novel family of C-type lectin transmembrane receptors which play a role in cell\u2013cell adhesion and host defence. CD248 is expressed in the cell surface of tumor-associated stroma cells, as well as in sarcoma and neuroblastoma cells."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  Drug-to-antibody ratio: 3 - 4"
      ],
      "linker": [
        "A maleimidocaproyl-valine-citrulline linker with a p-aminobenzylcarbamate spacer"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-endosialin"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Genzyme"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "HTI-1511",
      "names": [
        "HTI-1511"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Colon Cancer; Solid tumors; Lung Cancer; Cholangiocarcinoma; EGFR-positive tumors, including those with KRAS and BRAF mutations"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor (EGFR)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "Bis-alkylating linker (site specific ThioBridge\u2122 linker technology)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Halozyme"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMB-202",
      "names": [
        "IMB-202"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "Undisclosed intracellular tumor antigens"
      ],
      "payload": [],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "ImmunoBiochem"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMB-201",
      "names": [
        "IMB-201"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "Undisclosed intracellular tumor antigens."
      ],
      "payload": [],
      "linker": [
        "Stable (non-cleavable) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "ImmunoBiochem"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IGN523",
      "names": [
        "IGN523"
      ],
      "phases": [],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)/Acute Myeloid Leukemia(AML)"
      ],
      "targets": [
        "CD98 (gp125)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Igenica"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IGN786",
      "names": [
        "IGN786"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "follicular lymphoma, diffuse large B-cell lymphoma (DLBCL); Acute myeloid leukemia (AML); Chronic lymphocytic leukemia (CLL); Multiple myeloma; Pancreatic cancer."
      ],
      "targets": [
        "SAIL; Surface Antigen In Leukemia | c15orf54"
      ],
      "payload": [
        "Monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "A maleimidocaproyl (mc) linker"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [
        "anti-SAIL"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Igenica"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LCB14-15nm",
      "names": [
        "LCB14-15nm"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Legochem",
        "Takeda"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LCB14-17nn",
      "names": [
        "LCB14-17nn"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Mesothelin; a tumour differentiation antigen normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. It is also highly expressed in several cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of mesothelin is unknown however, recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Legochem"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LCB14-15xx | anti-CD37 ADC | NNV019",
      "names": [
        "LCB14-15xx",
        "anti-CD37 ADC",
        "NNV019"
      ],
      "phases": [],
      "conditions": [
        "Various Leukemias"
      ],
      "targets": [
        "Undisclosed",
        "CD37; a cell surface glycoprotein.  As a type III transmembrane protein CD37 is present on mature B cells, some T cells, and monocytes that may play a role in ion transport; Also expressed on B-cell lymphomas, B-cell chronic lymphocytic leukemia, and hairy cell leukemia."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology Hematology",
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Legochem",
        "Nordic Nanovector"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AR-001 | YBK-001 | YBL-001",
      "names": [
        "AR-001",
        "YBK-001",
        "YBL-001"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Y-Biologics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LCB14-19nm",
      "names": [
        "LCB14-19nm"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "EGFRvIII; Epidermal growth factor receptor variant III, a mutated form of EGFR which plays a prominent role in tumorigenesis."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Legochem",
        "Samsung Medical Center"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LCB14-2nm",
      "names": [
        "LCB14-2nm"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Legochem",
        "Seasun Biomaterials"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LCB14-0110 | Herceptin-LC-LBG-MMAF | Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF | LCB14 0110",
      "names": [
        "LCB14-0110",
        "Herceptin-LC-LBG-MMAF",
        "Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF",
        "LCB14 0110"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "(Breast | Stomach)",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Her 2 Positive Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "HER2; Human epidermal growth factor 2"
      ],
      "payload": [
        "Monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "LegoChem's proprietary linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Legochem",
        "Shanghai Fosun"
      ],
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04873362",
        "NCT05980481",
        "NCT00928330",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "Anti-ADAM9-sulfoSPDB-DM4 | Anti-ADAM9 ADC",
      "names": [
        "Anti-ADAM9 ADC",
        "Anti-ADAM9",
        "Anti-ADAM9-sulfoSPDB-DM4",
        "DGN549",
        "C442"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "ADAM9-expressing tumors; Prostate Cancer; Renal Cell Carcinoma; Pancreatic Cancer"
      ],
      "targets": [
        "ADAM-9; also known as MDC9 or  meltrin-\u03b3; A disintegrin and metalloproteinase)-9 is a cell-surface membrane glycoprotein, which enables various roles in a wide range of cellular process. Over-expression of ADAM-9 has been reported in several cancers",
        "ADAM-9; also known as MDC9 or meltrin-\u03b3; A disintegrin and metalloproteinase)-9 is a cell-surface membrane glycoprotein, which enables various roles in a wide range of cellular process. Over-expression of ADAM-9 has been reported in several cancers."
      ],
      "payload": [
        "Indolinobenzodiazepine DNA-alkylating monoimine (DGN549)  Drug-to-antibody ratio:  2",
        "Maytansine-derived microtubule  disruptor DM4   Drug-to-antibody ratio of ~3.5"
      ],
      "linker": [
        "Conjugated to engineered cysteine residues via a cleavable peptide linker.",
        "Lysine-linked via a cleavable sulfo-SPDB linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-ADAM9 antibody: AEX6003(S442C)",
        "Anti-ADAM9 antibody: AEX6003"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "IMMUNOGEN",
        "MacroGenics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "anti-TEM-1 - | TEM-1-ADC | Anti-TEM-1 -",
      "names": [
        "anti-TEM-1 -",
        "TEM-1-ADC",
        "Anti-TEM-1 -"
      ],
      "phases": [],
      "conditions": [
        "Sarcoma; Melanoma; Neuroblastoma; Colorectal carcinoma"
      ],
      "targets": [
        "CD248; also known as Endosialin, a member of a novel family of C-type lectin transmembrane receptors which play a role in cell\u2013cell adhesion and host defence. CD248 is expressed in the cell surface of tumor-associated stroma cells, as well as in sarcoma and neuroblastoma cells"
      ],
      "payload": [
        "A duocarmycin derivative"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "E.8-3, an anti-TEM-1 monoclonal antibody"
      ],
      "Max Phase": null,
      "developers": [
        "MediaPharma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "anti-CD22-NMS249 | Anti-CD22 Anthracycline-Based ADC | anti-CD22 Anthracycline-Based - | Anti-CD22-NMS249",
      "names": [
        "anti-CD22-NMS249",
        "Anti-CD22 Anthracycline-Based ADC",
        "anti-CD22 Anthracycline-Based -",
        "Anti-CD22-NMS249"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Non-Hodgkin lymphoma (NHL)"
      ],
      "targets": [
        "CD22; a molecule belonging to the SIGLEC family of lectins, found on the surface of mature B cells and to a lesser extent on some immature B cells"
      ],
      "payload": [
        "A anthracycline analogue (PNU-159682)"
      ],
      "linker": [
        "A protease-cleavable maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl linker (MC-vc-PAB)."
      ],
      "domain": [
        "Oncology; Hematology;"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Genentech"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Azonafide-ADC",
      "names": [
        "Azonafide-ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [
        "Azonafide (2-[2\u2032-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de, h]isoquinoline-1,3-dione) is the parent of a new series of anthracene-containing antitumor agents."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Oncolinx"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-MTX3:Nigrin Immuno | OMTX503",
      "names": [
        "Anti-MTX3:Nigrin Immuno",
        "OMTX503"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "MTX3; a membrane protein of endothelial cells"
      ],
      "payload": [
        "Nigrin B; a plant toxin from Sambucus nigra (bark) and a member of Type 2 RIP family; inhibit ribosomal activity."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-MTX3 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Oncomatryx"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "OMTX705 | Anti-MTX5:Cytolysin ADC",
      "names": [
        "OMTX705",
        "Anti-MTX5:Cytolysin ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Pancreatic cancer"
      ],
      "targets": [
        "MTX5; a membrane glycoprotein of cancer-associated fibroblasts"
      ],
      "payload": [
        "Highly cytotoxic synthetic Cytolysins; A synthetic tetrapeptidic analogues of the natural class tubulysins with a low MW: 780 g/mol"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "OMTX anti-MTX5 humanized mAb"
      ],
      "Max Phase": "1",
      "developers": [
        "Oncomatryx"
      ],
      "trials": [
        "NCT05547321"
      ],
      "locations": [
        "Spain",
        "United States"
      ]
    },
    {
      "heading": "SNG-8023 ADC",
      "names": [
        "SNG-8023 ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Liver cancer;  Leukemia; Breast cancer"
      ],
      "targets": [
        "ER-alpha36, a novel variant of estrogen receptor-alpha (ER-alpha), is expressed in ER-positive and -negative human breast carcinomas."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ER-alpha36 monoclonal antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Shenogen Pharma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-TM4SF1 ADC",
      "names": [
        "Anti-TM4SF1 ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Cancer; Non-small cell lung cancer; Pancreatic Cancer; Prostate Cancer,  Colon Cancers."
      ],
      "targets": [
        "TM4SF1; Tetraspanin-like protein; Highly expressed on the plasma membranes of many human cancer cells; Also expressed on the endothelial cells lining tumor blood vessels."
      ],
      "payload": [
        "An auristatin cytotoxic agent LP2 (chemical name mc-3377)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-human TM4SF1 monoclonal antibody, v1.10"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Angiex",
        "Pfizer"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TGM-004",
      "names": [
        "TGM-004"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TGM-005",
      "names": [
        "TGM-005"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TGM-001",
      "names": [
        "TGM-001"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TGM-002",
      "names": [
        "TGM-002"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TGM-003",
      "names": [
        "TGM-003"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-PRLR-ADC | REGN2878-DM1 | PRLR | Anti-Prolactin Receptor",
      "names": [
        "Anti-PRLR-ADC",
        "REGN2878-DM1",
        "PRLR",
        "Anti-Prolactin Receptor"
      ],
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "targets": [
        "Prolactin Receptor (PRLR); a type 1 cytokine receptor"
      ],
      "payload": [
        "Cytotoxic maytansine derivative DM1"
      ],
      "linker": [
        "Non-cleavable SMCC linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "High-affinity function-blocking anti-PRLR IgG1 antibody (REGN2878)"
      ],
      "Max Phase": null,
      "developers": [
        "Regeneron"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "HuMAB-5B1-ATAC",
      "names": [
        "HuMAB-5B1-ATAC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Metastatic pancreatic cancer"
      ],
      "targets": [
        "Unknown"
      ],
      "payload": [
        "Amanitin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Heidelberg Pharma",
        "MabVax",
        "Wilex"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti-CD19 ADC | Anti-CD19 ATAC | anti-CD19 ADC",
      "names": [
        "Anti-CD19 ADC",
        "Anti-CD19 ATAC",
        "anti-CD19 ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Burkitt Lymphoma; B-ALL;"
      ],
      "targets": [
        "CD19+; also known  as B-lymphocyte surface antigen B4, B4, CVID; Nalm-6"
      ],
      "payload": [
        "Maleimide Amanitin"
      ],
      "linker": [
        "Site-specific (THIOMAB\u2122). The THIOMAB platform provides one specific site on each heavy chain (Fab region) for drug attachment. As a result, conjugation of a THIOMAB generates a more homogenous ADC product with a primary DAR close to two. The resulting homogeneity of these ADCs leads to a simplified drug profile and improved therapeutic index."
      ],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Heidelberg Pharma",
        "Wilex"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LY3076226 | ADC LY3076226 | Anti-fibroblast Growth Factor Receptor 3 - | Anti-FGFR3 ADC LY3076226",
      "names": [
        "LY3076226",
        "Anti-fibroblast Growth Factor Receptor 3",
        "Anti-fibroblast Growth Factor Receptor 3 -",
        "Anti-FGFR3 ADC LY3076226",
        "ADC LY3076226"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced or metastatic cancer",
        "Metastatic Cancer"
      ],
      "targets": [
        "Fibroblast growth factor receptor (FGFR) family; consists of four members\u2014FGFR-1, FGFR-2, FGFR-3, and FGFR-4"
      ],
      "payload": [
        "Microtubule inhibitor, DM4"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-FGFR-3 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Eli Lilly"
      ],
      "trials": [
        "NCT02529553"
      ],
      "locations": [
        "Canada",
        "United States"
      ]
    },
    {
      "heading": "anti-HLA-DR-SN-38 ADC | IMMU-140",
      "names": [
        "anti-HLA-DR-SN-38 ADC",
        "IMMU-140"
      ],
      "phases": [],
      "conditions": [
        "Acute lymphocytic leukemia (ALL); Chronic lymphocytic leukemia (CLL); Multiple myeloma (MM);  Acute myeloid leukemia (AML); Diffuse large B-cell lymphoma (DLBCL);  Hodgkin lymphoma (HL);  Melanoma"
      ],
      "targets": [
        "HLA-DR. This target is a member of the MHC class II antigen family expressed on hematologic and solid tumors. Antibodies directed against HLA-DR have demonstrated some clinical success, but toxicities limited development."
      ],
      "payload": [
        "Active metabolite of irinotecan, SN-38"
      ],
      "linker": [],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "Humanized anti-HLA-DR IgG4 antibody (IMMU-114)"
      ],
      "Max Phase": null,
      "developers": [
        "Immunomedics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "MI130004",
      "names": [
        "MI130004"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Selectivity towards cell lines with high HER2 expression (IC50s 0.282 and 0.182 nM against HCC-1954 and SK-BR-3 cell lines)"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "PM050489"
      ],
      "linker": [
        "Linker containing a maleimide group to enable conjugation to Cys residues."
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "PharmaMar"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ST1",
      "names": [
        "ST1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Ovarian, colon, prostate, and pancreatic tumors"
      ],
      "targets": [
        "Sialyl-Thomsen-nouveau antigen (STn or Sialyl-Tn, also known as CD175s)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Siamab"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AVID300 | AVID 300",
      "names": [
        "AVID300",
        "AVID 300"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "EGF receptor, EGFR, ErbB-1 and HER1 in humans."
      ],
      "payload": [
        "DM1 (Mertansine, emtansine), a thiol-containing maytansinoid"
      ],
      "linker": [
        "Non-cleavable linker"
      ],
      "domain": [
        "Oncology | Hemtology"
      ],
      "antibody": [
        "Panitumumab (ABX-EGF), a fully human monoclonal antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Formation Biologics (Forbius)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMAB027-vcMMAE",
      "names": [
        "IMAB027-vcMMAE"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "targets": [
        "CLDN6-positive tumors. The transmembrane protein claudin (-CLDN) family play a key role in the maintenance of epithelial and endothelial tight junctions, and possibly as well as cellular signal transduction plays a role in maintaining the cytoskeleton. CLDN6 expressed in a number of different human cancer cells, while expression in normal tissues is limited to the placenta."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE, vedotin)"
      ],
      "linker": [
        "Lysosomally cleavable dipeptide, valine-citrulline (vc)"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "IMAB027"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Astellas",
        "Ganymed"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Satoreotide tetraxetan",
      "names": [
        "Satoreotide tetraxetan"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADCT-701",
      "names": [
        "ADCT-701"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Liver"
      ],
      "targets": [
        "DLK1"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "ADC Therapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "EV20/MMAF",
      "names": [
        "EV20/MMAF"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "HER3"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "MediaPharma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMGN 779 | IMGN779",
      "names": [
        "IMGN 779",
        "IMGN779"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML) With FLT3-ITD Mutations"
      ],
      "targets": [
        "CD33 (Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage"
      ],
      "payload": [
        "DGN462 (DNA-alkylating agent consisting of an indolino-benzodiazepine dimer containing a mono-imine moiety)"
      ],
      "linker": [
        "Disulfide linker / Sulfo-SPDB"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Z4681A"
      ],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "anti-GPC2 ADC | D3-GPC2-PBD",
      "names": [
        "anti-GPC2 ADC",
        "D3-GPC2-PBD"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "targets": [
        "GPC2; Glypican 2, also known cerebroglycan, a cell surface protein shown to be preferentially expressed on numerous pediatric cancers"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer, a potent cytotoxic DNA minor groove interstrand crosslinking agent.   Drug-to-antibody ratio: 2.6"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "D3-GPC2-IgG1"
      ],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "VIS705",
      "names": [
        "VIS705"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "P. aeruginosa"
      ],
      "targets": [
        "Pseudomonas aeruginosa, a type of Gram-negative bacterial infection. The antibody targets a core region of lipopolysaccharide present at high density on P. aeruginosa and common across serotypes."
      ],
      "payload": [
        "Anti-microbial cell-killing peptide."
      ],
      "linker": [],
      "domain": [
        "Antibacterials"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Visterra"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AVE9633 | IMGN-633",
      "names": [
        "AVE9633",
        "IMGN-633"
      ],
      "phases": [],
      "conditions": [
        "Acute myeloid leukemia (AML)"
      ],
      "targets": [
        "CD33, Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) a transmembrane receptor expressed on cells of myeloid lineage."
      ],
      "payload": [
        "DM4 (N2\u2032- Deacetyl-N2\u2032-(4-mercapto-4-methyl-1-oxopentyl)-maytansine)"
      ],
      "linker": [
        "A disulfide bond"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Humanized mAb, anti-CD33 antigen"
      ],
      "Max Phase": null,
      "developers": [
        "IMMUNOGEN"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB06318",
        "Name": "AVE9633",
        "Description": "AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate. \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "CD44v6-DM1 | Anti-CD44v6-DM1 | DM1 immuno | Anti-CD44v6 | BIWI-1 | Bivatuzumab mertansine",
      "names": [
        "CD44v6-DM1",
        "Anti-CD44v6-DM1",
        "DM1 immuno",
        "BIWI-1",
        "Anti-CD44v6",
        "BIWA-1-DM1",
        "Bivatuzumab mertansine",
        "BIVATUZUMAB MERTANSINE",
        "BIWA-4 MERTANSINE"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Breast Neoplasms",
        "Squamous cell carcinoma of the head and neck or esophagus"
      ],
      "targets": [
        "CD44v6 | (homing function and Indian blood group system, chondroitin sulfate proteoglycan 8, CSPG8) variant 6 (CD44v6, CD44V6)"
      ],
      "payload": [
        "DM1"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Boehringer Ingelheim",
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109288",
        "Name": "BIVATUZUMAB MERTANSINE",
        "Synonyms": "BIVATUZUMAB MERTANSINE|BIWA-1-DM1|BIWA-4 MERTANSINE|Bivatuzumab mertansine",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "trials": [
        "NCT02254005",
        "NCT02254018"
      ],
      "locations": []
    },
    {
      "heading": "Cirmtuzumab Vedotin | Cirmtuzumab Vedotin UC-961ADC3 | UC-961ADC3",
      "names": [
        "Cirmtuzumab Vedotin",
        "Cirmtuzumab Vedotin UC-961ADC3",
        "UC-961ADC3"
      ],
      "phases": [],
      "conditions": [
        "Chronic lymphocytic leukemia (CLL); B-cell lymphomas; Acute leukemias; Many different solid-tumors"
      ],
      "targets": [
        "Receptor  tyrosine-kinase  like  orphan  receptor  (ROR1), a  member  of  the tyrosine kinase family. (ROR1 expressing cells (e.g. CLL cells, JeKo-1 cells, or solid tumor cells) or ROR1-negative cells (e.g. Ramos and Jurkat cells)."
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "Lysine-linker with a drug to antibody ratio of 2.5  The proprietaryby  linker was developed Concortis Biosystems, San Diego, USA."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "UC-961 Cirmtuzumab"
      ],
      "Max Phase": null,
      "developers": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GM103",
      "names": [
        "GM103"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Anti-M\u00fcllerian hormone type II receptor (AMHRII)"
      ],
      "payload": [
        "Auristatin derivative"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GamaMabs"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Derlotuximab Biotin | \u00b9\u00b3\u00b9I-chTNT-1/B mAb",
      "names": [
        "IODINE I 131 DERLOTUXIMAB BIOTIN",
        "Cotara",
        "IODINE",
        "\u00b9\u00b3\u00b9I-chTNT-1/B mAb",
        "131I",
        "DERLOTUXIMAB BIOTIN",
        "IODINE I-131 DERLOTUXIMAB BIOTIN",
        "Derlotuximab Biotin"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Recurrent glioblastoma multiforme"
      ],
      "targets": [
        "DNA-histone H1 complex"
      ],
      "payload": [
        "Radio labeled  Iodine | 131 I"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "immunoglobulin G1-kappa, anti-[Homo sapiens DNA/histone 1 (H1) complex], chimeric monoclonal antibody (TNT-1/B monoclonal antibody)"
      ],
      "Max Phase": "2",
      "developers": [
        "Peregrine Pharmaceuticals"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3544924",
        "Name": "IODINE I 131 DERLOTUXIMAB BIOTIN",
        "Synonyms": "Cotara|IODINE (131I) DERLOTUXIMAB BIOTIN|IODINE I 131 DERLOTUXIMAB BIOTIN|IODINE I-131 DERLOTUXIMAB BIOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01224821"
      ],
      "locations": []
    },
    {
      "heading": "DT2219  Also known as: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein | DT2219ARL | GTB-1550 | GTB-1550 OXS-1550 | IND100780 | OXS-1550 | DT-2219ARL",
      "names": [
        "DT2219  Also known as: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein",
        "DT2219ARL",
        "GTB-1550",
        "GTB-1550 OXS-1550",
        "IND100780",
        "OXS-1550",
        "DT-2219ARL"
      ],
      "phases": [
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Neoplasms",
        "Advanced B-cell lymphoid malignancies.  Leukemia; Lymphoma"
      ],
      "targets": [
        "Two targets: CD19 and CD22.  CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development; also expressed on most B-cell mature lymphoma cells and leukemia cells.  CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia; Often co-expressed with CD19 on mature B-cell malignancies such as lymphoma."
      ],
      "payload": [
        "A modified form of diphtheria toxin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "GTB-1550 | OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.  When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload."
      ],
      "Max Phase": "2",
      "developers": [
        "Georgetown Translational (Oxis Biotech)"
      ],
      "trials": [
        "NCT04146610"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "IKS01",
      "names": [
        "IKS01"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Gastric Cancer",
        "Gastroesophageal-junction Cancer",
        "Solid Tumors",
        "Breast Cancer"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Iksuda"
      ],
      "trials": [
        "NCT05872295"
      ],
      "locations": [
        "Australia"
      ]
    },
    {
      "heading": "IKS02",
      "names": [
        "IKS02"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Iksuda"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IKS03",
      "names": [
        "IKS03"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Iksuda"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IKS04",
      "names": [
        "IKS04"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Iksuda"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "NBE-002 \u2013 ROR-1 | NBE-002 NBE-002 - ROR-1",
      "names": [
        "NBE-002",
        "NBE-002 \u2013 ROR-1",
        "NBE-002 NBE-002 - ROR-1"
      ],
      "phases": [
        "Preclinical",
        "Phase 1/2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC) Lung Cancer CLL - MCL"
      ],
      "targets": [
        "Receptor  tyrosine-kinase  like  orphan  receptor  (ROR1), a  member  of  the tyrosine kinase family. (ROR1 expressing cells (e.g. CLL cells, JeKo-1 cells, or solid tumor cells) or ROR1-negative cells (e.g. Ramos and Jurkat cells)."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "NBE Therapeutics"
      ],
      "ttd": "D79HBK",
      "locations": [],
      "trials": []
    },
    {
      "heading": "NBE-003",
      "names": [
        "NBE-003"
      ],
      "phases": [],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC) Pancreatic Carcinoma"
      ],
      "targets": [
        "Undisclosed target"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "NBE Therapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "NBE-001",
      "names": [
        "NBE-001"
      ],
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "targets": [
        "Undisclosed target"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "NBE Therapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SGN-19A SGN-CD19A hBU12-491 | SGN-19A | hBU12-491 | Denintuzumab mafodotin | SGN-CD19A",
      "names": [
        "SGN-19A SGN-CD19A hBU12-491",
        "DENINTUZUMAB MAFODOTIN",
        "SGN-19A",
        "hBU12-491",
        "Denintuzumab mafodotin",
        "SGN-CD19A"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Glioblastoma Multiforme",
        "Burkitt Lymphoma",
        "Malignant Glioma",
        "Lymphoma, Follicular",
        "Lymphoma, Mantle-Cell",
        "All ALL and NHL  Acute lymphoblastic leukemia (ALL)  Aggressive non-Hodgkin\u2019s lymphoma (NHL)  Refractory B-lineage non-Hodgkin lymphoma"
      ],
      "targets": [
        "CD19 (B lymphocyte surface antigen B4, Leu-12)"
      ],
      "payload": [
        "Monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "A noncleavable maleimidocaproxyl-valine-citrulline linker.  An average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "IgG1 - kappa  huBU12"
      ],
      "Max Phase": "2",
      "developers": [
        "Seagen"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3545371",
        "Name": "DENINTUZUMAB MAFODOTIN",
        "Synonyms": "DENINTUZUMAB MAFODOTIN|SGN-19A|SGN-CD19A",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01786135",
        "NCT01786096",
        "NCT02590263"
      ],
      "locations": [
        "United States",
        "Japan"
      ]
    },
    {
      "heading": "ABT-414 ABT-414/806 Depatux-M | ABT-414 | Depatuxizumab Mafodotin",
      "names": [
        "ABT-414 ABT-414/806 Depatux-M",
        "ABT-414",
        "Depatuxizumab Mafodotin",
        "DEPATUXIZUMAB MAFODOTIN"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Gliosarcoma",
        "Glioblastoma Multiforme",
        "Malignant Glioma",
        "Squamous Cell Tumors",
        "Glioblastoma",
        "1L and 2L Glioblastoma Multiforme (GBM) and solid tumors; Squamous cell tumors; non-small-cell lung cancer; Pediatric Brain Tumors"
      ],
      "targets": [
        "EGFR/EGFRde2-7 (EGFRvIII) | EGFR  (epidermal growth factor receptor, receptor tyrosine-protein  kinase erbB-1, ERBB1, HER1, HER-1, ERBB"
      ],
      "payload": [
        "Monomethyl Aurisatin F (MMAF)"
      ],
      "linker": [
        "A stable noncleavable maleimidocaproyl (mc) linker  on an average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa | Depatuxizumab (ABT-806)"
      ],
      "Max Phase": "3",
      "developers": [
        "AbbVie"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3707277",
        "Name": "DEPATUXIZUMAB MAFODOTIN",
        "Synonyms": "ABT-414|DEPATUXIZUMAB MAFODOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "trials": [
        "NCT02573324",
        "NCT01800695",
        "NCT02343406",
        "NCT01741727",
        "NCT02590263"
      ],
      "locations": [
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "Hong Kong",
        "Colombia",
        "United States",
        "Brazil",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "New Zealand",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "RG-7599 | Lifastuzumab Vedotin | DNIB0600A | MNIB2126A  Anti-NaPi2b ADC RG-7599",
      "names": [
        "DNIB-0600A",
        "RG-7599",
        "DNIB0600A",
        "MNIB2126A  Anti-NaPi2b ADC RG-7599",
        "LIFASTUZUMAB VEDOTIN",
        "NAPI3B",
        "Lifastuzumab Vedotin"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Non-small-cell lung cancer; Platinum-resistant ovarian cancer"
      ],
      "targets": [
        "Phosphate-sodium cotransporter SLC34A2 (solute carrier family 34 sodium phosphate member 2, sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b, NAPI-3B)."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker on an average of 3-4 cysteinyl  (Protease-cleavable peptide linker (vc- MMAE platform; Seattle Genetics)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "TAT211"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "ttd": "D05YYP",
      "chembl": {
        "ChEMBL ID": "CHEMBL4297938",
        "Name": "LIFASTUZUMAB VEDOTIN",
        "Synonyms": "DNIB-0600A|DNIB0600A|LIFASTUZUMAB VEDOTIN|NAPI3B|RG-7599",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Sofituzumab vedotin | DMUC5754A | RG7458 | Anti-MUC16 ADC",
      "names": [
        "SOFITUZUMAB VEDOTIN",
        "RG7458",
        "Anti-MUC16 ADC",
        "Sofituzumab vedotin",
        "DMUC5754A",
        "DMUC-5754A",
        "RG-7458"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Ovarian Cancer, Pancreatic Cancer",
        "Ovarian cancer, fallopian tube cancer, Pancreatic cancer, Peritoneal cancer"
      ],
      "targets": [
        "Mucin 16 (Mucin 16, MUC-16, cancer antigen 125, CA125)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Roche"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3545372",
        "Name": "SOFITUZUMAB VEDOTIN",
        "Synonyms": "Anti-MUC16 ADC|DMUC-5754A|DMUC5754A|RG-7458|SOFITUZUMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01335958"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "hCTMO1-calicheamicin CDP-671 | CMB-401 | hCTMO1-calicheamicin | CDP-671",
      "names": [
        "hCTMO1-calicheamicin CDP-671",
        "CMB-401",
        "hCTMO1-calicheamicin",
        "CDP-671"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Monotherapy for the treatment of recurrent platinum-sensitive epithelial ovarian carcinoma (EOC)"
      ],
      "targets": [
        "MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227)"
      ],
      "payload": [
        "Calicheamicin"
      ],
      "linker": [
        "Amide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - nd"
      ],
      "Max Phase": "2",
      "developers": [
        "Celltech",
        "Pfizer",
        "WYETH"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SGN-15 | BR96-DOX | SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin | BMS-182248",
      "names": [
        "SGN-15",
        "BR96-DOX",
        "SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin",
        "BMS-182248"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Ovarian Neoplasms",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Non-Small Cell Lung Carcinoma",
        "Lymphoma, T-cell",
        "Carcinoma, Non-Small-Cell Lung",
        "Stage IV Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Breast Neoplasms",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "HER2-positive Early Breast Cancer",
        "T-Cell Lymphoma",
        "DLBCL",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Locally Advanced or Early Breast Cancer",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Various leukemias and carcinomas; NSCLC; Prostate; Advanced breast cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Prostatic Neoplasms",
        "Refractory B Lymphoblastic Lymphoma",
        "Large B-Cell Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage II Childhood Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Hodgkin Disease",
        "Recurrent B Lymphoblastic Lymphoma",
        "Breast Cancer",
        "Stage III Childhood Hodgkin Lymphoma",
        "B-Cell Lymphoma"
      ],
      "targets": [
        "Lewis Y (Le(y)) antigen"
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [
        "A hydrazone linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Bristol Myers Squibb",
        "Seagen"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB05818",
        "Name": "SGN-15",
        "Description": "SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic. When it is combined with...",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 When it is combined with a monoclonal antibody, it forms a type of drug conjugate. ... Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to ... It combines a monoclonal antibody with the anticancer drug doxorubicin. \u2026",
        "Queries": "['antibody AND conjugate', '\"drug conjugate\"']",
        "Query Indices": "[0, 3]",
        "Score": 8
      },
      "trials": [
        "NCT04914741",
        "NCT03755804",
        "NCT06377566",
        "NCT01712490",
        "NCT01309789",
        "NCT06047080",
        "NCT04594798",
        "NCT02734771",
        "NCT01534078",
        "NCT02292979",
        "NCT05404945",
        "NCT06132958",
        "NCT06112379",
        "NCT04884035",
        "NCT01920932",
        "NCT03726879",
        "NCT02605915",
        "NCT00028483",
        "NCT04203641",
        "NCT05600686",
        "NCT02505269",
        "NCT03467373",
        "NCT00051571",
        "NCT01992653",
        "NCT01060904",
        "NCT06340568",
        "NCT03646123",
        "NCT00051584",
        "NCT01777152",
        "NCT04790903",
        "NCT05673785",
        "NCT01966471",
        "NCT02979522",
        "NCT00031187",
        "NCT03274492",
        "NCT03991884",
        "NCT06486441",
        "NCT05113251",
        "NCT04569032",
        "NCT00086333",
        "NCT03677141",
        "NCT04685616"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Portugal",
        "Peru",
        "United States",
        "Colombia",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Iceland",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "Aprutumab ixadotin | BAY 1187982 BAY1187982 FGFR2-ADC | BAY 1187982",
      "names": [
        "BAY 1187982 BAY1187982 FGFR2-ADC",
        "BAY 1187982",
        "BAY1187982",
        "APRUTUMAB IXADOTIN",
        "Aprutumab ixadotin",
        "FGFR2-ADC",
        "BAY-1187982"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors (overexpressing FGFR2)"
      ],
      "targets": [
        "FGFR2 (fibroblast growth factor receptor 2, | bacteria-expressed kinase (BEK) | Craniofacial dysostosis 1 (CFD1)| Jackson-Weiss syndrome (JWS) | Keratinocyte growth factor receptor (KGFR); Crouzon syndrome (CEK3) | ECT1 K-SAM | TK14 | TK25 | CD332."
      ],
      "payload": [
        "Auristatin W derivative   on an average of 4 lysyl"
      ],
      "linker": [
        "A noncleavable linker  An average of 4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - lambda (a fully human anti-FGFR2 antibody BAY 1179470)"
      ],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "ttd": "D01MZT",
      "chembl": {
        "ChEMBL ID": "CHEMBL4650293",
        "Name": "APRUTUMAB IXADOTIN",
        "Synonyms": "APRUTUMAB IXADOTIN|BAY 1187982|BAY-1187982|BAY1187982",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "h2H12ec-SGD-1910 | Vadastuximab talirine | SGN-CD33A | h2H12ec-mc-val-ala-SGD-1882 | EC-mAb",
      "names": [
        "VADASTUXIMAB TALIRINE",
        "EC-mAb",
        "h2H12ec-SGD-1910",
        "SGN - CD33A",
        "Vadastuximab talirine",
        "SGNCD33A",
        "SGN-CD33A",
        "h2H12ec-mc-val-ala-SGD-1882"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "Acute Promyelocytic Leukemia",
        "Acute Myeloid Leukemia",
        "Acute myeloid leukemia (AML); Ulcerative Colitis (UC);  Myelodysplastic syndromes (MDS);  Gastric Adenocarcinoma",
        "Acute Myelogenous Leukemia"
      ],
      "targets": [
        "CD33 (Sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer SGD-1882"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimidocaproyl type linker.   An average of 2 site-specific drug attachment engineered cysteines (C239, C239')"
      ],
      "domain": [
        "Oncology, Hematoloy, Immunology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Seagen"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3990021",
        "Name": "VADASTUXIMAB TALIRINE",
        "Synonyms": "SGN - CD33A|SGN-CD33A|SGNCD33A|VADASTUXIMAB TALIRINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01902329",
        "NCT02326584"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "Cantuzumab mertansine | SB-408075 | huC242-DM1 | SB408075",
      "names": [
        "CANTUZUMAB MERTANSINE",
        "HUC242-DM1",
        "Cantuzumab mertansine",
        "SB-408075",
        "HUC-242-DM1",
        "huC242-DM1",
        "SB408075"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Pancreatic cancer, biliary cancer, colorectal cancers, gastric cancers, uterine cancers, non-small cell lung cancers (NSCLC), and bladder cancer"
      ],
      "targets": [
        "CanAg (a glycoform of MUC1 (sialylated carbohydrate tumour-associated (CA242, cancer antigen 242)"
      ],
      "payload": [
        "Maytansinoid antimicrotubule agent DM1 | N(sup 2')-deacetyl-N(sup 2')-(3-sulfanylpropanoyl)maytansine"
      ],
      "linker": [
        "A stabel thiopentanoate linker (or reducible SPP (N-succinimidyl 4-(2-pyridyldithio)) linker)   An average of 4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "GlaxoSmithKline",
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1742997",
        "Name": "CANTUZUMAB MERTANSINE",
        "Synonyms": "CANTUZUMAB MERTANSINE|HUC-242-DM1|HUC242-DM1|SB-408075",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17239",
        "Name": "Cantuzumab mertansine",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Maytansine, n2-deacetyl-n2-(3-mercapto-1-oxopropyl)-, conjugated humanized c242 monoclonal antibody ... N2'-deacetyl-n2'-(3-mercapto-1-oxopropyl)-maytansine -conjugated humanized c242 monoclonal antibody \u2026 Matched Categories: \u2026 Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anetumab Ravtansine | BAY 94-9343",
      "names": [
        "BAY-94-9343",
        "BAY-949343",
        "Anetumab ravtansine",
        "Anetumab Ravtansine",
        "ANETUMAB RAVTANSINE",
        "BAY94-9343",
        "BAY 94-9343"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Mesothelioma",
        "Neoplasms",
        "Medical Oncology",
        "Oncology",
        "Solid tumors / Malignant pleural mesothelioma",
        "Pancreatic Cancer"
      ],
      "targets": [
        "Mesothelin | MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte potentiating factor, MPF, CAK1)"
      ],
      "payload": [
        "Maytansinoid DM4 (microtubule inhibitor)"
      ],
      "linker": [
        "A reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate] on an average of 3 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - lambda; BAY 86-1903"
      ],
      "Max Phase": "2",
      "developers": [
        "Bayer"
      ],
      "ttd": "D0CN9D",
      "chembl": {
        "ChEMBL ID": "CHEMBL2109629",
        "Name": "ANETUMAB RAVTANSINE",
        "Synonyms": "ANETUMAB RAVTANSINE|BAY 94-9343|BAY-94-9343|BAY-949343|BAY94-9343",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB14809",
        "Name": "Anetumab ravtansine",
        "Description": "Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Anti-mesothelin antibody-drug conjugate BAY 94-9343 \u2026 Matched Description: \u2026 Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab \u2026 Matched Categories: \u2026 Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT03023722",
        "NCT02639091",
        "NCT03102320",
        "NCT02610140",
        "NCT02696642",
        "NCT02751918",
        "NCT01439152",
        "NCT02485119",
        "NCT02824042"
      ],
      "locations": [
        "Moldova, Republic of",
        "Canada",
        "United Kingdom",
        "Belgium",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Turkey",
        "Spain",
        "Singapore",
        "Switzerland",
        "United States",
        "France",
        "Netherlands",
        "Italy",
        "Poland",
        "Finland"
      ]
    },
    {
      "heading": "SAR3419 | SAR 3419 | Coltuximab Ravtansine",
      "names": [
        "Coltuximab Ravtansine",
        "Coltuximab ravtansine",
        "COLTUXIMAB RAVTANSINE",
        "SAR 3419",
        "SAR-3419",
        "SAR3419"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma (DLBCL)/Acute lymphoblastic leukemia (ALL); Non-Hodgkin Lymphoma (NHL)",
        "Diffuse Large B-cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "CD19 | B lymphocyte surface antigen B4, Leu-12"
      ],
      "payload": [
        "Maytansine DM4 (microtubule inhibitor)"
      ],
      "linker": [
        "A reducible SPDB/(N-succinimidyl-4-(2-pyridyldithio)butyrate.  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109286",
        "Name": "COLTUXIMAB RAVTANSINE",
        "Synonyms": "COLTUXIMAB RAVTANSINE|SAR-3419|SAR3419",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB06342",
        "Name": "Coltuximab ravtansine",
        "Description": "Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Anti-CD19 humanized monoclonal antibody conjugated to DM4 \u2026 Matched Description: \u2026 Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic \u2026 Matched Categories: \u2026 Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "trials": [
        "NCT01470456",
        "NCT01472887"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Israel",
        "Austria",
        "Turkey",
        "Czechia",
        "Spain",
        "Norway",
        "United States",
        "France",
        "Italy",
        "Poland"
      ]
    },
    {
      "heading": "ABBV-838 | Azintuxizumab Vedotin | ABBV-838 ABBV838",
      "names": [
        "AZINTUXIZUMAB VEDOTIN",
        "ABBV-838",
        "Azintuxizumab Vedotin",
        "ABBV-838 ABBV838"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma (MM) |  Plasma cell myeloma"
      ],
      "targets": [
        "SLAMF7 (SLAM family member 7, CD2 subset 1, CS1, CD2-like receptor-activating cytotoxic cells, CRACC, 19A24, CD319)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.   On an average of 3 cysteinyl"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4297859",
        "Name": "AZINTUXIZUMAB VEDOTIN",
        "Synonyms": "ABBV-838|AZINTUXIZUMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Epitumomab cituxetan | Anti-MUC1 Therapeutic",
      "names": [
        "Epitumomab cituxetan",
        "Anti-MUC1 Therapeutic",
        "HMFG 1",
        "EPITUMOMAB CITUXETAN"
      ],
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Epithelial ovarian"
      ],
      "targets": [
        "MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "HMFG 1"
      ],
      "Max Phase": "3",
      "chembl": {
        "ChEMBL ID": "CHEMBL2108592",
        "Name": "EPITUMOMAB CITUXETAN",
        "Synonyms": "EPITUMOMAB CITUXETAN|Epitumomab cituxetan|HMFG 1",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Ibritumomab tiuxetan | In-111 Zevalin Y-90 Zevalin",
      "names": [
        "Ibritumomab tiuxetan",
        "IBRITUMOMAB TIUXETAN",
        "In-111 Zevalin Y-90 Zevalin",
        "ZEVALIN",
        "IDEC-129",
        "Zevalin Kit-Indium-111",
        "IDEC-Y2B8",
        "IDEC-Y2B8 IDEC-129",
        "IDEC-IN2B8"
      ],
      "phases": [
        "Phase 4"
      ],
      "conditions": [
        "Non-Hodgkin's lymphoma (NHL)"
      ],
      "targets": [
        "MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)"
      ],
      "payload": [
        "Conjugated with chelator tiuxetan  radiolabelled with Yttrium-90, Y-90 (Therapeutic) and Indium-111, In-111 (Diagnostic)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "4",
      "developers": [
        "Biogen",
        "Schering"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1201606",
        "Name": "IBRITUMOMAB TIUXETAN",
        "Synonyms": "IBRITUMOMAB TIUXETAN|IDEC-129|IDEC-IN2B8|IDEC-Y2B8|IDEC-Y2B8 IDEC-129|ZEVALIN|Zevalin Kit-Indium-111",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "BESPONSA\u00ae | Inotuzumab ozogamicin | CMC-544 CMC544 | CMC-544",
      "names": [
        "PF-05208773",
        "WAY-207294 CMC-544",
        "CMC-544 CMC544",
        "INOTUZUMAB OZOGAMICIN",
        "BESPONSA\u00ae",
        "Inotuzumab ozogamicin",
        "CMC-544",
        "Besponsa",
        "WAY-207294"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "ACUTE LYMPHOBLASTIC LEUKEMIA",
        "Aggressive non-Hodgkin\u2019s lymphoma; Acute Lymphoblastic Leukemia (ALL); B cell acute lymphoblastic leukemia (B cell ALL)",
        "Refractory B Acute Lymphoblastic Leukemia",
        "ALL",
        "Leukemia, Acute Lymphoblastic",
        "Diffuse Large B Cell Lymphoma",
        "Leukemia",
        "Lymphoma, B-Cell",
        "Recurrent B Lymphoblastic Lymphoma",
        "Precursor b-Cell Lymphoblastic Leukemia-Lymphoma",
        "Acute Lymphocytic Leukemia",
        "B-Cell Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "B-cell Acute Lymphoblastic Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Lymphoma"
      ],
      "targets": [
        "CD22  (Sialic Acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)"
      ],
      "payload": [
        "N-acetyl- \u03b3\u00a0Calicheamicin"
      ],
      "linker": [
        "Hydrazone (4-(4-acetylphenoxy) butanoic acid)"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "IgG4 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Pfizer",
        "WYETH"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108611",
        "Name": "INOTUZUMAB OZOGAMICIN",
        "Synonyms": "Besponsa|CMC-544|INOTUZUMAB OZOGAMICIN|Inotuzumab ozogamicin|PF-05208773|WAY-207294|WAY-207294 CMC-544",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 1
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB05889",
        "Name": "Inotuzumab ozogamicin",
        "Description": "Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Description: \u2026 Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting ... [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly ... monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... CD22-directed Antibody Interactions ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "fda_label": {
        "id": 222901,
        "description": "[\"11. DESCRIPTION Inotuzumab ozogamicin is a CD22-directed antibody and cytotoxic-drug conjugate (ADC) consisting of 3 components: 1) the recombinant humanized immunoglobulin class G subtype 4 (IgG4) kappa antibody inotuzumab, specific for human CD22, 2) N-acetyl-gamma-calicheamicin that causes double-stranded DNA breaks, and 3) an acid-cleavable linker composed of the condensation product of 4-(4'-acetylphenoxy)-butanoic acid (AcBut) and 3-methyl-3-mercaptobutane hydrazide (known as dimethylhydrazide) that covalently attaches N-acetyl-gamma-calicheamicin to inotuzumab. Inotuzumab ozogamicin has an approximate molecular weight of 160 kDa. The average number of calicheamicin derivative molecules conjugated to each inotuzumab molecule is approximately 6 with a distribution from 2\u20138. Inotuzumab ozogamicin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the semisynthetic calicheamicin derivative is produced by microbial fermentation followed by synthetic modification. BESPONSA (inotuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous administration. Each single-dose vial delivers 0.9 mg inotuzumab ozogamicin. Inactive ingredients are polysorbate 80 (0.36 mg), sodium chloride (2.16 mg), sucrose (180 mg), and tromethamine (8.64 mg). After reconstitution with 4 mL of Sterile Water for Injection, USP, the final concentration is 0.25 mg/mL of inotuzumab ozogamicin with a deliverable volume of 3.6 mL (0.9 mg) and a pH of approximately 8.0. Chemical Structure\"]",
        "generic_name": "[\"INOTUZUMAB OZOGAMICIN\"]",
        "brand_name": "[\"Besponsa\"]",
        "substance_name": "[\"INOTUZUMAB OZOGAMICIN\"]",
        "manufacturer_name": "[\"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.\"]"
      },
      "trials": [
        "NCT01679119",
        "NCT03962465",
        "NCT05687032",
        "NCT00717925",
        "NCT01363297",
        "NCT00299494",
        "NCT00724971",
        "NCT01564784",
        "NCT00868608",
        "NCT04307576",
        "NCT00867087",
        "NCT03677596",
        "NCT05748171",
        "NCT05016947",
        "NCT01055496",
        "NCT00073749",
        "NCT01134575",
        "NCT03913559",
        "NCT03991884"
      ],
      "locations": [
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Portugal",
        "United States",
        "Estonia",
        "Denmark",
        "India",
        "Canada",
        "Singapore",
        "France",
        "Iceland",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Ireland",
        "Japan",
        "Spain",
        "Germany",
        "Argentina",
        "Israel",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "Laprituximab emtansine | IMGN-289 | IMGN-289 IMGN289 J2898A-SMCC-DM1 | IMGN289",
      "names": [
        "Laprituximab emtansine",
        "IMGN-289",
        "IMGN-289 IMGN289 J2898A-SMCC-DM1",
        "IMGN289"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Cancers, head and neck, Cancers, non-small cell lung (NSCLC), Solid tumors (EGFR positive)",
        "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
        "Acute Lymphoblastic Leukemia",
        "Richter Syndrome",
        "Chronic Lymphocytic Leukemia",
        "High-grade B-cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "DLBCL",
        "Lymphoma, Non Hodgkin",
        "Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia",
        "Non-Hodgkin's Lymphoma",
        "B-cell Non Hodgkin Lymphoma",
        "Large B-Cell Lymphoma",
        "Non-Hodgkins Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "Lymphoma, T-Cell",
        "B-Cell Lymphoma",
        "Diffuse Large B-cell Lymphoma"
      ],
      "targets": [
        "EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB"
      ],
      "payload": [
        "Maytansinoid DM1"
      ],
      "linker": [
        "A noncleavable succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker.  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "IMMUNOGEN"
      ],
      "trials": [
        "NCT01691898",
        "NCT04914741",
        "NCT01679119",
        "NCT05171647",
        "NCT02600897",
        "NCT04182204",
        "NCT04594798",
        "NCT06047080",
        "NCT02734771",
        "NCT00299494",
        "NCT02611323",
        "NCT04404283",
        "NCT01421667",
        "NCT04884035",
        "NCT04679012",
        "NCT00867087",
        "NCT05600686",
        "NCT01290549",
        "NCT05800366",
        "NCT01209130",
        "NCT05798156",
        "NCT01992653",
        "NCT01796171",
        "NCT02677155",
        "NCT01134575",
        "NCT01470456",
        "NCT04790903",
        "NCT05498220",
        "NCT03671018",
        "NCT03274492",
        "NCT05283720",
        "NCT02729896",
        "NCT02257567",
        "NCT05991388"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "India",
        "Canada",
        "Singapore",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Hungary",
        "Australia",
        "New Zealand",
        "Japan",
        "Germany",
        "Croatia",
        "Spain",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "Lupartumab amadotin | BAY 1129980 | BAY 1129980 BAY-1129980 BAY1129980  Other synonyms  Anti-C4.4a - s - Bayer Anti-LY6-PLAUR domain containing 3 - s - Bayer Anti-LYPD3 - s - Bayer | LYPD3 protein-directed - s - Bayer",
      "names": [
        "Lupartumab amadotin",
        "BAY 1129980",
        "BAY 1129980 BAY-1129980 BAY1129980  Other synonyms  Anti-C4.4a - s - Bayer Anti-LY6-PLAUR domain containing 3 - s - Bayer Anti-LYPD3 - s - Bayer",
        "LYPD3 protein-directed - s - Bayer"
      ],
      "phases": [
        "Phase 1",
        "Phase i  i"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "targets": [
        "LYPD3 (LY6/PLAUR domain containing 3, C4.4A )"
      ],
      "payload": [
        "Auristatin W derivative"
      ],
      "linker": [
        "A partially reduced S-cystine sulfurhydryl groups.  On an average of KRN-23"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - lambda"
      ],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1 | lutetium | Lilotomab satetraxetan | 177lu",
      "names": [
        "LILOTOMAB SATETRAXETAN",
        "Lutetium",
        "lutetium",
        "lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1",
        "Lilotomab satetraxetan",
        "177Lu-PSMA-617",
        "LU177",
        "177Lu",
        "177lu",
        "Vipivotide Tetraxetan",
        "177Lu-DOTA-HH1",
        "177Lu-tetraxetan-HH1",
        "LUTETIUM",
        "Pluvicto\u00ae",
        "Vipivotide Tetraxetan  177Lu-PSMA-617"
      ],
      "phases": [
        "Approved",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive  metastatic castration-resistant prostate cancer (mCRPC) who have been  treated with androgen receptor (AR) pathway inhibition and taxane-based  chemotherapy.",
        "Non-Hodgkin's lymphoma (NHL)",
        "Metastatic Prostate Cancer"
      ],
      "targets": [
        "CD37 (tetraspanin-26, TSPAN26)",
        "Prostate-specific membrane antigen (PSMA), present in the majority of patients with mCRPC"
      ],
      "payload": [
        "A beta-emitting radioisotope (lutetium-177 or 177Lu), branded as EndolucinBeta\u00ae",
        "conjugated with chelator satetraxetan (DOTA derivative; p-SCN-Bn-DOTA)  radiolabelled with Lutetium-177, Lu-177"
      ],
      "linker": [],
      "domain": [
        "Oncology Hematology",
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa",
        "PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand."
      ],
      "Max Phase": "Approved",
      "developers": [
        "Nordic Nanovector"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4802261",
        "Name": "LUTETIUM (LU177) LILOTOMAB SATETRAXETAN",
        "Synonyms": "177Lu-DOTA-HH1|177Lu-tetraxetan-HH1|LUTETIUM (LU177) LILOTOMAB SATETRAXETAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "trials": [
        "NCT04786847"
      ],
      "locations": [
        "Australia"
      ]
    },
    {
      "heading": "Debio 1562 | naratuximab emtansine | K7153A-SMCC-DM1 | K7153A | Naratuximab emtansine | IMGN529",
      "names": [
        "Debio 1562",
        "IMGN 529",
        "NARATUXIMAB EMTANSINE",
        "naratuximab emtansine",
        "K7153A-SMCC-DM1",
        "K7153A",
        "DEBIO-1562",
        "IMGN-529",
        "Naratuximab emtansine",
        "IMGN529"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Chronic lymphocytic leukemia; non-Hodgkin\u2019s lymphoma; Lymphoma, diffuse large B cell (DLBCL)"
      ],
      "targets": [
        "CD37 (tetraspanin-26, TSPAN26)"
      ],
      "payload": [
        "Maytansine DM1 (microtubule inhibitor"
      ],
      "linker": [
        "a succinimidyl-4-(N-maleimidomethyl) cyclohexane-  1-carboxylate (SMCC) linker forming a nonreducible thioether bond.  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "humanized IgG1 antibody K7153A"
      ],
      "Max Phase": "2",
      "developers": [
        "Debiopharm",
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109268",
        "Name": "NARATUXIMAB EMTANSINE",
        "Synonyms": "DEBIO-1562|IMGN 529|IMGN-529|IMGN529|K7153A-SMCC-DM1|NARATUXIMAB EMTANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "DCDT2980S | DCDT-2989S | RO5541072-000 | Pinatuzumab vedotin | RG-7593 | ACD22-VCMMAE | FCU2803",
      "names": [
        "FCU-2703",
        "DCDT2980S",
        "DCDT-2989S",
        "RO-5541072-000",
        "ACD-22VCMMAE",
        "DCDT-2980S",
        "RO-5541072000",
        "RO5541072-000",
        "Pinatuzumab vedotin",
        "PINATUZUMAB VEDOTIN",
        "FCU2703",
        "ACD-22-VCMMAE",
        "RG-7593",
        "ACD22-VCMMAE",
        "FCU2803"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia",
        "Follicular Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL); B cell lymphoma"
      ],
      "targets": [
        "CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.   An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3301585",
        "Name": "PINATUZUMAB VEDOTIN",
        "Synonyms": "ACD-22-VCMMAE|ACD-22VCMMAE|ACD22-VCMMAE|DCDT-2980S|DCDT2980S|FCU-2703|FCU2703|PINATUZUMAB VEDOTIN|RG-7593|RO-5541072-000|RO-5541072000|RO5541072-000",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01209130",
        "NCT01691898"
      ],
      "locations": [
        "Canada",
        "Germany",
        "United States",
        "France",
        "Netherlands",
        "Italy"
      ]
    },
    {
      "heading": "RO5541077-000 | RG-7596 | DCDS4501A | ACD79B-VCMMAE | Polatuzumab vedotin | Polivy\u2122 | FCU2711 | DCDS-4501A",
      "names": [
        "Polivy",
        "RG7596",
        "Polatuzumab vedotin",
        "DCDS-4501A",
        "POLATUZUMAB VEDOTIN",
        "POLIVY",
        "FCU-2711",
        "RO-5541077-000",
        "ACD79B-VCMMAE",
        "DCDS4501A",
        "RO-5541077000",
        "RO5541077-000",
        "RG-7596",
        "ANTI-CD79B ADC",
        "POLATUZUMAB VEDOTIN PIIQ",
        "ACD-79B-VCMMAE",
        "ACD-79BVCMMAE",
        "Polivy\u2122",
        "FCU2711"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Follicular",
        "Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
        "Richter Syndrome",
        "Relapsed B-Cell Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "High-grade B-cell Lymphoma",
        "Grade 3a Follicular Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Relapsed Non Hodgkin Lymphoma",
        "DLBCL",
        "Grade 3b Follicular Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Lymphoma",
        "B-Cell Non-Hodgkin Lymphoma",
        "Marginal Zone Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Grade 1 Follicular Lymphoma",
        "Non-Hodgkin's Lymphoma",
        "Richter's Transformation",
        "Large B-Cell Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Aggressive Non-Hodgkin Lymphoma",
        "Large B-cell Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "Non-Hodgkins Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Diffuse Large B-Cell Lymphoma (DLBCL) / B-cell malignancies / Chronic lymphocytic leukemia (CLL) / Non-Hodgkin's lymphoma (NHL)",
        "Transformed Follic Lymph to Diff Large B-Cell Lymphoma",
        "Follicular Lymphoma",
        "Relapsed Diffuse Large B-cell Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "B-Cell Lymphoma",
        "Diffuse Large B-cell Lymphoma"
      ],
      "targets": [
        "CD79b | immunoglobulin-associated CD79 beta"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.   An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3301582",
        "Name": "POLATUZUMAB VEDOTIN",
        "Synonyms": "ACD-79B-VCMMAE|ACD-79BVCMMAE|ACD79B-VCMMAE|ANTI-CD79B ADC|DCDS-4501A|DCDS4501A|FCU-2711|FCU2711|POLATUZUMAB VEDOTIN|POLATUZUMAB VEDOTIN PIIQ|Polivy|RG-7596|RG7596|RO-5541077-000|RO-5541077000|RO5541077-000",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 1
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB12240",
        "Name": "Polatuzumab vedotin",
        "Description": "Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Description: \u2026 Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E ... [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody ... [L6658]\nPolatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... CD79b-directed Antibody\u2013Drug Conjugates ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "fda_label": {
        "id": 222041,
        "description": "[\"11 DESCRIPTION Polatuzumab vedotin-piiq is a CD79b-directed antibody and microtubule inhibitor conjugate. It consists of three components: 1) the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; 2) the small molecule anti-mitotic agent MMAE; and 3) a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to the polatuzumab antibody. Polatuzumab vedotin-piiq has an approximate molecular weight of 150 kDa. An average of 3.5 molecules of MMAE are attached to each antibody molecule. Polatuzumab vedotin-piiq is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. POLIVY (polatuzumab vedotin-piiq) for injection is supplied as a sterile, white to grayish-white, preservative-free, lyophilized powder, which has a cake-like appearance, for intravenous infusion after reconstitution and dilution. Each single-dose 30 mg POLIVY vial delivers 30 mg of polatuzumab vedotin-piiq, polysorbate-20 (1.8 mg), sodium hydroxide (0.82 mg), succinic acid (1.77 mg), and sucrose (62 mg). After reconstitution with 1.8 mL of Sterile Water for Injection, USP, the final concentration is 20 mg/mL with a pH of approximately 5.3. Each single-dose 140 mg POLIVY vial delivers 140 mg of polatuzumab vedotin-piiq, polysorbate-20 (8.4 mg), sodium hydroxide (3.80 mg), succinic acid (8.27 mg), and sucrose (288 mg). After reconstitution with 7.2 mL of Sterile Water for Injection, USP, the final concentration is 20 mg/mL with a pH of approximately 5.3. The POLIVY vial stoppers are not made with natural rubber latex. Chemical Structure\"]",
        "generic_name": "[\"POLATUZUMAB VEDOTIN\"]",
        "brand_name": "[\"POLIVY\"]",
        "substance_name": "[\"POLATUZUMAB VEDOTIN\"]",
        "manufacturer_name": "[\"Genentech, Inc.\"]"
      },
      "trials": [
        "NCT01691898",
        "NCT04914741",
        "NCT04844866",
        "NCT05171647",
        "NCT02600897",
        "NCT04182204",
        "NCT04594798",
        "NCT06047080",
        "NCT03533283",
        "NCT02611323",
        "NCT04833114",
        "NCT06043674",
        "NCT04970901",
        "NCT04884035",
        "NCT04679012",
        "NCT05260957",
        "NCT03677154",
        "NCT05633615",
        "NCT01290549",
        "NCT05800366",
        "NCT06071871",
        "NCT05798156",
        "NCT01992653",
        "NCT05169658",
        "NCT04790903",
        "NCT05498220",
        "NCT03671018",
        "NCT03274492",
        "NCT05283720",
        "NCT02729896",
        "NCT02257567",
        "NCT05410418",
        "NCT03677141",
        "NCT03467373"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "India",
        "Canada",
        "Singapore",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Hungary",
        "Australia",
        "New Zealand",
        "Japan",
        "Germany",
        "Croatia",
        "Spain",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "BL-B029A1 BL B029A1 | BL-B029A1",
      "names": [
        "BL-B029A1 BL B029A1",
        "BL-B029A1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Epithelial Tumor"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Systimmune"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BL M005A2 BL-M005A2 | BL-M005A2",
      "names": [
        "BL M005A2 BL-M005A2",
        "BL-M005A2"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "- Breast cancer;  - Non-small cell lung cancer  (NSCLC)"
      ],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Systimmune"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BL M002A2 BL-M002A2 | BL-M002A2",
      "names": [
        "BL M002A2 BL-M002A2",
        "BL-M002A2"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "- Glioma - Lung cancer"
      ],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Systimmune"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AVID100 | AVID 100 anti-EGFR ADC",
      "names": [
        "AVID100",
        "AVID 100 anti-EGFR ADC"
      ],
      "phases": [
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid tumors; Advanced epithelial  carcinomas including tumors resistant to currently approved anti-EGFR therapeutics.  - Solid Tumor,  - Adult Triple Negative Breast Cancer  - Head and Neck Squamous Cell Carcinoma  - Non Small Cell Lung Cancer"
      ],
      "targets": [
        "EGFR"
      ],
      "payload": [
        "Microtubule inhibitor Maytansinoid mertansine (DM1)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-EGFR antibody (MAB100)"
      ],
      "Max Phase": "2",
      "developers": [
        "Formation Biologics (Forbius)"
      ],
      "trials": [
        "NCT06210815"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "ALT-P7 | ALT-P7 ALT-P7 | HM2-MMAE",
      "names": [
        "ALT-P7",
        "ALT-P7 ALT-P7",
        "HM2-MMAE"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive breast cancer; Advanced or refractory breast cancer which is unresponsive to current standard therapy"
      ],
      "targets": [
        "HER2; Human epidermal growth factor receptor 2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab (biobetter)"
      ],
      "Max Phase": "1",
      "developers": [
        "3SBIO",
        "Alteogen"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17220",
        "Name": "ALT-P7",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 ADC ALT-P7 ... HM2/MMAE ADC ALT-P7 \u2026",
        "Queries": "['\"adc\"']",
        "Query Indices": "[2]",
        "Score": 5
      },
      "trials": [
        "NCT03281824"
      ],
      "locations": [
        "Korea, Republic of"
      ]
    },
    {
      "heading": "Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502 | Kadcyla\u00ae | T-DM1 | Trastuzumab Emtansine",
      "names": [
        "Kadcyla\u00ae",
        "Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502",
        "TRASTUZUMAB-MCC-DM1 T-DM1",
        "Trastuzumab Emtansine",
        "RG-3502",
        "Trastuzumab-DM1",
        "TRASTUZUMAB EMTANSINE",
        "trastuzumab emtansine",
        "Trastuzumab emtansine",
        "T-DM1",
        "Kadcyla",
        "PRO-132365",
        "KADCYLA",
        "ADO-TRASTUZUMAB EMTANSINE",
        "trastuzumab-emtansine"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Inflammatory Breast Cancer",
        "HER2 Mutations Breast Neoplasms",
        "HER2 Positive Breast Carcinoma",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Neoplasm Metastasis",
        "Solid Tumor Cancers",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "HER2-positive Breast Cancer",
        "Ovarian Cancer",
        "Urinary Tract Cancers",
        "Gastric Cancer",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Gastroesophageal Junction Adenocarcinoma",
        "Endometrial Cancer",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Breast Cancer",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Tumors",
        "Invasive Breast Carcinoma",
        "Cancer",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "HER2 Amplification",
        "Solid Tumors",
        "Residual Invasive Breast Cancer",
        "Breast Neoplasms",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "HER2-positive Early Breast Cancer",
        "Bladder Cancer",
        "Breast Cancer Metastatic",
        "HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Triple Negative Breast Neoplasms",
        "Neoplasia",
        "Advanced Unresectable or Metastatic Solid Malignancy",
        "Neoplasms",
        "Recurrent Breast Cancer",
        "HER2-Positive Primary Breast Cancer",
        "HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Left Ventricular Function Systolic Dysfunction",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Locally Advanced Breast Cancer",
        "Lung Cancer",
        "Breast Cancer Female",
        "HER2 Gene Mutation",
        "Brain Metastases",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Locally Advanced or Early Breast Cancer",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "HER2 Positive Breast Neoplasms",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Cholangiocellular Carcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Hormone Receptor Positive Breast Neoplasms",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Esophageal Adenocarcinoma",
        "Stage IIIB Breast Cancer",
        "Pancreas Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Solid Tumor",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Stage IIIC Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IV Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Non-small Cell Lung Cancer",
        "Advanced Solid Tumors",
        "HER-2 Positive Breast Cancer",
        "Synchronous Bilateral Breast Carcinoma",
        "HER2 Mutant Non-small Cell Lung Cancer",
        "Multifocal Breast Carcinoma",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Her 2 Positive Breast Cancer",
        "Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "HER2+ metastatic breast cancer (MBC)",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8"
      ],
      "targets": [
        "HER2/neu proto-oncogene (also called c-erbB-2)  ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Maytansine DM1, a microtubule inhibitor.   N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylmaytansine  on an average of 3-4 lysyl"
      ],
      "linker": [
        "Noncleavable succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "ttd": [
        "D0P4TH",
        "D0UG0K"
      ],
      "chembl": [
        {
          "ChEMBL ID": "CHEMBL1743082",
          "Name": "TRASTUZUMAB EMTANSINE",
          "Synonyms": "Kadcyla|PRO-132365|RG-3502|TRASTUZUMAB EMTANSINE|TRASTUZUMAB-MCC-DM1 T-DM1",
          "Type": "Antibody drug conjugate",
          "Max Phase": 4.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL2109399",
          "Name": "T-DM1",
          "Synonyms": "T-DM1",
          "Type": "Antibody drug conjugate",
          "Max Phase": 3.0,
          "Orphan": 0
        }
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB05773",
        "Name": "Trastuzumab emtansine",
        "Description": "Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis....",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Description: \u2026 conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent ... Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug ... First that trastuzumab emtansine and trastuzumab cannot be interchanged. \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "fda_label": {
        "id": 40508,
        "description": "[\"11 DESCRIPTION KADCYLA (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex. The antibody trastuzumab, is a well characterized recombinant monoclonal antibody product produced by mammalian (Chinese hamster ovary) cells, and the small molecule components (DM1 and MCC) are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody. Ado-trastuzumab emtansine has the following chemical structure: Note: The bracketed structure is DM1 plus MCC which represents the emtansine component. The n is, on average, 3.5 DM1 molecules per trastuzumab (Mab) molecule. KADCYLA (ado-trastuzumab emtansine) is a sterile, white to off-white preservative free lyophilized powder in single-dose vials. Each vial contains 100 mg or 160 mg ado-trastuzumab emtansine. Following reconstitution, each single-dose vial contains ado-trastuzumab emtansine (20 mg/mL), polysorbate 20 [0.02% (w/v)], sodium succinate (10 mM), and sucrose [6% (w/v)] with a pH of 5.0. The resulting solution containing 20 mg/mL ado-trastuzumab emtansine is administered by intravenous infusion following dilution. Chemical Structure\"]",
        "generic_name": "[\"ADO-TRASTUZUMAB EMTANSINE\"]",
        "brand_name": "[\"KADCYLA\"]",
        "substance_name": "[\"TRASTUZUMAB EMTANSINE\"]",
        "manufacturer_name": "[\"Genentech, Inc.\"]"
      },
      "trials": [
        "NCT04893109",
        "NCT06100874",
        "NCT04733118",
        "NCT06313086",
        "NCT03153163",
        "NCT02131064",
        "NCT00951665",
        "NCT04873362",
        "NCT06126640",
        "NCT01702571",
        "NCT05980481",
        "NCT01196052",
        "NCT02038010",
        "NCT02675829",
        "NCT00928330",
        "NCT03084939",
        "NCT05415215",
        "NCT00679211",
        "NCT04457596",
        "NCT01772472",
        "NCT04924699",
        "NCT02073487",
        "NCT04589845",
        "NCT04740918",
        "NCT04486352",
        "NCT01513083",
        "NCT03726879",
        "NCT00943670",
        "NCT00781612",
        "NCT01120184",
        "NCT05650879",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT04622319",
        "NCT02658734",
        "NCT05323955",
        "NCT05593094",
        "NCT03523585",
        "NCT00679341",
        "NCT00829166",
        "NCT01976169",
        "NCT02314481",
        "NCT05755048",
        "NCT03529110",
        "NCT04931342",
        "NCT02289833",
        "NCT05673928",
        "NCT01419197",
        "NCT03032107",
        "NCT02924883",
        "NCT01966471",
        "NCT06324357",
        "NCT01565200",
        "NCT04379596",
        "NCT01494662",
        "NCT04632992",
        "NCT04341181",
        "NCT00934856",
        "NCT00932373",
        "NCT05113251",
        "NCT02999672",
        "NCT01969643",
        "NCT00509769",
        "NCT00875979"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "TAK-522 | XMT1522 TAK-522 | XMT-1522",
      "names": [
        "TAK-522",
        "XMT1522 TAK-522",
        "XMT-1522"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Gastric Cancer",
        "Advanced Nonsmall Cell Lung Cancer",
        "Advanced Breast Cancer"
      ],
      "targets": [
        "Epidermal growth factor receptor 2  (HER2)"
      ],
      "payload": [
        "Auristatin F-hydroxypropylamide, (AF-HPA) | (MMAF-HPA)  An average drug-to-antibody ration (DAR) of 12"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An engineered novel mAb (HT-19) optimized for ADC; binds to a unique  epitope distinct from trastuzumab or  pertuzumab."
      ],
      "Max Phase": "1",
      "developers": [
        "Mersana"
      ],
      "trials": [
        "NCT02952729"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "ARX788 | ARX788 HER2 ADC",
      "names": [
        "Anvatabart opadotin",
        "ARX-788",
        "ARX788",
        "ARX788 ADC",
        "ARX788 HER2 ADC",
        "ANVATABART OPADOTIN",
        "ARX 788",
        "ANVATABART OPAFIDOTIN"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors (HER2 over-expressing tumors including breast, gastric, colon, pancreatic and ovarian cancers)",
        "Hormone Receptor Positive Breast Carcinoma",
        "HER2 Positive Metastatic Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Gastric Neoplasm",
        "HER2 Low Breast Carcinoma",
        "Breast Neoplasms",
        "Triple Negative Breast Cancer",
        "Solid Tumors"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)  Site-specific conjugation   DAR is 1.9"
      ],
      "linker": [
        "A non-natural amino acid linker para-acetyl-phenylalanine (pAcF)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Engineered IgG1  Modified Trastuzumab with a p-acetylphenylalanine (pAcPhe) residue"
      ],
      "Max Phase": "2",
      "developers": [
        "Ambrx"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4297892",
        "Name": "ANVATABART OPADOTIN",
        "Synonyms": "ANVATABART OPADOTIN|ANVATABART OPAFIDOTIN|ARX 788|ARX-788|ARX788|ARX788 ADC",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18290",
        "Name": "Anvatabart opadotin",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Arx-788 (anti-her2 mab paf- mmaf toxin oxime conjugate) ... tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "trials": [
        "NCT04983121",
        "NCT04829604",
        "NCT06224673",
        "NCT03255070"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "China",
        "United States",
        "France"
      ]
    },
    {
      "heading": "Nano-doxorubicin | MM-302",
      "names": [
        "Nano-doxorubicin",
        "MM-302"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Lymphoma, T-cell",
        "Locally advanced/metastatic HER2-positive breast cancer patients who have received prior treatment with trastuzumab in any setting and who have either progressed or are intolerant to each of pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting.",
        "Stage IV Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Breast Neoplasms",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "HER2-positive Early Breast Cancer",
        "T-Cell Lymphoma",
        "DLBCL",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Locally Advanced or Early Breast Cancer",
        "Refractory B Acute Lymphoblastic Leukemia",
        "HER2-Positive Metastatic Breast Cancer",
        "Refractory B Lymphoblastic Lymphoma",
        "Large B-Cell Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage II Childhood Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Hodgkin Disease",
        "Recurrent B Lymphoblastic Lymphoma",
        "Breast Cancer",
        "Stage III Childhood Hodgkin Lymphoma",
        "B-Cell Lymphoma"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Liposomal doxorubicin (Liposome-encapsulated doxorubicin)"
      ],
      "linker": [
        "PEG-DSPE"
      ],
      "domain": [],
      "antibody": [
        "scFv anti-HER2"
      ],
      "Max Phase": "3",
      "developers": [
        "Merrimack"
      ],
      "trials": [
        "NCT04914741",
        "NCT03755804",
        "NCT06377566",
        "NCT01712490",
        "NCT01309789",
        "NCT06047080",
        "NCT04594798",
        "NCT02734771",
        "NCT01534078",
        "NCT02292979",
        "NCT05404945",
        "NCT06132958",
        "NCT06112379",
        "NCT04884035",
        "NCT01920932",
        "NCT03726879",
        "NCT02605915",
        "NCT04203641",
        "NCT05600686",
        "NCT02505269",
        "NCT03467373",
        "NCT01992653",
        "NCT01060904",
        "NCT06340568",
        "NCT03646123",
        "NCT01777152",
        "NCT04790903",
        "NCT05673785",
        "NCT01966471",
        "NCT02979522",
        "NCT03274492",
        "NCT03991884",
        "NCT06486441",
        "NCT05113251",
        "NCT04569032",
        "NCT03677141",
        "NCT04685616"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "Bstrongximab-ADC",
      "names": [
        "Bstrongximab-ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "CureMeta"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "PF-06804103 PF 06804103 Anti-NG-HER2 ADC | PF-06804103 | Anti-NG-HER2 ADC",
      "names": [
        "PF-06804103 PF 06804103 Anti-NG-HER2 ADC",
        "PF-06804103",
        "Anti-NG-HER2 ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "(Metastatic) Solid tumors; Breast cancer; Gastric cancers.",
        "Breast Neoplasms"
      ],
      "targets": [
        "HER2 (human epidermal growth factor receptor 2)"
      ],
      "payload": [
        "Anti-Trop2 Aur0101"
      ],
      "linker": [
        "Cleavable valine-citrulline- linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Pfizer"
      ],
      "trials": [
        "NCT03284723"
      ],
      "locations": [
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Italy"
      ]
    },
    {
      "heading": "IPH43",
      "names": [
        "IPH43"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "MICA/B, a highly polymorphic ligand of the NK cell activating receptor NKG2D"
      ],
      "payload": [
        "Pyrrolobenzodiazepine dimers (PBDs)"
      ],
      "linker": [],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "AstraZeneca",
        "Innate"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anetumab corixetan",
      "names": [
        "Anetumab corixetan"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte-potentiating factor, MPF, CAK1)"
      ],
      "payload": [
        "Chelator corixetan, with anaverage of 0.5 chelator per antibody"
      ],
      "linker": [],
      "domain": [],
      "antibody": [
        "Immunoglobulin G1-lambda2"
      ],
      "Max Phase": null,
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV-3373",
      "names": [
        "ABBV-3373"
      ],
      "phases": [],
      "conditions": [
        "Rheumatoid arthritis (RA)"
      ],
      "targets": [
        "TNF"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Anti-TNF monoclonal antibodies / Antirheumatics"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BDC-1001",
      "names": [
        "BDC-1001",
        "TRASTUZUMAB IMBOTOLIMOD",
        "BDC1001",
        "BDC 1001"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "HER2-Expressing Solid Tumors, including metastatic breast and gastric cancers.",
        "HER2-positive Endometrial Cancer",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "HER2-positive Gastroesophageal Cancer",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "HER2-positive Breast Cancer",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Her 2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Colorectal Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-positive Solid Tumors",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "HER2 ((human epidermal growth factor receptor 2)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Bolt"
      ],
      "ttd": "D1XI9E",
      "chembl": {
        "ChEMBL ID": "CHEMBL5095315",
        "Name": "TRASTUZUMAB IMBOTOLIMOD",
        "Synonyms": "BDC 1001|BDC-1001|BDC1001|TRASTUZUMAB IMBOTOLIMOD",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04873362",
        "NCT05980481",
        "NCT05954143",
        "NCT00928330",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT04278144",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "RN765C",
      "names": [
        "RN765C"
      ],
      "phases": [],
      "conditions": [
        "Metastatic colorectal cancer, Metastatic non-small cell lung cancer, and  Head and neck cancer"
      ],
      "targets": [
        "Epidermal growth factor receptor (EGFR), a member of the ErbB family of type I receptor tyrosine kinases."
      ],
      "payload": [
        "PF-06380101 (Aur0101), an auristatin microtubule inhibitor (a cytotoxic Dolastatin 10 analogue)"
      ],
      "linker": [
        "AcLys-VC (valine-citruline)-PABC (cleavable linker)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-EGFR hIgG1 antibody,"
      ],
      "Max Phase": null,
      "developers": [
        "Pfizer",
        "Rinat"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CD38-077 | STI-6129 | STI-6129 LNDS1001 | LNDS1001",
      "names": [
        "STI-6129 LNDS1001",
        "LNDS1001",
        "STI-6129",
        "CD38-077"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced relapsed and/or refractory systemic amyloid light chain (AL) amyloidosis",
        "Light Chain (AL) Amyloidosis",
        "Multiple Myeloma",
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "targets": [
        "CD38"
      ],
      "payload": [
        "Duostatin 5.2 (Duo.5.2), a microtubule inhibitor. This is a  A novel cytotoxic payload derived from monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "A non-polyethylene glycol linker"
      ],
      "domain": [],
      "antibody": [
        "CD38 specific antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Sorrento Therapeutics"
      ],
      "trials": [
        "NCT05584709",
        "NCT05565807",
        "NCT04316442",
        "NCT05308225"
      ],
      "locations": [
        "China",
        "United States"
      ]
    },
    {
      "heading": "ZV05-ADC | ZV05-mcMMAF | 5T4-MMAF ADC | 5T4-MMAF ADC ZV05-mcMMAF ZV0501 | ZV0501",
      "names": [
        "ZV05-ADC",
        "ZV05-mcMMAF",
        "5T4-MMAF ADC",
        "5T4-MMAF ADC ZV05-mcMMAF ZV0501",
        "ZV0501"
      ],
      "phases": [],
      "conditions": [
        "NSCLC;  RCC;  Colorectal cancer; Ovarian cancer,  Pancreatic cancer; Gastric cancers."
      ],
      "targets": [
        "5T4 also known as TPBG or oncofetal antigen, is an N-glycosylated transmembrane 72 kDa glycoprotein."
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)"
      ],
      "linker": [
        "Proprietary linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ZV05"
      ],
      "Max Phase": null,
      "developers": [
        "Concortis",
        "Zova Biotherapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AG02",
      "names": [
        "AG02"
      ],
      "phases": [],
      "conditions": [
        "Mesothelioma"
      ],
      "targets": [
        "CSP-1 (surface protein named -1)"
      ],
      "payload": [
        "Saporin  (Routinely used as a cost-effective payload in ADCs for proof-of-concept (POC) studies)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "human cancer cell surface proteins (CSPs)"
      ],
      "Max Phase": null,
      "developers": [
        "A&G"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Zt/g4-DM1 | Anti-RON-ADC",
      "names": [
        "Zt/g4-DM1",
        "Anti-RON-ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "RON (a tyrosine kinase (TK) receptor of the Met proto-oncogene family., also known as macrophage stimulating 1 receptor or MST1R)"
      ],
      "payload": [
        "Maytansinoid (DM1)"
      ],
      "linker": [
        "A thioether linker"
      ],
      "domain": [],
      "antibody": [
        "Anti-RON mAb Zt/g4 (IgG1a/\u03ba))"
      ],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SAR566658 | SAR 566658",
      "names": [
        "SAR566658",
        "SAR-566658",
        "SAR 566658",
        "huDS6-DM4"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Ca6 positive tumors; Solid tumors;  ovarian, breast, and other epithelial cancers"
      ],
      "targets": [
        "Sialoglycotope CA6/huDS6 (Mucin 1)"
      ],
      "payload": [
        "Maytansine DM4\u00a0(microtubule inhibitor)"
      ],
      "linker": [
        "SPDB"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109635",
        "Name": "SAR-566658",
        "Synonyms": "SAR 566658|SAR-566658|SAR566658|huDS6-DM4",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "lintuzumab satetraxetan | Actinium | 225Ac",
      "names": [
        "lintuzumab satetraxetan",
        "Actinium",
        "225Ac"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Metastatic Colorectal Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Prostate Cancer"
      ],
      "targets": [
        "CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)"
      ],
      "payload": [
        "Actinium-225 (Ac 225) radiolabelled to satetraxetan (DOTA derivative); average of 1 or 2 lysyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "CD33"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT04946370",
        "NCT06147037"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "AstraZeneca",
        "Fusion Pharmaceuticals Inc"
      ]
    },
    {
      "heading": "Mirzotamab Clezutoclax | ABBV-155",
      "names": [
        "MIRZOTAMAB CLEZUTOCLAX",
        "Mirzotamab Clezutoclax",
        "ABBV155",
        "ABBV-155"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors, advanced or metastatic"
      ],
      "targets": [
        "CD276 (B7H3, B7-H3, B7-related protein 2, B7RP2, B7RP-2, B7 homolog 3, B7 homologue 3)"
      ],
      "payload": [
        "Clezutoclax (an inhibitor of BCL2L1)  Average of 2 cysteinyl"
      ],
      "linker": [
        "A cleavable dipeptide (valine-alanine) linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa | mirzotamab, P01-18-P10-18, huAb13v1, huAb13.1a"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "ttd": "DDE82F",
      "chembl": {
        "ChEMBL ID": "CHEMBL4594514",
        "Name": "MIRZOTAMAB CLEZUTOCLAX",
        "Synonyms": "ABBV-155|ABBV155|MIRZOTAMAB CLEZUTOCLAX",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "ST8176AA1",
      "names": [
        "ST8176AA1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "ErbB2+ solid tumors"
      ],
      "targets": [
        "ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2)"
      ],
      "payload": [
        "ST7464AA1, the active form of the prodrug HDAC (Histone deacetylase) inhibitor ST7612AA1  The average drug/antibody ratio (DAR) was 4.5 as measured by hydrophobic interaction chromatography (HIC)"
      ],
      "linker": [
        "A maleimide-thiol linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab. Trastuzumab was partially reduced with tris [2-carboxyethyl] phosphine (TCEP)."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Alfasigma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SGN-CD228A | SGN-CD228A  anti-CD228 -   Anti-CD228-MMAE",
      "names": [
        "SGN-CD228A",
        "SGN-CD228A  anti-CD228 -   Anti-CD228-MMAE"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors"
      ],
      "targets": [
        "Melanotransferrin (CD228 MFI2 MELTF), a cell-surfaced glycosylphosphatidylinoitol (GPI)-anchored glycoprotein that belongs to the transferrin family of iron-binding proteins.   CD228 was first described as an oncofetal protein highly expressed on malignant melanoma cells.  In addition to melanoma, CD228 is highly expressed in mesothelioma, non-small cell lung (NSCL), breast, colorectal, and pancreatic carcinomas."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE, vedotin)  Drug to antibody-ratio: 8"
      ],
      "linker": [
        "The payload is conjugated via a \u03b2-glucuronidase-cleavable linker, which incorporates a PEG side chain and self-stabilizing maleimide to achieve homogenous conjugation with decreased plasma clearance and increased preclinical antitumor activity."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hL49, an antibody specific for human CD228."
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "ttd": "DS6BE2",
      "locations": [],
      "trials": []
    },
    {
      "heading": "BTP-227 | PEN-221 | PEN221",
      "names": [
        "BTP-227",
        "PEN-221",
        "PEN221"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Neuroendocrine; Small cell lung cancers"
      ],
      "targets": [
        "Somatostatin receptor 2;  SSTR2"
      ],
      "payload": [
        "DM1 (emtansine), a thiol-containing maytansinoid"
      ],
      "linker": [
        "An optimized cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An SSTR2 targeting ligand"
      ],
      "Max Phase": "2",
      "developers": [
        "Tarveda"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "PEN-866 | PEN 866 HDC SN-38 PEN866 PEN-866 STA-12-8666 STA-8666",
      "names": [
        "PEN-866",
        "PEN 866 HDC SN-38 PEN866 PEN-866 STA-12-8666 STA-8666"
      ],
      "phases": [
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced solid tumors"
      ],
      "targets": [
        "Heat Shock Protein 90 (HSP90)"
      ],
      "payload": [
        "SN-38 (irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin)"
      ],
      "linker": [
        "An optimized cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Heat Shock Protein 90 (HSP90) Ligand (a chaperone protein)"
      ],
      "Max Phase": "2",
      "developers": [
        "Tarveda"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BT 1718 | BT1718 | BT-1718",
      "names": [
        "BT 1718",
        "BT1718",
        "BT-1718"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Triple negative breast cancer; non-small cell lung cancer; Soft tissue sarcoma;"
      ],
      "targets": [
        "Membrane type 1-matrix metalloprotease (MT1-MMP; MMP14)"
      ],
      "payload": [
        "DM1 (emtansine), a thiol-containing maytansinoid"
      ],
      "linker": [
        "A hindered disulfide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A bicyclic peptide"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Bicycle Therapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Rosopatamab Tetraxetan | DOTA-HUJ-591-GS DOTA-HUJ-591 HuJ591-DOTA",
      "names": [
        "Rosopatamab Tetraxetan",
        "DOTA-HUJ-591-GS DOTA-HUJ-591 HuJ591-DOTA"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Prostate cancer"
      ],
      "targets": [
        "FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)"
      ],
      "payload": [
        "Tetraxetan (DOTA), a chelator for yttrium-90, a radioisotope.  on an average of 3 to 5 lysyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-human prostate-specific membrane antigen."
      ],
      "Max Phase": "2",
      "developers": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "OTSA-101-DTPA | OTSA101-SS01 | OTSA-101-DTPA OTSA101-DTPA-90Y | Tabituximab Barzuxetan",
      "names": [
        "OTSA-101-DTPA",
        "OTSA101-SS01",
        "OTSA-101-DTPA OTSA101-DTPA-90Y",
        "Tabituximab Barzuxetan"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Synovial Sarcoma"
      ],
      "targets": [
        "FZD10 (frizzled class receptor 10, frizzled family receptor 10, Frizzled-10, CD350), a 7-transmenbrane receptor, member of the Wnt signalling receptor family."
      ],
      "payload": [
        "Barzuxetan, p-SCN-Bn-CHX-A\"-DPTA, a DPTA chelator derivative"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa Tabituximab"
      ],
      "Max Phase": "1",
      "developers": [
        "OncoTherapy Science (Japan)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ASP-1929 | Cetuximab sarotalocan | RM-1929 | ASP-1929  RM-1929 Cetuximab-irdye 700dx",
      "names": [
        "Cetuximab sarotalocan",
        "CETUXIMAB-IRDYE 700DX",
        "CETUXIMAB SAROTALOCAN",
        "CETUXIMAB SAROTALOCAN SODIUM",
        "ASP-1929  RM-1929 Cetuximab-irdye 700dx",
        "RM-1929",
        "Cetuximab-IRDye-700DX",
        "ASP-1929"
      ],
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Recurrent Head and Neck Cancer Oesophageal cancer"
      ],
      "targets": [
        "Epidermal growth factor (EGFR)  Anti-[Homo sapiens EGFR (epidermal growth factor receptor, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, ERBB)]"
      ],
      "payload": [
        "IRDye\u00ae 700DX (IR700, LI-COR; Lincoln, Nebraska) near-infrared (690 nm) photosensitizing dye"
      ],
      "linker": [
        "Undisclosed"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Cetuximab"
      ],
      "Max Phase": "3",
      "developers": [
        "Aspyrian",
        "Rakuten Medical"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4298088",
        "Name": "CETUXIMAB SAROTALOCAN",
        "Synonyms": "ASP-1929|CETUXIMAB SAROTALOCAN|CETUXIMAB SAROTALOCAN SODIUM|CETUXIMAB-IRDYE 700DX CONJUGATE|Cetuximab-IRDye-700DX|RM-1929",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "SC-003 | Anti-DPEP3 ADC | SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001 | Tamrintamab Pamozirine",
      "names": [
        "SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001",
        "SC-003",
        "Tamrintamab Pamozirine",
        "Anti-DPEP3 ADC",
        "Tamrintamab pamozirine"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "DPEP3 (dipeptidase 3) also known as MBD3, a glycosylphosphatidylinositol anchored membrane protein from the DPEP family of dipeptidase proteins, which are involved in the hydrolytic metabolism of various dipeptides and some antibiotics containing amide-like linkages."
      ],
      "payload": [
        "A pyrrolobenzodiazepine dimer (PBD) SC-DR002  An average of 2 cysteinyl (Cys215' and Cys215''')"
      ],
      "linker": [
        "Protease-cleavable maleimide linker (LD6.23)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens DPEP3 (dipeptidase 3)], humanized monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie",
        "Stemcentrx"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17222",
        "Name": "Tamrintamab pamozirine",
        "Description": "Tamrintamab pamozirine is an antibody-drug conjugate targeted against DPEP3.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 Tamrintamab pamozirine is an antibody-drug conjugate targeted against DPEP3. \u2026 Matched Categories: \u2026 Antibody-drug Conjugates \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Camidanlumab tesirine | HuMax-TAC-ADC | ADCT-301 | ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d",
      "names": [
        "ADCT301",
        "Camidanlumab tesirine",
        "ADCT 301",
        "CAMIDANLUMAB TESIRINE",
        "ADCT-301",
        "ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d",
        "ADCT 502",
        "HuMax-TAC-ADC",
        "ADCT-301 TESIRINE"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "- Non-Hodgkin's lymphoma (NHL) - Hodgkin lymphoma - Acute lymphocytic leukemia (ALL)  Other potential indications being investigated in clinical studies:  - Burkitt's Lymphoma Chronic  - Lymphocytic Leukemia  - Small Lymphocytic Lymphoma  - Large B-Cell Lymphoma - Diffuse Large B-Cell Lymphoma - Follicular Lymphoma - Mantle-Cell Lymphoma - Marginal Zone Waldenstrom's Macroglobulinaemia Lymphoma, - T-cell Cutaneous Lymphoma,  - Peripheral T-Cell Lymphoma,"
      ],
      "targets": [
        "CD25 (IL2RA - interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine dimer SG3199  On an average of 2 cysteinyl"
      ],
      "linker": [
        "A cleavable, valine-alanine dipeptide (as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "CD25 targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "ADC Therapeutics",
        "Genmab"
      ],
      "ttd": "D0LL1N",
      "chembl": {
        "ChEMBL ID": "CHEMBL4297871",
        "Name": "CAMIDANLUMAB TESIRINE",
        "Synonyms": "ADCT 301|ADCT 502|ADCT-301|ADCT-301 TESIRINE|ADCT301|CAMIDANLUMAB TESIRINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Cofetuzumab pelidotin | ABBV-647 | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020 | PF-06647020",
      "names": [
        "ABBV-647",
        "COFETUZUMAB PELIDOTIN",
        "PF-06647020",
        "Gedatolisib",
        "Cofetuzumab pelidotin",
        "PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020",
        "PTK7-ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Neoplasms",
        "Cancer",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Advanced Solid Tumors, including: - Ovarian Cancer,  - Triple Negative Breast Cancer - Recurrent non-small cell lung cancer (NSCLC)",
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "targets": [
        "Protein Tyrosine Kinase 7 (PTK7) | Colon carcinoma kinase 4 (CCK4).   Functions in developmental biology (Wnt signaling and planar cell polarity)  Expression linked to poor prognosis in patients with TNBC and NSCLC  Enriched on cancer stem cells (CSCs), which may contribute to treatment resistance and relapse."
      ],
      "payload": [
        "Auristatin-0101 microtubule inhibitor payload (Aur0101)"
      ],
      "linker": [
        "Cleavable valine-citrulline linker |  a  cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  An average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa  An anti-[Homo sapiens PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody."
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie",
        "Pfizer",
        "Stemcentrx"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3989983",
        "Name": "COFETUZUMAB PELIDOTIN",
        "Synonyms": "COFETUZUMAB PELIDOTIN|PF-06647020",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT02222922",
        "NCT03243331",
        "NCT04189614"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "Spain",
        "United States",
        "Israel",
        "Taiwan"
      ]
    },
    {
      "heading": "RO7032005 | DCDS0780A DCDS 0780A RO7032005 | Iladatuzumab vedotin | DCDS0780A",
      "names": [
        "RO7032005",
        "DCDS0780A DCDS 0780A RO7032005",
        "Iladatuzumab vedotin",
        "DCDS0780A"
      ],
      "phases": [
        "Phase 1/1",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin's lymphoma (NHL)"
      ],
      "targets": [
        "CD79B (immunoglobulin-associated CD79 beta)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  On an average of 2 cysteinyl."
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker."
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [
        "IgG1 - kappa Anti-[Homo sapiens CD79B (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Ladiratuzumab vedotin | SGN-LIV1A | Anti-LIV-1 ADC",
      "names": [
        "LADIRATUZUMAB VEDOTIN",
        "Ladiratuzumab vedotin",
        "SGN-LIV1A",
        "Anti-LIV-1 ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1",
        "Phase ii i"
      ],
      "conditions": [
        "- Breast Cancer,  - ERBB2 positive cancers including (potential other indications include melanoma, prostate, ovarian, and uterine cancer)  - Small Cell Lung Cancer,  - Non-small Cell Lung Cancer, - Squamous Non-small Cell Lung Cancer,  - Non-squamous Head and Neck Cancer, - Squamous Cell Carcinoma - Esophageal Squamous Cell - Carcinoma Gastric Adenocarcinoma  - Gastroesophageal Junction Adenocarcinoma",
        "HER2 Mutations Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "Hormone Receptor Positive Breast Neoplasms",
        "Breast Cancer",
        "Triple Negative Breast Neoplasms"
      ],
      "targets": [
        "Zinc transporter LIV-1 (anti-solute carrier family 39 zinc transporter member 6 (SLC39A6) or ZIP6."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  On an average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) (a proteolytically cleavable type linker)  Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody."
      ],
      "Max Phase": "2",
      "developers": [
        "Seagen"
      ],
      "ttd": "DS6B1L",
      "chembl": {
        "ChEMBL ID": "CHEMBL4298101",
        "Name": "LADIRATUZUMAB VEDOTIN",
        "Synonyms": "LADIRATUZUMAB VEDOTIN|SGN-LIV1A",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01969643",
        "NCT03310957",
        "NCT03424005"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Israel",
        "Spain",
        "Germany",
        "United States",
        "France",
        "United Kingdom"
      ]
    },
    {
      "heading": "AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | ASG-15ME | AGS-15vcMMAE | AGS-15E | Sirtratumab vedotin | Ha15-10ac.1vcMMAE | AGS15E",
      "names": [
        "AGS15C \u2013SGD-1006",
        "Ha15-10ac12vcMMAE",
        "ASG-15ME",
        "AGS-15vcMMAE",
        "AGS-15E",
        "Sirtratumab vedotin",
        "Ha15-10ac.1vcMMAE",
        "AGS15E"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Bladder Cancer Metastatic urothelial cancer"
      ],
      "targets": [
        "SLTRK6 (SLIT and NTRK like family member 6, \"SLIT and NTRK-like family, member 6\")"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)   On an average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "IgG2 - kappa anti-[Homo sapiens SLITRK6 (SLIT and NTRK like family member 6)], Homo sapiensmonoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Agensys",
        "Astellas",
        "Ligand Pharmaceuticals",
        "Seagen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV-321 | ABBV-321 Anti-Egfr/pbd -  ABBV-321 | Serclutamab Talirine",
      "names": [
        "ABBV-321",
        "ABBV-321 Anti-Egfr/pbd -  ABBV-321",
        "ABBV-321 TALIRINE",
        "SERCLUTAMAB TALIRINE",
        "Serclutamab Talirine"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands."
      ],
      "targets": [
        "EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PDB) dimer SGD-1882 with a fixed DAR of 2.0"
      ],
      "linker": [
        "A cathepsin-cleavable maleimidocaproyl-valine-alanine (MC-Val-Ala) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, affinity-matured humanized antibody (ABT-806 AM1) with a higher affinity for EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)."
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4594392",
        "Name": "SERCLUTAMAB TALIRINE",
        "Synonyms": "ABBV-321|ABBV-321 TALIRINE|SERCLUTAMAB TALIRINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV-221 | ABBV-221 ABBV221 | Losatuxizumab vedotin",
      "names": [
        "ABBV-221",
        "ABBV-221 ABBV221",
        "ABBV 221",
        "Losatuxizumab vedotin",
        "LOSATUXIZUMAB VEDOTIN"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors (overexpressing EGFR), including: - Head and Neck Squamous Cell Carcinoma  - Non-small Cell Lung Cancer  - Triple Negative Breast Cancer - Colorectal Carcinoma  - Glioblastoma Multiforme"
      ],
      "targets": [
        "EGFR (epidermal growth factor receptor, receptor tyrosine-protein  kinase erbB-1, ERBB1, HER1, HER-1, ERBB) delta 2-7 isoform (delta2-7EGFR, de2-7 EGFR, EGFRvIII)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  On an average of 3 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa affinity-matured ABT-806"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4594515",
        "Name": "LOSATUXIZUMAB VEDOTIN",
        "Synonyms": "ABBV 221|ABBV-221|LOSATUXIZUMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Glembatumumab vedotin | CDX-011 | DOX | CR011 CR011-vcMMAE",
      "names": [
        "CR-011-VCMMAE",
        "Glembatumumab vedotin",
        "GLEMBATUMUMAB VEDOTIN",
        "CR011 CR011-vcMMAE",
        "DOX",
        "CDX-011"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "DLBCL",
        "Recurrent Breast Carcinoma",
        "Grade 3b Follicular Lymphoma",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Ovarian Cancer",
        "B-cell Non-Hodgkin Lymphoma",
        "Transformed Follic Lymph to Diff Large B-Cell Lymphoma",
        "Endometrial Cancer",
        "Breast cancer (TNBC) Advanced or metastatic melanoma",
        "Hodgkin Disease",
        "Breast Cancer",
        "Stage III Breast Cancer",
        "Invasive Breast Carcinoma",
        "Peritoneal Cancer",
        "Lymphoma, Large-Cell, Anaplastic",
        "Lymphoma, T-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Breast Neoplasms",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "HER2-positive Early Breast Cancer",
        "Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "B-Cell Lymphoma",
        "Prostate Cancer",
        "Non-Hodgkin Lymphoma",
        "Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Leukemia, Acute Lymphoblastic",
        "Epithelial Ovarian Cancer",
        "High-grade B-cell Lymphoma",
        "Double-Expressor Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Primary Peritoneal Cancer",
        "T-Cell Lymphoma",
        "Metastatic gpNMB Over-expressing Triple Negative Breast Cancer",
        "Refractory Hodgkin Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Neoplasms, Ovarian",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Large B-Cell Lymphoma",
        "Recurrent B Lymphoblastic Lymphoma",
        "Unresectable Stage III or Stage IV Melanoma",
        "Ovarian Neoplasms",
        "Classical Hodgkin Lymphoma",
        "Lymphoma, B-Cell",
        "Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma",
        "Stage IIIB Breast Cancer",
        "Pancreas Cancer",
        "Stage IIIC Breast Cancer",
        "Richter Syndrome",
        "Stage IIIA Breast Cancer",
        "Stage IV Breast Cancer",
        "Primary Peritoneal Carcinoma",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent Hodgkin Lymphoma",
        "Solid Cancer",
        "Unresectable Breast Carcinoma",
        "Prostatic Neoplasms",
        "Refractory B Lymphoblastic Lymphoma",
        "HER2-Negative Metastatic Breast Cancer",
        "Lymphoma, NK-cell",
        "Triple-Negative Breast Carcinoma",
        "Stage III Childhood Hodgkin Lymphoma",
        "Platinum-resistant Ovarian Cancer"
      ],
      "targets": [
        "GPNMB (glycoprotein transmembrane NMB, hematopoeitic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain"
      ],
      "payload": [
        "Monomethyl Auristatin E\u00a0(MMAE)  On an average of 5 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG2 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Celldex"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1743028",
        "Name": "GLEMBATUMUMAB VEDOTIN",
        "Synonyms": "CDX-011|CR-011-VCMMAE|GLEMBATUMUMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB05996",
        "Name": "Glembatumumab vedotin",
        "Description": "A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E ... for the treatment of melanoma and breast cancer. \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "trials": [
        "NCT04914741",
        "NCT03755804",
        "NCT02751918",
        "NCT06377566",
        "NCT01712490",
        "NCT01309789",
        "NCT01868451",
        "NCT06047080",
        "NCT04594798",
        "NCT01534078",
        "NCT02734771",
        "NCT02292979",
        "NCT05404945",
        "NCT06132958",
        "NCT06112379",
        "NCT05922904",
        "NCT01997333",
        "NCT00412828",
        "NCT02423928",
        "NCT04884035",
        "NCT01920932",
        "NCT02606305",
        "NCT04679012",
        "NCT04307576",
        "NCT03726879",
        "NCT03971409",
        "NCT05870748",
        "NCT05633615",
        "NCT02605915",
        "NCT00028483",
        "NCT01156753",
        "NCT04203641",
        "NCT05600686",
        "NCT02505269",
        "NCT03467373",
        "NCT05800366",
        "NCT02227199",
        "NCT06161025",
        "NCT01992653",
        "NCT01060904",
        "NCT06340568",
        "NCT03646123",
        "NCT00051584",
        "NCT01777152",
        "NCT04209855",
        "NCT04790903",
        "NCT05673785",
        "NCT01966471",
        "NCT02979522",
        "NCT00704158",
        "NCT00031187",
        "NCT05613088",
        "NCT03274492",
        "NCT03991884",
        "NCT04274426",
        "NCT05283720",
        "NCT06486441",
        "NCT05113251",
        "NCT04569032",
        "NCT02631876",
        "NCT03677141",
        "NCT04685616"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Portugal",
        "Peru",
        "United States",
        "Colombia",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Iceland",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "MDX-1203 | BMS-936561 | \u03b1CD70_MED-A | BMS936561",
      "names": [
        "MDX-1203",
        "BMS-936561",
        "\u03b1CD70_MED-A",
        "BMS936561"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Renal Cell Carcinoma (RCC) | Non-Hodgkin's lymphoma",
        "Non-hodgkin's Lymphoma",
        "Renal Cell Carcinoma"
      ],
      "targets": [
        "CD70 (TNFSF7) | CD70, the ligand for the co-stimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells."
      ],
      "payload": [
        "A prodrug of a CC-1065 (rachelmycin) analogue  duocarmycin"
      ],
      "linker": [
        "Di-peptide"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Medarex"
      ],
      "trials": [
        "NCT00944905"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "Oxobuthyldithio | BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4 | Indatuximab Ravtansine | BT-062 | 1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal",
      "names": [
        "Oxobuthyldithio",
        "BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4",
        "Indatuximab Ravtansine",
        "Indatuximab ravtansine",
        "BT-062",
        "INDATUXIMAB RAVTANSINE",
        "1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal",
        "BT062 , intravenous administration",
        "BT062"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma (MM); Bladder cancer; Breast cancer",
        "Multiple Myeloma"
      ],
      "targets": [
        "CD138 | SDC1 (syndecan-1, CD138)"
      ],
      "payload": [
        "Maytansine DM4 (microtubule inhibitor) | [N2'-deacetyl-N2'-(4-mercapto-4-methyl- 1-oxopentyl)-maytansine]"
      ],
      "linker": [
        "A reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate].  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology, Hematology"
      ],
      "antibody": [
        "IgG4 - kappa - murine/human chimeric form of B-B4 (CD138-specific antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "BioTest",
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1743031",
        "Name": "INDATUXIMAB RAVTANSINE",
        "Synonyms": "BT-062|INDATUXIMAB RAVTANSINE|Indatuximab ravtansine",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01638936",
        "NCT01001442"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "Promiximab duocarmycin",
      "names": [
        "Promiximab duocarmycin"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid tumors - Small cell lung cancer (SCLC)"
      ],
      "targets": [
        "CD56"
      ],
      "payload": [
        "A DNA alkylating duocarmycin analog.  On an average DAR (Drug-to-Antibody Ratio) of about 2.04"
      ],
      "linker": [
        "Conjugated via reduced interchain disulfides.  valine-citrulline-seco"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hIgG1 anti-CD56 antibody promiximab"
      ],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADCT-401 | MEDI3726 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
      "names": [
        "ADCT-401",
        "MEDI3726",
        "Anti-PSMA/PBD ADC MEDI3726 ADCT-401"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer",
        "Castration resistant prostate cancer"
      ],
      "targets": [
        "An engineered version of the anti-Prostate-specific membrane antigen (PSMA) antibody J591"
      ],
      "payload": [
        "A highly cytotoxic DNA cross- linking pyrrolobenzodiazepine (PBD) dimer tesirine (SG319).   The drug-to-antibody ratio  [DAR] is 1.8"
      ],
      "linker": [
        "A valine-alanine dipeptide linker.  Site specifically conjugated"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized PSMA-specific IgG1 monoclonal antibody J591 engineered to enable site-specific conjugation"
      ],
      "Max Phase": "1",
      "developers": [
        "ADC Therapeutics",
        "AstraZeneca",
        "MedImmune"
      ],
      "trials": [
        "NCT02991911"
      ],
      "locations": [
        "Switzerland",
        "United Kingdom",
        "United States"
      ]
    },
    {
      "heading": "MEDI4276 | MEDI-4276 | MEDI 4276",
      "names": [
        "MEDI4276",
        "MEDI-4276",
        "MEDI 4276"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "HER2 Expressing Breast or Gastric/Stomach Cancers",
        "Breast cancer Gastric cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (HER2; ERBB2)"
      ],
      "payload": [
        "MMETA, a Tubulysin Payload also known as AZ13599185."
      ],
      "linker": [
        "Site-specific conjugation on mc-Lys-MMETA to 2 engineered cysteine residues on the heavy chain via a maleimidocaproyl linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab scFv (Binding to Domain IV of HER2)"
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca",
        "MedImmune"
      ],
      "trials": [
        "NCT02576548"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "BMS986148 | BMS-986148",
      "names": [
        "BMS986148",
        "BMS-986148"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Solid tumors - Lung Cancer (Mesothelioma),  - Ovarian cancer,  - Pancreatic cancer"
      ],
      "targets": [
        "Mesothelin, a GPI-anchored cell surface protein"
      ],
      "payload": [
        "Tubulysin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A fully human IgG1 anti-mesothelin monoclonal antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Bristol Myers Squibb"
      ],
      "trials": [
        "NCT02341625",
        "NCT02884726"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Hong Kong",
        "United States",
        "Netherlands",
        "Italy"
      ]
    },
    {
      "heading": "HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC | AXL-107-MMAE | Enapotamab vedotin | HuMax-AXL-ADC",
      "names": [
        "HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC",
        "AXL-107-MMAE",
        "HUMAX-AXL-ADC",
        "HuMax-AXL-ADC",
        "HUMAX AXL ADC",
        "ENAPOTAMAB VEDOTIN",
        "Enapotamab vedotin"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Non Small Cell Lung Cancer (NSCLC)",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Melanoma",
        "Solid Tumors",
        "Thyroid Cancer",
        "Sarcoma",
        "Solid tumors including - Ovarian cancer; - Non Small Cell Lung Cancer (NSCLC);  - Endometrial cancer; - Cervical cancer; - Thyroid Cancer."
      ],
      "targets": [
        "AXL (AXL receptor tyrosine kinase, tyrosine-protein kinase receptor UFO), a signaling molecule expressed on many solid cancers and implicated in tumor biology."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  An average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p- aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker  Protease Cleavable Linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa."
      ],
      "Max Phase": "2",
      "developers": [
        "Genmab",
        "Seagen"
      ],
      "ttd": "D0QI1K",
      "chembl": {
        "ChEMBL ID": "CHEMBL4297987",
        "Name": "ENAPOTAMAB VEDOTIN",
        "Synonyms": "AXL-107-MMAE|ENAPOTAMAB VEDOTIN|HUMAX AXL ADC|HUMAX-AXL-ADC",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB16156",
        "Name": "Enapotamab vedotin",
        "Description": "Enapotamab vedotin is under investigation in clinical trial NCT02988817 (Enapotamab Vedotin (Humax-axl-adc) Safety Study in Patients With Solid Tumors).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Humax axl adc ... HuMax-AXL-ADC \u2026 Matched Description: \u2026 Enapotamab vedotin is under investigation in clinical trial NCT02988817 (Enapotamab Vedotin (Humax-axl-adc \u2026",
        "Queries": "['\"adc\"']",
        "Query Indices": "[2]",
        "Score": 5
      },
      "trials": [
        "NCT02988817"
      ],
      "locations": [
        "Belgium",
        "Spain",
        "United States",
        "Netherlands",
        "United Kingdom",
        "Denmark"
      ]
    },
    {
      "heading": "CX-2029",
      "names": [
        "CX-2029"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Diffuse Large B Cell Lymphoma",
        "Non Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Head and Neck Cancer",
        "- Head and neck cancer - Squamous non-small cell lung cancer - Esophageal carcinoma - Diffuse large B cell lymphoma"
      ],
      "targets": [
        "CD71, a transferrin receptor 1 (TFR1) is a 95-kDa homodimeric transmembrane glycoprotein."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "AbbVie",
        "CytomX"
      ],
      "trials": [
        "NCT03543813"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "Korea, Republic of"
      ]
    },
    {
      "heading": "BMS-986288 BMS986288 | BMS986288 | BMS-986288",
      "names": [
        "BMS-986288 BMS986288",
        "BMS986288",
        "BMS-986288"
      ],
      "phases": [
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "targets": [
        "CTLA-4 (CTLA4; cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is a protein receptor that functions as an immune checkpoint and downregulates immune responses."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-CTLA-4 Probody.  BMS-986288 is a Probody version of the anti-CTLA-4 antibody ipilimumab (Yervoy\u00ae) (a non-fucosylated version of ipilimumab)"
      ],
      "Max Phase": "2",
      "developers": [
        "Bristol Myers Squibb",
        "CytomX"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CX-2009 | CD166 PDC | CX-2009 ADC CX-2009 | Praluzatamab Ravtansine | CD166 AADC",
      "names": [
        "CX-2009",
        "CX 2009",
        "CD166 PDC",
        "PRALUZATAMAB RAVTANSINE",
        "CX-2009 ADC CX-2009",
        "ANTI-CD166-DM4 CX-2009",
        "Praluzatamab Ravtansine",
        "CD166 AADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "CD166-postitive solid tumors"
      ],
      "targets": [
        "CD166 (activated leucocyte cell adhesion molecule, ALCAM)"
      ],
      "payload": [
        "Maytansinoid (DM4; N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine)  On an average of 3-4 lysyl"
      ],
      "linker": [
        "Reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa A recombinant antibody targeting the tumor-associated antigen (TAA) CD166"
      ],
      "Max Phase": "2",
      "developers": [
        "CytomX",
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4297736",
        "Name": "PRALUZATAMAB RAVTANSINE",
        "Synonyms": "ANTI-CD166-DM4 CX-2009|CX 2009|CX-2009|PRALUZATAMAB RAVTANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB16090",
        "Name": "CX-2009",
        "Description": "CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Anti-cd166 probody-drug conjugate cx-2009 \u2026 Matched Description: \u2026 clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug \u2026",
        "Queries": "['\"drug conjugate\"']",
        "Query Indices": "[3]",
        "Score": 3
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "hMN14-SN-38 | IMMU-130 | Labetuzumab-SN-38 IMMU-130 | Labetuzumab govitecan | hMN-14-SN38 hMN-14-SN-38 ADC hMN14-CL-SN-38",
      "names": [
        "hMN14-SN-38",
        "LABETUZUMAB GOVITECAN",
        "IMMU-130",
        "ANTI-CEACAM5-SN 38",
        "Labetuzumab-SN-38 IMMU-130",
        "Labetuzumab govitecan",
        "hMN-14-SN38 hMN-14-SN-38 ADC hMN14-CL-SN-38"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors - Colorectal cancer/CRC",
        "Metastatic Colorectal Cancer"
      ],
      "targets": [
        "CEACAM4, Carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e"
      ],
      "payload": [
        "Camptothecin analog (SN38) Irinotecan metabolite 7-ethyl-10 hydroxycamptothecin (active metabolite of irinotecan (CPT-11, camptothecin-11))"
      ],
      "linker": [
        "Lysine;  a maleimide-type cleavable linker (carbonate group, 4-aminobenzyl alcohol and cathepsine-B-cleavable dipeptide Phe-Lys) and containing a triazoline group and a spacer PEG (n=8)   An average of 6 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Immunomedics"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3544923",
        "Name": "LABETUZUMAB GOVITECAN",
        "Synonyms": "ANTI-CEACAM5-SN 38|IMMU-130|LABETUZUMAB GOVITECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01270698"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "hLL2-cys-PBD | ADC ADCT-602 -  ADCT-602 anti-CD22/PBD ADC ADCT-602 epratuzumab-cys-SG3249 epratuzumab-cys-tesirine hLL2-cys-PBD hLL2-cys-SG3249 | Epratuzumab Tesirine | ADCT 602 ADCT602 ADCT-602 | ADCT-602",
      "names": [
        "hLL2-cys-PBD",
        "ADC ADCT-602 -  ADCT-602 anti-CD22/PBD ADC ADCT-602 epratuzumab-cys-SG3249 epratuzumab-cys-tesirine hLL2-cys-PBD hLL2-cys-SG3249",
        "Epratuzumab Tesirine",
        "ADCT 602 ADCT602 ADCT-602",
        "ADCT-602"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "CD22 Positive",
        "Blasts 5 Percent or More of Bone Marrow Nucleated Cells",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive",
        "Clinical inducation includes:  - Follicular  lymphoma  (FL) - marginal  zone  lymphoma  (MZL) - Mantle cell lymphoma (MCL) - Difuse large B-cell lymphoma (DLBCL) - small lymphocytic lymphoma  (SLL) - chronic  lymphocytic  leukemia  (CLL)",
        "Recurrent B Acute Lymphoblastic Leukemia"
      ],
      "targets": [
        "CD22;  a type-I transmembrane sialoglycoprotein with expression restricted to the B-cell lineage"
      ],
      "payload": [
        "A Pyrrolobenzodiazepine (PBD) dimer toxin.  Antibody to drug ratio (DAR) is 1.7."
      ],
      "linker": [
        "The agent is stochastically conjugated via a cathepsin-cleavable valine-alanine (val-ala) peptide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-CD22 monoclonal antibody epratuzumab (hLL2)  Derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2)"
      ],
      "Max Phase": "2",
      "developers": [
        "ADC Therapeutics"
      ],
      "trials": [
        "NCT03698552"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "OBI-999 Anti-Globo H ADC | OBI-999 | Anti-Globo H ADC",
      "names": [
        "OBI-999 Anti-Globo H ADC",
        "OBI-999",
        "Anti-Globo H ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors"
      ],
      "targets": [
        "Globo H, an antigen expressed in epithelial cancers"
      ],
      "payload": [],
      "linker": [
        "Site-specific ThioBridge"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "OBI Pharma"
      ],
      "ttd": "D2H6NI",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17356",
        "Name": "OBI-999",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Humanized Anti-Globo H Monoclonal Antibody Monomethyl Auristatin E Conjugate \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "3A4-PL1601",
      "names": [
        "3A4-PL1601"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Advanced solid tumors with high unmet medical needs, including:  - platinum resistant ovarian cancer - triple negative breast cancer."
      ],
      "targets": [
        "KAAG1 (kidney-associated antigen 1), an 84 amino acid protein encoded by the reverse strand of a housekeeping gene called DCDC2."
      ],
      "payload": [
        "PL1601 (which contains Hydraspace, a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199)."
      ],
      "linker": [
        "Site-specifically conjugated using GlycoConnect technology"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "humanized monoclonal antibody 3A4, a humanized antibody against human KAAG1."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "ADC Therapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "MLN-0264 | TAK264 | MLN 0264 | Indusatumab Vedotin | TAK-264 | 5F9vcMMAE | MLN0264",
      "names": [
        "MLN-0264",
        "TAK264",
        "MLN 0264",
        "INDUSATUMAB VEDOTIN",
        "Indusatumab Vedotin",
        "TAK-264",
        "5F9vcMMAE",
        "MLN0264"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Gastrointestinal Malignancies",
        "Solid tumors | Pancreatic Adenocarcinoma; gastrointestinal tumors; solid tumor"
      ],
      "targets": [
        "Guanylyl cyclase C (GCC) / GUCY2C (guanylate cyclase 2C, guanylate cyclase C, GC-C, heat-stable enterotoxin receptor, hSTAR, intestinal guanylate cyclase"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa;   MLN2045; 5F9"
      ],
      "Max Phase": "2",
      "developers": [
        "Millennium",
        "Takeda"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4298045",
        "Name": "INDUSATUMAB VEDOTIN",
        "Synonyms": "INDUSATUMAB VEDOTIN|MLN-0264|MLN0264|TAK-264",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01577758"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "TAK-164 TAK164 Anti-GCC ADC Anti-GCC - | TAK-164",
      "names": [
        "TAK-164 TAK164 Anti-GCC ADC Anti-GCC -",
        "TAK-164"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors - Gastrointestinal Neoplasms; - Esophageal, Stomach, Pancreas, Colon Neoplasms;  - Malignant Tumors of Digestive Organ;  - Advanced Gastrointestinal Malignancies"
      ],
      "targets": [
        "The extracellular domain of guanylyl cyclase C (GCC; GUCY2C)).  GCC is a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain. This receptor is overexpressed on the surface of certain tumor cells."
      ],
      "payload": [
        "An indolino-benzodiazepine (IGN) dimer; a DNA alkylator DGN549 (also known as IGN-P1)"
      ],
      "linker": [
        "Peptide-linked  A central substituted phenyl spacer"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-GCC antibody.  A full-length, fully human IgG1 antibody (mAb) directed towards the extracellular domain of guanylyl cyclase C (GCC)."
      ],
      "Max Phase": "2",
      "developers": [
        "Millennium",
        "Takeda"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TR1801-ADC | MT-8633 | TR1801-ADC MT-8633",
      "names": [
        "TR1801-ADC",
        "MT-8633",
        "TR1801-ADC MT-8633"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Sold tumors; Lung, colorectal, and gastric cancers",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "targets": [
        "c-Met, also known as hepatocyte growth factor receptor (HGFR), a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) toxin-linker tesirine (SG3249)"
      ],
      "linker": [
        "Cleavable (Val\u2010Ala)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized, IgG2 monoclonal antibody, hD12; nonagonistic cMet targeting antibody."
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca",
        "MedImmune",
        "Open Innovation Partners",
        "Tanabe Research Laboratories USA"
      ],
      "ttd": "DU6H8Z",
      "trials": [
        "NCT03859752"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "JBH492",
      "names": [
        "JBH492"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma",
        "Non-hodgkins lymphoma Chronic lymphocytic leukemia",
        "Chronic Lymphocytic Leukemia"
      ],
      "targets": [
        "CCR7 (CC-chemokine receptor 7)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Novartis"
      ],
      "ttd": "DQVR30",
      "trials": [
        "NCT04240704"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "Spain",
        "Singapore",
        "Germany",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "NJH395 | NJH395 anti-HER2 ISAC NJH395",
      "names": [
        "NJH395",
        "NJH395 anti-HER2 ISAC NJH395"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "NON-breast HER2+ Malignancies",
        "Non-breast HER2-positive advanced malignancies"
      ],
      "targets": [
        "Antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "payload": [
        "Toll-like receptor (TLR) 7 and TLR8"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-HER2"
      ],
      "Max Phase": "1",
      "developers": [
        "Novartis"
      ],
      "ttd": "DEX8D5",
      "trials": [
        "NCT03696771"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "United States",
        "Japan"
      ]
    },
    {
      "heading": "FS-1502 Trastuzumab Monomethyl Auristatin F | FS-1502",
      "names": [
        "FS-1502 Trastuzumab Monomethyl Auristatin F",
        "FS-1502"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Patients with metastatic, HER2 positive metastatic breast cancer",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Her 2 Positive Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "HER2/neu"
      ],
      "payload": [
        "Monomethyl Auristatin F"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "3",
      "developers": [
        "Shanghai Fosun"
      ],
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04873362",
        "NCT05980481",
        "NCT00928330",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT05755048",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "CD30-MCC-DM1 | F0002-ADC CD30-MCC-DM1 | F0002-ADC",
      "names": [
        "CD30-MCC-DM1",
        "F0002-ADC CD30-MCC-DM1",
        "F0002-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Refractory or Recurrent CD30+ Hematologic Malignancies"
      ],
      "targets": [
        "CD30, also known as TNFRSF8, is a 120kD transmembrane protein of the tumor necrosis factor (TNF-) family and a known tumor marker found on many different types of lymphomas"
      ],
      "payload": [
        "DM1 or Mertansine, a thiol-containing maytansinoid"
      ],
      "linker": [
        "Stable SMCC linker"
      ],
      "domain": [
        "Hematology"
      ],
      "antibody": [
        "CD30 targeting antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "trials": [
        "NCT03894150"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "CC-99712 \u2013 Anti-BCMA ADC | CC-99712",
      "names": [
        "CC-99712 \u2013 Anti-BCMA ADC",
        "ISPECTAMAB DEBOTANSINE",
        "SP8919",
        "Ispectamab Debotansine \u2013 BMS-986352 \u2013 CC-99712",
        "BMS-986352",
        "CC-99712",
        "Ispectamab debotansine"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma (MM)",
        "Relapsed and refractory (r/r) multiple myeloma (MM)",
        "Multiple Myeloma"
      ],
      "targets": [
        "B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17)",
        "TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)"
      ],
      "payload": [
        "Debotansine, conjugated at C-4 of four specific phenylalanine residues with N2'-deacetylmaytansine (p-azidomethyl-L-phenyalanine or pAMF)"
      ],
      "linker": [
        "Noncleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Humanized monoclonal antibody; Immunoglobulin G1-kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Bristol Myers Squibb",
        "Celgene",
        "Sutro Biopharma"
      ],
      "ttd": "DH5BX2",
      "chembl": {
        "ChEMBL ID": "CHEMBL5095127",
        "Name": "ISPECTAMAB DEBOTANSINE",
        "Synonyms": "ISPECTAMAB DEBOTANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18456",
        "Name": "Ispectamab debotansine",
        "Description": "Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 ... humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT04036461"
      ],
      "locations": [
        "Canada",
        "Spain",
        "United States",
        "France",
        "Italy"
      ]
    },
    {
      "heading": "Ab1-18Hr1 | AbGn-107",
      "names": [
        "Ab1-18Hr1",
        "AbGn-107"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors - Colorectal cancer - Pancreatic cancer - Stomach / gastric cancers - Biliary cancer"
      ],
      "targets": [
        "Transferrin receptor protein 1 (CD71) glycotope."
      ],
      "payload": [
        "Tubulin inhibitor DM4"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 AG7 targeting CD71"
      ],
      "Max Phase": "1",
      "developers": [
        "AbGenomics BV"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SHR-A1201",
      "names": [
        "SHR-A1201"
      ],
      "phases": [],
      "conditions": [
        "Solid tumors HER-2 positive recurrent metastatic breast cancer"
      ],
      "targets": [
        "HER2/neu"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Jiangsu HengRui Medicine"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "HTI-1066 | SHR-A1403 | HTI-1066 SHR-A1403",
      "names": [
        "HTI-1066",
        "SHR-A1403",
        "HTI-1066 SHR-A1403"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors:  - Liver cancer - Stomach cancer - Colorectal cancer,  - Lung cancer - Breast cancers.",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "c-Met; a tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), a receptor tyrosine kinase (RTK) that is important in tumor growth, metastasis, and angiogenesis of many human malignancies."
      ],
      "payload": [
        "Undisclosed proprietary payload"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-c-Met antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Jiangsu HengRui Medicine"
      ],
      "trials": [
        "NCT03856541"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "AMG 224 | AMG 224 anti-BCMA\u2013MCC\u2013DM1",
      "names": [
        "AMG 224",
        "AMG 224 anti-BCMA\u2013MCC\u2013DM1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Relapsed or Refractory (r/r)Multiple Myeloma"
      ],
      "targets": [
        "BCMA; B-cell maturation antigen which belongs to the tumor necrosis factor receptor family and is expressed on late B-cells and plasma cells."
      ],
      "payload": [
        "DM1 is a semi-synthetic derivative of the ansamycin antibiotic maytansine conjugated to MCC."
      ],
      "linker": [
        "MCC is the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate conjugated to lysine residues in the antibody"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [
        "anti-human BCMA IgG1 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Amgen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GQ1001 \u2013 HER2 | GQ1001",
      "names": [
        "GQ1001 \u2013 HER2",
        "GQ1001"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "HER2-positive Biliary Tract Cancer",
        "HER2-Positive Advanced Solid Tumors",
        "Cancer - Any cancer",
        "HER2-Positive Salivary Gland Carcinomas",
        "Advanced/ Metastatic Her-2 Positive Breast Cancer",
        "HER2-positive solid tumors",
        "HER2-Positive Advanced Solid Tumor",
        "HER2-positive Breast Cancer"
      ],
      "targets": [
        "HER2+ tumors"
      ],
      "payload": [
        "DM1 [N2\u2019-deacetyl-N2\u2019-(3-mercapto-1-oxopropyl)-maytansine], a synthetic derivative of the microtubule-targeted agent maytansine"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "2",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "ttd": "DSOE74",
      "trials": [
        "NCT05575804",
        "NCT04450732",
        "ACTRN12620000592943"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ]
    },
    {
      "heading": "GQ1003 \u2013 TROP2",
      "names": [
        "GQ1003 \u2013 TROP2"
      ],
      "phases": [],
      "conditions": [
        "NSCLC, TNBC and other Solid Tumors"
      ],
      "targets": [
        "TROP2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GQ1005 \u2013 HER2",
      "names": [
        "GQ1005 \u2013 HER2"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "HER2 Expressing or Mutated Advanced Malignant Solid Tumors",
        "Low/medium Breast Cancer, Gastric or Gastroesophageal Junction Cancers and other HER2 expressing Solid Tumors"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "trials": [
        "NCT06154343"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "GC1007",
      "names": [
        "GC1007"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GC1009",
      "names": [
        "GC1009"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GQ1014",
      "names": [
        "GQ1014"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GQ1015",
      "names": [
        "GQ1015"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GQ1017",
      "names": [
        "GQ1017"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "GQ1018",
      "names": [
        "GQ1018"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "RC-48 | RC-48 RC 480-ADC RC48 | RC 480-ADC | Disitamab Vedotin | Aidixi\u00ae | \u7231\u5730\u5e0c\u00ae | RC48",
      "names": [
        "RC-48",
        "RC-48 RC 480-ADC RC48",
        "RC 480-ADC",
        "Disitamab Vedotin",
        "Aidixi\u00ae",
        "Disitamab vedotin",
        "DISITAMAB VEDOTIN",
        "\u7231\u5730\u5e0c\u00ae",
        "RC48"
      ],
      "phases": [
        "Phase 2",
        "Phase 1",
        "Phase 3",
        "Approved"
      ],
      "conditions": [
        "Cervical Cancer",
        "Capecitabine",
        "HER2",
        "Ovarian Neoplasms",
        "Muscle Invasive Bladder Carcinoma",
        "HER2 Positive Breast Carcinoma",
        "Metastatic Castration-resistant Prostate Cancer",
        "Colorectal Cancer",
        "Solid Tumors",
        "Non Small Cell Lung Cancer",
        "UTUC",
        "Metastatic Breast Cancer",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma",
        "Melanoma, Stage II",
        "HER2-positive Advanced Breast With Liver Metastases",
        "HER2-Positive Solid Tumors",
        "Salivary Gland Tumors",
        "Breast Neoplasms",
        "HER2-positive",
        "Upper Tract Urothelial Carcinoma",
        "Endometrial Neoplasms",
        "Non-muscle Invasive Bladder Cancer",
        "NMIBC",
        "Advanced Cancer",
        "Solid Tumor",
        "Castration-resistant Prostate Cancer",
        "HER2-positive Breast Cancer",
        "Bladder Cancer",
        "Non-small Cell Lung Cancer",
        "Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance",
        "HER2 Positive Breast Neoplasms",
        "High-risk Non-muscle Invasive Bladder Cancer",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "Urothelial Carcinoma",
        "Advanced Gastroesophageal Adenocarcinoma",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Solid Tumors Advanced Breast Cancer  ___  HER2-Expressing Gastric Cancer -Launched in China in June 2021)  HER2- Expressing Urothelial Carcinoma (China; Registration Trial/ Phase III)  HER2- Expressing Urothelial Carcinoma (Worldwide; Phase I / II)  HER-2 Expressing Gastric Cancer (Worldwide; Phase III)  HER2 Low-to-Non Expressing Urothelial Cancer (China; Phase II)  HER2 Expressing Biliary Tract Cancer (China; Phase II)  HER2 Expressing Non-Small Cell Lung Cancer (China; Phase I)",
        "Non-Muscle Invasive Bladder Cancer",
        "Triple Negative Breast Neoplasms",
        "Gynecological Malignancy",
        "Advanced Melanoma",
        "HER2-expressing",
        "HER2-expressing locally advanced or metastatic malignant solid tumor",
        "HER2 Overexpressing Gastric Carcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Stomach Neoplasms",
        "Breast Diseases",
        "HER2 Low Breast Neoplasms",
        "Breast Cancer",
        "Biliary Tract Cancer"
      ],
      "targets": [
        "Epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE) https://adc.expert/2Jmq1pT"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  On an average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "MabPlex",
        "RemeGen"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095273",
        "Name": "DISITAMAB VEDOTIN",
        "Synonyms": "DISITAMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17208",
        "Name": "Disitamab vedotin",
        "Description": "Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor \u2026 Matched Categories: \u2026 Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT05745740",
        "NCT03507166",
        "NCT06003231",
        "NCT06221748",
        "NCT04879329",
        "NCT05940896",
        "NCT06105008",
        "NCT06389006",
        "NCT05980481",
        "NCT05785325",
        "NCT06178159",
        "NCT05955209",
        "NCT06155383",
        "NCT05356351",
        "NCT06157892",
        "NCT04264936",
        "NCT05514158",
        "NCT05911295",
        "NCT04280341",
        "NCT04965519",
        "NCT06227117",
        "NCT05016973",
        "NCT06074484",
        "NCT05917158",
        "NCT05601401",
        "NCT05135715",
        "NCT06378242",
        "NCT03556345",
        "NCT03052634",
        "NCT02881190",
        "NCT06178601",
        "NCT04311034",
        "NCT05996952",
        "NCT04073602",
        "NCT04714190",
        "ChiCTR2200055827",
        "NCT05417230",
        "NCT04329429",
        "NCT05331326",
        "NCT06227156",
        "NCT05297552",
        "NCT02881138",
        "NCT03809013",
        "NCT06155396",
        "NCT05957757",
        "NCT05403242",
        "NCT05302284",
        "NCT05943379",
        "NCT03500380",
        "NCT04400695"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Israel",
        "Japan",
        "China",
        "Spain",
        "Singapore",
        "United States",
        "Argentina",
        "United Kingdom",
        "Chile",
        "Taiwan"
      ]
    },
    {
      "heading": "RC108",
      "names": [
        "RC108"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Digestive Cancer",
        "Solid Tumor",
        "Solid tumors"
      ],
      "targets": [
        "c-MET"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "MabPlex",
        "RemeGen"
      ],
      "trials": [
        "NCT04617314",
        "NCT05628857"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "ADCT-901",
      "names": [
        "ADCT-901"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Advanced solid tumors with high unmet medical needs, including:  - platinum resistant ovarian cancer - triple negative breast cancer."
      ],
      "targets": [
        "KAAG1 (kidney-associated antigen 1), an 84 amino acid protein encoded by the reverse strand of a housekeeping gene called DCDC2."
      ],
      "payload": [
        "SG3199, a pyrrolobenzodiazepine (PBD)-dimer cytotoxin."
      ],
      "linker": [
        "A cathepsin-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "humanized monoclonal antibody 3A4.  3A4 is a humanized antibody against human KAAG1."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "ADC Therapeutics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ICON-2 Tissue Factor ADC  XB002 | XB002 ICON-2 Tissue Factor ADC",
      "names": [
        "ICON-2 Tissue Factor ADC  XB002",
        "XB002 ICON-2 Tissue Factor ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Esophageal SCC",
        "Endometrial Cancer",
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Epithelial Ovarian Cancer",
        "Solid tumors",
        "Tissue Factor-Expressing Solid Tumors",
        "SCCHN",
        "Pancreatic Cancer"
      ],
      "targets": [
        "Tissue Factor (TF) is a 47-kDa membrane-bound cell surface receptor. It is also known as thromboplastin, coagulation factor III (fIII) or CD142. TF is highly expressed on tumor cells and in the tumor microenvironment, and overexpression, while not oncogenic itself, facilitates angiogenesis, metastasis and other processes important to tumor development and progression."
      ],
      "payload": [
        "Microtubule disrupting agent monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease cleavable valine-citrulline (vc) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Human tissue factor specific antibody (TF-011)"
      ],
      "Max Phase": "1",
      "developers": [
        "Exelixis",
        "Iconic",
        "Zymeworks"
      ],
      "trials": [
        "NCT04925284"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ]
    },
    {
      "heading": "MRG004A",
      "names": [
        "MRG004A"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Solid Tumors"
      ],
      "targets": [
        "Tissue Factor (TF) is a 47-kDa membrane-bound cell surface receptor. It is also known as thromboplastin, coagulation factor III (fIII) or CD142. TF is highly expressed on tumor cells and in the tumor"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Lepu Biopharma",
        "Shanghai Miracogen"
      ],
      "trials": [
        "NCT04843709"
      ],
      "locations": [
        "China",
        "United States"
      ]
    },
    {
      "heading": "REGN3124-PBD",
      "names": [
        "REGN3124-PBD"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Glioblastoma Multiforme (GBM)"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor variant III (EGFRvIII)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "Tesirine (SG3249) linker payload A cathepsin B-cleavable valine-alanine linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "REGN3124"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Regeneron"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SOT102 | SO-N102 | CLDN18.2 ADC",
      "names": [
        "SOT102",
        "SO-N102",
        "CLDN18.2 ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors Gastric cancer Pancreatic cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Pancreatic Cancer",
        "Gastric and pancreatic adenocarcinoma  MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 100000004864   MedDRA version: 21.1 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 100000004864"
      ],
      "targets": [
        "Claudin 18.2"
      ],
      "payload": [
        "DAR-2 PNU-159682, an anthracycline derivative."
      ],
      "linker": [
        "Site Specific Non-cleavable Amide/Peptide Linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Proprietary monoclonal antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "SOTIO Bio"
      ],
      "trials": [
        "NCT05525286",
        "EUCTR2021-005873-25-ES"
      ],
      "locations": [
        "Belgium",
        "Czechia",
        "Spain",
        "United States",
        "France"
      ]
    },
    {
      "heading": "DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA | RG6148 | DHES0815A | anti-HER2/PBD-monoamide anti-HER2/PBD-MA",
      "names": [
        "DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA",
        "RG6148",
        "DHES0815A",
        "anti-HER2/PBD-monoamide anti-HER2/PBD-MA"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Relapsed or refractory Acute Myeloid Leukemia."
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2)"
      ],
      "payload": [
        "DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA)"
      ],
      "linker": [
        "Disulfide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "THIOMAB humanized IgG1 anti-HER2 monoclonal antibody (hu7C2), which binds domain 1 of the HER2 ECD"
      ],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADCT-402 | ADCT-402 RB4v1.2-SG-3249 | Zynlonta | Loncastuximab tesirine",
      "names": [
        "ADCT-402 TESIRINE",
        "LONCASTUXIMAB TESIRINE",
        "Zynlonta",
        "Loncastuximab tesirine",
        "ADCT-402",
        "ZYNLONTA",
        "ADCT-402 RB4v1.2-SG-3249"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Double-Expressor Lymphoma",
        "B-Cell Non-Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Diffuse large B cell lymphoma (DLBCL) and Lymphoma, mantle cell lymphoma  Relapsed/refractory (R/R) B-cell lineage non-Hodgkin lymphoma.",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "B-cell Non Hodgkin Lymphoma",
        "Relapsed B-Cell Non-Hodgkin Lymphoma"
      ],
      "targets": [
        "CD19 (B lymphocyte surface antigen B4, Leu-12)"
      ],
      "payload": [
        "SG3199 / Pyrrolobenzodiazepine (PDB) dimer SCX  Average of two molecules of tesirine"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)   On an average of 2 cysteinyl"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "Immunoglobulin G1, anti-human CD19 | immunoglobulin G1-kappa, anti-[Homo sapiens CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "ADC Therapeutics"
      ],
      "ttd": [
        "D0HV4B",
        "D8L5PA"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4297778",
        "Name": "LONCASTUXIMAB TESIRINE",
        "Synonyms": "ADCT-402|ADCT-402 TESIRINE|LONCASTUXIMAB TESIRINE|Zynlonta",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB16222",
        "Name": "Loncastuximab tesirine",
        "Description": "Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through \u2026 Matched Description: \u2026 [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug ... conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta. ... and improve survival. \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "fda_label": {
        "id": 133719,
        "description": "[\"11 DESCRIPTION Loncastuximab tesirine-lpyl is a CD19-directed antibody and alkylating agent conjugate, consisting of a humanized IgG1 kappa monoclonal antibody conjugated to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxic alkylating agent, through a protease-cleavable valine-alanine linker. SG3199 attached to the linker is designated as SG3249, also known as tesirine. Loncastuximab tesirine-lpyl has an approximate molecular weight of 151 kDa. An average of 2.3 molecules of SG3249 are attached to each antibody molecule. Loncastuximab tesirine-lpyl is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. ZYNLONTA (loncastuximab tesirine-lpyl) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder, which has a cake-like appearance, for intravenous infusion after reconstitution and dilution. Each single-dose vial delivers 10 mg of loncastuximab tesirine-lpyl, L-histidine (2.8 mg), L-histidine monohydrochloride (4.6 mg), polysorbate 20 (0.4 mg), and sucrose (119.8 mg). After reconstitution with 2.2 mL Sterile Water for Injection, USP, the final concentration is 5 mg/mL with a pH of approximately 6.0. Chemical Structure\"]",
        "generic_name": "[\"LONCASTUXIMAB TESIRINE\"]",
        "brand_name": "[\"ZYNLONTA\"]",
        "substance_name": "[\"LONCASTUXIMAB TESIRINE\"]",
        "manufacturer_name": "[\"ADC Therapeutics America, Inc.\"]"
      },
      "trials": [
        "NCT05600686",
        "NCT04970901",
        "NCT05991388"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Czechia",
        "Spain",
        "United States",
        "Italy"
      ]
    },
    {
      "heading": "HuMax\u00ae-TF-ADC | Tisotumab Vedotin | TF-011-MMAE  HuMax-TF-ADC | Tivdak",
      "names": [
        "HuMax-TF-ADC",
        "IGG1-1015-011-1006",
        "Tisotumab Vedotin",
        "TF-011-MMAE",
        "Tivdak",
        "GCT1015-04",
        "TISOTUMAB VEDOTIN",
        "TISOTUMAB VEDOTIN TFTV",
        "Tisotumab vedotin",
        "TF-011-MMAE  HuMax-TF-ADC",
        "TIVDAK",
        "HuMax\u00ae-TF-ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Fallopian Tube Cancer",
        "Solid Malignancies",
        "Peritoneal Cancer",
        "Recurrent or stage IVB cervical cancer  MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)  MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10080244 Term: Peritoneal cancer index System Organ Class: 10022891 - Investigations",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (non-small cell lung cancer [NSCLC]  MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Carcinoma, Non-Small-Cell Lung",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "Solid Tumor  Cervical Cancer",
        "recurrent or metastatic cervical cancer  MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castrationresistant prostate cancer [CRPC]), esophagus, lung (non-small cell lung cancer [NSCLC]), and Squamous cell carcinoma of the head and neck (SCCHN)                   MedDRA version: 20.0                 Level: PT                 Classification code 10060862                 Term: Prostate cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: HLT                 Classification code 10014742                 Term: Endometrial neoplasms malignant                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10008342                 Term: Cervix carcinoma                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10023774                 Term: Large cell lung cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10062878                 Term: Gastrooesophageal cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10005003                 Term: Bladder cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: SOC",
        "Ovary Cancer",
        "Bladder Cancer",
        "Therapeutic area: Diseases [C] - Neoplasms [C04]",
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)                   MedDRA version: 20.0                 Level: PT                 Classification code 10033128                 Term: Ovarian cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10016180                 Term: Fallopian tube cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10080244                 Term: Peritoneal cancer index                 System Organ Class: 10022891 - Investigations",
        "Endometrium Cancer",
        "Ovarian Cancer",
        "Exocrine Pancreatic Cancer",
        "Second- or Third-Line Recurrent or Metastatic Cervical Cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Lung Cancer, Nonsmall Cell",
        "Lung Cancer (NSCLC)",
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Prostate Cancer (CRPC)",
        "Colorectal Neoplasms",
        "Esophagus Cancer",
        "recurrent or stage IVB cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), esophagus or lung (non-small cell lung cancer [NSCLC])  MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Cervix Cancer",
        "Lung Cancer(NSCLC)",
        "Prostate Cancer"
      ],
      "targets": [
        "Tissue Factor (TF), coagulation factor III (thromboplastin) also known as CD142, a protein encoded by the F3 gene present in subendothelial tissue and leukocytes."
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker on an average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Genmab"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4297841",
        "Name": "TISOTUMAB VEDOTIN",
        "Synonyms": "GCT1015-04|HuMax-TF-ADC|IGG1-1015-011-1006|TF-011-MMAE|TISOTUMAB VEDOTIN|TISOTUMAB VEDOTIN TFTV|Tivdak",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB16732",
        "Name": "Tisotumab vedotin",
        "Description": "Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via a protease-cleavable valine-citrulline linker. Each monoclonal antibody molecule carries an average of four MMAE molecules. Tisotumab vedotin is the first TF-directed ADC...",
        "Groups": "['Approved']",
        "Highlights": "Matched Description: \u2026 This is the first and only approved antibody-drug conjugate for this therapeutic indication. ... Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue ... Each monoclonal antibody molecule carries an average of four MMAE molecules. \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "fda_label": {
        "id": 62802,
        "description": "[\"11 DESCRIPTION Tisotumab vedotin-tftv is a Tissue Factor (TF) directed antibody drug conjugate (ADC) comprised of a human anti-TF IgG1-kappa antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable vc (valine-citrulline) linker. The monoclonal antibody is produced in a mammalian cell cline (Chinese hamster ovary). MMAE and the linker are produced by chemical synthesis. Each monoclonal antibody molecule carries an average of 4 MMAE molecules. Tisotumab vedotin-tftv has an approximate molecular weight of 153 kDa. The chemical structure is as follows: Figure 1. Structural Formula TIVDAK (tisotumab vedotin-tftv) for injection, is provided as a sterile, preservative-free, white to off-white lyophilized cake or powder in a single-dose vial for infusion after dilution. Following reconstitution with 4 mL of Sterile Water for Injection, a clear to slightly opalescent, colorless to brownish-yellow solution containing 10 mg/mL tisotumab vedotin-tftv is produced [see Dosage and Administration ( 2.3 )]. Each mL of reconstituted solution contains 10 mg of tisotumab vedotin-tftv, d-mannitol (30 mg), l-histidine (2.11 mg), l-histidine monohydrochloride (3.44 mg), and sucrose (30 mg), at pH 6.0.\"]",
        "generic_name": "[\"TISOTUMAB VEDOTIN\"]",
        "brand_name": "[\"TIVDAK\"]",
        "substance_name": "[\"TISOTUMAB VEDOTIN\"]",
        "manufacturer_name": "[\"Seagen Inc.\"]"
      },
      "trials": [
        "EUCTR2017-003413-25-IT",
        "NCT03485209",
        "NCT05866354",
        "EUCTR2016-004743-37-BE",
        "EUCTR2017-003413-25-CZ",
        "NCT03657043",
        "NCT03245736",
        "NCT02552121",
        "EUCTR2019-001219-22-IE",
        "EUCTR2019-001655-39-ES",
        "EUCTR2017-004758-40-DK",
        "CTIS2023-508832-68-00",
        "EUCTR2013-001074-15-GB",
        "NCT02001623",
        "EUCTR2019-001219-22-ES",
        "EUCTR2017-003413-25-DK",
        "EUCTR2017-003413-25-DE",
        "NCT03786081",
        "EUCTR2015-001120-29-DK",
        "NCT04697628",
        "NCT03438396"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Czech Republic",
        "Sweden",
        "Czechia",
        "Turkey",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Peru",
        "United States",
        "Estonia",
        "Brazil",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Austria",
        "Japan",
        "Spain",
        "Germany",
        "Croatia",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "SGN-PDL1V",
      "names": [
        "SGN-PDL1V"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Non-small cell lung cancer (NSCLC) Head and neck squamous cell carcinomas (HNSCC)"
      ],
      "targets": [
        "T cell checkpoint ligand, PD-(L)1. PD-(L)1 is a target with limited normal tissue expression and clinically validated expression across a variety of malignancies, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinomas (HNSCC)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease-cleavable peptide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-PD-L1 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "DS-7300a | MABX-9001a | Ifinatamab Deruxtecan \u2013 DS-7300a",
      "names": [
        "MABX-9001A CYSTEINYL-DERUXTECAN",
        "MABX-9001a",
        "DS-7300A",
        "DS 7300A",
        "DS-7300a",
        "IFINATAMAB DERUXTECAN",
        "Ifinatamab Deruxtecan \u2013 DS-7300a",
        "DS7300A"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer",
        "Extensive Stage-small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Advanced Solid and Malignant Tumors"
      ],
      "targets": [
        "B7-H3 (CD276), a type I transmembrane protein belonging to the B7 family which includes immune checkpoint molecules CTLA-4 ligands and PD-L1. B7-H3 is highly expressed in various types of solid tumors with low expression in normal  (healthy) tissues. Several studies have reported that B7-H3 overexpression is associated with poor prognosis in several types of cancers"
      ],
      "payload": [
        "Deruxtecan (an exatecan derivative, DXd, that is a potent DNA topoisomerase I inhibitor) conjugated, on an average of 4 cysteinyl"
      ],
      "linker": [
        "A thioether, an enzymatically cleavable peptide-based linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti\u2013B7-H3 IgG1 monoclonal antibody (MABX-9001a)"
      ],
      "Max Phase": "3",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095331",
        "Name": "IFINATAMAB DERUXTECAN",
        "Synonyms": "DS 7300A|DS-7300A|DS7300A|IFINATAMAB DERUXTECAN|MABX-9001A CYSTEINYL-DERUXTECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT06362252",
        "NCT05280470",
        "NCT06203210"
      ],
      "locations": [
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "Japan",
        "Spain",
        "Germany"
      ]
    },
    {
      "heading": "BA3021 | Ozuriftamab Vedotin | CAB-ROR2-ADC | BA3021 Anti-ROR2 ADC  CAB-ROR2-ADC | Anti-ROR2 ADC",
      "names": [
        "BA-3021",
        "BA3021",
        "Ozuriftamab Vedotin",
        "CAB-ROR2-ADC",
        "OZURIFTAMAB VEDOTIN",
        "BA3021 Anti-ROR2 ADC  CAB-ROR2-ADC",
        "Anti-ROR2 ADC",
        "Ozuriftamab vedotin"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Advanced solid tumors including non-small cell lung cancer (NSCLC), triple negative breast cancer and soft tissue sarcoma.",
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Melanoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Metastatic Squamous Cell Carcinoma of the Head and Neck",
        "Head and Neck Cancer",
        "Metastatic Cancer"
      ],
      "targets": [
        "Ror2, also known as receptor tyrosine kinase-like orphan receptor 2, is a membrane- bound RTK that is activated by non-canonical Wnt signaling through its association with the Wnt5A glycoprotein during normal bone and cartilage development."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE); vedotin, on an average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "BioAtla"
      ],
      "ttd": [
        "D08RWO",
        "D82BZH"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095285",
        "Name": "OZURIFTAMAB VEDOTIN",
        "Synonyms": "BA-3021|BA3021|CAB-ROR2-ADC (BA-3021)|OZURIFTAMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT05271604",
        "NCT03504488"
      ],
      "locations": [
        "Greece",
        "Spain",
        "Hong Kong",
        "Germany",
        "United States",
        "Italy",
        "Poland",
        "Taiwan"
      ]
    },
    {
      "heading": "Mecbotamab Vedotin | BA3011 | CAB-anti-Axl-ADC | CAB-Axl-ADC | CAB-anti-Axl-ADC BA3011",
      "names": [
        "Mecbotamab Vedotin",
        "BA3011",
        "CAB-AXL-ADC",
        "Mecbotamab vedotin",
        "BA-3011",
        "CAB-anti-Axl-ADC",
        "CAB-Axl-ADC",
        "CAB-anti-Axl-ADC BA3011",
        "MECBOTAMAB VEDOTIN"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors Pancreatic cancer; Colon cancer,  melanoma,  CML, Esophageal, Liver Cancer AML, NSCLC, Breast, Ovarian Cancer",
        "Non-Small-Cell Lung Cancer",
        "Myxofibrosarcoma",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "targets": [
        "AXL, a TAM family receptor tyrosine kinase and oncogene involved in the stimulation of cell proliferation. (AXL receptor tyrosine kinase, ARK, JTK11, Tyro7, UFO) [Homo sapiens]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE) (Vedotin)"
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker on an average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [
        "IgG1 - kappa CAB-Axl antibodies"
      ],
      "Max Phase": "2",
      "developers": [
        "BioAtla",
        "Sinobioway Biomedicine"
      ],
      "ttd": [
        "D00OON",
        "DYI4L2"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095312",
        "Name": "MECBOTAMAB VEDOTIN",
        "Synonyms": "BA-3011|BA3011|MECBOTAMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17442",
        "Name": "Mecbotamab vedotin",
        "Description": "Mecbotamab vedotin is an anti-Axl humanized monoclonal antibody conjugated to monomethyl auristatin E using a cleavable linker (CAB-Axl-ADC).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 humanized monoclonal antibody conjugated to monomethyl auristatin E using a cleavable linker (CAB-Axl-ADC \u2026",
        "Queries": "['\"adc\"']",
        "Query Indices": "[2]",
        "Score": 5
      },
      "trials": [
        "NCT04681131",
        "NCT03425279"
      ],
      "locations": [
        "Greece",
        "Spain",
        "Hong Kong",
        "Germany",
        "United States",
        "Italy",
        "Poland",
        "Taiwan"
      ]
    },
    {
      "heading": "SBT6050 | Pertuzumab Zuvotolimod",
      "names": [
        "SBT 6050",
        "PERTUZUMAB ZUVOTOLIMOD",
        "SBT6050",
        "Pertuzumab Zuvotolimod"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "HER2-Negative Metastatic Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Recurrent Breast Cancer",
        "Solid tumors HER2-Expressing Tumors",
        "Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "HER2-positive Breast Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens]"
      ],
      "payload": [
        "Analogue of motolimod (an agonist for the toll-like receptor 8, TLR8) on an average of 4 cysteinyl"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340); humanized monoclonal antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "Silverback"
      ],
      "ttd": "DUA7P2",
      "chembl": {
        "ChEMBL ID": "CHEMBL5095143",
        "Name": "PERTUZUMAB ZUVOTOLIMOD",
        "Synonyms": "PERTUZUMAB ZUVOTOLIMOD |SBT 6050",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT01966471",
        "NCT01904903",
        "NCT04538742",
        "NCT02131064",
        "NCT05323955",
        "NCT00934856",
        "NCT02073487",
        "NCT05113251",
        "NCT03726879",
        "NCT00943670",
        "NCT00781612",
        "NCT01120184",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT05954143"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Portugal",
        "Peru",
        "China",
        "Colombia",
        "Hong Kong",
        "United States",
        "Norway",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Austria",
        "New Zealand",
        "Japan",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel"
      ]
    },
    {
      "heading": "KSI-301 | OG1953 | KSI301 | Tarcocimab Tedromer | KSI 301",
      "names": [
        "KSI-301",
        "OG-1953",
        "TARCOCIMAB TEDROMER",
        "OG1953",
        "KSI301",
        "Tarcocimab Tedromer",
        "KSI 301"
      ],
      "phases": [
        "Phase 3"
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion",
        "Wet Age-related Macular Degeneration",
        "Age-related macular degeneration (AMD), neovascular (wet) Diabetic macular edema"
      ],
      "targets": [
        "VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)(humanized)"
      ],
      "payload": [
        "The biopolymer tedromer on an average of 2 cysteinyl"
      ],
      "linker": [],
      "domain": [
        "Ophthalmology Immunology;"
      ],
      "antibody": [
        "The Humanized monoclonal antibody tarcocimab conjugated via a linker to a nonaantennary dendrimer with phosphorylcholine polymer end groups"
      ],
      "Max Phase": "3",
      "developers": [
        "Kodiak Sciences"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095154",
        "Name": "TARCOCIMAB TEDROMER",
        "Synonyms": "KSI-301|OG-1953|OG1953|TARCOCIMAB TEDROMER",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "trials": [
        "NCT04592419",
        "NCT04964089"
      ],
      "locations": [
        "Puerto Rico",
        "Israel",
        "Hungary",
        "Czechia",
        "Latvia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Poland",
        "Slovakia"
      ]
    },
    {
      "heading": "Trastuzumab Corixetan | BAY 2635190 | BAY-2635190 | BAY2635190",
      "names": [
        "BAY2635190",
        "BAY 2635190",
        "BAY-2635190",
        "Trastuzumab Corixetan",
        "TRASTUZUMAB CORIXETAN"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Her 2 Positive Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Radiolabeled; Corixetan; Octadentate 3,2-HOPO chelator (BAY 1903150)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab conjugated to the chelator group corixetan on an average of 0.5 lysyl per antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "Bayer"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095155",
        "Name": "TRASTUZUMAB CORIXETAN",
        "Synonyms": "TRASTUZUMAB CORIXETAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04873362",
        "NCT05980481",
        "NCT00928330",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "AEX4089DC1 | MGC018 | Vobramitamab Duocarmazine | Anti-B7-H3 ADC | AEX4089DC1 Anti-B7-H3 ADC",
      "names": [
        "AEX4089DC1",
        "VOBRAMITAMAB DUOCARMAZINE",
        "Vobramitamab Duocarmazine",
        "MGC018",
        "Anti-B7-H3 ADC",
        "AEX4089DC1 Anti-B7-H3 ADC",
        "MGC-018",
        "Vobramitamab duocarmazine",
        "MGC 018"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Malignant Melanoma",
        "Hepatocellular Cancer",
        "Advanced Solid Tumor",
        "Renal Cell Carcinoma",
        "Castration-Resistant Prostatic Cancer",
        "Solid tumors Non-small cell lung cancer (NSCLC) Melanoma Metastatic prostate cancer Triple-negative breast cancer (TNBC) Head and neck squamous cell carcinoma (HNSCC)",
        "Epithelial Ovarian Cancer",
        "Pancreatic Ductal Carcinoma"
      ],
      "targets": [
        "B7-H3 (CD276), an immune checkpoint member of the B7 and CD28 families; Induced on antigen-presenting cells and plays an important role in the inhibition of T-cell function; highly overexpressed on a wide range of human solid cancers; Often correlates with both negative prognosis and poor clinical outcome in patients."
      ],
      "payload": [
        "A synthetic duocarmycin analogs.  (pro-drug seco-duocarmycin-p-hydroxybenzamide-azaindole (seco- DUBA) with an average of 2.7 cysteines"
      ],
      "linker": [
        "A cleavable N-[2-(2 maleimidoethoxy)ethoxycarbonyl]-L-valyl-L-citrullinyl- p-aminobenzyloxycarbonyl-N-[2-(2-hydroxyethoxy)ethyl]- N-[2-(methylamino)ethyl]carbamoyl linker  A duocarmycin-based, linker-drug; valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MacroGenics proprietary B7-H3 antibody (humanized B7-H3 mAb)"
      ],
      "Max Phase": "2",
      "developers": [
        "MacroGenics"
      ],
      "ttd": "DDP74J",
      "chembl": {
        "ChEMBL ID": "CHEMBL4594576",
        "Name": "VOBRAMITAMAB DUOCARMAZINE",
        "Synonyms": "AEX4089DC1|MGC 018|MGC-018|MGC018|VOBRAMITAMAB DUOCARMAZINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18871",
        "Name": "Vobramitamab duocarmazine",
        "Description": "Vobramitamab duocarmazine is under investigation in clinical trial NCT05551117 (A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Anti-b7h3 antibody-drug conjugate mgc018 \u2026 Matched Description: \u2026 Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT05293496"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "PSMA-TTC | PSMA-TTC PSMA targeted thorium-227 | BAY-2315497 | Pelgifatamab Corixetan",
      "names": [
        "PSMA-TTC",
        "PSMA-TTC PSMA targeted thorium-227",
        "BAY-2315497",
        "BAY2315497 Injection",
        "Pelgifatamab Corixetan"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic prostate cancer",
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "targets": [
        "FOLH1 (folate hydrolase, prostate-specific membrane antigen, PSMA) [Homo sapiens]"
      ],
      "payload": [
        "Chelator corixetan conjugated on an average of 1 lysine (0.8 chelator per antibody)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "trials": [
        "NCT03724747"
      ],
      "locations": [
        "United Kingdom",
        "United States",
        "Finland"
      ]
    },
    {
      "heading": "Grisnilimab setaritox | WT1-RTA",
      "names": [
        "Grisnilimab setaritox",
        "WT1-RTA"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Graft-versus-host disease (GvHD)"
      ],
      "targets": [
        "[CD7 (CD7 antigen (p41),GP40, LEU-9, TP41, Tp40)"
      ],
      "payload": [
        "An aglycosylated ricin toxin A (RTA), known as ricinus communis ricin A, conjugated on an average of 1.6 lysyl"
      ],
      "linker": [],
      "domain": [
        "Immunology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Xenikos"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SPV-T3a-RTA | Dafsolimab Setaritox",
      "names": [
        "SPV-T3a-RTA",
        "Dafsolimab Setaritox"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Graft-versus-host disease (GvHD)"
      ],
      "targets": [
        "CD3E (CD3 epsilon, Leu-4)]"
      ],
      "payload": [
        "An aglycosylated ricin toxin A (RTA), known as ricinus communis ricin A, conjugated on an average of 1.6 lysyl"
      ],
      "linker": [],
      "domain": [
        "Immunology"
      ],
      "antibody": [
        "Immunoglobulin G2B-kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Xenikos"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Mipasetamab Uzoptirine | ADCT-601",
      "names": [
        "Mipasetamab Uzoptirine",
        "MIPASETAMAB UZOPTIRINE",
        "ADCT-601"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors (eg, lung, breast, prostate, pancreas, glioma, and esophageal) and Hematological malignancies (eg, acute and chronic myeloid leukemia)."
      ],
      "targets": [
        "AXL (AXL receptor tyrosine kinase, ARK, JTK11, Tyro7, UFO)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PDB) dimer SG3199 on an average of 2 glycoengineered CH2 N84.4"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "1",
      "developers": [
        "ADC Therapeutics"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095300",
        "Name": "MIPASETAMAB UZOPTIRINE",
        "Synonyms": "ADCT-601|MIPASETAMAB UZOPTIRINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Zalsenertant Tetraxetan | Lutetium Lu 177 Zalsenertant Tetraxetan",
      "names": [
        "Zalsenertant Tetraxetan",
        "Lutetium Lu 177 Zalsenertant Tetraxetan"
      ],
      "phases": [],
      "conditions": [
        "Ductal pancreatic adenocarcinoma"
      ],
      "targets": [],
      "payload": [
        "Neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227)  Beta-emitting radioisotope lutetium Lu 177"
      ],
      "linker": [
        "Chelating agent, dodecanetetraacetic acid (DOTA)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMGN-632 | IMGN632 | MGN 632 | Pivekimab Sunirine | IMGN 632",
      "names": [
        "IMGN-632",
        "PIVEKIMAB SUNIRINE",
        "IMGN632",
        "MGN 632",
        "Pivekimab Sunirine",
        "IMGN 632"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Refractory Acute Myeloid Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Refractory/relapsed acute myeloid leukemia (AML)  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).",
        "Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Refractory T Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Myeloproliferative Neoplasm",
        "Mixed Phenotype Acute Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia"
      ],
      "targets": [
        "CD123 | The alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative advantage of leukemic cells."
      ],
      "payload": [
        "DNA mono-alkylating payload of the indolinobenzodiazepine pseudodimer (IGN) class of cytotoxic compounds (sulfonated DGN462).  Site-specific, via engineered cysteines  2 payload molecules are attached per antibody  The payload alkylates DNA without cross-linking"
      ],
      "linker": [
        "Peptide, stable in circulation, cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-CD123 antibody G4723A"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4297991",
        "Name": "PIVEKIMAB SUNIRINE",
        "Synonyms": "IMGN-632|IMGN632|PIVEKIMAB SUNIRINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17337",
        "Name": "IMGN632",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "trials": [
        "NCT06034470",
        "NCT04086264",
        "NCT05320380",
        "NCT03386513"
      ],
      "locations": [
        "United Kingdom",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ]
    },
    {
      "heading": "IMGC936",
      "names": [
        "IMGC-936",
        "IMGC936",
        "IMGC 936",
        "IZELTABART TAPATANSINE"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Multiple solid tumor types - non-small cell lung cancer, - gastric,  - pancreatic,  - triple-negative breast - colorectal)",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "ADAM9, a cell surface protein that belongs to the ADAM (a disintegrin and metalloproteinase) family of proteases, which have been implicated in cytokine and growth factor shedding and cell migration. Dysregulation of ADAM9 has been implicated in tumor progression and metastasis, as well as pathological neovascularization."
      ],
      "payload": [
        "DM21C, a next-generation maytansinoid microtubule-disrupting payload with greater stability and bystander activity than other DM compounds. DM21C is linked to the antibody by site-specific conjugation to two engineered cysteines (DAR=2)"
      ],
      "linker": [
        "A stable tripeptide linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MGA021: a high-affinity humanized anti-ADAM9 with YTE mutation"
      ],
      "Max Phase": "2",
      "developers": [
        "MacroGenics"
      ],
      "ttd": "DA4O8C",
      "chembl": {
        "ChEMBL ID": "CHEMBL5095346",
        "Name": "IZELTABART TAPATANSINE",
        "Synonyms": "IMGC 936|IMGC-936|IMGC936|IZELTABART TAPATANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT04622774"
      ],
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ]
    },
    {
      "heading": "IMGN151",
      "names": [
        "IMGN151"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Tumors with a broad range of FR\u03b1-expression including: - ovarian cancer - endometrial cancer - triple-negative breast cancer - non-small cell lung cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "High Grade Serous Adenocarcinoma of Ovary",
        "Endometrial Cancer"
      ],
      "targets": [
        "Folate Receptor alpha (FR\u03b1)"
      ],
      "payload": [
        "Maytansinoid derivative DM21.  The average drug per antibody ratio is 3.5."
      ],
      "linker": [
        "Stable cleavable peptide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A bivalent, biparatopic antibody targeting two independent epitopes of FR\u03b1."
      ],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN"
      ],
      "trials": [
        "NCT05527184"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "PRO1184",
      "names": [
        "PRO1184",
        "Rinatabart Sesutecan",
        "Rina-S"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Non-small Cell Lung Cancer",
        "Primary Peritoneal Carcinoma",
        "Mesothelioma",
        "Ovarian Cancer",
        "Hormone Receptor-positive/Her2 Negative Breast Cancer",
        "Locally advanced and/or metastatic solid tumors Ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma",
        "Endometrial Cancer",
        "Triple Negative Breast Cancer",
        "High Grade Epithelial Ovarian Cancer",
        "Ovarian, lung, and breast cancers",
        "Breast Adenocarcinoma"
      ],
      "targets": [
        "Folate receptor alpha (FOLR1), a glycosyl phosphatidylinositol anchored membrane protein.",
        "Folate receptor alpha"
      ],
      "payload": [
        "Exatecan, a topoisomerase 1 inhibitor.",
        "Exatecan payload"
      ],
      "linker": [
        "A cleavable, hydrophilic linker",
        "ProfoundBio's novel, proprietary hydrophilic linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A human monoclonal antibody that selectively binds to FOLR1",
        "A folate receptor alpha-directed antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "ProfoundBio"
      ],
      "trials": [
        "NCT05579366"
      ],
      "locations": [
        "China",
        "United States"
      ]
    },
    {
      "heading": "PRO1160",
      "names": [
        "PRO1160"
      ],
      "phases": [],
      "conditions": [
        "Multiple hematologic malignancies"
      ],
      "targets": [
        "CD70, an antigen that is aberrantly overexpressed in multiple hematologic malignancies and carcinomas with limited normal tissue expression."
      ],
      "payload": [
        "Exatecan, a topoisomerase 1 inhibitor"
      ],
      "linker": [
        "A cleavable, hydrophilic linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Human monoclonal antibody that selectively binds to CD70"
      ],
      "Max Phase": null,
      "developers": [
        "ProfoundBio"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ETx-22",
      "names": [
        "ETx-22"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Bladder and triple negative breast cancer (TNBC) as well as malignancies with medium and low nectin-4 expression levels, including ovarian, head and neck and lung cancer"
      ],
      "targets": [
        "Nectin-4, a protein located on the surface of cells that is highly expressed in bladder cancer and triple negative breast cancer as well as ovarian cancer and head and neck cancer."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Emergence"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "HS-20089",
      "names": [
        "HS-20089"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Fallopian Tube Cancer",
        "Advanced Solid Tumors",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Primary Peritoneal Cancer",
        "Advanced Solid tumors"
      ],
      "targets": [
        "B7-H4"
      ],
      "payload": [
        "Undisclosed Payload, DAR = 6"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Shanghai Hansoh Biomedical"
      ],
      "trials": [
        "NCT06014190",
        "NCT06336707",
        "NCT05263479"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "AZD8205",
      "names": [
        "AZD8205"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumors; Including breast, ovarian, endometrial, and cholangiocarcinoma.",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Biliary Tract Carcinoma",
        "Breast Cancer"
      ],
      "targets": [
        "B7-H4; This target has been associated with decreased inflammatory CD4+ T-cell responses and a correlation between B7-H4-expressing tumor-associated macrophages and FoxP3+ regulatory T cells (Tregs) within the tumor microenvironment. Since B7-H4 is expressed on tumor cells and tumor-associated macrophages in various cancer types, therapeutic blockade of B7-H4 could favorably alter the tumor microenvironment allowing for antigen-specific clearance tumor cells.  B7-H4 has limited expression in normal tissues, but is overexpressed in solid tumors, including breast, ovarian, endometrial, and cholangiocarcinoma, and is a potential target for tumor immunotherapy."
      ],
      "payload": [
        "A novel topoisomerase 1 inhibitor (TOP1i)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Antibody against B7-H4"
      ],
      "Max Phase": "2",
      "developers": [
        "AstraZeneca"
      ],
      "ttd": "DD10IZ",
      "trials": [
        "NCT05123482"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Japan",
        "China",
        "Spain",
        "United States",
        "Netherlands",
        "Thailand",
        "Italy",
        "Poland",
        "Taiwan"
      ]
    },
    {
      "heading": "SGN-B7H4V",
      "names": [
        "SGN-B7H4V"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Breast cancer Ovarian cancer Endometrial tumors."
      ],
      "targets": [
        "B7-H4, a member of the B7 family of immune checkpoint ligands. B7-H4 expression is elevated on a variety of solid tumors including breast, ovarian, and endometrial tumors."
      ],
      "payload": [
        "Microtubule disrupting agent monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease-cleavable peptide linker, valine-citrulline"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Fully human IgG1 anti-B7-H4 monoclonal antibody (mAb)"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TORL-2-307-ADC",
      "names": [
        "TORL-2-307-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "- Advanced Solid Tumor - Gastric Cancer - Pancreas Cancer - Gastroesophageal Junction Adenocarcinoma",
        "Pancreas Cancer"
      ],
      "targets": [
        "CLDN 18.2.  The Claudin 18.2 or CLDN18 protein is an isoform of claudin18, a member of the tight junction protein family and a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer.   CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors."
      ],
      "payload": [
        "MMAE (Monomethyl auristatin E, a synthetic antineoplastic)."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "TORL Biotherapeutics",
        "Translational Research in Oncology"
      ],
      "trials": [
        "NCT05156866"
      ],
      "locations": [
        "United States",
        "Korea, Republic of"
      ]
    },
    {
      "heading": "Anti-BCMA - | Anti-CD269-amanitin-ADC | anti-BCMA-ADC | Anti-BCMA-ATAC | Anti-CD269-ADC | HDP-101",
      "names": [
        "Anti-BCMA -",
        "Anti-CD269-amanitin-ADC",
        "anti-BCMA-ADC",
        "Anti-BCMA-ATAC",
        "Anti-CD269-ADC",
        "HDP-101"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "- Multiple Myeloma (MM); - Non Hodgkin Lymphoma (B-cell) - Plasma Cell Disorder"
      ],
      "targets": [
        "CD269; also known as B cell maturation antigen (BCMA); a member of the TNF-receptor superfamily that is preferentially expressed in mature B lymphocytes. CD269 promotes B cell survival and plays a role in the regulation of humoral immunity."
      ],
      "payload": [
        "Amanitin (amatoxin family); a small bicyclic peptide naturally occurring in the death cap mushroom.  DAR = 2"
      ],
      "linker": [
        "Cleavable linker / Site specific"
      ],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [
        "anti-CD269 mAb"
      ],
      "Max Phase": "2",
      "developers": [
        "Heidelberg Pharma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "MGTA-117 \u2013 Amanitin ADC",
      "names": [
        "MGTA-117 \u2013 Amanitin ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "targets": [
        "CD117 (c-Kit)"
      ],
      "payload": [
        "Amanitin"
      ],
      "linker": [],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Heidelberg Pharma",
        "Magenta"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "A166 ADC A166 anti-HER2 ADC A166 | A166 ADC",
      "names": [
        "A166 ADC A166 anti-HER2 ADC A166",
        "A166 ADC",
        "A166"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Mucoepidermoid Carcinoma",
        "Mucinous Breast Cancer Recurrent",
        "Rectal Cancer",
        "Rectal Cancer Stage III",
        "Mucinous Adenocarcinoma Gastric",
        "Salivary Gland Neoplasms",
        "Pancreatic Cancer",
        "Lung Cancer",
        "Rectal Cancer Stage I",
        "Larynx Cancer",
        "Primary Peritoneal Carcinoma",
        "Cholangiocarcinoma",
        "Recurrent Colon Cancer",
        "Mouth Cancer",
        "HER2 Gene Mutation",
        "HER2 Positive Gastric Cancer",
        "Salivary Gland Cancer",
        "Solid Tumor",
        "Head and Neck Cancer",
        "HER2-positive Breast Cancer",
        "Bladder Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Ovarian Carcinoma",
        "Rare Diseases",
        "Recurrent Gastric Cancer",
        "Urologic Cancer",
        "Breast Neoplasm Malignant Primary",
        "Head and Neck Carcinoma",
        "Salivary Gland Tumor",
        "Relapsed/refractory cancers expressing HER2 Antigen or having amplified HER2 Gene.  Breast cancer",
        "Tongue Cancer",
        "Palate Cancer",
        "Skin Cancer",
        "Salivary Gland Carcinoma",
        "HER-2 Gene Amplification",
        "Recurrent Breast Cancer",
        "Colo-rectal Cancer",
        "Liver Cancer",
        "Lip Cancer Stage I",
        "Rectal Cancer Stage II",
        "Recurrent Prostate Cancer",
        "Bile Duct Cancer",
        "Tonsil Cancer",
        "Prostate Cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "payload": [
        "Auristatin-based payload"
      ],
      "linker": [
        "A site-specific conjugation and cleavable Val-Cit linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-HER2 antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "KLUS"
      ],
      "ttd": "DD94ZN",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17413",
        "Name": "A166",
        "Description": "A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to Duostatin-5 \u2026 Matched Description: \u2026 A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) ... site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT03602079"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "SKB315",
      "names": [
        "SKB315"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "targets": [
        "CLDN 18.2.  The Claudin 18.2 or CLDN18 protein is an isoform of claudin18, a member of the tight junction protein family and a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer.   CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors."
      ],
      "payload": [
        "A topoisomerase I inhibitor"
      ],
      "linker": [
        "A site-specific conjugation and highly stable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A anti-Claudin 18.2 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "KLUS"
      ],
      "ttd": "D56AJO",
      "trials": [
        "NCT05367635"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "SKB264 ADC",
      "names": [
        "SKB264",
        "SKB264 ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "Endometrial Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Small-Cell Lung Cancer",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Gastroesophageal Junction Adenocarcinoma",
        "Urothelial Carcinoma",
        "Endometrial Cancer",
        "Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies, including:  - Ovarian epithelial cancer - Gastric adenocarcinoma - Pancreatic adenocarcinoma - Triple negative breast cancer - Bladder cancer",
        "Epithelial Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Breast Cancer",
        "Gastric Adenocarcinoma"
      ],
      "targets": [
        "TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is highly expressed on several types of solid tumors."
      ],
      "payload": [
        "A proprietary cytotoxic, belotecan-derived payload. Belotecan (Camtobell\u00ae; CKD602) is a novel camptothecin derivative antitumor agent."
      ],
      "linker": [
        "via site-specific conjugation and highly stable linker; Average DAR (Drug Antibody Ratio) of 7.4."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "KLUS"
      ],
      "ttd": "DOS62C",
      "trials": [
        "NCT06132958",
        "NCT04152499",
        "NCT06074588"
      ],
      "locations": [
        "Puerto Rico",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Canada",
        "Malaysia",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Japan",
        "Spain",
        "Argentina",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "AMG-595 | AMG595",
      "names": [
        "AMG-595",
        "AMG595"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Glioma (GBM) / Brain cancer"
      ],
      "targets": [
        "EGFRviii"
      ],
      "payload": [
        "Maytansine DM1"
      ],
      "linker": [
        "Non-cleavable linker; Hetero-bifunctional linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-EGFRvIII antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Amgen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "DS-9606-a | DS-9606a",
      "names": [
        "DS-9606-a",
        "DS-9606a"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "- Advanced Cancer - Metastatic Cancer - Ovarian Cancer - Germ Cell Tumor"
      ],
      "targets": [
        "Undisclosed"
      ],
      "payload": [
        "Undisclosed"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "YL201",
      "names": [
        "YL201"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Solid Tumors"
      ],
      "targets": [
        "Undisclosed"
      ],
      "payload": [
        "Undisclosed"
      ],
      "linker": [
        "Tumor Microenvironment Activable Linker (TMALIN)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "MediLink"
      ],
      "trials": [
        "NCT05434234",
        "NCT06057922"
      ],
      "locations": [
        "China",
        "United States"
      ]
    },
    {
      "heading": "BB-1705",
      "names": [
        "BB-1705"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid tumors"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor (EGFR)"
      ],
      "payload": [
        "Eribulin,  a fully synthetic, structurally simplified, macrocyclic ketone analogue of the marine natural product halichondrin B, produced from the marine sponge Halichondria okadai. Eribulin\u2019s anti-tumor activity is mediated by the inhibition of microtubule elongation and mitotic spindle formation, which results in apoptosis.  DAR = 2"
      ],
      "linker": [
        "REsidue-SPEcific Conjugation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An Anti-EGFR antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Bliss (Hangzhou)"
      ],
      "trials": [
        "NCT05217693"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "GSK2857916 | Belantamab mafodotin | J6M0-mcMMAF | GSK2857916  2857916 GSK '916 J6M0-mcMMAF | Blenrep\u00ae",
      "names": [
        "BELANTAMAB",
        "BELANTAMAB MAFODOTIN",
        "GSK2857916",
        "Belantamab mafodotin",
        "BELANTAMAB MAFODOTIN BLMF",
        "GSK-2857916",
        "Blenrep",
        "J6M0-mcMMAF",
        "GSK2857916  2857916 GSK '916 J6M0-mcMMAF",
        "Blenrep\u00ae"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Malignant Glioma",
        "Multiple myeloma (BTD and PRIME)",
        "Refractory Multiple Myeloma",
        "Health Condition 1: -  Health Condition 2: D758- Other specified diseases of bloodand blood-forming organs Health Condition 3: D758- Other specified diseases of bloodand blood-forming organs",
        "Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864",
        "Multiple Myeloma",
        "Relapsed Cancer"
      ],
      "targets": [
        "TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)."
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)   An average of 4 cysteinyl"
      ],
      "linker": [
        "A noncleavable maleimidocaproyl (mc) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Humanized monoclonal antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "GlaxoSmithKline",
        "Seagen"
      ],
      "ttd": "D52NZX",
      "chembl": {
        "ChEMBL ID": "CHEMBL4298209",
        "Name": "BELANTAMAB MAFODOTIN",
        "Synonyms": "BELANTAMAB MAFODOTIN|BELANTAMAB MAFODOTIN BLMF|Blenrep|GSK-2857916|GSK2857916",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 1
      },
      "fda_label": {
        "id": 151385,
        "description": "[\"11 DESCRIPTION Belantamab mafodotin-blmf is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate. Belantamab mafodotin-blmf is an antibody conjugate composed of 3 components: 1) afucosylated, humanized immunoglobulin G1 monoclonal antibody covalently linked to 2) the microtubule inhibitor MMAF via 3) a protease-resistant maleimidocaproyl linker. The antibody is produced in a mammalian cell line (Chinese Hamster Ovary) using recombinant DNA technology and the microtubule inhibitor and linker are produced by chemical synthesis. Approximately 4 molecules of mafodotin are attached to each antibody molecule. The molecular weight of belantamab mafodotin-blmf is approximately 152 kDa. Belantamab mafodotin-blmf has the following structure: BLENREP (belantamab mafodotin-blmf) for injection is a sterile, preservative-free, white to yellow, lyophilized powder in a single-dose vial for reconstitution and further dilution prior to intravenous use. BLENREP is supplied as 100 mg per vial and requires reconstitution with 2 mL of Sterile Water for Injection, USP, to obtain a concentration of 50 mg/mL . Each mL of reconstituted solution contains belantamab mafodotin-blmf (50 mg) and the inactive ingredients, citric acid (0.42 mg), disodium edetate dihydrate (0.019 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.6 mg), and trisodium citrate dihydrate (6.7 mg). The pH of the reconstituted solution is 6.2. Belantamab mafodotin-blmf chemical structure\"]",
        "generic_name": "[\"BELANTAMAB\"]",
        "brand_name": "[\"Blenrep\"]",
        "substance_name": "[\"BELANTAMAB MAFODOTIN\"]",
        "manufacturer_name": "[\"GlaxoSmithKline LLC\"]"
      },
      "trials": [
        "NCT04484623",
        "NCT03544281",
        "CTRI/2022/05/042713",
        "NCT05064358",
        "NCT03763370",
        "NCT03828292",
        "NCT04246047",
        "NCT02064387",
        "NCT04822337",
        "NCT03525678",
        "NCT04177823",
        "NCT05922501",
        "EUCTR2018-002816-29-DE",
        "NCT02590263",
        "EUCTR2017-004810-25-DE"
      ],
      "locations": [
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Republic of Korea",
        "Belgium",
        "China",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "United States of America",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Ireland",
        "New Zealand",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ]
    },
    {
      "heading": "RC118",
      "names": [
        "RC118"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Solid Tumors including gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer."
      ],
      "targets": [
        "Claudin 18.2, also known as CLDN18.2, is an isoform of claudin 18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer.   Claudin 18.2 is involved in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE), a potent tubulin binder with a half maximal inhibitory concentration (IC50) in the subnanomolar range,"
      ],
      "linker": [
        "Cathepsin cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-CLDN18.2 antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "MabPlex",
        "RemeGen"
      ],
      "ttd": "D5R8YF",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18428",
        "Name": "RC118",
        "Description": "RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Recombinant humanized anti-MSLN monoclonal antibody- monomethyl auristatin E conjugate \u2026 Matched Description: \u2026 RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal ... antibody conjugated to MMAE. \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT06038396",
        "NCT05205850"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "CRB-701 | SYS6002",
      "names": [
        "CRB-701",
        "SYS6002"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Advanced solid tumors, focusing\u00a0on urothelial cancer and other Nectin-4-positive solid tumors potentially including lung, breast and prostate cancer."
      ],
      "targets": [
        "Nectin-4"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Neticin-4 targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Corbus"
      ],
      "trials": [
        "NCT06265727"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "Turkey"
      ]
    },
    {
      "heading": "PYX-201",
      "names": [
        "PYX-201"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors, including breast, head and neck, lung, and thyroid cancer."
      ],
      "targets": [
        "Fibronectin extra-domain B (ED-B)"
      ],
      "payload": [
        "Auristatin"
      ],
      "linker": [
        "A cathepsin B-cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Human IgG1 anti-fibronectin extra-domain B monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Pyxis Oncology"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18382",
        "Name": "PYX-201",
        "Description": "PYX-201 is an antibody-drug conjugate directed against the extra domain-B splice variant of fibronectin.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 PYX-201 is an antibody-drug conjugate directed against the extra domain-B splice variant of fibronectin \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Anti 5T4 ADC SYD1875 | SYD1875",
      "names": [
        "Anti 5T4 ADC SYD1875",
        "SYD1875"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid tumors"
      ],
      "targets": [
        "5T4, a 72 kD, heavily N-glycosylated proteins with several leucine-rich repeats which are often associated with protein-protein interactions. The protein is expressed by many different cancers but rarely in normal adult tissues."
      ],
      "payload": [
        "Duocarmycin analogues  http://www.adcreview.com/duocarmycin-analogues/"
      ],
      "linker": [
        "Cleavable valine-citrulline-seco (vc-seco)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "humanized IgG1 5T4 oncofetal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Byondis"
      ],
      "trials": [
        "NCT04202705"
      ],
      "locations": [
        "Belgium",
        "France"
      ]
    },
    {
      "heading": "BYON3521 ADC | BYON3521",
      "names": [
        "BYON3521 ADC",
        "BYON3521"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid tumors"
      ],
      "targets": [
        "c-MET, also known as tyrosine-protein kinase MET [Mesenchymal Epithelial Transition] factor or HGFR [Hepatocyte Growth Factor Receptor]), is a proto-oncogene active in normal cell division, growth and differentiation."
      ],
      "payload": [
        "A DNA-alkylating duocarmycin analog.   Duocarmycin hydroxybenzamide azaindole (DUBA), is rapidly degraded in the plasma, potentially increasing the maximum tolerated doses.  http://www.adcreview.com/duocarmycin-analogues/"
      ],
      "linker": [
        "Cleavable valine-citrulline-seco (vc-seco)  A cleavable linker-drug called valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA or SYD980)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized IgG1 c-MET-targeting monoclonal antibody, SYD2884."
      ],
      "Max Phase": "1",
      "developers": [
        "Byondis"
      ],
      "trials": [
        "NCT05323045"
      ],
      "locations": [
        "United Kingdom",
        "Italy",
        "Belgium",
        "Netherlands"
      ]
    },
    {
      "heading": "BYON4413 BYON4413 ADC | BYON4413 ADC",
      "names": [
        "BYON4413 BYON4413 ADC",
        "BYON4413 ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Relapsed / Refractory AML",
        "Relapsed / Refractory MDS"
      ],
      "targets": [
        "Directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed on many hemato-oncological malignancies."
      ],
      "payload": [
        "A DNA-alkylating duocarmycin analog  Duocarmycin hydroxybenzamide azaindole (DUBA), is rapidly degraded in the plasma, potentially increasing the maximum tolerated doses.  http://www.adcreview.com/duocarmycin-analogues/"
      ],
      "linker": [
        "Cleavable valine-citrulline-seco (vc-seco)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Byondis"
      ],
      "trials": [
        "NCT06359002"
      ],
      "locations": [
        "Spain",
        "Belgium",
        "Netherlands"
      ]
    },
    {
      "heading": "PSMA-ADC",
      "names": [
        "PSMA-ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Prostate cancer and Glioblastoma Multiforme (GBM)"
      ],
      "targets": [
        "FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Progenics Pharmaceuticals"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "STRO-001 | Anti-CD74-ADC",
      "names": [
        "STRO-001",
        "Anti-CD74-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma (MM),  Diffuse large B-cell lymphoma; Mantle cell lymphoma",
        "B Cells--Tumors",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Indolent Lymphoma",
        "Multiple Myeloma",
        "Non Hodgkin Lymphoma",
        "B-cell Lymphoma"
      ],
      "targets": [
        "CD74; a type II transmembrane glycoprotein involved in the formation and transport of MHC class II protein. CD74 is rapidly internalized and highly expressed in many B-cell malignancies with limited expression in normal tissues."
      ],
      "payload": [
        "Maytansoid  A drug-antibody ratio (DAR) of 2"
      ],
      "linker": [
        "A non-cleavable dibenzocyclooctyne (DBCO) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "a p-azido-methyl-phenylalanine (pAMF)-containing anti-CD74 aglycosylated human IgG1 antibody (SP7219)"
      ],
      "Max Phase": "1",
      "developers": [
        "Sutro Biopharma"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17224",
        "Name": "STRO-001",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) and two non-cleavable ... Anti-CD74 antibody-drug conjugate STRO-001 ... STRO-001, a site-specific anti-CD74 antibody-drug conjugate \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT03424603"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "SYD985 | Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole | SYD 985 | Trastuzumab vc-seco-DUBA | Trastuzumab duocarmazine",
      "names": [
        "SYD985",
        "Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole",
        "SYD 985",
        "Trastuzumab vc-seco-DUBA",
        "Trastuzumab duocarmazine",
        "TRASTUZUMAB DUOCARMAZINE",
        "SYD-985"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Solid Tumors",
        "Metastatic Breast Cancer",
        "Solid tumors (HER2-expressing breast cancer) - Breast cancer - Uterine Serous Carcinoma (USC)",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Solid Tumor",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Her 2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Endometrial Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Duocarmycin / Seco-DUBA"
      ],
      "linker": [
        "A cleavable linker N-[2-(2 maleimidoethoxy)ethoxycarbonyl]-L-valyl-L-citrullinyl- p-aminobenzyloxycarbonyl-N-[2-(2-hydroxyethoxy)ethyl]- N-[2-(methylamino)ethyl]carbamoyl   An average of 2 or 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Byondis"
      ],
      "ttd": [
        "D0HL5N",
        "DI0ED3"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4298178",
        "Name": "TRASTUZUMAB DUOCARMAZINE",
        "Synonyms": "SYD-985|SYD985|TRASTUZUMAB DUOCARMAZINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB16342",
        "Name": "Trastuzumab duocarmazine",
        "Description": "Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibody \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT02277717",
        "NCT04205630",
        "NCT04873362",
        "NCT05980481",
        "NCT03262935",
        "NCT00928330",
        "NCT04235101",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Kenya",
        "Portugal",
        "China",
        "Peru",
        "Hong Kong",
        "Colombia",
        "United States",
        "Norway",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Dominican Republic",
        "Chile",
        "Taiwan",
        "Bosnia and Herzegovina",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "Uganda",
        "Spain",
        "Germany",
        "New Zealand",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel"
      ]
    },
    {
      "heading": "BAT8007",
      "names": [
        "BAT8007"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "Nectin-4, a tumor-associated antigen found on the surface of solid tumor cells/"
      ],
      "payload": [
        "A small molecule topoisomerase I inhibitor and high DAR."
      ],
      "linker": [
        "Proprietary ADC linker-payload with a cleavable but systemically stable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-Nectin4"
      ],
      "Max Phase": "1",
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV-319",
      "names": [
        "ABBV-319"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "CD19, a marker essential for B-cell proliferation and has high expression across B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL)."
      ],
      "payload": [
        "A proprietary glucocorticosteroid / glucocorticoid receptor modulators [GRMs]) payload"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An optimized high-affinity immunoglobulin G1 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV-400",
      "names": [
        "ABBV-400"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors including squamous and non squamous non-small cell lung cancer, gastric cancer, gastroesophageal adenocarcinoma, head and neck cancer squamous cell carcinoma, colorectal cancer, renal cell carcinoma."
      ],
      "targets": [
        "c-Met (hepatocyte growth factor receptor; HGFR), a receptor tyrosine kinase over-expressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis."
      ],
      "payload": [
        "An undisclosed topoisomerase inhibitor"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV-706",
      "names": [
        "ABBV-706"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Recurrent or refractory solid tumors including small cell lung cancer (SCLC), high grade central nervous system tumors like grade-4 glioblastoma (GBM), grade-3 oligodendroglioma, grade 3/4 astrocytoma, neuroendocrine carcinomas like neuroendocrine prostate cancer (NEPC), gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), large cell neuroendocrine carcinoma (LCNEC), and SCLC transformed from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)."
      ],
      "targets": [
        "Seizure-related homolog 6 (SEZ6)."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18710",
        "Name": "ABBV-706",
        "Description": "ABBV-706 is an antibody-drug conjugate that is anti-SEZ6.[L49156,L49161]",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 ABBV-706 is an antibody-drug conjugate that is anti-SEZ6.[L49156,L49161] \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "GMF-1A3-MMAE | GMF-1A3",
      "names": [
        "GMF-1A3-MMAE",
        "GMF-1A3"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Breast cancer"
      ],
      "targets": [
        "Amphiregulin ( (AREG) , a key proliferative effector of estrogen receptor signaling in breast cancer and other malignancies.   Amphiregulin is a single-pass transmembrane protein proteolytically processed by TACE/ADAM17 to release the soluble EGFR ligand, leaving a residual transmembrane stalk that is subsequently internalized."
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TH1902 | Sudocetaxel Zendusortide",
      "names": [
        "TH1902",
        "Sudocetaxel Zendusortide"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Solid Malignancies",
        "Carcinoma, Non-Small-Cell Lung",
        "Neoplasm Metastasis",
        "Prostatic Neoplasms, Castration-Resistant",
        "Lung Cancer",
        "Androgen-Resistant Prostatic Neoplasms",
        "Advanced or Metastatic Non-Small-Cell Lung Cancer",
        "Breast Neoplasms",
        "Resectable Non-Small-Cell Lung Cancer",
        "Solid Tumor",
        "Bladder Cancer",
        "Prostatic Cancer, Castration-Resistant",
        "Locally Advanced or Early Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Locally Advanced or Metastatic Unresectable Urothelial Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Non-Small Cell Lung Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Ureteral Cancer",
        "Urothelial Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "Sortilin (SORT1) receptor.  A novel receptor that is highly expressed in many types of cancer and is associated with poor prognosis and decreased survival"
      ],
      "payload": [
        "Docetaxel (2:1 ratio),"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [],
      "antibody": [
        "TH19P01, a proprietary, sortilin-targeting peptide"
      ],
      "Max Phase": "3",
      "developers": [
        "Theratechnologies"
      ],
      "trials": [
        "NCT02131064",
        "NCT04880863",
        "NCT03337698",
        "NCT04381832",
        "NCT00781612",
        "NCT01120184",
        "NCT04794699",
        "NCT02605915",
        "NCT05089734",
        "NCT00132379",
        "NCT06074588",
        "NCT03474107",
        "NCT04527991",
        "NCT00051571",
        "NCT00679341",
        "NCT05633667",
        "NCT01966471",
        "NCT05006794",
        "NCT00934856"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "Belgium",
        "Bahamas",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Ireland",
        "Hungary",
        "New Zealand",
        "Japan",
        "Romania",
        "Germany",
        "Spain",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel"
      ]
    },
    {
      "heading": "XMT1536 | XMT-1536 XMT 1536 UpRi Upifitamab Rilsodotin | XMT-1536 | UpRi | Upifitamab Rilsodotin",
      "names": [
        "XMT1536",
        "XMT-1536 XMT 1536 UpRi Upifitamab Rilsodotin",
        "XMT-1536",
        "UpRi",
        "Upifitamab rilsodotin",
        "Upifitamab Rilsodotin"
      ],
      "phases": [
        "Preclinical",
        "Phase 3"
      ],
      "conditions": [
        "Solid tumors; NSCLC; Ovarian cancer"
      ],
      "targets": [
        "NaPi2b; Sodium-dependent phosphate transport protein 2B is involved in actively transporting phosphate into cells via Na+ co-transport. NaPi2b is highly expressed in 75 to 90% of both non-squamous NSCLC and epithelial ovarian cancer."
      ],
      "payload": [
        "A proprietary auristatin payload (3 to 5 flexible polymers PHF-BA-EG2-MI-AF-HPA-Ala, each comprising maleimide (MI) bioconjugation linkers and 3 to 4 auristatin F- hydroxypropylamide-L-alanine (AF-HPA-Ala), with a drug to antibody ratio (DASR) of 12:1 to 15:1"
      ],
      "linker": [
        "Thioether bond (Protease cleavable)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Mersana"
      ],
      "ttd": "D0QFD2",
      "locations": [],
      "trials": []
    },
    {
      "heading": "M9346A-sulfo-SPDB-DM4 | Elahere | Anti-FOLR1 monoclonal -maytansinoid | IMGN853 | IMGN-853 | Mirvetuximab Soravtansine",
      "names": [
        "MIRVETUXIMAB SORAVTANSINE GYNX",
        "Mirvetuximab Soravtansine",
        "ELAHERE",
        "M9346A-sulfo-SPDB-DM4",
        "Elahere",
        "Anti-FOLR1 monoclonal -maytansinoid",
        "Mirvetuximab soravtansine",
        "MIRVETUXIMAB SORAVTANSINE",
        "IMGN-853",
        "IMGN853",
        "MIRVETUXIMAB SORAVTANSINE-GYNX"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Solid Tumors",
        "Epithelial Ovarian Cancer",
        "Folate Receptor-Alpha Positive",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma",
        "Platinum Resistant Ovarian Cancer",
        "Recurrent Fallopian Tube Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Recurrent Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "BRCA2 Gene Mutation",
        "Recurrent Uterine Serous Carcinoma",
        "Ovary Cancer",
        "Recurrent Ovarian Carcinoma",
        "Ovarian Cancer",
        "Recurrent Uterine Corpus Carcinoma",
        "BRCA1 Gene Mutation",
        "Folate Receptor Alpha Positive",
        "Ovarian tumor; non-small cell lung cancer (NSCLC) and other solid tumor",
        "Endometrial Cancer",
        "High Grade Ovarian Cancer",
        "Recurrent Uterine Carcinosarcoma",
        "Tumors"
      ],
      "targets": [
        "Folate receptor 1 (FR\u03b1/ Folate Receptor \u03b1, FOLRI 1)"
      ],
      "payload": [
        "Maytansinoid DM4  (N2'- Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine"
      ],
      "linker": [
        "N-Succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate linker (Sulfo-SPDB).  Linker specifically designed to counteract multi-drug resistance"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa M9346A anti- FR\u03b1 antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3545132",
        "Name": "MIRVETUXIMAB SORAVTANSINE",
        "Synonyms": "ELAHERE|Elahere|IMGN-853|IMGN853|MIRVETUXIMAB SORAVTANSINE|MIRVETUXIMAB SORAVTANSINE GYNX|MIRVETUXIMAB SORAVTANSINE-GYNX",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB12489",
        "Name": "Mirvetuximab soravtansine",
        "Description": "Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FR\u03b1), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853 \u2026 Matched Description: \u2026 Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody ... DM4 leads to cell-cycle arrest and apoptosis and is also able to diffuse into neighboring cells and induce ... [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "fda_label": {
        "id": 17148,
        "description": "[\"11 DESCRIPTION Mirvetuximab soravtansine-gynx is a folate receptor alpha (FR\u03b1)-directed antibody-drug conjugate (ADC) consisting of three components: 1) an anti-FR\u03b1 monoclonal antibody of IgG1 subtype 2) the small molecule anti-tubulin agent DM4 (a maytansine derivative) and 3) a linker, sulfo-SPDB (1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid) that covalently attaches DM4 to the mirvetuximab antibody. Mirvetuximab soravtansine-gynx has an approximate molecular weight of 150 kDa. An average of 3.4 molecules of DM4 are attached to each antibody molecule. Mirvetuximab soravtansine-gynx is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. Mirvetuximab soravtansine-gynx has the following structure: ELAHERE (mirvetuximab soravtansine-gynx) injection is supplied as a sterile, preservative-free, clear to slightly opalescent, colorless solution containing 100 mg/20 mL of mirvetuximab soravtansine-gynx in single-dose vials. Each mL of solution contains 5 mg of mirvetuximab soravtansine-gynx, and glacial acetic acid (0.22 mg), polysorbate 20 (0.1 mg), sodium acetate (0.53 mg), sucrose (90 mg), and Water for Injection. The pH is approximately 5.0. The ELAHERE vial stoppers are not made with natural rubber latex. Chemical Structure\"]",
        "generic_name": "[\"MIRVETUXIMAB SORAVTANSINE\"]",
        "brand_name": "[\"ELAHERE\"]",
        "substance_name": "[\"MIRVETUXIMAB SORAVTANSINE\"]",
        "manufacturer_name": "[\"ImmunoGen, Inc.\"]"
      },
      "trials": [
        "NCT05887609",
        "NCT04296890",
        "NCT05445778",
        "NCT01609556",
        "NCT03552471",
        "NCT04274426",
        "NCT06390995",
        "NCT02606305",
        "NCT05041257",
        "NCT05456685",
        "NCT04209855",
        "NCT02631876",
        "NCT03832361",
        "NCT05622890",
        "NCT06365853",
        "NCT03835819"
      ],
      "locations": [
        "Ukraine",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Georgia",
        "Canada",
        "Bulgaria",
        "Serbia",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Japan",
        "Spain",
        "Germany",
        "Bosnia and Herzegovina",
        "Israel"
      ]
    },
    {
      "heading": "Basiliximab Sarotalocan",
      "names": [
        "BASILIXIMAB SAROTALOCAN",
        "Basiliximab Sarotalocan"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "Anti-[Homo sapiens IL2RA (interleukin 2 receptor subunit alpha; IL-2RA, TAC, p55, CD25)]"
      ],
      "payload": [
        "IRDye 700DX (IR700) near-infrared photosensitizing dye Conjugated on an average of 2 or 3 lysyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens IL2RA (interleukin 2 receptor subunit alpha; IL-2RA, TAC, p55, CD25)], chimeric monoclonal antibody"
      ],
      "Max Phase": "2",
      "chembl": {
        "ChEMBL ID": "CHEMBL5314724",
        "Name": "BASILIXIMAB SAROTALOCAN",
        "Synonyms": "BASILIXIMAB SAROTALOCAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Maridebart cafraglutide",
      "names": [
        "MARIDEBART CAFRAGLUTIDE",
        "Maridebart cafraglutide"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "Glucagon-like peptide 1 (GLP-1) receptor GIPR (gastric inhibitory polypeptide receptor)"
      ],
      "payload": [
        "Two identical glucagon-like peptide 1 (GLP-1) analogues"
      ],
      "linker": [
        "A fused 18-mer linker (diglycyl- tris(tetraglycyl-seryl)- lysinamide"
      ],
      "domain": [],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens GIPR (gastric inhibitory polypeptide receptor)], Homo sapiens monoclonal antibody"
      ],
      "Max Phase": "2",
      "chembl": {
        "ChEMBL ID": "CHEMBL5314751",
        "Name": "MARIDEBART CAFRAGLUTIDE",
        "Synonyms": "MARIDEBART CAFRAGLUTIDE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Oberotatug Ravtansine",
      "names": [
        "Oberotatug Ravtansine",
        "OBEROTATUG RAVTANSINE"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "LY75 (human lymphocyte antigen 75, C-type lectin domain family 13 member B, CLEC13B, DEC-205, CD205)]"
      ],
      "payload": [
        "maytansinoid DM4 [N2'- deacetyl-N2'-(4-mercapto-4- methyl-1-oxopentyl)-maytansine]"
      ],
      "linker": [
        "A reducible SPDB linker [N- succinimidyl 4-(2-pyridyldithio)butanoate]"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A human immunoglobulin G1-kappa, anti-[Homo sapiens LY75 (human lymphocyte antigen 75, C-type lectin domain family 13 member B, CLEC13B, DEC-205, CD205)]"
      ],
      "Max Phase": "2",
      "chembl": {
        "ChEMBL ID": "CHEMBL5314757",
        "Name": "OBEROTATUG RAVTANSINE",
        "Synonyms": "OBEROTATUG RAVTANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Puxitatug samrotecan",
      "names": [
        "Puxitatug samrotecan",
        "PUXITATUG SAMROTECAN"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)"
      ],
      "payload": [
        "A  topoisomerase I inhibitor"
      ],
      "linker": [],
      "domain": [],
      "antibody": [
        "immunoglobulin G1-kappa, anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)], Homo sapiens monoclonal antibody"
      ],
      "Max Phase": "2",
      "chembl": {
        "ChEMBL ID": "CHEMBL5314766",
        "Name": "PUXITATUG SAMROTECAN",
        "Synonyms": "PUXITATUG SAMROTECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Trastuzumab Botidotin",
      "names": [
        "A 166",
        "A-166",
        "Trastuzumab Botidotin",
        "TRASTUZUMAB BOTIDOTIN"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Her 2 Positive Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Duostatin-5 (Duo-5) with a drug-antibody ratio (DAR) of 2"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An immunoglobulin G1-kappa, anti-ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody"
      ],
      "Max Phase": "3",
      "chembl": {
        "ChEMBL ID": "CHEMBL5314782",
        "Name": "TRASTUZUMAB BOTIDOTIN",
        "Synonyms": "A 166|A-166|TRASTUZUMAB BOTIDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04873362",
        "NCT05980481",
        "NCT00928330",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "developers": [
        "RemeGen"
      ]
    },
    {
      "heading": "REGN5093 \u2013 M114",
      "names": [
        "REGN5093-M114",
        "REGN5093 \u2013 M114"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced NSCLC",
        "MET Overexpressing Advanced Cancer"
      ],
      "targets": [
        "Two different epitopes of Mesenchymal Epithelial Transition Factor (MET)"
      ],
      "payload": [
        "M24 (maytansine derivative) with a drug to antibody ratio of about 3.2."
      ],
      "linker": [
        "M114, a protease cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "REGN5093, a 1+1 asymmetric bispecific antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Regeneron"
      ],
      "trials": [
        "NCT04982224"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "M1231",
      "names": [
        "M1231"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Metastatic Solid Tumors",
        "Metastatic Solid Tumors Esophageal Cancer Non-Small Cell Lung Cancer"
      ],
      "targets": [
        "EGFR (Epidermal growth factor receptor, a protein that is present on the surface of both normal cells and cancer cells and is involved in cell growth) and MUC1 (a glycoprotein involved in the metastasis and invasion of multiple tumor types)"
      ],
      "payload": [
        "Hemiasterlin derivative, conjugates using Sutro's proprietary fixed-point coupling technology attach to specific amino acid sites of the antibody with with a drug-to-antibody ratio (DAR) of about 4."
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Sutro Biopharma"
      ],
      "trials": [
        "NCT04695847"
      ],
      "locations": [
        "Canada",
        "United States"
      ]
    },
    {
      "heading": "Trastuzumab deruxtecan | ENHERTU\u00ae | DS-8201 | DS-8201a",
      "names": [
        "TRASTUZUMAB DERUXTECAN-NXKI",
        "DS-8201A",
        "FAM-TRASTUZUMAB DERUXTECAN-NXKI",
        "ENHERTU\u00ae",
        "Trastuzumab deruxtecan",
        "DS-8201",
        "DS-8201a",
        "TRASTUZUMAB DERUXTECAN",
        "Enhertu",
        "Trastuzumab-Deruxtecan (T-DXd)",
        "TRASTUZUMAB DERUXTECAN NXKI"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Neoplasm, Gastrointestinal",
        "HER2 Mutations Breast Neoplasms",
        "HER2 Low Breast Adenocarcinoma",
        "HER-2 Protein Overexpression",
        "Invasive Breast Cancer",
        "Neoplasm Metastasis",
        "Adenocarcinoma Gastric Stage IV With Metastases",
        "Esophageal Cancer",
        "Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",
        "HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864",
        "Advanced Cancer",
        "Advanced or Metastatic Breast Cancer",
        "HER2-positive Breast Cancer",
        "Advanced Solid Tumor",
        "Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Malignant Neoplasm of Breast",
        "Leptomeningeal Metastasis",
        "Advanced Solid Malignancies",
        "Gastric Cancer",
        "Non-small Cell Lung Carcinoma",
        "Gastric Cancer, Adenocarcinoma",
        "Inflammatory Breast Cancer Stage III",
        "Gastroesophageal Junction Adenocarcinoma",
        "Breast Cancer",
        "Stage III Breast Cancer",
        "HER2 Amplification",
        "Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)",
        "Residual Invasive Breast Cancer",
        "Gastroesophageal-junction Cancer",
        "Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864",
        "Breast Neoplasms",
        "Gastrooesophageal Cancer",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Metastatic",
        "Advanced Colorectal Cancer",
        "Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast",
        "Non-Small Cell Lung Cancer",
        "HER2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Solid tumors (including Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer)",
        "Triple Negative Breast Neoplasms",
        "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Neoplasm, Breast",
        "Brain Cancer",
        "HER2-Positive Primary Breast Cancer",
        "Recurrent Breast Cancer",
        "Early-stage Breast Cancer",
        "BREAST CANCER",
        "Left Ventricular Function Systolic Dysfunction",
        "Adenocarcinoma, Gastric",
        "Stage II Breast Cancer",
        "Locally Advanced Breast Cancer",
        "Colorectal Neoplasm",
        "Unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumab-containing regimen     MedDRA version: 21.1 Level: LLT Classification code 10071114 Term: Metastatic gastric adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
        "Breast Cancer Female",
        "HER2-mutant Non-Small Cell Lung Cancer",
        "HER2 Gene Mutation",
        "Brain Metastases",
        "Breast Cancer Stage IV",
        "Chemotherapy-induced Alopecia",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Stage IIA Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Gastric Adenocarcinoma",
        "Hormone Receptor Positive Breast Neoplasms",
        "Glioblastoma",
        "Esophageal Adenocarcinoma",
        "HER2-over-expressing or HER2-mutated unresectable and/or metastatic non-squamous NSCLC",
        "Metastatic Breast Cancer",
        "HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Adenocarcinoma - GEJ",
        "Breast Cancer; HER2-positive; Metastatic",
        "Her2-positive, unresectable and/or metastatic breast cancer.",
        "Advanced Solid Tumors",
        "HER2 Mutant Non-small Cell Lung Cancer",
        "Breast Tumors",
        "Her 2 Positive Breast Cancer",
        "Recurrent Glioblastoma",
        "Stage IIB Breast Cancer",
        "Metastatic Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "Biliary Tract Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine- protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "A topoisomerase I inhibitor payload, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative).  Average drug-to-antibody ratio 7 - 8"
      ],
      "linker": [
        "A tetrapeptide linker, Gly-Phe-Leu-Gly (GFLG).  An average of 8 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "AstraZeneca",
        "DAIICHI SANKYO"
      ],
      "ttd": "D06BHB",
      "chembl": {
        "ChEMBL ID": "CHEMBL4297844",
        "Name": "TRASTUZUMAB DERUXTECAN",
        "Synonyms": "DS-8201|DS-8201A|DS-8201a|Enhertu|TRASTUZUMAB DERUXTECAN|TRASTUZUMAB DERUXTECAN NXKI|TRASTUZUMAB DERUXTECAN-NXKI",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB14962",
        "Name": "Trastuzumab deruxtecan",
        "Description": "Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of...",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Description: \u2026 [L10842] It is classified as an antibody-drug conjugate. ... The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from ... A188988]\nTrastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "fda_label": {
        "id": 89182,
        "description": "[\"11 DESCRIPTION Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody and topoisomerase inhibitor conjugate. Fam-trastuzumab deruxtecan-nxki is an antibody-drug conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase inhibitor, via 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease-cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative. The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology, and the topoisomerase inhibitor and linker are produced by chemical synthesis. Approximately 8 molecules of deruxtecan are attached to each antibody molecule. Fam-trastuzumab deruxtecan-nxki has the following structure: ENHERTU (fam-trastuzumab deruxtecan-nxki) is a sterile, white to yellowish white, preservative-free lyophilized powder in single-dose vials. Each vial delivers 100 mg of fam-trastuzumab deruxtecan-nxki, L-histidine (4.45 mg), L-histidine hydrochloride monohydrate (20.2 mg), polysorbate 80 (1.5 mg), and sucrose (450 mg). Following reconstitution with 5 mL of Sterile Water for Injection, USP, the resulting concentration of fam-trastuzumab deruxtecan-nxki is 20 mg/mL with a pH of 5.5. The resulting solution is administered by intravenous infusion following dilution. Chemical Structure\"]",
        "generic_name": "[\"FAM-TRASTUZUMAB DERUXTECAN-NXKI\"]",
        "brand_name": "[\"Enhertu\"]",
        "substance_name": "[\"TRASTUZUMAB DERUXTECAN\"]",
        "manufacturer_name": "[\"Daiichi Sankyo Inc.\"]"
      },
      "trials": [
        "EUCTR2019-002991-15-ES",
        "NCT04873362",
        "NCT00928330",
        "NCT02564900",
        "NCT03726879",
        "NCT05650879",
        "NCT04744831",
        "NCT06172127",
        "NCT04556773",
        "NCT03329690",
        "NCT03383692",
        "NCT04042701",
        "NCT05950945",
        "NCT05765851",
        "NCT00679341",
        "NCT03248492",
        "NCT03529110",
        "NCT05048797",
        "NCT06324357",
        "NCT06244485",
        "NCT06467357",
        "NCT03368196",
        "NCT05704829",
        "NCT03505710",
        "NCT06100874",
        "NCT05274048",
        "NCT04539938",
        "NCT04704934",
        "NCT05980481",
        "NCT04494425",
        "NCT02073487",
        "NCT03366428",
        "NCT04014075",
        "NCT00781612",
        "EUCTR2018-000221-31-CZ",
        "EUCTR2019-004531-22-FR",
        "NCT03523585",
        "NCT04686305",
        "NCT03734029",
        "NCT04739761",
        "EUCTR2018-000764-29-PL",
        "NCT05113251",
        "NCT03384940",
        "NCT01969643",
        "NCT02131064",
        "NCT06174987",
        "NCT05744375",
        "NCT03742102",
        "NCT05795101",
        "EUCTR2018-000764-29-GB",
        "JPRN-jRCT2080223860",
        "NCT04986579",
        "NCT06058988",
        "NCT06271837",
        "NCT04639219",
        "NCT04553770",
        "NCT01772472",
        "NCT05633979",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT03424005",
        "NCT06048718",
        "EUCTR2020-003427-42-NL",
        "EUCTR2020-001574-29-BE",
        "NCT05965479",
        "NCT04379596",
        "NCT04538742",
        "NCT05034887",
        "EUCTR2019-001512-34-BE",
        "EUCTR2020-001574-29-PL",
        "EUCTR2018-000221-31-BE",
        "NCT05480384",
        "NCT04482309",
        "NCT06429761",
        "NCT05246514",
        "EUCTR2019-004531-22-PL",
        "NCT04752059",
        "NCT03334617",
        "NCT04622319",
        "NCT04989816",
        "NCT05323955",
        "NCT04132960",
        "NCT05982678",
        "NCT04644237",
        "NCT01966471",
        "NCT04420598",
        "NCT05417594",
        "EUCTR2020-003427-42-FR"
      ],
      "locations": [
        "Ukraine",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Europe",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Kenya",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Norway",
        "United States",
        "Colombia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "North America",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Dominican Republic",
        "Taiwan",
        "Bosnia and Herzegovina",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "Ireland",
        "Japan",
        "Uganda",
        "Spain",
        "Germany",
        "New Zealand",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Turkiye",
        "Finland"
      ]
    },
    {
      "heading": "BL-B01D1",
      "names": [
        "BL-B01D1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic gastrointestinal tumors and other solid tumor"
      ],
      "targets": [
        "EGFR and HER3, members of the human epidermal growth factor receptor (ErbB) family."
      ],
      "payload": [
        "A topoisomerase I inhibitor agent (Ed-04), which is a derivative of the alkaloid camptothecin conjugates to the cysteine site of the antibody with a Drug to Antibody Ratio (DAR) between 7.5 and 8."
      ],
      "linker": [
        "A cathepsin B cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Izalontamab, bispecific antibody against EGFR/HER3 (SI-B001)"
      ],
      "Max Phase": "1",
      "developers": [
        "Sichuan Baili",
        "Systimmune"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BAT8001",
      "names": [
        "BAT8001"
      ],
      "phases": [
        "Phase 3"
      ],
      "conditions": [
        "HER2-positive stomach cancer and breast cancer"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "A maytansine derivative"
      ],
      "linker": [
        "A novel uncleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "3",
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BAT8003",
      "names": [
        "BAT8003"
      ],
      "phases": [
        "Phase 1  i"
      ],
      "conditions": [
        "Advanced Solid Cancer Triple-negative-breast-cancer"
      ],
      "targets": [
        "Trophoblast cell surface antigen 2 (TROP2)"
      ],
      "payload": [
        "A potent cytotoxic maytansine derivative."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Trodelvy | hRS7-SN-38 | hRS7-[CL-SN-38] hrS7-SN-38 | Sacituzumab govitecan | hRS7-SN-38-ADC | hRS7-SN38 | IMMU-132",
      "names": [
        "sacituzumab govitecan",
        "Trodelvy",
        "hRS7-SN-38",
        "hRS7-[CL-SN-38] hrS7-SN-38",
        "HRS7-SN38---",
        "Sacituzumab govitecan",
        "SACITUZUMAB GOVITECAN HZIY",
        "hRS7-SN-38-ADC",
        "TRODELVY",
        "HRS7-SN38",
        "SACITUZUMAB GOVITECAN",
        "Sacituzumab govetican",
        "hRS7-SN38",
        "IMMU-132"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Hormone-receptor-positive Breast Cancer",
        "NSCLC Stage IV",
        "Triple-Negative Breast Cancer",
        "Thymoma",
        "Differentiated Thyroid Cancer",
        "Metastatic Urothelial Cancer",
        "Invasive Breast Cancer",
        "Pancreatic Cancer",
        "HR-Positive Breast Cancer",
        "Esophageal Cancer",
        "HER2-negative Breast Cancer",
        "Muscle-Invasive Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Carcinoma Breast Stage IV",
        "Hepatocellular Carcinoma",
        "Advanced Solid Tumor",
        "Glioblastoma Multiforme",
        "Anaplastic Thyroid Cancer",
        "Locally Advanced or Metastatic Urothelial Carcinoma",
        "Renal Cell Cancer",
        "PD-L1 Negative",
        "Locally Advanced or Unresectable Metastatic Breast Cancer",
        "Circulating Tumor DNA",
        "Stage II Bladder Cancer AJCC v8",
        "Ovarian Epithelial Cancer",
        "Endometrial Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Mesothelioma; Pleura",
        "Breast Cancer",
        "Stage III Breast Cancer",
        "Invasive Breast Carcinoma",
        "Liver Failure",
        "Cancer",
        "PD-L1 Positive",
        "Urothelial Bladder Carcinoma",
        "Carcinoma, Non-Small-Cell Lung",
        "Metastatic Solid tumor; epithelial cancers | bladder, colorectal, head and neck, kidney, NSCLC, SCLC, ovary, pancreas, prostate, gastrointestina",
        "Endometrial Carcinoma",
        "Androgen-Resistant Prostatic Neoplasms",
        "Advanced or Metastatic Non-Small-Cell Lung Cancer",
        "Resectable Non-Small-Cell Lung Cancer",
        "Hormone-refractory Prostate Cancer",
        "Solid Tumor",
        "Bladder Cancer",
        "Breast Cancer Metastatic",
        "Prostatic Cancer, Castration-Resistant",
        "Metastatic HER2 Negative Breast Carcinoma",
        "Localized Muscle Invasive Bladder Urothelial Carcinoma",
        "Urothelial Carcinoma",
        "Castration Resistant Prostatic Neoplasms",
        "Non-Small Cell Lung Cancer",
        "Esophagogastric Adenocarcinoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Urothelial Cancer",
        "Metastatic Triple-negative Breast Cancer",
        "Prostate Cancer",
        "Solid Malignancies",
        "Muscle Invasive Bladder Carcinoma",
        "Mesotheliomas Pleural",
        "Metastatic Triple-Negative Breast Cancer",
        "Small Cell Lung Cancer",
        "Prostatic Neoplasms, Castration-Resistant",
        "Lung Cancer",
        "Breast Cancer Female",
        "Chemotherapy-induced Alopecia",
        "HR+/HER2- Metastatic Breast Cancer",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Locally Advanced or Metastatic Unresectable Urothelial Cancer",
        "Thymic Carcinoma",
        "Advanced Breast Cancer",
        "Triple Negative Breast Cancer",
        "Head and Neck Cancers- Squamous Cell",
        "Advanced or Metastatic Solid Tumor",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Gland",
        "Gastric Adenocarcinoma",
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Cervical Cancer",
        "Ovarian Carcinoma",
        "Solid Tumor, Adult",
        "Urinary Bladder Neoplasms",
        "Glioblastoma",
        "Stage IIIB Breast Cancer",
        "Metastatic Breast Cancer",
        "Gastrointestinal Cancer",
        "Metastatic Solid Tumor",
        "Stage IIIC Breast Cancer",
        "Human Epidermal Growth Factor 2 Low Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage IV Breast Cancer",
        "Brain Metastases, Adult",
        "PR-Negative Breast Cancer",
        "Salivary Gland Cancers",
        "Non-small Cell Lung Cancer",
        "Advanced Solid Tumors",
        "Residual Cancer",
        "Unresectable Breast Carcinoma",
        "Her 2 Positive Breast Cancer",
        "Mesothelioma",
        "ER-Negative Breast Cancer",
        "Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma"
      ],
      "targets": [
        "TACSTD2 | tumor-associated calcium signal transducer 2) or EGP1 | M1S1, Gastrointestinal tumor-associated antigen GA7331, Pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2"
      ],
      "payload": [
        "Camptothecin analog (SN38) Irinotecan metabolite 7-ethyl-10 hydroxycamptothecin"
      ],
      "linker": [
        "Carbonate"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "GILEAD",
        "Immunomedics"
      ],
      "ttd": "D8LAE2",
      "chembl": {
        "ChEMBL ID": "CHEMBL3545262",
        "Name": "SACITUZUMAB GOVITECAN",
        "Synonyms": "HRS7-SN38|HRS7-SN38-ANTIBODY-DRUG-CONJUGATE|IMMU-132|SACITUZUMAB GOVITECAN|SACITUZUMAB GOVITECAN HZIY|Trodelvy",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB12893",
        "Name": "Sacituzumab govitecan",
        "Description": "Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Description: \u2026 Commission and Health Canada respectively. ... [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent ... sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "fda_label": {
        "id": 16817,
        "description": "[\"11 DESCRIPTION Sacituzumab govitecan-hziy is a Trop-2 directed antibody and topoisomerase inhibitor conjugate, composed of the following three components: the humanized monoclonal antibody, hRS7 IgG1\u03ba (also called sacituzumab), which binds to Trop-2 (the trophoblast cell-surface antigen-2); the drug SN-38, a topoisomerase inhibitor; a hydrolysable linker (called CL2A), which links the humanized monoclonal antibody to SN-38. The recombinant monoclonal antibody is produced by mammalian (murine myeloma) cells, while the small molecule components SN-38 and CL2A are produced by chemical synthesis. Sacituzumab govitecan-hziy contains on average 7 to 8 molecules of SN-38 per antibody molecule. Sacituzumab govitecan-hziy has a molecular weight of approximately 160 kilodaltons. Sacituzumab govitecan-hziy has the following chemical structure. TRODELVY (sacituzumab govitecan-hziy) for injection is a sterile, preservative-free, off-white to yellowish lyophilized powder for intravenous use in a 50 mL clear glass single-dose vial, with a rubber stopper and crimp-sealed with an aluminum flip-off cap. Each single-dose vial of TRODELVY delivers 180 mg sacituzumab govitecan-hziy, 77.3 mg 2-(N-morpholino) ethane sulfonic acid (MES), 1.8 mg polysorbate 80 and 154 mg trehalose dihydrate. Reconstitution with 20 mL of 0.9% Sodium Chloride Injection, USP, results in a concentration of 10 mg/mL with a pH of 6.5. Chemical Structure\"]",
        "generic_name": "[\"SACITUZUMAB GOVITECAN\"]",
        "brand_name": "[\"TRODELVY\"]",
        "substance_name": "[\"SACITUZUMAB GOVITECAN\"]",
        "manufacturer_name": "[\"Gilead Sciences\"]"
      },
      "trials": [
        "NCT05097599",
        "NCT06100874",
        "NCT05186974",
        "NCT02574455",
        "NCT06123468",
        "NCT04454437",
        "NCT03995706",
        "NCT04724018",
        "NCT06081244",
        "NCT03337698",
        "NCT04448886",
        "NCT05609968",
        "NCT05382286",
        "NCT04039230",
        "NCT06329869",
        "NCT04986579",
        "NCT05840211",
        "NCT04381832",
        "NCT03725761",
        "NCT05101096",
        "NCT04468061",
        "NCT04434040",
        "NCT03971409",
        "NCT04794699",
        "NCT05552001",
        "NCT05089734",
        "NCT06235216",
        "NCT04639986",
        "NCT01631552",
        "NCT06133517",
        "NCT04527991",
        "NCT03424005",
        "NCT05675579",
        "NCT05581589",
        "NCT05113966",
        "NCT04230109",
        "NCT04251416",
        "NCT04958785",
        "NCT05838521",
        "NCT05143229",
        "NCT05884320",
        "NCT05633667",
        "NCT04595565",
        "NCT03964727",
        "NCT04863885",
        "NCT05119907",
        "NCT05006794",
        "NCT06248515",
        "NCT03901339",
        "NCT03547973",
        "NCT06263543",
        "NCT04647916",
        "NCT05327530",
        "NCT06065371",
        "NCT06238921",
        "NCT05520723",
        "NCT05382299",
        "NCT06486441",
        "NCT06477419",
        "NCT06401824",
        "NCT03869190",
        "NCT05833867",
        "NCT06028932",
        "NCT04617522",
        "NCT04143711",
        "NCT06167317",
        "NCT05633654"
      ],
      "locations": [
        "Puerto Rico",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "Peru",
        "China",
        "Hong Kong",
        "United States",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Singapore",
        "Philippines",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Australia",
        "Romania",
        "Hungary",
        "Japan",
        "Latvia",
        "Spain",
        "Germany",
        "Croatia",
        "Argentina",
        "Israel",
        "Slovakia"
      ]
    },
    {
      "heading": "GQ1010",
      "names": [
        "GQ1010"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "targets": [
        "Trophoblast cell surface antigen 2 (TROP2)"
      ],
      "payload": [
        "Next generation camptothecin analogue"
      ],
      "linker": [
        "A stable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "GeneQuantum (Suzhou, China)",
        "Pyramid Biosciences"
      ],
      "trials": [
        "NCT06384807"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "ZB131-DXd | ZB131  ZB131-MMAE  ZB131-DXd | ZB131 | ZB131-MMAE",
      "names": [
        "ZB131-DXd",
        "ZB131  ZB131-MMAE  ZB131-DXd",
        "ZB131",
        "ZB131-MMAE"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors; Adult Pancreatic Ductal; Adenocarcinoma Ovarian Serous Adenocarcinoma Biliary Cancer Metastatic  Ovarian Serous Cystadenocarcinoma"
      ],
      "targets": [
        "Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, including ovarian cancer."
      ],
      "payload": [
        "ZB131-MMAE (ZB131 conjugated to monomethyl auristatin E) with drug-to-antibody ratio (DAR) of 3 \u2013 4   ZB131-DXd (ZB131 conjugated to deruxtecan) with DAR of 7 \u2013 8"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ZB131, an antibody directed against CSP."
      ],
      "Max Phase": "2",
      "developers": [
        "ZielBio"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BB-1701 | HER2-Targeting ADC",
      "names": [
        "BB-1701",
        "HER2-Targeting ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Locally advanced/metastatic HER2 positive solid tumors  - Breast cancer,  - Gastric/gastroesophageal junction cancer, - Bladder cancer - Colon cancer",
        "Breast Cancer"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Eribulin, a fully synthetic, structurally simplified, macrocyclic ketone analogue of the marine natural product halichondrin B, produced from the marine sponge Halichondria okadai. Eribulin\u2019s anti-tumor activity is mediated by the inhibition of microtubule elongation and mitotic spindle formation, which results in apoptosis."
      ],
      "linker": [
        "REsidue-SPEcific Conjugation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-HER2 Antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Bliss (Hangzhou)",
        "Eisai"
      ],
      "ttd": "D56ECJ",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17443",
        "Name": "BB-1701",
        "Description": "BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Humanized IgG1kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin \u2026 Matched Description: \u2026 BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "trials": [
        "NCT06188559"
      ],
      "locations": [
        "United States",
        "Japan"
      ]
    },
    {
      "heading": "TQB2103",
      "names": [
        "TQB2103"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "claudin18.2 positive human gastric and pancreatic cancer",
        "Advanced Malignant Neoplasm"
      ],
      "targets": [
        "Claudin18.2"
      ],
      "payload": [
        "A small-molecule toxin"
      ],
      "linker": [
        "An enzymatically cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A proprietary claudin18.2-targeted monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Sino Biopharmaceutical"
      ],
      "trials": [
        "NCT05867563"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "LM-302 BMS-986476 TPX-4589 | TPX-4589 | BMS-986476 | LM-302",
      "names": [
        "LM-302",
        "LM-302 BMS-986476 TPX-4589",
        "BMS-986476",
        "TPX-4589"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Gastrointestinal cancer, including gastric, gastroesophageal junction and pancreatic cancer"
      ],
      "targets": [
        "Claudin 18.2.  CLDN18.2 expression is associated with tumor pathogenesis, proliferation, and metastasis, making it a promising target for cancer therapies."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Ant0-Claudin 18.2 antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "LaNova",
        "Turning Point therapeutics"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18604",
        "Name": "TPX-4589",
        "Description": "TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload \u2026 Matched Description: \u2026 TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 ... and linker-payload MC-VC-PAB-MMAE. \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "CMG901",
      "names": [
        "CMG901"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Gastroesophageal Junction Cancer",
        "Gastric Cancer",
        "Pancreatic Adenocarcinoma",
        "Gastric cancer, Gastroesophageal junction cancer",
        "Solid tumors that express the cell surface protein Claudin 18.2, including gastric cancers."
      ],
      "targets": [
        "Claudin 18.2 | Claudin 18.2 a transmembrane protein, also known as CLDN18.2, is an isoform of claudin 18, a member of the tight junction protein family. It is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer.[1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A antibody targeting Claudin 18.2 /CLDN18.2"
      ],
      "Max Phase": "2",
      "developers": [
        "AstraZeneca",
        "KYM Biosciences",
        "Keymed Biosciences",
        "Lepu Biopharma"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18619",
        "Name": "CMG901",
        "Description": "CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload \u2026 Matched Description: \u2026 CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload. \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "trials": [
        "JPRN-jRCT2031230569",
        "NCT06219941"
      ],
      "locations": [
        "Moldova, Republic of",
        "Canada",
        "United Kingdom",
        "Republic of Korea",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Republic of Moldova",
        "Japan",
        "Spain",
        "Singapore",
        "United States",
        "Poland",
        "United States of America",
        "Georgia",
        "Taiwan"
      ]
    },
    {
      "heading": "ABBV-011",
      "names": [
        "ABBV-011"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "targets": [
        "Seizure-related homolog 6 (SEZ6), a surface-expressed SCLC target with broad expression in small cell lung cancer (SCLC) and minimal normal, healthy, tissue expression."
      ],
      "payload": [
        "Calicheamicin-based ADC  A novel calicheamicin linker drug, LD19.10, that lacks the acid-labile DMH found in previous calicheamicin ADCs"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "SC17, an antibody targeting SEZ6 that is rapidly internalized upon receptor binding."
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "ttd": "D4J9HV",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18622",
        "Name": "ABBV-011",
        "Description": "ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related \u2026 Matched Description: \u2026 ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "DB-1303 | DB-1303 BNT323 | BNT323",
      "names": [
        "DB-1303",
        "DB-1303 BNT323",
        "BNT323"
      ],
      "phases": [
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Advanced/unresectable, recurrent, or metastatic HER2-expressing malignant solid tumors.  Endometrial carcinoma",
        "Endometrial Cancer"
      ],
      "targets": [
        "HER2 (human epidermal growth factor receptor 2)."
      ],
      "payload": [
        "A  proprietary topoisomerase I inhibitor P1003"
      ],
      "linker": [
        "An enzymatically cleavable peptide-linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-HER2 antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "Duality Biologics"
      ],
      "trials": [
        "NCT06340568"
      ],
      "locations": []
    },
    {
      "heading": "DB-1311",
      "names": [
        "DB-1311"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Duality Biologics"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056 | XMT-2056",
      "names": [
        "XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056",
        "XMT-2056"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "Directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)."
      ],
      "payload": [
        "An agonist for the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "HT-19, a monoclonal antibody  linked to a payload composed of an"
      ],
      "Max Phase": "1",
      "developers": [
        "Mersana"
      ],
      "ttd": "D7AT3H",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18230",
        "Name": "XMT-2056",
        "Description": "XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "Teliso-V | ABT-700-vcMMAE | ABBV 399 | ABBV-399 | Telisotuzumab Vedotin | ABBV-399 ABBV399 ABBV 399 ABT-700-vcMMAE Teliso-V cMet-Targeted ADC",
      "names": [
        "ABT-700-VCMMAE",
        "ABBV-399",
        "PR-1420682",
        "Telisotuzumab Vedotin",
        "ABT-700-vcMMAE",
        "Teliso-V",
        "ABBV 399",
        "ABT-399",
        "TELISOTUZUMAB VEDOTIN",
        "ABBV-399 ABBV399 ABBV 399 ABT-700-vcMMAE Teliso-V cMet-Targeted ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/1",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Non-small Cell Lung Cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Advanced Solid Tumors Cancer",
        "Non Small Cell Lung Cancer",
        "Solid Tumors (c-Met expressing Non Small Cell Lung Cancer / NSCLC)"
      ],
      "targets": [
        "c-MET (Met proto-oncogene, Hepatocyte growth factor (HGF) receptor, HGFR, Scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)  On an average of 3-4 lysyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa  ABT-700"
      ],
      "Max Phase": "3",
      "developers": [
        "AbbVie"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3990032",
        "Name": "TELISOTUZUMAB VEDOTIN",
        "Synonyms": "ABBV 399|ABBV-399|ABT-399|ABT-700-VCMMAE|PR-1420682|TELISOTUZUMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "trials": [
        "NCT03539536",
        "EUCTR2018-001772-38-IE",
        "EUCTR2018-001772-38-HU",
        "NCT04928846",
        "NCT02099058"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Czech Republic",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Romania",
        "Hungary",
        "Ireland",
        "Japan",
        "New Zealand",
        "Germany",
        "Spain",
        "Argentina",
        "Israel",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "huN901-DM1 | BB-10901 IMGN901 huN901-DM1 IMGN-901 | IMGN-901 | Lorvotuzumab mertansine",
      "names": [
        "huN901-DM1",
        "BB-10901",
        "Lorvotuzumab mertansine",
        "HUN901-DM1",
        "LORVOTUZUMAB MERTANSINE",
        "IMGN-901",
        "BB-10901 IMGN901 huN901-DM1 IMGN-901"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Leukemia",
        "Merkel Cell Carcinoma",
        "Multiple Myeloma",
        "SCLC",
        "Small Cell Lung Cancer",
        "Small-cell lung cancer (SCLC); Leukemia; multiple myeloma;  Independent Children's  Oncology Group study trials in children with: Relapsed or refractory Wilms tumor;  rhabdomyosarcoma; neuroblastoma; pleuropulmonary blastoma; malignant peripheral nerve sheath tumor (MPNST); Synovial sarcoma."
      ],
      "targets": [
        "CD56 | NCAM1 (neural cell adhesion molecule 1, CD56, NCAM-1)"
      ],
      "payload": [
        "Maytansine DM1 (microtubule inhibitor)"
      ],
      "linker": [
        "A thiopentanoate linker (or reducible SPP (N-succinimidyl 4-(2-pyridyldithio)) linker)   An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "A humanized version of the murine monoclonal antibody N901  IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1743037",
        "Name": "LORVOTUZUMAB MERTANSINE",
        "Synonyms": "HUN901-DM1, BB-10901|IMGN-901|LORVOTUZUMAB MERTANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT02420873",
        "NCT00991562",
        "NCT00346385",
        "NCT00346255",
        "NCT00065429"
      ],
      "locations": [
        "Argentina",
        "United Kingdom",
        "United States"
      ]
    },
    {
      "heading": "Patritumab Deruxtecan | U3-1402 U3-1402A Anti-HER3 - | U3-1402 | HER3 ADC",
      "names": [
        "PATRITUMAB DERUXTECAN",
        "U3-1402",
        "Patritumab deruxtecan",
        "U3 1402",
        "U3-1402 U3-1402A Anti-HER3 -",
        "HER3-DXd (CTM-1 Lyo-DP)",
        "U3-1402A",
        "U3-1402 U3-1402A Anti-HER3",
        "Patritumab Deruxtecan",
        "U31402",
        "HER3-DXd (FL-DP)",
        "HER3 ADC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Solid Tumor, Adult",
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Solid tumors; Non-small cell lung (NSCLC) and breast cancer"
      ],
      "targets": [
        "HER3-positive (human epidermal growth factor receptor HER3 (ErbB3)."
      ],
      "payload": [
        "Deruxtecan, DX-8951 derivative (DXd, topoisomerase I inhibitor), a camptothecin derivative  On an average of 8 cysteinyl"
      ],
      "linker": [
        "Peptide cleavable linker ( a tetrapeptide-based cleavable linker)  The antibody is covalently conjugated, via cysteine residues, through a tumor selective cleavable linker to the payload."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa  Patritumab, also known as AMG 888 and U3-1287"
      ],
      "Max Phase": "3",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "ttd": "DX5A8D",
      "chembl": {
        "ChEMBL ID": "CHEMBL4594611",
        "Name": "PATRITUMAB DERUXTECAN",
        "Synonyms": "PATRITUMAB DERUXTECAN|U3 1402|U3-1402|U3-1402A|U31402",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "trials": [
        "NCT05865990",
        "NCT04965766",
        "NCT02980341",
        "NCT04610528",
        "NCT03260491"
      ],
      "locations": [
        "Korea, Republic of",
        "Austria",
        "Japan",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Taiwan"
      ]
    },
    {
      "heading": "TROP2 ADC | DS-1062 DS1062 DS-1062A Anti-TRP2/dxd | Datopotamab deruxtecan | DS-1062",
      "names": [
        "DS-1062 DS1062 DS-1062A Anti-TRP2/dxd",
        "DATOPOTAMAB DERUXTECAN",
        "ADC DS-1062A",
        "Datopotamab deruxtecan",
        "DS-1062a",
        "TROP2 ADC",
        "DS-1062A",
        "DS1062",
        "Dato-DXd",
        "DS-1062"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Breast Neoplasm",
        "Additional Indications Below for Module 4 and 5",
        "Metastatic Castration-resistant Prostate Cancer",
        "Colorectal Cancer",
        "Triple-negative Breast Cancer",
        "Solid Tumors; unresectable advanced NSCLC",
        "Carcinoma, Non-Small-Cell Lung",
        "Hormone Receptor Positive Tumor",
        "ER Positive Breast Cancer",
        "Pancreatic Cancer",
        "various Advanced/Metastatic solid tumour types  - Endometrial Cancer  - Gastric Cancer  - Ovarian Cancer - Metastatic castration-resistant prostate cancer - Colorectal cancer  MedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "HER2 Negative Breast Carcinoma",
        "NSCLC",
        "Breast Cancer Female",
        "HER2-negative Breast Cancer",
        "C349",
        "Biliary Cancer",
        "Bladder Cancer",
        "Advanced Solid Tumor",
        "Non-small Cell Lung Cancer",
        "Advanced Solid Malignancies",
        "Ovarian Cancer",
        "Metastatic Lung Cancer",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "Triple Negative Breast Cancer",
        "Small Cell Lung Cancer Only in Module 5",
        "Triple Negative Breast Neoplasms",
        "C349 Bronchus or lung, unspecified  Bronchus or lung, unspecified",
        "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy  MedDRA version: 23.0 Level: PT Classification code 10083232 Term: HER2 negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Stage I-III triple-negative breast cancer with residual invasive disease after neoadjuvant therapy.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Endometrial Cancer",
        "ER-negative Breast Cancer",
        "Urothelial Cancer",
        "Breast Cancer",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Biliary Tract Cancer",
        "Prostate Cancer"
      ],
      "targets": [
        "TACSTD also known as tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)"
      ],
      "payload": [
        "A topoisomerase I inhibitor payload  With an average of 4 cysteinyl"
      ],
      "linker": [
        "A tetrapeptide-based linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-TROP2 monoclonal antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "ttd": "DP41HV",
      "chembl": {
        "ChEMBL ID": "CHEMBL4297939",
        "Name": "DATOPOTAMAB DERUXTECAN",
        "Synonyms": "ADC DS-1062A|DATOPOTAMAB DERUXTECAN|DS-1062|DS-1062A|DS-1062a|DS1062|Dato-DXd",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "trials": [
        "NCT05749588",
        "EUCTR2022-000776-19-PL",
        "NCT03742102",
        "NCT05824325",
        "EUCTR2020-005620-12-ES",
        "NCT05489211",
        "NCT06112379",
        "NCT04644068",
        "NCT05460273",
        "PER-062-22",
        "NCT05629585",
        "NCT05104866",
        "NCT04656652",
        "NCT05374512",
        "NCT05594095",
        "NCT06176261",
        "EUCTR2022-002680-30-DE",
        "NCT05687266",
        "NCT04940325",
        "EUCTR2018-000764-29-PL",
        "NCT06244485",
        "NCT06103864",
        "NCT04484142",
        "NCT05417594"
      ],
      "locations": [
        "Puerto Rico",
        "Hungaria",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "United Kindgdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Korea South",
        "China",
        "Hong Kong",
        "Peru",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "Japan",
        "Spain",
        "Germany",
        "Argentina"
      ]
    },
    {
      "heading": "SAR 408701 | SAR408701 SAR 408701 SAR-408701 | SAR408701 | Tusamitamab Ravtansine | SAR-408701",
      "names": [
        "MAYTANSIN-LOADED ANTI-CEACAM5 MAB",
        "SAR 408701",
        "TUSAMITAMAB RAVTANSINE",
        "Tusamitamab ravtansine",
        "SAR408701 SAR 408701 SAR-408701",
        "SAR408701",
        "Tusamitamab Ravtansine",
        "SAR-408701"
      ],
      "phases": [
        "Phase 3",
        "Phase 1/2"
      ],
      "conditions": [
        "NSCLC; Solid Tumors;  Solid tumors CRC;  Stomach; Adenocarcinoma"
      ],
      "targets": [
        "CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5 | CEA | CD66e [Homo sapiens]"
      ],
      "payload": [
        "Maytansinoid DM4 on an average of 3-4 lysyl"
      ],
      "linker": [
        "SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "CEACAM5 targeting antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "ttd": [
        "D05TBQ",
        "D2D6NJ"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4298098",
        "Name": "TUSAMITAMAB RAVTANSINE",
        "Synonyms": "MAYTANSIN-LOADED ANTI-CEACAM5 MAB|SAR 408701|SAR-408701|SAR408701|TUSAMITAMAB RAVTANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17448",
        "Name": "Tusamitamab ravtansine",
        "Description": "Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "MORAb-202 MORAb-003-VCP-eribulin | Farletuzumab Ecteribulin | MORAb-202",
      "names": [
        "MORAb-202 MORAb-003-VCP-eribulin",
        "Farletuzumab Ecteribulin",
        "FARLETUZUMAB ECTERIBUL",
        "MORAB-202",
        "MORAb-202",
        "FARLETUZUMAB ECTERIBULIN",
        "Farletuzumab ecteribulin"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 3",
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Platinum-sensitive solid tumors:  - Ovarian Cancer; - Endometrial Cancer; - Gastric cancer; - Non-small cell lung (NSCLC); - Triple-negative Breast Cancer (TNBC);",
        "Chemotherapy-induced Alopecia",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Carcinoma, Non-Small-Cell Lung",
        "Solid Tumor",
        "Neoplasms, Ovarian"
      ],
      "targets": [
        "Folate receptor alpha (FRA)"
      ],
      "payload": [
        "The microtubule-targeting agent (MTA), eribulin, a derivative of the macrocyclic polyether natural product halichondrin B.   Conjugated on an average drug-to-antibody ratio of 4.0."
      ],
      "linker": [
        "Cathepsin-cleavable linker   A reduced interchain disulfide bonds to maleimido-PEG2-valine-citrulline-p-aminobenzylcarbamyl linker - designed to be cleaved by cathepsin B, a lysosomal cysteine protease."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "The humanized anti-human folate receptor alpha (FRA) antibody farletuzumab."
      ],
      "Max Phase": "3",
      "developers": [
        "Eisai",
        "Morphotek"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4802212",
        "Name": "FARLETUZUMAB ECTERIBULIN",
        "Synonyms": "FARLETUZUMAB ECTERIBUL|FARLETUZUMAB ECTERIBULIN|MORAB-202|MORAb-202",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18857",
        "Name": "Farletuzumab ecteribulin",
        "Description": "Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (Fr\u03b1)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Eribulin/farletuzumab antibody drug conjugate \u2026 Matched Description: \u2026 Conjugate (ADC) in Participants With Selected Tumor Types). ... is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and ... Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (Fr\u03b1)-targeting Antibody-drug \u2026 Matched Categories: \u2026 Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "trials": [
        "NCT03901339",
        "NCT04300556",
        "NCT05613088",
        "NCT02574455",
        "NCT05104866",
        "NCT03734029",
        "NCT05577715",
        "NCT04986579"
      ],
      "locations": [
        "Sweden",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ]
    },
    {
      "heading": "LM-305",
      "names": [
        "LM-305"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma"
      ],
      "targets": [
        "G protein-coupled receptor, class C, group 5, member D (GPRC5D)  GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a member of the G protein-coupled receptors (GPCRs) family. As a novel GPCR drug target, GPRC5D is an orphan receptor with no endogenous ligand found. GPRC5D is mainly expressed in malignant bone marrow plasma cells and hair follicles, while in normal tissues, little or no expression is observed. Studies have shown that GPRC5D is specifically highly expressed in patients with multiple myeloma (MM) in a BCMA-independent manner Therefore, GPRC5D has attracted great attention as a key new target in the treatment of MM."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A protease-degradable linker"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "anti-GPRC5D antibody."
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ATG-022",
      "names": [
        "ATG-022"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors Gastric cancer Pancreatic cancer"
      ],
      "targets": [
        "Claudin 18.2  (CLDN18.2)   Claudins are cell adhesion molecules normally expressed within the tight junctions between cells to form a barrier that regulates cell permeability. In cancer, Claudins are expressed at the cell surface due to changes in cell polarity. The Claudin 18.2 isoform is overexpressed in various primary malignant tumors including gastric, esophageal and pancreatic cancers."
      ],
      "payload": [
        "The antimitotic agent, monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A valine-citrulline (vc-) type linker (mc-vc-PABC-MMAE)  This ADC includes a maleimidocaproyl (mc) spacer, a protease-sensitive dipeptide, valine-citrulline (vc), a self-immolative spacer, para-amino benzyloxycarbonyl (PABC)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IMAB362, an antibody targeting CLDN18.2."
      ],
      "Max Phase": "1",
      "developers": [
        "Antengene"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CPO301",
      "names": [
        "CPO301"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Cancer",
        "Advanced Solid Tumors  Treatment of metastatic EGFR-mutated non-small cell lung cancer (NSCLC) patients refractory to relapsed/refractory to or are ineligible EGFR-targeted therapies, such as 3rd-generation EGFR inhibitors including osimertinib.    - EGFR C797S Mutation Non-small Cell Lung Cancer, - EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer, - EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma",
        "Cancer, Lung"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor (EGFR) C797S + EGFR T790M + EGFR-Ex19del ( C797S + Epidermal Growth Factor Receptor T790M + EGFR exon 19 deletion)."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "CSPC Pharmaceutical Group"
      ],
      "trials": [
        "NCT05948865"
      ],
      "locations": [
        "Canada",
        "United States"
      ]
    },
    {
      "heading": "W0101 | W0101 W-0101 | W-0101 | Lonigutamab Ugodotin",
      "names": [
        "W0101",
        "W0101 W-0101",
        "Lonigutamab Ugodotin",
        "W-0101"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Advanced or metastatic solid tumors, including:  - squamous non-small-cell lung cancer (sqNSCLC) - head-and-neck cancer - ER+ HER2- invasive breast cancer."
      ],
      "targets": [
        "Insulin-like growth factor type 1 receptor (IGF-1R)/IGF1R; CD221) [Homo sapiens]"
      ],
      "payload": [
        "Conjugated with dolastatin/auristatin derivative (ugodotin) derivative on an average of 4 cysteinyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hz208F2-4"
      ],
      "Max Phase": "2",
      "developers": [
        "Pierre Fabre",
        "Roche"
      ],
      "trials": [
        "NCT03316638"
      ],
      "locations": [
        "Spain",
        "France"
      ]
    },
    {
      "heading": "Trastuzumab rezetecan | Trastuzumab rezetecan SHR-A1811 | SHR-A1811",
      "names": [
        "Trastuzumab rezetecan",
        "SHR-A1811",
        "TRASTUZUMAB REZETECAN",
        "Trastuzumab rezetecan SHR-A1811",
        "SHR A1811"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Early-stage Breast Cancer",
        "Breast Neoplasm",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple-negative Breast Cancer",
        "Metastatic Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Neoplasm Metastasis",
        "Hormone Receptor Negative Tumor",
        "Locally Advanced Breast Cancer",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "HER2-negative Breast Cancer",
        "Brain Metastases",
        "Breast cancer Gastric cancer,  Colorectal cancer, and  NSCLC",
        "Breast Cancer; HER2-positive; Metastatic",
        "HER2-positive Breast Cancer",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Tumors",
        "Her 2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Triple-Negative Breast Cancer (TNBC)",
        "HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",
        "Recurrent Breast Cancer",
        "HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy",
        "Breast Cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "payload": [
        "SHR9265, a novel topoisomerase I inhibitor payload.  Rezetecan (SHR9265) is a delicately selected exatecan derivative (a camptothecin derivative) with a better liposolubility and cellular permeability.  SHR-A1811 has a drug-to-antibody ratio (DAR) of 5.7,"
      ],
      "linker": [
        "A stable and cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab  A humanized immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "Max Phase": "3",
      "developers": [
        "Luzsana Biotechnology"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314712",
        "Name": "TRASTUZUMAB REZETECAN",
        "Synonyms": "SHR A1811|TRASTUZUMAB REZETECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT05749588",
        "NCT06100874",
        "NCT02131064",
        "NCT05824325",
        "NCT04873362",
        "NCT06126640",
        "NCT05980481",
        "NCT00928330",
        "NCT06123494",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT05582499",
        "NCT01904903",
        "NCT05594095",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ]
    },
    {
      "heading": "cMET-ADC MYTX-011 | MYTX-011",
      "names": [
        "cMET-ADC MYTX-011",
        "MYTX-011"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Advanced Non-Small Cell Lung Cancer",
        "NSCLC Stage IV",
        "NSCLC Stage IIIB",
        "NSCLC",
        "Advanced Non-Small Cell Non-Squamous Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "Locally advanced, recurrent or metastatic NSCLC"
      ],
      "targets": [
        "cMET (mesenchymal-epithelial transition factor), which belongs to the MET family, is a type of receptor tyrosine kinase that is expressed on the surfaces of various epithelial cells.  cMET is also known as tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR).  As a type of proto-oncogene, abnormal activation of c-Met can promote the development and progression of a variety of cancers including liver, lung, colon, breast, pancreatic, ovarian, prostate, and gastric carcinomas, as well as cancers of the nervous system such as glioblastoma."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  Drug-to-antibody ratio (DAR) = 2"
      ],
      "linker": [
        "Val-Cit (Valine\u2013citrulline/vc) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized IgG1 pH-dependent anti-cMET antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Mythic Therapeutics"
      ],
      "trials": [
        "NCT05652868"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "United Kingdom",
        "Taiwan"
      ]
    },
    {
      "heading": "DP303c",
      "names": [
        "DP303c"
      ],
      "phases": [
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive advanced solid tumors."
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "A monomethyl auristatin E (MMAE) with an average drug-to-antibody ratio (DAR) of 2.0.  The two MMAE molecules are attached site-specifically through transamidation to residue Q295 in the antibody heavy chain\u2019s constant region."
      ],
      "linker": [
        "A cleavable linker (LND1002, manufactured by Levena)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A HER2-targeting antibody (DP001)"
      ],
      "Max Phase": "3",
      "developers": [
        "CSPC Pharmaceutical Group"
      ],
      "trials": [
        "NCT06313086"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "ABBV-085 | Samrotamab vedotin | PR-1498487-MMAE | PR-1498487-MMAE PR-1498487 PAB-MMAE | Anti-huLRRC15 -  anti-huLR C15 ADC ABBV-085",
      "names": [
        "PR-1498487 PAB-MMAE",
        "ABBV085",
        "ABBV-085",
        "Samrotamab vedotin",
        "ABBV 085",
        "PR-1498487-MMAE",
        "Anti-huLRRC15 -  anti-huLR C15 ADC ABBV-085",
        "PR-1498487-MMAE PR-1498487 PAB-MMAE",
        "SAMROTAMAB VEDOTIN",
        "-  ABBV-085",
        "ADC ABBV-085"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Carcinoma of the Breast",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Undifferentiated Pleomorphic Sarcoma",
        "Solid tumors in which huLRRC15 is expressed in the tumor stromal microenvironment."
      ],
      "targets": [
        "LRRC15 (leucine-rich repeat-containing protein 15, leucine-rich repeat induced by beta-amyloid homolog); LIB [1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)   On an average of 2 cysteinyl."
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p- aminobenzyloxycarbonyl (mc-val-cit-PABC)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa  Humanized and chimeric monoclonal antibody.  IgG1 - kappa anti-LRRC15-targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4594513",
        "Name": "SAMROTAMAB VEDOTIN",
        "Synonyms": "ABBV 085|ABBV-085|ABBV085|ADC ABBV-085|ANTIBODY-DRUG CONJUGATE ABBV-085|PR-1498487 PAB-MMAE|SAMROTAMAB VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT02565758"
      ],
      "locations": [
        "Spain",
        "United States",
        "France"
      ]
    },
    {
      "heading": "JS108",
      "names": [
        "JS108"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is highly expressed on several types of solid tumors"
      ],
      "payload": [
        "Tub196"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-Trop2 mAb"
      ],
      "Max Phase": "1",
      "developers": [
        "Shanghai Junshi"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ARX517-PSMA-ADC | anti-PSMA ADC | ARX517",
      "names": [
        "ARX517-PSMA-ADC",
        "anti-PSMA ADC",
        "PSMA ADC",
        "ARX517"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "GBM",
        "Gliosarcoma",
        "Glioblastoma Multiforme",
        "Prostate Cancer"
      ],
      "targets": [
        "PSMA; Prostrate-specific membrane antigen"
      ],
      "payload": [
        "AS269 /  pAF-AS269, a proprietary microtubule inhibitor drug payload   The payload AS269 is conjugated to the synthetic amino acids para-acetylphenylalanine (pAF) in a humanized mAb."
      ],
      "linker": [
        "Site-specific Non-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A fully humanized anti-PSMA mAb"
      ],
      "Max Phase": "2",
      "developers": [
        "Ambrx"
      ],
      "ttd": "D08VJC",
      "trials": [
        "NCT01414296",
        "NCT02020135",
        "NCT01856933",
        "NCT01695044",
        "NCT04662580",
        "NCT01414283"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "EO-3021 also known as SYSA1801",
      "names": [
        "EO-3021 also known as SYSA1801"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Neoplasms by Site",
        "Neoplasms",
        "Gastrointestinal Neoplasms",
        "Stomach Neoplasm",
        "Digestive System Neoplasm",
        "Oncology",
        "Pancreas Neoplasm"
      ],
      "targets": [
        "Claudin 18.2 | Claudin 18.2 a transmembrane protein, also known as CLDN18.2, is an isoform of claudin 18, a member of the tight junction protein family. It is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer.[1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)   A drug-to-antibody ratio (DAR) of 2"
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [],
      "antibody": [
        "A antibody targeting Claudin 18.2 /CLDN18.2"
      ],
      "Max Phase": "1",
      "developers": [
        "CSPC Pharmaceutical Group",
        "Elevation Oncology"
      ],
      "trials": [
        "NCT05980416"
      ],
      "locations": [
        "United States",
        "Japan"
      ]
    },
    {
      "heading": "CUSP06",
      "names": [
        "CUSP06"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumor",
        "Ovarian, renal, uterine, thyroid, lung, and cholangiocarcinoma."
      ],
      "targets": [
        "Cadherin-6 (CDH6) Cadherin-6 (CDH6) is a class II Cadherin (CDH)"
      ],
      "payload": [
        "An exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor).  The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies.  A drug-to-antibody ratio (DAR) of 8  In preclinical data, this linker/payload has been shown to have a stronger \"bystander effect\" than competitor ADCs."
      ],
      "linker": [
        "A protease-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A proprietary antibody with high CDH6 binding affinity"
      ],
      "Max Phase": "1",
      "developers": [
        "OnCusp Therapeutics"
      ],
      "trials": [
        "NCT06234423"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "BAT8006",
      "names": [
        "BAT8006"
      ],
      "phases": [],
      "conditions": [
        "Ovarian, lung, breast cancer"
      ],
      "targets": [
        "Folate-Receptor-\u03b1 (FR\u03b1)"
      ],
      "payload": [
        "A small molecule topoisomerase I inhibitor"
      ],
      "linker": [
        "Bio-Thera's proprietary ADC linker-payload combination.  A systemically stable and cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-FR\u03b1 antibody"
      ],
      "Max Phase": null,
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADRX-0706",
      "names": [
        "ADRX-0706"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Solid Tumors"
      ],
      "targets": [
        "Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis."
      ],
      "payload": [
        "A novel tubulin inhibitor payload  A drug-antibody ratio of eight (DAR 8)."
      ],
      "linker": [
        "A proprietary conjugation technology"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-Nectin-4 antibody."
      ],
      "Max Phase": "1",
      "developers": [
        "Adcentrx"
      ],
      "trials": [
        "NCT06036121"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "BRY812",
      "names": [
        "BRY812"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced malignant tumors"
      ],
      "targets": [
        "LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "BioRay"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Raludotatug Deruxtecan | Raludotatug Deruxtecan  DS-6000a R-DXd | DS-6000a R-DXd",
      "names": [
        "DS-6000",
        "DS 6000A",
        "DS6000A",
        "RALUDOTATUG DERUXTECAN",
        "DS-6000A",
        "Raludotatug Deruxtecan",
        "Raludotatug Deruxtecan  DS-6000a R-DXd",
        "DS-6000a R-DXd"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Solid Cancer",
        "Renal Cell Carcinoma Ovarian Tumor"
      ],
      "targets": [
        "CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation."
      ],
      "payload": [
        "Deruxtecan   MAAA-1181a (DXd), the cytotoxic DNA topoisomerase I inhibitor derivative of exatecan, with potential antineoplastic activity."
      ],
      "linker": [
        "An enzymatically cleavable tetrapeptide-based linker."
      ],
      "domain": [
        "Onclology"
      ],
      "antibody": [
        "A monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6)"
      ],
      "Max Phase": "3",
      "ttd": "DISJ28",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095329",
        "Name": "RALUDOTATUG DERUXTECAN",
        "Synonyms": "DS 6000A|DS-6000A|DS6000A|RALUDOTATUG DERUXTECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "trials": [
        "NCT06161025"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "Taiwan",
        "Japan"
      ]
    },
    {
      "heading": "SGN-CEACAM5C",
      "names": [
        "SGN-CEACAM5C"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Colorectal Neoplasms Carcinoma,  Non-Small-Cell Lung Cancer, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma,"
      ],
      "targets": [
        "CEACAM5C is a Cell adhesion molecule.   Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e, is a member of the carcinoembryonic antigen (CEA) gene family.  It has limited expression in normal. healthy, adult tissues, but is overexpressed in carcinomas of the gastrointestinal tract, the genitourinary and respiratory systems, and breast cancer."
      ],
      "payload": [
        "Topoisomerase I inhibitor payloads."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-CEACAM5 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "HLX43",
      "names": [
        "HLX43"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "targets": [
        "PDL-1"
      ],
      "payload": [
        "camptothecin payload with an drug-antibody ratio (DAR) of 8"
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-PD-L1 humanized IgG1 monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Shanghai Henlius"
      ],
      "trials": [
        "NCT06115642"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "HBM9033",
      "names": [
        "HBM9033"
      ],
      "phases": [],
      "conditions": [
        "solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers"
      ],
      "targets": [
        "human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Nona Bioscience",
        "Pfizer"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SGN-B6A",
      "names": [
        "SGN-B6A"
      ],
      "phases": [
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Lung Cancer (NSCLC), Pancreatic, pharyngeal, and bladder carcinomas"
      ],
      "targets": [
        "Integrin beta-6 (ITGB6) | The integrins are a large family of cell surface receptors with diverse roles in cellular adhesion, motility, and cytokinesis. Functional integrins exist as heterodimers consisting of single alpha and beta chains. Within this family, integrin beta-6 (which dimerizes exclusively with isoform alpha-v) is of particular note for its role in cancer. Integrin beta-6 is overexpressed in numerous solid tumors. [1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE). T"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An antibody is specific for integrin beta-6 which does not bind other alpha-v family members."
      ],
      "Max Phase": "3",
      "developers": [
        "Pfizer",
        "Seagen"
      ],
      "ttd": "DJYD13",
      "locations": [],
      "trials": []
    },
    {
      "heading": "Luveltamab Tazevibulin \u2013 S\u03a4RO-002 \u2013 Luvelta | STRO-002 STRO 002 SP8193",
      "names": [
        "Luveltamab Tazevibulin \u2013 S\u03a4RO-002 \u2013 Luvelta",
        "SP-8193",
        "LUVELTAMAB TAZEVIBULIN",
        "SP8193",
        "STRO-002 STRO 002 SP8193",
        "STRO-002",
        "Luveltamab tazevibulin"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Fallopian Tube Cancer",
        "Neoplasm Malignant",
        "Primary Peritoneal Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Ovarian Cancer",
        "Solid Tumors;  Ovarian Endometrial Carcinoma Fallopian tube Primary peritoneal carcinoma (PPC)",
        "Endometrial Cancer",
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Ovary Cancer",
        "Platinum-resistant Ovarian Cancer"
      ],
      "targets": [
        "FolR\u03b1/FOLR1 (Folate receptor alpha, folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18) [Homo sapiens], is overexpressed in platinum-resistant ovarian cancer and other solid tumors."
      ],
      "payload": [
        "A tubulin-targeting 3-aminophenyl hemiasterlin payload, SC209, which has potent cytotoxic activity and is a weak substrate for efflux pumps."
      ],
      "linker": [
        "The SC239 drug-linker is conjugated via a protease cleavable valine citrulline p-aminobenzyl carbamate linker functionalized with dibenzocyclooctyne (DBCO)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-FolRa human IgG1 antibody (SP8166)  on an average of 4 p-azidomethyl-L-phenyalanine (pAMF)"
      ],
      "Max Phase": "3",
      "developers": [
        "Sutro Biopharma"
      ],
      "ttd": "D10GPJ",
      "chembl": {
        "ChEMBL ID": "CHEMBL5095133",
        "Name": "LUVELTAMAB TAZEVIBULIN",
        "Synonyms": "LUVELTAMAB TAZEVIBULIN|SP-8193|SP8193|STRO-002",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17563",
        "Name": "Luveltamab tazevibulin",
        "Description": "Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolR\u03b1) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 conjugate. ... Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer). ... tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolR\u03b1) targeting antibody-drug \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT05200364",
        "NCT03748186",
        "NCT06238687",
        "NCT05870748"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "China",
        "Singapore",
        "United States",
        "Israel"
      ]
    },
    {
      "heading": "BSI-992 | OBI-992",
      "names": [
        "BSI-992",
        "OBI-992"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and gastric cancer (GC), Several other cancers are also potential targets."
      ],
      "targets": [
        "Human trophoblast cell-surface antigen 2 (TROP2)"
      ],
      "payload": [
        "A potent topoisomerase I inhibitor payload"
      ],
      "linker": [
        "A differentiated hydrophilic, enzyme-cleavable linker that is stable in circulation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "TROP2 targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Biosion (China)",
        "OBI Pharma"
      ],
      "trials": [
        "NCT06480240"
      ],
      "locations": [
        "United States"
      ]
    },
    {
      "heading": "STRO-003",
      "names": [
        "STRO-003"
      ],
      "phases": [],
      "conditions": [
        "Lung cancer Breast cancer"
      ],
      "targets": [
        "Receptor tyrosine kinase ROR1   Receptor tyrosine kinase ROR1 plays an essential role in embryogenesis and is overexpressed in many types of malignant tumors."
      ],
      "payload": [
        "A next-generation exatecan class of payloads, known for their ability to inhibit topoisomerase-1 (TOPO-1) and cause DNA disruption.  DASR = 8.0"
      ],
      "linker": [
        "\u03b2-Glucuronidase-cleavable linkers"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Sutro Biopharma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "STRO-004",
      "names": [
        "STRO-004"
      ],
      "phases": [],
      "conditions": [
        "Multiple solid tumor indications including HNSCC, breast and  lung cancer"
      ],
      "targets": [
        "Tissue Factor (TF)  Tissue Factor is expressed in the subendothelium. When endothelium is  damaged, tissue factor combines with circulating factor VII to activate factor  X. Activated factor X initiates  the coagulation cascade"
      ],
      "payload": [
        "Potent exatecan payload, broadly active against solid tumor indications \u2013 Potent topoisomerase I inhibitor (nM) \u2013 Strong bystander activity,  \u2013 Limited susceptibility to efflux by drug pumps  Conjugation at sites optimized for stability in circulation, tumor specific payload release \u2013 Homogeneous DAR4, no DAR distribution"
      ],
      "linker": [
        "Optimized linker, designed for tumor-selective payload release \u2013 Hydrophilic linker supporting improved solubility and PK \u2013 PEG chain further enhances solubility, supporting high DAR \u2013 Stable in circulation \u2013 Efficiently cleaved by \u03b2-glucuronidase enzyme"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "A TF-targeting antibody"
      ],
      "Max Phase": null,
      "developers": [
        "Sutro Biopharma"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "VLS-101 | MK-2140 | VLS-101 MK-2140 | Zilovertamab vedotin",
      "names": [
        "VLS-101",
        "MK-2140",
        "VLS-101 MK-2140",
        "Zilovertamab vedotin"
      ],
      "phases": [
        "Phase 2",
        "Phase 2/3",
        "Phase 1"
      ],
      "conditions": [
        "- Chronic Lymphocytic Leukemia  - Mantle Cell Lymphoma Follicular  - Lymphoma Marginal Zone - Lymphoma Diffuse Large B-cell  - Lymphoma Richter Transformation - Lymphoma Burkitt Lymphoma  - Lymphoplasmacytoid Lymphoma  - T-cell Non-Hodgkin Lymphoma  - Acute Lymphoid Leukemia Acute  - Myeloid Leukemia Waldenstrom Macroglobulinemia"
      ],
      "targets": [
        "Receptor tyrosine kinase-like orphan receptor 1 (ROR1)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE),  an anti-microtubule cytotoxin, with an average of 4 cysteinyl"
      ],
      "linker": [
        "A proteolytically maleimidocaproyl-valyl-citrullinyl-p- aminobenzyloxycarbonyl (mc-val-cit-PABC) type cleavable linker"
      ],
      "domain": [
        "Hematology Oncology"
      ],
      "antibody": [
        "A humanized monoclonal antibody recognizing extracellular ROR1"
      ],
      "Max Phase": "3",
      "developers": [
        "VelosBio"
      ],
      "ttd": [
        "D1CG5M",
        "D3YJZ7"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18457",
        "Name": "Zilovertamab vedotin",
        "Description": "Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody ... proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "locations": [],
      "trials": []
    },
    {
      "heading": "BHV-1500",
      "names": [
        "BHV-1500"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "targets": [
        "CD30 is a member of the tumor necrosis factor receptor superfamily, which is characteristically expressed in certain hematopoietic malignancies, including Hodgkin lymphoma, among others."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE, vedotin)"
      ],
      "linker": [],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Biohaven"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BHV-1510",
      "names": [
        "BHV-1510"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid tumors"
      ],
      "targets": [
        "Trophoblast cell-surface antigen 2 (Trop-2; also known as epithelial glycoprotein-1, gastrointestinal antigen 733-1, membrane component surface marker-1, and tumor-associated calcium signal transducer-2).   Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expression. Trop-2 is an ideal candidate for targeted therapeutics due to it being a transmembrane protein with an extracellular domain over-expressed on a wide variety of tumors as well as its upregulated expression relative to normal cells."
      ],
      "payload": [
        "Proprietary potential best-in-class Topolx, site-specifically conjugated via Enzymatic (non-cysteine) with a drug to antibody-ratio of 4."
      ],
      "linker": [
        "Proprietary highly stable (irreversible) and protease cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Sacituzumab, an antitrophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Biohaven"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AMT-562",
      "names": [
        "AMT-562"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced solid tumors"
      ],
      "targets": [
        "HER3, a unique member of the EGFR family of tyrosine kinases, which is broadly expressed in several cancers, including breast, lung, pancreatic, colorectal, gastric, prostate, and bladder cancers and is often associated with poor patient outcomes and therapeutic resistance. [1]"
      ],
      "payload": [
        "Site specifically conjugated to exatecan.  Drug to Antibody-ratio is 8.0"
      ],
      "linker": [
        "A via valine-alanine cleavable linker and a modified self-immolative PABC spacer (T800)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized HER-3 targeted monoclonal antibody (Ab562)"
      ],
      "Max Phase": "1",
      "developers": [
        "Multitude"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "RC88",
      "names": [
        "RC88"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumor",
        "Mesothelioma Bile Duct Carcinoma Pancreatic cancer Lung Adenocarcinoma Ovarian Cancer other Solid Tumors"
      ],
      "targets": [
        "Mesothelin (MSLN)"
      ],
      "payload": [
        "Mmicrotubule inhibitor monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MSLN-targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "MabPlex",
        "RemeGen"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18697",
        "Name": "RC88",
        "Description": "RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "trials": [
        "NCT04175847"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "9MW2821",
      "names": [
        "9MW2821"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors metastatic esophageal squamous cell carcinoma"
      ],
      "targets": [
        "Nectin-4;  Nectin cell adhesion protein 4 (Nectin-4) is overexpressed in multiple human malignancies. Such aberrant expression is correlated with cancer progression and poor prognostic."
      ],
      "payload": [
        "Monomethyl auristatin E"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Mabwell (Shanghai)"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Elevation Oncology \u2013 Proof of Concept ADC | HER3-ADC",
      "names": [
        "Elevation Oncology \u2013 Proof of Concept ADC",
        "HER3-ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "HER3-expressing solid tumors",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "HER3 (ERBB3) , which is expressed on the cell surface of breast cancer, EGFR-mutated non-small cell lung cancer and other solid tumor"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE), a potent anti-cancer microtubule-targeting agent"
      ],
      "linker": [
        "A cleavable valine-citrulline linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "seribantumab, a fully human IgG2 anti-HER3 mAb"
      ],
      "Max Phase": "1",
      "developers": [
        "Elevation Oncology"
      ],
      "trials": [
        "NCT06298058"
      ],
      "locations": []
    },
    {
      "heading": "hP67.6-calicheamicin | WAY-CMA-676 | CDP-771 | CMA-676 | Mylotarg\u00ae | Gemtuzumab ozogamicin",
      "names": [
        "GEMTUZUMAB OZOGAMICIN RECOMBINANT",
        "CMC-676",
        "L01XC05",
        "hP67.6-calicheamicin",
        "WAY-CMA-676",
        "Mylotarg",
        "GEMTUZUMAB OZOGAMICIN",
        "CDP-771",
        "CMA-676",
        "Mylotarg\u00ae",
        "Gemtuzumab ozogamicin"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Refractory Acute Myeloid Leukemia",
        "Leukemia, Myeloid, Acute",
        "Myelodysplastic Syndromes",
        "Leukemia, Myelocytic, Acute",
        "Acute Myelogenous Leukemia",
        "Safety",
        "Leukaemia  Cancer  Leukaemia",
        "Acute Myeloid Leukaemia",
        "ECG",
        "Leukemia",
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia",
        "Infusions, Intravenous",
        "Leukemia, Myeloid",
        "Relapsed AML (Acute myeloid leukemia) | CD33 positive",
        "Pharmacokinetics",
        "Recurrent Acute Myeloid Leukemia"
      ],
      "targets": [
        "CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)"
      ],
      "payload": [
        "Calicheamicin (N-acetyl-\u03b3 calicheamicin 1,2-dimethyl hydrazine dichloride)"
      ],
      "linker": [
        "Covalent linkage (condensation) of a bifunctional linker, 4-(4-acetylphenoxy)butanoic acid (AcBut linker)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG4 - kappa /  hP67.6 (produced from a murine antibody (mP67.6) by complementarity-determining region (CDR) grafting. The resulting humanized hP67.6 antibody is an IgG4 that contains sequences derived from the murine antibody in the antigen-binding region only, thereby reducing the potential for human antimouse antibody (HAMA) responses."
      ],
      "Max Phase": "Approved",
      "developers": [
        "Pfizer",
        "WYETH"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1201506",
        "Name": "GEMTUZUMAB OZOGAMICIN",
        "Synonyms": "CDP-771|CMA-676|CMC-676|GEMTUZUMAB OZOGAMICIN|GEMTUZUMAB OZOGAMICIN RECOMBINANT|L01XC05|Mylotarg|WAY-CMA-676",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 1
      },
      "fda_label": {
        "id": 54277,
        "description": "[\"11. DESCRIPTION Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in NS0 cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab. MYLOTARG (gemtuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder for intravenous administration. Each single-dose vial delivers 4.5 mg gemtuzumab ozogamicin. Inactive ingredients are dextran 40 (41.0 mg), sodium chloride (26.1 mg), sodium phosphate dibasic anhydrous (2.7 mg), sodium phosphate monobasic monohydrate (0.45 mg), and sucrose (69.8 mg). After reconstitution with 5 mL of Sterile Water for Injection USP, the concentration is 1 mg/mL of gemtuzumab ozogamicin with a deliverable volume of 4.5 mL (4.5 mg). Chemical Structure\"]",
        "generic_name": "[\"GEMTUZUMAB OZOGAMICIN\"]",
        "brand_name": "[\"Mylotarg\"]",
        "substance_name": "[\"GEMTUZUMAB OZOGAMICIN\"]",
        "manufacturer_name": "[\"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.\"]"
      },
      "trials": [
        "NCT00037596",
        "NCT03531918",
        "NCT00233909",
        "NCT03727750",
        "NCT00882102",
        "NCT06448013",
        "NCT04385290",
        "NCT04207190",
        "NCT00017589",
        "NCT02724163",
        "NCT03839446",
        "NCT04849910",
        "NCT00003673",
        "NCT05558124",
        "NCT04070768",
        "NCT00962767",
        "ISRCTN17161961",
        "NCT05183035",
        "NCT05955261",
        "NCT03737955",
        "NCT03374332",
        "NCT00003131",
        "NCT00304447",
        "NCT00044733",
        "NCT00766116",
        "NCT00860639",
        "NCT00037583",
        "NCT05904106"
      ],
      "locations": [
        "Sweden",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Portugal",
        "Norway",
        "United States",
        "Denmark",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Ireland",
        "Australia",
        "Hungary",
        "Austria",
        "New Zealand",
        "Spain",
        "Germany",
        "Wales",
        "Israel",
        "Finland"
      ]
    },
    {
      "heading": "Brentuximab vedotin | Adcetris\u00ae | SGN-35 cAC10-Val-Cit-MMAE | SGN35",
      "names": [
        "CAC10-1006",
        "CAC10",
        "SGN 30",
        "Brentuximab vedotin",
        "Adcetris",
        "CAC-10",
        "CAC10-VCMMAE",
        "MONOCLONAL  SGN-30",
        "ADCETRIS",
        "SGN-35",
        "BRENTUXIMAB VEDOTIN",
        "Adcetris\u00ae",
        "BRENTUXIMAB VEDOTIN BRENTUXIMAB",
        "SGN-35 cAC10-Val-Cit-MMAE",
        "SGN35"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Hodgkin's Lymphoma",
        "Refractory Follicular Lymphoma",
        "Safety",
        "Leukemia, Lymphoblastic,Acute",
        "Mycosis Fungoides",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "Diffuse Large B-cell-lymphoma",
        "Systemic Mastocytosis",
        "Hodgkin Lymphoma (HL);  Anaplastic Large Cell Lymphoma (ALCL)",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Relapsed or Refractory Hodgkin Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Myelodysplastic Syndromes",
        "Clinical Efficacy",
        "Leukemia, Acute Myeloid",
        "Hodgkin Disease",
        "Anaplastic Large-cell Lymphoma",
        "Acute Lymphoid Leukemia",
        "Lymphoma, Large-Cell, Anaplastic",
        "Solid Tumors",
        "Lymphoma, T-cell",
        "Cutaneous Lymphomas",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Lymphoma, Primary Cutaneous Anaplastic Large Cell",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Lymphoma",
        "Skin Lymphoma",
        "Non-Hodgkin's Disease",
        "Cutaneous T-cell Lymphoma (CTCL)",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma",
        "Mast Cell Leukemia",
        "Neoplasms",
        "Enteropathy Associated T-cell Lymphoma",
        "Graft vs. Host Disease",
        "Stage II Childhood Hodgkin Lymphoma",
        "Carcinomas",
        "Subtopic: Lymphoma",
        "Cutaneous T Cell Lymphoma",
        "Lymphoma, T-Cell",
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Sezary Syndrome",
        "Recurrent Follicular Lymphoma",
        "Acute Myeloid Leukemia",
        "Adult T-Cell Leukemia/Lymphoma",
        "Topic: National Cancer Research Network",
        "T-Cell Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Hodgkin Lymphoma, Adult",
        "Diffuse Cutaneous Systemic Sclerosis",
        "dcSSc",
        "Aggressive Systemic Mastocytosis",
        "CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma",
        "CLASSICAL HODGKIN LYMPHOMA",
        "Lymphomatoid Papulosis",
        "NK/T Cell Lymphoma Nos",
        "Scleroderma",
        "Lymphoma, T-Cell, Cutaneous",
        "Lymphatic Diseases",
        "Diffuse Large B-cell Lymphoma",
        "Disease: Lymphoma (Hodgkin's)  Cancer  Hodgkin lymphoma",
        "Classical Hodgkin Lymphoma",
        "Lymphoma, B-Cell",
        "Non-Hodgkin Lymphoma (NHL)",
        "Cutaneous Lymphoma",
        "Recurrent Hodgkin Lymphoma",
        "Germ Cell Cancer",
        "Lymphoma, Non-Hodgkin",
        "Non-small Cell Lung Cancer",
        "Anemia, Refractory, With Excess of Blasts",
        "Lymphoma, T-Cell, Peripheral",
        "Peripheral T Cell Lymphoma",
        "Cutaneous T-Cell Lymphoma",
        "Lymphoma, NK-cell",
        "Melanoma",
        "S\u00e9zary Syndrome",
        "Stage III Childhood Hodgkin Lymphoma",
        "Hematologic Disorder",
        "Relapsed or Refractory Anaplastic Large-cell Lymphoma"
      ],
      "targets": [
        "TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, KI-1, CD30)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "Valine-citrulline (protease-cleavable)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa (cAC10)"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Seagen",
        "Takeda"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1742994",
        "Name": "BRENTUXIMAB VEDOTIN",
        "Synonyms": "Adcetris|BRENTUXIMAB VEDOTIN|BRENTUXIMAB VEDOTIN BRENTUXIMAB|CAC-10|CAC10|CAC10-1006(4)|CAC10-VCMMAE|CAC10-VCMMAE(4)|MONOCLONAL ANTIBODY SGN-30|SGN 30|SGN-35",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 1
      },
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB08870",
        "Name": "Brentuximab vedotin",
        "Description": "Brentuximab vedotin, also known as Adcetris\u00ae, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the...",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Monoclonal antibody SGN-30 \u2026 Matched Description: \u2026 Brentuximab vedotin, also known as Adcetris\u00ae, is an antibody-drug conjugate that combines an anti-CD30 ... antibody with the drug monomethyl auristatin E (MMAE). ... Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... CD30-directed Antibody Interactions ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "fda_label": {
        "id": 84421,
        "description": "[\"11 DESCRIPTION ADCETRIS (brentuximab vedotin) is a CD30-directed antibody and microtubule inhibitor conjugate consisting of three components: 1) the chimeric IgG1 antibody cAC10, specific for human CD30, 2) the microtubule disrupting agent MMAE, and 3) a protease-cleavable linker that covalently attaches MMAE to cAC10. Brentuximab vedotin has an approximate molecular weight of 153 kDa. Approximately 4 molecules of MMAE are attached to each antibody molecule. Brentuximab vedotin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. ADCETRIS (brentuximab vedotin) for injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder in single-dose vials. Following reconstitution with 10.5 mL Sterile Water for Injection, USP, a solution containing 5 mg/mL brentuximab vedotin is produced. The reconstituted product contains 70 mg/mL trehalose dihydrate, 5.6 mg/mL sodium citrate dihydrate, 0.21 mg/mL citric acid monohydrate, and 0.20 mg/mL polysorbate 80 and water for injection. The pH is approximately 6.6.\"]",
        "generic_name": "[\"BRENTUXIMAB VEDOTIN\"]",
        "brand_name": "[\"ADCETRIS\"]",
        "substance_name": "[\"BRENTUXIMAB VEDOTIN\"]",
        "manufacturer_name": "[\"SEAGEN INC.\"]"
      },
      "trials": [
        "NCT03755804",
        "NCT01700751",
        "NCT01026415",
        "NCT02734771",
        "NCT00848926",
        "NCT06186986",
        "NCT01508312",
        "NCT06254495",
        "NCT02467946",
        "NCT03222492",
        "NCT01060904",
        "NCT02581631",
        "NCT00866047",
        "NCT01777152",
        "NCT02927769",
        "NCT02684292",
        "ISRCTN77650947",
        "NCT02243436",
        "NCT02429375",
        "NCT05313243",
        "NCT03217643",
        "NCT01026233",
        "NCT05357794",
        "NCT06377566",
        "NCT02086604",
        "NCT02616965",
        "NCT02292979",
        "NCT04404283",
        "NCT01421667",
        "NCT01396070",
        "NCT01492088",
        "NCT02164006",
        "NCT03587844",
        "NCT01874054",
        "NCT01909934",
        "NCT01851200",
        "NCT02227199",
        "NCT01807598",
        "NCT01716806",
        "NCT06120504",
        "NCT01596218",
        "NCT01868451",
        "NCT01534078",
        "NCT05442554",
        "NCT01352520",
        "NCT02939014",
        "NCT01461538",
        "NCT01920932",
        "NCT00430846",
        "NCT01578499",
        "NCT05316246",
        "NCT03646123",
        "NCT00947856",
        "NCT04609566",
        "NCT02979522",
        "NCT01100502",
        "NCT04569032",
        "NCT02686346",
        "NCT02572167",
        "NCT01712490",
        "NCT01309789",
        "NCT03264131",
        "NCT05404945",
        "NCT05922904",
        "NCT01990534",
        "NCT01578967",
        "NCT02822586",
        "NCT05149768",
        "NCT02280785",
        "NCT01950364",
        "NCT02505269",
        "NCT02567851",
        "NCT05180097",
        "NCT05414500",
        "NCT05673785",
        "NCT04587687",
        "NCT03198689",
        "NCT04685616"
      ],
      "locations": [
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Norway",
        "Portugal",
        "Hong Kong",
        "China",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Romania",
        "Hungary",
        "Ireland",
        "New Zealand",
        "Japan",
        "Austria",
        "Spain",
        "Germany",
        "Croatia",
        "Israel"
      ]
    },
    {
      "heading": "MRG003",
      "names": [
        "MRG003"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "EGFR-positive refractory: - Advanced squamous cell carcinomas of the head and neck (SCCHN),  - Nasopharyngeal carcinoma (NPC),  - Colorectal cancer (CRC).",
        "Recurrent or Metastatic Nasopharyngeal Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Advanced or Metastatic Biliary Tract Cancer"
      ],
      "targets": [
        "EGFR-positive Cancers"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Valine-citrulline linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-epidermal growth factor receptor (EGFR) humanized immunoglobulin G1 monoclonal antibody."
      ],
      "Max Phase": "3",
      "developers": [
        "Lepu Biopharma",
        "Shanghai Miracogen"
      ],
      "trials": [
        "NCT04838964",
        "NCT05688605",
        "NCT04868344",
        "NCT05126719",
        "NCT05751512"
      ],
      "locations": [
        "China"
      ]
    },
    {
      "heading": "TAA013",
      "names": [
        "TAA013"
      ],
      "phases": [
        "Phase 3"
      ],
      "conditions": [],
      "targets": [
        "Human epidermal growth factor 2 (HER2)"
      ],
      "payload": [
        "DM1 (Maytansine)  DAR: 3.5"
      ],
      "linker": [
        "Lysine-SMCC"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab (IgG1)"
      ],
      "Max Phase": "3",
      "developers": [
        "TOT Biopharm"
      ],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ZW49 | ZW49 HER2 x HER2 Bispecific - | Zanidatamab Zovodotin",
      "names": [
        "ZW49 HER2 x HER2 Bispecific -",
        "ZW49 HER2 x HER2 Bispecific",
        "Zanidatamab Zovodotin",
        "ZW49",
        "Zanidatamab zovodotin"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Solid tumors  Locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents.  - Gastric cancer - Breast cancer",
        "Metastatic Solid Tumors"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] biparatopic"
      ],
      "payload": [
        "A novel, proprietary, N-acyl sulfonamide auristatin cytotoxin designed to take advantage of the enhanced antibody-HER2 internalization of ZW25. | Conjugated  on an average of 2-3 cysteinyl"
      ],
      "linker": [
        "A proprietary cleavable, 1-maleimido-3,6,9-trioxadodecan-12-oyl-valyl-citrullyl linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ZW25;  an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab.  ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent e\ufb00ector function."
      ],
      "Max Phase": "2",
      "developers": [
        "BeiGene",
        "Zymeworks"
      ],
      "ttd": "DH09QZ",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB15472",
        "Name": "Zanidatamab zovodotin",
        "Description": "According to Zymeworks, \"ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload.\" It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to...",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 anti-HER2 x HER2 ADC \u2026 Matched Description: \u2026 According to Zymeworks, \"ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on \u2026",
        "Queries": "['\"adc\"']",
        "Query Indices": "[2]",
        "Score": 5
      },
      "trials": [
        "NCT04695847"
      ],
      "locations": [
        "Canada",
        "United States"
      ]
    },
    {
      "heading": "ABBV-154",
      "names": [
        "ABBV-154"
      ],
      "ttd": "D2AQW7",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "MRG002",
      "names": [
        "TRASTUZUMAB VEDOTIN",
        "TRASTUZUMAB--VCMMAE",
        "MRG 002",
        "MRG-002",
        "MRG002"
      ],
      "ttd": "DM7WY2",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "developers": [
        "Shanghai Miracogen"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5315030",
        "Name": "TRASTUZUMAB VEDOTIN",
        "Synonyms": "MRG 002|MRG-002|MRG002|TRASTUZUMAB VEDOTIN|TRASTUZUMAB--VCMMAE CONJUGATE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04742153",
        "NCT04873362",
        "NCT05980481",
        "NCT05338957",
        "NCT05754853",
        "NCT00928330",
        "NCT01772472",
        "NCT04924699",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "Advanced or Metastatic Urothelium Cancer",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Advanced or Metastatic Breast Cancer",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "Advanced Malignant Solid Tumors",
        "HER2 Positive Breast Neoplasms",
        "Advanced Breast Cancer",
        "Gastric Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Her 2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "PSMA ADC therapeutic",
      "names": [
        "PSMA ADC therapeutic"
      ],
      "ttd": "D0A7LL",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "developers": [
        "Progenics Pharmaceuticals"
      ],
      "trials": [
        "NCT01414296",
        "NCT01856933",
        "NCT02020135",
        "NCT01695044",
        "NCT01414283"
      ],
      "conditions": [
        "GBM",
        "Gliosarcoma",
        "Glioblastoma Multiforme",
        "Prostate Cancer"
      ],
      "locations": [
        "United States"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "Milatuzumab-doxorubicin",
      "names": [
        "Milatuzumab-doxorubicin"
      ],
      "ttd": "D0Y6BO",
      "phases": [
        "Phase 2",
        "Phase 1/2",
        "Phase 1",
        "Phase 3"
      ],
      "Max Phase": "3",
      "developers": [
        "Immunomedics"
      ],
      "trials": [
        "NCT04914741",
        "NCT03755804",
        "NCT06377566",
        "NCT01712490",
        "NCT01309789",
        "NCT06047080",
        "NCT04594798",
        "NCT02734771",
        "NCT01534078",
        "NCT02292979",
        "NCT05404945",
        "NCT06132958",
        "NCT06112379",
        "NCT04884035",
        "NCT01920932",
        "NCT03726879",
        "NCT02605915",
        "NCT04203641",
        "NCT05600686",
        "NCT02505269",
        "NCT03467373",
        "NCT01992653",
        "NCT01060904",
        "NCT06340568",
        "NCT03646123",
        "NCT01777152",
        "NCT04790903",
        "NCT05673785",
        "NCT01966471",
        "NCT02979522",
        "NCT03274492",
        "NCT03991884",
        "NCT06486441",
        "NCT05113251",
        "NCT04569032",
        "NCT03677141",
        "NCT04685616"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Lymphoma, T-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Breast Neoplasms",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "HER2-positive Early Breast Cancer",
        "T-Cell Lymphoma",
        "DLBCL",
        "Disease, Hodgkin",
        "Anaplastic Large-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Locally Advanced or Early Breast Cancer",
        "Refractory B Acute Lymphoblastic Leukemia",
        "HER2-Positive Metastatic Breast Cancer",
        "Refractory B Lymphoblastic Lymphoma",
        "Large B-Cell Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage II Childhood Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Hodgkin Disease",
        "Recurrent B Lymphoblastic Lymphoma",
        "Breast Cancer",
        "Stage III Childhood Hodgkin Lymphoma",
        "B-Cell Lymphoma"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "XMT-1592",
      "names": [
        "XMT-1592"
      ],
      "ttd": "DDL79K",
      "phases": [
        "Phase 1/2"
      ],
      "Max Phase": "2",
      "developers": [
        "Mersana"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CX2029",
      "names": [
        "CX2029"
      ],
      "ttd": "DZ1F3N",
      "phases": [
        "Phase 1/2"
      ],
      "Max Phase": "2",
      "developers": [
        "CytomX"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "FOR46",
      "names": [
        "FOR46"
      ],
      "ttd": "D48ZBO",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "developers": [
        "Fortis Therapeutics"
      ],
      "trials": [
        "NCT03650491",
        "NCT03575819",
        "NCT05011188"
      ],
      "conditions": [
        "Prostate Cancer Metastatic",
        "Multiple Myeloma in Relapse",
        "Metastatic Castration-resistant Prostate Cancer",
        "Multiple Myeloma With Failed Remission",
        "Multiple Myeloma",
        "Prostate Cancer"
      ],
      "locations": [
        "United States"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "INBRX-109",
      "names": [
        "INBRX-109"
      ],
      "ttd": "D56ERU",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Inhibrx"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABBV-CX-2029",
      "names": [
        "ABBV-CX-2029"
      ],
      "ttd": "D58AMF",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie",
        "CytomX"
      ],
      "trials": [
        "NCT03543813"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Diffuse Large B Cell Lymphoma",
        "Non Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Head and Neck Cancer"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "Korea, Republic of"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TAK-500",
      "names": [
        "TAK-500"
      ],
      "ttd": "D9ICV2",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Takeda"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SGN-CD30C",
      "names": [
        "SGN-CD30C"
      ],
      "ttd": "DDG8W9",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "MEDI2228",
      "names": [
        "MEDI2228"
      ],
      "ttd": "DG80IS",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca"
      ],
      "trials": [
        "NCT03489525"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "locations": [
        "Greece",
        "Australia",
        "Spain",
        "United States",
        "France"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "DS-6157",
      "names": [
        "DS-6157"
      ],
      "ttd": "DJ4X7D",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CLT030",
      "names": [
        "CLT030"
      ],
      "ttd": "DW01LJ",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Cellerant Therapeutics"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADC-1013",
      "names": [
        "ADC-1013"
      ],
      "ttd": "D0C5LJ",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "developers": [
        "Alligator Bioscience AB"
      ],
      "trials": [
        "EUCTR2020-005182-14-FR",
        "NCT02379741"
      ],
      "conditions": [
        "Neoplasms",
        "Metastatic Pancreatic Ductal Adenocarcinoma  MedDRA version: 20.0 Level: PT Classification code 10073364 Term: Ductal adenocarcinoma of pancreas System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Solid Tumors",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "locations": [
        "Sweden",
        "United Kingdom",
        "Denmark",
        "France"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "Glypican3-ADC",
      "names": [
        "Glypican3-ADC"
      ],
      "ttd": "D0YP8F",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Bristol Myers Squibb"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CA9-ADC",
      "names": [
        "CA9-ADC"
      ],
      "ttd": "D01BUS",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "MorphoSys AG"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADC-1001",
      "names": [
        "ADC-1001"
      ],
      "ttd": "D01NGB",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Alligator Bioscience AB"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADC-3680",
      "names": [
        "ADC-3680"
      ],
      "ttd": "D02JND",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "Argenta Discovery Ltd"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "d-trastuzumab",
      "names": [
        "d-trastuzumab"
      ],
      "ttd": "D0C2CP",
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "developers": [
        "IATRICa Inc"
      ],
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04873362",
        "NCT05980481",
        "NCT00928330",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Her 2 Positive Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "ADC-1012",
      "names": [
        "ADC-1012"
      ],
      "ttd": "D0G0AQ",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Alligator Bioscience AB"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Maclizumab",
      "names": [
        "Maclizumab"
      ],
      "ttd": "D0J5EQ",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Cytoguide ApS"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADC-7828",
      "names": [
        "ADC-7828"
      ],
      "ttd": "D0K2MT",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Argenta Discovery Ltd"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "CD79-targeted immunotoxins",
      "names": [
        "CD79-targeted immunotoxins"
      ],
      "ttd": "D0M7EP",
      "phases": [
        "Preclinical",
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech"
      ],
      "trials": [
        "NCT00071539"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "locations": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "ADC-5510",
      "names": [
        "ADC-5510"
      ],
      "ttd": "D0TA3V",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Adolor Corp"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADC-9971",
      "names": [
        "ADC-9971"
      ],
      "ttd": "D0U3YW",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Argenta Discovery Ltd"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "OP-06",
      "names": [
        "OP-06"
      ],
      "ttd": "D0WM5H",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Onco-Pharmakon Inc"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "DSTA-4637S",
      "names": [
        "DSTA-4637S"
      ],
      "ttd": "D1A5GK",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Genentech"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BAY 2315497",
      "names": [
        "BAY 2315497"
      ],
      "ttd": "DENO78",
      "phases": [
        "Phase 3"
      ],
      "Max Phase": "3",
      "developers": [
        "Progenics Pharmaceuticals"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADC-03",
      "names": [
        "ADC-03"
      ],
      "ttd": "D0AN9V",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Almac Discovery"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADC-01",
      "names": [
        "ADC-01"
      ],
      "ttd": "DRJU35",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Almac Discovery"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "YH012",
      "names": [
        "YH012"
      ],
      "ttd": "DKHL40",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Biocytogen"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "YH013",
      "names": [
        "YH013"
      ],
      "ttd": "D0AM9O",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Biocytogen"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ZCE025 | HYBRI-CEAKER | MAB-35 | ALTUMOMAB | ALTUMOMAB PENTETATE | Altumomab pentetate | ZCE-025 | INDIUM IN 111 ALTUMOMAB PENTETATE",
      "names": [
        "ZCE025",
        "HYBRI-CEAKER",
        "MAB-35",
        "ALTUMOMAB",
        "ALTUMOMAB PENTETATE",
        "Altumomab pentetate",
        "ZCE-025",
        "INDIUM IN 111 ALTUMOMAB PENTETATE"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109040",
        "Name": "INDIUM IN 111 ALTUMOMAB PENTETATE",
        "Synonyms": "ALTUMOMAB|ALTUMOMAB PENTETATE|Altumomab pentetate|HYBRI-CEAKER|INDIUM IN 111 ALTUMOMAB PENTETATE|MAB-35|ZCE-025|ZCE025",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BEVACIZUMAB GAMMA",
      "names": [
        "BEVACIZUMAB GAMMA"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314727",
        "Name": "BEVACIZUMAB GAMMA",
        "Synonyms": "BEVACIZUMAB GAMMA",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT05200364",
        "NCT03424005",
        "NCT05445778",
        "NCT06336707",
        "NCT02606305",
        "NCT06039202",
        "NCT05464030",
        "NCT05647122",
        "NCT03786081",
        "NCT04486352",
        "NCT04931342",
        "NCT03337698",
        "NCT05489211"
      ],
      "conditions": [
        "Cervical Cancer",
        "Ovarian Carcinoma",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Advanced Solid Tumours",
        "Metastatic Castration-resistant Prostate Cancer",
        "Colorectal Cancer",
        "Epithelial Ovarian Cancer",
        "Carcinoma, Non-Small-Cell Lung",
        "Primary Peritoneal Carcinoma",
        "Primary Peritoneal Cancer",
        "Ovary Cancer",
        "Head and Neck Neoplasms",
        "Advanced Solid Tumors",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Carcinoma Non-small Cell Lung",
        "Colorectal Neoplasms",
        "Endometrial Cancer",
        "Urothelial Cancer",
        "Breast Cancer",
        "Biliary Tract Cancer",
        "Metastatic Colorectal Cancer"
      ],
      "locations": [
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "China",
        "United States",
        "Denmark",
        "Canada",
        "Malaysia",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Ireland",
        "Japan",
        "Spain",
        "Germany",
        "Israel"
      ],
      "developers": [
        "EMD Serono",
        "Merck KGaA, Darmstadt, Germany"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "OPELKIBART ELMANITIN",
      "names": [
        "OPELKIBART ELMANITIN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314859",
        "Name": "OPELKIBART ELMANITIN",
        "Synonyms": "OPELKIBART ELMANITIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "SP-8166 | LUVELTAMAB TAZIDE | SP8166",
      "names": [
        "SP-8166",
        "LUVELTAMAB TAZIDE",
        "SP8166"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5095134",
        "Name": "LUVELTAMAB TAZIDE",
        "Synonyms": "LUVELTAMAB TAZIDE|SP-8166|SP8166",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT05870748"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Platinum-resistant Ovarian Cancer"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Australia",
        "Singapore",
        "United States",
        "Israel"
      ],
      "developers": [
        "GOG Foundation",
        "Sutro Biopharma"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "DELPACIBART ETEDESIRAN",
      "names": [
        "DELPACIBART ETEDESIRAN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314669",
        "Name": "DELPACIBART ETEDESIRAN",
        "Synonyms": "DELPACIBART ETEDESIRAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ZEVALIN INDIUM IN-111 | ZEVALIN IN-111 | INDIUM IN 111 IBRITUMOMAB TIUXETAN | 111INDIUM-ZEVALIN | IBRITUMOMAB TIUXETAN IN-111",
      "names": [
        "ZEVALIN INDIUM IN-111",
        "ZEVALIN IN-111",
        "INDIUM IN 111 IBRITUMOMAB TIUXETAN",
        "111INDIUM-ZEVALIN",
        "IBRITUMOMAB TIUXETAN IN-111"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108610",
        "Name": "INDIUM IN 111 IBRITUMOMAB TIUXETAN",
        "Synonyms": "111INDIUM-ZEVALIN|IBRITUMOMAB TIUXETAN IN-111|INDIUM IN 111 IBRITUMOMAB TIUXETAN|ZEVALIN IN-111|ZEVALIN INDIUM IN-111",
        "Type": "Antibody drug conjugate",
        "Max Phase": -1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase -1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "90Y-DOTA-HMN14 | YTTRIUM Y 90 LABETUZUMAB TETRAXETAN",
      "names": [
        "90Y-DOTA-HMN14",
        "YTTRIUM Y 90 LABETUZUMAB TETRAXETAN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108668",
        "Name": "YTTRIUM Y 90 LABETUZUMAB TETRAXETAN",
        "Synonyms": "90Y-DOTA-HMN14|YTTRIUM Y 90 LABETUZUMAB TETRAXETAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": -1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase -1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM | ZIRCONIUM Zr 89 CREFMIRLIMAB BERDOXAM",
      "names": [
        "ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM",
        "ZIRCONIUM Zr 89 CREFMIRLIMAB BERDOXAM"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314651",
        "Name": "ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM",
        "Synonyms": "ZIRCONIUM Zr 89 CREFMIRLIMAB BERDOXAM",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Taplitumomab paptox | TAPLITUMOMAB PAPTOX",
      "names": [
        "Taplitumomab paptox",
        "TAPLITUMOMAB PAPTOX"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2107890",
        "Name": "TAPLITUMOMAB PAPTOX",
        "Synonyms": "TAPLITUMOMAB PAPTOX|Taplitumomab paptox",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Tecnemab K1 | ANTI-MELANOMA MAB FRAGMENTS",
      "names": [
        "Tecnemab K1",
        "ANTI-MELANOMA MAB FRAGMENTS"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5315106",
        "Name": "ANTI-MELANOMA MAB FRAGMENTS",
        "Synonyms": "Tecnemab K1",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "NACOLOMAB TAFENATOX | Nacolomab tafenatox",
      "names": [
        "NACOLOMAB TAFENATOX",
        "Nacolomab tafenatox"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108151",
        "Name": "NACOLOMAB TAFENATOX",
        "Synonyms": "NACOLOMAB TAFENATOX|Nacolomab tafenatox",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TELIMOMAB ARITOX | T-101 | T101 | Telimomab aritox",
      "names": [
        "TELIMOMAB ARITOX",
        "T-101",
        "T101",
        "Telimomab aritox"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108790",
        "Name": "TELIMOMAB ARITOX",
        "Synonyms": "T-101|T101|TELIMOMAB ARITOX|Telimomab aritox",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05600686"
      ],
      "conditions": [
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Double-Expressor Lymphoma"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "ADC Therapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "EMD-273066 | EMD 273066 | HUKS-IL2 | TUCOTUZUMAB CELMOLEUKIN | KSA-INTERLEUKIN-2",
      "names": [
        "EMD-273066",
        "EMD 273066",
        "HUKS-IL2",
        "TUCOTUZUMAB CELMOLEUKIN",
        "KSA-INTERLEUKIN-2"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108660",
        "Name": "TUCOTUZUMAB CELMOLEUKIN",
        "Synonyms": "EMD 273066|EMD-273066|HUKS-IL2|KSA-INTERLEUKIN-2|TUCOTUZUMAB CELMOLEUKIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ADALIMUMAB FOSIMDESONIDE",
      "names": [
        "ADALIMUMAB FOSIMDESONIDE"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314652",
        "Name": "ADALIMUMAB FOSIMDESONIDE",
        "Synonyms": "ADALIMUMAB FOSIMDESONIDE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "FIBRISCINT | Biciromab brallobarbital | T2G1S | BICIROMAB BRALLOBARBITAL",
      "names": [
        "FIBRISCINT",
        "Biciromab brallobarbital",
        "T2G1S",
        "BICIROMAB BRALLOBARBITAL"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109283",
        "Name": "BICIROMAB BRALLOBARBITAL",
        "Synonyms": "BICIROMAB BRALLOBARBITAL|Biciromab brallobarbital|FIBRISCINT|T2G1S",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IZALONTAMAB BRENGITECAN",
      "names": [
        "IZALONTAMAB BRENGITECAN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314841",
        "Name": "IZALONTAMAB BRENGITECAN",
        "Synonyms": "IZALONTAMAB BRENGITECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "YTTRIUM Y-90 IBRITUMOMAB TIUXETAN | IBRITUMOMAB TIUXETAN YTTRIUM Y-90 | 90Y IBRITUMOMAB TIUXETAN | 90Y-IBRITUMOMAB | Y-IBRITUMOMAB TIUXETAN | YTTRIUM Y 90 IBRITUMOMAB TIUXETAN | IBRITUMOMAB TIUXETAN Y-90",
      "names": [
        "YTTRIUM Y-90 IBRITUMOMAB TIUXETAN",
        "IBRITUMOMAB TIUXETAN YTTRIUM Y-90",
        "90Y IBRITUMOMAB TIUXETAN",
        "90Y-IBRITUMOMAB",
        "Y-IBRITUMOMAB TIUXETAN",
        "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN",
        "IBRITUMOMAB TIUXETAN Y-90"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108667",
        "Name": "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN",
        "Synonyms": "(90)Y-IBRITUMOMAB TIUXETAN|90Y IBRITUMOMAB TIUXETAN|90Y-IBRITUMOMAB|IBRITUMOMAB TIUXETAN Y-90|IBRITUMOMAB TIUXETAN YTTRIUM Y-90|YTTRIUM Y 90 IBRITUMOMAB TIUXETAN|YTTRIUM Y-90 IBRITUMOMAB TIUXETAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ST-1 4197X-RA | MDX-RA | DORLIMOMAB ARITOX | Dorlimomab aritox",
      "names": [
        "ST-1 4197X-RA",
        "MDX-RA",
        "DORLIMOMAB ARITOX",
        "Dorlimomab aritox"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109124",
        "Name": "DORLIMOMAB ARITOX",
        "Synonyms": "DORLIMOMAB ARITOX|Dorlimomab aritox|MDX-RA|ST-1 4197X-RA",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ABR-214936 | ANATUMOMAB MAFENATOX | Anatumomab mafenatox | ANYARA | PNU-214936",
      "names": [
        "NAPTUMOMAB ESTAFENATOX",
        "ABR-214936",
        "Naptumomab estafenatox",
        "TTS-CD3",
        "ABR-217620",
        "ANATUMOMAB MAFENATOX",
        "Anatumomab mafenatox",
        "TTS CD3",
        "ANYARA",
        "PNU-214936",
        "ANYARA TTS CD3"
      ],
      "chembl": [
        {
          "ChEMBL ID": "CHEMBL2108248",
          "Name": "ANATUMOMAB MAFENATOX",
          "Synonyms": "ABR-214936|ANATUMOMAB MAFENATOX|ANYARA|Anatumomab mafenatox|PNU-214936",
          "Type": "Antibody drug conjugate",
          "Max Phase": 2.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL1743045",
          "Name": "NAPTUMOMAB ESTAFENATOX",
          "Synonyms": "ABR-217620|ANYARA|ANYARA TTS CD3|NAPTUMOMAB ESTAFENATOX|Naptumomab estafenatox|TTS CD3|TTS-CD3",
          "Type": "Antibody drug conjugate",
          "Max Phase": 2.0,
          "Orphan": 0
        }
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT00056537",
        "NCT04880863",
        "NCT00420888",
        "NCT03983954",
        "NCT00132379"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Colorectal Cancer Metastatic",
        "Carcinoma, Non-Small-Cell Lung",
        "Pancreatic Cancer",
        "Renal Cell Carcinoma",
        "NSCLC",
        "Pancreatic Adenocarcinoma",
        "HER2-negative Breast Cancer",
        "Non-Small-Cell Lung Carcinoma",
        "Hepatocellular Carcinoma",
        "Bladder Cancer",
        "Non-small Cell Lung Cancer",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "ER+ Breast Cancer",
        "GastroEsophageal Cancer",
        "Cervical Squamous Cell Carcinoma",
        "Mesothelioma",
        "Endometrial Cancer",
        "Melanoma",
        "Urothelial Cancer",
        "NSCL2 Gene Mutation",
        "Prostate Cancer"
      ],
      "locations": [
        "Ukraine",
        "Bulgaria",
        "Russian Federation",
        "Israel",
        "Romania",
        "Norway",
        "United States",
        "United Kingdom",
        "Denmark"
      ],
      "developers": [
        "Active Biotech AB"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "names": [
        "Enfortumab vedotin",
        "ENFORTUMAB VEDOTIN",
        "AGS-22MSE",
        "AGS-22CE",
        "ASG-22CE",
        "AGS-22M6E",
        "ASG-22ME",
        "PADCEV EJFV",
        "Enfortumab Vedotin",
        "Padcev",
        "ASG-22MSE",
        "AGS-22ME",
        "AGS-22M",
        "Enfortumab",
        "ENFORTUMAB VEDOTIN EJFV"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 4",
        "Approved",
        "Phase 1"
      ],
      "conditions": [
        "Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation",
        "Malignant Ureter Neoplasm",
        "Unresectable Bladder Carcinoma",
        "Cancer",
        "Urinary Bladder Neoplasms",
        "Bladder, breast, lung, pancreas cancer and solid tumor",
        "Locally Advanced Bladder Carcinoma",
        "Metastatic Urothelial Cancer (Solid Tumors)",
        "Locally Advanced Urothelial Carcinoma",
        "Lung Cancer",
        "Bladder Squamous Cell Carcinoma",
        "Unresectable Urothelial Carcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Malignant Renal Pelvis Neoplasm",
        "Renal Pelvis and Ureter Urothelial Carcinoma",
        "Metastatic Bladder Carcinoma",
        "Carcinoma, Transitional Cell",
        "Renal Pelvis Neoplasms",
        "Gene Abnormality",
        "Bladder Cancer",
        "Stage III Bladder Cancer AJCC v8",
        "Urothelial Carcinoma",
        "Urachal Adenocarcinoma",
        "Advanced or Metastatic Solid Malignancies",
        "Malignant Urethral Neoplasm",
        "Urethral Neoplasms",
        "Ureteral Cancer",
        "Urologic Neoplasms",
        "Urothelial Cancer",
        "Bladder Adenocarcinoma",
        "Gene Product Sequence Variation",
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Ureteral Neoplasms",
        "Metastatic Urothelial Carcinoma"
      ],
      "targets": [
        "Cell Surface Protein Nectin 4 (PVRL4 / poliovirus receptor-related 4, nectin-4, nectin 4, PPR4, LNIR)",
        "Nectin 4 (PVRL4, Poliovirus receptor-related 4, nectin-4, nectin 4, PPR4, LNIR)"
      ],
      "payload": [
        "Monomethyl Auristatin E \u00a0(MMAE)",
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "Valine\u2013citrulline",
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker   on an average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "AGS-22C3 or AGSM6"
      ],
      "developers": [
        "Seagen",
        "Astellas"
      ],
      "ttd": [
        "DORB45",
        "DAG87H"
      ],
      "heading": "Enfortumab vedotin | AGS-22CE | ASG-22CE | AGS-22M6E | ASG-22ME | Enfortumab Vedotin | Padcev | ASG-22MSE | AGS-22ME | AGS-22M | Enfortumab",
      "chembl": {
        "ChEMBL ID": "CHEMBL3301589",
        "Name": "ENFORTUMAB VEDOTIN",
        "Synonyms": "AGS-22CE|AGS-22M6E|AGS-22ME|AGS-22MSE|ASG-22CE|ASG-22ME|ENFORTUMAB VEDOTIN|ENFORTUMAB VEDOTIN EJFV|Padcev",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "Max Phase": "Approved",
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB13007",
        "Name": "Enfortumab vedotin",
        "Description": "Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to brentuximab vedotin, another...",
        "Groups": "['Approved', 'Investigational']",
        "Highlights": "Matched Description: \u2026 Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant ... [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting ... [L10836] It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD \u2026 Matched Categories: \u2026 MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Antibody-drug Conjugates ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "fda_label": {
        "id": 221578,
        "description": "[\"11 DESCRIPTION Enfortumab vedotin-ejfv is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD-1006). Conjugation takes place on cysteine residues that comprise the interchain disulfide bonds of the antibody to yield a product with a drug-to-antibody ratio of approximately 3.8:1. The molecular weight is approximately 152 kDa. Figure 1. Structural Formula Approximately 4 molecules of MMAE are attached to each antibody molecule. Enfortumab vedotin-ejfv is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells and the small molecule components are produced by chemical synthesis. PADCEV (enfortumab vedotin-ejfv) for injection is provided as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials for intravenous use. PADCEV is supplied as a 20 mg per vial and a 30 mg per vial and requires reconstitution with Sterile Water for Injection, USP, (2.3 mL and 3.3 mL, respectively) resulting in a clear to slightly opalescent, colorless to slightly yellow solution with a final concentration of 10 mg/mL [see Dosage and Administration ( 2.3 )]. After reconstitution, each vial allows the withdrawal of 2 mL (20 mg) and 3 mL (30 mg). Each mL of reconstituted solution contains 10 mg of enfortumab vedotin-ejfv, histidine (1.4 mg), histidine hydrochloride monohydrate (2.31 mg), polysorbate 20 (0.2 mg) and trehalose dihydrate (55 mg) with a pH of 6.0. Enfortumab vedotin structural formula\"]",
        "generic_name": "[\"ENFORTUMAB VEDOTIN\"]",
        "brand_name": "[\"PADCEV EJFV\"]",
        "substance_name": "[\"ENFORTUMAB VEDOTIN\"]",
        "manufacturer_name": "[\"SEAGEN INC.\"]"
      },
      "trials": [
        "NCT05756569",
        "NCT03474107",
        "NCT03192501",
        "NCT04878029",
        "NCT04724018",
        "NCT03288545",
        "NCT03869190",
        "NCT03219333",
        "NCT04887870",
        "NCT05775471"
      ],
      "locations": [
        "Puerto Rico",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Denmark",
        "Canada",
        "France",
        "Italy",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ]
    },
    {
      "heading": "LMB-1",
      "names": [
        "LMB-1"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109306",
        "Name": "LMB-1",
        "Synonyms": "LMB-1",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "names": [
        "Satumomab Penditide",
        "CYT-356",
        "INDIUM IN 111 CAPROMAB PENDETIDE",
        "CYT-351",
        "INDIUM IN 111 CYT-103",
        "ProstaScint",
        "90Y-CYT-356",
        "C-4",
        "PROSTASCINT",
        "CYT-356 90Y",
        "INDIUM IN-111 CAPROMAB PENDETIDE",
        "CYT-103 111 IN",
        "YTTRIUM Y 90 CAPROMAB PENDETIDE",
        "INDIUM IN-111 SATUMOMAB PENDETIDE",
        "CYT-356-Y-90",
        "MONAB B72.3-GYK-DTPA-111IN",
        "7E11-C5.3",
        "INDIUM",
        "INDIUM IN-111 MYOSCINT",
        "INDIUM IN-111 IMCIROMAB PENTETATE",
        "ONCOLTAD",
        "satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide",
        "CAPROMAB PENDETIDE",
        "B72.3",
        "CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium",
        "CYT-356-90Y",
        "IMCIROMAB",
        "SATUMOMAB PENDETIDE INDIUM IN-111",
        "111IN",
        "CYT-103",
        "MYOSCINT INDIUM IN-111",
        "SATUMOMAB PENDETIDE 111IN",
        "INDIUM IN 111 IMCIROMAB PENTETATE",
        "IN-CAPROMAB PENDETIDE",
        "111In",
        "SATUMOMAB PENDETIDE",
        "SUP 111",
        "INDIUM IN 111 SATUMOMAB PENDETIDE",
        "Satumomab pendetide",
        "IMCIROMAB PENTETATE",
        "CYT-099",
        "ONCOSCINT",
        "OncoScint\u00ae CR/OV",
        "SATUMOMAB"
      ],
      "phases": [
        "Phase 2",
        "Phase 1",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Metastatic Colorectal Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Colorectal cancer Ovarian Cancer"
      ],
      "targets": [
        "Tumor-associated antigen, T AG-72, which is found in many adenocarcinomas."
      ],
      "payload": [
        "Indium-111"
      ],
      "linker": [
        "DTPA as a linker for the added In-111.   Site-specific conjugation of a linker-chelator to the oxidized oligosaccharide component of the B72.3 molecule (CYT-103)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "B72.3 (CYT-099)"
      ],
      "developers": [
        "Knoll (Europe)",
        "Lonza Biologics"
      ],
      "chembl": [
        {
          "ChEMBL ID": "CHEMBL1743091",
          "Name": "INDIUM IN 111 SATUMOMAB PENDETIDE",
          "Synonyms": "B72.3|CYT-099|CYT-103|CYT-103 111 IN|INDIUM (111IN) SATUMOMAB PENDETIDE|INDIUM IN 111 CYT-103|INDIUM IN 111 SATUMOMAB PENDETIDE|INDIUM IN-111 SATUMOMAB PENDETIDE|MONAB B72.3-GYK-DTPA-111IN|ONCOSCINT|SATUMOMAB|SATUMOMAB PENDETIDE|SATUMOMAB PENDETIDE 111IN|SATUMOMAB PENDETIDE INDIUM IN-111|Satumomab pendetide",
          "Type": "Antibody drug conjugate",
          "Max Phase": 4.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL2109038",
          "Name": "IMCIROMAB PENTETATE",
          "Synonyms": "C-4|IMCIROMAB|IMCIROMAB PENTETATE|INDIUM (111IN) IMCIROMAB|INDIUM IN 111 IMCIROMAB PENTETATE|INDIUM IN-111 IMCIROMAB PENTETATE|INDIUM IN-111 MYOSCINT|MYOSCINT INDIUM IN-111",
          "Type": "Antibody drug conjugate",
          "Max Phase": 4.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL2109552",
          "Name": "YTTRIUM Y 90 CAPROMAB PENDETIDE",
          "Synonyms": "90Y-CYT-356|CYT-356 90Y|CYT-356-90Y|CYT-356-Y-90|ONCOLTAD|YTTRIUM Y 90 CAPROMAB PENDETIDE",
          "Type": "Antibody drug conjugate",
          "Max Phase": 2.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL1201579",
          "Name": "CAPROMAB PENDETIDE",
          "Synonyms": "7E11-C5.3|CAPROMAB PENDETIDE|CYT-351|CYT-356|ProstaScint",
          "Type": "Antibody drug conjugate",
          "Max Phase": 4.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL2108800",
          "Name": "INDIUM IN 111 CAPROMAB PENDETIDE",
          "Synonyms": "(SUP 111)IN-CAPROMAB PENDETIDE|7E11-C5.3|CYT-351|INDIUM (111IN) CAPROMAB PENDETIDE|INDIUM IN 111 CAPROMAB PENDETIDE|INDIUM IN-111 CAPROMAB PENDETIDE|PROSTASCINT",
          "Type": "Antibody drug conjugate",
          "Max Phase": 4.0,
          "Orphan": 0
        }
      ],
      "heading": "Satumomab Penditide | CYT-356 | CYT-351 | INDIUM IN 111 CYT-103 | ProstaScint | 90Y-CYT-356 | C-4 | CYT-356 90Y | CYT-103 111 IN | YTTRIUM Y 90 CAPROMAB PENDETIDE | INDIUM IN-111 SATUMOMAB PENDETIDE | CYT-356-Y-90 | MONAB B72.3-GYK-DTPA-111IN | 7E11-C5.3 | INDIUM | INDIUM IN-111 MYOSCINT | INDIUM IN-111 IMCIROMAB PENTETATE | ONCOLTAD | satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide | CAPROMAB PENDETIDE | B72.3 | CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium | CYT-356-90Y | IMCIROMAB | SATUMOMAB PENDETIDE INDIUM IN-111 | 111IN | CYT-103 | MYOSCINT INDIUM IN-111 | SATUMOMAB PENDETIDE 111IN | INDIUM IN 111 IMCIROMAB PENTETATE | 111In | SATUMOMAB PENDETIDE | INDIUM IN 111 SATUMOMAB PENDETIDE | Satumomab pendetide | IMCIROMAB PENTETATE | CYT-099 | ONCOSCINT | OncoScint\u00ae CR/OV | SATUMOMAB",
      "Max Phase": "Approved",
      "trials": [
        "NCT06147037"
      ],
      "locations": [
        "Canada",
        "United States"
      ]
    },
    {
      "heading": "VB6-845 | CITATUZUMAB BOGATOX | Citatuzumab bogatox",
      "names": [
        "VB6-845",
        "CITATUZUMAB BOGATOX",
        "Citatuzumab bogatox"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1743000",
        "Name": "CITATUZUMAB BOGATOX",
        "Synonyms": "CITATUZUMAB BOGATOX|Citatuzumab bogatox|VB6-845",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Lumoxiti | MOXETUMOMAB PASUDOTOX TDFK | Moxetumomab pasudotox | CAT-8015 | HA22 | HA-22 | MOXETUMOMAB PASUDOTOX",
      "names": [
        "Lumoxiti",
        "MOXETUMOMAB PASUDOTOX TDFK",
        "Moxetumomab pasudotox",
        "HA22",
        "CAT-8015",
        "HA-22",
        "MOXETUMOMAB PASUDOTOX"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1743043",
        "Name": "MOXETUMOMAB PASUDOTOX",
        "Synonyms": "CAT-8015|HA-22|HA22|Lumoxiti|MOXETUMOMAB PASUDOTOX|MOXETUMOMAB PASUDOTOX TDFK|Moxetumomab pasudotox",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1",
        "Phase 4"
      ],
      "Max Phase": "4",
      "trials": [
        "NCT01829711",
        "NCT00659425",
        "NCT01030536",
        "NCT00586924"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Non-Hodgkin's Lymphoma",
        "Hairy Cell Leukemia",
        "Leukemia, Hairy Cell",
        "Acute Lymphoblastic Leukemia",
        "Chronic Lymphocytic Leukemia"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Ireland",
        "Israel",
        "Serbia",
        "Czechia",
        "Norway",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Poland"
      ],
      "developers": [
        "MedImmune"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "LMB-7",
      "names": [
        "LMB-7"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109307",
        "Name": "LMB-7",
        "Synonyms": "LMB-7",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "VICINIUM | Vicinium | Vicineum | XD60E5X7FI | OPORTUZUMAB MONATOX | VB4-845 | Proxinium | 4D5MOCB-ETA | PROXINIUM",
      "names": [
        "VICINIUM",
        "Vicinium",
        "Vicineum",
        "XD60E5X7FI",
        "OPORTUZUMAB MONATOX",
        "VB4-845",
        "Proxinium",
        "4D5MOCB-ETA",
        "PROXINIUM"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL1743052",
        "Name": "OPORTUZUMAB MONATOX",
        "Synonyms": "4D5MOCB-ETA|OPORTUZUMAB MONATOX|PROXINIUM|Proxinium, Vicinium|VB4-845|VICINIUM|Vicineum|XD60E5X7FI",
        "Type": "Antibody drug conjugate",
        "Max Phase": 3.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 3"
      ],
      "Max Phase": "3",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ALEMTUZUMAB BETA",
      "names": [
        "ALEMTUZUMAB BETA"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314722",
        "Name": "ALEMTUZUMAB BETA",
        "Synonyms": "ALEMTUZUMAB BETA",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Qarziba | previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron | DINUTUXIMAB BETA",
      "names": [
        "Qarziba",
        "previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron",
        "DINUTUXIMAB BETA"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5315068",
        "Name": "DINUTUXIMAB BETA",
        "Synonyms": "Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 1
      },
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "177LU-TETRAXETAN-TETULOMAB | TETULOMAB TETRAXETAN LU-177 | SUP 177 | 177LU-TETULOMAB | BETALUTIN | LU-TETULOMAB",
      "names": [
        "177LU-TETRAXETAN-TETULOMAB",
        "SUP 177",
        "TETULOMAB TETRAXETAN LU-177",
        "177LU-TETULOMAB",
        "BETALUTIN",
        "LU-TETULOMAB"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL4297907",
        "Name": "TETULOMAB TETRAXETAN LU-177",
        "Synonyms": "(SUP 177)LU-TETULOMAB|177LU-TETRAXETAN-TETULOMAB|177LU-TETULOMAB|BETALUTIN|TETULOMAB TETRAXETAN LU-177",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT01796171"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Follicular Lymphoma"
      ],
      "locations": [
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Norway",
        "United States",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Australia",
        "Austria",
        "Spain",
        "Croatia",
        "Israel",
        "Finland"
      ],
      "developers": [
        "Nordic Nanovector"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "SIGVOTATUG VEDOTIN",
      "names": [
        "SIGVOTATUG VEDOTIN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314879",
        "Name": "SIGVOTATUG VEDOTIN",
        "Synonyms": "SIGVOTATUG VEDOTIN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "S9S0Y-DOTA-HLL2 | 90Y-DOTA-HLL2 | Y-DOTA-HLL2 | Y-90-DOTA-HLL2 | YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN | 90Y-EPRATUZUMAB | SUP 90 | 2F35K89X9W",
      "names": [
        "S9S0Y-DOTA-HLL2",
        "90Y-DOTA-HLL2",
        "Y-DOTA-HLL2",
        "Y-90-DOTA-HLL2",
        "YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN",
        "90Y-EPRATUZUMAB",
        "SUP 90",
        "2F35K89X9W"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108666",
        "Name": "YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN",
        "Synonyms": "(SUP 90)Y-DOTA-HLL2|2F35K89X9W|90Y-DOTA-HLL2|90Y-EPRATUZUMAB|S9S0Y-DOTA-HLL2|Y-90-DOTA-HLL2|YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ZX-CD5 | H-65RTA | XOMA ZYME H 65 | H-65-RTA | ZOLIMOMAB ARITOX | H65-RTA | ORTHOZYME CD 5 PLUS",
      "names": [
        "ZX-CD5",
        "H-65RTA",
        "XOMA ZYME H 65",
        "H-65-RTA",
        "ZOLIMOMAB ARITOX",
        "H65-RTA",
        "ORTHOZYME CD 5 PLUS"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2108785",
        "Name": "ZOLIMOMAB ARITOX",
        "Synonyms": "H-65-RTA|H-65RTA|H65-RTA|ORTHOZYME CD 5 PLUS|XOMA ZYME H 65|ZOLIMOMAB ARITOX|ZX-CD5",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "RG-7813 | RO-6895882 | RO6895882 | CERGUTUZUMAB AMUNALEUKIN | RG7813",
      "names": [
        "RG-7813",
        "RO-6895882",
        "RO6895882",
        "CERGUTUZUMAB AMUNALEUKIN",
        "RG7813"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL3990018",
        "Name": "CERGUTUZUMAB AMUNALEUKIN",
        "Synonyms": "CERGUTUZUMAB AMUNALEUKIN|RG-7813|RG7813|RO-6895882|RO6895882",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "NOFETUMOMAB MERPENTAN | NOFETUMOMAB MERPENTAN 99TC | VERLUMA | TECHNETIUM TC 99M NOFETUMOMAB MERPENTAN | 99MTC | TECHNETIUM | Nofetumomab merpentan 99Tc",
      "names": [
        "NOFETUMOMAB MERPENTAN",
        "NOFETUMOMAB MERPENTAN 99TC",
        "VERLUMA",
        "TECHNETIUM TC 99M NOFETUMOMAB MERPENTAN",
        "99MTC",
        "TECHNETIUM",
        "Nofetumomab merpentan 99Tc"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109287",
        "Name": "TECHNETIUM TC 99M NOFETUMOMAB MERPENTAN",
        "Synonyms": "NOFETUMOMAB MERPENTAN 99TC|Nofetumomab merpentan 99Tc|TECHNETIUM (99MTC) NOFETUMOMAB MERPENTAN|TECHNETIUM TC 99M NOFETUMOMAB MERPENTAN|VERLUMA",
        "Type": "Antibody drug conjugate",
        "Max Phase": 4.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "names": [
        "YTTRIUM",
        "HPAM-4",
        "S9S0HY-PAM4",
        "HPAM4-DOTA",
        "90Y",
        "IgG-DOTA",
        "hPAM4-DOTA",
        "HPAM-DOTA HY-PAM4",
        "Clivatucyn",
        "HAFP-31",
        "CLIVATUZUMAB TETRAXETAN",
        "90Y-HPAM4",
        "HPAM-4-DOTA",
        "hPAM4",
        "IMMU-107",
        "90HY-PAM4",
        "hPAM4 IgG-DOTA",
        "Clivatuzumab Tetraxetan",
        "YTTRIUM Y 90 TACATUZUMAB TETRAXETAN",
        "TACATUZUMAB TETRAXETAN",
        "90Y-HPAMA4",
        "AFP-CIDE",
        "YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN",
        "HPAM4-CIDE",
        "Tacatuzumab Tetraxetan"
      ],
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "targets": [
        "MUC1  (mucin 1) is a glycoprotein with extensive O-linked glycosylation of its extracellular domain."
      ],
      "payload": [
        "Yttrium-90-labeled (90Y)   Chelator tetraxetan (DOTA)",
        "Tetraxetan (a chelator for yttrium-90, a radioisotope)"
      ],
      "linker": [
        "Conjugated, on an average of 4 to 7 lysyl, linked to the chelator by their N6."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Clivatuzumab",
        "Tacatuzumab"
      ],
      "developers": [
        "Immunomedics"
      ],
      "chembl": [
        {
          "ChEMBL ID": "CHEMBL3301586",
          "Name": "CLIVATUZUMAB TETRAXETAN",
          "Synonyms": "CLIVATUZUMAB TETRAXETAN|Clivatucyn|HPAM-4|IMMU-107|IgG-DOTA|hPAM4",
          "Type": "Antibody drug conjugate",
          "Max Phase": 2.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL2108708",
          "Name": "YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN",
          "Synonyms": "90HY-PAM4|90Y-HPAM4|90Y-HPAMA4|HPAM-4-DOTA|HPAM-DOTA HY-PAM4|HPAM4-CIDE|HPAM4-DOTA|IMMU-107|S9S0HY-PAM4|YTTRIUM (90Y) CLIVATUZUMAB TETRAXETAN|YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN",
          "Type": "Antibody drug conjugate",
          "Max Phase": 3.0,
          "Orphan": 0
        },
        {
          "ChEMBL ID": "CHEMBL2108669",
          "Name": "YTTRIUM Y 90 TACATUZUMAB TETRAXETAN",
          "Synonyms": "AFP-CIDE|HAFP-31|YTTRIUM (90Y) TACATUZUMAB TETRAXETAN|YTTRIUM Y 90 TACATUZUMAB TETRAXETAN",
          "Type": "Antibody drug conjugate",
          "Max Phase": 2.0,
          "Orphan": 0
        }
      ],
      "heading": "YTTRIUM | HPAM-4 | S9S0HY-PAM4 | HPAM4-DOTA | 90Y | IgG-DOTA | hPAM4-DOTA | HPAM-DOTA HY-PAM4 | Clivatucyn | CLIVATUZUMAB TETRAXETAN | 90Y-HPAM4 | HPAM-4-DOTA | hPAM4 | IMMU-107 | 90HY-PAM4 | hPAM4 IgG-DOTA | Clivatuzumab Tetraxetan | 90Y-HPAMA4 | YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN | HPAM4-CIDE | Tacatuzumab Tetraxetan",
      "Max Phase": "3",
      "locations": [],
      "trials": []
    },
    {
      "heading": "CMD-193",
      "names": [
        "CMD-193"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109504",
        "Name": "CMD-193",
        "Synonyms": "CMD-193",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ISPECTAMAB TAZIDE | SP-8893",
      "names": [
        "ISPECTAMAB TAZIDE",
        "SP-8893"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314684",
        "Name": "ISPECTAMAB TAZIDE",
        "Synonyms": "ISPECTAMAB TAZIDE|SP-8893",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LMB-2",
      "names": [
        "LMB-2"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109367",
        "Name": "LMB-2",
        "Synonyms": "LMB-2",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "TRASTUZUMAB BRENGITECAN",
      "names": [
        "TRASTUZUMAB BRENGITECAN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314886",
        "Name": "TRASTUZUMAB BRENGITECAN",
        "Synonyms": "TRASTUZUMAB BRENGITECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT06100874",
        "NCT02131064",
        "NCT04873362",
        "NCT05980481",
        "NCT00928330",
        "NCT01772472",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT02605915",
        "NCT04784715",
        "NCT02390427",
        "NCT01904903",
        "NCT05323955",
        "NCT03523585",
        "NCT00679341",
        "NCT01966471",
        "NCT04379596",
        "NCT05113251",
        "NCT01969643"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Metastatic Breast Cancer",
        "Neoplasm Metastasis",
        "Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Breast Cancer Female",
        "Brain Metastases",
        "Breast Cancer; HER2-positive; Metastatic",
        "Breast Cancer Metastatic",
        "Locally Advanced or Early Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "Gastric Cancer",
        "Advanced Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Her 2 Positive Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "HER2-Negative Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Breast Cancer"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "developers": [
        "RemeGen"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "DSFV | LMB-9 | -PE | PSEUDOMONAS AERUGINOSA EXOTOXIN A",
      "names": [
        "DSFV",
        "LMB-9",
        "-PE",
        "PSEUDOMONAS AERUGINOSA EXOTOXIN A"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109503",
        "Name": "LMB-9",
        "Synonyms": "B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38|LMB-9",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "DRKS00002954",
        "NCT06377566"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Malignant neoplasm of prostate",
        "C61"
      ],
      "locations": [
        "Germany",
        "United States"
      ],
      "developers": [
        "Seagen"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "ASG-5ME",
      "names": [
        "ASG-5ME"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109574",
        "Name": "ASG-5ME",
        "Synonyms": "ASG-5ME",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT01166490"
      ],
      "conditions": [
        "Pancreatic Neoplasms",
        "Gastric Neoplasms"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Agensys",
        "Seagen"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "SACITUZUMAB TIRUMOTECAN",
      "names": [
        "SACITUZUMAB TIRUMOTECAN"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314875",
        "Name": "SACITUZUMAB TIRUMOTECAN",
        "Synonyms": "SACITUZUMAB TIRUMOTECAN",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT06132958",
        "NCT06074588"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "Endometrial Cancer"
      ],
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "developers": [
        "GOG Foundation",
        "Merck Sharp & Dohme"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "BEZETABART DEBOTANSINE",
      "names": [
        "BEZETABART DEBOTANSINE"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314812",
        "Name": "BEZETABART DEBOTANSINE",
        "Synonyms": "BEZETABART DEBOTANSINE",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "ARX788 mAb | ARX-788 MAB | ANVATABART PACTIL",
      "names": [
        "ANVATABART PACTIL",
        "ARX-788 MAB",
        "ARX788 mAb"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL5314616",
        "Name": "ANVATABART PACTIL",
        "Synonyms": "ANVATABART PACTIL|ARX-788 MAB|ARX788 mAb",
        "Type": "Antibody drug conjugate",
        "Max Phase": 2.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT04829604",
        "NCT06224673",
        "NCT03255070"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Carcinoma",
        "HER2 Positive Metastatic Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Gastric Neoplasm",
        "HER2 Low Breast Carcinoma",
        "Breast Neoplasms",
        "Triple Negative Breast Cancer",
        "Solid Tumors"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "China",
        "United States",
        "France"
      ],
      "developers": [
        "Ambrx"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "AVE-9633 | HUMY9-6",
      "names": [
        "AVE-9633",
        "HUMY9-6"
      ],
      "chembl": {
        "ChEMBL ID": "CHEMBL2109266",
        "Name": "AVE-9633",
        "Synonyms": "AVE-9633|HUMY9-6",
        "Type": "Antibody drug conjugate",
        "Max Phase": 1.0,
        "Orphan": 0
      },
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "DP-303c",
      "names": [
        "DP-303c"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17212",
        "Name": "DP-303c",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 antibody-drug conjugate DP303c \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"adc\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 2, 3]",
        "Score": 23
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "DCLL-9718S",
      "names": [
        "DCLL-9718S"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17392",
        "Name": "DCLL-9718S",
        "Description": "DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1). DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer ... THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal \u2026 Matched Description: \u2026 DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1). \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "BVX-001",
      "names": [
        "BVX-001"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18733",
        "Name": "BVX-001",
        "Description": "BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate. \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "IMMU-114",
      "names": [
        "IMMU-114"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18458",
        "Name": "IMMU-114",
        "Description": "IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate', '\"antibody drug conjugate\"', '\"drug conjugate\"']",
        "Query Indices": "[0, 1, 3]",
        "Score": 18
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197  vaccine",
      "names": [
        "Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197  vaccine"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB10061",
        "Name": "Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine",
        "Description": "Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria Neisseria meningitidis entering the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia. Several serogroups of N....",
        "Groups": "['Approved']",
        "Highlights": "Matched Name: \u2026 Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine \u2026 Matched Description: \u2026 Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used ... [A253277] Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine ... [L43518]\nMeningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AOC-1020",
      "names": [
        "AOC-1020"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18621",
        "Name": "AOC-1020",
        "Description": "AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 An antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector ... function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide \u2026 Matched Description: \u2026 AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting ... , effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AOC 1001",
      "names": [
        "AOC 1001"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18620",
        "Name": "AOC 1001",
        "Description": "AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting ... , effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA ( \u2026 Matched Description: \u2026 AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 ... (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Tositumomab I-131",
      "names": [
        "Tositumomab I-131"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB17991",
        "Name": "Tositumomab I-131",
        "Description": "",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Tositumomab conjugate with 131I ... Anti-b1 antibody I-131 ... Iodine-131 anti-b1 antibody \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "LMB-100",
      "names": [
        "LMB-100"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18591",
        "Name": "LMB-100",
        "Description": "LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion \u2026 Matched Categories: \u2026 Amino Acids, Peptides, and Proteins \u2026",
        "Queries": "['antibody AND conjugate']",
        "Query Indices": "[0]",
        "Score": 5
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Zenocutuzumab",
      "names": [
        "Zenocutuzumab"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB15559",
        "Name": "Zenocutuzumab",
        "Description": "Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) \u2026",
        "Queries": "['\"adc\"']",
        "Query Indices": "[2]",
        "Score": 5
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "Mitazalimab",
      "names": [
        "Mitazalimab"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB15225",
        "Name": "Mitazalimab",
        "Description": "Mitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).",
        "Groups": "['Investigational']",
        "Highlights": "Matched Description: \u2026 Mitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study). \u2026",
        "Queries": "['\"adc\"']",
        "Query Indices": "[2]",
        "Score": 5
      },
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "trials": [
        "EUCTR2020-005182-14-FR"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma  MedDRA version: 20.0 Level: PT Classification code 10073364 Term: Ductal adenocarcinoma of pancreas System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "locations": [
        "France"
      ],
      "developers": [
        "Alligator Bioscience AB"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "Nendratareotide uzatansine",
      "names": [
        "Nendratareotide uzatansine"
      ],
      "drugbank": {
        "URL": "https://go.drugbank.com/drugs/DB18351",
        "Name": "Nendratareotide uzatansine",
        "Description": "Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated to the cytotoxin mertansine.",
        "Groups": "['Investigational']",
        "Highlights": "Matched Synonyms: \u2026 Peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl \u2026 Matched Description: \u2026 Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated \u2026",
        "Queries": "['\"drug conjugate\"']",
        "Query Indices": "[3]",
        "Score": 3
      },
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": []
    },
    {
      "heading": "AGS67E",
      "names": [
        "AGS67E"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT02175433"
      ],
      "conditions": [
        "Refractory Lymphoid Malignancy",
        "Relapsed Lymphoid Malignancy"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "Astellas"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "AGX101",
      "names": [
        "AGX101"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06440005"
      ],
      "conditions": [
        "Cancer",
        "Locally Advanced Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Triple Negative Breast Cancer",
        "Pancreas Cancer",
        "Metastatic Solid Tumor",
        "Advanced Cancer"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Angiex"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "AMT-151",
      "names": [
        "AMT-151"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05498597"
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Ovarian Clear Cell Carcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Lung Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Malignant Pleural Mesothelioma",
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Endometrial Adenocarcinoma",
        "Advanced Carcinoma",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Epithelial Cancer",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Cancer",
        "Endometrial Endometrioid Adenocarcinoma",
        "Ovarian Clear Cell Adenocarcinoma"
      ],
      "locations": [
        "China",
        "Australia"
      ],
      "developers": [
        "Multitude"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "AZD9592",
      "names": [
        "AZD9592"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05647122"
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Head and Neck Neoplasms",
        "Advanced Solid Tumours",
        "Carcinoma Non-small Cell Lung"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Japan",
        "China",
        "Spain",
        "United States",
        "France",
        "Italy",
        "Taiwan"
      ],
      "developers": [
        "AstraZeneca"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "BAT8009 | BAT8009 for Injection",
      "names": [
        "BAT8009",
        "BAT8009 for Injection"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05405621"
      ],
      "conditions": [
        "Locally Advanced/Metastatic Solid Tumours"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Bio thera Solutions"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "BB-1709",
      "names": [
        "BB-1709"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06241898"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Bliss (Hangzhou)"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "BG-C9074",
      "names": [
        "BG-C9074"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06233942"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [
        "Australia"
      ],
      "developers": [
        "BeiGene"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "BGB-C354",
      "names": [
        "BGB-C354"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06422520"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [],
      "developers": [
        "BeiGene"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "BIO-106",
      "names": [
        "BIO-106"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05320588"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Oncology",
        "Cancer"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "BiOneCure Therapeutics Inc"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "B003",
      "names": [
        "B003"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT03953833"
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Shanghai Pharmaceuticals Holding"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "CA102N",
      "names": [
        "CA102N"
      ],
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06039202"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "locations": [],
      "developers": [
        "Holy Stone Healthcare Co., Ltd"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "CS5001",
      "names": [
        "CS5001"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05279300"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Lymphoma"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "developers": [
        "CStone Pharmaceuticals"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "FDA018-ADC",
      "names": [
        "FDA018-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05174637"
      ],
      "conditions": [
        "Advanced/ Metastatic Solid Tumors"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "FDA022 | FDA022 Monoclonal -  for injection Phase Ib | FDA022 Monoclonal -  for injection Phase Ia",
      "names": [
        "FDA022",
        "FDA022 Monoclonal -  for injection Phase Ib",
        "FDA022 Monoclonal -  for injection Phase Ia",
        "FDA022-BB05"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06413615",
        "NCT05564858"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Solid Tumors"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "DXC006",
      "names": [
        "DXC006"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06224855"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Hematological Malignancies"
      ],
      "locations": [],
      "developers": [
        "Hangzhou DAC Biotechnology Co., Ltd"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "EBC-129",
      "names": [
        "EBC-129"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05701527"
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "locations": [
        "Singapore",
        "United States"
      ],
      "developers": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "FZ-AD004",
      "names": [
        "FZ-AD004"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05914545"
      ],
      "conditions": [
        "Advanced and Metastatic Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "HLX42",
      "names": [
        "HLX42"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06210815"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Shanghai Henlius"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "HS-20093 (Phase Ib: Dose expansion) | HS-20093 | HS-20093 (Phase Ia: Dose escalation)",
      "names": [
        "HS-20093",
        "HS-20093 (Phase Ia: Dose escalation)",
        "HS-20093 (Phase Ib: Dose expansion)"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05276609",
        "NCT06112704",
        "NCT06464055"
      ],
      "conditions": [
        "Advanced Malignant Solid Tumors",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Shanghai Hansoh Biomedical"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "HS-20105",
      "names": [
        "HS-20105"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06144723"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [],
      "developers": [
        "Shanghai Hansoh Biomedical"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "JSKN003",
      "names": [
        "JSKN003"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05494918"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "locations": [
        "Australia"
      ],
      "developers": [
        "Alphamab Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "KM501",
      "names": [
        "KM501"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05804864"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Xuanzhu Biopharm"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "L-DOS47",
      "names": [
        "L-DOS47"
      ],
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT04203641",
        "EUCTR2010-020729-42-PL",
        "NCT02340208"
      ],
      "conditions": [
        "Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer  MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Non-Small Cell Lung Cancer",
        "Pancreas Cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "locations": [
        "Poland",
        "United States"
      ],
      "developers": [
        "Helix BioPharma",
        "Pharm-Olam International"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "LCB84",
      "names": [
        "LCB84"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05941507"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "Legochem"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "LY4052031",
      "names": [
        "LY4052031"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06465069"
      ],
      "conditions": [
        "Cervical Cancer",
        "Bladder Cancer",
        "Advanced Solid Tumor",
        "Non-small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Esophageal Cancer",
        "Recurrent Solid Tumor",
        "Metastatic Solid Tumor",
        "Renal Pelvis Cancer",
        "Pancreatic Cancer",
        "Urinary Bladder Neoplasm",
        "Prostate Cancer"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Eli Lilly",
        "Loxo Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "LY4101174",
      "names": [
        "LY4101174"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06238479"
      ],
      "conditions": [
        "Cervical Cancer",
        "Bladder Cancer",
        "Advanced Solid Tumor",
        "Non-small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Esophageal Cancer",
        "Recurrent Solid Tumor",
        "Metastatic Solid Tumor",
        "Renal Pelvis Cancer",
        "Pancreatic Cancer",
        "Urinary Bladder Neoplasm",
        "Prostate Cancer"
      ],
      "locations": [
        "Australia",
        "United States",
        "Japan"
      ],
      "developers": [
        "Eli Lilly",
        "Loxo Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "LY4170156",
      "names": [
        "LY4170156"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06400472"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Colorectal Neoplasms",
        "Pancreatic Neoplasm",
        "Endometrial Neoplasms",
        "Uterine Cervical Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Triple Negative Breast Neoplasms"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Eli Lilly",
        "Loxo Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "M9140",
      "names": [
        "M9140"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05464030"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "locations": [
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "China",
        "United States",
        "Denmark",
        "Canada",
        "Malaysia",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Ireland",
        "Japan",
        "Spain",
        "Germany",
        "Israel"
      ],
      "developers": [
        "EMD Serono",
        "Merck KGaA, Darmstadt, Germany"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "ORM-5029",
      "names": [
        "ORM-5029"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05511844"
      ],
      "conditions": [
        "HER-2 Gene Amplification",
        "HER-2 Protein Overexpression",
        "HER2 Gene Mutation",
        "HER2-positive Breast Cancer"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Orum Therapeutics USA, Inc"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "PBI-410",
      "names": [
        "PBI-410"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06384807"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Biohaven"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "SIBP-A13 formulation for injection | SIBP-A13",
      "names": [
        "SIBP-A13 formulation for injection",
        "SIBP-A13"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06298058"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [],
      "developers": [
        "Shanghai Institute Of Biological Products"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TAC-001",
      "names": [
        "TAC-001"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05399654"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "developers": [
        "Tallac Therapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TAK-853",
      "names": [
        "TAK-853"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06390995"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumors"
      ],
      "locations": [
        "Japan"
      ],
      "developers": [
        "Takeda"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TORL-1-23",
      "names": [
        "TORL-1-23"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05103683"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Advanced Solid Tumor",
        "NSCLC",
        "Endometrial Cancer"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "TORL Biotherapeutics",
        "Translational Research in Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TORL-3-600",
      "names": [
        "TORL-3-600"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05948826"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Colorectal Cancer"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "TORL Biotherapeutics",
        "Translational Research in Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TORL-4-500",
      "names": [
        "TORL-4-500"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06005740"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "TORL Biotherapeutics",
        "Translational Research in Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TQB2102 for injection | TQB2102 | TQB2102 injection",
      "names": [
        "TQB2102 for injection",
        "TQB2102",
        "TQB2102 injection"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06431490",
        "NCT06198751",
        "NCT06115902",
        "NCT06452706",
        "NCT05735496"
      ],
      "conditions": [
        "Biliary Tract Cancer",
        "Advanced Cancer",
        "Breast Cancer"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Chiatai Tianqing"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "TUB-040",
      "names": [
        "TUB-040"
      ],
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06303505"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Tubulis"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "VIP943",
      "names": [
        "VIP943"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06034275"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "B-cell Acute Lymphoblastic Leukemia",
        "High-risk Myelodysplastic Syndrome"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Vincerx Pharma, Inc"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "WTX212A | WTX212A injection",
      "names": [
        "WTX212A",
        "WTX212A injection"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06106152"
      ],
      "conditions": [
        "Advanced Lung Cancer"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Westlake Therapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "YL202 should be intravenously infused | YL202",
      "names": [
        "YL202 should be intravenously infused",
        "YL202"
      ],
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06439771",
        "NCT06107686"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer",
        "Locally Advanced or Metastatic Solid Tumors",
        "NSCLC",
        "HNSCC",
        "Breast Cancer"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "MediLink"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    },
    {
      "heading": "AMG 595",
      "names": [
        "AMG 595"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT01475006"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Advanced Malignant Glioma",
        "Anaplastic Astrocytomas"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "developers": [
        "Amgen"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": []
    }
  ],
  "orgs": [
    {
      "heading": "3SBIO",
      "names": [
        "3SBIO"
      ],
      "HQ City": "Shenyang",
      "HQ Country": "China",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "http://www.3sbio.com/",
      "Acquisition": "-",
      "drugs": [
        "ALT-P7 | ALT-P7 ALT-P7 | HM2-MMAE"
      ],
      "co-developers": [
        "Alteogen"
      ],
      "# co-developers": 1,
      "locations": [
        "Korea, Republic of"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "A&G",
      "names": [
        "A&G Pharmaceutical Inc",
        "A&G",
        "A&G Pharmaceuticals"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05627960"
      ],
      "drugs": [
        "AG02"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ADC Therapeutics",
      "names": [
        "ADC Therapeutics Murray Hill, NJ",
        "ADC Therapeutics in collaboration with MedImmune",
        "ADC Therapeutics America, Inc",
        "ADC Therapeutics",
        "ADC Terapeutics",
        "ADC Therapeutics S.A",
        "ADC Therapeutics SA"
      ],
      "HQ City": "Lausanne",
      "HQ Country": "Switzerland",
      "Founding Year": "2011",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://adctherapeutics.com",
      "Acquisition": "-",
      "ttd": [
        "D05CRY",
        "D0HV4B",
        "D0LL1N",
        "D8L5PA"
      ],
      "fda_label": [
        {
          "id": 133719,
          "description": "[\"11 DESCRIPTION Loncastuximab tesirine-lpyl is a CD19-directed antibody and alkylating agent conjugate, consisting of a humanized IgG1 kappa monoclonal antibody conjugated to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxic alkylating agent, through a protease-cleavable valine-alanine linker. SG3199 attached to the linker is designated as SG3249, also known as tesirine. Loncastuximab tesirine-lpyl has an approximate molecular weight of 151 kDa. An average of 2.3 molecules of SG3249 are attached to each antibody molecule. Loncastuximab tesirine-lpyl is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. ZYNLONTA (loncastuximab tesirine-lpyl) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder, which has a cake-like appearance, for intravenous infusion after reconstitution and dilution. Each single-dose vial delivers 10 mg of loncastuximab tesirine-lpyl, L-histidine (2.8 mg), L-histidine monohydrochloride (4.6 mg), polysorbate 20 (0.4 mg), and sucrose (119.8 mg). After reconstitution with 2.2 mL Sterile Water for Injection, USP, the final concentration is 5 mg/mL with a pH of approximately 6.0. Chemical Structure\"]",
          "generic_name": "[\"LONCASTUXIMAB TESIRINE\"]",
          "brand_name": "[\"ZYNLONTA\"]",
          "substance_name": "[\"LONCASTUXIMAB TESIRINE\"]",
          "manufacturer_name": "[\"ADC Therapeutics America, Inc.\"]"
        }
      ],
      "trials": [
        "NCT05600686",
        "NCT03698552",
        "NCT04970901",
        "NCT05991388"
      ],
      "drugs": [
        "ADCT-401 | MEDI3726 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
        "Mipasetamab Uzoptirine | ADCT-601",
        "ADCT-402 | ADCT-402 RB4v1.2-SG-3249 | Zynlonta | Loncastuximab tesirine",
        "TELIMOMAB ARITOX | T-101 | T101 | Telimomab aritox",
        "3A4-PL1601",
        "ADCT-901",
        "ADCT-701",
        "Camidanlumab tesirine | HuMax-TAC-ADC | ADCT-301 | ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d",
        "ADCT-502",
        "hLL2-cys-PBD | ADC ADCT-602 -  ADCT-602 anti-CD22/PBD ADC ADCT-602 epratuzumab-cys-SG3249 epratuzumab-cys-tesirine hLL2-cys-PBD hLL2-cys-SG3249 | Epratuzumab Tesirine | ADCT 602 ADCT602 ADCT-602 | ADCT-602"
      ],
      "co-developers": [
        "Genmab",
        "MedImmune",
        "AstraZeneca"
      ],
      "# co-developers": 3,
      "locations": [
        "Belgium",
        "Italy",
        "Czechia",
        "Spain",
        "Switzerland",
        "United States",
        "United Kingdom"
      ],
      "# locations": 7,
      "# drugs": 10,
      "# Preclinical drugs": 3,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AGO Research",
      "names": [
        "AGO Research GmbH",
        "AGO Research"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT04274426"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ALX Oncology",
      "names": [
        "ALX Oncology"
      ],
      "HQ City": "Burlingame",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.alxoncology.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AbGenomics BV",
      "names": [
        "AbGenomics BV",
        "AbGenomics International",
        "Taiwan Branch"
      ],
      "HQ City": "Oss",
      "HQ Country": "Netherlands",
      "Founding Year": "2009",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.abgenomics.com",
      "Acquisition": "-",
      "drugs": [
        "Ab1-18Hr1 | AbGn-107",
        "AbGn-110",
        "AbGn-108"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AbbVie",
      "names": [
        "AbbVie Stemcentrx LLC",
        "AbbVie",
        "CytomX and AbbVie",
        "AbbVie, Inc",
        "AbbVie Deutschland GmbH & Co. KG",
        "Abbvie",
        "Stemcentrx (now part of AbbVie)",
        "Pfizer Stemcentrx (now AbbVie) In collaboration with Indiana University",
        "AbbVie (prior sponsor, Abbott)"
      ],
      "HQ City": "North Chicago",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.abbvie.com",
      "Acquisition": "-",
      "ttd": [
        "D2AQW7",
        "D4J9HV",
        "D58AMF",
        "DDE82F"
      ],
      "trials": [
        "NCT03539536",
        "NCT02674568",
        "NCT02573324",
        "EUCTR2018-001772-38-IE",
        "NCT03061812",
        "NCT01800695",
        "NCT03000257",
        "NCT03543358",
        "NCT02565758",
        "NCT03086239",
        "EUCTR2018-001772-38-HU",
        "NCT04928846",
        "NCT02590263",
        "NCT04070768",
        "NCT02099058",
        "NCT05016947",
        "NCT05183035",
        "NCT05955261",
        "NCT04189614",
        "NCT05283720",
        "NCT02343406",
        "NCT01741727",
        "NCT05904106"
      ],
      "drugs": [
        "CX-2029",
        "Teliso-V | ABT-700-vcMMAE | ABBV 399 | ABBV-399 | Telisotuzumab Vedotin | ABBV-399 ABBV399 ABBV 399 ABT-700-vcMMAE Teliso-V cMet-Targeted ADC",
        "SC-006 | SC006",
        "ABBV-011",
        "ABBV-400",
        "ABBV-3373",
        "ABT-414 ABT-414/806 Depatux-M | ABT-414 | Depatuxizumab Mafodotin",
        "ABBV-085 | Samrotamab vedotin | PR-1498487-MMAE | PR-1498487-MMAE PR-1498487 PAB-MMAE | Anti-huLRRC15 -  anti-huLR C15 ADC ABBV-085",
        "Mirzotamab Clezutoclax | ABBV-155",
        "ABBV-154",
        "ABBV-838 | Azintuxizumab Vedotin | ABBV-838 ABBV838",
        "ABBV 176 | ABBV-176 | ABV176 | ABBV176",
        "ABBV-319",
        "ABBV-706",
        "SC-003 | Anti-DPEP3 ADC | SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001 | Tamrintamab Pamozirine",
        "ABBV-CX-2029",
        "ABBV-321 | ABBV-321 Anti-Egfr/pbd -  ABBV-321 | Serclutamab Talirine",
        "ABBV-221 | ABBV-221 ABBV221 | Losatuxizumab vedotin",
        "Cofetuzumab pelidotin | ABBV-647 | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020 | PF-06647020"
      ],
      "co-developers": [
        "Pfizer",
        "CytomX",
        "Stemcentrx"
      ],
      "# co-developers": 3,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Czech Republic",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "Hong Kong",
        "Colombia",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Romania",
        "Hungary",
        "Ireland",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Argentina",
        "Israel",
        "Slovakia",
        "Finland"
      ],
      "# locations": 43,
      "# drugs": 19,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 7,
      "# Phase 2 drugs": 8,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 23,
      "# Phase 1 trials": 9,
      "# Phase 2 trials": 8,
      "# Phase 3 trials": 6,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Abbott Diabetes Care",
      "names": [
        "Abbott Diabetes Care"
      ],
      "HQ City": "Alameda",
      "HQ Country": "United States",
      "Founding Year": "1888",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.abbott.com/diabetes-care.html",
      "Acquisition": "-",
      "trials": [
        "NCT01432275"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Acepodia Biotech",
      "names": [
        "Acepodia Biotech, Inc",
        "Acepodia Biotech"
      ],
      "HQ City": "Milpitas",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.acepodia.com",
      "Acquisition": "-",
      "trials": [
        "NCT06415487",
        "NCT05653271"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Actinium",
      "names": [
        "Actinium"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1971",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.actiniumpharma.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Active Biotech AB",
      "names": [
        "Active Biotech AB"
      ],
      "HQ City": "Lund",
      "HQ Country": "Sweden",
      "Founding Year": "1983",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.activebiotech.com/",
      "Acquisition": "-",
      "trials": [
        "NCT00056537",
        "NCT00420888",
        "NCT00132379"
      ],
      "drugs": [
        "ABR-214936 | ANATUMOMAB MAFENATOX | Anatumomab mafenatox | ANYARA | PNU-214936"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Bulgaria",
        "Russian Federation",
        "Israel",
        "Romania",
        "Norway",
        "United States",
        "United Kingdom",
        "Denmark"
      ],
      "# locations": 9,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Adcentrx",
      "names": [
        "Adcentrx",
        "Adcentrx Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06036121"
      ],
      "drugs": [
        "ADRX-0706"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Adimab",
      "names": [
        "Mersana Therapeutics in collaboration with Takeda. Antibody development: Adimab",
        "Adimab"
      ],
      "HQ City": "Lebanon",
      "HQ Country": "United States",
      "Founding Year": "2007",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.adimab.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Adolor Corp",
      "names": [
        "Adolor Corp"
      ],
      "HQ City": "Exton",
      "HQ Country": "USA",
      "Founding Year": "1994",
      "Public/Private": "-",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Cubist Pharmaceuticals in 2011",
      "ttd": [
        "D0TA3V"
      ],
      "drugs": [
        "ADC-5510"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Affinicon",
      "names": [
        "Affinicon"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "Cymac-001 | anti-CD163-dexamethasone | CD163-dexamethasone ADC | anti-CD163-dexamethasone ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Sweden",
        "Czechia",
        "Turkey",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Serbia",
        "Belarus",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "New Zealand",
        "Japan",
        "Latvia",
        "Spain",
        "Germany",
        "Croatia",
        "Israel"
      ],
      "# locations": 35,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Agensys",
      "names": [
        "Agensys",
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas",
        "Agensys and Seattle Genetics",
        "Agensys, Inc"
      ],
      "HQ City": "Santa Monica",
      "HQ Country": "United States",
      "Founding Year": "1996",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Astellas in 2007",
      "trials": [
        "NCT01166490"
      ],
      "drugs": [
        "AGS-16C3F | AGS-16M8F | AGS 16C3F",
        "ASG-5ME",
        "AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | ASG-15ME | AGS-15vcMMAE | AGS-15E | Sirtratumab vedotin | Ha15-10ac.1vcMMAE | AGS15E",
        "AGS62P1 | AGS 62P1"
      ],
      "co-developers": [
        "Ligand Pharmaceuticals",
        "Seagen",
        "Astellas"
      ],
      "# co-developers": 3,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Aivita Biomedical",
      "names": [
        "Aivita Biomedical",
        "Aivita Biomedical, Inc"
      ],
      "HQ City": "Irvine",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://aivitabiomedical.com",
      "Acquisition": "-",
      "trials": [
        "NCT03743298",
        "NCT04690387",
        "NCT05100641",
        "NCT05007496"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alaunos Therapeutics",
      "names": [
        "Alaunos Therapeutics"
      ],
      "HQ City": "Houston",
      "HQ Country": "United States",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.alaunos.com",
      "Acquisition": "-",
      "trials": [
        "NCT00815607"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alethia",
      "names": [
        "Alethia Biotherapeutics",
        "Alethia"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "AB-3A4-ADC | AB-3A4 | AB-3A4 ADC | AB-3A4-vcMMAE"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alfasigma",
      "names": [
        "Alfasigma"
      ],
      "HQ City": "Bologna",
      "HQ Country": "Italy",
      "Founding Year": "1948",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.alfasigma.com/",
      "Acquisition": "-",
      "drugs": [
        "ST8176AA1"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alliance Foundation Trials",
      "names": [
        "Alliance for Clinical Trials in Oncology",
        "Alliance Foundation Trials, LLC",
        "Alliance Foundation Trials"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.alliancefoundationtrials.org",
      "Acquisition": "-",
      "trials": [
        "NCT04457596",
        "NCT04486352",
        "NCT05633654"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alligator Bioscience AB",
      "names": [
        "Alligator Bioscience AB"
      ],
      "HQ City": "Lund",
      "HQ Country": "Sweden",
      "Founding Year": "2001",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.alligatorbioscience.com",
      "Acquisition": "-",
      "ttd": [
        "D0C5LJ",
        "D01NGB",
        "D0G0AQ"
      ],
      "trials": [
        "EUCTR2020-005182-14-FR",
        "NCT02379741"
      ],
      "drugs": [
        "Mitazalimab",
        "ADC-1013",
        "ADC-1012",
        "ADC-1001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Sweden",
        "United Kingdom",
        "Denmark",
        "France"
      ],
      "# locations": 4,
      "# drugs": 4,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Almac Discovery",
      "names": [
        "Almac Discovery"
      ],
      "HQ City": "Craigavon",
      "HQ Country": "UK",
      "Founding Year": "2001",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.almacgroup.com",
      "Acquisition": "-",
      "ttd": [
        "D0AN9V",
        "DRJU35"
      ],
      "drugs": [
        "ADC-01",
        "ADC-03"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alphamab Oncology",
      "names": [
        "Alphamab (Australia) Co Pty Ltd",
        "Alphamab Oncology"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2011",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.alphamaboncology.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05494918"
      ],
      "drugs": [
        "JSKN003"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Australia"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alteogen",
      "names": [
        "Alteogen",
        "Alteogen, Inc"
      ],
      "HQ City": "Daejeon",
      "HQ Country": "South Korea",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.alteogen.com",
      "Acquisition": "-",
      "trials": [
        "NCT03281824"
      ],
      "drugs": [
        "Q5-",
        "ALT-P7 | ALT-P7 ALT-P7 | HM2-MMAE"
      ],
      "co-developers": [
        "3SBIO"
      ],
      "# co-developers": 1,
      "locations": [
        "Korea, Republic of"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alzamend Neuro",
      "names": [
        "Alzamend Neuro",
        "Alzamend Neuro, Inc"
      ],
      "HQ City": "Tampa",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.alzamend.com",
      "Acquisition": "-",
      "trials": [
        "NCT05834296"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Ambrx",
      "names": [
        "Merck & Co and Ambrx",
        "Ambrx",
        "Ambrx, Inc"
      ],
      "HQ City": "La Jolla",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.ambrx.com",
      "Acquisition": "-",
      "trials": [
        "NCT04829604",
        "NCT06224673",
        "NCT04662580",
        "NCT03255070"
      ],
      "drugs": [
        "ARX788 | ARX788 HER2 ADC",
        "CD184-FK506",
        "anti-CD70 ADC | Anti-CD70-ADC | CD70 ADC | CD70-ADC",
        "ARX788 mAb | ARX-788 MAB | ANVATABART PACTIL",
        "CD70-glucocorticoid ADC",
        "ARX517-PSMA-ADC | anti-PSMA ADC | ARX517",
        "CD184-Dasatinib-ADC | CD184-Dasatinib"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Korea, Republic of",
        "Australia",
        "China",
        "United States",
        "France"
      ],
      "# locations": 5,
      "# drugs": 7,
      "# Preclinical drugs": 4,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Amgen",
      "names": [
        "Daiichi Sankyo  The antibody part is developed in collaboration with Amgen",
        "Amgen",
        "Amgen, Inc",
        "Daiichi Sankyo The antibody part is developed in collaboration with Amgen"
      ],
      "HQ City": "Thousand Oaks",
      "HQ Country": "United States",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.amgen.com",
      "Acquisition": "-",
      "trials": [
        "NCT04822337",
        "NCT01475006",
        "NCT04307576",
        "NCT01497821"
      ],
      "drugs": [
        "AMG-595 | AMG595",
        "AMG172",
        "AMG 595",
        "AMG 224 | AMG 224 anti-BCMA\u2013MCC\u2013DM1"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Germany",
        "Australia",
        "United States",
        "France"
      ],
      "# locations": 4,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Amphera BV",
      "names": [
        "Amphera BV"
      ],
      "HQ City": "Leiden",
      "HQ Country": "Netherlands",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.amphera.nl",
      "Acquisition": "-",
      "trials": [
        "NCT03610360"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Amsterdam UMC",
      "names": [
        "Amsterdam UMC"
      ],
      "HQ City": "Amsterdam",
      "HQ Country": "Netherlands",
      "Founding Year": "-",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.amsterdamumc.org",
      "Acquisition": "-",
      "trials": [
        "NL-OMON56595"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Angiex",
      "names": [
        "The Center for Vascular Biology Research and the Departments of Angiex",
        "Angiex, Inc",
        "The Center for Vascular Biology Research and the Departments of  Angiex",
        "Angiex"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "USA",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.angiex.com",
      "Acquisition": "-",
      "trials": [
        "NCT06440005"
      ],
      "drugs": [
        "Anti-TM4SF1 ADC",
        "AGX101"
      ],
      "co-developers": [
        "Pfizer"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Antengene",
      "names": [
        "Antengene",
        "Antengene Corporation (Antengene Biologics)",
        "Antengene Corporation ( Antengene Biologics)"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2017",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.antengene.com/",
      "Acquisition": "-",
      "drugs": [
        "ATG-022"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AntibodyChem Biosciences",
      "names": [
        "AntibodyChem Biosciences",
        "AntibodyChem Biosciences, Inc"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Apices Soluciones S.L",
      "names": [
        "Apices Soluciones S.L"
      ],
      "HQ City": "Madrid",
      "HQ Country": "Spain",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.apices.es",
      "Acquisition": "-",
      "trials": [
        "NCT06133517"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Arcus",
      "names": [
        "Arcus Biosciences, Inc",
        "Arcus"
      ],
      "HQ City": "Hayward",
      "HQ Country": "USA",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.arcusbio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05633667",
        "NCT04381832"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Argenta Discovery Ltd",
      "names": [
        "Argenta Discovery Ltd"
      ],
      "HQ City": "Harlow",
      "HQ Country": "UK",
      "Founding Year": "2000",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.argentadiscovery.com",
      "Acquisition": "-",
      "ttd": [
        "D02JND",
        "D0K2MT",
        "D0U3YW"
      ],
      "drugs": [
        "ADC-9971",
        "ADC-3680",
        "ADC-7828"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Array BioPharma",
      "names": [
        "Array BioPharma"
      ],
      "HQ City": "Boulder",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Pfizer in 2019",
      "trials": [
        "NCT03971409"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Arterica",
      "names": [
        "Arterica, Inc",
        "Arterica"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "ACTRN12620000773932"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Artiva",
      "names": [
        "Artiva"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.artivabio.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Asana BioSciences",
      "names": [
        "Asana BioSciences",
        "Asana Biosciences"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "ASN 004 | ASN-004 | ASN-004 ASN004 ASN 004"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Aspyrian",
      "names": [
        "Rakuten Medical (Aspyrian Therapeutics)",
        "Aspyrian"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "ASP-1929 | Cetuximab sarotalocan | RM-1929 | ASP-1929  RM-1929 Cetuximab-irdye 700dx"
      ],
      "co-developers": [
        "Rakuten Medical"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Astellas",
      "names": [
        "Astellas",
        "Astellas Pharma (Agensys)",
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas",
        "Astellas Pharma Inc",
        "Astellas (Ganymed Pharmaceuticals)",
        "Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas",
        "Astellas Pharma Global Development, Inc",
        "Astellas Northbrook, IL Seattle Genetics Bothell, WA"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2005",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.astellas.com",
      "Acquisition": "-",
      "ttd": [
        "DORB45",
        "DAG87H"
      ],
      "trials": [
        "NCT02175433",
        "NCT02171143",
        "NCT02140125",
        "NCT05756569",
        "NCT03474107",
        "NCT02150070",
        "NCT02052375",
        "NCT02125435",
        "NCT03869190",
        "NCT03219333",
        "NCT03288545"
      ],
      "drugs": [
        "Enfortumab vedotin | AGS-22CE | ASG-22CE | AGS-22M6E | ASG-22ME | Enfortumab Vedotin | Padcev | ASG-22MSE | AGS-22ME | AGS-22M | Enfortumab",
        "IMAB027-vcMMAE",
        "AGS67E",
        "AGS-16C3F | AGS-16M8F | AGS 16C3F",
        "AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | ASG-15ME | AGS-15vcMMAE | AGS-15E | Sirtratumab vedotin | Ha15-10ac.1vcMMAE | AGS15E",
        "IMAB362-vcMMAE",
        "AGS62P1 | AGS 62P1"
      ],
      "co-developers": [
        "Ganymed",
        "Ligand Pharmaceuticals",
        "Seagen",
        "Agensys"
      ],
      "# co-developers": 4,
      "locations": [
        "Puerto Rico",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Denmark",
        "Canada",
        "France",
        "Italy",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "# locations": 22,
      "# drugs": 7,
      "# Preclinical drugs": 2,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 11,
      "# Phase 1 trials": 6,
      "# Phase 2 trials": 4,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AstraZeneca",
      "names": [
        "Daiichi Sankyo and AstraZeneca",
        "Innate Pharma in collaboration with AstraZeneca",
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca",
        "ASTRAZENECA AB",
        "LaNova AstraZeneca",
        "AstraZeneca",
        "AstraZeneca AB",
        "AstraZeneca UK Limited"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United Kingdom",
      "Founding Year": "1999",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.astrazeneca.com",
      "Acquisition": "-",
      "ttd": [
        "DP41HV",
        "DD10IZ",
        "DG80IS"
      ],
      "trials": [
        "NCT05480384",
        "EUCTR2022-000776-19-PL",
        "NCT03505710",
        "NCT06106945",
        "NCT06174987",
        "NCT04482309",
        "NCT05744375",
        "NCT03742102",
        "NCT04704934",
        "EUCTR2020-005620-12-ES",
        "NCT05795101",
        "EUCTR2018-000764-29-GB",
        "EUCTR2020-001574-29-PL",
        "NCT05489211",
        "NCT05797168",
        "NCT06429761",
        "NCT04494425",
        "NCT06112379",
        "NCT04986579",
        "NCT06058988",
        "NCT02564900",
        "NCT04644068",
        "NCT06271837",
        "NCT04639219",
        "NCT05460273",
        "NCT06219941",
        "PER-062-22",
        "NCT05629585",
        "NCT03366428",
        "NCT05104866",
        "NCT05246514",
        "NCT04014075",
        "NCT04784715",
        "EUCTR2019-004531-22-PL",
        "NCT06467357",
        "NCT05374512",
        "NCT03334617",
        "NCT04744831",
        "EUCTR2019-004531-22-FR",
        "NCT04622319",
        "NCT04989816",
        "NCT03523585",
        "NCT04556773",
        "NCT03329690",
        "NCT03383692",
        "NCT04042701",
        "NCT05950945",
        "NCT04686305",
        "NCT05765851",
        "EUCTR2022-002680-30-DE",
        "EUCTR2020-001574-29-BE",
        "NCT05048797",
        "NCT03248492",
        "NCT03529110",
        "NCT05982678",
        "NCT05687266",
        "NCT00198380",
        "NCT03734029",
        "NCT05965479",
        "NCT05123482",
        "NCT05702229",
        "NCT04739761",
        "NCT04644237",
        "NCT03983954",
        "NCT04379596",
        "NCT04538742",
        "EUCTR2018-000764-29-PL",
        "NCT05113251",
        "NCT06103864",
        "NCT05647122",
        "NCT06147037",
        "NCT05417594",
        "NCT03384940",
        "EUCTR2021-005223-21-IT",
        "NCT03368196",
        "NCT05704829"
      ],
      "drugs": [
        "LM-305",
        "lintuzumab satetraxetan | Actinium | 225Ac",
        "ADCT-401 | MEDI3726 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
        "TR1801-ADC | MT-8633 | TR1801-ADC MT-8633",
        "CMG901",
        "MEDI2228",
        "Trastuzumab deruxtecan | ENHERTU\u00ae | DS-8201 | DS-8201a",
        "MEDI4276 | MEDI-4276 | MEDI 4276",
        "IPH43",
        "AZD9592",
        "AZD8205"
      ],
      "co-developers": [
        "MedImmune",
        "Open Innovation Partners",
        "ADC Therapeutics",
        "Innate",
        "DAIICHI SANKYO",
        "KYM Biosciences",
        "Keymed Biosciences",
        "Lepu Biopharma",
        "Fusion Pharmaceuticals Inc",
        "Tanabe Research Laboratories USA"
      ],
      "# co-developers": 10,
      "locations": [
        "Ukraine",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Europe",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Republic of Korea",
        "South Africa",
        "Belgium",
        "North Macedonia",
        "Kenya",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Norway",
        "United States",
        "Colombia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "Saudi Arabia",
        "North America",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Poland",
        "Italy",
        "United States of America",
        "Chile",
        "Taiwan",
        "Dominican Republic",
        "Bosnia and Herzegovina",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Republic of Moldova",
        "Hungary",
        "Austria",
        "Romania",
        "Japan",
        "Ireland",
        "Spain",
        "Germany",
        "Uganda",
        "New Zealand",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Turkiye",
        "Finland"
      ],
      "# locations": 68,
      "# drugs": 11,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 6,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 76,
      "# Phase 1 trials": 11,
      "# Phase 2 trials": 34,
      "# Phase 3 trials": 29,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Bayer",
      "names": [
        "Bayer HealthCare Pharmaceuticals in association with  ImmunoGen Inc",
        "Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc",
        "Bayer HealthCare Pharmaceuticals",
        "Bayer HealthCare",
        "Bayer Pharmaceuticals Whippany, NJ",
        "Bayer AG",
        "Bayer"
      ],
      "HQ City": "Leverkusen",
      "HQ Country": "Germany",
      "Founding Year": "1863",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.bayer.com",
      "Acquisition": "-",
      "ttd": [
        "D0CN9D"
      ],
      "trials": [
        "NCT03023722",
        "NCT02639091",
        "NCT03102320",
        "NCT02610140",
        "NCT02581878",
        "NCT02696642",
        "NCT02751918",
        "NCT01439152",
        "NCT02485119",
        "NCT03724747",
        "NCT04147819",
        "NCT02824042"
      ],
      "drugs": [
        "Trastuzumab Corixetan | BAY 2635190 | BAY-2635190 | BAY2635190",
        "Lupartumab amadotin | BAY 1129980 | BAY 1129980 BAY-1129980 BAY1129980  Other synonyms  Anti-C4.4a - s - Bayer Anti-LY6-PLAUR domain containing 3 - s - Bayer Anti-LYPD3 - s - Bayer | LYPD3 protein-directed - s - Bayer",
        "Aprutumab ixadotin | BAY 1187982 BAY1187982 FGFR2-ADC | BAY 1187982",
        "PSMA-TTC | PSMA-TTC PSMA targeted thorium-227 | BAY-2315497 | Pelgifatamab Corixetan",
        "Anetumab Ravtansine | BAY 94-9343",
        "BAY 794620 | BAY 79-4620 | BAY79-4620 | 3ee9"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 73,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 12,
      "# Phase 1 trials": 10,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BeiGene",
      "names": [
        "BeiGene",
        "Zymeworks In collaboration with BeiGene"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.beigene.com",
      "Acquisition": "-",
      "trials": [
        "NCT06233942",
        "NCT05316246",
        "NCT05957757",
        "NCT06422520",
        "NCT05350917"
      ],
      "drugs": [
        "ZW49 | ZW49 HER2 x HER2 Bispecific - | Zanidatamab Zovodotin",
        "BG-C9074",
        "BGB-C354"
      ],
      "co-developers": [
        "Zymeworks"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States",
        "Australia"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BiOneCure Therapeutics Inc",
      "names": [
        "BiOneCure Therapeutics Inc"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05320588"
      ],
      "drugs": [
        "BIO-106"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bicycle Therapeutics",
      "names": [
        "Bicycle Therapeutics"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United Kingdom",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Linker Developer, ADC Platform Technology",
      "Website URL": "https://bicycletherapeutics.com/",
      "Acquisition": "-",
      "drugs": [
        "BT 1718 | BT1718 | BT-1718"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bio thera Solutions",
      "names": [
        "Bio-Thera Solutions, Ltd",
        "Bio thera Solutions",
        "Bio-Thera Solutions",
        "Bio-Thera Solutions (Guangzhou, China)"
      ],
      "HQ City": "Guangzhou",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.biother\u0430\u0441olutions.com",
      "Acquisition": "-",
      "trials": [
        "NCT05405621"
      ],
      "drugs": [
        "BAT8001",
        "BAT8007",
        "BAT8003",
        "BAT8009 | BAT8009 for Injection",
        "BAT8006"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioAtla",
      "names": [
        "BioAtla in collaboration with Sinobioway Biomedicine",
        "BioAtla San Diego, CA",
        "BioAtla",
        "BioAlta",
        "BioAtla, Inc",
        "BioAtlaSan Diego, CA"
      ],
      "HQ City": "San Diego",
      "HQ Country": "USA",
      "Founding Year": "2007",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.bioatla.com",
      "Acquisition": "-",
      "ttd": [
        "D00OON",
        "D08RWO",
        "D82BZH",
        "DYI4L2"
      ],
      "trials": [
        "NCT04681131",
        "NCT05271604",
        "NCT03425279",
        "NCT03504488"
      ],
      "drugs": [
        "Mecbotamab Vedotin | BA3011 | CAB-anti-Axl-ADC | CAB-Axl-ADC | CAB-anti-Axl-ADC BA3011",
        "BA3021 | Ozuriftamab Vedotin | CAB-ROR2-ADC | BA3021 Anti-ROR2 ADC  CAB-ROR2-ADC | Anti-ROR2 ADC"
      ],
      "co-developers": [
        "Sinobioway Biomedicine"
      ],
      "# co-developers": 1,
      "locations": [
        "Greece",
        "Spain",
        "Hong Kong",
        "Germany",
        "United States",
        "Italy",
        "Poland",
        "Taiwan"
      ],
      "# locations": 8,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 4,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioNTech",
      "names": [
        "BioNTech",
        "BioNTech SE"
      ],
      "HQ City": "Mainz",
      "HQ Country": "Germany",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://biontech.de",
      "Acquisition": "-",
      "trials": [
        "NCT06340568"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioRay",
      "names": [
        "BioRay Pharmaceutical Co",
        "BioRay"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "BRY812"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioTest",
      "names": [
        "Biotest",
        "Biotest Pharmaceuticals Corporation",
        "BioTest"
      ],
      "HQ City": "Dreieich",
      "HQ Country": "Germany",
      "Founding Year": "-",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer, Linker Developer",
      "Website URL": "https://www.biotest.com",
      "Acquisition": "-",
      "trials": [
        "NCT01638936",
        "NCT01001442"
      ],
      "drugs": [
        "Oxobuthyldithio | BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4 | Indatuximab Ravtansine | BT-062 | 1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biocytogen",
      "names": [
        "Biocytogen"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "2009",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.biocytogen.com",
      "Acquisition": "-",
      "ttd": [
        "D5R8YF",
        "DKHL40",
        "D0AM9O"
      ],
      "drugs": [
        "YH012",
        "YH013"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biogen",
      "names": [
        "Biogen Schering AG  Spectrum Pharmaceuticals",
        "Biogen"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "USA",
      "Founding Year": "1978",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.biogen.com",
      "Acquisition": "-",
      "trials": [
        "NCT00674947"
      ],
      "drugs": [
        "Ibritumomab tiuxetan | In-111 Zevalin Y-90 Zevalin",
        "BIIB-015 | BIIB015"
      ],
      "co-developers": [
        "Schering"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 1,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biohaven",
      "names": [
        "Biohaven Therapeutics Ltd",
        "Biohaven"
      ],
      "HQ City": "New Haven",
      "HQ Country": "USA",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.biohavenpharma.com",
      "Acquisition": "Acquired by Pfizer in 2022",
      "trials": [
        "NCT06384807"
      ],
      "drugs": [
        "PBI-410",
        "BHV-1510",
        "BHV-1500"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biosion (China)",
      "names": [
        "Biosion (China)",
        "OBI Pharma (ex-China) and  Biosion (China)"
      ],
      "HQ City": "Nanjing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.biosion.com",
      "Acquisition": "-",
      "drugs": [
        "BSI-992 | OBI-992"
      ],
      "co-developers": [
        "OBI Pharma"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bliss (Hangzhou)",
      "names": [
        "Bliss Biopharmaceutical",
        "Bliss (Hangzhou)",
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China) in collaboration with Eisai & Co, Ltd",
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "ttd": [
        "D56ECJ"
      ],
      "trials": [
        "NCT06188559",
        "NCT05217693",
        "NCT06241898"
      ],
      "drugs": [
        "BB-1705",
        "BB-1709",
        "BB-1701 | HER2-Targeting ADC"
      ],
      "co-developers": [
        "Eisai"
      ],
      "# co-developers": 1,
      "locations": [
        "China",
        "United States",
        "Japan"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Boehringer Ingelheim",
      "names": [
        "Boehringer Ingelheim"
      ],
      "HQ City": "Ingelheim am Rhein",
      "HQ Country": "Germany",
      "Founding Year": "1885",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer, ADC Platform Technology",
      "Website URL": "https://www.boehringer-ingelheim.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06324357",
        "NCT02254005",
        "NCT02254018"
      ],
      "drugs": [
        "CD44v6-DM1 | Anti-CD44v6-DM1 | DM1 immuno | Anti-CD44v6 | BIWI-1 | Bivatuzumab mertansine"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bolt",
      "names": [
        "Bolt Biotherapeutics",
        "Bolt",
        "Bolt Biotherapeutics, Inc"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.boltbio.com/",
      "Acquisition": "-",
      "ttd": [
        "D1XI9E"
      ],
      "trials": [
        "NCT04278144",
        "NCT05954143"
      ],
      "drugs": [
        "BDC-1001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 72,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bristol Myers Squibb",
      "names": [
        "Seattle Genetics (Licensed from  Bristol-Myers Squibb (BMS) with technology licensed from Enzon)",
        "Bristol-Myers Squibb",
        "Bristol Myers Squibb",
        "Bristol Myers Squibb  In collaboration with CytomX",
        "BMS",
        "Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)",
        "Bristol Myers Squibb In collaboration with CytomX",
        "Bristol-Myers Squibb Princeton, NJ",
        "Bristol-Myers Squibb (BMS)",
        "Bristol-Myers Squibb (Celgene) Sutro Biopharma"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1887",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.bms.com",
      "Acquisition": "-",
      "ttd": [
        "DH5BX2",
        "D0YP8F"
      ],
      "trials": [
        "NCT04863885",
        "NCT02884726",
        "NCT02572167",
        "NCT04300556",
        "NCT05613088",
        "NCT00944905",
        "NCT02927769",
        "NCT02341625",
        "NCT01716806",
        "NCT03646123",
        "NCT04278144",
        "NCT02581631",
        "NCT05577715"
      ],
      "drugs": [
        "MDX-060 | iratumumab",
        "CC-99712 \u2013 Anti-BCMA ADC | CC-99712",
        "Glypican3-ADC",
        "BMS-986288 BMS986288 | BMS986288 | BMS-986288",
        "SGN-15 | BR96-DOX | SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin | BMS-182248",
        "BMS986148 | BMS-986148"
      ],
      "co-developers": [
        "Celgene",
        "CytomX",
        "Seagen",
        "Sutro Biopharma",
        "Medarex"
      ],
      "# co-developers": 5,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Portugal",
        "Peru",
        "United States",
        "Colombia",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Iceland",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 60,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 13,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 11,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Byondis",
      "names": [
        "Byondis",
        "Byondis B.V"
      ],
      "HQ City": "Nijmegen",
      "HQ Country": "Netherlands",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.byondis.com",
      "Acquisition": "-",
      "ttd": [
        "DI0ED3"
      ],
      "trials": [
        "NCT04202705",
        "NCT04235101",
        "NCT02277717",
        "NCT04205630",
        "NCT06359002",
        "NCT03262935",
        "NCT05323045"
      ],
      "drugs": [
        "BYON4413 BYON4413 ADC | BYON4413 ADC",
        "SYD985 | Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole | SYD 985 | Trastuzumab vc-seco-DUBA | Trastuzumab duocarmazine",
        "BYON3521 ADC | BYON3521",
        "Anti 5T4 ADC SYD1875 | SYD1875"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Kenya",
        "Portugal",
        "China",
        "Peru",
        "Hong Kong",
        "Colombia",
        "United States",
        "Norway",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Dominican Republic",
        "Chile",
        "Taiwan",
        "Bosnia and Herzegovina",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "Uganda",
        "Spain",
        "Germany",
        "New Zealand",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel"
      ],
      "# locations": 58,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 7,
      "# Phase 1 trials": 5,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CSPC Pharmaceutical Group",
      "names": [
        "CSPC Pharmaceutical Group",
        "CSPC ZhongQi Pharmaceutical Technology Co., Ltd",
        "CSPC ZhongQi Pharmaceutical Technology Co",
        "CSPC Megalith Biopharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group Limited",
        "CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd",
        "CSPC ZhongQi Pharmaceutical"
      ],
      "HQ City": "Shijiazhuang",
      "HQ Country": "China",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.cspc.com.cn",
      "Acquisition": "-",
      "trials": [
        "NCT04146610",
        "NCT06313086",
        "NCT06265727"
      ],
      "drugs": [
        "EO-3021 also known as SYSA1801",
        "CPO301",
        "DP303c"
      ],
      "co-developers": [
        "Elevation Oncology"
      ],
      "# co-developers": 1,
      "locations": [
        "China",
        "Canada",
        "United States",
        "Japan"
      ],
      "# locations": 4,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CStone Pharmaceuticals",
      "names": [
        "CStone Pharmaceuticals"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.cstonepharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05279300"
      ],
      "drugs": [
        "CS5001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cambridge Antibody Technology",
      "names": [
        "Cambridge Antibody Technology"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United Kingdom",
      "Founding Year": "1989",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by AstraZeneca in 2006",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Caris Life Sciences",
      "names": [
        "Caris Life Sciences"
      ],
      "HQ City": "Irving",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.carislifesciences.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Catalent",
      "names": [
        "Catalent Pharma Solutions and Triphase Accelerator Corporation",
        "Catalent",
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience"
      ],
      "HQ City": "Somerset",
      "HQ Country": "United States",
      "Founding Year": "2007",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker Developer, ADC Platform",
      "Website URL": "https://www.catalent.com/",
      "Acquisition": "-",
      "drugs": [
        "CD22-4AP"
      ],
      "co-developers": [
        "Triphase Accelerator Corporation"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Celgene",
      "names": [
        "Celgene",
        "Celgene in collaboration with Sutro",
        "Celgene Corporation",
        "Bristol-Myers Squibb (Celgene) Sutro Biopharma"
      ],
      "HQ City": "Summit",
      "HQ Country": "United States",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.celgene.com/",
      "Acquisition": "Acquired by Bristol-Myers Squibb in 2019",
      "trials": [
        "NCT04036461",
        "NCT04884035",
        "NCT00766116",
        "NCT02073487",
        "NCT02616965",
        "NCT02086604"
      ],
      "drugs": [
        "CC-99712 \u2013 Anti-BCMA ADC | CC-99712"
      ],
      "co-developers": [
        "Sutro Biopharma",
        "Bristol Myers Squibb"
      ],
      "# co-developers": 2,
      "locations": [
        "Canada",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Celldex",
      "names": [
        "Celldex Therapeutics, Inc",
        "Celldex Therapeutics",
        "Celldex"
      ],
      "HQ City": "Hampton",
      "HQ Country": "USA",
      "Founding Year": "1983",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.celldex.com",
      "Acquisition": "-",
      "trials": [
        "NCT01997333",
        "NCT01156753"
      ],
      "drugs": [
        "Glembatumumab vedotin | CDX-011 | DOX | CR011 CR011-vcMMAE",
        "CDX014 | CDX-014 | CR 014-vcMMAE | CR014-vcMMAE"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Portugal",
        "Peru",
        "United States",
        "Colombia",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Iceland",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 60,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cellerant Therapeutics",
      "names": [
        "Cellerant Therapeutics"
      ],
      "HQ City": "San Carlos",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.cellerant.com/",
      "Acquisition": "-",
      "ttd": [
        "DW01LJ"
      ],
      "drugs": [
        "CLT030"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Celltech",
      "names": [
        "Celltech"
      ],
      "HQ City": "Slough",
      "HQ Country": "United Kingdom",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "-",
      "Acquisition": "Acquired by UCB in 2004",
      "drugs": [
        "hCTMO1-calicheamicin CDP-671 | CMB-401 | hCTMO1-calicheamicin | CDP-671"
      ],
      "co-developers": [
        "WYETH",
        "Pfizer"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Centrose",
      "names": [
        "Centrose",
        "Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)"
      ],
      "HQ City": "Madison",
      "HQ Country": "USA",
      "Founding Year": "2004",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.centrose.com",
      "Acquisition": "-",
      "drugs": [
        "DYS-ADC | DYS-EDC | EDC1 | EDC-1",
        "EDC-CD20 | EDC9"
      ],
      "co-developers": [
        "Wisconsin Alumni Research Foundation - WARF"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Chiatai Tianqing",
      "names": [
        "Chiatai Tianqing",
        "Chia Tai Tianqing Pharmaceutical Group Co., Ltd",
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd"
      ],
      "HQ City": "Nanjing",
      "HQ Country": "China",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.ctgpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06431490",
        "NCT06198751",
        "NCT06115902",
        "NCT06452706",
        "NCT05867563",
        "NCT05735496"
      ],
      "drugs": [
        "TQB2102 for injection | TQB2102 | TQB2102 injection"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Chiron Pharma",
      "names": [
        "Chiron Pharma"
      ],
      "HQ City": "Emeryville",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Novartis in 2006",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Chugai",
      "names": [
        "Chugai Pharmaceutical",
        "Chugai"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "1925",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.chugai-pharm.co.jp",
      "Acquisition": "-",
      "trials": [
        "NCT03726879",
        "NCT00860639"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Clovis Oncology",
      "names": [
        "Clovis Oncology",
        "Clovis Oncology, Inc"
      ],
      "HQ City": "Boulder",
      "HQ Country": "United States",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.clovisoncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT03552471"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Coherent Biopharma",
      "names": [
        "Coherent Biopharma"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Concortis",
      "names": [
        "Concortis",
        "Concortis Biotherapeutics (a subsidiary of Sorrento Therapeutics)",
        "Concortis Biotherapeutics"
      ],
      "HQ City": "San Diego",
      "HQ Country": "USA",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Linker developer",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "c-MET ADC",
        "ZV05-ADC | ZV05-mcMMAF | 5T4-MMAF ADC | 5T4-MMAF ADC ZV05-mcMMAF ZV0501 | ZV0501",
        "ZV203"
      ],
      "co-developers": [
        "Zova Biotherapeutics"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Conjugate Light (Australia) Pty Ltd",
      "names": [
        "Conjugate Light (Australia) Pty Ltd"
      ],
      "HQ City": "Melbourne",
      "HQ Country": "Australia",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Conjupro Biotherapeutics",
      "names": [
        "Conjupro Biotherapeutics",
        "Conjupro Biotherapeutics, Inc"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05948865"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Corbus",
      "names": [
        "Corbus Pharmaceuticals Inc",
        "Corbus",
        "Corbus Pharmaceuticals CSPC Megalith Biopharmaceutical, a subsidiary of CSPC Pharmaceutical Group"
      ],
      "HQ City": "Norwood",
      "HQ Country": "United States",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.corbuspharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06265727"
      ],
      "drugs": [
        "CRB-701 | SYS6002"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "Turkey"
      ],
      "# locations": 4,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CuraGen Corporation",
      "names": [
        "CuraGen Corporation"
      ],
      "HQ City": "Branford",
      "HQ Country": "United States",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Celldex Therapeutics in 2009",
      "trials": [
        "NCT00704158",
        "NCT00412828"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CureMeta",
      "names": [
        "CureMeta"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.curemeta.com/",
      "Acquisition": "-",
      "drugs": [
        "Bstrongximab-ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cytogen",
      "names": [
        "Cytogen"
      ],
      "HQ City": "Princeton",
      "HQ Country": "United States",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by EUSA Pharma in 2008",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cytoguide ApS",
      "names": [
        "Cytoguide ApS"
      ],
      "HQ City": "Copenhagen",
      "HQ Country": "Denmark",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.cytoguide.com/",
      "Acquisition": "-",
      "ttd": [
        "D0J5EQ"
      ],
      "drugs": [
        "Maclizumab"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CytomX",
      "names": [
        "CytomX",
        "Bristol Myers Squibb  In collaboration with CytomX",
        "CytomX and AbbVie",
        "CytomX Therapeutics ImmunoGen (Originator)",
        "CytomX Therapeutics South San Francisco, CA",
        "Bristol Myers Squibb In collaboration with CytomX",
        "CytomX Therapeutics"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.cytomx.com",
      "Acquisition": "-",
      "ttd": [
        "DZ1F3N",
        "D58AMF"
      ],
      "trials": [
        "NCT03543813"
      ],
      "drugs": [
        "CX-2009 | CD166 PDC | CX-2009 ADC CX-2009 | Praluzatamab Ravtansine | CD166 AADC",
        "CX-2029",
        "ABBV-CX-2029",
        "BMS-986288 BMS986288 | BMS986288 | BMS-986288",
        "CX2029"
      ],
      "co-developers": [
        "IMMUNOGEN",
        "Bristol Myers Squibb",
        "AbbVie"
      ],
      "# co-developers": 3,
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "Korea, Republic of"
      ],
      "# locations": 4,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 5,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "DAIICHI SANKYO",
      "names": [
        "Daiichi Sankyo and AstraZeneca",
        "DAIICHI SANKYO Co.,Ltd",
        "Daiichi Sankyo Co., Ltd",
        "Daiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd.)",
        "Daiichi Sankyo Company, Limited",
        "Daiichi Sankyo The antibody part is developed in collaboration with Amgen",
        "DAIICHI SANKYO",
        "Daiichi Sankyo",
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo",
        "Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company",
        "Daiichi Sankyo Inc",
        "Daiichi Sankyo, Inc",
        "Daiichi Sankyo  The antibody part is developed in collaboration with Amgen",
        "Daiichi Sankyo Basking Ridge, NJ",
        "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company",
        "Daiichi Sankyo Company"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2005",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.daiichisankyo.com",
      "Acquisition": "-",
      "ttd": [
        "D06BHB",
        "DISJ28",
        "DJ4X7D",
        "DT8R1L",
        "DX5A8D"
      ],
      "fda_label": [
        {
          "id": 89182,
          "description": "[\"11 DESCRIPTION Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody and topoisomerase inhibitor conjugate. Fam-trastuzumab deruxtecan-nxki is an antibody-drug conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase inhibitor, via 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease-cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative. The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology, and the topoisomerase inhibitor and linker are produced by chemical synthesis. Approximately 8 molecules of deruxtecan are attached to each antibody molecule. Fam-trastuzumab deruxtecan-nxki has the following structure: ENHERTU (fam-trastuzumab deruxtecan-nxki) is a sterile, white to yellowish white, preservative-free lyophilized powder in single-dose vials. Each vial delivers 100 mg of fam-trastuzumab deruxtecan-nxki, L-histidine (4.45 mg), L-histidine hydrochloride monohydrate (20.2 mg), polysorbate 80 (1.5 mg), and sucrose (450 mg). Following reconstitution with 5 mL of Sterile Water for Injection, USP, the resulting concentration of fam-trastuzumab deruxtecan-nxki is 20 mg/mL with a pH of 5.5. The resulting solution is administered by intravenous infusion following dilution. Chemical Structure\"]",
          "generic_name": "[\"FAM-TRASTUZUMAB DERUXTECAN-NXKI\"]",
          "brand_name": "[\"Enhertu\"]",
          "substance_name": "[\"TRASTUZUMAB DERUXTECAN\"]",
          "manufacturer_name": "[\"Daiichi Sankyo Inc.\"]"
        }
      ],
      "trials": [
        "NCT03505710",
        "NCT06174987",
        "NCT04482309",
        "NCT04704934",
        "NCT05795101",
        "NCT04965766",
        "JPRN-jRCT2080223860",
        "NCT05489211",
        "NCT04986579",
        "NCT04494425",
        "NCT06112379",
        "NCT02564900",
        "NCT06271837",
        "NCT04639219",
        "NCT05460273",
        "NCT04553770",
        "NCT05633979",
        "NCT05280470",
        "NCT05629585",
        "NCT03366428",
        "NCT05104866",
        "NCT05246514",
        "NCT04014075",
        "NCT04610528",
        "NCT04784715",
        "EUCTR2018-000221-31-CZ",
        "NCT04656652",
        "NCT04752059",
        "NCT05374512",
        "NCT06467357",
        "NCT04744831",
        "NCT04622319",
        "NCT06176261",
        "NCT04989816",
        "EUCTR2020-003427-42-NL",
        "NCT06048718",
        "NCT03523585",
        "NCT04132960",
        "NCT04556773",
        "NCT03383692",
        "NCT04042701",
        "NCT05950945",
        "NCT06161025",
        "NCT04686305",
        "NCT03329690",
        "NCT05765851",
        "NCT05048797",
        "NCT03248492",
        "NCT03529110",
        "NCT02980341",
        "NCT05982678",
        "NCT04940325",
        "NCT03734029",
        "NCT04644237",
        "NCT04739761",
        "NCT03260491",
        "NCT04379596",
        "NCT04538742",
        "NCT05034887",
        "NCT03384940",
        "NCT05865990",
        "NCT06244485",
        "NCT04420598",
        "NCT06103864",
        "NCT05113251",
        "NCT04484142",
        "EUCTR2019-001512-34-BE",
        "NCT06203210",
        "EUCTR2020-003427-42-FR",
        "NCT06362252",
        "NCT03368196",
        "EUCTR2018-000221-31-BE"
      ],
      "drugs": [
        "DS-6157",
        "DS-7300 | B7-H3 ADC",
        "DS-7300a | MABX-9001a | Ifinatamab Deruxtecan \u2013 DS-7300a",
        "DS-9606-a | DS-9606a",
        "Trastuzumab deruxtecan | ENHERTU\u00ae | DS-8201 | DS-8201a",
        "Patritumab Deruxtecan | U3-1402 U3-1402A Anti-HER3 - | U3-1402 | HER3 ADC",
        "Raludotatug Deruxtecan | Raludotatug Deruxtecan  DS-6000a R-DXd | DS-6000a R-DXd",
        "TROP2 ADC | DS-1062 DS1062 DS-1062A Anti-TRP2/dxd | Datopotamab deruxtecan | DS-1062"
      ],
      "co-developers": [
        "AstraZeneca"
      ],
      "# co-developers": 1,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Hungaria",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Europe",
        "Netherlands",
        "United Kingdom",
        "United Kindgdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Korea South",
        "Kenya",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Norway",
        "United States",
        "Colombia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "North America",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Dominican Republic",
        "Taiwan",
        "Bosnia and Herzegovina",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "Ireland",
        "Japan",
        "Uganda",
        "Spain",
        "Germany",
        "New Zealand",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Turkiye",
        "Finland"
      ],
      "# locations": 68,
      "# drugs": 8,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 4,
      "# Phase 4 drugs": 0,
      "# trials": 72,
      "# Phase 1 trials": 12,
      "# Phase 2 trials": 33,
      "# Phase 3 trials": 26,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Debiopharm",
      "names": [
        "ImmunoGen  Debiopharm Internaltional",
        "ImmunoGen Debiopharm Internaltional",
        "Debiopharm"
      ],
      "HQ City": "Lausanne",
      "HQ Country": "Switzerland",
      "Founding Year": "1980",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.debiopharm.com/",
      "Acquisition": "-",
      "drugs": [
        "Debio 1562 | naratuximab emtansine | K7153A-SMCC-DM1 | K7153A | Naratuximab emtansine | IMGN529"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Dendreon",
      "names": [
        "Dendreon"
      ],
      "HQ City": "Seattle",
      "HQ Country": "United States",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Sanpower Group in 2017",
      "trials": [
        "NCT06100705"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Dizal",
      "names": [
        "Dizal"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.dizalpharma.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Dragonfly",
      "names": [
        "Dragonfly",
        "Dragonfly Therapeutics"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.dragonflyimmune.com",
      "Acquisition": "-",
      "trials": [
        "NCT04143711"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Duality Biologics",
      "names": [
        "DualityBio Inc",
        "Duality Biologics in collaboration with BioNTech",
        "Duality Biologics",
        "Duality Biologics in collaboration with BionTech"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.dualitybio.com",
      "Acquisition": "-",
      "trials": [
        "NCT06340568"
      ],
      "drugs": [
        "DB-1311",
        "DB-1303 | DB-1303 BNT323 | BNT323"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "EDDC (Experimental Drug Development Centre), A*STAR Research Entities",
      "names": [
        "EDDC (Experimental Drug Development Centre), A*STAR Research Entities"
      ],
      "HQ City": "Singapore",
      "HQ Country": "Singapore",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.a-star.edu.sg/eddc",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "EMD Serono",
      "names": [
        "EMD Serono Research & Development Institute, Inc",
        "EMD Serono"
      ],
      "HQ City": "Rockland",
      "HQ Country": "United States",
      "Founding Year": "1919",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.emdserono.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05327530",
        "NCT04695847",
        "NCT05464030"
      ],
      "drugs": [
        "BEVACIZUMAB GAMMA",
        "M9140"
      ],
      "co-developers": [
        "Merck KGaA, Darmstadt, Germany"
      ],
      "# co-developers": 1,
      "locations": [
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "China",
        "United States",
        "Denmark",
        "Canada",
        "Malaysia",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Ireland",
        "Japan",
        "Spain",
        "Germany",
        "Israel"
      ],
      "# locations": 24,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Eisai",
      "names": [
        "Morphotek\u00c2\u00ae (a subsidiary of Eisai)",
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China) in collaboration with Eisai & Co, Ltd",
        "Eisai Inc",
        "Morphotek\u00ae, a subsidiary of Eisai Eisai Co Bristol Myers Squibb",
        "Eisai",
        "NanoCarrier Co.,Ltd (Japan) and Eisai"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "1941",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.eisai.com",
      "Acquisition": "-",
      "trials": [
        "NCT06188559",
        "NCT04300556",
        "NCT05613088",
        "NCT05577715",
        "NCT00882102",
        "NCT04986579"
      ],
      "drugs": [
        "ADCM-E7974 | NC-6201",
        "MORAb-202 MORAb-003-VCP-eribulin | Farletuzumab Ecteribulin | MORAb-202",
        "BB-1701 | HER2-Targeting ADC"
      ],
      "co-developers": [
        "Morphotek",
        "Bliss (Hangzhou)",
        "NanoCarrier (Japan)"
      ],
      "# co-developers": 3,
      "locations": [
        "Sweden",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "# locations": 28,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 6,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Elevation Oncology",
      "names": [
        "Elevation Oncology"
      ],
      "HQ City": "New York City",
      "HQ Country": "USA",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.elevationoncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT05980416"
      ],
      "drugs": [
        "EO-3021 also known as SYSA1801",
        "Elevation Oncology \u2013 Proof of Concept ADC | HER3-ADC"
      ],
      "co-developers": [
        "CSPC Pharmaceutical Group"
      ],
      "# co-developers": 1,
      "locations": [
        "United States",
        "Japan"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Eli Lilly",
      "names": [
        "Eli Lilly and Company",
        "Eli Lilly"
      ],
      "HQ City": "Indianapolis",
      "HQ Country": "United States",
      "Founding Year": "1876",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.lilly.com",
      "Acquisition": "-",
      "trials": [
        "NCT06465069",
        "NCT06238479",
        "NCT04486352",
        "NCT02529553",
        "NCT06400472"
      ],
      "drugs": [
        "LY4052031",
        "LY4170156",
        "LY3076226 | ADC LY3076226 | Anti-fibroblast Growth Factor Receptor 3 - | Anti-FGFR3 ADC LY3076226",
        "LY4101174"
      ],
      "co-developers": [
        "Loxo Oncology"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States",
        "Australia",
        "Japan"
      ],
      "# locations": 4,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Emergence",
      "names": [
        "Emergence",
        "Emergence Therapeutics"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.emergencebio.com/",
      "Acquisition": "-",
      "drugs": [
        "ETx-22"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Endocyte",
      "names": [
        "Endocyte",
        "Endocyte, Merck",
        "Endocyte (now part of Novartis) Advanced Accelerator Applications"
      ],
      "HQ City": "West Lafayette",
      "HQ Country": "USA",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Novartis in 2018",
      "drugs": [
        "EC1169",
        "EC2629",
        "EC145/MK 8109 | VYNFINIT\u00ae | MK 8109 | Vintafolide | MK8109 | EC145"
      ],
      "co-developers": [
        "Merck Sharp & Dohme"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Enliven",
      "names": [
        "Enliven Therapeutics",
        "Enliven"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05650879"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Enzon",
      "names": [
        "Enzon",
        "Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)"
      ],
      "HQ City": "Piscataway",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker developer, ADC platform technology",
      "Website URL": "-",
      "Acquisition": "Divested its specialty pharmaceutical business in 2012",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Esperance",
      "names": [
        "Esperance Pharmaceuticals",
        "Esperance"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.esperancepharma.com/",
      "Acquisition": "-",
      "drugs": [
        "EP-400"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "EuPAL",
      "names": [
        "EuPAL"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05183035"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Exelixis",
      "names": [
        "Exelixis"
      ],
      "HQ City": "Alameda",
      "HQ Country": "United States",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.exelixis.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04878029",
        "NCT04925284"
      ],
      "drugs": [
        "ICON-2 Tissue Factor ADC  XB002 | XB002 ICON-2 Tissue Factor ADC"
      ],
      "co-developers": [
        "Iconic",
        "Zymeworks"
      ],
      "# co-developers": 2,
      "locations": [
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ],
      "# locations": 9,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Formation Biologics (Forbius)",
      "names": [
        "Formation Biologics",
        "Formation Biologics (Forbius)",
        "Forbius"
      ],
      "HQ City": "Toronto",
      "HQ Country": "Canada",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.forbius.com",
      "Acquisition": "-",
      "drugs": [
        "AVID300 | AVID 300",
        "AVID100 | AVID 100 anti-EGFR ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Fortis Therapeutics",
      "names": [
        "Fortis Therapeutics, Inc",
        "Fortis Therapeutics"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://fortistx.com/",
      "Acquisition": "-",
      "ttd": [
        "D48ZBO"
      ],
      "trials": [
        "NCT03650491",
        "NCT03575819",
        "NCT05011188"
      ],
      "drugs": [
        "FOR46"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Fudan-Zhangjiang",
      "names": [
        "Fudan-Zhangjiang Bio-Pharmaceutica",
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd",
        "Fudan-Zhangjiang"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "-",
      "Acquisition": "Need clarification on company name",
      "trials": [
        "NCT05174637",
        "NCT05914545",
        "NCT05564858",
        "NCT06413615",
        "NCT03894150"
      ],
      "drugs": [
        "FZ-AD004",
        "FDA022 | FDA022 Monoclonal -  for injection Phase Ib | FDA022 Monoclonal -  for injection Phase Ia",
        "FDA018-ADC",
        "CD30-MCC-DM1 | F0002-ADC CD30-MCC-DM1 | F0002-ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Fusion Pharmaceuticals Inc",
      "names": [
        "Fusion Pharmaceuticals Inc"
      ],
      "HQ City": "Hamilton",
      "HQ Country": "Canada",
      "Founding Year": "2014",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://fusionpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06147037"
      ],
      "drugs": [
        "lintuzumab satetraxetan | Actinium | 225Ac"
      ],
      "co-developers": [
        "AstraZeneca"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "G1 Therapeutics",
      "names": [
        "G1 Therapeutics",
        "G1 Therapeutics, Inc"
      ],
      "HQ City": "Research Triangle Park",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.g1therapeutics.com",
      "Acquisition": "-",
      "trials": [
        "NCT05113966"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GILEAD",
      "names": [
        "Gilead Sciences",
        "GILEAD",
        "Gilead Sciences (previously Immunomedics)",
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics",
        "Gilead Sciences, Inc.",
        "Kite, A Gilead Company",
        "Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas",
        "Gilead"
      ],
      "HQ City": "Foster City",
      "HQ Country": "USA",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.gilead.com",
      "Acquisition": "-",
      "ttd": [
        "D8LAE2"
      ],
      "fda_label": [
        {
          "id": 16817,
          "description": "[\"11 DESCRIPTION Sacituzumab govitecan-hziy is a Trop-2 directed antibody and topoisomerase inhibitor conjugate, composed of the following three components: the humanized monoclonal antibody, hRS7 IgG1\u03ba (also called sacituzumab), which binds to Trop-2 (the trophoblast cell-surface antigen-2); the drug SN-38, a topoisomerase inhibitor; a hydrolysable linker (called CL2A), which links the humanized monoclonal antibody to SN-38. The recombinant monoclonal antibody is produced by mammalian (murine myeloma) cells, while the small molecule components SN-38 and CL2A are produced by chemical synthesis. Sacituzumab govitecan-hziy contains on average 7 to 8 molecules of SN-38 per antibody molecule. Sacituzumab govitecan-hziy has a molecular weight of approximately 160 kilodaltons. Sacituzumab govitecan-hziy has the following chemical structure. TRODELVY (sacituzumab govitecan-hziy) for injection is a sterile, preservative-free, off-white to yellowish lyophilized powder for intravenous use in a 50 mL clear glass single-dose vial, with a rubber stopper and crimp-sealed with an aluminum flip-off cap. Each single-dose vial of TRODELVY delivers 180 mg sacituzumab govitecan-hziy, 77.3 mg 2-(N-morpholino) ethane sulfonic acid (MES), 1.8 mg polysorbate 80 and 154 mg trehalose dihydrate. Reconstitution with 20 mL of 0.9% Sodium Chloride Injection, USP, results in a concentration of 10 mg/mL with a pH of 6.5. Chemical Structure\"]",
          "generic_name": "[\"SACITUZUMAB GOVITECAN\"]",
          "brand_name": "[\"TRODELVY\"]",
          "substance_name": "[\"SACITUZUMAB GOVITECAN\"]",
          "manufacturer_name": "[\"Gilead Sciences\"]"
        }
      ],
      "trials": [
        "NCT05097599",
        "NCT06100874",
        "NCT05186974",
        "NCT02574455",
        "NCT01826877",
        "NCT06123468",
        "NCT03995706",
        "NCT06081244",
        "NCT04724018",
        "NCT06167317",
        "NCT04448886",
        "NCT05609968",
        "NCT05382286",
        "NCT06329869",
        "NCT04986579",
        "NCT05840211",
        "NCT04381832",
        "NCT05101096",
        "NCT03725761",
        "NCT04468061",
        "NCT03971409",
        "NCT05552001",
        "NCT05089734",
        "NCT06235216",
        "NCT04639986",
        "NCT01631552",
        "NCT01270698",
        "NCT04527991",
        "NCT03424005",
        "NCT05675579",
        "NCT05581589",
        "NCT04230109",
        "NCT04251416",
        "NCT04958785",
        "NCT05838521",
        "NCT05143229",
        "NCT05884320",
        "NCT05633667",
        "NCT04595565",
        "NCT03964727",
        "NCT04863885",
        "NCT05119907",
        "NCT05006794",
        "NCT06248515",
        "NCT03901339",
        "NCT03547973",
        "NCT06263543",
        "NCT04647916",
        "NCT05327530",
        "NCT06065371",
        "NCT06238921",
        "NCT05520723",
        "NCT05382299",
        "NCT06486441",
        "NCT06477419",
        "NCT06401824",
        "NCT03869190",
        "NCT05833867",
        "NCT06028932",
        "NCT04617522",
        "NCT04454437",
        "NCT05633654"
      ],
      "drugs": [
        "Trodelvy | hRS7-SN-38 | hRS7-[CL-SN-38] hrS7-SN-38 | Sacituzumab govitecan | hRS7-SN-38-ADC | hRS7-SN38 | IMMU-132"
      ],
      "co-developers": [
        "Immunomedics"
      ],
      "# co-developers": 1,
      "locations": [
        "Puerto Rico",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "Peru",
        "China",
        "Hong Kong",
        "United States",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Singapore",
        "Philippines",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Australia",
        "Romania",
        "Hungary",
        "Japan",
        "Latvia",
        "Spain",
        "Germany",
        "Croatia",
        "Argentina",
        "Israel",
        "Slovakia"
      ],
      "# locations": 46,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 62,
      "# Phase 1 trials": 10,
      "# Phase 2 trials": 39,
      "# Phase 3 trials": 13,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GOG Foundation",
      "names": [
        "GOG Foundation"
      ],
      "HQ City": "Philadelphia",
      "HQ Country": "United States",
      "Founding Year": "1970",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://gog.org/",
      "Acquisition": "-",
      "trials": [
        "NCT06132958",
        "NCT05445778",
        "NCT04931342",
        "NCT06486441",
        "NCT03786081",
        "NCT05870748"
      ],
      "drugs": [
        "SP-8166 | LUVELTAMAB TAZIDE | SP8166",
        "SACITUZUMAB TIRUMOTECAN"
      ],
      "co-developers": [
        "Sutro Biopharma",
        "Merck Sharp & Dohme"
      ],
      "# co-developers": 2,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Ireland",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 54,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 4,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GWT-TUD GmbH",
      "names": [
        "GWT-TUD GmbH"
      ],
      "HQ City": "Dresden",
      "HQ Country": "Germany",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.gwt-tud.de",
      "Acquisition": "-",
      "trials": [
        "NCT04833114"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GamaMabs",
      "names": [
        "GamaMabs"
      ],
      "HQ City": "Toulouse",
      "HQ Country": "France",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.gamamabs.com/",
      "Acquisition": "-",
      "drugs": [
        "GM103"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Ganymed",
      "names": [
        "Ganymed",
        "Astellas (Ganymed Pharmaceuticals)",
        "Ganymed Pharmaceuticals"
      ],
      "HQ City": "Mainz",
      "HQ Country": "Germany",
      "Founding Year": "2001",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Astellas Pharma in 2016",
      "drugs": [
        "IMAB027-vcMMAE",
        "IMAB362-vcMMAE"
      ],
      "co-developers": [
        "Astellas"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GeneQuantum (Suzhou, China)",
      "names": [
        "GeneQuantum Healthcare",
        "GeneQuantum Healthcare (Suzhou, China)",
        "Pyramid Biosciences GeneQuantum Healthcare (Suzhou) Co",
        "GeneQuantum (Suzhou, China)",
        "GeneQuantum Healthcare (Suzhou) Co., Ltd"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.genequantum.com",
      "Acquisition": "-",
      "ttd": [
        "DSOE74"
      ],
      "trials": [
        "NCT05575804",
        "NCT04450732",
        "NCT06154343",
        "NCT06464055"
      ],
      "drugs": [
        "GQ1010",
        "GQ1005 \u2013 HER2",
        "GC1007",
        "GQ1003 \u2013 TROP2",
        "GQ1017",
        "GQ1001 \u2013 HER2 | GQ1001",
        "GQ1014",
        "GQ1015",
        "GQ1018",
        "GC1009"
      ],
      "co-developers": [
        "Pyramid Biosciences"
      ],
      "# co-developers": 1,
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 10,
      "# Preclinical drugs": 4,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genentech",
      "names": [
        "GenentechSouth San Francisco, CA",
        "Genentech Roche  In collaboration with ImmunoGen",
        "Genentech, Inc",
        "Genentech",
        "Genentech Inc",
        "Genentech F. Hoffmann-La Roche",
        "Roche-Genentech",
        "Genentech Inc. (South San Francisco, CA, USA)",
        "Genentech Roche In collaboration with ImmunoGen",
        "Genentech and Nerviano Medical Sciences"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "1976",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.gene.com",
      "Acquisition": "Acquired by Roche in 2009",
      "ttd": [
        "D0P4TH",
        "D0UG0K",
        "D05YYP",
        "D0M7EP",
        "D1A5GK"
      ],
      "fda_label": [
        {
          "id": 40508,
          "description": "[\"11 DESCRIPTION KADCYLA (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex. The antibody trastuzumab, is a well characterized recombinant monoclonal antibody product produced by mammalian (Chinese hamster ovary) cells, and the small molecule components (DM1 and MCC) are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody. Ado-trastuzumab emtansine has the following chemical structure: Note: The bracketed structure is DM1 plus MCC which represents the emtansine component. The n is, on average, 3.5 DM1 molecules per trastuzumab (Mab) molecule. KADCYLA (ado-trastuzumab emtansine) is a sterile, white to off-white preservative free lyophilized powder in single-dose vials. Each vial contains 100 mg or 160 mg ado-trastuzumab emtansine. Following reconstitution, each single-dose vial contains ado-trastuzumab emtansine (20 mg/mL), polysorbate 20 [0.02% (w/v)], sodium succinate (10 mM), and sucrose [6% (w/v)] with a pH of 5.0. The resulting solution containing 20 mg/mL ado-trastuzumab emtansine is administered by intravenous infusion following dilution. Chemical Structure\"]",
          "generic_name": "[\"ADO-TRASTUZUMAB EMTANSINE\"]",
          "brand_name": "[\"KADCYLA\"]",
          "substance_name": "[\"TRASTUZUMAB EMTANSINE\"]",
          "manufacturer_name": "[\"Genentech, Inc.\"]"
        },
        {
          "id": 222041,
          "description": "[\"11 DESCRIPTION Polatuzumab vedotin-piiq is a CD79b-directed antibody and microtubule inhibitor conjugate. It consists of three components: 1) the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; 2) the small molecule anti-mitotic agent MMAE; and 3) a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to the polatuzumab antibody. Polatuzumab vedotin-piiq has an approximate molecular weight of 150 kDa. An average of 3.5 molecules of MMAE are attached to each antibody molecule. Polatuzumab vedotin-piiq is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. POLIVY (polatuzumab vedotin-piiq) for injection is supplied as a sterile, white to grayish-white, preservative-free, lyophilized powder, which has a cake-like appearance, for intravenous infusion after reconstitution and dilution. Each single-dose 30 mg POLIVY vial delivers 30 mg of polatuzumab vedotin-piiq, polysorbate-20 (1.8 mg), sodium hydroxide (0.82 mg), succinic acid (1.77 mg), and sucrose (62 mg). After reconstitution with 1.8 mL of Sterile Water for Injection, USP, the final concentration is 20 mg/mL with a pH of approximately 5.3. Each single-dose 140 mg POLIVY vial delivers 140 mg of polatuzumab vedotin-piiq, polysorbate-20 (8.4 mg), sodium hydroxide (3.80 mg), succinic acid (8.27 mg), and sucrose (288 mg). After reconstitution with 7.2 mL of Sterile Water for Injection, USP, the final concentration is 20 mg/mL with a pH of approximately 5.3. The POLIVY vial stoppers are not made with natural rubber latex. Chemical Structure\"]",
          "generic_name": "[\"POLATUZUMAB VEDOTIN\"]",
          "brand_name": "[\"POLIVY\"]",
          "substance_name": "[\"POLATUZUMAB VEDOTIN\"]",
          "manufacturer_name": "[\"Genentech, Inc.\"]"
        }
      ],
      "trials": [
        "NCT04893109",
        "NCT01691898",
        "NCT00951665",
        "NCT04594798",
        "NCT02675829",
        "NCT00928330",
        "NCT06043674",
        "NCT00679211",
        "NCT04679012",
        "NCT04434040",
        "NCT04160494",
        "NCT05260957",
        "NCT04486352",
        "NCT00943670",
        "NCT00781612",
        "NCT01120184",
        "NCT05633615",
        "NCT01335958",
        "NCT02390427",
        "NCT01290549",
        "NCT05800366",
        "NCT01904903",
        "NCT01209130",
        "NCT01992653",
        "NCT05169658",
        "NCT05183035",
        "NCT05673928",
        "NCT04632992",
        "NCT05498220",
        "NCT00932373",
        "NCT05410418",
        "NCT00509769"
      ],
      "drugs": [
        "DFRF 4539A | RG-7598 | RG 7598 | RG7598",
        "RO5541077-000 | RG-7596 | DCDS4501A | ACD79B-VCMMAE | Polatuzumab vedotin | Polivy\u2122 | FCU2711 | DCDS-4501A",
        "DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA | RG6148 | DHES0815A | anti-HER2/PBD-monoamide anti-HER2/PBD-MA",
        "RG-7636 | Anti-ETBR",
        "RG7861 | Anti-S. aureus TAC | DSTA4637S",
        "RO7032005 | DCDS0780A DCDS 0780A RO7032005 | Iladatuzumab vedotin | DCDS0780A",
        "RG7986",
        "DSTP-3086S | DSTP3086S | Anti-STEAP1 ADC | RG7450 | RG-7450 | MSTP2109A | Vandortuzumab vedotin",
        "DSTA-4637S",
        "Anti-Ly6E | RG-7841 | Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | DLYE5953A",
        "RG 7600 | DMOT-4039A | DMOT4039A | RG7600",
        "RG-7599 | Lifastuzumab Vedotin | DNIB0600A | MNIB2126A  Anti-NaPi2b ADC RG-7599",
        "CD79-targeted immunotoxins",
        "anti-CD22-NMS249 | Anti-CD22 Anthracycline-Based ADC | anti-CD22 Anthracycline-Based - | Anti-CD22-NMS249",
        "DCDT2980S | DCDT-2989S | RO5541072-000 | Pinatuzumab vedotin | RG-7593 | ACD22-VCMMAE | FCU2803",
        "Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502 | Kadcyla\u00ae | T-DM1 | Trastuzumab Emtansine"
      ],
      "co-developers": [
        "Seagen",
        "Roche"
      ],
      "# co-developers": 2,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Portugal",
        "United States",
        "Colombia",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Ecuador",
        "Dominican Republic",
        "Indonesia",
        "Mexico",
        "Uganda",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Hungary",
        "Australia",
        "New Zealand",
        "Japan",
        "Romania",
        "Germany",
        "Croatia",
        "Spain",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 73,
      "# drugs": 16,
      "# Preclinical drugs": 1,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 8,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 32,
      "# Phase 1 trials": 7,
      "# Phase 2 trials": 23,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genitope Corporation",
      "names": [
        "Genitope Corporation"
      ],
      "HQ City": "Redwood City",
      "HQ Country": "United States",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Genitope Pharmaceuticals in 2008",
      "trials": [
        "NCT00071955"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genmab",
      "names": [
        "Genmab in collaboration with Seattle Genetics",
        "Genmab",
        "GenmabPrinceton, NJSeattle GeneticsBothell, WA",
        "Co-developed by Genmab and Seattle Genetics",
        "Genmab A/S"
      ],
      "HQ City": "Copenhagen",
      "HQ Country": "Denmark",
      "Founding Year": "1999",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.genmab.com",
      "Acquisition": "-",
      "ttd": [
        "D0QI1K"
      ],
      "trials": [
        "EUCTR2017-003413-25-IT",
        "EUCTR2017-003413-25-DK",
        "EUCTR2016-004743-37-BE",
        "EUCTR2017-003413-25-DE",
        "EUCTR2019-001655-39-ES",
        "EUCTR2017-003413-25-CZ",
        "EUCTR2017-004758-40-DK",
        "NCT05283720",
        "CTIS2023-508832-68-00",
        "NCT03438396",
        "EUCTR2013-001074-15-GB",
        "NCT02001623",
        "NCT03786081",
        "NCT03657043",
        "EUCTR2015-001120-29-DK",
        "NCT03245736",
        "NCT02552121",
        "NCT02988817"
      ],
      "drugs": [
        "HuMax\u00ae-TF-ADC | Tisotumab Vedotin | TF-011-MMAE  HuMax-TF-ADC | Tivdak",
        "Camidanlumab tesirine | HuMax-TAC-ADC | ADCT-301 | ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d",
        "HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC | AXL-107-MMAE | Enapotamab vedotin | HuMax-AXL-ADC"
      ],
      "co-developers": [
        "Seagen",
        "ADC Therapeutics"
      ],
      "# co-developers": 2,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Czech Republic",
        "Sweden",
        "Czechia",
        "Turkey",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Peru",
        "United States",
        "Estonia",
        "Brazil",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Austria",
        "Japan",
        "Spain",
        "Germany",
        "Croatia",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 36,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 18,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 8,
      "# Phase 3 trials": 10,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genta",
      "names": [
        "Genta Incorporated",
        "Genta"
      ],
      "HQ City": "Berkeley Heights",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Genasense in 2009",
      "trials": [
        "NCT00017589"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genzyme",
      "names": [
        "Genzyme"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sanofi.com/",
      "Acquisition": "Acquired by Sanofi in 2011",
      "drugs": [
        "Anti-endosialin-MC-VC-PABC-MMAE"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Georgetown Translational (Oxis Biotech)",
      "names": [
        "Georgetown Translational (Oxis Biotech)",
        "GT Biopharma.  Previously known as  Oxis Biotech (Georgetown Translational Pharmaceuticals)"
      ],
      "HQ City": "Los Angeles",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oxisbiotech.com/",
      "Acquisition": "-",
      "drugs": [
        "DT2219  Also known as: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein | DT2219ARL | GTB-1550 | GTB-1550 OXS-1550 | IND100780 | OXS-1550 | DT-2219ARL"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GlaxoSmithKline",
      "names": [
        "GlaxoSmithKline",
        "GlaxoSmithKline Research Development Limited",
        "GlaxoSmithKline (GSK) Co-developer: Seattle Genetics",
        "GlaxoSmithKline (GSK)",
        "Glaxo Wellcome",
        "GlaxoSmithKline LLC",
        "GlaxoSmithKline Research  Development Limited",
        "GlaxoSmithKline  (GSK) Co-developer: Seattle Genetics",
        "GlaxoSmithKline Research & Development Ltd"
      ],
      "HQ City": "Brentford",
      "HQ Country": "UK",
      "Founding Year": "2000",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.gsk.com",
      "Acquisition": "-",
      "ttd": [
        "D7AT3H"
      ],
      "fda_label": [
        {
          "id": 151385,
          "description": "[\"11 DESCRIPTION Belantamab mafodotin-blmf is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate. Belantamab mafodotin-blmf is an antibody conjugate composed of 3 components: 1) afucosylated, humanized immunoglobulin G1 monoclonal antibody covalently linked to 2) the microtubule inhibitor MMAF via 3) a protease-resistant maleimidocaproyl linker. The antibody is produced in a mammalian cell line (Chinese Hamster Ovary) using recombinant DNA technology and the microtubule inhibitor and linker are produced by chemical synthesis. Approximately 4 molecules of mafodotin are attached to each antibody molecule. The molecular weight of belantamab mafodotin-blmf is approximately 152 kDa. Belantamab mafodotin-blmf has the following structure: BLENREP (belantamab mafodotin-blmf) for injection is a sterile, preservative-free, white to yellow, lyophilized powder in a single-dose vial for reconstitution and further dilution prior to intravenous use. BLENREP is supplied as 100 mg per vial and requires reconstitution with 2 mL of Sterile Water for Injection, USP, to obtain a concentration of 50 mg/mL . Each mL of reconstituted solution contains belantamab mafodotin-blmf (50 mg) and the inactive ingredients, citric acid (0.42 mg), disodium edetate dihydrate (0.019 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.6 mg), and trisodium citrate dihydrate (6.7 mg). The pH of the reconstituted solution is 6.2. Belantamab mafodotin-blmf chemical structure\"]",
          "generic_name": "[\"BELANTAMAB\"]",
          "brand_name": "[\"Blenrep\"]",
          "substance_name": "[\"BELANTAMAB MAFODOTIN\"]",
          "manufacturer_name": "[\"GlaxoSmithKline LLC\"]"
        }
      ],
      "trials": [
        "NCT00861744",
        "NCT00856297",
        "CTRI/2022/05/042713",
        "NCT00002163",
        "NCT04246047",
        "NCT01224821",
        "NCT04177823",
        "NCT00322049",
        "NCT00624819",
        "NCT03544281",
        "NCT02064387",
        "NCT04484623",
        "NCT00891176",
        "NCT05064358",
        "NCT03763370",
        "NCT04822337",
        "NCT03525678",
        "NCT05922501",
        "NCT04341181",
        "NCT03828292",
        "EUCTR2018-002816-29-DE",
        "EUCTR2017-004810-25-DE"
      ],
      "drugs": [
        "GSK2857916 | Belantamab mafodotin | J6M0-mcMMAF | GSK2857916  2857916 GSK '916 J6M0-mcMMAF | Blenrep\u00ae",
        "Cantuzumab mertansine | SB-408075 | huC242-DM1 | SB408075"
      ],
      "co-developers": [
        "IMMUNOGEN",
        "Seagen"
      ],
      "# co-developers": 2,
      "locations": [
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Republic of Korea",
        "Belgium",
        "China",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "United States of America",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Ireland",
        "New Zealand",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "# locations": 30,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 22,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 10,
      "# Phase 3 trials": 8,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Halozyme",
      "names": [
        "Halozyme"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker Developer, ADC Platform",
      "Website URL": "https://www.halozyme.com/",
      "Acquisition": "-",
      "drugs": [
        "HTI-1511"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Hangzhou DAC Biotechnology Co., Ltd",
      "names": [
        "Hangzhou DAC Biotechnology Co., Ltd"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.dacbio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06224855"
      ],
      "drugs": [
        "DXC006"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Hangzhou Zhongmei Huadong",
      "names": [
        "Hangzhou Zhongmei Huadong",
        "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05622890"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Heading Medicine",
      "names": [
        "Heading Medicine"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Heidelberg Pharma",
      "names": [
        "Heidelberg Pharma in collaboration with Heading Medicine Co. Ltd",
        "Heidelberg Pharma",
        "Magenta Therapeutics in collaboration with Heidelberg Pharma (Originator Harvard University)",
        "Heidelberg Pharma in collaboration with MabVax"
      ],
      "HQ City": "Ladenburg",
      "HQ Country": "Germany",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.heidelberg-pharma.com",
      "Acquisition": "-",
      "drugs": [
        "Anti-BCMA - | Anti-CD269-amanitin-ADC | anti-BCMA-ADC | Anti-BCMA-ATAC | Anti-CD269-ADC | HDP-101",
        "MGTA-117 \u2013 Amanitin ADC",
        "HuMAB-5B1-ATAC",
        "Anti-CD19 ADC | Anti-CD19 ATAC | anti-CD19 ADC"
      ],
      "co-developers": [
        "Wilex",
        "MabVax",
        "Magenta"
      ],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 4,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Helix BioPharma",
      "names": [
        "Helix BioPharma",
        "Helix BioPharma Corp",
        "Helix BioPharma Corporation"
      ],
      "HQ City": "Aurora",
      "HQ Country": "Canada",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.helixbiopharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04203641",
        "EUCTR2010-020729-42-PL",
        "NCT02340208"
      ],
      "drugs": [
        "L-DOS47"
      ],
      "co-developers": [
        "Pharm-Olam International"
      ],
      "# co-developers": 1,
      "locations": [
        "Poland",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Holy Stone Healthcare Co., Ltd",
      "names": [
        "Holy Stone Healthcare Co., Ltd"
      ],
      "HQ City": "Taipei",
      "HQ Country": "Taiwan",
      "Founding Year": "1991",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.holystonehealth.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06039202"
      ],
      "drugs": [
        "CA102N"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "IATRICa Inc",
      "names": [
        "IATRICa Inc"
      ],
      "HQ City": "Sunnyvale",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://iatrica.com/",
      "Acquisition": "-",
      "ttd": [
        "D0C2CP"
      ],
      "drugs": [
        "d-trastuzumab"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 72,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ICON plc",
      "names": [
        "ICON plc"
      ],
      "HQ City": "Dublin",
      "HQ Country": "Ireland",
      "Founding Year": "1990",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.iconplc.com",
      "Acquisition": "-",
      "trials": [
        "NCT04844866"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "IDEAYA",
      "names": [
        "IDEAYA Biosciences",
        "IDEAYA"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.ideayabio.com",
      "Acquisition": "-",
      "trials": [
        "NCT04794699"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "IMMUNOGEN",
      "names": [
        "IMMUNOGEN",
        "Immunogen",
        "ImmunoGen and MorphoSys",
        "ImmunoGen Debiopharm Internaltional",
        "ImmunoGen, Inc",
        "ImmunoGen",
        "ImmunoGen  Debiopharm Internaltional",
        "ImmunoGen (Cambridge MA USA)",
        "ImmungoGen",
        "CytomX Therapeutics ImmunoGen (Originator)",
        "ImmunogGen and Novartis",
        "Macrogenics and ImmunoGen",
        "ImmunoGen (previously also Sanofi)"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.immunogen.com",
      "Acquisition": "-",
      "ttd": [
        "DA4O8C"
      ],
      "fda_label": [
        {
          "id": 17148,
          "description": "[\"11 DESCRIPTION Mirvetuximab soravtansine-gynx is a folate receptor alpha (FR\u03b1)-directed antibody-drug conjugate (ADC) consisting of three components: 1) an anti-FR\u03b1 monoclonal antibody of IgG1 subtype 2) the small molecule anti-tubulin agent DM4 (a maytansine derivative) and 3) a linker, sulfo-SPDB (1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid) that covalently attaches DM4 to the mirvetuximab antibody. Mirvetuximab soravtansine-gynx has an approximate molecular weight of 150 kDa. An average of 3.4 molecules of DM4 are attached to each antibody molecule. Mirvetuximab soravtansine-gynx is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. Mirvetuximab soravtansine-gynx has the following structure: ELAHERE (mirvetuximab soravtansine-gynx) injection is supplied as a sterile, preservative-free, clear to slightly opalescent, colorless solution containing 100 mg/20 mL of mirvetuximab soravtansine-gynx in single-dose vials. Each mL of solution contains 5 mg of mirvetuximab soravtansine-gynx, and glacial acetic acid (0.22 mg), polysorbate 20 (0.1 mg), sodium acetate (0.53 mg), sucrose (90 mg), and Water for Injection. The pH is approximately 5.0. The ELAHERE vial stoppers are not made with natural rubber latex. Chemical Structure\"]",
          "generic_name": "[\"MIRVETUXIMAB SORAVTANSINE\"]",
          "brand_name": "[\"ELAHERE\"]",
          "substance_name": "[\"MIRVETUXIMAB SORAVTANSINE\"]",
          "manufacturer_name": "[\"ImmunoGen, Inc.\"]"
        }
      ],
      "trials": [
        "NCT00991562",
        "NCT03386513",
        "NCT01609556",
        "NCT04296890",
        "NCT05445778",
        "NCT03552471",
        "NCT00346385",
        "NCT02606305",
        "NCT05041257",
        "NCT06365853",
        "NCT00065429",
        "NCT05887609",
        "NCT03102320",
        "NCT02610140",
        "NCT04622774",
        "NCT02420873",
        "NCT00346255",
        "NCT03832361",
        "NCT04209855",
        "NCT03835819",
        "NCT06034470",
        "NCT04086264",
        "NCT05456685",
        "NCT02631876",
        "NCT05527184"
      ],
      "drugs": [
        "IMGN 289",
        "Laprituximab emtansine | IMGN-289 | IMGN-289 IMGN289 J2898A-SMCC-DM1 | IMGN289",
        "PCA-062 | PCA062 PCA-062 | PCA062",
        "IMGN388 | CNTO 365 | IMGN-388 | CNTO 95-DM4",
        "SAR428926 SAR 428926 | SAR428926",
        "IMGN-242",
        "M9346A-sulfo-SPDB-DM4 | Elahere | Anti-FOLR1 monoclonal -maytansinoid | IMGN853 | IMGN-853 | Mirvetuximab Soravtansine",
        "CD44v6-DM1 | Anti-CD44v6-DM1 | DM1 immuno | Anti-CD44v6 | BIWI-1 | Bivatuzumab mertansine",
        "IMGN-632 | IMGN632 | MGN 632 | Pivekimab Sunirine | IMGN 632",
        "Cantuzumab mertansine | SB-408075 | huC242-DM1 | SB408075",
        "Debio 1562 | naratuximab emtansine | K7153A-SMCC-DM1 | K7153A | Naratuximab emtansine | IMGN529",
        "AVE9633 | IMGN-633",
        "Anti-ADAM9-sulfoSPDB-DM4 | Anti-ADAM9 ADC",
        "Oxobuthyldithio | BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4 | Indatuximab Ravtansine | BT-062 | 1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal",
        "SAR 408701 | SAR408701 SAR 408701 SAR-408701 | SAR408701 | Tusamitamab Ravtansine | SAR-408701",
        "SAR566658 | SAR 566658",
        "huN901-DM1 | BB-10901 IMGN901 huN901-DM1 IMGN-901 | IMGN-901 | Lorvotuzumab mertansine",
        "IMGN151",
        "IMGN 779 | IMGN779",
        "SAR3419 | SAR 3419 | Coltuximab Ravtansine",
        "CX-2009 | CD166 PDC | CX-2009 ADC CX-2009 | Praluzatamab Ravtansine | CD166 AADC"
      ],
      "co-developers": [
        "GlaxoSmithKline",
        "CytomX",
        "MacroGenics",
        "Boehringer Ingelheim",
        "Novartis",
        "Debiopharm",
        "BioTest",
        "Sanofi"
      ],
      "# co-developers": 8,
      "locations": [
        "Ukraine",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Portugal",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Serbia",
        "Singapore",
        "Philippines",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Hungary",
        "Australia",
        "New Zealand",
        "Japan",
        "Germany",
        "Croatia",
        "Spain",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 46,
      "# drugs": 21,
      "# Preclinical drugs": 1,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 6,
      "# Phase 2 drugs": 9,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 25,
      "# Phase 1 trials": 8,
      "# Phase 2 trials": 13,
      "# Phase 3 trials": 4,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Iconic",
      "names": [
        "Iconic Therapeutics in collaboration with Zymeworks",
        "Iconic",
        "Iconic Therapeutics, Inc",
        "Iconic Therapeutics  in collaboration with Zymeworks"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.iconictx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02771340",
        "NCT02358889",
        "NCT01485588"
      ],
      "drugs": [
        "ICON-2 Tissue Factor ADC  XB002 | XB002 ICON-2 Tissue Factor ADC"
      ],
      "co-developers": [
        "Zymeworks",
        "Exelixis"
      ],
      "# co-developers": 2,
      "locations": [
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ],
      "# locations": 9,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Igenica",
      "names": [
        "Igenica",
        "Igenica Biotherapeutics"
      ],
      "HQ City": "Burlingame",
      "HQ Country": "USA",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Xencor in 2015",
      "drugs": [
        "IGN523",
        "IGN786"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Iksuda",
      "names": [
        "Iksuda (Glythera)",
        "Iksuda Therapeutics (formerly known as Glythera)",
        "Iksuda Therapeutics Ltd",
        "Iksuda"
      ],
      "HQ City": "Newcastle upon Tyne",
      "HQ Country": "United Kingdom",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.iksuda.com",
      "Acquisition": "-",
      "trials": [
        "NCT05872295"
      ],
      "drugs": [
        "IKS01",
        "IKS04",
        "IKS03",
        "IKS02"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Australia"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Immune Tolerance Network (ITN)",
      "names": [
        "Immune Tolerance Network (ITN)"
      ],
      "HQ City": "-",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.immunetolerance.org",
      "Acquisition": "-",
      "trials": [
        "NCT03222492"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ImmunityBio",
      "names": [
        "ImmunityBio"
      ],
      "HQ City": "Culver City",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.immunitybio.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ImmunoBiochem",
      "names": [
        "ImmunoBiochem"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "IMB-201",
        "IMB-202"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Immunomedics",
      "names": [
        "Immunmedics",
        "Immunomedics",
        "Gilead Sciences (previously Immunomedics)"
      ],
      "HQ City": "Morris Plains",
      "HQ Country": "United States",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Gilead Sciences in 2020",
      "ttd": [
        "D0Y6BO"
      ],
      "drugs": [
        "hMN14-SN-38 | IMMU-130 | Labetuzumab-SN-38 IMMU-130 | Labetuzumab govitecan | hMN-14-SN38 hMN-14-SN-38 ADC hMN14-CL-SN-38",
        "Epratuzumab\u2013SN-38",
        "anti-HLA-DR-SN-38 ADC | IMMU-140",
        "Trodelvy | hRS7-SN-38 | hRS7-[CL-SN-38] hrS7-SN-38 | Sacituzumab govitecan | hRS7-SN-38-ADC | hRS7-SN38 | IMMU-132",
        "YTTRIUM | HPAM-4 | S9S0HY-PAM4 | HPAM4-DOTA | 90Y | IgG-DOTA | hPAM4-DOTA | HPAM-DOTA HY-PAM4 | Clivatucyn | CLIVATUZUMAB TETRAXETAN | 90Y-HPAM4 | HPAM-4-DOTA | hPAM4 | IMMU-107 | 90HY-PAM4 | hPAM4 IgG-DOTA | Clivatuzumab Tetraxetan | 90Y-HPAMA4 | YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN | HPAM4-CIDE | Tacatuzumab Tetraxetan",
        "hLL1 | IMMU-110 | Milatuzumab doxorubicin | MEDI-115 | CD74-DOX | hLL1-DOX",
        "Milatuzumab-doxorubicin"
      ],
      "co-developers": [
        "GILEAD"
      ],
      "# co-developers": 1,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "Peru",
        "China",
        "Hong Kong",
        "Norway",
        "United States",
        "Estonia",
        "Colombia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "Saudi Arabia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Australia",
        "Romania",
        "Hungary",
        "Japan",
        "Latvia",
        "Spain",
        "Germany",
        "Croatia",
        "New Zealand",
        "Guatemala",
        "Argentina",
        "Israel",
        "Slovakia",
        "Finland"
      ],
      "# locations": 59,
      "# drugs": 7,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 3,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Inhibrx",
      "names": [
        "Inhibrx"
      ],
      "HQ City": "La Jolla",
      "HQ Country": "United States",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.inhibrx.com/",
      "Acquisition": "-",
      "ttd": [
        "D56ERU"
      ],
      "drugs": [
        "INBRX-109"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Innate",
      "names": [
        "Innate Pharma in collaboration with AstraZeneca",
        "Innate"
      ],
      "HQ City": "Marseille",
      "HQ Country": "France",
      "Founding Year": "1999",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.innate-pharma.com/",
      "Acquisition": "-",
      "drugs": [
        "IPH43"
      ],
      "co-developers": [
        "AstraZeneca"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Innovent",
      "names": [
        "Innovent"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2011",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.innoventbio.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Istari Oncology",
      "names": [
        "Istari Oncology",
        "Istari Oncology, Inc"
      ],
      "HQ City": "Durham",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.istarioncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT04160494"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Jazz Pharmaceuticals",
      "names": [
        "Jazz Pharmaceuticals"
      ],
      "HQ City": "Dublin",
      "HQ Country": "Ireland",
      "Founding Year": "2003",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.jazzpharma.com",
      "Acquisition": "-",
      "trials": [
        "NCT05558124"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Jiangsu HengRui Medicine",
      "names": [
        "Jiangsu HengRui Medicine",
        "Jiangsu Hengrui Medicine Co",
        "Jiangsu Hengrui Medicine Co. in collaboration with Beijing Shijitan Hospital",
        "Jiangsu Hengrui Pharmaceutical Co., Ltd",
        "Jiangsu HengRui Medicine Co., Ltd"
      ],
      "HQ City": "Lianyungang",
      "HQ Country": "China",
      "Founding Year": "1970",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.hrs.com.cn",
      "Acquisition": "-",
      "trials": [
        "NCT03856541",
        "NCT05350917",
        "NCT06123494",
        "NCT06126640"
      ],
      "drugs": [
        "HTI-1066 | SHR-A1403 | HTI-1066 SHR-A1403",
        "SHR-A1201"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Johnson & Johnson",
      "names": [
        "Johnson & Johnson"
      ],
      "HQ City": "New Brunswick",
      "HQ Country": "United States",
      "Founding Year": "1886",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer, Linker developer, ADC platform technology",
      "Website URL": "https://www.jnj.com",
      "Acquisition": "-",
      "trials": [
        "NCT04662580"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "KLUS",
      "names": [
        "Klus Pharma, the US subsidiary of China-based Kelun-Biotech",
        "KLUS Pharma",
        "KLUS Pharma, a subsidiary of Kelun Pharmaceuticals (Sichuan Chengdu, China)",
        "Klus Pharma Inc",
        "KLUS",
        "Klus Pharma"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "ttd": [
        "DD94ZN",
        "DOS62C",
        "D56AJO"
      ],
      "trials": [
        "NCT04152499",
        "NCT03602079"
      ],
      "drugs": [
        "SKB264 ADC",
        "SKB315",
        "A166 ADC A166 anti-HER2 ADC A166 | A166 ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Puerto Rico",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Canada",
        "Malaysia",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Japan",
        "Spain",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 33,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "KYM Biosciences",
      "names": [
        "KYM Biosciences",
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.kymbiosciences.com/",
      "Acquisition": "-",
      "drugs": [
        "CMG901"
      ],
      "co-developers": [
        "Lepu Biopharma",
        "Keymed Biosciences",
        "AstraZeneca"
      ],
      "# co-developers": 3,
      "locations": [
        "Moldova, Republic of",
        "Canada",
        "United Kingdom",
        "Republic of Korea",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Republic of Moldova",
        "Japan",
        "Spain",
        "Singapore",
        "United States",
        "Poland",
        "United States of America",
        "Georgia",
        "Taiwan"
      ],
      "# locations": 16,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kanisa",
      "names": [
        "Kanisa Pharmaceuticals",
        "Kanisa"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT00233909"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Keymed Biosciences",
      "names": [
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca",
        "Keymed Biosciences"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.keymedbio.com/",
      "Acquisition": "-",
      "drugs": [
        "CMG901"
      ],
      "co-developers": [
        "KYM Biosciences",
        "Lepu Biopharma",
        "AstraZeneca"
      ],
      "# co-developers": 3,
      "locations": [
        "Moldova, Republic of",
        "Canada",
        "United Kingdom",
        "Republic of Korea",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Republic of Moldova",
        "Japan",
        "Spain",
        "Singapore",
        "United States",
        "Poland",
        "United States of America",
        "Georgia",
        "Taiwan"
      ],
      "# locations": 16,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kirilys Therapeutics",
      "names": [
        "Kirilys Therapeutics Inc",
        "Kirilys Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT04410224"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Knoll (Europe)",
      "names": [
        "Knoll (Europe)",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe) Manufacturer: Lonza Biologics",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe)  Manufacturer: Lonza Biologics"
      ],
      "HQ City": "Ludwigshafen",
      "HQ Country": "Germany",
      "Founding Year": "1886",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.knoll.basf.com/",
      "Acquisition": "Acquired by BASF in 1990",
      "drugs": [
        "Satumomab Penditide | CYT-356 | CYT-351 | INDIUM IN 111 CYT-103 | ProstaScint | 90Y-CYT-356 | C-4 | CYT-356 90Y | CYT-103 111 IN | YTTRIUM Y 90 CAPROMAB PENDETIDE | INDIUM IN-111 SATUMOMAB PENDETIDE | CYT-356-Y-90 | MONAB B72.3-GYK-DTPA-111IN | 7E11-C5.3 | INDIUM | INDIUM IN-111 MYOSCINT | INDIUM IN-111 IMCIROMAB PENTETATE | ONCOLTAD | satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide | CAPROMAB PENDETIDE | B72.3 | CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium | CYT-356-90Y | IMCIROMAB | SATUMOMAB PENDETIDE INDIUM IN-111 | 111IN | CYT-103 | MYOSCINT INDIUM IN-111 | SATUMOMAB PENDETIDE 111IN | INDIUM IN 111 IMCIROMAB PENTETATE | 111In | SATUMOMAB PENDETIDE | INDIUM IN 111 SATUMOMAB PENDETIDE | Satumomab pendetide | IMCIROMAB PENTETATE | CYT-099 | ONCOSCINT | OncoScint\u00ae CR/OV | SATUMOMAB"
      ],
      "co-developers": [
        "Lonza Biologics"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kodiak Sciences",
      "names": [
        "Kodiak Sciences Inc",
        "Kodiak Sciences"
      ],
      "HQ City": "Palo Alto",
      "HQ Country": "United States",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.kodiak.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04592419",
        "NCT04964089"
      ],
      "drugs": [
        "KSI-301 | OG1953 | KSI301 | Tarcocimab Tedromer | KSI 301"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Puerto Rico",
        "Israel",
        "Hungary",
        "Czechia",
        "Latvia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Poland",
        "Slovakia"
      ],
      "# locations": 12,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kolltan",
      "names": [
        "Kolltan",
        "Kolltan Pharmaceuticals"
      ],
      "HQ City": "New Haven",
      "HQ Country": "USA",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Celldex Therapeutics in 2016",
      "drugs": [
        "KTN0182A",
        "KTN0125"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kura Oncology",
      "names": [
        "Kura Oncology, Inc",
        "Kura Oncology"
      ],
      "HQ City": "La Jolla",
      "HQ Country": "United States",
      "Founding Year": "2014",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://kuraoncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT06448013"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kyowa Kirin",
      "names": [
        "Kyowa Kirin",
        "Kyowa Kirin, Inc"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "1949",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.kyowakirin.com",
      "Acquisition": "-",
      "trials": [
        "NCT05414500"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "LaNova",
      "names": [
        "LaNova",
        "LaNova BMS (ex-China excl. Korea) Turning Point therapeutics (now part of BMS)"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.lanovabio.com/",
      "Acquisition": "-",
      "drugs": [
        "LM-302 BMS-986476 TPX-4589 | TPX-4589 | BMS-986476 | LM-302"
      ],
      "co-developers": [
        "Turning Point therapeutics"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Legochem",
      "names": [
        "LigaChem Biosciences, Inc",
        "LegoChem Biosciences and Takeda",
        "LegoChem Biosciences and Nordic Nanovector",
        "LegoChem Biosciences and Seasun Biomaterials",
        "LegoChem Biosciences and Y-Biologics",
        "Legochem",
        "LegoChem Biosiences and Samsung Medical Center",
        "Legochem Biosciences and Fosun Pharma",
        "LegoChem Biosciences and Gree Cross"
      ],
      "HQ City": "Daejeon",
      "HQ Country": "South Korea",
      "Founding Year": "2002",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker developer",
      "Website URL": "https://www.legochembio.com",
      "Acquisition": "-",
      "trials": [
        "NCT05941507"
      ],
      "drugs": [
        "LCB14-15xx | anti-CD37 ADC | NNV019",
        "LCB14-15nm",
        "LCB14-17nn",
        "LCB14-19nm",
        "LCB14-2nm",
        "LCB14-0110 | Herceptin-LC-LBG-MMAF | Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF | LCB14 0110",
        "LCB84"
      ],
      "co-developers": [
        "Takeda",
        "Shanghai Fosun",
        "Seasun Biomaterials",
        "Nordic Nanovector",
        "Samsung Medical Center"
      ],
      "# co-developers": 5,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 72,
      "# drugs": 7,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Lepu Biopharma",
      "names": [
        "Shanghai Miracogen, a fully owned subsidiary of Lepu Biopharma",
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca",
        "Shanghai Miracogen in partnership with Lepu Biopharma",
        "Shanghai Miracogen  in partnership with Lepu Biopharma",
        "Lepu Biopharma"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.lepubiopharma.com",
      "Acquisition": "-",
      "drugs": [
        "MRG003",
        "CMG901",
        "MRG004A"
      ],
      "co-developers": [
        "KYM Biosciences",
        "Shanghai Miracogen",
        "Keymed Biosciences",
        "AstraZeneca"
      ],
      "# co-developers": 4,
      "locations": [
        "Moldova, Republic of",
        "Canada",
        "United Kingdom",
        "Republic of Korea",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Republic of Moldova",
        "Japan",
        "China",
        "Singapore",
        "Spain",
        "United States",
        "Poland",
        "United States of America",
        "Georgia",
        "Taiwan"
      ],
      "# locations": 17,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Ligand Pharmaceuticals",
      "names": [
        "Ligand Pharmaceuticals",
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics Co-developed by Astellas",
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker Developer, ADC Platform",
      "Website URL": "https://www.ligand.com/",
      "Acquisition": "-",
      "drugs": [
        "AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | ASG-15ME | AGS-15vcMMAE | AGS-15E | Sirtratumab vedotin | Ha15-10ac.1vcMMAE | AGS15E"
      ],
      "co-developers": [
        "Seagen",
        "Agensys",
        "Astellas"
      ],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Lisata Therapeutics",
      "names": [
        "Lisata Therapeutics, Inc",
        "Lisata Therapeutics"
      ],
      "HQ City": "Basking Ridge",
      "HQ Country": "United States",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://lisatatx.com",
      "Acquisition": "-",
      "trials": [
        "NCT00012064"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Lonza Biologics",
      "names": [
        "Lonza Biologics",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe) Manufacturer: Lonza Biologics",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe)  Manufacturer: Lonza Biologics"
      ],
      "HQ City": "Visp",
      "HQ Country": "Switzerland",
      "Founding Year": "1897",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker Developer, ADC Platform",
      "Website URL": "https://www.lonza.com/",
      "Acquisition": "-",
      "drugs": [
        "Satumomab Penditide | CYT-356 | CYT-351 | INDIUM IN 111 CYT-103 | ProstaScint | 90Y-CYT-356 | C-4 | CYT-356 90Y | CYT-103 111 IN | YTTRIUM Y 90 CAPROMAB PENDETIDE | INDIUM IN-111 SATUMOMAB PENDETIDE | CYT-356-Y-90 | MONAB B72.3-GYK-DTPA-111IN | 7E11-C5.3 | INDIUM | INDIUM IN-111 MYOSCINT | INDIUM IN-111 IMCIROMAB PENTETATE | ONCOLTAD | satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide | CAPROMAB PENDETIDE | B72.3 | CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium | CYT-356-90Y | IMCIROMAB | SATUMOMAB PENDETIDE INDIUM IN-111 | 111IN | CYT-103 | MYOSCINT INDIUM IN-111 | SATUMOMAB PENDETIDE 111IN | INDIUM IN 111 IMCIROMAB PENTETATE | 111In | SATUMOMAB PENDETIDE | INDIUM IN 111 SATUMOMAB PENDETIDE | Satumomab pendetide | IMCIROMAB PENTETATE | CYT-099 | ONCOSCINT | OncoScint\u00ae CR/OV | SATUMOMAB"
      ],
      "co-developers": [
        "Knoll (Europe)"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Loxo Oncology",
      "names": [
        "Loxo Oncology, Inc",
        "Loxo Oncology"
      ],
      "HQ City": "Stamford",
      "HQ Country": "USA",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Eli Lilly in 2019",
      "trials": [
        "NCT06465069",
        "NCT06400472",
        "NCT06238479"
      ],
      "drugs": [
        "LY4052031",
        "LY4170156",
        "LY4101174"
      ],
      "co-developers": [
        "Eli Lilly"
      ],
      "# co-developers": 1,
      "locations": [
        "Australia",
        "United States",
        "Japan"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Luzsana Biotechnology",
      "names": [
        "Luzsana Biotechnology"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.luzsana.com/",
      "Acquisition": "-",
      "drugs": [
        "Trastuzumab rezetecan | Trastuzumab rezetecan SHR-A1811 | SHR-A1811"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 72,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MBrace Therapeutics",
      "names": [
        "MBrace Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06014658"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MFAR",
      "names": [
        "MFAR"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06235216"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MabPlex",
      "names": [
        "MabPlex",
        "Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)",
        "MabPlex (Yantai, China)"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.mabplexinc.com",
      "Acquisition": "-",
      "drugs": [
        "Hertuzumab-vcMMAE | Hertuzumab Vedotin",
        "RC88",
        "RC118",
        "RC108",
        "RC-48 | RC-48 RC 480-ADC RC48 | RC 480-ADC | Disitamab Vedotin | Aidixi\u00ae | \u7231\u5730\u5e0c\u00ae | RC48"
      ],
      "co-developers": [
        "Rongchang",
        "RemeGen"
      ],
      "# co-developers": 2,
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Israel",
        "Japan",
        "China",
        "Spain",
        "Singapore",
        "United States",
        "Argentina",
        "United Kingdom",
        "Chile",
        "Taiwan"
      ],
      "# locations": 13,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MabVax",
      "names": [
        "MabVax",
        "Heidelberg Pharma in collaboration with MabVax"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2006",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.mabvax.com/",
      "Acquisition": "-",
      "drugs": [
        "HuMAB-5B1-ATAC"
      ],
      "co-developers": [
        "Wilex",
        "Heidelberg Pharma"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mabwell (Shanghai)",
      "names": [
        "Mabwell (Shanghai) Bioscience Co., Ltd",
        "Mabwell (Shanghai)"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2016",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.mabwell.com/",
      "Acquisition": "-",
      "drugs": [
        "9MW2821"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MacroGenics",
      "names": [
        "50 co-development between MacroGenics and Immunogen",
        "MacroGenics",
        "Macrogenics and ImmunoGen"
      ],
      "HQ City": "Rockville",
      "HQ Country": "USA",
      "Founding Year": "2000",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.macrogenics.com",
      "Acquisition": "-",
      "ttd": [
        "DDP74J",
        "DA4O8C"
      ],
      "trials": [
        "NCT05293496",
        "NCT04622774"
      ],
      "drugs": [
        "Anti-ADAM9-sulfoSPDB-DM4 | Anti-ADAM9 ADC",
        "IMGC936",
        "AEX4089DC1 | MGC018 | Vobramitamab Duocarmazine | Anti-B7-H3 ADC | AEX4089DC1 Anti-B7-H3 ADC"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "# co-developers": 1,
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Magenta",
      "names": [
        "Magenta Therapeutics in collaboration with Heidelberg Pharma (Originator Harvard University)",
        "Magenta"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.magentatx.com/",
      "Acquisition": "-",
      "drugs": [
        "MGTA-117 \u2013 Amanitin ADC"
      ],
      "co-developers": [
        "Heidelberg Pharma"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MedImmune",
      "names": [
        "ADC Therapeutics in collaboration with MedImmune",
        "Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune",
        "Medimmune",
        "MedImmune",
        "MedImmune LLC"
      ],
      "HQ City": "Gaithersburg",
      "HQ Country": "United States",
      "Founding Year": "1988",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by AstraZeneca in 2007",
      "trials": [
        "NCT01829711",
        "NCT03489525",
        "NCT02576548",
        "NCT00586924",
        "NCT02991911",
        "NCT00126646",
        "NCT01030536",
        "NCT00659425",
        "NCT00077493"
      ],
      "drugs": [
        "ADCT-401 | MEDI3726 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
        "TR1801-ADC | MT-8633 | TR1801-ADC MT-8633",
        "MEDI-547 | MEDI547",
        "Lumoxiti | MOXETUMOMAB PASUDOTOX TDFK | Moxetumomab pasudotox | CAT-8015 | HA22 | HA-22 | MOXETUMOMAB PASUDOTOX",
        "MEDI4276 | MEDI-4276 | MEDI 4276"
      ],
      "co-developers": [
        "Tanabe Research Laboratories USA",
        "Open Innovation Partners",
        "ADC Therapeutics",
        "AstraZeneca"
      ],
      "# co-developers": 4,
      "locations": [
        "Canada",
        "Italy",
        "Belgium",
        "Ireland",
        "Israel",
        "Serbia",
        "Czechia",
        "Norway",
        "Spain",
        "Switzerland",
        "Germany",
        "United States",
        "France",
        "United Kingdom",
        "Poland"
      ],
      "# locations": 15,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 1,
      "# trials": 9,
      "# Phase 1 trials": 7,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MedSIR",
      "names": [
        "MedSIR"
      ],
      "HQ City": "Barcelona",
      "HQ Country": "Spain",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.medsir.org",
      "Acquisition": "-",
      "trials": [
        "NCT06172127",
        "NCT04733118",
        "NCT06048718",
        "NCT05520723",
        "NCT05865990",
        "NCT04420598"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 6,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Medarex",
      "names": [
        "Medarex Bristol-Myers Squibb",
        "Medarex"
      ],
      "HQ City": "Princeton",
      "HQ Country": "USA",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Bristol-Myers Squibb in 2009",
      "drugs": [
        "MDX-1203 | BMS-936561 | \u03b1CD70_MED-A | BMS936561",
        "MDX-060 | iratumumab"
      ],
      "co-developers": [
        "Bristol Myers Squibb"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MediLink",
      "names": [
        "MediLink Therapeutics (Suzhou) Co., Ltd",
        "MediLink",
        "MediLink (Suzhou)"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05434234",
        "NCT06057922",
        "NCT06107686",
        "NCT06439771"
      ],
      "drugs": [
        "YL201",
        "YL202 should be intravenously infused | YL202"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MediaPharma",
      "names": [
        "MediaPharma S.r.l",
        "MediaPharma",
        "Mediapharma"
      ],
      "HQ City": "L'Aquila",
      "HQ Country": "Italy",
      "Founding Year": "2010",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "EV20/MMAF",
        "anti-TEM-1 - | TEM-1-ADC | Anti-TEM-1 -",
        "anti-HER-3 ADC | Anti-HER-3 -"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Medivation",
      "names": [
        "Medivation",
        "Medivation, Inc",
        "Medivation, Inc."
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Pfizer in 2016",
      "trials": [
        "NCT00377715"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Menarini Ricerche",
      "names": [
        "Co-developed by Menarini Ricerche and Oxford BioTherapeutics",
        "Menarini Ricerche"
      ],
      "HQ City": "Florence",
      "HQ Country": "Italy",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.menarini.com/",
      "Acquisition": "-",
      "drugs": [
        "MEN 1309 MEN1309 OBT076 | OBT076 | MEN1309"
      ],
      "co-developers": [
        "Oxford BioTherapeutics"
      ],
      "# co-developers": 1,
      "locations": [
        "Greece",
        "Belgium",
        "Spain",
        "United States",
        "France"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Merck KGaA, Darmstadt, Germany",
      "names": [
        "Merck",
        "Merck KGaA, Darmstadt, Germany",
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics"
      ],
      "HQ City": "Darmstadt",
      "HQ Country": "Germany",
      "Founding Year": "1668",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.merckgroup.com/",
      "Acquisition": "-",
      "ttd": [
        "D3YJZ7"
      ],
      "trials": [
        "NCT05327530",
        "NCT04695847",
        "NCT05464030",
        "NCT03547973"
      ],
      "drugs": [
        "BEVACIZUMAB GAMMA",
        "M9140"
      ],
      "co-developers": [
        "EMD Serono"
      ],
      "# co-developers": 1,
      "locations": [
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "China",
        "United States",
        "Denmark",
        "Canada",
        "Malaysia",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Ireland",
        "Japan",
        "Spain",
        "Germany",
        "Israel"
      ],
      "# locations": 24,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Merck Sharp & Dohme",
      "names": [
        "Merck",
        "Merck Sharp & Dohme",
        "Merck Sharp & Dohme LLC",
        "MSD"
      ],
      "HQ City": "Kenilworth",
      "HQ Country": "USA",
      "Founding Year": "1891",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.msd.com",
      "Acquisition": "-",
      "ttd": [
        "D3YJZ7"
      ],
      "trials": [
        "NCT05097599",
        "NCT04879329",
        "NCT05756569",
        "NCT05186974",
        "NCT06081244",
        "NCT04448886",
        "NCT05382286",
        "NCT05609968",
        "NCT05404945",
        "NCT03288545",
        "NCT06132958",
        "NCT05922904",
        "NCT03310957",
        "NCT05280470",
        "NCT00777608",
        "NCT05911295",
        "NCT04468061",
        "NCT06074588",
        "NCT04042701",
        "NCT06161025",
        "NCT05180097",
        "NCT02677155",
        "NCT04946370",
        "NCT03032107",
        "NCT03835819",
        "NCT04609566",
        "NCT02684292",
        "NCT03786081",
        "NCT06203210",
        "NCT05313243",
        "NCT06362252",
        "NCT05775471"
      ],
      "drugs": [
        "EC145/MK 8109 | VYNFINIT\u00ae | MK 8109 | Vintafolide | MK8109 | EC145",
        "SACITUZUMAB TIRUMOTECAN"
      ],
      "co-developers": [
        "Endocyte",
        "GOG Foundation"
      ],
      "# co-developers": 2,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 54,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 32,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 21,
      "# Phase 3 trials": 8,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Merrimack",
      "names": [
        "Merrimack",
        "Merrimack Pharmaceuticals, Inc"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.merrimack.com/",
      "Acquisition": "-",
      "drugs": [
        "Nano-doxorubicin | MM-302"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 54,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mersana",
      "names": [
        "Mersana Therapeutics in collaboration with Takeda. Antibody development: Adimab",
        "Mersana Therapeutics in collaboration with Takeda.  Antibody development: Adimab",
        "Mersana",
        "Mersana Therapeutics Cambridge, MA",
        "Mersana Therapeutics"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2001",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.mersana.com",
      "Acquisition": "-",
      "ttd": [
        "D0QFD2",
        "DDL79K"
      ],
      "trials": [
        "NCT02952729"
      ],
      "drugs": [
        "TAK-522 | XMT1522 TAK-522 | XMT-1522",
        "XMT1536 | XMT-1536 XMT 1536 UpRi Upifitamab Rilsodotin | XMT-1536 | UpRi | Upifitamab Rilsodotin",
        "XMT-1592",
        "XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056 | XMT-2056"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MethylGene",
      "names": [
        "MethylGene Inc.",
        "MethylGene Inc",
        "MethylGene"
      ],
      "HQ City": "Montreal",
      "HQ Country": "Canada",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Mirati Therapeutics in 2013",
      "trials": [
        "NCT02429375"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Millennium",
      "names": [
        "Millennium: The Takeda Oncology Company",
        "Millennium Pharmaceuticals",
        "Millennium Pharmaceuticals, Inc",
        "Millennium",
        "Takeda (listed as Millennium Pharmaceuticals) ImmunoGen"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Takeda in 2008",
      "trials": [
        "NCT00052000",
        "NCT01026233",
        "NCT01026415",
        "NCT01309789",
        "NCT00848926",
        "NCT02292979",
        "NCT01990534",
        "NCT01492088",
        "NCT02467946",
        "NCT02280785",
        "NCT01950364",
        "NCT02567851",
        "NCT01851200",
        "NCT01578499",
        "NCT01060904",
        "NCT01777152",
        "NCT00866047",
        "NCT00947856",
        "NCT01100502",
        "NCT01577758",
        "NCT02243436",
        "NCT00070837",
        "NCT02686346"
      ],
      "drugs": [
        "MLN-0264 | TAK264 | MLN 0264 | Indusatumab Vedotin | TAK-264 | 5F9vcMMAE | MLN0264",
        "TAK-164 TAK164 Anti-GCC ADC Anti-GCC - | TAK-164",
        "MLN2704 | MLN-2704"
      ],
      "co-developers": [
        "Takeda"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 23,
      "# Phase 1 trials": 7,
      "# Phase 2 trials": 12,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Miltenyi Biomedicine GmbH",
      "names": [
        "Miltenyi Biomedicine GmbH"
      ],
      "HQ City": "Bergisch Gladbach",
      "HQ Country": "Germany",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.miltenyibiotec.com",
      "Acquisition": "-",
      "trials": [
        "NCT04844866"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Minghui Pharmaceutical (Hangzhou) Ltd",
      "names": [
        "Minghui Pharmaceutical Pty Ltd",
        "Minghui Pharmaceutical (Hangzhou) Ltd"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05652855",
        "NCT06373406"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mirati Therapeutics",
      "names": [
        "Mirati Therapeutics Inc",
        "Mirati Therapeutics Inc.",
        "Mirati Therapeutics"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.mirati.com",
      "Acquisition": "-",
      "trials": [
        "NCT04887870"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MorphoSys AG",
      "names": [
        "MorphoSys AG"
      ],
      "HQ City": "Planegg",
      "HQ Country": "Germany",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.morphosys.com/",
      "Acquisition": "-",
      "ttd": [
        "D01BUS"
      ],
      "trials": [
        "NCT03102320"
      ],
      "drugs": [
        "CA9-ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Morphotek",
      "names": [
        "Morphotek",
        "Morphotek\u00c2\u00ae (a subsidiary of Eisai)",
        "Morphotek\u00ae, a subsidiary of Eisai Eisai Co Bristol Myers Squibb"
      ],
      "HQ City": "Exton",
      "HQ Country": "United States",
      "Founding Year": "2000",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.morphotek.com/",
      "Acquisition": "Acquired by Eisai in 2007",
      "drugs": [
        "MORAb-202 MORAb-003-VCP-eribulin | Farletuzumab Ecteribulin | MORAb-202"
      ],
      "co-developers": [
        "Eisai"
      ],
      "# co-developers": 1,
      "locations": [
        "Sweden",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "# locations": 28,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Multitude",
      "names": [
        "Multitude Therapeutics (Australia) Pty Ltd",
        "Multitude Therapeutics Inc",
        "Multitude"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05498597"
      ],
      "drugs": [
        "AMT-562",
        "AMT-151"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China",
        "Australia"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mundipharma EDO",
      "names": [
        "Mundipharma EDO GmbH",
        "Mundipharma EDO"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "UK",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.mundipharma.com",
      "Acquisition": "-",
      "drugs": [
        "EDO-772P/B776",
        "EDO-B278"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mythic Therapeutics",
      "names": [
        "Mythic Therapeutics,,",
        "Mythic Therapeutics,",
        "Mythic Therapeutics"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.mythictx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05652868"
      ],
      "drugs": [
        "cMET-ADC MYTX-011 | MYTX-011"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "United Kingdom",
        "Taiwan"
      ],
      "# locations": 6,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NBE Therapeutics",
      "names": [
        "NBE-Therapeutics",
        "NBE Therapeutics GmbH",
        "NBE Therapeutics"
      ],
      "HQ City": "Basel",
      "HQ Country": "Switzerland",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.nbe-therapeutics.com",
      "Acquisition": "-",
      "ttd": [
        "D79HBK"
      ],
      "drugs": [
        "NBE-001",
        "NBE-002 \u2013 ROR-1 | NBE-002 NBE-002 - ROR-1",
        "NBE-003"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NSABP Foundation",
      "names": [
        "NSABP Foundation Inc",
        "NSABP Foundation",
        "NSABP Foundation Inc."
      ],
      "HQ City": "-",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.nsabp.org",
      "Acquisition": "-",
      "trials": [
        "NCT01772472",
        "NCT04622319",
        "NCT05633654"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NanoCarrier (Japan)",
      "names": [
        "NanoCarrier Co.,Ltd (Japan) and Eisai",
        "NanoCarrier (Japan)"
      ],
      "HQ City": "Chiba",
      "HQ Country": "Japan",
      "Founding Year": "1996",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker Developer, ADC Platform",
      "Website URL": "https://www.nanocarrier.co.jp/",
      "Acquisition": "-",
      "drugs": [
        "ADCM-E7974 | NC-6201"
      ],
      "co-developers": [
        "Eisai"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NanoValent",
      "names": [
        "NanoValent",
        "NanoValent Pharmaceuticals"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.nanovalent.com",
      "Acquisition": "-",
      "drugs": [
        "Irinotecan-anti-CD99 | NV103",
        "Doxorubicin-anti-CD99 | NV101",
        "NV102 | Doxorubicin-anti-CD19"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Republic of Korea",
        "South Africa",
        "Belgium",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "Saudi Arabia",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "United States of America",
        "Chile",
        "Taiwan",
        "Bosnia and Herzegovina",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Republic of Moldova",
        "Ireland",
        "Austria",
        "Hungary",
        "Japan",
        "Romania",
        "Spain",
        "Germany",
        "New Zealand",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 58,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Natera",
      "names": [
        "Natera, Inc",
        "Natera",
        "Natera, Inc."
      ],
      "HQ City": "Austin",
      "HQ Country": "United States",
      "Founding Year": "2004",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.natera.com",
      "Acquisition": "-",
      "trials": [
        "NCT05965479"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nektar Therapeutics",
      "names": [
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics",
        "Nektar Therapeutics"
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "1990",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Linker developer, ADC platform technology",
      "Website URL": "https://www.nektar.com",
      "Acquisition": "-",
      "trials": [
        "NCT05327530"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NeoTX Therapeutics Ltd",
      "names": [
        "NeoTX Therapeutics Ltd"
      ],
      "HQ City": "Jerusalem",
      "HQ Country": "Israel",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.neotx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03983954",
        "NCT04880863"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nerviano Medical Sciences",
      "names": [
        "Nerviano Medical Sciences"
      ],
      "HQ City": "Nerviano",
      "HQ Country": "Italy",
      "Founding Year": "1963",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.nervianoms.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Neuronix Ltd",
      "names": [
        "Neuronix Ltd"
      ],
      "HQ City": "Yokneam",
      "HQ Country": "Israel",
      "Founding Year": "2009",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.neuronixmedical.com/",
      "Acquisition": "-",
      "trials": [
        "NCT01825317"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nona Bioscience",
      "names": [
        "Nona Bioscience and Pfizer",
        "Nona Bioscience"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.nonabio.com/",
      "Acquisition": "-",
      "drugs": [
        "HBM9033"
      ],
      "co-developers": [
        "Pfizer"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NordForsk",
      "names": [
        "NordForsk"
      ],
      "HQ City": "Oslo",
      "HQ Country": "Norway",
      "Founding Year": "2005",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.nordforsk.org/",
      "Acquisition": "-",
      "trials": [
        "NCT04307576"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nordic Nanovector",
      "names": [
        "Nordic Nanovector",
        "Nordic Nanovector ASA",
        "LegoChem Biosciences and Nordic Nanovector"
      ],
      "HQ City": "Oslo",
      "HQ Country": "Norway",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.nordicnanovector.com",
      "Acquisition": "-",
      "trials": [
        "NCT01796171"
      ],
      "drugs": [
        "177LU-TETRAXETAN-TETULOMAB | TETULOMAB TETRAXETAN LU-177 | SUP 177 | 177LU-TETULOMAB | BETALUTIN | LU-TETULOMAB",
        "lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1 | lutetium | Lilotomab satetraxetan | 177lu",
        "LCB14-15xx | anti-CD37 ADC | NNV019"
      ],
      "co-developers": [
        "Legochem"
      ],
      "# co-developers": 1,
      "locations": [
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Norway",
        "United States",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Australia",
        "Austria",
        "Spain",
        "Croatia",
        "Israel",
        "Finland"
      ],
      "# locations": 24,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nova Laboratories Limited",
      "names": [
        "Nova Laboratories Limited"
      ],
      "HQ City": "Leicester",
      "HQ Country": "United Kingdom",
      "Founding Year": "1984",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.novalabs.co.uk/",
      "Acquisition": "-",
      "trials": [
        "NCT04307576"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Novartis",
      "names": [
        "Novartis and ImmunoGen",
        "Endocyte (now part of Novartis) Advanced Accelerator Applications",
        "Novartis Vaccines",
        "ImmunogGen and Novartis",
        "Novartis",
        "Novartis Pharmaceuticals"
      ],
      "HQ City": "Basel",
      "HQ Country": "Switzerland",
      "Founding Year": "1996",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.novartis.com",
      "Acquisition": "-",
      "ttd": [
        "DEX8D5",
        "DQVR30"
      ],
      "trials": [
        "NCT00856297",
        "NCT01125527",
        "NCT04385290",
        "NCT02073487",
        "NCT03696771",
        "NCT04240704",
        "NCT05143229",
        "NCT02038010"
      ],
      "drugs": [
        "JBH492",
        "CDH6-ADC | HKT288 | HKT-288 | Maytansine-based ADC HKT-288",
        "NJH395 | NJH395 anti-HER2 ISAC NJH395",
        "PCA-062 | PCA062 PCA-062 | PCA062",
        "Anti-proto-oncogene protein c-kit IgG1/kappa -maitansine | LOP-628 | LOP628 | LOP 628 | Anti-c-kit humanised IgG1/\u03ba -maitansine"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "# co-developers": 1,
      "locations": [
        "Italy",
        "Korea, Republic of",
        "Japan",
        "Spain",
        "Singapore",
        "Germany",
        "China",
        "United States",
        "Israel",
        "Finland"
      ],
      "# locations": 10,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 8,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Novavax",
      "names": [
        "Novavax"
      ],
      "HQ City": "Gaithersburg",
      "HQ Country": "USA",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.novavax.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05135273"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NovoCure Ltd",
      "names": [
        "NovoCure Ltd"
      ],
      "HQ City": "St. Helier",
      "HQ Country": "Jersey",
      "Founding Year": "2000",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.novocure.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05764954"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "OBI Pharma",
      "names": [
        "Oncomatryx",
        "OBI Pharma (ex-China) and  Biosion (China)",
        "OBI Pharma",
        "OBI Pharma, Inc",
        "OBI Pharma (ex-China) and Biosion (China)"
      ],
      "HQ City": "Taipei",
      "HQ Country": "Taiwan",
      "Founding Year": "2002",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.obipharma.com",
      "Acquisition": "-",
      "ttd": [
        "D2H6NI"
      ],
      "trials": [
        "NCT06480240"
      ],
      "drugs": [
        "BSI-992 | OBI-992",
        "OBI-999 Anti-Globo H ADC | OBI-999 | Anti-Globo H ADC"
      ],
      "co-developers": [
        "Biosion (China)"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "OnCusp Therapeutics",
      "names": [
        "OnCusp Therapeutics, Inc",
        "OnCusp Therapeutics"
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oncusptx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06234423"
      ],
      "drugs": [
        "CUSP06"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Onco-Pharmakon Inc",
      "names": [
        "Onco-Pharmakon Inc"
      ],
      "HQ City": "Montreal",
      "HQ Country": "Canada",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://onco-pharmakon.com/",
      "Acquisition": "-",
      "ttd": [
        "D0WM5H"
      ],
      "drugs": [
        "OP-06"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "OncoTherapy Science (Japan)",
      "names": [
        "OncoTherapy Science (Japan)",
        "OncoTherapy Science (Japan) Centre Leon Berard"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2001",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oncotherapy.co.jp/",
      "Acquisition": "-",
      "drugs": [
        "OTSA-101-DTPA | OTSA101-SS01 | OTSA-101-DTPA OTSA101-DTPA-90Y | Tabituximab Barzuxetan"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oncolinx",
      "names": [
        "Oncolinx"
      ],
      "HQ City": "Boston",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Linker Developer, ADC Platform",
      "Website URL": "https://www.oncolinx.com/",
      "Acquisition": "-",
      "drugs": [
        "Azonafide-ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oncomatryx",
      "names": [
        "Oncomatryx Biopharma S.L",
        "Oncomatryx Biopharma",
        "Oncomatryx"
      ],
      "HQ City": "Bilbao",
      "HQ Country": "Spain",
      "Founding Year": "2011",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05547321"
      ],
      "drugs": [
        "OMTX705 | Anti-MTX5:Cytolysin ADC",
        "Anti-MTX3:Nigrin Immuno | OMTX503"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Spain",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Open Innovation Partners",
      "names": [
        "Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune",
        "Open Innovation Partners",
        "Open Innovation Partners, Inc"
      ],
      "HQ City": "Boston",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://openinnovationpartners.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03859752"
      ],
      "drugs": [
        "TR1801-ADC | MT-8633 | TR1801-ADC MT-8633"
      ],
      "co-developers": [
        "MedImmune",
        "Tanabe Research Laboratories USA",
        "AstraZeneca"
      ],
      "# co-developers": 3,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Orano Med LLC",
      "names": [
        "Orano Med LLC"
      ],
      "HQ City": "Rockville",
      "HQ Country": "USA",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.oranomed.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05283330"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Orum Therapeutics USA, Inc",
      "names": [
        "Orum Therapeutics USA, Inc"
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.orumtx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05511844"
      ],
      "drugs": [
        "ORM-5029"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oxford BioMedica",
      "names": [
        "Oxford BioMedica"
      ],
      "HQ City": "Oxford",
      "HQ Country": "United Kingdom",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Viral Vector Platform",
      "Website URL": "https://www.oxfordbiomedica.co.uk/",
      "Acquisition": "-",
      "drugs": [
        "Anti-5T4 monoclonal | PF-06263507 | A1-mafodotin | PF06263507 | PF 06263507 | A1-mcMMAF"
      ],
      "co-developers": [
        "WYETH",
        "Pfizer"
      ],
      "# co-developers": 2,
      "locations": [
        "Japan"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oxford BioTherapeutics",
      "names": [
        "Co-developed by Menarini Ricerche and Oxford BioTherapeutics",
        "Oxford BioTherapeutics Ltd",
        "Oxford BioTherapeutics"
      ],
      "HQ City": "Oxford",
      "HQ Country": "United Kingdom",
      "Founding Year": "2004",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oxfordbiotherapeutics.com/",
      "Acquisition": "-",
      "ttd": [
        "D8DJX0"
      ],
      "trials": [
        "NCT04064359"
      ],
      "drugs": [
        "MEN 1309 MEN1309 OBT076 | OBT076 | MEN1309"
      ],
      "co-developers": [
        "Menarini Ricerche"
      ],
      "# co-developers": 1,
      "locations": [
        "Greece",
        "Belgium",
        "Spain",
        "United States",
        "France"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PPD",
      "names": [
        "PPD"
      ],
      "HQ City": "Wilmington",
      "HQ Country": "USA",
      "Founding Year": "1985",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.ppd.com/",
      "Acquisition": "Acquired by Thermo Fisher Scientific in 2021",
      "trials": [
        "NCT03222492"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PT AIVITA Biomedika Indonesia",
      "names": [
        "PT AIVITA Biomedika Indonesia"
      ],
      "HQ City": "Jakarta",
      "HQ Country": "Indonesia",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT04690387",
        "NCT05007496"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PT. Prodia Stem Cell Indonesia",
      "names": [
        "PT. Prodia Stem Cell Indonesia"
      ],
      "HQ City": "Jakarta",
      "HQ Country": "Indonesia",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05261750"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Palleos Healthcare GmbH",
      "names": [
        "Palleos Healthcare GmbH"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05425550"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Paxman Coolers Limited",
      "names": [
        "Paxman Coolers Limited"
      ],
      "HQ City": "Huddersfield",
      "HQ Country": "United Kingdom",
      "Founding Year": "1969",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://paxmanscalpcooling.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04986579"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Peregrine Pharmaceuticals",
      "names": [
        "Peregrine Pharmaceuticals, Inc",
        "Peregrine Pharmaceuticals"
      ],
      "HQ City": "Tustin",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.peregrineinc.com/",
      "Acquisition": "-",
      "drugs": [
        "Derlotuximab Biotin | \u00b9\u00b3\u00b9I-chTNT-1/B mAb"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pfizer",
      "names": [
        "Pfizer (Wyeth)",
        "Nona Bioscience and Pfizer",
        "Pfizer (Wyeth Pharmaceuticals)",
        "Seagen (Pfizer)",
        "Pfizer",
        "Pfizer Stemcentrx (now AbbVie) In collaboration with Indiana University",
        "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc",
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1849",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.pfizer.com",
      "Acquisition": "-",
      "fda_label": [
        {
          "id": 54277,
          "description": "[\"11. DESCRIPTION Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in NS0 cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab. MYLOTARG (gemtuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder for intravenous administration. Each single-dose vial delivers 4.5 mg gemtuzumab ozogamicin. Inactive ingredients are dextran 40 (41.0 mg), sodium chloride (26.1 mg), sodium phosphate dibasic anhydrous (2.7 mg), sodium phosphate monobasic monohydrate (0.45 mg), and sucrose (69.8 mg). After reconstitution with 5 mL of Sterile Water for Injection USP, the concentration is 1 mg/mL of gemtuzumab ozogamicin with a deliverable volume of 4.5 mL (4.5 mg). Chemical Structure\"]",
          "generic_name": "[\"GEMTUZUMAB OZOGAMICIN\"]",
          "brand_name": "[\"Mylotarg\"]",
          "substance_name": "[\"GEMTUZUMAB OZOGAMICIN\"]",
          "manufacturer_name": "[\"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.\"]"
        },
        {
          "id": 222901,
          "description": "[\"11. DESCRIPTION Inotuzumab ozogamicin is a CD22-directed antibody and cytotoxic-drug conjugate (ADC) consisting of 3 components: 1) the recombinant humanized immunoglobulin class G subtype 4 (IgG4) kappa antibody inotuzumab, specific for human CD22, 2) N-acetyl-gamma-calicheamicin that causes double-stranded DNA breaks, and 3) an acid-cleavable linker composed of the condensation product of 4-(4'-acetylphenoxy)-butanoic acid (AcBut) and 3-methyl-3-mercaptobutane hydrazide (known as dimethylhydrazide) that covalently attaches N-acetyl-gamma-calicheamicin to inotuzumab. Inotuzumab ozogamicin has an approximate molecular weight of 160 kDa. The average number of calicheamicin derivative molecules conjugated to each inotuzumab molecule is approximately 6 with a distribution from 2\u20138. Inotuzumab ozogamicin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the semisynthetic calicheamicin derivative is produced by microbial fermentation followed by synthetic modification. BESPONSA (inotuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous administration. Each single-dose vial delivers 0.9 mg inotuzumab ozogamicin. Inactive ingredients are polysorbate 80 (0.36 mg), sodium chloride (2.16 mg), sucrose (180 mg), and tromethamine (8.64 mg). After reconstitution with 4 mL of Sterile Water for Injection, USP, the final concentration is 0.25 mg/mL of inotuzumab ozogamicin with a deliverable volume of 3.6 mL (0.9 mg) and a pH of approximately 8.0. Chemical Structure\"]",
          "generic_name": "[\"INOTUZUMAB OZOGAMICIN\"]",
          "brand_name": "[\"Besponsa\"]",
          "substance_name": "[\"INOTUZUMAB OZOGAMICIN\"]",
          "manufacturer_name": "[\"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.\"]"
        }
      ],
      "trials": [
        "NCT05097599",
        "NCT00037596",
        "NCT03531918",
        "NCT01679119",
        "NCT03962465",
        "NCT00743652",
        "NCT05687032",
        "NCT03727750",
        "NCT00717925",
        "NCT03284723",
        "NCT01363297",
        "NCT00299494",
        "NCT00724971",
        "NCT04039230",
        "NCT01564784",
        "NCT01026038",
        "NCT04385290",
        "NCT04207190",
        "NCT00868608",
        "NCT02724163",
        "NCT03839446",
        "NCT02222922",
        "NCT00003673",
        "NCT00148824",
        "NCT04486352",
        "NCT04307576",
        "NCT03971409",
        "NCT00867087",
        "NCT02312037",
        "NCT03677596",
        "NCT04070768",
        "NCT00962767",
        "NCT05748171",
        "NCT01055496",
        "NCT01976169",
        "NCT00073749",
        "NCT01134575",
        "NCT03737955",
        "NCT04189614",
        "NCT03374332",
        "NCT01847781",
        "NCT01562990",
        "NCT04341181",
        "NCT03913559",
        "NCT00003131",
        "NCT03159117",
        "NCT00304447",
        "NCT00044733",
        "NCT00766116",
        "NCT03991884",
        "NCT00037583"
      ],
      "drugs": [
        "hP67.6-calicheamicin | WAY-CMA-676 | CDP-771 | CMA-676 | Mylotarg\u00ae | Gemtuzumab ozogamicin",
        "RN765C",
        "PF06688992 | GD3 ADC | PF-06688992",
        "PF-6650808 | PF06650808 | Anti-NOTCH3-ADC | Anti-NOTCH3 ADC | PF-06650808",
        "PF-06804103 PF 06804103 Anti-NG-HER2 ADC | PF-06804103 | Anti-NG-HER2 ADC",
        "Anti-5T4 monoclonal | PF-06263507 | A1-mafodotin | PF06263507 | PF 06263507 | A1-mcMMAF",
        "RN927C | PF06664178 | PF 06664178 | PF-06664178",
        "Anti-TM4SF1 ADC",
        "BESPONSA\u00ae | Inotuzumab ozogamicin | CMC-544 CMC544 | CMC-544",
        "HBM9033",
        "PF-06647263 | PF-06647263 EFNA4-ADC | anti-EFNA4-ADC",
        "SGN-B6A",
        "Cofetuzumab pelidotin | ABBV-647 | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020 | PF-06647020",
        "hCTMO1-calicheamicin CDP-671 | CMB-401 | hCTMO1-calicheamicin | CDP-671"
      ],
      "co-developers": [
        "AbbVie",
        "Oxford BioMedica",
        "WYETH",
        "Seagen",
        "Rinat",
        "Nona Bioscience",
        "Stemcentrx",
        "Celltech",
        "Angiex"
      ],
      "# co-developers": 9,
      "locations": [
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "Norway",
        "China",
        "Hong Kong",
        "United States",
        "Estonia",
        "Denmark",
        "India",
        "Canada",
        "Singapore",
        "France",
        "Iceland",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Hungary",
        "Austria",
        "New Zealand",
        "Japan",
        "Spain",
        "Germany",
        "Wales",
        "Argentina",
        "Israel",
        "Slovakia",
        "Finland"
      ],
      "# locations": 39,
      "# drugs": 14,
      "# Preclinical drugs": 1,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 51,
      "# Phase 1 trials": 13,
      "# Phase 2 trials": 27,
      "# Phase 3 trials": 6,
      "# Phase 4 trials": 4
    },
    {
      "heading": "Pharm-Olam International",
      "names": [
        "Pharm-Olam International"
      ],
      "HQ City": "Houston",
      "HQ Country": "USA",
      "Founding Year": "1994",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.pharm-olam.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02340208"
      ],
      "drugs": [
        "L-DOS47"
      ],
      "co-developers": [
        "Helix BioPharma"
      ],
      "# co-developers": 1,
      "locations": [
        "Poland",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PharmaMar",
      "names": [
        "PharmaMar"
      ],
      "HQ City": "Madrid",
      "HQ Country": "Spain",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://pharmamar.com/",
      "Acquisition": "-",
      "drugs": [
        "MI130004"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pheon Therapeutics",
      "names": [
        "Pheon Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06457997"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pierre Fabre",
      "names": [
        "Pierre Fabre",
        "Pierre Fabre Medicament",
        "Pierre Fabre In collaboration with Roche"
      ],
      "HQ City": "Castres",
      "HQ Country": "France",
      "Founding Year": "1961",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.pierre-fabre.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03316638"
      ],
      "drugs": [
        "W0101 | W0101 W-0101 | W-0101 | Lonigutamab Ugodotin"
      ],
      "co-developers": [
        "Roche"
      ],
      "# co-developers": 1,
      "locations": [
        "Spain",
        "France"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Precision Life Sciences Group",
      "names": [
        "Precision Life Sciences Group"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT01280552",
        "NCT02049489"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Prima BioMed Ltd",
      "names": [
        "Prima BioMed Ltd"
      ],
      "HQ City": "Sydney",
      "HQ Country": "Australia",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.primabiomed.com.au/",
      "Acquisition": "-",
      "trials": [
        "NCT01068509",
        "NCT01617629"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ProfoundBio",
      "names": [
        "ProfoundBio US Co",
        "ProfoundBio"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.profoundbio.com",
      "Acquisition": "-",
      "trials": [
        "NCT05579366"
      ],
      "drugs": [
        "PRO1184",
        "PRO1160"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Progenics Pharmaceuticals",
      "names": [
        "Progenics Pharmaceuticals",
        "Progenics pharmaceuticals",
        "Progenics Pharmaceuticals, Inc. (Tarrytown NY USA)",
        "Progenics Pharmaceuticals New York, NY",
        "Progenics Pharmaceuticals, Inc"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Lantheus in 2019",
      "ttd": [
        "D08VJC",
        "D0A7LL",
        "DENO78"
      ],
      "trials": [
        "NCT01414296",
        "NCT01856933",
        "NCT02020135",
        "NCT01695044",
        "NCT01414283"
      ],
      "drugs": [
        "BAY 2315497",
        "PSMA ADC therapeutic",
        "PSMA-ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Puma Biotechnology, Inc",
      "names": [
        "Puma Biotechnology, Inc"
      ],
      "HQ City": "Los Angeles",
      "HQ Country": "USA",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.pumabiotechnology.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05274048",
        "NCT01494662"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pyramid Biosciences",
      "names": [
        "Pyramid Biosciences",
        "Pyramid Biosciences GeneQuantum Healthcare (Suzhou) Co"
      ],
      "HQ City": "Boston",
      "HQ Country": "United States",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://pyramidbio.com/",
      "Acquisition": "-",
      "drugs": [
        "GQ1010"
      ],
      "co-developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pyxis Oncology",
      "names": [
        "Pyxis Oncology"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2018",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.pyxisoncology.com/",
      "Acquisition": "-",
      "drugs": [
        "PYX-201"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Radiation Therapy Oncology Group",
      "names": [
        "Radiation Therapy Oncology Group"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.rtog.org/",
      "Acquisition": "-",
      "trials": [
        "NCT02573324"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Rakuten Medical",
      "names": [
        "Rakuten Medical",
        "Rakuten Medical (Aspyrian Therapeutics)"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2005",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.rakuten-med.com/",
      "Acquisition": "-",
      "drugs": [
        "ASP-1929 | Cetuximab sarotalocan | RM-1929 | ASP-1929  RM-1929 Cetuximab-irdye 700dx"
      ],
      "co-developers": [
        "Aspyrian"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Redwood Bioscience",
      "names": [
        "Redwood Bioscience",
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience",
        "Redwood Bioscience."
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Catalent in 2014",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Regeneron",
      "names": [
        "Regeneron Pharmaceuticals, Tarrytown, NY",
        "Regeneron Pharmaceuticals",
        "Regenron",
        "Regeneron"
      ],
      "HQ City": "Tarrytown",
      "HQ Country": "United States",
      "Founding Year": "1988",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.regeneron.com",
      "Acquisition": "-",
      "trials": [
        "NCT04982224",
        "NCT05991388"
      ],
      "drugs": [
        "REGN5093 \u2013 M114",
        "Anti-PRLR-ADC | REGN2878-DM1 | PRLR | Anti-Prolactin Receptor",
        "REGN3124-PBD"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "RemeGen",
      "names": [
        "RemeGen",
        "RemeGen Co., Ltd",
        "Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)"
      ],
      "HQ City": "Yantai",
      "HQ Country": "China",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.remegen.com",
      "Acquisition": "-",
      "trials": [
        "NCT05745740",
        "NCT03507166",
        "NCT06221748",
        "NCT05628857",
        "NCT05940896",
        "NCT06105008",
        "NCT06389006",
        "NCT05205850",
        "NCT05980481",
        "NCT06178159",
        "NCT06155383",
        "NCT06157892",
        "NCT05514158",
        "NCT05911295",
        "NCT04280341",
        "NCT04965519",
        "NCT06227117",
        "NCT05350917",
        "NCT06038396",
        "NCT05135715",
        "NCT06378242",
        "NCT05943379",
        "NCT03556345",
        "NCT04617314",
        "NCT03052634",
        "NCT02881190",
        "NCT04311034",
        "NCT05996952",
        "NCT04073602",
        "NCT04714190",
        "NCT04329429",
        "NCT06227156",
        "NCT05297552",
        "NCT02881138",
        "NCT03809013",
        "NCT06155396",
        "NCT05957757",
        "NCT05302284",
        "NCT04175847",
        "NCT03500380",
        "NCT04400695"
      ],
      "drugs": [
        "Trastuzumab Botidotin",
        "RC88",
        "RC118",
        "RC108",
        "TRASTUZUMAB BRENGITECAN",
        "RC-48 | RC-48 RC 480-ADC RC48 | RC 480-ADC | Disitamab Vedotin | Aidixi\u00ae | \u7231\u5730\u5e0c\u00ae | RC48"
      ],
      "co-developers": [
        "MabPlex"
      ],
      "# co-developers": 1,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 72,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 41,
      "# Phase 1 trials": 6,
      "# Phase 2 trials": 28,
      "# Phase 3 trials": 7,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Rinat",
      "names": [
        "Rinat"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2001",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.rinatcorp.com/",
      "Acquisition": "Acquired by Pfizer in 2006",
      "drugs": [
        "RN765C"
      ],
      "co-developers": [
        "Pfizer"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Roche",
      "names": [
        "Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)",
        "Roche (in collaboration with Seattle Genetic)",
        "Hoffmann-La Roche",
        "Genentech Roche  In collaboration with ImmunoGen",
        "Roche Pharma AG",
        "F. Hoffmann-La Roche (Roche)",
        "Pierre Fabre In collaboration with Roche",
        "Roche, F. Hoffmann-La Roche (Roche)",
        "Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)",
        "Genentech F. Hoffmann-La Roche",
        "Roche-Genentech",
        "Genentech Roche In collaboration with ImmunoGen",
        "Roche, F. Hoffmann-La Roche",
        "Roche"
      ],
      "HQ City": "Basel",
      "HQ Country": "Switzerland",
      "Founding Year": "1896",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.roche.com",
      "Acquisition": "-",
      "trials": [
        "NCT05535244",
        "NCT04914741",
        "NCT04733118",
        "NCT03153163",
        "NCT02131064",
        "NCT04487756",
        "NCT05171647",
        "NCT02600897",
        "NCT04873362",
        "NCT04182204",
        "NCT03337698",
        "NCT01702571",
        "NCT06047080",
        "NCT03533283",
        "NCT01196052",
        "NCT05954143",
        "NCT02611323",
        "NCT03084939",
        "NCT04833114",
        "NCT05415215",
        "NCT01772472",
        "NCT04589845",
        "NCT04740918",
        "NCT01513083",
        "NCT03726879",
        "NCT00781612",
        "NCT01120184",
        "NCT03677154",
        "NCT02605915",
        "NCT06172127",
        "NCT02658734",
        "NCT03424005",
        "NCT06071871",
        "NCT00679341",
        "NCT00829166",
        "NCT05798156",
        "NCT02314481",
        "NCT04931342",
        "NCT02289833",
        "NCT05183035",
        "NCT01419197",
        "NCT02924883",
        "NCT04790903",
        "NCT01966471",
        "NCT01565200",
        "NCT04341181",
        "NCT03671018",
        "NCT03274492",
        "NCT00934856",
        "NCT02729896",
        "NCT03869190",
        "NCT02999672",
        "NCT02257567",
        "NCT03677141",
        "NCT03467373",
        "NCT00875979"
      ],
      "drugs": [
        "DFRF 4539A | RG-7598 | RG 7598 | RG7598",
        "W0101 | W0101 W-0101 | W-0101 | Lonigutamab Ugodotin",
        "RO5541077-000 | RG-7596 | DCDS4501A | ACD79B-VCMMAE | Polatuzumab vedotin | Polivy\u2122 | FCU2711 | DCDS-4501A",
        "DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA | RG6148 | DHES0815A | anti-HER2/PBD-monoamide anti-HER2/PBD-MA",
        "RG-7636 | Anti-ETBR",
        "RO7032005 | DCDS0780A DCDS 0780A RO7032005 | Iladatuzumab vedotin | DCDS0780A",
        "RG7986",
        "DSTP-3086S | DSTP3086S | Anti-STEAP1 ADC | RG7450 | RG-7450 | MSTP2109A | Vandortuzumab vedotin",
        "Anti-Ly6E | RG-7841 | Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | DLYE5953A",
        "RG 7600 | DMOT-4039A | DMOT4039A | RG7600",
        "RG-7599 | Lifastuzumab Vedotin | DNIB0600A | MNIB2126A  Anti-NaPi2b ADC RG-7599",
        "Sofituzumab vedotin | DMUC5754A | RG7458 | Anti-MUC16 ADC",
        "DCDT2980S | DCDT-2989S | RO5541072-000 | Pinatuzumab vedotin | RG-7593 | ACD22-VCMMAE | FCU2803",
        "Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502 | Kadcyla\u00ae | T-DM1 | Trastuzumab Emtansine"
      ],
      "co-developers": [
        "Pierre Fabre",
        "Genentech",
        "Seagen"
      ],
      "# co-developers": 3,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Norway",
        "China",
        "Hong Kong",
        "Peru",
        "Portugal",
        "United States",
        "Colombia",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Ecuador",
        "Dominican Republic",
        "Indonesia",
        "Mexico",
        "Uganda",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Hungary",
        "Australia",
        "New Zealand",
        "Japan",
        "Romania",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 73,
      "# drugs": 14,
      "# Preclinical drugs": 0,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 6,
      "# Phase 2 drugs": 5,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 56,
      "# Phase 1 trials": 5,
      "# Phase 2 trials": 32,
      "# Phase 3 trials": 18,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Rongchang",
      "names": [
        "Rongchang Pharmaceuticals",
        "Yantai Rongchang Biological Engineering",
        "Rongchang"
      ],
      "HQ City": "Chongqing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "Hertuzumab-vcMMAE | Hertuzumab Vedotin"
      ],
      "co-developers": [
        "MabPlex"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "SICHUAN BIOKIN",
      "names": [
        "Baili-Bio (Chengdu) (Sichuan Biokin)",
        "SICHUAN BIOKIN"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "SOTIO Bio",
      "names": [
        "SOTIO a.s",
        "SOTIO Bio",
        "SOTIO Biotech a.s"
      ],
      "HQ City": "Prague",
      "HQ Country": "Czech Republic",
      "Founding Year": "2010",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.sotio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05525286",
        "NCT04834544",
        "EUCTR2021-005873-25-ES"
      ],
      "drugs": [
        "SOT102 | SO-N102 | CLDN18.2 ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Belgium",
        "Czechia",
        "Spain",
        "United States",
        "France"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Samsung Medical Center",
      "names": [
        "Samsung Medical Center",
        "LegoChem Biosiences and Samsung Medical Center"
      ],
      "HQ City": "Seoul",
      "HQ Country": "South Korea",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.samsunghospital.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02280785"
      ],
      "drugs": [
        "LCB14-19nm"
      ],
      "co-developers": [
        "Legochem"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sanofi",
      "names": [
        "Sanofi",
        "ImmunoGen (previously also Sanofi)",
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "HQ City": "Paris",
      "HQ Country": "France",
      "Founding Year": "2004",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.sanofi.com",
      "Acquisition": "-",
      "ttd": [
        "D05TBQ",
        "D2D6NJ"
      ],
      "trials": [
        "NCT00258856",
        "NCT00654901",
        "NCT01444781",
        "NCT01983540",
        "NCT06397768",
        "NCT04142242",
        "NCT01472887",
        "NCT05922501",
        "NCT01470456",
        "NCT00772070",
        "NCT02610348"
      ],
      "drugs": [
        "SAR 408701 | SAR408701 SAR 408701 SAR-408701 | SAR408701 | Tusamitamab Ravtansine | SAR-408701",
        "SAR428926 SAR 428926 | SAR428926",
        "SAR3419 | SAR 3419 | Coltuximab Ravtansine",
        "SAR566658 | SAR 566658"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "# co-developers": 1,
      "locations": [
        "United Kingdom",
        "Belgium",
        "Israel",
        "Austria",
        "Turkey",
        "Czechia",
        "Spain",
        "Norway",
        "United States",
        "France",
        "Italy",
        "Poland"
      ],
      "# locations": 12,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 11,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 5,
      "# Phase 3 trials": 5,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Schering",
      "names": [
        "Schering",
        "Biogen Schering AG  Spectrum Pharmaceuticals"
      ],
      "HQ City": "Berlin",
      "HQ Country": "Germany",
      "Founding Year": "1885",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.bayer.com/",
      "Acquisition": "Acquired by Bayer in 2006",
      "drugs": [
        "Ibritumomab tiuxetan | In-111 Zevalin Y-90 Zevalin"
      ],
      "co-developers": [
        "Biogen"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 1,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Seagen",
      "names": [
        "Genmab in collaboration with Seattle Genetics",
        "GenmabPrinceton, NJSeattle GeneticsBothell, WA",
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas",
        "Seattle genetics, Inc. (Bothell WA USA)",
        "Astellas Northbrook, IL Seattle Genetics Bothell, WA",
        "Seattle genetics",
        "Seagen, Inc",
        "Agensys, Inc. Seattle Genetics, Inc",
        "Seagen",
        "Seagen Sanofi",
        "Seattle Genetics, Inc",
        "Roche (in collaboration with Seattle Genetic)",
        "Seagen Inc",
        "GlaxoSmithKline  (GSK) Co-developer: Seattle Genetics",
        "SEAGEN INC",
        "Seattle Genetics",
        "Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)",
        "Seagen (Pfizer)",
        "Seattle Genetics (Licensed from  Bristol-Myers Squibb (BMS) with technology licensed from Enzon)"
      ],
      "HQ City": "Bothell",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.seagen.com",
      "Acquisition": "Acquired by Pfizer in 2023",
      "ttd": [
        "D0QI1K",
        "DDG8W9",
        "DJYD13",
        "DS6BE2",
        "DORB45",
        "DS6B1L"
      ],
      "fda_label": [
        {
          "id": 62802,
          "description": "[\"11 DESCRIPTION Tisotumab vedotin-tftv is a Tissue Factor (TF) directed antibody drug conjugate (ADC) comprised of a human anti-TF IgG1-kappa antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable vc (valine-citrulline) linker. The monoclonal antibody is produced in a mammalian cell cline (Chinese hamster ovary). MMAE and the linker are produced by chemical synthesis. Each monoclonal antibody molecule carries an average of 4 MMAE molecules. Tisotumab vedotin-tftv has an approximate molecular weight of 153 kDa. The chemical structure is as follows: Figure 1. Structural Formula TIVDAK (tisotumab vedotin-tftv) for injection, is provided as a sterile, preservative-free, white to off-white lyophilized cake or powder in a single-dose vial for infusion after dilution. Following reconstitution with 4 mL of Sterile Water for Injection, a clear to slightly opalescent, colorless to brownish-yellow solution containing 10 mg/mL tisotumab vedotin-tftv is produced [see Dosage and Administration ( 2.3 )]. Each mL of reconstituted solution contains 10 mg of tisotumab vedotin-tftv, d-mannitol (30 mg), l-histidine (2.11 mg), l-histidine monohydrochloride (3.44 mg), and sucrose (30 mg), at pH 6.0.\"]",
          "generic_name": "[\"TISOTUMAB VEDOTIN\"]",
          "brand_name": "[\"TIVDAK\"]",
          "substance_name": "[\"TISOTUMAB VEDOTIN\"]",
          "manufacturer_name": "[\"Seagen Inc.\"]"
        },
        {
          "id": 84421,
          "description": "[\"11 DESCRIPTION ADCETRIS (brentuximab vedotin) is a CD30-directed antibody and microtubule inhibitor conjugate consisting of three components: 1) the chimeric IgG1 antibody cAC10, specific for human CD30, 2) the microtubule disrupting agent MMAE, and 3) a protease-cleavable linker that covalently attaches MMAE to cAC10. Brentuximab vedotin has an approximate molecular weight of 153 kDa. Approximately 4 molecules of MMAE are attached to each antibody molecule. Brentuximab vedotin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis. ADCETRIS (brentuximab vedotin) for injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder in single-dose vials. Following reconstitution with 10.5 mL Sterile Water for Injection, USP, a solution containing 5 mg/mL brentuximab vedotin is produced. The reconstituted product contains 70 mg/mL trehalose dihydrate, 5.6 mg/mL sodium citrate dihydrate, 0.21 mg/mL citric acid monohydrate, and 0.20 mg/mL polysorbate 80 and water for injection. The pH is approximately 6.6.\"]",
          "generic_name": "[\"BRENTUXIMAB VEDOTIN\"]",
          "brand_name": "[\"ADCETRIS\"]",
          "substance_name": "[\"BRENTUXIMAB VEDOTIN\"]",
          "manufacturer_name": "[\"SEAGEN INC.\"]"
        },
        {
          "id": 221578,
          "description": "[\"11 DESCRIPTION Enfortumab vedotin-ejfv is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD-1006). Conjugation takes place on cysteine residues that comprise the interchain disulfide bonds of the antibody to yield a product with a drug-to-antibody ratio of approximately 3.8:1. The molecular weight is approximately 152 kDa. Figure 1. Structural Formula Approximately 4 molecules of MMAE are attached to each antibody molecule. Enfortumab vedotin-ejfv is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells and the small molecule components are produced by chemical synthesis. PADCEV (enfortumab vedotin-ejfv) for injection is provided as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials for intravenous use. PADCEV is supplied as a 20 mg per vial and a 30 mg per vial and requires reconstitution with Sterile Water for Injection, USP, (2.3 mL and 3.3 mL, respectively) resulting in a clear to slightly opalescent, colorless to slightly yellow solution with a final concentration of 10 mg/mL [see Dosage and Administration ( 2.3 )]. After reconstitution, each vial allows the withdrawal of 2 mL (20 mg) and 3 mL (30 mg). Each mL of reconstituted solution contains 10 mg of enfortumab vedotin-ejfv, histidine (1.4 mg), histidine hydrochloride monohydrate (2.31 mg), polysorbate 20 (0.2 mg) and trehalose dihydrate (55 mg) with a pH of 6.0. Enfortumab vedotin structural formula\"]",
          "generic_name": "[\"ENFORTUMAB VEDOTIN\"]",
          "brand_name": "[\"PADCEV EJFV\"]",
          "substance_name": "[\"ENFORTUMAB VEDOTIN\"]",
          "manufacturer_name": "[\"SEAGEN INC.\"]"
        }
      ],
      "trials": [
        "NCT03755804",
        "NCT05756569",
        "NCT04879329",
        "NCT03485209",
        "NCT01700751",
        "NCT01026415",
        "NCT02734771",
        "NCT00848926",
        "NCT01508312",
        "NCT06254495",
        "NCT03222492",
        "NCT00079755",
        "NCT02216890",
        "NCT02001623",
        "NCT01060904",
        "NCT02581631",
        "NCT05673928",
        "NCT00866047",
        "NCT01777152",
        "NCT02927769",
        "NCT00031187",
        "NCT04697628",
        "NCT03438396",
        "NCT01026233",
        "NCT05357794",
        "NCT06377566",
        "NCT04539938",
        "NCT02086604",
        "NCT02616965",
        "NCT04404283",
        "NCT01421667",
        "NCT06157892",
        "NCT01015911",
        "NCT01396070",
        "NCT03587844",
        "NCT01874054",
        "NCT02227199",
        "NCT01807598",
        "NCT01716806",
        "NCT00051584",
        "NCT06120504",
        "NCT01786135",
        "NCT01596218",
        "NCT01969643",
        "NCT02552121",
        "NCT05775471",
        "NCT01868451",
        "NCT01534078",
        "NCT01352520",
        "NCT01786096",
        "NCT01461538",
        "NCT01920932",
        "NCT00430846",
        "NCT00028483",
        "EUCTR2019-001219-22-IE",
        "NCT03474107",
        "NCT03424005",
        "NCT01578499",
        "EUCTR2019-001219-22-ES",
        "NCT03646123",
        "NCT00947856",
        "NCT04609566",
        "NCT01100502",
        "NCT04569032",
        "NCT03786081",
        "NCT06003231",
        "NCT01166490",
        "NCT02572167",
        "NCT01712490",
        "NCT01309789",
        "NCT03264131",
        "NCT03288545",
        "NCT05922904",
        "NCT04457596",
        "NCT03310957",
        "NCT05911295",
        "NCT02822586",
        "NCT05149768",
        "NCT01578967",
        "NCT03657043",
        "NCT03245736",
        "NCT02505269",
        "NCT05323955",
        "NCT00051571",
        "NCT05180097",
        "NCT03219333",
        "NCT05414500",
        "NCT01902329",
        "NCT04587687",
        "NCT03198689",
        "NCT02326584",
        "NCT00086333",
        "NCT04685616"
      ],
      "drugs": [
        "Brentuximab vedotin | Adcetris\u00ae | SGN-35 cAC10-Val-Cit-MMAE | SGN35",
        "SGN-CD19B",
        "HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC | AXL-107-MMAE | Enapotamab vedotin | HuMax-AXL-ADC",
        "SGN-B7H4V",
        "SGN-CD30C",
        "SGN CD70 A | superseding SGN-75 | SGN-CD70A",
        "Ladiratuzumab vedotin | SGN-LIV1A | Anti-LIV-1 ADC",
        "SGN-B6A",
        "Enfortumab vedotin | AGS-22CE | ASG-22CE | AGS-22M6E | ASG-22ME | Enfortumab Vedotin | Padcev | ASG-22MSE | AGS-22ME | AGS-22M | Enfortumab",
        "GSK2857916 | Belantamab mafodotin | J6M0-mcMMAF | GSK2857916  2857916 GSK '916 J6M0-mcMMAF | Blenrep\u00ae",
        "Vorsetuzumab mafodotin | SGN-75",
        "SGN-19A SGN-CD19A hBU12-491 | SGN-19A | hBU12-491 | Denintuzumab mafodotin | SGN-CD19A",
        "ASG-5ME",
        "SGN-CEACAM5C",
        "h2H12ec-SGD-1910 | Vadastuximab talirine | SGN-CD33A | h2H12ec-mc-val-ala-SGD-1882 | EC-mAb",
        "SGN-CD352a",
        "SGN-CD228A | SGN-CD228A  anti-CD228 -   Anti-CD228-MMAE",
        "Anti-Ly6E | RG-7841 | Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | DLYE5953A",
        "SGN-PDL1V",
        "SGN-15 | BR96-DOX | SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin | BMS-182248",
        "AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | ASG-15ME | AGS-15vcMMAE | AGS-15E | Sirtratumab vedotin | Ha15-10ac.1vcMMAE | AGS15E",
        "DSFV | LMB-9 | -PE | PSEUDOMONAS AERUGINOSA EXOTOXIN A"
      ],
      "co-developers": [
        "Takeda",
        "GlaxoSmithKline",
        "Bristol Myers Squibb",
        "Genmab",
        "Genentech",
        "Ligand Pharmaceuticals",
        "Agensys",
        "Pfizer",
        "Astellas",
        "Roche"
      ],
      "# co-developers": 10,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Republic of Korea",
        "South Africa",
        "Belgium",
        "Norway",
        "Portugal",
        "Hong Kong",
        "China",
        "Peru",
        "United States",
        "Colombia",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Moldova, Republic of",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Lithuania",
        "Italy",
        "Poland",
        "United States of America",
        "Chile",
        "Taiwan",
        "Bosnia and Herzegovina",
        "Iceland",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Romania",
        "Hungary",
        "Ireland",
        "New Zealand",
        "Japan",
        "Austria",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "# locations": 62,
      "# drugs": 22,
      "# Preclinical drugs": 1,
      "# Approved drugs": 3,
      "# Phase 1 drugs": 10,
      "# Phase 2 drugs": 5,
      "# Phase 3 drugs": 3,
      "# Phase 4 drugs": 0,
      "# trials": 93,
      "# Phase 1 trials": 21,
      "# Phase 2 trials": 58,
      "# Phase 3 trials": 12,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Seasun Biomaterials",
      "names": [
        "LegoChem Biosciences and Seasun Biomaterials",
        "Seasun Biomaterials"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2014",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.seasunbio.com/",
      "Acquisition": "-",
      "drugs": [
        "LCB14-2nm"
      ],
      "co-developers": [
        "Legochem"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Servier",
      "names": [
        "Servier"
      ],
      "HQ City": "Suresnes",
      "HQ Country": "France",
      "Founding Year": "1954",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://servier.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04307576"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Fosun",
      "names": [
        "Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd",
        "Shanghai Fosun Pharmaceutical Development Co, Ltd",
        "Shanghai Fosun",
        "Fosun",
        "Legochem Biosciences and Fosun Pharma"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.fosunpharma.com",
      "Acquisition": "-",
      "trials": [
        "NCT05755048"
      ],
      "drugs": [
        "FS-1502 Trastuzumab Monomethyl Auristatin F | FS-1502",
        "LCB14-0110 | Herceptin-LC-LBG-MMAF | Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF | LCB14 0110"
      ],
      "co-developers": [
        "Legochem"
      ],
      "# co-developers": 1,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 72,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Hansoh Biomedical",
      "names": [
        "Hansoh BioMedical R&D Company",
        "Hansoh (Shanghai)",
        "Shanghai Hansoh Biomedical Co., Ltd",
        "Hansoh BioMedical R&D Company ( Shanghai Hansoh Biomedical Co., Ltd",
        "Shanghai Hansoh Biomedical"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2004",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.hansohbio.com",
      "Acquisition": "-",
      "trials": [
        "NCT05276609",
        "NCT06144723",
        "NCT06336707",
        "NCT06014190",
        "NCT05263479",
        "NCT06112704"
      ],
      "drugs": [
        "HS-20089",
        "HS-20105",
        "HS-20093 (Phase Ib: Dose expansion) | HS-20093 | HS-20093 (Phase Ia: Dose escalation)"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Henlius",
      "names": [
        "Shanghai Henlius",
        "Shanghai Henlius Biotech"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.henlius.com",
      "Acquisition": "-",
      "trials": [
        "NCT06115642",
        "NCT06210815"
      ],
      "drugs": [
        "HLX42",
        "HLX43"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Institute Of Biological Products",
      "names": [
        "Shanghai Institute Of Biological Products"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06298058"
      ],
      "drugs": [
        "SIBP-A13 formulation for injection | SIBP-A13"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Junshi",
      "names": [
        "Shanghai Junshi Bioscience Co., Ltd",
        "Shanghai Junshi"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2012",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.junshipharma.com/",
      "Acquisition": "-",
      "drugs": [
        "JS108"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Miracogen",
      "names": [
        "Miracogen",
        "Shanghai Miracogen, a fully owned subsidiary of Lepu Biopharma",
        "Shanghai Miracogen Inc",
        "Shanghai Miracogen in partnership with Lepu Biopharma",
        "Shanghai Miracogen  in partnership with Lepu Biopharma",
        "Shanghai Miracogen"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.miracogen.com",
      "Acquisition": "-",
      "ttd": [
        "DM7WY2"
      ],
      "trials": [
        "NCT04838964",
        "NCT05688605",
        "NCT04868344",
        "NCT04742153",
        "NCT04924699",
        "NCT05126719",
        "NCT04843709",
        "NCT05751512",
        "NCT05338957",
        "NCT05754853"
      ],
      "drugs": [
        "MRG003",
        "MRG004A",
        "MRG002"
      ],
      "co-developers": [
        "Lepu Biopharma"
      ],
      "# co-developers": 1,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "United Arab Emirates",
        "Czech Republic",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Kenya",
        "Costa Rica",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Luxembourg",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "El Salvador",
        "Venezuela",
        "Singapore",
        "Philippines",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Dominican Republic",
        "Indonesia",
        "Uganda",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Ireland",
        "Austria",
        "Japan",
        "New Zealand",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel",
        "Vietnam",
        "Slovakia",
        "Finland"
      ],
      "# locations": 72,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 10,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 6,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Pharmaceuticals Holding",
      "names": [
        "Shanghai Pharmaceuticals Holding Co., Ltd",
        "Shanghai Pharmaceuticals Holding"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sphchina.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03953833"
      ],
      "drugs": [
        "B003"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shattuck Labs",
      "names": [
        "Shattuck Labs"
      ],
      "HQ City": "Austin",
      "HQ Country": "USA",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.shattucklabs.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shenogen Pharma",
      "names": [
        "Shenogen Pharma Group",
        "Shenogen Pharma"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "SNG-8023 ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Siamab",
      "names": [
        "Siamab Therapeutics",
        "Siamab"
      ],
      "HQ City": "Newton",
      "HQ Country": "United States",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.siamab.com/",
      "Acquisition": "-",
      "drugs": [
        "ST1"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sichuan Baili",
      "names": [
        "Sichuan Baili",
        "SystImmune, Inc in collaboration with Sichuan Baili Pharmaceutical Co"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "BL-B01D1"
      ],
      "co-developers": [
        "Systimmune"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sichuan Kelun",
      "names": [
        "Sichuan Kelun",
        "Sichuan Kelun Pharmaceutical Research Institute Co., Ltd"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "http://www.kelunpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05367635"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Silverback",
      "names": [
        "Silverback",
        "Silverback Therapeutics"
      ],
      "HQ City": "Seattle",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://silverbacktx.com/",
      "Acquisition": "-",
      "ttd": [
        "DUA7P2"
      ],
      "drugs": [
        "SBT6050 | Pertuzumab Zuvotolimod"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "South Africa",
        "Belgium",
        "Bahamas",
        "Portugal",
        "Peru",
        "China",
        "Colombia",
        "Hong Kong",
        "United States",
        "Norway",
        "Thailand",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "Georgia",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Austria",
        "New Zealand",
        "Japan",
        "Spain",
        "Germany",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel"
      ],
      "# locations": 53,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sino Biopharmaceutical",
      "names": [
        "Sino Biopharmaceutical"
      ],
      "HQ City": "Hong Kong",
      "HQ Country": "China",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sinobiopharm.com/",
      "Acquisition": "-",
      "drugs": [
        "TQB2103"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sinobioway Biomedicine",
      "names": [
        "BioAtla in collaboration with Sinobioway Biomedicine",
        "Sinobioway Biomedicine"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "Mecbotamab Vedotin | BA3011 | CAB-anti-Axl-ADC | CAB-Axl-ADC | CAB-anti-Axl-ADC BA3011"
      ],
      "co-developers": [
        "BioAtla"
      ],
      "# co-developers": 1,
      "locations": [
        "Greece",
        "Spain",
        "Hong Kong",
        "Germany",
        "United States",
        "Italy",
        "Poland",
        "Taiwan"
      ],
      "# locations": 8,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sorrento Therapeutics",
      "names": [
        "Sorrento Therapeutics",
        "Sorrento Therapeutics, Inc"
      ],
      "HQ City": "San Diego",
      "HQ Country": "USA",
      "Founding Year": "2006",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.sorrentotherapeutics.com",
      "Acquisition": "-",
      "trials": [
        "NCT05584709",
        "NCT04316442",
        "NCT05308225"
      ],
      "drugs": [
        "Anti-cMET ADC | CBT-161",
        "CD38-077 | STI-6129 | STI-6129 LNDS1001 | LNDS1001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Spectrum Pharmaceuticals",
      "names": [
        "Spectrum Pharmaceuticals"
      ],
      "HQ City": "Henderson",
      "HQ Country": "USA",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sppirx.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Spirogen",
      "names": [
        "Spirogen"
      ],
      "HQ City": "London",
      "HQ Country": "United Kingdom",
      "Founding Year": "1995",
      "Public/Private": "-",
      "Established/Startup": "Established",
      "Specialty": "Linker Developer, ADC Platform Technology",
      "Website URL": "https://www.spirogen.com/",
      "Acquisition": "Acquired by AstraZeneca in 2013",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Stemcentrx",
      "names": [
        "AbbVie Stemcentrx LLC",
        "Stemcentrx (now part of AbbVie)",
        "Stemcentrx",
        "Pfizer Stemcentrx (now AbbVie) In collaboration with Indiana University",
        "Stem CentRx"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "-",
      "Acquisition": "Acquired by AbbVie in 2016",
      "trials": [
        "NCT02874664",
        "NCT01901653"
      ],
      "drugs": [
        "Cofetuzumab pelidotin | ABBV-647 | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020 | PF-06647020",
        "SC-006 | SC006",
        "SC-003 | Anti-DPEP3 ADC | SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001 | Tamrintamab Pamozirine",
        "SC16LD6.5"
      ],
      "co-developers": [
        "Pfizer",
        "AbbVie"
      ],
      "# co-developers": 2,
      "locations": [
        "Ukraine",
        "Sweden",
        "Turkey",
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Serbia",
        "Belarus",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Hungary",
        "Romania",
        "Japan",
        "Latvia",
        "Spain",
        "Germany",
        "Croatia",
        "Israel",
        "Finland"
      ],
      "# locations": 36,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Strata Oncology",
      "names": [
        "Strata Oncology"
      ],
      "HQ City": "Ann Arbor",
      "HQ Country": "USA",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.strataoncology.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05097599"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sutro Biopharma",
      "names": [
        "Bristol-Myers Squibb (Celgene) Sutro Biopharma",
        "Sutro Biopharma, Inc",
        "Sutro Biopharma",
        "Celgene in collaboration with Sutro",
        "EMD Serono Merck KGaA, Darmstadt, Germany Sutro Biopharma",
        "SUTRO"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.sutrobio.com",
      "Acquisition": "-",
      "ttd": [
        "D10GPJ"
      ],
      "trials": [
        "NCT05200364",
        "NCT06238687",
        "NCT03748186",
        "NCT05870748",
        "NCT03424603"
      ],
      "drugs": [
        "SP-8166 | LUVELTAMAB TAZIDE | SP8166",
        "CC-99712 \u2013 Anti-BCMA ADC | CC-99712",
        "Luveltamab Tazevibulin \u2013 S\u03a4RO-002 \u2013 Luvelta | STRO-002 STRO 002 SP8193",
        "M1231",
        "STRO-001 | Anti-CD74-ADC",
        "STRO-004",
        "STRO-003"
      ],
      "co-developers": [
        "Celgene",
        "GOG Foundation",
        "Bristol Myers Squibb"
      ],
      "# co-developers": 3,
      "locations": [
        "Canada",
        "Italy",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Singapore",
        "China",
        "United States",
        "France",
        "Israel"
      ],
      "# locations": 10,
      "# drugs": 7,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Suzhou Zanrong Pharma",
      "names": [
        "Suzhou Zanrong Pharma Limited",
        "Suzhou Zanrong Pharma"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05593094"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Synthon Pharmaceuticals Durham, NC",
      "names": [
        "Synthon Pharmaceuticals Durham, NC"
      ],
      "HQ City": "Durham",
      "HQ Country": "USA",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Synthon Holding B.V. in 2015",
      "ttd": [
        "D0HL5N"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Systimmune",
      "names": [
        "Systimmune",
        "SystImmune, Inc in collaboration with Sichuan Baili Pharmaceutical Co"
      ],
      "HQ City": "Bothell",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.systimmune.com",
      "Acquisition": "-",
      "drugs": [
        "BL M005A2 BL-M005A2 | BL-M005A2",
        "BL M002A2 BL-M002A2 | BL-M002A2",
        "BL-B01D1",
        "BL-B029A1 BL B029A1 | BL-B029A1"
      ],
      "co-developers": [
        "Sichuan Baili"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 4,
      "# Preclinical drugs": 3,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TG Therapeutics, Inc",
      "names": [
        "TG Therapeutics, Inc"
      ],
      "HQ City": "New York",
      "HQ Country": "USA",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.tgtherapeutics.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02164006"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TMC Pharma",
      "names": [
        "TMC Pharma"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT03610360"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TORL Biotherapeutics",
      "names": [
        "TORL Biotherapeutics, LLC",
        "TORL Biotherapeutics"
      ],
      "HQ City": "Irvine",
      "HQ Country": "United States",
      "Founding Year": "2021",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.torlbio.com",
      "Acquisition": "-",
      "trials": [
        "NCT05156866",
        "NCT05948826",
        "NCT06005740",
        "NCT05103683"
      ],
      "drugs": [
        "TORL-2-307-ADC",
        "TORL-3-600",
        "TORL-4-500",
        "TORL-1-23"
      ],
      "co-developers": [
        "Translational Research in Oncology"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States",
        "Korea, Republic of"
      ],
      "# locations": 3,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TOT Biopharm",
      "names": [
        "TOT Biopharm"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.totbiopharm.com/",
      "Acquisition": "-",
      "drugs": [
        "TAA013"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Takeda",
      "names": [
        "Takeda",
        "Millennium: The Takeda Oncology Company",
        "Mersana Therapeutics in collaboration with Takeda. Antibody development: Adimab",
        "LegoChem Biosciences and Takeda",
        "Takeda Development Center Americas, Inc",
        "Mersana Therapeutics in collaboration with Takeda.  Antibody development: Adimab",
        "Takeda Pharmaceutical Co. Ltd. (Osaka Japan)",
        "Millennium",
        "Takeda (listed as Millennium Pharmaceuticals) ImmunoGen"
      ],
      "HQ City": "Osaka",
      "HQ Country": "Japan",
      "Founding Year": "1781",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.takeda.com",
      "Acquisition": "-",
      "ttd": [
        "D9ICV2"
      ],
      "trials": [
        "NCT02979522",
        "NCT05442554",
        "NCT01909934",
        "NCT05316246",
        "NCT02939014",
        "NCT06390995",
        "NCT01712490",
        "NCT04685616",
        "NCT02467946",
        "NCT06186986",
        "NCT03217643",
        "NCT05673785"
      ],
      "drugs": [
        "Brentuximab vedotin | Adcetris\u00ae | SGN-35 cAC10-Val-Cit-MMAE | SGN35",
        "MLN-0264 | TAK264 | MLN 0264 | Indusatumab Vedotin | TAK-264 | 5F9vcMMAE | MLN0264",
        "LCB14-15nm",
        "TAK-853",
        "TAK-164 TAK164 Anti-GCC ADC Anti-GCC - | TAK-164",
        "TAK-500",
        "MLN2704 | MLN-2704"
      ],
      "co-developers": [
        "Millennium",
        "Seagen",
        "Legochem"
      ],
      "# co-developers": 3,
      "locations": [
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Norway",
        "Portugal",
        "Hong Kong",
        "China",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Serbia",
        "France",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Romania",
        "Hungary",
        "Ireland",
        "New Zealand",
        "Japan",
        "Austria",
        "Spain",
        "Germany",
        "Croatia",
        "Israel"
      ],
      "# locations": 38,
      "# drugs": 7,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 12,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 7,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 2
    },
    {
      "heading": "Tallac Therapeutics",
      "names": [
        "Tallac Therapeutics"
      ],
      "HQ City": "Burlingame",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://tallactherapeutics.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05399654"
      ],
      "drugs": [
        "TAC-001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Australia",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tanabe Research Laboratories USA",
      "names": [
        "Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune",
        "Tanabe Research Laboratories",
        "Tanabe Research Laboratories USA"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.tanabe-usa.com/",
      "Acquisition": "-",
      "ttd": [
        "DU6H8Z"
      ],
      "drugs": [
        "TR1801-ADC | MT-8633 | TR1801-ADC MT-8633"
      ],
      "co-developers": [
        "MedImmune",
        "Open Innovation Partners",
        "AstraZeneca"
      ],
      "# co-developers": 3,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Targetome SA",
      "names": [
        "Targetome SA, a spin-off from the University of Li\u00c3\u00a8ge (ULg), Belgium.",
        "Targetome SA, a spin-off from the University of Li\u00c3\u00a8ge (ULg), Belgium",
        "Targetome SA",
        "Targetome SA, a spin-off from the University of Li\u00c3\u00a8ge (ULg), Belgium.,",
        "Targetome SA, a spin-off from the University of Li\u00e8ge (ULg), Belgium"
      ],
      "HQ City": "Li\u00e8ge",
      "HQ Country": "Belgium",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.targetome.com",
      "Acquisition": "-",
      "drugs": [
        "TGM-005",
        "TGM-004",
        "TGM-002",
        "TGM-001",
        "TGM-003"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tarveda",
      "names": [
        "Tarveda",
        "Tarveda Therapeutics"
      ],
      "HQ City": "Watertown",
      "HQ Country": "USA",
      "Founding Year": "2011",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Centrose in 2022",
      "drugs": [
        "PEN-866 | PEN 866 HDC SN-38 PEN866 PEN-866 STA-12-8666 STA-8666",
        "BTP-227 | PEN-221 | PEN221"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tasly Pharmaceutical Group Co., Ltd",
      "names": [
        "Tasly Pharmaceutical Group Co., Ltd"
      ],
      "HQ City": "Tianjin",
      "HQ Country": "China",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "http://www.tasly.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06238687"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Telix Pharmaceuticals",
      "names": [
        "Telix Pharmaceuticals",
        "Telix Pharmaceuticals (Innovations) Pty Limited"
      ],
      "HQ City": "Melbourne",
      "HQ Country": "Australia",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.telixpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04786847"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Teva",
      "names": [
        "Teva",
        "Teva Pharmaceuticals USA",
        "Teva Branded Pharmaceutical Products R&D, Inc"
      ],
      "HQ City": "Petah Tikva",
      "HQ Country": "Israel",
      "Founding Year": "1901",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.tevapharm.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03755804",
        "NCT00071539"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Theradex",
      "names": [
        "Theradex"
      ],
      "HQ City": "Princeton",
      "HQ Country": "United States",
      "Founding Year": "1983",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.theradex.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04203641"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Theratechnologies",
      "names": [
        "Theratechnologies"
      ],
      "HQ City": "Montreal",
      "HQ Country": "Canada",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.theratech.com/",
      "Acquisition": "-",
      "drugs": [
        "TH1902 | Sudocetaxel Zendusortide"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Ukraine",
        "Puerto Rico",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "Belgium",
        "Bahamas",
        "Portugal",
        "China",
        "Hong Kong",
        "Peru",
        "Colombia",
        "United States",
        "Norway",
        "Thailand",
        "Brazil",
        "Denmark",
        "Georgia",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Ireland",
        "Hungary",
        "New Zealand",
        "Japan",
        "Romania",
        "Germany",
        "Spain",
        "Croatia",
        "Guatemala",
        "Argentina",
        "Israel"
      ],
      "# locations": 53,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Translational Drug Development",
      "names": [
        "Translational Drug Development"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Translational Research in Oncology",
      "names": [
        "Translational Research in Oncology",
        "Translational Research in Oncology-U.S"
      ],
      "HQ City": "Omaha",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.trio-cancer.org",
      "Acquisition": "-",
      "trials": [
        "NCT06005740",
        "NCT04553770",
        "NCT05948826",
        "NCT05103683",
        "NCT05156866"
      ],
      "drugs": [
        "TORL-2-307-ADC",
        "TORL-3-600",
        "TORL-4-500",
        "TORL-1-23"
      ],
      "co-developers": [
        "TORL Biotherapeutics"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States",
        "Korea, Republic of"
      ],
      "# locations": 3,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Triphase Accelerator Corporation",
      "names": [
        "Triphase Research and Development III Corp",
        "Triphase Accelerator Corporation",
        "Catalent Pharma Solutions and Triphase Accelerator Corporation",
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience",
        "Triphase Accelerator",
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience,"
      ],
      "HQ City": "Toronto",
      "HQ Country": "Canada",
      "Founding Year": "2011",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://triphaseco.com/",
      "Acquisition": "-",
      "ttd": [
        "DQC80I"
      ],
      "trials": [
        "NCT03682796"
      ],
      "drugs": [
        "CD22-4AP"
      ],
      "co-developers": [
        "Catalent"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tubulis",
      "names": [
        "Tubulis GmbH",
        "Tubulis"
      ],
      "HQ City": "Munich",
      "HQ Country": "Germany",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Linker Developer, ADC Platform",
      "Website URL": "https://tubulis.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06303505"
      ],
      "drugs": [
        "TUB-040"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Turning Point therapeutics",
      "names": [
        "LaNova BMS (ex-China excl. Korea) Turning Point therapeutics (now part of BMS)",
        "Turning Point therapeutics"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.tptherapeutics.com/",
      "Acquisition": "Acquired by Bristol Myers Squibb in 2021",
      "drugs": [
        "LM-302 BMS-986476 TPX-4589 | TPX-4589 | BMS-986476 | LM-302"
      ],
      "co-developers": [
        "LaNova"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "UCB Pharma",
      "names": [
        "UCB Pharma",
        "UCB Pharma SA"
      ],
      "HQ City": "Brussels",
      "HQ Country": "Belgium",
      "Founding Year": "1928",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.ucb.com/",
      "Acquisition": "-",
      "trials": [
        "NCT01590966",
        "NCT00868608",
        "NCT00356408",
        "NCT01055496",
        "NCT00867087",
        "NCT01363297",
        "NCT00299494",
        "NCT01564784"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 8,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 4,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 0
    },
    {
      "heading": "UNICANCER",
      "names": [
        "UNICANCER"
      ],
      "HQ City": "Paris",
      "HQ Country": "France",
      "Founding Year": "1964",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.unicancer.fr/",
      "Acquisition": "-",
      "trials": [
        "NCT05552001",
        "NCT04132960",
        "NCT04595565"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Varian Inc",
      "names": [
        "Varian Inc"
      ],
      "HQ City": "Palo Alto",
      "HQ Country": "USA",
      "Founding Year": "1948",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.varian.com/",
      "Acquisition": "Acquired by Siemens Healthineers in 2021",
      "trials": [
        "NCT05833867"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "VelosBio",
      "names": [
        "VelosBio",
        "Merck & Co (VelosBio)"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://velosbio.com/",
      "Acquisition": "Acquired by Merck & Co. in 2020",
      "ttd": [
        "D1CG5M"
      ],
      "drugs": [
        "VLS-101 | MK-2140 | VLS-101 MK-2140 | Zilovertamab vedotin"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Veru Inc.",
      "names": [
        "Veru Inc."
      ],
      "HQ City": "Miami",
      "HQ Country": "USA",
      "Founding Year": "1996",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://verupharma.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Vincerx Pharma, Inc",
      "names": [
        "Vincerx Pharma, Inc"
      ],
      "HQ City": "Palo Alto",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://vincerx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06034275"
      ],
      "drugs": [
        "VIP943"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Visterra",
      "names": [
        "Visterra"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.visterrainc.com/",
      "Acquisition": "Acquired by Otsuka Pharmaceutical in 2018",
      "drugs": [
        "VIS705"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Vor Biopharma",
      "names": [
        "Vor Biopharma"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "USA",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.vorbio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04849910"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "WYETH",
      "names": [
        "Pfizer (Wyeth)",
        "WYETH",
        "Pfizer (Wyeth Pharmaceuticals)",
        "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc",
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "HQ City": "Madison",
      "HQ Country": "United States",
      "Founding Year": "1926",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Pfizer in 2009",
      "fda_label": [
        {
          "id": 54277,
          "description": "[\"11. DESCRIPTION Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in NS0 cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab. MYLOTARG (gemtuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder for intravenous administration. Each single-dose vial delivers 4.5 mg gemtuzumab ozogamicin. Inactive ingredients are dextran 40 (41.0 mg), sodium chloride (26.1 mg), sodium phosphate dibasic anhydrous (2.7 mg), sodium phosphate monobasic monohydrate (0.45 mg), and sucrose (69.8 mg). After reconstitution with 5 mL of Sterile Water for Injection USP, the concentration is 1 mg/mL of gemtuzumab ozogamicin with a deliverable volume of 4.5 mL (4.5 mg). Chemical Structure\"]",
          "generic_name": "[\"GEMTUZUMAB OZOGAMICIN\"]",
          "brand_name": "[\"Mylotarg\"]",
          "substance_name": "[\"GEMTUZUMAB OZOGAMICIN\"]",
          "manufacturer_name": "[\"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.\"]"
        },
        {
          "id": 222901,
          "description": "[\"11. DESCRIPTION Inotuzumab ozogamicin is a CD22-directed antibody and cytotoxic-drug conjugate (ADC) consisting of 3 components: 1) the recombinant humanized immunoglobulin class G subtype 4 (IgG4) kappa antibody inotuzumab, specific for human CD22, 2) N-acetyl-gamma-calicheamicin that causes double-stranded DNA breaks, and 3) an acid-cleavable linker composed of the condensation product of 4-(4'-acetylphenoxy)-butanoic acid (AcBut) and 3-methyl-3-mercaptobutane hydrazide (known as dimethylhydrazide) that covalently attaches N-acetyl-gamma-calicheamicin to inotuzumab. Inotuzumab ozogamicin has an approximate molecular weight of 160 kDa. The average number of calicheamicin derivative molecules conjugated to each inotuzumab molecule is approximately 6 with a distribution from 2\u20138. Inotuzumab ozogamicin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the semisynthetic calicheamicin derivative is produced by microbial fermentation followed by synthetic modification. BESPONSA (inotuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous administration. Each single-dose vial delivers 0.9 mg inotuzumab ozogamicin. Inactive ingredients are polysorbate 80 (0.36 mg), sodium chloride (2.16 mg), sucrose (180 mg), and tromethamine (8.64 mg). After reconstitution with 4 mL of Sterile Water for Injection, USP, the final concentration is 0.25 mg/mL of inotuzumab ozogamicin with a deliverable volume of 3.6 mL (0.9 mg) and a pH of approximately 8.0. Chemical Structure\"]",
          "generic_name": "[\"INOTUZUMAB OZOGAMICIN\"]",
          "brand_name": "[\"Besponsa\"]",
          "substance_name": "[\"INOTUZUMAB OZOGAMICIN\"]",
          "manufacturer_name": "[\"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.\"]"
        }
      ],
      "trials": [
        "NCT00962767",
        "NCT00037596",
        "NCT00304447",
        "NCT00044733",
        "NCT00148824",
        "NCT00717925",
        "NCT01134575",
        "NCT00037583"
      ],
      "drugs": [
        "hP67.6-calicheamicin | WAY-CMA-676 | CDP-771 | CMA-676 | Mylotarg\u00ae | Gemtuzumab ozogamicin",
        "PF-6650808 | PF06650808 | Anti-NOTCH3-ADC | Anti-NOTCH3 ADC | PF-06650808",
        "Anti-5T4 monoclonal | PF-06263507 | A1-mafodotin | PF06263507 | PF 06263507 | A1-mcMMAF",
        "RN927C | PF06664178 | PF 06664178 | PF-06664178",
        "BESPONSA\u00ae | Inotuzumab ozogamicin | CMC-544 CMC544 | CMC-544",
        "hCTMO1-calicheamicin CDP-671 | CMB-401 | hCTMO1-calicheamicin | CDP-671"
      ],
      "co-developers": [
        "Celltech",
        "Oxford BioMedica",
        "Pfizer"
      ],
      "# co-developers": 3,
      "locations": [
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "Norway",
        "China",
        "Hong Kong",
        "United States",
        "Estonia",
        "Denmark",
        "India",
        "Canada",
        "Singapore",
        "France",
        "Iceland",
        "Lithuania",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Hungary",
        "Austria",
        "New Zealand",
        "Japan",
        "Spain",
        "Germany",
        "Wales",
        "Argentina",
        "Israel",
        "Slovakia",
        "Finland"
      ],
      "# locations": 38,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 8,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 5,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Westlake Therapeutics",
      "names": [
        "Westlake Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06106152"
      ],
      "drugs": [
        "WTX212A | WTX212A injection"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Wilex",
      "names": [
        "Wilex"
      ],
      "HQ City": "Munich",
      "HQ Country": "Germany",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "HuMAB-5B1-ATAC",
        "Anti-CD19 ADC | Anti-CD19 ATAC | anti-CD19 ADC"
      ],
      "co-developers": [
        "MabVax",
        "Heidelberg Pharma"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Wisconsin Alumni Research Foundation - WARF",
      "names": [
        "Wisconsin Alumni Research Foundation - WARF",
        "Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)"
      ],
      "HQ City": "Madison",
      "HQ Country": "USA",
      "Founding Year": "1925",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.warf.org",
      "Acquisition": "-",
      "drugs": [
        "DYS-ADC | DYS-EDC | EDC1 | EDC-1",
        "EDC-CD20 | EDC9"
      ],
      "co-developers": [
        "Centrose"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Xadcera",
      "names": [
        "Xadcera"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Xenikos",
      "names": [
        "Xenikos"
      ],
      "HQ City": "Nijmegen",
      "HQ Country": "Netherlands",
      "Founding Year": "2006",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.xenikos.com",
      "Acquisition": "-",
      "drugs": [
        "Grisnilimab setaritox | WT1-RTA",
        "SPV-T3a-RTA | Dafsolimab Setaritox"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Xuanzhu Biopharm",
      "names": [
        "Xuanzhu Biopharmaceutical Co., Ltd",
        "Xuanzhu Biopharm"
      ],
      "HQ City": "-",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05804864"
      ],
      "drugs": [
        "KM501"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Y-Biologics",
      "names": [
        "Y-Biologics",
        "LegoChem Biosciences and Y-Biologics"
      ],
      "HQ City": "-",
      "HQ Country": "South Korea",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://ybiologics.com/en/",
      "Acquisition": "-",
      "drugs": [
        "AR-001 | YBK-001 | YBL-001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zai Lab (Shanghai)",
      "names": [
        "Zai Lab (Shanghai) Co., Ltd",
        "Zai Lab (Shanghai)"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2014",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.zailaboratory.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05866354"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zhejiang ACEA Pharmaceutical Co. Ltd",
      "names": [
        "Zhejiang ACEA Pharmaceutical Co. Ltd"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05565807"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zhejiang Medicine",
      "names": [
        "Zhejiang Medicine",
        "Zhejiang Medicine Co"
      ],
      "HQ City": "Shaoxing",
      "HQ Country": "China",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "API & Intermediates, Human/Animal Nutrition",
      "Website URL": "https://www.zmc.top/en/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ZielBio",
      "names": [
        "ZielBio",
        "ZielBio, Inc"
      ],
      "HQ City": "Charlottesville",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.zielbio.com",
      "Acquisition": "-",
      "drugs": [
        "ZB131-DXd | ZB131  ZB131-MMAE  ZB131-DXd | ZB131 | ZB131-MMAE"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zionexa",
      "names": [
        "Zionexa"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06195709"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zova Biotherapeutics",
      "names": [
        "Zova Biotherapeutics (Zova Bio)",
        "Zova Biotherapeutics"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "ZV05-ADC | ZV05-mcMMAF | 5T4-MMAF ADC | 5T4-MMAF ADC ZV05-mcMMAF ZV0501 | ZV0501"
      ],
      "co-developers": [
        "Concortis"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zymeworks",
      "names": [
        "Zymeworks In collaboration with BeiGene",
        "Iconic Therapeutics in collaboration with Zymeworks",
        "Zymeworks",
        "Iconic Therapeutics  in collaboration with Zymeworks"
      ],
      "HQ City": "Vancouver",
      "HQ Country": "Canada",
      "Founding Year": "2003",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.zymeworks.com",
      "Acquisition": "-",
      "ttd": [
        "DH09QZ"
      ],
      "drugs": [
        "ZW49 | ZW49 HER2 x HER2 Bispecific - | Zanidatamab Zovodotin",
        "ICON-2 Tissue Factor ADC  XB002 | XB002 ICON-2 Tissue Factor ADC"
      ],
      "co-developers": [
        "BeiGene",
        "Iconic",
        "Exelixis"
      ],
      "# co-developers": 3,
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ],
      "# locations": 10,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "bioRASI, LLC",
      "names": [
        "bioRASI, LLC"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05834296"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "company: K The Power",
      "names": [
        "company: K The Power"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT01825317"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "mobile Health AG",
      "names": [
        "mobile Health AG"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05425550"
      ],
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "pharmaand GmbH",
      "names": [
        "pharmaand GmbH"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    }
  ],
  "trials": [
    {
      "id": "NCT05174637",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "FDA018-ADC",
        "Drug: FDA018-ADC",
        "FDA018-Antibody-drug Conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "78",
        78
      ],
      "conditions": [
        "Advanced/ Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2021-10-22",
        "2021-11-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03489525",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)",
        "Dose Escalation, MEDI2228, ADC (antibody drug conjugate)",
        "Dose Expansion, MEDI2228, ADC (antibody drug conjugate)",
        "Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)"
      ],
      "locations": [
        "Greece",
        "Australia",
        "Spain",
        "United States",
        "France"
      ],
      "enrollment": [
        107,
        "107"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "Start Date": [
        "2018-03-17",
        "2018-05-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04829604",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Ambrx, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "antibody drug conjugate (ADC)",
        "ARX788"
      ],
      "locations": [
        "Australia",
        "Korea, Republic of",
        "United States",
        "France"
      ],
      "enrollment": [
        71
      ],
      "conditions": [
        "HER2 Positive Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2021-10-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05156866",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "Drug: TORL-2-307-ADC",
        "TORL-2-307-ADC"
      ],
      "locations": [
        "United States",
        "Korea, Republic of"
      ],
      "enrollment": [
        "70",
        70
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Pancreas Cancer",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": [
        "2022-02-02",
        "2021-01-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01414283",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        52,
        "52"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2011-09-08",
        "2008-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01414296",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        10,
        "10"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2011-09-08",
        "2009-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01695044",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        "119",
        119
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2012-09",
        "2012-09-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04681131",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "PD-1 inhibitor",
        "Biological: CAB-AXL-ADC",
        "BA3011",
        "CAB-AXL-ADC",
        "Biological: PD-1 inhibitor"
      ],
      "locations": [
        "Greece",
        "Spain",
        "Hong Kong",
        "Germany",
        "United States",
        "Italy",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        240,
        "240"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "Start Date": [
        "2020-08-12",
        "2021-03-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04329429",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        57,
        "57"
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": [
        "2020-03-27",
        "2020-08-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04073602",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        19,
        "19"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": [
        "2019-08-19",
        "2019-08-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04132960",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "UNICANCER"
      ],
      "collaborators": [
        "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company"
      ],
      "interventions": [
        "DS-8201a"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        186
      ],
      "conditions": [
        "Breast Tumors"
      ],
      "Start Date": [
        "2019-10-21"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02988817",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab"
      ],
      "collaborators": [],
      "interventions": [
        "Biological: Enapotamab vedotin (HuMax-AXL-ADC)",
        "Enapotamab vedotin (HuMax-AXL-ADC)"
      ],
      "locations": [
        "Belgium",
        "Spain",
        "United States",
        "Netherlands",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        "306",
        306
      ],
      "conditions": [
        "Cervical Cancer",
        "Non Small Cell Lung Cancer (NSCLC)",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Melanoma",
        "Solid Tumors",
        "Thyroid Cancer",
        "Sarcoma"
      ],
      "Start Date": [
        "2016-11-23",
        "2016-01-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03504488",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "BA3021",
        "PD-1 inhibitor",
        "Biological: CAB-ROR2-ADC",
        "CAB-ROR2-ADC",
        "Biological: PD-1 inhibitor"
      ],
      "locations": [
        "Greece",
        "Spain",
        "Hong Kong",
        "Germany",
        "United States",
        "Italy",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        420,
        "420"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma"
      ],
      "Start Date": [
        "2018-06-27",
        "2018-12-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05205850",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC118-ADC",
        "RC118 for injection",
        "RC118-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "135",
        135
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2022-03-03",
        "2021-11-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06014658",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MBrace Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: Antibody-Drug Conjugate",
        "Antibody-Drug Conjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        90,
        "90"
      ],
      "conditions": [
        "Cancer"
      ],
      "Start Date": [
        "2023-01-08",
        "2023-11-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02020135",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        9,
        "9"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2013-10",
        "2013-12-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04695847",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "EMD Serono Research & Development Institute, Inc."
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany"
      ],
      "interventions": [
        "Bispecific antibody drug conjugate (ADC)",
        "M1231"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        23
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2021-01-13"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03255070",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Ambrx, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "antibody drug conjugate (ADC)",
        "ARX788"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": [
        106
      ],
      "conditions": [
        "Solid Tumors",
        "Gastric Neoplasm",
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2018-03-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04240704",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Novartis Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "JBH492"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "Spain",
        "Singapore",
        "Germany",
        "Israel",
        "Finland"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "Start Date": [
        "2020-09-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03425279",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "CAB-AXL-ADC",
        "PD-1 inhibitor",
        "Biological: PD-1 inhibitor",
        "Biological: CAB-AXL-ADC"
      ],
      "locations": [
        "Hong Kong",
        "United States",
        "Taiwan"
      ],
      "enrollment": [
        300,
        "300"
      ],
      "conditions": [
        "Myxofibrosarcoma",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "Start Date": [
        "2018-01-22",
        "2018-02-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04064359",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Oxford BioTherapeutics Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: OBT076, a CD205-directed antibody-drug conjugate",
        "OBT076, a CD205-directed antibody-drug conjugate",
        "MEN1309"
      ],
      "locations": [
        "Greece",
        "Belgium",
        "Spain",
        "United States",
        "France"
      ],
      "enrollment": [
        200,
        "200"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2019-07-25",
        "2019-08-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02001623",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "TIVDAK",
        "Drug: Tisotumab Vedotin (HuMax-TF-ADC)",
        "Tisotumab Vedotin (HuMax-TF-ADC)"
      ],
      "locations": [
        "Belgium",
        "Sweden",
        "United States",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        "195",
        195
      ],
      "conditions": [
        "Bladder Cancer",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "Prostate Cancer (CRPC)",
        "Endometrium Cancer",
        "Esophagus Cancer",
        "Cervix Cancer",
        "Lung Cancer(NSCLC)",
        "Ovary Cancer"
      ],
      "Start Date": [
        "2013-11-30",
        "2013-11-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04617314",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC108",
        "RC108 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2021-03-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05564858",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia",
        "Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia",
        "FDA022-BB05",
        "Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib",
        "FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        107,
        "107"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2022-09-20",
        "2023-01-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06440005",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Angiex, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ADC",
        "AGX101"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Cancer",
        "Locally Advanced Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Triple Negative Breast Cancer",
        "Pancreas Cancer",
        "Metastatic Solid Tumor",
        "Advanced Cancer"
      ],
      "Start Date": [
        "2024-05"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05011188",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Rahul Aggarwal"
      ],
      "collaborators": [
        "Fortis Therapeutics, Inc."
      ],
      "interventions": [
        "XTANDI",
        "Enzalutamide",
        "anti-CD46 antibody conjugate",
        "FOR46",
        "Pegfilgrastim",
        "Antibody-Drug Conjugate (ADC)",
        "G-CSF"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2022-01-19"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05996952",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "West China Hospital"
      ],
      "collaborators": [
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "RC48-ADC",
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "77",
        77
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer"
      ],
      "Start Date": [
        "2023-03-08",
        "2023-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06234423",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "OnCusp Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "CUSP06"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        180
      ],
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumor"
      ],
      "Start Date": [
        "2024-02-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04316442",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Sorrento Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129",
        "anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        60
      ],
      "conditions": [
        "Light Chain (AL) Amyloidosis"
      ],
      "Start Date": [
        "2021-04-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04662580",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Ambrx, Inc."
      ],
      "collaborators": [
        "Johnson & Johnson"
      ],
      "interventions": [
        "ARX517"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        262
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2021-07-27"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06457997",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pheon Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "PHN-010"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        273
      ],
      "conditions": [
        "Lung Cancer",
        "Cervical Cancer",
        "Advanced Solid Tumor",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Advanced Cancer",
        "Colon Cancer"
      ],
      "Start Date": [
        "2024-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04152499",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Klus Pharma Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SKB264"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Turkey",
        "China",
        "United States"
      ],
      "enrollment": [
        1300
      ],
      "conditions": [
        "Endometrial Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Small-Cell Lung Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Urothelial Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Epithelial Ovarian Cancer",
        "Breast Cancer",
        "Gastric Adenocarcinoma"
      ],
      "Start Date": [
        "2020-02-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04400695",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: Docetaxel Injection",
        "Vinorelbine Tartrate Injection",
        "Drug: Vinorelbine Tartrate Injection",
        "Capecitabine Tablets",
        "Taxotere",
        "Taxol",
        "Drug: Capecitabine Tablets",
        "RC48-ADC",
        "Navelbine",
        "Docetaxel Injection",
        "Drug: Paclitaxel Injection",
        "Paclitaxel Injection",
        "RC48",
        "Xeloda"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "366",
        366
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2020-09-29",
        "2020-04-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05103683",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "TORL-1-23"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "Ovarian Cancer",
        "Advanced Solid Tumor",
        "NSCLC",
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2021-11-17"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05217693",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "BB-1705"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        288
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2022-06-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05308225",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Sorrento Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        72
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2023-02-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04610528",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "SOLTI Breast Cancer Research Group"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "U3 1402",
        "Patritumab Deruxtecan"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2020-12-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06198751",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "7.5 mg/kg of TQB2102 for injection",
        "6.0 mg/kg of TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        104
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2024-02-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05297552",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: JS001",
        "RC48-ADC",
        "Drug: RC48-ADC",
        "JS001"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        40,
        "40"
      ],
      "conditions": [
        "Muscle Invasive Bladder Carcinoma"
      ],
      "Start Date": [
        "2022-03-17",
        "2022-05-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04202705",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD1875"
      ],
      "locations": [
        "Belgium",
        "France"
      ],
      "enrollment": [
        31
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2020-02-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05323045",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "BYON3521"
      ],
      "locations": [
        "United Kingdom",
        "Italy",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": [
        31
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2022-03-21"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05514158",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC98",
        "Drug: RC48-ADC",
        "RC98 injection",
        "RC48-ADC injection",
        "RC48-ADC",
        "Drug: RC98"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        24,
        "24"
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": [
        "2022-09-28",
        "2022-04-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05135715",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        50,
        "50"
      ],
      "conditions": [
        "Advanced Melanoma",
        "Melanoma, Stage II",
        "HER2-positive"
      ],
      "Start Date": [
        "2021-11-15",
        "2022-04-19"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05941507",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "LigaChem Biosciences, Inc."
      ],
      "collaborators": [
        "AntibodyChem Biosciences, Inc."
      ],
      "interventions": [
        "LCB84",
        "Anti-PD-1 monoclonal antibody"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        300
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2023-10-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02874664",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Stemcentrx"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab Tesirine",
        "SC16LD6.5"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        46
      ],
      "conditions": [
        "Small Cell Lung Carcinoma"
      ],
      "Start Date": [
        "2016-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05527184",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN151"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        227
      ],
      "conditions": [
        "Primary Peritoneal Carcinoma",
        "High Grade Serous Adenocarcinoma of Ovary",
        "Fallopian Tube Cancer",
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2023-01-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02881138",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd.",
        "RemeGen"
      ],
      "collaborators": [],
      "interventions": [
        "RC48-ADC",
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        24,
        "24"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": [
        "2016-08-20",
        "2016-03-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03366428",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Experimental product",
        "DS-8201a"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        51
      ],
      "conditions": [
        "Malignant Neoplasm of Breast"
      ],
      "Start Date": [
        "2017-12-26"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02552121",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab",
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "Tisotumab vedotin (HuMax-TF-ADC)",
        "Drug: Tisotumab vedotin (HuMax-TF-ADC)"
      ],
      "locations": [
        "Belgium",
        "Hungary",
        "United States",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        33,
        "33"
      ],
      "conditions": [
        "Bladder Cancer",
        "Lung Cancer (NSCLC)",
        "Endometrium Cancer",
        "Esophagus Cancer",
        "Cervix Cancer",
        "Prostate Cancer (CRPC)",
        "Ovary Cancer"
      ],
      "Start Date": [
        "2015-11-30",
        "2015-09-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02674568",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "SC16LD6.5",
        "Rovalpituzumab tesirine"
      ],
      "locations": [],
      "enrollment": [
        342
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2016-01-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05745740",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC",
        "Pyrotinib",
        "RC48-ADC",
        "Drug: Pyrotinib",
        "DV"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        26,
        "26"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2023-02-16",
        "2024-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06210815",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Henlius Biotech"
      ],
      "collaborators": [],
      "interventions": [
        "HLX42",
        "Anti-EGFR ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        42
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2024-03-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05565807",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Zhejiang ACEA Pharmaceutical Co. Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        84
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "Start Date": [
        "2023-02-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06005740",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "TORL-4-500"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2023-12-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04965519",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        120,
        "120"
      ],
      "conditions": [
        "Gynecological Malignancy"
      ],
      "Start Date": [
        "2021-07-07",
        "2021-12-21"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02881190",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd.",
        "RemeGen"
      ],
      "collaborators": [],
      "interventions": [
        "RC48-ADC",
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        57,
        "57"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": [
        "2015-12-14",
        "2016-08-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06452706",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        42
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2024-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06431490",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        103
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": [
        "2024-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06038396",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JS001",
        "RC118 for injection",
        "Toripalimab for injection",
        "Toripalimab",
        "RC118"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        64
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2023-08-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03507166",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd.",
        "RemeGen"
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        43,
        "43"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Advanced Cancer"
      ],
      "Start Date": [
        "2017-12-28",
        "2018-08-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03556345",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "127",
        127
      ],
      "conditions": [
        "Gastric Cancer",
        "HER2 Overexpressing Gastric Carcinoma"
      ],
      "Start Date": [
        "2018-01-06",
        "2018-07-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05367635",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sichuan Kelun Pharmaceutical Research Institute Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "SKB315 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        206
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2022-03-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05460273",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "DS-1062a",
        "Datopotamab Deruxtecan (Dato-DXd)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        119
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Triple Negative Breast Cancer"
      ],
      "Start Date": [
        "2022-07-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05525286",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "SOTIO Biotech a.s."
      ],
      "collaborators": [],
      "interventions": [
        "SOT102",
        "Drug: SOT102"
      ],
      "locations": [
        "Belgium",
        "Czechia",
        "Spain",
        "United States",
        "France"
      ],
      "enrollment": [
        160,
        "160"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "Start Date": [
        "2022-03-31",
        "2021-07-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05652855",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Minghui Pharmaceutical Pty Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "MHB088C for Injection"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        48
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2023-01-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03809013",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        64,
        "64"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": [
        "2019-01-07",
        "2019-01-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01807598",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jason Robert Gotlib"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris",
        "SGN-35",
        "anti-CD30 ADC",
        "anti-CD30 antibody-drug conjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        10
      ],
      "conditions": [
        "Mast Cell Leukemia",
        "Systemic Mastocytosis",
        "Aggressive Systemic Mastocytosis"
      ],
      "Start Date": [
        "2013-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06384807",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Biohaven Therapeutics Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "BHV1510",
        "GQ1010",
        "PBI-410"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        170
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2024-04-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05320588",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "BiOneCure Therapeutics Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Pembrolizumab",
        "BIO-106",
        "Keytruda"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        332
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Oncology",
        "Cancer"
      ],
      "Start Date": [
        "2022-03-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06115642",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Henlius Biotech"
      ],
      "collaborators": [],
      "interventions": [
        "Anti-PD-L1 ADC",
        "HLX43"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2023-11-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06115902",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        150
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-11-17"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03052634",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC 2.5 mg/kg (HER2 Positive)",
        "RC48-ADC 1.5 mg/kg (HER2 Positive)",
        "Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression)",
        "RC48-ADC 2.0 mg/kg (HER2 Positive)",
        "RC48-ADC 2.5 mg/kg (HER2 Positive)",
        "Drug: RC48-ADC 1.5 mg/kg (HER2 Positive)",
        "RC48-ADC 2.0 mg/kg (HER2 Low Expression)",
        "Drug: RC48-ADC 2.0 mg/kg (HER2 Positive)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        112,
        "112"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "Start Date": [
        "2017-04-01",
        "2016-12-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02277717",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD985 (trastuzumab vc-seco-DUBA)"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": [
        185
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": [
        "2014-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03748186",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STRO-002"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": [
        160
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Ovary Cancer"
      ],
      "Start Date": [
        "2019-02-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05652868",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Mythic Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "MYTX-011"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        150
      ],
      "conditions": [
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Advanced Non-Small Cell Lung Cancer",
        "NSCLC Stage IV",
        "NSCLC Stage IIIB",
        "NSCLC",
        "Advanced Non-Small Cell Non-Squamous Lung Cancer",
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2023-03-23"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04280341",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Peking University"
      ],
      "collaborators": [
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "Biological: RC48-ADC in combinaton with JS001",
        "RC48-ADC in combinaton with JS001"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        50,
        "50"
      ],
      "conditions": [
        "HER2-Positive Solid Tumors"
      ],
      "Start Date": [
        "2020-06-03",
        "2019-12-30"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00031187",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seattle Genetics, Inc.",
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: SGN-15 (cBR96-doxorubicin immunoconjugate)",
        "Drug: Taxotere (docetaxel)",
        "Taxotere (docetaxel)",
        "SGN-15 (cBR96-doxorubicin immunoconjugate)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        160,
        "160"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "Start Date": [
        "2000-10",
        "2002-02-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03248492",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd.",
        "AstraZeneca"
      ],
      "interventions": [
        "Experimental product",
        "DS-8201a"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Japan",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        253
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2017-08-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03505710",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd.",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Experimental product",
        "DS-8201a"
      ],
      "locations": [
        "Japan",
        "Spain",
        "United States",
        "France",
        "Netherlands"
      ],
      "enrollment": [
        181
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2018-05-21"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03725761",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Wisconsin, Madison"
      ],
      "collaborators": [
        "Gilead Sciences",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        31
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2018-10-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01432275",
      "phases": [],
      "sponsor": [
        "Abbott Diabetes Care"
      ],
      "collaborators": [],
      "interventions": [
        "ADC blood glucose meter with insulin calculator active",
        "Lifescan Verio Pro or",
        "ADC blood glucose meter",
        "Roche Accu-Chek Aviva Nano",
        "Device: ADC blood glucose meter with insulin calculator active",
        "Device: Comparator blood glucose meter",
        "Abbott Freestyle InsuLinx",
        "Comparator blood glucose meter",
        "Bayer Contour USB",
        "Abbott FreeStyle InsuLinx",
        "Device: ADC blood glucose meter"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": [
        179,
        "179"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "Start Date": [
        "2011-09",
        "2011-09-09"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT06265727",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Corbus Pharmaceuticals Inc."
      ],
      "collaborators": [
        "CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd."
      ],
      "interventions": [
        "CRB-701"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "Turkey"
      ],
      "enrollment": [
        420
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "Start Date": [
        "2024-04-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06263543",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Reshma L. Mahtani, D.O."
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        75
      ],
      "conditions": [
        "Hormone-receptor-positive Breast Cancer",
        "Advanced Breast Cancer",
        "Metastatic Breast Cancer",
        "Breast Cancer",
        "Human Epidermal Growth Factor 2 Low Breast Cancer"
      ],
      "Start Date": [
        "2024-06-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06155396",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Disitamab Vedotin \uff08RC48-ADC)",
        "Disitamab Vedotin",
        "Zimberelimab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        116
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": [
        "2024-01-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05584709",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sorrento Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129",
        "Anti-CD38 antibody drug conjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        34
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2023-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00126646",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Procedure: immunotoxin therapy",
        "BL22 immunotoxin",
        "Drug: BL22 immunotoxin",
        "antibody-drug conjugate therapy",
        "immunotoxin therapy",
        "Procedure: antibody-drug conjugate therapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        24,
        "24"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "Start Date": [
        "2005-02-08",
        "2005-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05980481",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab",
        "Drug: Toripalimab",
        "Capecitabine",
        "Oxaliplatin",
        "Drug: RC48-ADC",
        "Drug: Herceptin",
        "Disitamab Vedotin",
        "Capecitabine Tablets",
        "Oxaliplatin injection",
        "JS001",
        "Drug: Oxaliplatin injection",
        "RC48-ADC",
        "Drug: Capecitabine",
        "Toripalimab",
        "Trastuzumab Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "60",
        130
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": [
        "2023-08-04",
        "2023-01-07"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05943379",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC48-ADC in Combination with gemcitabine",
        "Drug: RC48-ADC in Combination with gemcitabine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "85",
        85
      ],
      "conditions": [
        "NMIBC"
      ],
      "Start Date": [
        "2023-06-08",
        "2023-03-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04868344",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG003"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        61
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2018-05-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06224855",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hangzhou DAC Biotechnology Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized Antibody-drug conjugate",
        "DXC006"
      ],
      "locations": [],
      "enrollment": [
        110
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Hematological Malignancies"
      ],
      "Start Date": [
        "2024-01-24"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05914545",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "FZ-AD004",
        "FZ-AD004-Antibody-drug Conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        121
      ],
      "conditions": [
        "Advanced and Metastatic Solid Tumor"
      ],
      "Start Date": [
        "2023-06-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03682796",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Triphase Research and Development III Corp."
      ],
      "collaborators": [],
      "interventions": [
        "TRPH-222"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, B-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Marginal Zone",
        "Lymphoma"
      ],
      "Start Date": [
        "2018-10-15"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03368196",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a"
      ],
      "locations": [
        "Taiwan"
      ],
      "enrollment": [
        12
      ],
      "conditions": [
        "Neoplasm, Breast",
        "Adenocarcinoma, Gastric"
      ],
      "Start Date": [
        "2018-04-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03650491",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fortis Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "FOR46"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        31
      ],
      "conditions": [
        "Multiple Myeloma With Failed Remission",
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2019-04-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03575819",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fortis Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "FOR46"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        56
      ],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "Start Date": [
        "2019-02-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05866354",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Zai Lab (Shanghai) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Tisotumab Vedotin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        19
      ],
      "conditions": [
        "Solid Malignancies"
      ],
      "Start Date": [
        "2023-06-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03384940",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "DS-8201a"
      ],
      "locations": [
        "United Kingdom",
        "Japan",
        "Spain",
        "United States",
        "Italy"
      ],
      "enrollment": [
        86
      ],
      "conditions": [
        "Colorectal Neoplasm"
      ],
      "Start Date": [
        "2018-02-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05464030",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "EMD Serono Research & Development Institute, Inc."
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany"
      ],
      "interventions": [
        "Bevacizumab",
        "Capecitabine",
        "M9140"
      ],
      "locations": [
        "Spain",
        "United States",
        "Japan"
      ],
      "enrollment": [
        180
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "Start Date": [
        "2022-08-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05797168",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "AZD5305",
        "AZD5335"
      ],
      "locations": [
        "Canada",
        "Australia",
        "Israel",
        "Japan",
        "China",
        "Spain",
        "United States",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        150
      ],
      "conditions": [
        "Ovarian Cancer",
        "Lung Adenocarcinoma"
      ],
      "Start Date": [
        "2023-06-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03500380",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Capecitabine",
        "Drug: RC48-ADC",
        "Lapatinib",
        "RC48-ADC",
        "Drug: Capecitabine",
        "RC48",
        "Drug: Lapatinib"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "301",
        301
      ],
      "conditions": [
        "Capecitabine",
        "HER2-positive Advanced Breast With Liver Metastases",
        "Breast Neoplasms",
        "HER2 Positive Breast Carcinoma",
        "Breast Diseases",
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2018-04-24",
        "2018-08-04"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05302284",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: Toripalimab",
        "Drug: RC48-ADC",
        "Drug: Gemcitabine",
        "Disitamab Vedotin",
        "Drug: Cisplatin",
        "Drug: Carboplatin",
        "JS001",
        "RC48-ADC",
        "Cisplatin",
        "Toripalimab",
        "Gemcitabine",
        "Carboplatin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        452,
        "452"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "HER2-expressing"
      ],
      "Start Date": [
        "2022-03-21",
        "2022-06-14"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06105008",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Disitamab Vedotin",
        "JS001",
        "Toripalimab",
        "RC48-ADC, DV"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2024-12-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05751512",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Methotrexate Injection",
        "Cetuximab injection",
        "MRG003"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        180
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "Start Date": [
        "2023-03"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04965766",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gustave Roussy, Cancer Campus, Grand Paris"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "HER3-DXd",
        "U3-1402"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        170
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2021-05-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03602079",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Klus Pharma Inc."
      ],
      "collaborators": [],
      "interventions": [
        "A166"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        49
      ],
      "conditions": [
        "Cervical Cancer",
        "Mucoepidermoid Carcinoma",
        "Mucinous Breast Cancer Recurrent",
        "Rectal Cancer",
        "Rectal Cancer Stage III",
        "Mucinous Adenocarcinoma Gastric",
        "Salivary Gland Neoplasms",
        "Pancreatic Cancer",
        "Lung Cancer",
        "Rectal Cancer Stage I",
        "Larynx Cancer",
        "Primary Peritoneal Carcinoma",
        "Cholangiocarcinoma",
        "Recurrent Colon Cancer",
        "Mouth Cancer",
        "HER2 Gene Mutation",
        "HER2 Positive Gastric Cancer",
        "Salivary Gland Cancer",
        "Solid Tumor",
        "Head and Neck Cancer",
        "HER2-positive Breast Cancer",
        "Bladder Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Ovarian Carcinoma",
        "Rare Diseases",
        "Recurrent Gastric Cancer",
        "Urologic Cancer",
        "Breast Neoplasm Malignant Primary",
        "Head and Neck Carcinoma",
        "Salivary Gland Tumor",
        "Tongue Cancer",
        "Palate Cancer",
        "Skin Cancer",
        "Salivary Gland Carcinoma",
        "HER-2 Gene Amplification",
        "Recurrent Breast Cancer",
        "Colo-rectal Cancer",
        "Liver Cancer",
        "Lip Cancer Stage I",
        "Rectal Cancer Stage II",
        "Recurrent Prostate Cancer",
        "Bile Duct Cancer",
        "Tonsil Cancer",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2018-07-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04925284",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Exelixis"
      ],
      "collaborators": [],
      "interventions": [
        "Nivolumab",
        "XB002"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ],
      "enrollment": [
        573
      ],
      "conditions": [
        "Cervical Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "SCCHN",
        "Endometrial Cancer",
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Epithelial Ovarian Cancer",
        "Tissue Factor-Expressing Solid Tumors",
        "Esophageal SCC",
        "Pancreatic Cancer"
      ],
      "Start Date": [
        "2021-06-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06238479",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [
        "Loxo Oncology, Inc."
      ],
      "interventions": [
        "LY4101174"
      ],
      "locations": [
        "Australia",
        "United States",
        "Japan"
      ],
      "enrollment": [
        280
      ],
      "conditions": [
        "Cervical Cancer",
        "Bladder Cancer",
        "Advanced Solid Tumor",
        "Non-small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Esophageal Cancer",
        "Recurrent Solid Tumor",
        "Metastatic Solid Tumor",
        "Renal Pelvis Cancer",
        "Pancreatic Cancer",
        "Urinary Bladder Neoplasm",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2024-03-05"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01497821",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Amgen"
      ],
      "collaborators": [],
      "interventions": [
        "AMG 172"
      ],
      "locations": [
        "Germany",
        "United States",
        "France"
      ],
      "enrollment": [
        37
      ],
      "conditions": [
        "Renal Cell Adenocarcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Clear Cell Renal Carcinoma"
      ],
      "Start Date": [
        "2012-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03734029",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd.",
        "AstraZeneca"
      ],
      "interventions": [
        "Nab-paclitaxel",
        "Capecitabine",
        "Paclitaxel",
        "Drug: Trastuzumab deruxtecan (DS-8201a)",
        "Eribulin",
        "Drug: Gemcitabine",
        "Drug: Eribulin",
        "Drug: Nab-paclitaxel",
        "Trastuzumab deruxtecan (DS-8201a)",
        "Drug: Capecitabine",
        "DS-8201a",
        "Drug: Paclitaxel",
        "Gemcitabine"
      ],
      "locations": [
        "Sweden",
        "Switzerland",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Canada",
        "France",
        "Italy",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Israel"
      ],
      "enrollment": [
        "557",
        557
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2018-06-11",
        "2018-12-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04924699",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab Emtansine for Injection",
        "MRG002"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        350
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer"
      ],
      "Start Date": [
        "2021-06-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06224673",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Laura Huppert, MD, BA"
      ],
      "collaborators": [
        "Ambrx, Inc."
      ],
      "interventions": [
        "Biospecimen Collection",
        "Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788",
        "Antibody-drug Conjugate ARX788",
        "ARX788",
        "Computed Tomography (CT)",
        "Anvatabart Opadotin",
        "Biological Sample Collection",
        "PET/CT",
        "CT Scan",
        "Specimen Collection"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "HER2 Low Breast Carcinoma",
        "Hormone-receptor-positive Breast Cancer"
      ],
      "Start Date": [
        "2024-07-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03677596",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "inotuzumab ozogamicin-dose level 2",
        "Inotuzumab ozogamicin-dose level 1",
        "Besponsa"
      ],
      "locations": [
        "Hungary",
        "Turkey",
        "Spain",
        "Singapore",
        "United States",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        102
      ],
      "conditions": [
        "Precursor b-Cell Lymphoblastic Leukemia-Lymphoma",
        "ACUTE LYMPHOBLASTIC LEUKEMIA",
        "Leukemia"
      ],
      "Start Date": [
        "2019-07-01"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT05126719",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Capecitabine tablets",
        "MRG003",
        "Docetaxel injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        238
      ],
      "conditions": [
        "Recurrent or Metastatic Nasopharyngeal Carcinoma"
      ],
      "Start Date": [
        "2021-08-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04838964",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG003"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Advanced or Metastatic Biliary Tract Cancer"
      ],
      "Start Date": [
        "2021-04-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06048718",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "DS-8021a, ENHERTU",
        "Trastuzumab-Deruxtecan (T-DXd)"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        27
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Breast Cancer"
      ],
      "Start Date": [
        "2024-06-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04843709",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG004A"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "enrollment": [
        181
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2021-07-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05688605",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG003+HX008"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2022-06-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04742153",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG002"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        66
      ],
      "conditions": [
        "Advanced or Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2021-05-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05293496",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MacroGenics"
      ],
      "collaborators": [],
      "interventions": [
        "MGD019",
        "vobramitamab duocarmazine",
        "lorigerlimab",
        "MGC018"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        278
      ],
      "conditions": [
        "Hepatocellular Cancer",
        "Malignant Melanoma",
        "Advanced Solid Tumor",
        "Renal Cell Carcinoma",
        "Castration-Resistant Prostatic Cancer",
        "Epithelial Ovarian Cancer",
        "Pancreatic Ductal Carcinoma"
      ],
      "Start Date": [
        "2022-04-19"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04940325",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gustave Roussy, Cancer Campus, Grand Paris"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "DS-1062a"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        100
      ],
      "conditions": [
        "Metastatic Lung Cancer"
      ],
      "Start Date": [
        "2021-05-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04235101",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD985 + Niraparib",
        "(vic-)trastuzumab duocarmazine + Zejula"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2020-06-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02564900",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a (DP1)",
        "DS-8201a (DP)",
        "DS-8201a (DP2)"
      ],
      "locations": [
        "United States",
        "Japan"
      ],
      "enrollment": [
        292
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2015-09-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04714190",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: Irinotecan Hydrochloride Injection",
        "Aitan",
        "Apatinib Mesylate Tablets",
        "Taxol",
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "RC48-ADC",
        "CAMPTO",
        "Drug: Paclitaxel injection",
        "Irinotecan Hydrochloride Injection",
        "Paclitaxel injection",
        "Drug: Apatinib Mesylate Tablets"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "351",
        351
      ],
      "conditions": [
        "Gastric Cancer",
        "HER2 Overexpressing Gastric Carcinoma"
      ],
      "Start Date": [
        "2021-03-24",
        "2021-01-15"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04300556",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Eisai Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "Dexamethasone",
        "Prednisolone",
        "MORAb-202",
        "Prednisone",
        "Farletuzumab ecteribulin"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "France"
      ],
      "enrollment": [
        142
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2020-08-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01439152",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY94-9343 (2.2 mg/kg)",
        "BAY94-9343",
        "BAY94-9343 (Expansion)",
        "BAY94-9343 (1.8 mg/kg)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        148
      ],
      "conditions": [
        "Oncology"
      ],
      "Start Date": [
        "2011-09-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05338957",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG002+HX008"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Advanced Malignant Solid Tumors"
      ],
      "Start Date": [
        "2022-08-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05872295",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Iksuda Therapeutics Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "IKS014"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        165
      ],
      "conditions": [
        "Gastric Cancer",
        "Gastroesophageal-junction Cancer",
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-09-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05754853",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Gemcitabine Hydrochloride for Injection",
        "Pemetrexed Disodium Injection",
        "Docetaxel Injection",
        "Paclitaxel Injection",
        "MRG002"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        290
      ],
      "conditions": [
        "Advanced or Metastatic Urothelium Cancer"
      ],
      "Start Date": [
        "2023-04-06"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04311034",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC48"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        37
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2018-09-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05865990",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "HER3-DXd",
        "Patritumab deruxtecan"
      ],
      "locations": [
        "Spain",
        "Austria"
      ],
      "enrollment": [
        60
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2023-11-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05950945",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab Deruxtecan",
        "T-DXd",
        "DS-8201a (trastuzumab derextecan)",
        "Enhertu\u00ae"
      ],
      "locations": [
        "Brazil",
        "United States"
      ],
      "enrollment": [
        250
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-12-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05280470",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "DS-7300a",
        "Ifinatamab Deruxtecan (I-DXd)"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "China",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Taiwan"
      ],
      "enrollment": [
        187
      ],
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "Start Date": [
        "2022-03-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05276609",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Hansoh Biomedical Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20093 (Phase Ib: Dose expansion)",
        "HS-20093 (Phase Ia: Dose escalation)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        177
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2021-11-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05800366",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jennifer Crombie, MD"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Rituximab",
        "Cyclophosphamide",
        "Glofitamab",
        "Doxorubicin Hydrochloride",
        "Polatuzumab",
        "Hydroxydaunomycin",
        "Cytophosphane, Cytoxan",
        "Polatuzumab vedotin, DCDS4501S, RG7596",
        "RO7082859",
        "Rituxan",
        "Prednisone",
        "Prednisolone, Methylprednisolone"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        40
      ],
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma"
      ],
      "Start Date": [
        "2023-04-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06465069",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [
        "Loxo Oncology, Inc."
      ],
      "interventions": [
        "LY4052031"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        220
      ],
      "conditions": [
        "Cervical Cancer",
        "Bladder Cancer",
        "Advanced Solid Tumor",
        "Non-small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Esophageal Cancer",
        "Recurrent Solid Tumor",
        "Metastatic Solid Tumor",
        "Renal Pelvis Cancer",
        "Pancreatic Cancer",
        "Urinary Bladder Neoplasm",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2024-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04887870",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Mirati Therapeutics Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Pembrolizumab",
        "Sitravatinib",
        "Nivolumab",
        "OPDIVO",
        "KEYTRUDA",
        "PADCEV",
        "Ipilimumab",
        "Enfortumab Vedotin-Ejfv",
        "YERVOY",
        "MGCD516"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        55
      ],
      "conditions": [
        "Advanced or Metastatic Solid Malignancies"
      ],
      "Start Date": [
        "2021-06-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03894150",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: F0002-ADC",
        "F0002-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "45",
        45
      ],
      "conditions": [
        "Refractory or Recurrent CD30+ Hematologic Malignancies"
      ],
      "Start Date": [
        "2019-03-26",
        "2019-04-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05748171",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "ALLR3",
        "R3",
        "Inotuzumab ozogamicin",
        "Besponsa"
      ],
      "locations": [
        "Greece",
        "Belgium",
        "Israel",
        "Austria",
        "Sweden",
        "Hungary",
        "Czechia",
        "Norway",
        "Spain",
        "Switzerland",
        "Germany",
        "Netherlands",
        "France",
        "Italy",
        "Denmark",
        "Poland",
        "Slovakia",
        "Finland"
      ],
      "enrollment": [
        100
      ],
      "conditions": [
        "ACUTE LYMPHOBLASTIC LEUKEMIA"
      ],
      "Start Date": [
        "2023-05-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04410224",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Kirilys Therapeutics Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ASN004"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        19
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2022-04-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03383692",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Ritonavir",
        "Itraconazole",
        "Norvir",
        "DS-8201a",
        "Sporanox",
        "Orungal"
      ],
      "locations": [
        "Korea, Republic of",
        "Taiwan",
        "Japan"
      ],
      "enrollment": [
        40
      ],
      "conditions": [
        "Neoplasm Metastasis"
      ],
      "Start Date": [
        "2018-01-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06112704",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20093"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        220
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-02-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02565758",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "ABBV-085"
      ],
      "locations": [
        "Spain",
        "United States",
        "France"
      ],
      "enrollment": [
        85
      ],
      "conditions": [
        "Undifferentiated Pleomorphic Sarcoma",
        "Carcinoma of the Breast",
        "Advanced Solid Tumors",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "Start Date": [
        "2015-09-18"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00052000",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MLN2704 (DM1 conjugated monoclonal antibody MLN591)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        29
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2002-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00070837",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MLN2704 (DM1 conjugated monoclonal antibody MLN591)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        46
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "Start Date": [
        "2003-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04042701",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca UK Limited",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Trastuzumab deruxtecan (DS-8201a)"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "France"
      ],
      "enrollment": [
        115
      ],
      "conditions": [
        "Non-small Cell Lung Carcinoma",
        "Breast Cancer"
      ],
      "Start Date": [
        "2020-02-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05410418",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Washington University School of Medicine"
      ],
      "collaborators": [
        "Institute for Follicular Lymphoma",
        "Genentech, Inc."
      ],
      "interventions": [
        "RO7030816",
        "Mosunetuzumab",
        "RO5541077",
        "DCDS4501A",
        "BTCT4465A",
        "Polatuzumab vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        34
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Lymphoma, Follicular"
      ],
      "Start Date": [
        "2022-10-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00258856",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "Menactra\u00ae",
        "Polysaccharide Diphtheria Conjugate Vaccine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        234
      ],
      "conditions": [
        "Meningococcal Infection",
        "Meningitis"
      ],
      "Start Date": [
        "2006-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06203210",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Topotecan",
        "Lurbinectedin",
        "Amrubicin",
        "I-DXd",
        "Ifinatamab deruxtecan"
      ],
      "locations": [
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "Japan",
        "Germany",
        "Spain"
      ],
      "enrollment": [
        468
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2024-05-21"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04142242",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "MenQuadfi",
        "Blood sample",
        "Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine",
        "MenACYW Conjugate vaccine"
      ],
      "locations": [
        "United States",
        "Puerto Rico"
      ],
      "enrollment": [
        471
      ],
      "conditions": [
        "Meningococcal Infection (Healthy Volunteers)"
      ],
      "Start Date": [
        "2019-10-04"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01856933",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Heinrich Elinzano, MD"
      ],
      "collaborators": [
        "Rhode Island Hospital",
        "Progenics Pharmaceuticals, Inc.",
        "University of Texas"
      ],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        "6",
        6
      ],
      "conditions": [
        "GBM",
        "Gliosarcoma",
        "Glioblastoma Multiforme"
      ],
      "Start Date": [
        "2013-08-01",
        "2013-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03953833",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Pharmaceuticals Holding Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003."
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2019-04-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05887609",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Colorado, Denver"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Mirvetuximab Soravtansine",
        "Olaparib",
        "IMGN853",
        "MIRV"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        53
      ],
      "conditions": [
        "Peritoneal Cancer",
        "Fallopian Tube Cancer",
        "Ovary Cancer"
      ],
      "Start Date": [
        "2023-10-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06132958",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [
        "European Network for Gynaecological Oncological Trial groups(ENGOT)",
        "GOG Foundation"
      ],
      "interventions": [
        "Doxorubicin",
        "TAXOL\u00ae",
        "Paclitaxel",
        "Sacituzumab tirumotecan",
        "ADRIAMYCIN\u00ae",
        "SKB264 MK-2870"
      ],
      "locations": [
        "Puerto Rico",
        "Sweden",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Malaysia",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Japan",
        "Spain",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "enrollment": [
        710
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2023-12-06"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05755048",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)",
        "Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        314
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-03-28"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06244485",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [],
      "interventions": [
        "Valemetostat tosylate",
        "T-DXd",
        "DS-8201a",
        "DS-1062a",
        "Dato-DXd",
        "DS-3201b",
        "ENHERTU"
      ],
      "locations": [
        "United States",
        "Japan"
      ],
      "enrollment": [
        210
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-02-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04205630",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD985",
        "(vic-)trastuzumab duocarmazine",
        "Trastuzumab vc-seco-DUBA"
      ],
      "locations": [
        "Ukraine",
        "Russian Federation",
        "Korea, Republic of",
        "Serbia",
        "Singapore",
        "United States",
        "Poland"
      ],
      "enrollment": [
        64
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2020-05-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00071955",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genitope Corporation"
      ],
      "collaborators": [],
      "interventions": [
        "sargramostim",
        "autologous immunoglobulin idiotype-KLH conjugate vaccine"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        null
      ],
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": [
        "2003-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01577758",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MLN0264"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        41
      ],
      "conditions": [
        "Advanced Gastrointestinal Malignancies"
      ],
      "Start Date": [
        "2012-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03529110",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd.",
        "AstraZeneca"
      ],
      "interventions": [
        "Ado-trastuzumab emtansine (T-DM1)",
        "Drug: Trastuzumab deruxtecan (T-DXd)",
        "Drug: Ado-trastuzumab emtansine (T-DM1)",
        "T-DM1",
        "Trastuzumab deruxtecan (T-DXd)",
        "DS-8201a"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Italy",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "China",
        "Hong Kong",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        "524",
        524
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2018-04-13",
        "2018-08-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04175847",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC88",
        "RC88 for Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        200
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2020-04-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00856297",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Novartis Vaccines"
      ],
      "collaborators": [
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Licensed comparator",
        "MenACWY-CRM conjugate vaccine",
        "Quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        389
      ],
      "conditions": [
        "Meningococcal Meningitis"
      ],
      "Start Date": [
        "2009-02"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01396070",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Youn Kim"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris",
        "SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Cutaneous T-cell Lymphoma (CTCL)",
        "Sezary Syndrome",
        "Non-Hodgkin Lymphoma (NHL)",
        "Mycosis Fungoides",
        "Cutaneous Lymphoma"
      ],
      "Start Date": [
        "2011-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04878029",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Emory University"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)",
        "Exelixis"
      ],
      "interventions": [
        "Cabozantinib S-malate",
        "XL184",
        "Anti-Nectin 4 ADC ASG-22CE",
        "AGS 22ME",
        "BMS-907351",
        "Cometriq",
        "XL-184",
        "AGS-22M6E",
        "ASG-22CE",
        "Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E",
        "Enfortumab Vedotin",
        "Quality-of-Life Assessment",
        "Padcev",
        "Quality of Life Assessment",
        "Questionnaire Administration",
        "Cabometyx",
        "Enfortumab Vedotin-ejfv"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Unresectable Urothelial Carcinoma",
        "Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma"
      ],
      "Start Date": [
        "2021-07-23"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01631552",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Sacituzumab Govitecan-hziy (SG)",
        "hRS7-SN38",
        "IMMU-132"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        515
      ],
      "conditions": [
        "Cervical Cancer",
        "Hepatocellular Carcinoma",
        "Non-small Cell Lung Cancer",
        "Glioblastoma Multiforme",
        "Ovarian Epithelial Cancer",
        "Urinary Bladder Neoplasms",
        "Endometrial Cancer",
        "Triple Negative Breast Cancer",
        "Esophageal Cancer",
        "Head and Neck Cancers- Squamous Cell",
        "Renal Cell Cancer",
        "Hormone-refractory Prostate Cancer",
        "Gastric Adenocarcinoma",
        "Pancreatic Cancer",
        "Small Cell Lung Cancer",
        "Carcinoma Breast Stage IV"
      ],
      "Start Date": [
        "2012-12-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03424603",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STRO-001"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "B Cells--Tumors",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Indolent Lymphoma",
        "Multiple Myeloma",
        "Non Hodgkin Lymphoma",
        "B-cell Lymphoma"
      ],
      "Start Date": [
        "2018-02-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06107686",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL202 should be intravenously infused"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        200
      ],
      "conditions": [
        "HNSCC",
        "NSCLC",
        "Breast Cancer",
        "Locally Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2023-12-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06057922",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL201 for Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        640
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2023-09-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05991388",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "University of Birmingham"
      ],
      "collaborators": [
        "ADC Therapeutics SA",
        "Cancer Research UK",
        "Regeneron Pharmaceuticals",
        "Fight Kids Cancer"
      ],
      "interventions": [
        "REGN-1979",
        "Etoposide Phosphate",
        "Rituximab",
        "Dexamethasone",
        "Odronextamab",
        "Ifosfamide",
        "Etoposide",
        "Loncastuximab tesirine",
        "ADCT-402",
        "CAR T-cells (TBC)",
        "Carboplatin"
      ],
      "locations": [],
      "enrollment": [
        210
      ],
      "conditions": [
        "B-cell Non Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2024-05"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05434234",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL201"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "enrollment": [
        196
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2022-05-25"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00148824",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "French National Agency for Research on AIDS and Viral Hepatitis"
      ],
      "collaborators": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "interventions": [
        "7-valent pneumococcal conjugate vaccine (vaccine)",
        "23-valent pneumococcal conjugate vaccine (vaccine)"
      ],
      "locations": [],
      "enrollment": [
        212
      ],
      "conditions": [
        "HIV Infections"
      ],
      "Start Date": [
        "2003-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04494425",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo"
      ],
      "interventions": [
        "Capecitabine",
        "DS-8201a; T-DXd",
        "Paclitaxel",
        "Trastuzumab deruxtecan",
        "Nab-Paclitaxel"
      ],
      "locations": [
        "Sweden",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "India",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        866
      ],
      "conditions": [
        "Advanced or Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2020-07-24"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04622774",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "MacroGenics"
      ],
      "interventions": [
        "IMGC936"
      ],
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ],
      "enrollment": [
        56
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2020-10-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02952729",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Mersana Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "XMT-1522"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        120
      ],
      "conditions": [
        "Advanced Gastric Cancer",
        "Advanced Nonsmall Cell Lung Cancer",
        "Advanced Breast Cancer"
      ],
      "Start Date": [
        "2016-11-21"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03386513",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN632"
      ],
      "locations": [
        "United Kingdom",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        179
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Myeloproliferative Neoplasm"
      ],
      "Start Date": [
        "2018-01-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02567851",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Birmingham"
      ],
      "collaborators": [
        "Leukaemia Lymphoma Research",
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Adcetris",
        "Brentuximab Vedotin"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": [
        38
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": [
        "2014-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05143229",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Kansas Medical Center"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Novartis Pharmaceuticals"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan",
        "Piqray",
        "Alpelisib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2022-03-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01026038",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "13-valent pneumococcal conjugate vaccine"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        263
      ],
      "conditions": [
        "13-valent Pneumococcal Vaccine",
        "Safety",
        "Immunization",
        "Antibody Response"
      ],
      "Start Date": [
        "2010-04"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT00743652",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "13-valent Pneumococcal Conjugate Vaccine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        373
      ],
      "conditions": [
        "13-valent Pneumococcal Vaccine",
        "Pneumococcal Disease"
      ],
      "Start Date": [
        "2009-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04587687",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Joseph Tuscano"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)",
        "Seagen Inc."
      ],
      "interventions": [
        "Anti-CD30 Monoclonal Antibody-MMAE SGN-35",
        "Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35",
        "Anti-CD30 Antibody-Drug Conjugate SGN-35",
        "Bendamustin Hydrochloride",
        "Bendamustine Hydrochloride",
        "Cytostasan Hydrochloride",
        "Treanda",
        "Adcetris",
        "SGN-35",
        "Brentuximab Vedotin",
        "Levact",
        "Ribomustin",
        "SyB L-0501",
        "ADC SGN-35",
        "Bendeka",
        "cAC10-vcMMAE"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        23
      ],
      "conditions": [
        "Recurrent Follicular Lymphoma",
        "Refractory Follicular Lymphoma"
      ],
      "Start Date": [
        "2020-12-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05200364",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Bevacizumab",
        "STRO-002",
        "Avastin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        58
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Ovarian Cancer",
        "Ovary Cancer"
      ],
      "Start Date": [
        "2022-03-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03316638",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Pierre Fabre Medicament"
      ],
      "collaborators": [],
      "interventions": [
        "Dose escalation Phase",
        "Expansion Phase",
        "W0101 - Cohort A2",
        "W0101 - Expansion Phase",
        "W0101 - Cohort A1"
      ],
      "locations": [
        "Spain",
        "France"
      ],
      "enrollment": [
        316
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2017-11-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06235216",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Grupo Espanol de Tumores Neuroendocrinos"
      ],
      "collaborators": [
        "Gilead Sciences",
        "MFAR"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        42
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Differentiated Thyroid Cancer"
      ],
      "Start Date": [
        "2024-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05613088",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Eisai Inc."
      ],
      "interventions": [
        "Topotecan",
        "Paclitaxel",
        "BMS-986445",
        "Farletuzumab Ecteribulin",
        "Caelyx",
        "MORAb-202",
        "Hycamtin",
        "Bendalis",
        "Pegylated Liposomal Doxorubicin (PLD)"
      ],
      "locations": [
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Israel",
        "Japan",
        "Spain",
        "United States",
        "Italy",
        "Chile"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "Neoplasms, Ovarian"
      ],
      "Start Date": [
        "2023-02-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04036461",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Celgene"
      ],
      "collaborators": [],
      "interventions": [
        "BMS-986405",
        "GSI (Gamma secretase inhibitor)",
        "CC-99712"
      ],
      "locations": [
        "Canada",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        160
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2019-08-26"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01847781",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Karolinska University Hospital"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Prevenar13"
      ],
      "locations": [
        "Sweden"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "IgG Deficiency"
      ],
      "Start Date": [
        "2013-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05405621",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bio-Thera Solutions"
      ],
      "collaborators": [],
      "interventions": [
        "BAT8009 for Injection",
        "Recombinant Humanized Anti-B7H3 Monoclonal Antibody-Exatecan Conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        48
      ],
      "conditions": [
        "Locally Advanced/Metastatic Solid Tumours"
      ],
      "Start Date": [
        "2022-08-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06188559",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Eisai Inc."
      ],
      "collaborators": [
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd"
      ],
      "interventions": [
        "BB-1701"
      ],
      "locations": [
        "United States",
        "Japan"
      ],
      "enrollment": [
        135
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2024-04-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05629585",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "SWOG Clinical Trials Partnerships",
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "Capecitabine",
        "Durvalumab",
        "XELODA\u00ae, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord",
        "MEDI4736",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "KEYTRUDA\u00ae",
        "Dato-DXd"
      ],
      "locations": [
        "Canada",
        "Greece",
        "United Kingdom",
        "Puerto Rico",
        "Belgium",
        "Korea, Republic of",
        "Sweden",
        "Japan",
        "China",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "Italy",
        "Denmark",
        "Taiwan"
      ],
      "enrollment": [
        1075
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2022-11-28"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03281824",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alteogen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ALT-P7 (HM2-MMAE)"
      ],
      "locations": [
        "Korea, Republic of"
      ],
      "enrollment": [
        27
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2018-01-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01475006",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Amgen"
      ],
      "collaborators": [],
      "interventions": [
        "AMG 595"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Advanced Malignant Glioma",
        "Anaplastic Astrocytomas"
      ],
      "Start Date": [
        "2012-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05838521",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": [
        "2023-06-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04647916",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "SWOG Cancer Research Network"
      ],
      "collaborators": [
        "Gilead Sciences",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab Govitecan-hziy",
        "RS7-SN38",
        "hRS7-SN38 Antibody Drug Conjugate",
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        44
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Metastatic HER2 Negative Breast Carcinoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Invasive Breast Carcinoma"
      ],
      "Start Date": [
        "2021-06-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05980416",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Elevation Oncology"
      ],
      "collaborators": [],
      "interventions": [
        "EO-3021"
      ],
      "locations": [
        "United States",
        "Japan"
      ],
      "enrollment": [
        120
      ],
      "conditions": [
        "Neoplasms by Site",
        "Neoplasms",
        "Gastrointestinal Neoplasms",
        "Stomach Neoplasm",
        "Digestive System Neoplasm",
        "Pancreas Neoplasm"
      ],
      "Start Date": [
        "2023-08-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04982224",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Regeneron Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "REGN5093-M114",
        "Cemiplimab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        237
      ],
      "conditions": [
        "Advanced NSCLC"
      ],
      "Start Date": [
        "2021-11-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04644068",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel",
        "AZD5305",
        "T- Dxd",
        "Camizestrant",
        "Dato-DXd",
        "Carboplatin"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Japan",
        "Czechia",
        "China",
        "Spain",
        "United States",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        804
      ],
      "conditions": [
        "Cervical Cancer",
        "Bladder Cancer",
        "Non-small Cell Lung Cancer",
        "Ovarian Cancer",
        "Additional Indications Below for Module 4 and 5",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Endometrial Cancer",
        "Small Cell Lung Cancer Only in Module 5",
        "Breast Cancer",
        "Biliary Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2020-11-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05940896",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Disitamab vedotin",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2023-06-29"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04251416",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Endometrial Carcinoma"
      ],
      "Start Date": [
        "2020-03-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04039230",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Talazoparib",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        75
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2019-10-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04450732",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "GQ1001"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "enrollment": [
        96
      ],
      "conditions": [
        "HER2-Positive Advanced Solid Tumor",
        "HER2-Positive Salivary Gland Carcinomas",
        "HER2-positive Biliary Tract Cancer",
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2020-07-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05948826",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "TORL-3-600"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Colorectal Cancer"
      ],
      "Start Date": [
        "2023-09-29"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01270698",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "hMN14-SN38",
        "IMMU-130"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        26
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "Start Date": [
        "2011-05"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02529553",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [],
      "interventions": [
        "LY3076226"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "Start Date": [
        "2015-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04278144",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Bolt Biotherapeutics, Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "BDC-1001",
        "Nivolumab",
        "Opdivo"
      ],
      "locations": [
        "Korea, Republic of",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        390
      ],
      "conditions": [
        "HER2-positive Colorectal Cancer",
        "HER2-positive Solid Tumors",
        "HER2-positive Endometrial Cancer",
        "HER2-positive Gastroesophageal Cancer",
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2020-02-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05399654",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Tallac Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "TAC-001"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": [
        200
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2022-06-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06154343",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "GQ1005"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        150
      ],
      "conditions": [
        "HER2 Expressing or Mutated Advanced Malignant Solid Tumors"
      ],
      "Start Date": [
        "2022-11-23"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05489211",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Folinic acid",
        "Capecitabine",
        "Prednisolone",
        "Adrucil",
        "MEDI4736",
        "Bevacizumab",
        "Volrustomig",
        "AZD5305",
        "5-Fluorouracil",
        "MEDI5752",
        "DS-1062a",
        "Prednisone/ prednisolone",
        "Avastin",
        "AZD2936",
        "Paraplatin",
        "Saruparib",
        "Carboplatin",
        "IMFINZI",
        "Datopotamab deruxtecan (Dato-DXd)",
        "Leucovorin LV",
        "Durvalumab",
        "Rilvegostomig",
        "Xeloda"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Korea, Republic of",
        "Japan",
        "Turkey",
        "China",
        "Spain",
        "Switzerland",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        531
      ],
      "conditions": [
        "Ovarian Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Endometrial Cancer",
        "Urothelial Cancer",
        "Biliary Tract Cancer"
      ],
      "Start Date": [
        "2022-09-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06238687",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Tasly Pharmaceutical Group Co., Ltd"
      ],
      "collaborators": [
        "Sutro Biopharma, Inc."
      ],
      "interventions": [
        "STRO-002"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        132
      ],
      "conditions": [
        "Neoplasm Malignant"
      ],
      "Start Date": [
        "2023-11-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06373406",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Minghui Pharmaceutical (Hangzhou) Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "MHB036C"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        200
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2023-05-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06036121",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Adcentrx Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "ADRX-0706"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        114
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": [
        "2023-09-26"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03159117",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "GD3 ADC",
        "PF-06688992"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        7
      ],
      "conditions": [
        "Melanoma"
      ],
      "Start Date": [
        "2017-05-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04538742",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited"
      ],
      "interventions": [
        "Paclitaxel",
        "Durvalumab",
        "Trastuzumab deruxtecan",
        "MEDI4736",
        "Tucatinib",
        "Pertuzumab",
        "DS-8201a, T-DXd",
        "ONT-380"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Turkey",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "Italy",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        245
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2020-12-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06106152",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Second Affiliated Hospital, School of Medicine, Zhejiang University"
      ],
      "collaborators": [
        "Westlake Therapeutics"
      ],
      "interventions": [
        "autologous red blood cell PD-1 inhibitor conjugate",
        "PD -1/PD-L1 monoclonal antibody",
        "WTX212A injection",
        "PD -1/PD-L1antibody"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Advanced Lung Cancer"
      ],
      "Start Date": [
        "2023-12-05"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03260491",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [],
      "interventions": [
        "HER3-DXd (CTM-3 Lyo-DP)",
        "HER3-DXd (FL-DP)",
        "HER3-DXd (CTM-1 Lyo-DP)"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "Spain",
        "United States",
        "Netherlands",
        "Taiwan"
      ],
      "enrollment": [
        309
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "Start Date": [
        "2017-10-30"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06480240",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "OBI Pharma, Inc"
      ],
      "collaborators": [],
      "interventions": [
        "OBI-992"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        117
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-06-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06413615",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "FDA022-BB05"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        150
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-05-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02606305",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Pembrolizumab",
        "Mirvetuximab soravtansine",
        "Pegylated Liposomal Doxorubicin",
        "Bevacizumab",
        "IMGN853",
        "Carboplatin"
      ],
      "locations": [
        "Spain",
        "Canada",
        "United States",
        "Belgium"
      ],
      "enrollment": [
        264
      ],
      "conditions": [
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2016-03-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06362252",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Atezolizumab",
        "Etoposide",
        "I-DXd",
        "Ifinatamab deruxtecan",
        "Carboplatin"
      ],
      "locations": [],
      "enrollment": [
        149
      ],
      "conditions": [
        "Extensive Stage-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2024-06-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04434040",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Stand Up To Cancer",
        "Genentech, Inc."
      ],
      "interventions": [
        "Trodelvy, IMMU-132",
        "Sacituzumab govitecan",
        "Tecentriq",
        "Atezolizumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        40
      ],
      "conditions": [
        "Residual Cancer",
        "Triple Negative Breast Cancer",
        "Circulating Tumor DNA",
        "Breast Cancer"
      ],
      "Start Date": [
        "2020-07-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06074588",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Pemetrexed",
        "Sacituzumab tirumotecan",
        "ALIMTA\u00ae",
        "Docetaxel",
        "TAXOTERE\u00ae",
        "SKB264, MK-2870"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "China",
        "Hong Kong",
        "United States",
        "Thailand",
        "Brazil",
        "Israel",
        "Chile",
        "Taiwan"
      ],
      "enrollment": [
        556
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "Start Date": [
        "2023-11-12"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04189614",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Cofetuzumab Pelidotin",
        "ABBV-647"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "Spain",
        "United States",
        "Israel",
        "Taiwan"
      ],
      "enrollment": [
        65
      ],
      "conditions": [
        "Cancer",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "Start Date": [
        "2020-02-13"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04724018",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab Govitecan (SG)",
        "Padcev",
        "Enfortumab vedotin-ejfv (EV)",
        "Trodelvy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Bladder Cancer",
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Urothelial Cancer",
        "Metastatic Urothelial Carcinoma"
      ],
      "Start Date": [
        "2021-05-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02822586",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Virginia Commonwealth University"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "total skin electron beam",
        "Brentuximab vedotin",
        "Adcetris",
        "TSEB",
        "TSEB Therapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        5
      ],
      "conditions": [
        "S\u00e9zary Syndrome",
        "Mycosis Fungoides"
      ],
      "Start Date": [
        "2016-12-19"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02631876",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "Gynecologic Oncology Group"
      ],
      "interventions": [
        "Pegylated liposomal doxorubicin",
        "Topotecan",
        "Paclitaxel",
        "Mirvetuximab soravtansine"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Russian Federation",
        "Ireland",
        "Serbia",
        "Czechia",
        "Spain",
        "Switzerland",
        "United States",
        "France",
        "Bosnia and Herzegovina",
        "Italy"
      ],
      "enrollment": [
        366
      ],
      "conditions": [
        "Primary Peritoneal Carcinoma",
        "Ovarian Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2016-03-02"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05498597",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Multitude Therapeutics Inc."
      ],
      "collaborators": [
        "Tigermed Consulting Co., Ltd"
      ],
      "interventions": [
        "AMT-151"
      ],
      "locations": [
        "China",
        "Australia"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Ovarian Clear Cell Carcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Lung Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Malignant Pleural Mesothelioma",
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Endometrial Adenocarcinoma",
        "Advanced Carcinoma",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Epithelial Cancer",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Cancer",
        "Endometrial Endometrioid Adenocarcinoma",
        "Ovarian Clear Cell Adenocarcinoma"
      ],
      "Start Date": [
        "2023-01-25"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05374512",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Capecitabine",
        "Nab-paclitaxel",
        "Paclitaxel",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Eribulin mesylate",
        "Dato-DXd",
        "Carboplatin"
      ],
      "locations": [
        "Turkey",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "China",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Hungary",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        600
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2022-05-16"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05775471",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jonsson Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Biospecimen Collection",
        "Pembrolizumab",
        "BIOPSY_TYPE",
        "Biopsy",
        "ASG-22CE",
        "Ureteronephrectomy",
        "Biospecimen Collected",
        "Enfortumab Vedotin-ejfv",
        "Keytruda",
        "Anti-Nectin 4 ADC ASG-22CE",
        "AGS 22ME",
        "MK-3475",
        "MR Urography",
        "Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E",
        "Padcev",
        "AGS-22M6E",
        "Bx",
        "SCH 900475",
        "Magnetic Resonance Urography",
        "Lambrolizumab",
        "Nephroureterectomy",
        "Enfortumab Vedotin",
        "Biological Sample Collection",
        "Specimen Collection"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        21
      ],
      "conditions": [
        "Renal Pelvis and Ureter Urothelial Carcinoma"
      ],
      "Start Date": [
        "2024-12-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05701527",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "EDDC (Experimental Drug Development Centre), A*STAR Research Entities"
      ],
      "collaborators": [
        "Parexel"
      ],
      "interventions": [
        "Pembrolizumab",
        "EBC-129"
      ],
      "locations": [
        "Singapore",
        "United States"
      ],
      "enrollment": [
        84
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "Start Date": [
        "2023-04-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03696771",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Novartis Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "NJH395"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "United States",
        "Japan"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "NON-breast HER2+ Malignancies"
      ],
      "Start Date": [
        "2018-12-27"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06028932",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan",
        "IMMU-132"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Ovarian Carcinoma"
      ],
      "Start Date": [
        "2024-01-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03023722",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Bayer"
      ],
      "interventions": [
        "anetumab ravtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "Start Date": [
        "2017-05-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04595565",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "German Breast Group"
      ],
      "collaborators": [
        "Gilead Sciences",
        "ETOP IBCSG Partners Foundation",
        "Spanish Breast Cancer Research Group (GEICAM)",
        "UNICANCER",
        "Austrian Breast & Colorectal Cancer Study Group",
        "Cancer Trials Ireland"
      ],
      "interventions": [
        "Trodelvy",
        "Capecitabine",
        "Sacituzumab govitecan",
        "Xeloda",
        "Platinol",
        "Paraplatin",
        "Cisplatin",
        "Carboplatin"
      ],
      "locations": [
        "Belgium",
        "Ireland",
        "Austria",
        "Spain",
        "Switzerland",
        "Germany",
        "France"
      ],
      "enrollment": [
        1332
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "Start Date": [
        "2020-10-28"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05445778",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "GOG Foundation"
      ],
      "interventions": [
        "Bevacizumab",
        "Mirvetuximab soravtansine plus Bevacizumab",
        "MIRV"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Israel",
        "Czechia",
        "Spain",
        "United States",
        "Philippines",
        "Italy"
      ],
      "enrollment": [
        418
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2022-12-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05271604",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Ozuriftamab Vedotin",
        "PD-1 inhibitor"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Squamous Cell Carcinoma of Head and Neck",
        "Metastatic Squamous Cell Carcinoma of the Head and Neck",
        "Head and Neck Cancer",
        "Metastatic Cancer"
      ],
      "Start Date": [
        "2022-12-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03543813",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "CytomX Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "CX-2029"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "Korea, Republic of"
      ],
      "enrollment": [
        133
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Diffuse Large B Cell Lymphoma",
        "Non Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Head and Neck Cancer"
      ],
      "Start Date": [
        "2018-06-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06298058",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Institute Of Biological Products"
      ],
      "collaborators": [
        "Shanghai Pulmonary Hospital, Shanghai, China"
      ],
      "interventions": [
        "SIBP-A13 formulation for injection",
        "Her3-ADC"
      ],
      "locations": [],
      "enrollment": [
        144
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-03-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05867563",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2103 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        71
      ],
      "conditions": [
        "Advanced Malignant Neoplasm"
      ],
      "Start Date": [
        "2023-07-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03245736",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "TIVDAK",
        "Tisotumab Vedotin"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": [
        5
      ],
      "conditions": [
        "Bladder Cancer",
        "Endometrium Cancer",
        "Esophagus Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Lung Cancer, Nonsmall Cell",
        "Cervix Cancer",
        "Ovary Cancer",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2017-08-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05798156",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Institut f\u00fcr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest"
      ],
      "collaborators": [
        "University of Salzburg",
        "Hoffmann-La Roche",
        "Roche Pharma AG",
        "Charite University, Berlin, Germany",
        "Zentrum f\u00fcr Klinische Studien Leipzig",
        "Arbeitsgemeinschaft medikamentoese Tumortherapie"
      ],
      "interventions": [
        "Rituximab",
        "Obinutuzumab",
        "Glofitamab",
        "Polatuzumab vedotin"
      ],
      "locations": [
        "Germany",
        "Austria"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": [
        "2023-03-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05653271",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Acepodia Biotech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Cyclophosphamide",
        "ACE1831",
        "Obinutuzumab",
        "Fludarabine"
      ],
      "locations": [
        "United States",
        "Taiwan"
      ],
      "enrollment": [
        42
      ],
      "conditions": [
        "Marginal Zone Lymphoma",
        "Follicular Lymphoma",
        "DLBCL",
        "Non Hodgkin Lymphoma",
        "B-cell Lymphoma",
        "Primary Mediastinal Large B Cell Lymphoma"
      ],
      "Start Date": [
        "2023-01-21"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02099058",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Telisotuzumab vedotin",
        "Nivolumab",
        "Osimertinib",
        "Erlotinib",
        "ABBV-399"
      ],
      "locations": [
        "Belgium",
        "Korea, Republic of",
        "Japan",
        "United States",
        "France",
        "Netherlands",
        "Italy",
        "Taiwan",
        "Finland"
      ],
      "enrollment": [
        237
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "Start Date": [
        "2014-01-15"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00674947",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Biogen"
      ],
      "collaborators": [],
      "interventions": [
        "BIIB015"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        55
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": [
        "2008-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05965479",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Southampton"
      ],
      "collaborators": [
        "Natera, Inc.",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Enhertu"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Gastrooesophageal Cancer"
      ],
      "Start Date": [
        "2024-04-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00624819",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "GSK1024805A",
        "Havrix",
        "Infanrix hexa",
        "Varilrix",
        "Synflorix",
        "Prevenar"
      ],
      "locations": [
        "Poland"
      ],
      "enrollment": [
        524
      ],
      "conditions": [
        "Infections, Streptococcal",
        "Streptococcus Pneumoniae Vaccines"
      ],
      "Start Date": [
        "2008-03-03"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06100874",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Adrienne G. Waks"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trastuzumab",
        "Trodelvy",
        "Herceptin",
        "Herceptin Hylecta",
        "Trastuzumab and Hyaluronidase-oysk",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        40
      ],
      "conditions": [
        "Breast Cancer Metastatic",
        "Breast Cancer Female",
        "Her 2 Positive Breast Cancer"
      ],
      "Start Date": [
        "2023-11-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02073487",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Methodist Hospital Research Institute"
      ],
      "collaborators": [
        "Novartis",
        "Celgene Corporation"
      ],
      "interventions": [
        "Trastuzumab",
        "Abraxane",
        "Paclitaxel",
        "tykerb",
        "Herceptin",
        "Taxol",
        "Lapatinib",
        "trastuzumab emtansine",
        "nab-paclitaxel",
        "T-DM1",
        "Kadcyla",
        "Perjeta",
        "Pertuzumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2014-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03737955",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Gemtuzumab Ozogamicin",
        "Mylotarg",
        "Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody",
        "CDP-771",
        "Quality-of-Life Assessment"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2018-11-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05622890",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Mirvetuximab Soravtansine",
        "IMGN853",
        "MIRV"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        35
      ],
      "conditions": [
        "Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2022-08-18"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04143711",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Dragonfly Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "Sacituzumab Govitecan-hziy",
        "DF1001",
        "Nab paclitaxel",
        "Nivolumab"
      ],
      "locations": [
        "Belgium",
        "United States",
        "France",
        "Netherlands",
        "Denmark"
      ],
      "enrollment": [
        378
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "Start Date": [
        "2019-11-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06176261",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sarah Sammons, MD"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Datopotamab Deruxtecan",
        "DS-1062; DS-1062a, Dato-DXd"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        58
      ],
      "conditions": [
        "HER2 Negative Breast Carcinoma",
        "ER-negative Breast Cancer",
        "Breast Cancer Female",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Breast Cancer",
        "HER2-negative Breast Cancer",
        "ER Positive Breast Cancer"
      ],
      "Start Date": [
        "2023-12-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01125527",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Novartis Vaccines"
      ],
      "collaborators": [],
      "interventions": [
        "Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)",
        "Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        700
      ],
      "conditions": [
        "Haemophilus Influenzae Type b (Hib) Infection"
      ],
      "Start Date": [
        "2009-08"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01060904",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "bleomycin",
        "brentuximab vedotin",
        "vinblastine",
        "dacarbazine",
        "SGN-35",
        "doxorubicin"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        51
      ],
      "conditions": [
        "Disease, Hodgkin"
      ],
      "Start Date": [
        "2010-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02485119",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY94-9343"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        12
      ],
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": [
        "2015-08-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05123482",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: AZD8205 and AZD2936 (Rilvegostomig)",
        "AZD8205",
        "AZD8205 and AZD2936 (Rilvegostomig)",
        "Drug: AZD8205"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Italy",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Japan",
        "China",
        "Spain",
        "United States",
        "Netherlands",
        "Thailand",
        "United Kingdom",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        "340",
        340
      ],
      "conditions": [
        "Ovarian Cancer",
        "Biliary Tract Carcinoma",
        "Breast Cancer",
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2021-10-13",
        "2021-10-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04296890",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Mirvetuximab Soravtansine",
        "IMGN853",
        "MIRV"
      ],
      "locations": [
        "Belgium",
        "Bulgaria",
        "Australia",
        "Ireland",
        "Israel",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        106
      ],
      "conditions": [
        "Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2020-07-23"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04014075",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Drug: Trastuzumab deruxtecan",
        "DS-8201a"
      ],
      "locations": [
        "Belgium",
        "Italy",
        "Spain",
        "United States",
        "United Kingdom"
      ],
      "enrollment": [
        "79",
        79
      ],
      "conditions": [
        "Adenocarcinoma Gastric Stage IV With Metastases",
        "Adenocarcinoma - GEJ"
      ],
      "Start Date": [
        "2019-08-07",
        "2019-11-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06415487",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Acepodia Biotech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Cyclophosphamide",
        "Pembrolizumab",
        "Fludarabine",
        "ACE2016"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Locally Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-05-31"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03835819",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "ImmunoGen, Inc.",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Elahere",
        "Mirvetuximab soravtansine",
        "IMGN853",
        "Keytruda"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2020-01-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05547321",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Oncomatryx Biopharma S.L."
      ],
      "collaborators": [],
      "interventions": [
        "OMTX705",
        "NA at this moment",
        "Pembrolizumab",
        "Keytruda (trademark)"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": [
        120
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2022-10-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04822337",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Wake Forest University Health Sciences"
      ],
      "collaborators": [
        "GlaxoSmithKline",
        "Amgen"
      ],
      "interventions": [
        "Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2021-05-19"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02980341",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Patritumab Deruxtecan",
        "U3-1402"
      ],
      "locations": [
        "United States",
        "Japan"
      ],
      "enrollment": [
        184
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2016-11-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06219941",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Leucovorin",
        "LV",
        "I-LV",
        "Irinotecan",
        "5-Fluorouracil",
        "Nanoliposomal Irinotecan",
        "CMG901",
        "5-FU",
        "Camptosar",
        "ONIVYDE",
        "l-leucovorin",
        "Gemzar",
        "Gemcitabine",
        "AZD0901"
      ],
      "locations": [
        "Moldova, Republic of",
        "Canada",
        "United Kingdom",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Japan",
        "Spain",
        "Singapore",
        "United States",
        "Poland",
        "Georgia",
        "Taiwan"
      ],
      "enrollment": [
        123
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Gastroesophageal Junction Cancer",
        "Gastric Cancer"
      ],
      "Start Date": [
        "2023-12-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05735496",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        71
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "Start Date": [
        "2023-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04556773",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited",
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Capecitabine",
        "Paclitaxel",
        "Durvalumab",
        "Trastuzumab deruxtecan",
        "Taxol A",
        "Anastrozol",
        "AZD5363",
        "MEDI4736",
        "Fulvestrant",
        "Anastrozole",
        "Capivasertib",
        "DS-8201a, T-DXd"
      ],
      "locations": [
        "Canada",
        "Mexico",
        "Belgium",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "United States",
        "France",
        "Brazil",
        "Taiwan"
      ],
      "enrollment": [
        138
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2020-12-17"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06233942",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "BeiGene"
      ],
      "collaborators": [],
      "interventions": [
        "BG-C9074",
        "Tislelizumab"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        150
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-04-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00947856",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "Adcetris"
      ],
      "locations": [
        "United States",
        "France"
      ],
      "enrollment": [
        110
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Disease, Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": [
        "2009-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06359002",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "BYON4413"
      ],
      "locations": [
        "Spain",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": [
        100
      ],
      "conditions": [
        "Relapsed / Refractory AML",
        "Relapsed / Refractory MDS"
      ],
      "Start Date": [
        "2024-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06336707",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "Bevacizumab",
        "Cisplatin / carboplatin",
        "HS-20089",
        "Adebrelimab"
      ],
      "locations": [],
      "enrollment": [
        1048
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2024-04-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06003231",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "RC48, RC48-ADC",
        "disitamab vedotin"
      ],
      "locations": [
        "Canada",
        "United States",
        "Australia"
      ],
      "enrollment": [
        160
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Endometrial Neoplasms",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Ovarian Neoplasms"
      ],
      "Start Date": [
        "2023-11-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06422520",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "BeiGene"
      ],
      "collaborators": [],
      "interventions": [
        "Tislelizumab",
        "BGB-C354"
      ],
      "locations": [],
      "enrollment": [
        62
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-06-24"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01472887",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi"
      ],
      "collaborators": [],
      "interventions": [
        "SAR3419"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Israel",
        "Turkey",
        "Czechia",
        "Spain",
        "United States",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        61
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": [
        "2012-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06112379",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "Doxorubicin",
        "Capecitabine",
        "Paclitaxel",
        "Durvalumab",
        "Cyclophosphamide",
        "LYNPARZA\u00ae",
        "Olaparib",
        "XELODA\u00ae, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord",
        "MEDI4736",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "KEYTRUDA\u00ae",
        "Dato-DXd",
        "Carboplatin",
        "Epirubicin"
      ],
      "locations": [
        "Turkey",
        "Switzerland",
        "United Kingdom",
        "Belgium",
        "China",
        "Hong Kong",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "Bulgaria",
        "Malaysia",
        "Singapore",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain"
      ],
      "enrollment": [
        1728
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-11-14"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01470456",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi"
      ],
      "collaborators": [],
      "interventions": [
        "SAR3419",
        "rituximab"
      ],
      "locations": [
        "Austria",
        "France",
        "Norway"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2011-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05804864",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Xuanzhu Biopharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "KM501"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        96
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2023-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06303505",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Tubulis GmbH"
      ],
      "collaborators": [],
      "interventions": [
        "TUB-040"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        100
      ],
      "conditions": [
        "Ovarian Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2024-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04246047",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: Dexamethasone",
        "Dexamethasone",
        "Drug: Daratumumab",
        "Bortezomib",
        "Belantamab mafodotin",
        "Drug: Bortezomib",
        "Drug: Belantamab mafodotin",
        "Daratumumab"
      ],
      "locations": [
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "China",
        "United States",
        "Brazil",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "New Zealand",
        "Japan",
        "Germany",
        "Spain",
        "Israel"
      ],
      "enrollment": [
        "571",
        571
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2020-05-07",
        "2020-01-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05535244",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Tocilizumab",
        "Cevostamab"
      ],
      "locations": [
        "Belgium",
        "Australia",
        "Israel",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2022-10-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00891176",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "MeningitecTM",
        "PrevenarTM",
        "InfanrixTM IPV",
        "InfanrixTM IPV/Hib",
        "NeisVac-CTM",
        "MenitorixTM",
        "InfanrixTM penta",
        "Pneumococcal conjugate vaccine GSK1024850A",
        "InfanrixTM hexa"
      ],
      "locations": [
        "Spain",
        "Poland",
        "Germany"
      ],
      "enrollment": [
        582
      ],
      "conditions": [
        "Haemophilus Influenzae Type b",
        "Neisseria Meningitidis"
      ],
      "Start Date": [
        "2009-05-14"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06103864",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "Nab-paclitaxel",
        "Paclitaxel",
        "Durvalumab",
        "MEDI4736",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Gemcitabine",
        "Dato-DXd",
        "Carboplatin"
      ],
      "locations": [
        "Turkey",
        "United Kingdom",
        "South Africa",
        "China",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "Singapore",
        "Philippines",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        625
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-11-23"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06147037",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fusion Pharmaceuticals Inc."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "FPI-2053",
        "[111In]-FPI-2107",
        "[225Ac]-FPI-2068"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        110
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Metastatic Colorectal Carcinoma",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "Start Date": [
        "2024-07-31"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06429761",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab deruxtecan"
      ],
      "locations": [],
      "enrollment": [
        100
      ],
      "conditions": [
        "BREAST CANCER"
      ],
      "Start Date": [
        "2024-09-30"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT05104866",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Capecitabine",
        "Eribulin Mesylate",
        "Vinorelbine",
        "Eribulin",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Gemcitabine",
        "Dato-DXd"
      ],
      "locations": [
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "China",
        "United States",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Hungary",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        732
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2021-10-18"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05609968",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy\u00ae",
        "Pembrolizumab",
        "Keytruda\u00ae",
        "MK-3475",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "Turkey",
        "United Kingdom",
        "Greece",
        "Peru",
        "China",
        "United States",
        "Estonia",
        "Thailand",
        "Brazil",
        "Canada",
        "Malaysia",
        "Philippines",
        "Lithuania",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "Romania",
        "Japan",
        "Latvia",
        "Germany",
        "Israel"
      ],
      "enrollment": [
        614
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": [
        "2023-02-06"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03724747",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY2315497 Injection",
        "Darolutamide(BAY1841788)"
      ],
      "locations": [
        "United Kingdom",
        "United States",
        "Finland"
      ],
      "enrollment": [
        63
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "Start Date": [
        "2018-12-18"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02884726",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [],
      "interventions": [
        "BMS-986148"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        8
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "Start Date": [
        "2016-10-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03856541",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Jiangsu HengRui Medicine Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "HTI-1066",
        "SHR-A1403"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        9
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2019-02-13"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05687266",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Pembrolizumab",
        "Paclitaxel",
        "Durvalumab",
        "Datopotamab deruxtecan",
        "MEDI4736, Imfinzi",
        "Pemetrexed",
        "Cisplatin",
        "Dato-DXd",
        "Carboplatin"
      ],
      "locations": [
        "Sweden",
        "Turkey",
        "United Kingdom",
        "Greece",
        "Peru",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "India",
        "Canada",
        "Bulgaria",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain"
      ],
      "enrollment": [
        1280
      ],
      "conditions": [
        "NSCLC"
      ],
      "Start Date": [
        "2022-12-29"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01100502",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "Adcetris",
        "SGN-35",
        "placebo"
      ],
      "locations": [
        "United Kingdom",
        "Russian Federation",
        "Bulgaria",
        "Romania",
        "Serbia",
        "Hungary",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        329
      ],
      "conditions": [
        "Disease, Hodgkin"
      ],
      "Start Date": [
        "2010-04-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05456685",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "Carboplatin",
        "Mirvetuximab soravtansine",
        "MIRV"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Spain",
        "United States",
        "United Kingdom",
        "Georgia"
      ],
      "enrollment": [
        114
      ],
      "conditions": [
        "Primary Peritoneal Cancer",
        "High Grade Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2022-09-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00848926",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "ADCETRIS",
        "SGN-35"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        102
      ],
      "conditions": [
        "Disease, Hodgkin"
      ],
      "Start Date": [
        "2009-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04879329",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "KEYTRUDA\u00ae",
        "RC48-ADC",
        "disitamab vedotin",
        "pembrolizumab"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Israel",
        "Japan",
        "Spain",
        "United States",
        "Argentina",
        "United Kingdom",
        "Chile"
      ],
      "enrollment": [
        332
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": [
        "2022-05-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03828292",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Belantamab mafodotin",
        "Pomalidomide",
        "Dexamethasone",
        "Bortezomib"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        15
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2019-03-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05922501",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "GlaxoSmithKline",
        "Sanofi"
      ],
      "interventions": [
        "Dexamethasone",
        "Isatuximab",
        "GSK2857916",
        "Belantamab mafodotin",
        "Pomalidomide",
        "SAR650984"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Relapsed Cancer",
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2024-06-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04147819",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY2701439"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": [
        14
      ],
      "conditions": [
        "Cancers With HER2 Expression"
      ],
      "Start Date": [
        "2020-07-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06014190",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20089"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        460
      ],
      "conditions": [
        "Primary Peritoneal Cancer",
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2023-12-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06227117",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "CTX, cyclophosphamide",
        "Toripalimab \uff0812weeks\uff09",
        "Epirubicin",
        "DV,RC48-ADC",
        "Toripalimab \uff0818weeks\uff09",
        "JS001",
        "Disitamab Vedotin Injection \uff0812 weeks\uff09",
        "Sequential CTX",
        "Sequential Epirubicin",
        "Carboplatin",
        "Disitamab Vedotin Injection \uff0818 weeks\uff09"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        120
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-07-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05425550",
      "phases": [],
      "sponsor": [
        "Palleos Healthcare GmbH"
      ],
      "collaborators": [
        "mobile Health AG"
      ],
      "interventions": [
        "medidux\u2122 app"
      ],
      "locations": [
        "Switzerland"
      ],
      "enrollment": [
        585
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2022-08-29"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT01874054",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Adcetris; SGN-35",
        "brentuximab vedotin",
        "bendamustine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        55
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": [
        "2013-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06397768",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine",
        "RSVt vaccine",
        "M-M-R\u00ae II",
        "Vaxelis\u00ae",
        "Pentacel\u00ae",
        "PREVNAR 20\u00ae",
        "Placebo",
        "534",
        "Streptococcus pneumoniae vaccine",
        "Rotavirus vaccine",
        "RotaTeq\u00ae",
        "VARIVAX\u00ae",
        "Hepatitis B vaccine",
        "Measles, mumps, and rubella vaccine",
        "Varicella virus vaccine",
        "RECOMBIVAX HB\u00ae or alternate monovalent hepatitis B vaccine",
        "Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine"
      ],
      "locations": [
        "United States",
        "Puerto Rico"
      ],
      "enrollment": [
        2226
      ],
      "conditions": [
        "RSV Immunization"
      ],
      "Start Date": [
        "2024-05-13"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01026415",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "midazolam",
        "brentuximab vedotin",
        "SGN-35",
        "ketoconazole",
        "ADCETRIS; SGN-35",
        "rifampin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        73
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Neoplasms",
        "Lymphoma, Large-Cell, Anaplastic",
        "Carcinomas",
        "Disease, Hodgkin"
      ],
      "Start Date": [
        "2009-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06161025",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "R-DXd",
        "Topotecan",
        "Paclitaxel",
        "PLD",
        "Pegylated Liposomal Doxorubicin",
        "Gemcitabine",
        "DS-6000a"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "Taiwan",
        "Japan"
      ],
      "enrollment": [
        650
      ],
      "conditions": [
        "Solid Cancer"
      ],
      "Start Date": [
        "2024-02-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01712490",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "bleomycin",
        "Adriamycin",
        "brentuximab vedotin",
        "DTIC",
        "vinblastine",
        "dacarbazine",
        "ADCETRIS\u00ae",
        "SGN-35",
        "doxorubicin"
      ],
      "locations": [
        "Turkey",
        "Czechia",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Norway",
        "Hong Kong",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Japan",
        "Spain"
      ],
      "enrollment": [
        1334
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2012-11-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06178159",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "DV,RC48-ADC",
        "JS001",
        "Disitamab Vedotin Injection",
        "Toripalimab",
        "Pertuzumab Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-11-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01224821",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab"
      ],
      "locations": [],
      "enrollment": [
        47
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "Start Date": [
        "1995-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05169658",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Polatuzumab Vedotin",
        "RO7030816",
        "GA-101",
        "Anti-CD20 Monoclonal Antibody R7159",
        "CD20/CD3 BiMAb BTCT4465A",
        "FCU 2711",
        "Polivy",
        "RG7596",
        "Antibody-Drug Conjugate DCDS4501A",
        "BTCT4465A",
        "RG7828",
        "Ro 5541077-000",
        "Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A",
        "RO 5072759",
        "RO-5072759",
        "RG 7828",
        "Gazyva",
        "BTCT-4465A",
        "949142-50-1",
        "BTCT 4465A",
        "1313206-42-6",
        "huMAB(CD20)",
        "GA101",
        "DCDS4501A",
        "Obinutuzumab",
        "ADC DCDS4501A",
        "polatuzumab vedotin-piiq",
        "RG-7828",
        "RO5072759",
        "Lunsumio",
        "Mosunetuzumab",
        "1905409-39-3",
        "R7159",
        "Mosunetuzumab-axgb"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        42
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Grade 3a Follicular Lymphoma",
        "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Marginal Zone Lymphoma",
        "Grade 1 Follicular Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue"
      ],
      "Start Date": [
        "2022-03-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02572167",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "brentuximab vedotin",
        "nivolumab",
        "SGN-35, ADCETRIS",
        "BMS-936558, OPDIVO"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        93
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2015-10-31"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03657043",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "TIVDAK",
        "tisotumab vedotin"
      ],
      "locations": [
        "Belgium",
        "Ireland",
        "Spain",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        98
      ],
      "conditions": [
        "Peritoneal Cancer",
        "Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2019-03-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03544281",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [
        "Iqvia Pty Ltd"
      ],
      "interventions": [
        "Belantamab mafodotin",
        "Lenalidomide",
        "Bortezomib",
        "Dexamethasone"
      ],
      "locations": [
        "Canada",
        "Australia",
        "Spain",
        "United States",
        "United Kingdom"
      ],
      "enrollment": [
        153
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2018-09-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02724163",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University of Birmingham"
      ],
      "collaborators": [
        "National Cancer Institute, France",
        "Cancer Research UK",
        "Assistance Publique - H\u00f4pitaux de Paris",
        "Pfizer"
      ],
      "interventions": [
        "Fludarabine",
        "Busulfan",
        "Cytarabine",
        "Cyclophosphamide",
        "Liposomal daunorubicin",
        "Mylotarg",
        "Mitoxantrone",
        "Gemtuzumab ozogamicin"
      ],
      "locations": [
        "Ireland",
        "Australia",
        "New Zealand",
        "Switzerland",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        700
      ],
      "conditions": [
        "Acute Myeloid Leukaemia"
      ],
      "Start Date": [
        "2016-04"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05948865",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Conjupro Biotherapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "CPO301",
        "SYS6010"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        102
      ],
      "conditions": [
        "Cancer",
        "Cancer, Lung"
      ],
      "Start Date": [
        "2023-06-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03474107",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Vinflunine",
        "Paclitaxel",
        "ASG-22ME",
        "ASG-22CE",
        "Enfortumab Vedotin",
        "Docetaxel"
      ],
      "locations": [
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Portugal",
        "United States",
        "Denmark",
        "Canada",
        "France",
        "Italy",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        608
      ],
      "conditions": [
        "Bladder Cancer",
        "Ureteral Cancer",
        "Urothelial Cancer"
      ],
      "Start Date": [
        "2018-06-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04484623",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Belantamab mafodotin",
        "Pomalidomide",
        "Bortezomib",
        "Dexamethasone"
      ],
      "locations": [
        "Greece",
        "United Kingdom",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Israel",
        "New Zealand",
        "Japan",
        "Turkey",
        "China",
        "Spain",
        "Germany",
        "Czechia",
        "United States",
        "France",
        "Brazil",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        357
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2020-10-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT00322049",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "U.S. Army Medical Research and Development Command"
      ],
      "collaborators": [
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Tetravalent live attenuated dengue vaccine",
        "Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine"
      ],
      "locations": [
        "Thailand"
      ],
      "enrollment": [
        51
      ],
      "conditions": [
        "Dengue"
      ],
      "Start Date": [
        "2004-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03262935",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD985",
        "Vinorelbine (Vino)",
        "Physician's choice",
        "Trastuzumab vc-seco-DUBA",
        "Lapatinib (Lap)",
        "Trastuzumab (T)",
        "(vic-)trastuzumab duocarmazine",
        "Capecitabine (Cap)",
        "Eribulin (Eri)"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Sweden",
        "Spain",
        "Singapore",
        "United States",
        "Netherlands",
        "France",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        437
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2017-12-15"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03523585",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd.",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab",
        "Capecitabine",
        "T-DXd",
        "Investigator's Choice Comparative Therapy",
        "Trastuzumab deruxtecan",
        "Lapatinib",
        "DS-8201a"
      ],
      "locations": [
        "Greece",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Israel",
        "Japan",
        "Turkey",
        "Spain",
        "Germany",
        "Czechia",
        "United States",
        "France",
        "Brazil",
        "Italy"
      ],
      "enrollment": [
        608
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2018-08-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04639986",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "Capecitabine Oral Product",
        "Sacituzumab Govitecan-hziy",
        "Gemcitabine Injection",
        "Halaven",
        "GS-0132",
        "Eribulin Mesylate Injection",
        "Navelbine",
        "Gemzar",
        "Vinorelbine injection",
        "IMMU-132",
        "Xeloda"
      ],
      "locations": [
        "China",
        "Taiwan",
        "Korea, Republic of"
      ],
      "enrollment": [
        331
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2020-11-23"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04487756",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Instituto Oncologico Dr Rosell",
        "Instituto Oncol\u00f3gico Dr Rosell"
      ],
      "collaborators": [
        "Roche Pharma AG",
        "Fundacion Clinic per a la Recerca Biom\u00e9dica"
      ],
      "interventions": [
        "Atezolizumab 1200 mg in 20 ML Injection",
        "Tecentriq",
        "Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine",
        "Drug: Atezolizumab 1200 mg in 20 ML Injection",
        "Biological: ADC Vaccine",
        "ADC Vaccine",
        "Drug: Carboplatin",
        "Carboplatin",
        "Carboplatino (Teva/Accord/Pharmacia)"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        20,
        "20"
      ],
      "conditions": [
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2021-03-17",
        "2020-07-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02326584",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "vadastuximab talirine",
        "Daunorubicin",
        "High dose cytarabine for consolidation",
        "SGN-CD33A",
        "Standard dose cytarabine for induction"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        116
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": [
        "2014-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05647122",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Leucovorin",
        "AZD9592",
        "Osimertinib",
        "Bevacizumab",
        "5-Fluorouracil (5-FU)"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Japan",
        "China",
        "Spain",
        "United States",
        "France",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        162
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Head and Neck Neoplasms",
        "Advanced Solid Tumours",
        "Carcinoma Non-small Cell Lung"
      ],
      "Start Date": [
        "2022-12-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05279300",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "CStone Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "CS5001"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "enrollment": [
        156
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Lymphoma"
      ],
      "Start Date": [
        "2022-03-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06400472",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [
        "Loxo Oncology, Inc."
      ],
      "interventions": [
        "LY4170156"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        220
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Colorectal Neoplasms",
        "Pancreatic Neoplasm",
        "Endometrial Neoplasms",
        "Uterine Cervical Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Triple Negative Breast Neoplasms"
      ],
      "Start Date": [
        "2024-05-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04381832",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Arcus Biosciences, Inc."
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "SG",
        "Enzalutamide",
        "Etrumadenant",
        "Taxotere",
        "Quemliclustat",
        "Zimberelimab",
        "Docetaxel",
        "AB680",
        "AB122",
        "Xtandi",
        "AB928"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        173
      ],
      "conditions": [
        "Androgen-Resistant Prostatic Neoplasms",
        "Castration Resistant Prostatic Neoplasms",
        "Prostatic Cancer, Castration-Resistant",
        "Prostatic Neoplasms, Castration-Resistant"
      ],
      "Start Date": [
        "2020-07-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05954143",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bolt Biotherapeutics, Inc."
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Perjeta\u00ae",
        "BDC-1001",
        "Pertuzumab"
      ],
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ],
      "enrollment": [
        66
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2023-11-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04786847",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Telix Pharmaceuticals (Innovations) Pty Limited"
      ],
      "collaborators": [],
      "interventions": [
        "177Lu-DOTA-TLX591"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "Start Date": [
        "2022-01-30"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05327530",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "EMD Serono Research & Development Institute, Inc."
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics"
      ],
      "interventions": [
        "Trodelvy\u2122",
        "NKTR-255",
        "GS-0132",
        "M6223",
        "Avelumab",
        "MSB0010718C",
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "Canada",
        "Greece",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Denmark",
        "Taiwan"
      ],
      "enrollment": [
        252
      ],
      "conditions": [
        "Locally Advanced or Metastatic Urothelial Carcinoma"
      ],
      "Start Date": [
        "2022-08-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05149768",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Lawson Health Research Institute"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "ADCETRIS, SGN-35"
      ],
      "locations": [
        "Canada"
      ],
      "enrollment": [
        11
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "Start Date": [
        "2024-02-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01969643",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab",
        "LV",
        "Herceptin",
        "ladiratuzumab vedotin",
        "SGN-LIV1A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        290
      ],
      "conditions": [
        "HER2 Mutations Breast Neoplasms",
        "Triple Negative Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "Hormone Receptor Positive Breast Neoplasms"
      ],
      "Start Date": [
        "2013-10-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01826877",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Jonsson Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Kite, A Gilead Company"
      ],
      "interventions": [
        "autologous dendritic cells",
        "AdGMCAIX-transduced autologous dendritic cells",
        "therapeutic autologous dendritic cells",
        "ADC",
        "DC-AdGMCAIX",
        "dendritic cells transduced with AdGMCA9 expressing GM-CSF-carbonic anhydrase IX fusion protein",
        "laboratory biomarker analysis"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        12
      ],
      "conditions": [
        "Stage IV Renal Cell Cancer",
        "Clear Cell Renal Cell Carcinoma",
        "Recurrent Renal Cell Cancer"
      ],
      "Start Date": [
        "2013-01-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06043674",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Christine Ryan"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Tecentriq",
        "Polatuzumab Vedotin",
        "Glofitamab",
        "RO5072759, GA101, GAZYVA, GAZYVARO",
        "Obinutuzumab",
        "Tocilizumab",
        "Atezolizumab",
        "RO7082859",
        "Actemra"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        66
      ],
      "conditions": [
        "Richter's Transformation",
        "Chronic Lymphocytic Leukemia"
      ],
      "Start Date": [
        "2024-01-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05494918",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alphamab (Australia) Co Pty Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JSKN003",
        "anti-Her2 ADC JSKN003"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        45
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "Start Date": [
        "2022-09-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01026233",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "Germany",
        "United States"
      ],
      "enrollment": [
        52
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Disease, Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": [
        "2010-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05577715",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Eisai Inc."
      ],
      "interventions": [
        "BMS-986445",
        "Farletuzumab Ecteribulin",
        "MORAb-202"
      ],
      "locations": [
        "Belgium",
        "Australia",
        "Spain",
        "United States",
        "France",
        "Chile"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": [
        "2022-11-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05870748",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "GOG Foundation",
        "Asia-Pacific Gynecologic Oncology Trials Group (APGOT)"
      ],
      "interventions": [
        "Paclitaxel",
        "Topotecan",
        "Pegfilgrastim",
        "STRO-002",
        "Pegylated liposomal doxorubicin",
        "Luvelta",
        "Gemcitabine",
        "Luveltamab tazevibulin",
        "Neulasta"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Australia",
        "Singapore",
        "United States",
        "Israel"
      ],
      "enrollment": [
        600
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Platinum-resistant Ovarian Cancer"
      ],
      "Start Date": [
        "2023-07-12"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01716806",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "nivolumab",
        "brentuximab vedotin",
        "dacarbazine",
        "Adcetris; SGN-35",
        "bendamustine"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        131
      ],
      "conditions": [
        "Hodgkin Disease",
        "Peripheral T Cell Lymphoma"
      ],
      "Start Date": [
        "2012-10-31"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03525678",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Belantamab mafodotin lyophilized powder",
        "",
        "Belantamab mafodotin frozen liquid"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        "221",
        221
      ],
      "conditions": [
        "",
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2018-06-18",
        "2018-03-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00866047",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "ADCETRIS",
        "SGN-35"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        58
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": [
        "2009-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05581589",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Complete Cystectomy",
        "Trodelvy",
        "Sacituzumab Govitecan-hziy",
        "Lymph Node Excision",
        "Radical Cystectomy",
        "RS7-SN38",
        "Lymphadenectomy",
        "excision of the lymph node",
        "hRS7-SN38 Antibody Drug Conjugate",
        "IMMU-132",
        "Lymph Node Dissection",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Stage II Bladder Cancer AJCC v8",
        "Muscle Invasive Bladder Carcinoma",
        "Stage IIIA Bladder Cancer AJCC v8"
      ],
      "Start Date": [
        "2023-06-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05756569",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Emory University"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "National Cancer Institute (NCI)",
        "Seagen Inc.",
        "Astellas Pharma Inc"
      ],
      "interventions": [
        "Biospecimen Collection",
        "Pembrolizumab",
        "MRI Scan",
        "NMR Imaging",
        "ASG-22CE",
        "NMRI",
        "MR Imaging",
        "Nuclear Magnetic Resonance Imaging",
        "Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance",
        "Biospecimen Collected",
        "Enfortumab Vedotin-ejfv",
        "Keytruda",
        "Magnetic Resonance Imaging",
        "MR",
        "Anti-Nectin 4 ADC ASG-22CE",
        "AGS 22ME",
        "MK-3475",
        "Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E",
        "CT",
        "Padcev",
        "Magnetic Resonance Imaging Scan",
        "MRI",
        "Computerized Axial Tomography",
        "CAT Scan",
        "AGS-22M6E",
        "SCH 900475",
        "tomography",
        "Computed Axial Tomography",
        "Lambrolizumab",
        "Magnetic Resonance",
        "Computed Tomography",
        "Enfortumab Vedotin",
        "Biological Sample Collection",
        "CAT",
        "Computerized Tomography",
        "CT Scan",
        "Questionnaire Administration",
        "Specimen Collection"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Malignant Urethral Neoplasm",
        "Bladder Squamous Cell Carcinoma",
        "Malignant Ureter Neoplasm",
        "Unresectable Bladder Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Malignant Renal Pelvis Neoplasm",
        "Locally Advanced Bladder Carcinoma",
        "Metastatic Bladder Carcinoma",
        "Bladder Adenocarcinoma",
        "Urachal Adenocarcinoma"
      ],
      "Start Date": [
        "2023-09-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02038010",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Northwestern University"
      ],
      "collaborators": [
        "Novartis",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "pharmacological study",
        "trastuzumab-MCC-DM1",
        "PI3K inhibitor BYL719",
        "ado-trastuzumab emtansine",
        "phosphoinositide 3-kinase inhibitor BYL719",
        "trastuzumab-MCC-DM1 antibody-drug conjugate",
        "T-DM1",
        "Kadcyla",
        "BYL719",
        "pharmacological studies",
        "trastuzumab-DM1",
        "laboratory biomarker analysis"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        17
      ],
      "conditions": [
        "Stage IV Breast Cancer",
        "HER2-positive Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IIIA Breast Cancer"
      ],
      "Start Date": [
        "2014-05-21"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06241898",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "BB-1709"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        300
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2023-10-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05064358",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Belantamab mafodotin"
      ],
      "locations": [
        "Switzerland",
        "United Kingdom",
        "Greece",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        177
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2022-03-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00430846",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-35",
        "brentuximab vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        45
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Disease, Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": [
        "2006-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01902329",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "HMA",
        "vadastuximab talirine",
        "SGN-CD33A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        195
      ],
      "conditions": [
        "Acute Promyelocytic Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": [
        "2013-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05313243",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Pembrolizumab",
        "Adcetris",
        "Keytruda"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        43
      ],
      "conditions": [
        "T-Cell Lymphoma"
      ],
      "Start Date": [
        "2023-07-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03198689",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Lawson Health Research Institute"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab Vedotin",
        "ADCETRIS, SGN-35"
      ],
      "locations": [
        "Canada"
      ],
      "enrollment": [
        11
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "Start Date": [
        "2019-05-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02064387",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "GSK2857916"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "United States"
      ],
      "enrollment": [
        79
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2014-07-29"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05633615",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "SWOG Cancer Research Network"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)",
        "Genentech, Inc."
      ],
      "interventions": [
        "CD20/CD3 BiMAb BTCT4465A",
        "FCU 2711",
        "Genoxal",
        "Polivy",
        "RG7828",
        "Biospecimen Collected",
        "Cycloblastine",
        "Ro 5541077-000",
        "Cyclophosphamidum",
        "Watchful Waiting",
        "2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate",
        "BTCT-4465A",
        "CTX",
        "Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017",
        "Positron Emission Tomography",
        "polatuzumab vedotin-piiq",
        "Cyclophosphamid monohydrate",
        "Cicloxal",
        "Yescarta",
        "KTE C19",
        "Specimen Collection",
        "JCAR017",
        "Polatuzumab Vedotin",
        "RO7030816",
        "Positron Emission Tomography Scan",
        "Patient Observation",
        "Antibody-Drug Conjugate DCDS4501A",
        "Cytoxan",
        "Cyclophosphane",
        "Ciclofosfamida",
        "expectant management",
        "Syklofosfamid",
        "CT",
        "RG 7828",
        "CP monohydrate",
        "PT",
        "Cyclostine",
        "Medical Imaging, Positron Emission Tomography",
        "CART-19",
        "Fludarabine",
        "KTE-C19 CAR",
        "DCDS4501A",
        "PET",
        "Positron-Emission Tomography",
        "Cyclophosphanum",
        "Genuxal",
        "Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017",
        "Mosunetuzumab",
        "Revimmune",
        "Biological Sample Collection",
        "Cyclostin",
        "Ledoxina",
        "CT Scan",
        "Biospecimen Collection",
        "Cyclophosphamide",
        "Ciclofosfamide",
        "Cytophosphane",
        "Mitoxan",
        "RG7596",
        "BTCT4465A",
        "Observation",
        "Cycloblastin",
        "(-)-Cyclophosphamide",
        "Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017",
        "PET Scan",
        "Carloxan",
        "CTL019",
        "Computed Axial Tomography",
        "Breyanzi",
        "Clafen",
        "Computed Tomography",
        "CYCLO-cell",
        "JCAR 017",
        "CART19",
        "Kymriah",
        "Cyclophosphamide Monohydrate",
        "Lisocabtagene Maraleucel",
        "Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A",
        "CTL019 T-cells",
        "KTE-C19",
        "Neosar",
        "Active Surveillance",
        "Computerized Axial Tomography",
        "CAT Scan",
        "WR- 138719",
        "BTCT 4465A",
        "Cyclophospham",
        "Fluradosa",
        "Tisagenlecleucel-T",
        "deferred therapy",
        "ADC DCDS4501A",
        "RG-7828",
        "Fosfaseron",
        "tomography",
        "Claphene",
        "Tisagenlecleucel",
        "Axicabtagene Ciloleucel",
        "CAT",
        "Cyclophosphan",
        "Computerized Tomography",
        "proton magnetic resonance spectroscopic imaging",
        "Cytophosphan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        396
      ],
      "conditions": [
        "Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma",
        "Transformed Follic Lymph to Diff Large B-Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Grade 3b Follicular Lymphoma"
      ],
      "Start Date": [
        "2023-06-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06439771",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL202 should be intravenously infused"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        180
      ],
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2024-04-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04686305",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Other Name: MEDI5752",
        "T-DXd",
        "Durvalumab",
        "Rilvegostomig",
        "DS-8201a, Trastuzumab deruxtecan",
        "Pemetrexed",
        "Other Name: AZD2936",
        "Cisplatin",
        "MEDI4736",
        "Carboplatin",
        "Volrustomig"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Thailand",
        "Israel",
        "Turkey",
        "Spain",
        "Singapore",
        "United States",
        "Philippines",
        "Netherlands",
        "France",
        "Italy",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        248
      ],
      "conditions": [
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2021-03-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01309789",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "vincristine",
        "cyclophosphamide",
        "brentuximab vedotin",
        "prednisone",
        "SGN-35",
        "doxorubicin"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": [
        39
      ],
      "conditions": [
        "Lymphoma, T-cell",
        "Lymphoma, NK-cell",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": [
        "2011-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02581878",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY1862864"
      ],
      "locations": [
        "United Kingdom",
        "Sweden"
      ],
      "enrollment": [
        21
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "Start Date": [
        "2015-11-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01015911",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-75"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        58
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Carcinoma, Renal Cell"
      ],
      "Start Date": [
        "2009-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00772070",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "Menomune\u00ae",
        "A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune\u00ae)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        173
      ],
      "conditions": [
        "Meningococcemia",
        "Neisseria Meningitidis",
        "Meningitis"
      ],
      "Start Date": [
        "2003-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05628857",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC108"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        240
      ],
      "conditions": [
        "Digestive Cancer"
      ],
      "Start Date": [
        "2022-11-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05911295",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "RemeGen Co., Ltd.",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Gemzar",
        "gemcitabine",
        "carboplatin",
        "RC48, RC48-ADC",
        "cisplatin",
        "disitamab vedotin",
        "KEYTRUDA\u00ae",
        "pembrolizumab"
      ],
      "locations": [
        "Canada",
        "Australia",
        "Singapore",
        "United States",
        "Taiwan"
      ],
      "enrollment": [
        700
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": [
        "2023-09-22"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01796171",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Nordic Nanovector"
      ],
      "collaborators": [
        "ICON Clinical Research"
      ],
      "interventions": [
        "15 MBq/kg Betalutin",
        "20 MBq/kg Betalutin",
        "100 mg/m2 lilotomab",
        "Rituximab",
        "10 MBq/kg Betalutin",
        "40 mg lilotomab",
        "60 mg/m2 lilotomab",
        "12.5 mBq/kg Betalutin"
      ],
      "locations": [
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Norway",
        "United States",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Australia",
        "Austria",
        "Spain",
        "Croatia",
        "Israel",
        "Finland"
      ],
      "enrollment": [
        191
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Follicular Lymphoma"
      ],
      "Start Date": [
        "2012-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05511844",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Orum Therapeutics USA, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ORM-5029"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        87
      ],
      "conditions": [
        "HER-2 Gene Amplification",
        "HER-2 Protein Overexpression",
        "HER2 Gene Mutation",
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2022-10-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03438396",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab",
        "Belgian Gynaecological Oncology Group",
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "Gynecologic Oncology Group"
      ],
      "interventions": [
        "TIVDAK",
        "tisotumab vedotin"
      ],
      "locations": [
        "Belgium",
        "Sweden",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        102
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": [
        "2018-06-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01909934",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [
        "Takeda Development Center Americas, Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35",
        "ADCETRIS"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Romania",
        "Hungary",
        "Turkey",
        "Portugal",
        "Spain",
        "Croatia",
        "Czechia",
        "Poland"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": [
        "2014-01-30"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT05764954",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "NovoCure Ltd."
      ],
      "interventions": [
        "NovoTTF-200T System"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Adenocarcinoma of Lung"
      ],
      "Start Date": [
        "2023-08-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06157892",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "tucatinib",
        "RC48, RC48-ADC",
        "disitamab vedotin",
        "TUKYSA, ONT-380, ARRY-380"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        198
      ],
      "conditions": [
        "HER2 Positive Breast Neoplasms",
        "Breast Neoplasms",
        "Stomach Neoplasms",
        "Gastroesophageal Junction Adenocarcinoma",
        "HER2 Low Breast Neoplasms",
        "Triple Negative Breast Neoplasms"
      ],
      "Start Date": [
        "2024-05-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01777152",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "vincristine",
        "cyclophosphamide",
        "brentuximab vedotin",
        "prednisone",
        "Adcetris; SGN-35",
        "doxorubicin"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Korea, Republic of",
        "Australia",
        "Romania",
        "Israel",
        "Hungary",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Denmark",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        452
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Anaplastic Large-Cell Lymphoma",
        "T-Cell Lymphoma"
      ],
      "Start Date": [
        "2013-01-31"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01166490",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Agensys, Inc."
      ],
      "interventions": [
        "ASG-5ME"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        51
      ],
      "conditions": [
        "Pancreatic Neoplasms",
        "Gastric Neoplasms"
      ],
      "Start Date": [
        "2010-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06464055",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "phase II",
        "Dose Expansion1",
        "Dose Escalation",
        "Dose Expansion2"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        220
      ],
      "conditions": [
        "Advanced Malignant Solid Tumors"
      ],
      "Start Date": [
        "2024-05-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06365853",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MIRV",
        "Lubricating Eye Drops",
        "IMGN853",
        "Mirvetuximab Soravtansine",
        "Brimonidine tartrate ophthalmic solution eye drops",
        "Prednisolone acetate ophthalmic suspension 1% eye drops"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Ireland",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        100
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Folate Receptor-Alpha Positive"
      ],
      "Start Date": [
        "2024-06-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05041257",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "Mirvetuximab soravtansine",
        "MIRV"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Ireland",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        79
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2021-08-31"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00198380",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Intergroupe Francophone de Cancerologie Thoracique"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Gefitinib"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "Pneumonic-type Adenocarcinoma (P-ADC)",
        "Lung Adenocarcinoma With Bronchiolo-alveolar Feature"
      ],
      "Start Date": [
        "2005-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06144723",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20105"
      ],
      "locations": [],
      "enrollment": [
        402
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2024-03-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01997333",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Celldex Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "CDX-011",
        "Capecitabine"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        327
      ],
      "conditions": [
        "Metastatic gpNMB Over-expressing Triple Negative Breast Cancer"
      ],
      "Start Date": [
        "2013-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04209855",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "Gynecologic Oncology Group",
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)"
      ],
      "interventions": [
        "Topotecan",
        "Paclitaxel",
        "MIRV",
        "IMGN853",
        "Pegylated liposomal doxorubicin",
        "Mirvetuximab Soravtansine"
      ],
      "locations": [
        "Ukraine",
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Canada",
        "Bulgaria",
        "Serbia",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Germany",
        "Spain",
        "Israel"
      ],
      "enrollment": [
        453
      ],
      "conditions": [
        "Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": [
        "2019-12-31"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06039202",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Holy Stone Healthcare Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "TAS-102",
        "Nim-HA cinjugate",
        "Trifluridine/tipiracil",
        "Bevacizumab",
        "CA102N"
      ],
      "locations": [],
      "enrollment": [
        100
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "Start Date": [
        "2024-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01421667",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Adcetris; SGN-35",
        "brentuximab vedotin",
        "rituximab"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        176
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, T-Cell",
        "Lymphoma, B-Cell",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": [
        "2011-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01461538",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Adcetris; SGN-35",
        "brentuximab vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        84
      ],
      "conditions": [
        "Acute Lymphoid Leukemia",
        "Acute Myeloid Leukemia",
        "Solid Tumors",
        "Anemia, Refractory, With Excess of Blasts"
      ],
      "Start Date": [
        "2011-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05135273",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "National Institute of Allergy and Infectious Diseases (NIAID)"
      ],
      "collaborators": [
        "Malaria Research and Training Center, Bamako, Mali",
        "Novavax"
      ],
      "interventions": [
        "Pfs230D1-EPA/Matrix-M Vaccine",
        "Verorab Rabies Vaccine"
      ],
      "locations": [
        "Mali"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Malaria,Falciparum"
      ],
      "Start Date": [
        "2021-10-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04177823",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Belantamab mafodotin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        6
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2019-12-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05263479",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Hansoh Biomedical Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20089 (Phase Ib: Dose expansion)",
        "HS-20089 (Phase Ia\uff1aDose escalation )"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        177
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2022-01-05"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01950364",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "brentuximab vedotin",
        "Brentuximab vedotin and rifampicin",
        "SGN-35"
      ],
      "locations": [
        "Lithuania",
        "Belgium",
        "Spain"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Anaplastic Large-cell Lymphoma"
      ],
      "Start Date": [
        "2013-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01786096",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-CD19A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        92
      ],
      "conditions": [
        "Burkitt Lymphoma",
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma"
      ],
      "Start Date": [
        "2013-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02216890",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-CD70A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        38
      ],
      "conditions": [
        "Mantle-Cell Lymphoma",
        "Follicular Lymphoma, Grade 3",
        "Renal Cell Carcinoma",
        "Diffuse, Large B-Cell, Lymphoma"
      ],
      "Start Date": [
        "2014-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04207190",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Roswell Park Cancer Institute"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "gemtuzumab",
        "Gemtuzumab Ozogamicin",
        "Talazoparib",
        "hP67.6-Calicheamicin",
        "WAY-CMA-676",
        "Mylotarg",
        "Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody",
        "Quality of Life Assessment",
        "CDP-771",
        "Quality-of-Life Assessment",
        "BMN-673",
        "CMA-676",
        "Talzenna",
        "Talazoparib Tosylate",
        "Questionnaire Administration",
        "BMN 673"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Refractory Acute Myeloid Leukemia",
        "Recurrent Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2020-10-23"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05575804",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "collaborators": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "interventions": [
        "GQ1001+pyrotinib",
        "pyrotinib+capecitabine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        75
      ],
      "conditions": [
        "Advanced/ Metastatic Her-2 Positive Breast Cancer"
      ],
      "Start Date": [
        "2022-10-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03219333",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Astellas Pharma Inc"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Enfortumab vedotin",
        "ASG-22CE",
        "ASG-22ME"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Netherlands",
        "Italy"
      ],
      "enrollment": [
        219
      ],
      "conditions": [
        "Urinary Bladder Neoplasms",
        "Urethral Neoplasms",
        "Urologic Neoplasms",
        "Urothelial Cancer",
        "Renal Pelvis Neoplasms",
        "Carcinoma, Transitional Cell",
        "Ureteral Neoplasms"
      ],
      "Start Date": [
        "2017-10-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04086264",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Decitabine",
        "IMGN632",
        "Azacitidine",
        "Venclexta",
        "Venclyxto",
        "Venetoclax",
        "Vidaza",
        "CD123-targeted ADC"
      ],
      "locations": [
        "United Kingdom",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        218
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2019-11-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06106945",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "AZD0305"
      ],
      "locations": [
        "Canada",
        "Australia",
        "Japan",
        "China",
        "Spain",
        "Germany",
        "United States",
        "France"
      ],
      "enrollment": [
        84
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2023-12-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02227199",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)",
        "Seagen Inc."
      ],
      "interventions": [
        "Anti-CD30 Monoclonal Antibody-MMAE SGN-35",
        "Carboplatin Hexal",
        "Ifomide",
        "CBDCA",
        "Paraplatine",
        "Asta Z 4942",
        "Toposar",
        "Displata",
        "Adcetris",
        "Ifomida",
        "Ifolem",
        "JM-8",
        "Brentuximab Vedotin",
        "Lastet",
        "IFO",
        "Ifosfamide",
        "Etoposide",
        "ADC SGN-35",
        "IFX",
        "IFO-Cell",
        "Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35",
        "Ifoxan",
        "Z 4942",
        "Holoxan",
        "Mitoxana",
        "Laboratory Biomarker Analysis",
        "Blastocarb",
        "Seromida",
        "Iphosphamid",
        "Paraplatin AQ",
        "Iphosphamide",
        "Tronoxal",
        "EPEG",
        "VP-16",
        "Naxamide",
        "Carbotec",
        "Paraplatin",
        "VP-16-213",
        "MJF-9325",
        "MJF 9325",
        "Platinwas",
        "Ifex",
        "Carboplatin",
        "Vepesid",
        "Ribocarbo",
        "Ercar",
        "Isophosphamide",
        "Isoendoxan",
        "Carbosol",
        "Z-4942",
        "Ifosfamidum",
        "Anti-CD30 Antibody-Drug Conjugate SGN-35",
        "Carboplat",
        "Holoxane",
        "Asta Z-4942",
        "Demethyl Epipodophyllotoxin Ethylidine Glucoside",
        "Cyfos",
        "SGN-35",
        "Iso-Endoxan",
        "cAC10-vcMMAE",
        "Novoplatinum",
        "Carbosin",
        "VP 16-213",
        "Nealorin",
        "Carboplatino"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        45
      ],
      "conditions": [
        "Refractory Hodgkin Lymphoma",
        "Recurrent Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2014-10-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06340568",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "BioNTech SE"
      ],
      "collaborators": [
        "DualityBio Inc."
      ],
      "interventions": [
        "BNT323/DB-1303",
        "Doxorubicin",
        "Paclitaxel"
      ],
      "locations": [],
      "enrollment": [
        468
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2024-08"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06034275",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Vincerx Pharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "VIP943"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "B-cell Acute Lymphoblastic Leukemia",
        "High-risk Myelodysplastic Syndrome"
      ],
      "Start Date": [
        "2023-09-13"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06195709",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Institut Curie"
      ],
      "collaborators": [
        "Zionexa"
      ],
      "interventions": [
        "Endocrine therapy",
        "Endocrine therapy combined with the local treatment of FES-negative lesions",
        "Standardized chemotherapy regimen",
        "Chemotherapy",
        "Standardized endocrine therapy regimen"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        300
      ],
      "conditions": [
        "Breast Carcinoma"
      ],
      "Start Date": [
        "2024-05-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03698552",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)",
        "ADC Therapeutics S.A."
      ],
      "interventions": [
        "ADCT-602",
        "ADCT-602 (CN); hLL2-cys-PBD (SY); ADCT602 (CN); ADCT 602 (CN); hLL2-cys-SG3249 (SY); ; ADC ADCT-602"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        65
      ],
      "conditions": [
        "CD22 Positive",
        "Blasts 5 Percent or More of Bone Marrow Nucleated Cells",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive",
        "Recurrent B Acute Lymphoblastic Leukemia"
      ],
      "Start Date": [
        "2018-08-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06034470",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fred Hutchinson Cancer Center"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Alexan",
        "Biospecimen Collected",
        "Aracytidine",
        "Aracytine",
        "IMGN-632",
        "CD123-targeted ADC IMGN632",
        "Arabinofuranosylcytosine",
        "Radionuclide Ventriculography",
        "Granulocyte Colony-Stimulating Factor",
        "Colony-Stimulating Factor (Granulocyte)",
        "Udicil",
        "Pluripoietin",
        "Colony Stimulating Factor 3",
        "Specimen Collection",
        "Beta-Cytosine Arabinoside",
        "Bone Marrow Biopsy",
        "Cytosine Arabinoside",
        "Colony-Stimulating Factor 3",
        "MUGA",
        "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        "Synchronized Multigated Acquisition Scanning",
        "IMGN 632",
        "4-DMDR",
        "SYMA Scanning",
        "Fludarabine",
        "Erpalfa",
        "CSF3",
        "Granulocyte Colony Stimulating Factor",
        "Cytarbel",
        "Biopsy of Bone Marrow",
        "Tarabine PFS",
        "IMGN632",
        "Biological Sample Collection",
        "G CSF",
        "Multi-Gated Acquisition Scan",
        "G-CSF",
        "Echocardiography",
        "EC",
        "Biospecimen Collection",
        "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-",
        "Aracytin",
        "Gated Blood Pool Imaging",
        "U 19920",
        "Cytosar",
        "MUGA Scan",
        "WR-28453",
        "RNVG",
        "Cytosine-beta-arabinoside",
        ".beta.-Cytosine arabinoside",
        "Ara-C",
        "1-Beta-D-arabinofuranosylcytosine",
        "4-Demethoxydaunomycin",
        "Multigated Acquisition Scan",
        "Arabine",
        "Idarubicin",
        "Blood Pool Scan",
        "Equilibrium Radionuclide Angiography",
        "1-.beta.-D-Arabinofuranosylcytosine",
        "ARA-cell",
        "Arabinosylcytosine",
        "Starasid",
        "Antibody-drug Conjugate IMGN632",
        "Bone Marrow Aspiration",
        "4-Demethoxydaunorubicin",
        "CHX-3311",
        "Cytarabine",
        "Cytosine-.beta.-arabinoside",
        "Fluradosa",
        "Gated Heart Pool Scan",
        "Radionuclide Ventriculogram Scan",
        "1.beta.-D-Arabinofuranosylcytosine",
        "Biopsy, Bone Marrow",
        "Anti-CD123 ADC IMGN632",
        "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-",
        "U-19920",
        "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        "Cytarabinum",
        "Pivekimab Sunirine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Acute Myeloid Leukemia",
        "Mixed Phenotype Acute Leukemia"
      ],
      "Start Date": [
        "2023-12-18"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01983540",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine",
        "DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine",
        "Infanrix hexa + Prevenar + Rotarix vaccine"
      ],
      "locations": [
        "Colombia",
        "Costa Rica"
      ],
      "enrollment": [
        558
      ],
      "conditions": [
        "Hepatitis B",
        "Haemophilus Influenzae Type b",
        "Tetanus",
        "Poliomyelitis",
        "Whooping Cough",
        "Diphtheria"
      ],
      "Start Date": [
        "2013-10"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02610348",
      "phases": [],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "DTaP-HB-IPV and Pneumococcal polysaccharide vaccines",
        "DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines"
      ],
      "locations": [
        "Thailand"
      ],
      "enrollment": [
        122
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "Start Date": [
        "2015-11"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT02573324",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [
        "Radiation Therapy Oncology Group"
      ],
      "interventions": [
        "Temozolomide",
        "ABT-414",
        "Radiation",
        "Placebo for ABT-414",
        "Depatuxizumab mafodotin"
      ],
      "locations": [
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "Hong Kong",
        "Colombia",
        "United States",
        "Brazil",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "New Zealand",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        691
      ],
      "conditions": [
        "Gliosarcoma",
        "Glioblastoma"
      ],
      "Start Date": [
        "2015-01-04"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04946370",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Weill Medical College of Cornell University"
      ],
      "collaborators": [
        "United States Department of Defense",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "68Ga-PSMA-11",
        "68Ga-PSMA-HBED-CC",
        "225Ac-J591",
        "Androgen receptor pathway inhibitor"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        76
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2021-08-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00654901",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "Infanrix Hexa\u2122",
        "DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)",
        "DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)",
        "DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)"
      ],
      "locations": [
        "Mexico"
      ],
      "enrollment": [
        881
      ],
      "conditions": [
        "Hepatitis B",
        "Haemophilus Influenzae Type B Infection",
        "Tetanus",
        "Poliomyelitis",
        "Pertussis",
        "Diphtheria"
      ],
      "Start Date": [
        "2008-03"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01786135",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-CD19A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        64
      ],
      "conditions": [
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Burkitt Lymphoma",
        "Lymphoma, Follicular",
        "Lymphoma, Mantle-Cell"
      ],
      "Start Date": [
        "2013-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03786081",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab",
        "Belgian Gynaecological Oncology Group",
        "GOG Foundation",
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Tisotumab Vedotin",
        "Paraplatin",
        "KEYTRUDA\u00ae",
        "Bevacizumab",
        "TIVDAK",
        "Carboplatin",
        "Avastin"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Ireland",
        "Turkey",
        "Czechia",
        "Spain",
        "United States",
        "Netherlands",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        214
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": [
        "2019-02-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03284723",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "PF-06804103",
        "PF-06804103 + Palbociclib +Letrozole"
      ],
      "locations": [
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Italy"
      ],
      "enrollment": [
        95
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2017-11-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01590966",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University Hospital, Ghent"
      ],
      "collaborators": [
        "UCB Pharma SA"
      ],
      "interventions": [
        "Immunoscintigraphy with radiolabeled Cimzia\u00ae.",
        "administration of Cimzia\u00ae"
      ],
      "locations": [
        "Belgium"
      ],
      "enrollment": [
        41
      ],
      "conditions": [
        "Axial and Peripheral Spondyloarthritis",
        "Rheumatoid Arthritis"
      ],
      "Start Date": [
        "2012-10-18"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03288545",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [
        "Seagen Inc.",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Keytruda",
        "ASG-22CE",
        "enfortumab vedotin (EV)",
        "ASG-22ME",
        "PADCEV",
        "gemcitabine",
        "carboplatin",
        "cisplatin",
        "pembrolizumab"
      ],
      "locations": [
        "Canada",
        "Puerto Rico",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        348
      ],
      "conditions": [
        "Urinary Bladder Neoplasms",
        "Urethral Neoplasms",
        "Urologic Neoplasms",
        "Urothelial Cancer",
        "Renal Pelvis Neoplasms",
        "Carcinoma, Transitional Cell",
        "Ureteral Neoplasms"
      ],
      "Start Date": [
        "2017-10-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01990534",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-35",
        "Brentuximab Vedotin",
        "ADCETRIS"
      ],
      "locations": [
        "Malaysia",
        "Turkey",
        "Czechia",
        "Spain",
        "Germany",
        "Thailand",
        "Poland"
      ],
      "enrollment": [
        60
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2014-03-14"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT05350917",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The First Affiliated Hospital of Zhengzhou University"
      ],
      "collaborators": [
        "RemeGen Co., Ltd.",
        "BeiGene",
        "Jiangsu Hengrui Pharmaceutical Co., Ltd."
      ],
      "interventions": [
        "DisitamabVedotin",
        "Pyrotinib maleate",
        "Tislelizumab"
      ],
      "locations": [],
      "enrollment": [
        20
      ],
      "conditions": [
        "HER2-positive or Mutated Advanced Colorectal Cancer"
      ],
      "Start Date": [
        "2022-06-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02222922",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "PF-06647020 Q3W",
        "PF-06647020 Q2W",
        "PF-06647020 combined with Avelumab",
        "fluconazole"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": [
        138
      ],
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": [
        "2014-10-17"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00861744",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "M-M-R\u00ae II (Merck and Co)",
        "GSK Biological's investigational vaccine 209762",
        "Prevnar\u00ae",
        "Varivax\u00ae",
        "Havrix\u00ae"
      ],
      "locations": [
        "United States",
        "Puerto Rico"
      ],
      "enrollment": [
        1259
      ],
      "conditions": [
        "Measles",
        "Rubella",
        "Mumps",
        "Measles-Mumps-Rubella Vaccine"
      ],
      "Start Date": [
        "2009-06-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06123494",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Jiangsu HengRui Medicine Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "SHR-A1811",
        "Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        360
      ],
      "conditions": [
        "HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": [
        "2024-01-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT00012064",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Lisata Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "therapeutic autologous dendritic cells"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        56
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "Start Date": [
        "2000-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01444781",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide",
        "DTaP-IPV-Hep B-PRP~T vaccine",
        "Prevenar\u2122",
        "DTaP-IPV-Hep B-PRP~T combined vaccine",
        "DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide",
        "DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine",
        "Infanrix hexa\u2122"
      ],
      "locations": [
        "Colombia",
        "Costa Rica"
      ],
      "enrollment": [
        1106
      ],
      "conditions": [
        "Hepatitis B",
        "Tetanus",
        "Poliomyelitis",
        "Whooping Cough",
        "Diphtheria"
      ],
      "Start Date": [
        "2011-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05702229",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Capecitabine",
        "XELOX",
        "AZD0901",
        "AZD7789",
        "Rilvegostomig",
        "5-Fluorouracil",
        "FOLFOX",
        "Volrustomig"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan",
        "China",
        "Spain",
        "United States",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        240
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": [
        "2023-01-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02343406",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [
        "European Organisation for Research and Treatment of Cancer - EORTC"
      ],
      "interventions": [
        "Temozolomide",
        "ABT-414",
        "TMZ",
        "Depatuxizumab mafodotin",
        "Gleostine",
        "Lomustine"
      ],
      "locations": [
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "United States",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Australia",
        "Austria",
        "Germany",
        "Spain",
        "Finland"
      ],
      "enrollment": [
        266
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "Start Date": [
        "2015-02-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00051571",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-15",
        "Docetaxel"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        60
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": [
        null
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06065371",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Henry Ford Health System"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Capecitabine",
        "Xeloda",
        "Sacituzumab govetican"
      ],
      "locations": [],
      "enrollment": [
        20
      ],
      "conditions": [
        "Gastrointestinal Cancer"
      ],
      "Start Date": [
        "2024-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02340208",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Helix BioPharma Corporation"
      ],
      "collaborators": [
        "Pharm-Olam International"
      ],
      "interventions": [
        "L-DOS47"
      ],
      "locations": [
        "Poland"
      ],
      "enrollment": [
        76
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2012-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04592419",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Kodiak Sciences Inc"
      ],
      "collaborators": [],
      "interventions": [
        "KSI-301",
        "Eylea",
        "Aflibercept",
        "Sham Procedure"
      ],
      "locations": [
        "Puerto Rico",
        "Israel",
        "Hungary",
        "Czechia",
        "Latvia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Poland",
        "Slovakia"
      ],
      "enrollment": [
        568
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "Start Date": [
        "2020-09-25"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT00356408",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "UCB Pharma"
      ],
      "collaborators": [],
      "interventions": [
        "CDP870",
        "Cimzia",
        "Certolizumab pegol",
        "CZP"
      ],
      "locations": [
        "Germany",
        "Canada",
        "United States"
      ],
      "enrollment": [
        106
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "Start Date": [
        "2007-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05579366",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "ProfoundBio US Co."
      ],
      "collaborators": [],
      "interventions": [
        "PRO1184",
        "PRO1184 intravenous infusion of PRO1184"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "enrollment": [
        374
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Non-small Cell Lung Cancer",
        "Primary Peritoneal Carcinoma",
        "Mesothelioma",
        "Ovarian Cancer",
        "Hormone Receptor-positive/Her2 Negative Breast Cancer",
        "Endometrial Cancer",
        "Triple Negative Breast Cancer",
        "High Grade Epithelial Ovarian Cancer",
        "Breast Adenocarcinoma"
      ],
      "Start Date": [
        "2022-12-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02677155",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Oslo University Hospital"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Norwegian Cancer Society"
      ],
      "interventions": [
        "GM-CSF",
        "Pembrolizumab",
        "Rituximab",
        "Mabthera",
        "Autologous dendritic cells",
        "Anti-PD1",
        "Sagramostim",
        "Radiotherapy"
      ],
      "locations": [
        "Norway"
      ],
      "enrollment": [
        10
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "Start Date": [
        "2016-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04203641",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Helix BioPharma Corporation"
      ],
      "collaborators": [
        "Theradex"
      ],
      "interventions": [
        "Doxorubicin",
        "L-DOS47"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Pancreas Cancer"
      ],
      "Start Date": [
        "2019-12-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05283330",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Orano Med LLC"
      ],
      "collaborators": [],
      "interventions": [
        "\u00b2\u00b9\u00b2Pb-DOTAM-GRPR1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Cervical Cancer",
        "Cutaneous Melanoma",
        "NSCLC",
        "Prostate Cancer Metastatic",
        "Breast Cancer",
        "Colon Cancer"
      ],
      "Start Date": [
        "2022-12-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04964089",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Kodiak Sciences Inc"
      ],
      "collaborators": [],
      "interventions": [
        "KSI-301",
        "Eylea",
        "Aflibercept",
        "Sham Procedure"
      ],
      "locations": [
        "United States",
        "Puerto Rico"
      ],
      "enrollment": [
        557
      ],
      "conditions": [
        "Wet Age-related Macular Degeneration"
      ],
      "Start Date": [
        "2021-06-23"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05600686",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Joseph Tuscano"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)",
        "ADC Therapeutics S.A."
      ],
      "interventions": [
        "Rituximab Biosimilar RTXM83",
        "Deltasone",
        "Econosone",
        "C2B8 Monoclonal Antibody",
        "Genoxal",
        "Prednilonga",
        "Cycloblastine",
        "Cyclophosphamidum",
        "Cortancyl",
        "Panafcort",
        "2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate",
        ".delta.1-Cortisone",
        "IDEC-C2B8",
        "CTX",
        "Decortisyl",
        "Prednidib",
        "Vepesid",
        "Rituximab Biosimilar JHL1101",
        "Monoclonal Antibody IDEC-C2B8",
        "Meprosona-F",
        "Cyclophosphamid monohydrate",
        "Panasol-S",
        "Rayos",
        "Rituximab-arrx",
        "Hydroxydaunomycin",
        "Rituximab Biosimilar PF-05280586",
        "Cicloxal",
        "ADCT-402",
        "Rituximab Biosimilar CT-P10",
        "Rituximab Biosimilar ABP 798",
        "Rituximab-pvvr",
        "Metacortandracin",
        "Prednitone",
        "Deltadehydrocortisone",
        "Paracort",
        "Cytoxan",
        "Rituximab Biosimilar SAIT101",
        "Servisone",
        "Cyclophosphane",
        "Rituximab Biosimilar BI 695500",
        "Rituximab PVVR",
        "Deltacortene",
        "Ciclofosfamida",
        "CT-P10",
        "Syklofosfamid",
        "Deltacortisone",
        "Rituximab Biosimilar SIBP-02",
        "1, 2-Dehydrocortisone",
        "Deltison",
        "CP monohydrate",
        "VP 16",
        "Delta-Dome",
        "VCR",
        "Cyclostine",
        "Ofisolona",
        "Prednicen-M",
        "MabThera",
        "Predniment",
        "Truxima",
        "Prednisone",
        "Leurocristine",
        "rituximab-abbs",
        "Hydroxyldaunorubicin",
        "Cyclophosphanum",
        "Genuxal",
        "Rituximab ABBS",
        "Prednisone Intensol",
        "rituximab biosimilar TQB2303",
        "Rituximab ARRX",
        "Hydroxyl Daunorubicin",
        "Chimeric Anti-CD20 Antibody",
        "Revimmune",
        "Cyclostin",
        "Ledoxina",
        "ABP 798",
        "Toposar",
        "Cyclophosphamide",
        "Ciclofosfamide",
        "Cytophosphane",
        "Mitoxan",
        "Orasone",
        "IDEC-102",
        "Doxorubicin",
        "Delta 1-Cortisone",
        "Loncastuximab Tesirine",
        "ADC ADCT-402",
        "Promifen",
        "Rituximab Biosimilar GB241",
        "Perrigo Prednisone",
        "Cycloblastin",
        "Prednisonum",
        "Vincristine",
        "Rituxan",
        "(-)-Cyclophosphamide",
        "SK-Prednisone",
        "Vincrystine",
        "Prednicort",
        "VP-16",
        "Anti-CD19 PBD-conjugate ADCT-402",
        "Carloxan",
        "VP-16-213",
        "PF-05280586",
        "Deltra",
        "Rituximab",
        "BI 695500",
        "Dacortin",
        "Clafen",
        "Rituximab Biosimilar IBI301",
        "CYCLO-cell",
        "Predicor",
        "VP 16-213",
        "PRED",
        "DeCortin",
        "Lastet",
        "Etoposide",
        "Cyclophosphamide Monohydrate",
        "Decorton",
        "Meticorten",
        "RTXM83",
        "Adriablastin",
        "Riabni",
        "Neosar",
        "VP16",
        "EPEG",
        "IDEC-C2B8 Monoclonal Antibody",
        "WR- 138719",
        "Cyclophospham",
        "Zynlonta",
        "Predicorten",
        "Adasone",
        "Lisacort",
        "Fosfaseron",
        "Claphene",
        "Loncastuximab Tesirine-lpyl",
        "Ruxience",
        "Demethyl Epipodophyllotoxin Ethylidine Glucoside",
        "Cyclophosphan",
        "Cytophosphan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Double-Expressor Lymphoma"
      ],
      "Start Date": [
        "2023-05-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05627960",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "A&G Pharmaceutical Inc."
      ],
      "collaborators": [
        "University of Maryland Greenebaum Cancer Center"
      ],
      "interventions": [
        "AG-01 Compound"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        77
      ],
      "conditions": [
        "Mesothelioma",
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Hormone-Resistant Breast Cancer"
      ],
      "Start Date": [
        "2022-02-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01825317",
      "phases": [],
      "sponsor": [
        "Neuronix Ltd"
      ],
      "collaborators": [
        "Chungnam National University Hospital",
        "company: K The Power"
      ],
      "interventions": [
        "Control device",
        "NICE",
        "NeuroAD",
        "Sham device"
      ],
      "locations": [
        "Korea, Republic of"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "Start Date": [
        "2013-03"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT01280552",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Precision Life Sciences Group"
      ],
      "collaborators": [],
      "interventions": [
        "ICT-107",
        "Placebo DC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        124
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "Start Date": [
        "2011-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05261750",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "PT. Prodia Stem Cell Indonesia"
      ],
      "collaborators": [],
      "interventions": [
        "Allo-Dendritic-Secretome Adjuvant Therapy",
        "Auto-Dendritic Adjuvant Therapy"
      ],
      "locations": [
        "Indonesia"
      ],
      "enrollment": [
        15
      ],
      "conditions": [
        "Nasopharyngeal Cancer"
      ],
      "Start Date": [
        "2022-04-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03743298",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "AV-MEL-1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "Start Date": [
        "2021-04-21"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00377715",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Medivation, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Placebo",
        "Dimebon"
      ],
      "locations": [
        "Russian Federation"
      ],
      "enrollment": [
        183
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "Start Date": [
        "2005-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00777608",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Comparator: Placebo 5-10 mg",
        "Comparator: Placebo 5mg (run in)",
        "Donepezil 5 - 10 mg",
        "Donepezil 10 mg"
      ],
      "locations": [],
      "enrollment": [
        106
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "Start Date": [
        "2008-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02049489",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Precision Life Sciences Group"
      ],
      "collaborators": [],
      "interventions": [
        "ICT-121 DC vaccine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "Start Date": [
        "2013-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03531918",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Fred Hutchinson Cancer Center"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "CL 232315",
        "Cytosine Arabinoside",
        "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-",
        "hP67.6-Calicheamicin",
        "Mitroxone",
        "Novantrone",
        "Mylotarg",
        "Mitozantrone Hydrochloride",
        "Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody",
        "Aracytin",
        "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        "1-.beta.-D-Arabinofuranosylcytosine",
        "RWJ-26251",
        "Alexan",
        "Aracytidine",
        "Aracytine",
        "Onkotrone",
        "ARA-cell",
        "Arabinosylcytosine",
        "2-CdA",
        "Recombinant Colony-Stimulating Factor 3",
        "Mitoxantrone Dihydrochloride",
        "Starasid",
        "U 19920",
        "Arabinofuranosylcytosine",
        "Laboratory Biomarker Analysis",
        "Cytosar",
        "Cladribine",
        "WR-28453",
        "Recombinant Granulocyte Colony-Stimulating Factor",
        "CHX-3311",
        "Neotalem",
        "CdA",
        "Leustatine",
        "Leustatin",
        "DHAD",
        "Cytarabine",
        "Leustat",
        "Beta-cytosine Arabinoside",
        "Erpalfa",
        "Cytosine-beta-arabinoside",
        "Cytosine-.beta.-arabinoside",
        "Udicil",
        ".beta.-Cytosine arabinoside",
        "Ara-C",
        "WAY-CMA-676",
        "143011-72-7",
        "1-Beta-D-arabinofuranosylcytosine",
        "Cytarbel",
        "Arabine",
        "DHAQ",
        "Mitoxantroni Hydrochloridum",
        "1.beta.-D-Arabinofuranosylcytosine",
        "Gemtuzumab Ozogamicin",
        "gemtuzumab",
        "Tarabine PFS",
        "Pralifan",
        "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-",
        "U-19920",
        "2CDA",
        "CDP-771",
        "Cladribina",
        "CMA-676",
        "Mitoxantrone Hydrochloride",
        "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        "Cytarabinum",
        "Dihydroxyanthracenedione Dihydrochloride",
        "rhG-CSF"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        66
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2018-09-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04690387",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [
        "PT AIVITA Biomedika Indonesia",
        "National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",
        "Indonesia Ministry of Health"
      ],
      "interventions": [
        "GM-CSF",
        "AV-COVID-19"
      ],
      "locations": [
        "Indonesia"
      ],
      "enrollment": [
        27
      ],
      "conditions": [
        "COVID-19"
      ],
      "Start Date": [
        "2020-12-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00086333",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-15, Docetaxel"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Non-Small Cell Lung Carcinoma"
      ],
      "Start Date": [
        "2004-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02771340",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Iconic Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "human Immuno-conjugate 1",
        "ICON-1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        10
      ],
      "conditions": [
        "Uveal Melanoma",
        "Choroid Neoplasm"
      ],
      "Start Date": [
        "2016-05"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01068509",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Prima BioMed Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "Cvac"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": [
        63
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "Start Date": [
        "2010-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05100641",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Autologous monocytes",
        "AV-GBM-1"
      ],
      "locations": [],
      "enrollment": [
        672
      ],
      "conditions": [
        "Primary Glioblastoma"
      ],
      "Start Date": [
        "2024-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04834544",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Peking University Third Hospital"
      ],
      "collaborators": [
        "SOTIO a.s."
      ],
      "interventions": [
        "Placebo",
        "DCVAC/OvCa"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        75
      ],
      "conditions": [
        "Primary Peritoneal Carcinoma",
        "Epithelial Ovarian Carcinoma",
        "Fallopian Tube Carcinoma"
      ],
      "Start Date": [
        "2021-04-19"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01617629",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Prima BioMed Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "MUC1 Dendritic Cell Vaccine (Cvac)"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": [
        9
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "Start Date": [
        "2011-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04160494",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Darell Bigner"
      ],
      "collaborators": [
        "Istari Oncology, Inc.",
        "National Cancer Institute (NCI)",
        "Genentech, Inc."
      ],
      "interventions": [
        "Tecentriq",
        "Atezolizumab (1200 mg every three weeks)",
        "D2C7-IT (6920 ng/mL via convection-enhanced delivery)",
        "D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Malignant Glioma"
      ],
      "Start Date": [
        "2020-02-25"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03543358",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "rovalpituzumab tesirine",
        "SC16LD6.5"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        3
      ],
      "conditions": [
        "Cancer"
      ],
      "Start Date": [
        "2018-09-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03610360",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Amphera BV"
      ],
      "collaborators": [
        "TMC Pharma"
      ],
      "interventions": [
        "MesoPher"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "France",
        "Netherlands",
        "Italy"
      ],
      "enrollment": [
        176
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "Start Date": [
        "2018-06-21"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05007496",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [
        "PT AIVITA Biomedika Indonesia",
        "Kariadi Hospital",
        "Central Army Hospital RSPAD Gatot Soebroto"
      ],
      "interventions": [
        "AV-COVID-19"
      ],
      "locations": [
        "Indonesia"
      ],
      "enrollment": [
        145
      ],
      "conditions": [
        "COVID-19"
      ],
      "Start Date": [
        "2021-04-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00815607",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alaunos Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "INXN-3001",
        "INXN-1001"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        12
      ],
      "conditions": [
        "Melanoma"
      ],
      "Start Date": [
        "2009-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04744831",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Drug: DS-8201a 6.4 mg/kg Q3W",
        "T-DXd",
        "Drug: DS-8201a 5.4 mg/kg Q3W",
        "DS-8201a 6.4 mg/kg Q3W",
        "DS-8201a 5.4 mg/kg Q3W"
      ],
      "locations": [
        "Belgium",
        "Italy",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Spain",
        "United States",
        "France",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        "122",
        122
      ],
      "conditions": [
        "Advanced Colorectal Cancer"
      ],
      "Start Date": [
        "2021-01-19",
        "2021-03-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02358889",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Iconic Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ranibizumab",
        "Lucentis\u00ae",
        "human Immuno-conjugate 1",
        "hI-con1",
        "Sham injection"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        88
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Age-related Macular Degeneration"
      ],
      "Start Date": [
        "2015-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00420888",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Active Biotech AB"
      ],
      "collaborators": [],
      "interventions": [
        "ABR-217620/naptumomab estafenatox",
        "naptumomab estafenatox",
        "IFN-alpha",
        "Referon-A"
      ],
      "locations": [
        "Ukraine",
        "Bulgaria",
        "Russian Federation",
        "Romania",
        "United Kingdom"
      ],
      "enrollment": [
        526
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "Start Date": [
        "2007-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06477419",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan-hziy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        33
      ],
      "conditions": [
        "Mesothelioma",
        "Mesothelioma; Pleura",
        "Mesotheliomas Pleural"
      ],
      "Start Date": [
        "2024-06-21"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06390995",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Mirvetuximab Soravtansine",
        "TAK-853"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumors"
      ],
      "Start Date": [
        "2024-05-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06378242",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Disitamab Vedotin for injection",
        "RC48"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "High-risk Non-muscle Invasive Bladder Cancer"
      ],
      "Start Date": [
        "2024-04-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06329869",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "National Taiwan University Hospital"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan"
      ],
      "locations": [],
      "enrollment": [
        35
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma"
      ],
      "Start Date": [
        "2024-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06248515",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Georgetown University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan-hziy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Thymic Carcinoma",
        "Thymoma"
      ],
      "Start Date": [
        "2024-04-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06238921",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "H. Lee Moffitt Cancer Center and Research Institute"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Stereotactic Radiation",
        "Sacituzumab govitecan",
        "Zimberelimab",
        "Trodelvy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        31
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Breast Cancer"
      ],
      "Start Date": [
        "2024-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06227156",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Disitamab Vedotin Injection",
        "DV,RC48"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        40
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer"
      ],
      "Start Date": [
        "2024-04-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06174987",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "T-DXd",
        "DS8201a"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Spain",
        "United States",
        "France",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "Start Date": [
        "2024-01-05"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06167317",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "GS-0201",
        "GS-0132",
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "Israel",
        "United States"
      ],
      "enrollment": [
        254
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2024-01-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06133517",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fundaci\u00f3n para el Progreso de la Oncolog\u00eda en Cantabria"
      ],
      "collaborators": [
        "Apices Soluciones S.L."
      ],
      "interventions": [
        "Domvanalimab",
        "Sacituzumab govitecan",
        "Zimberelimab",
        "Trodelvy"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "Urothelial Bladder Carcinoma"
      ],
      "Start Date": [
        "2024-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06123468",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Institut f\u00fcr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "Germany",
        "Austria"
      ],
      "enrollment": [
        56
      ],
      "conditions": [
        "Esophagogastric Adenocarcinoma"
      ],
      "Start Date": [
        "2024-04-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05884320",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Gland",
        "Salivary Gland Cancers"
      ],
      "Start Date": [
        "2023-07-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05833867",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Omar Mian"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Varian Inc"
      ],
      "interventions": [
        "Sacituzumab govitecan",
        "TRODELVY",
        "Adaptive Radiotherapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma",
        "Localized Muscle Invasive Bladder Urothelial Carcinoma"
      ],
      "Start Date": [
        "2024-04-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05552001",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "UNICANCER"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan",
        "trodelvy"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        96
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2023-10-05"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05260957",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Lazaros Lekakis"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Polatuzumab Vedotin",
        "Mosunetuzumab",
        "RO5541077",
        "CAR-T Cell Therapy",
        "Polatuzumab",
        "Polivy",
        "BTCT4465A",
        "Chimeric antigen receptor T-Cell Therapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        40
      ],
      "conditions": [
        "Aggressive Non-Hodgkin Lymphoma",
        "Relapsed Non Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2022-12-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05119907",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "IMMU-132",
        "GS-0132",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        300
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2021-10-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05113966",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "G1 Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy",
        "CDK 4/6 inhibitor",
        "Sacituzumab Govitecan-hziy",
        "Trilaciclib",
        "G1T28",
        "IMMU-132"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "Start Date": [
        "2021-11-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05101096",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "IMMU-132",
        "GS-0132",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        143
      ],
      "conditions": [
        "Metastatic Triple-Negative Breast Cancer",
        "Advanced Solid Tumor",
        "HR+/HER2- Metastatic Breast Cancer",
        "Metastatic Urothelial Cancer"
      ],
      "Start Date": [
        "2021-10-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04617522",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "IMMU-132",
        "GS-0132",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "United States",
        "France"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Liver Failure",
        "Advanced or Metastatic Solid Tumor"
      ],
      "Start Date": [
        "2021-04-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04454437",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "IMMU-132",
        "GS-0132",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Metastatic Triple-negative Breast Cancer"
      ],
      "Start Date": [
        "2020-10-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03995706",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "The University of Texas Health Science Center at San Antonio"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        26
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "Start Date": [
        "2019-07-17"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03964727",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "IMMU-132",
        "GS-0132",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Spain",
        "Hong Kong",
        "United States",
        "France",
        "Taiwan"
      ],
      "enrollment": [
        165
      ],
      "conditions": [
        "Metastatic Solid Tumor"
      ],
      "Start Date": [
        "2019-10-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03832361",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Alessandro Santin"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "mirvetuximab soravtansine",
        "IMGN853"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2020-07-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03677154",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Tocilizumab",
        "Polatuzumab Vedotin",
        "Mosunetuzumab Subcutaneous (SC)",
        "Mosunetuzumab Intravenous (IV)"
      ],
      "locations": [
        "Korea, Republic of",
        "Israel",
        "Spain",
        "United States",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        188
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": [
        "2019-05-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03329690",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Experimental product",
        "Standard of Care",
        "DS-8201a",
        "Physician's Choice"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan"
      ],
      "enrollment": [
        233
      ],
      "conditions": [
        "Neoplasm, Gastrointestinal"
      ],
      "Start Date": [
        "2017-11-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03086239",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab tesirine"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        29
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2017-04-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02991911",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "MEDI3726 & Enzalutamide Combo",
        "MEDI3726 Post-Chemo",
        "MEDI3726 Pre-Chemo"
      ],
      "locations": [
        "Switzerland",
        "United Kingdom",
        "United States"
      ],
      "enrollment": [
        33
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "Start Date": [
        "2017-01-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02576548",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "MEDI4276"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        47
      ],
      "conditions": [
        "HER2 Expressing Breast or Gastric/Stomach Cancers"
      ],
      "Start Date": [
        "2015-09-23"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06401824",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Maastricht University Medical Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab",
        "sacituzumab govitecan; zirabev"
      ],
      "locations": [
        "Netherlands"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Brain Metastases, Adult",
        "NSCLC Stage IV"
      ],
      "Start Date": [
        "2024-07-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02175433",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "AGS67E"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        71
      ],
      "conditions": [
        "Refractory Lymphoid Malignancy",
        "Relapsed Lymphoid Malignancy"
      ],
      "Start Date": [
        "2014-10-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02171143",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ASP2409",
        "Placebo"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        58
      ],
      "conditions": [
        "Pharmacokinetics of ASP2409",
        "Rheumatoid Arthritis"
      ],
      "Start Date": [
        "2012-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02150070",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Placebo",
        "ASP2408"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Pharmacokinetics of ASP2408",
        "Healthy Subjects"
      ],
      "Start Date": [
        "2011-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02140125",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Inc"
      ],
      "collaborators": [],
      "interventions": [
        "Placebo",
        "ASP2408"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Pharmacokinetics of ASP2408",
        "Healthy"
      ],
      "Start Date": [
        "2012-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02125435",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Placebo",
        "ASP2408"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        65
      ],
      "conditions": [
        "Pharmacokinetics of ASP2408",
        "Healthy Subjects"
      ],
      "Start Date": [
        "2011-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02052375",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Placebo",
        "ASP2408"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Pharmacokinetics of ASP2408",
        "Rheumatoid Arthritis"
      ],
      "Start Date": [
        "2012-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01901653",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Stemcentrx"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab tesirine (SC16LD6.5)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        82
      ],
      "conditions": [
        "Recurrent Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2013-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01741727",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie (prior sponsor, Abbott)"
      ],
      "collaborators": [],
      "interventions": [
        "ABT-414"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        57
      ],
      "conditions": [
        "Squamous Cell Tumors"
      ],
      "Start Date": [
        "2012-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01638936",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Biotest Pharmaceuticals Corporation"
      ],
      "collaborators": [
        "Biotest"
      ],
      "interventions": [
        "BT062 , intravenous administration",
        "Indatuximab Ravtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        64
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2012-07-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01485588",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Iconic Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "hI-con1\u2122 300\u00b5l",
        "hI-con1\u2122 150\u00b5l",
        "hI-con1\u2122 60\u00b5l"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "Start Date": [
        "2010-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01335958",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "DMUC5754A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        77
      ],
      "conditions": [
        "Ovarian Cancer, Pancreatic Cancer"
      ],
      "Start Date": [
        "2011-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01001442",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Biotest Pharmaceuticals Corporation"
      ],
      "collaborators": [
        "Biotest"
      ],
      "interventions": [
        "Indatuximab ravtansine",
        "BT062"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        35
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2010-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00944905",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [],
      "interventions": [
        "MDX-1203"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        46
      ],
      "conditions": [
        "Non-hodgkin's Lymphoma",
        "Renal Cell Carcinoma"
      ],
      "Start Date": [
        "2009-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00071539",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Teva Branded Pharmaceutical Products R&D, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "immunotoxin",
        "TP38",
        "TP-38"
      ],
      "locations": [],
      "enrollment": [
        56
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "Start Date": [
        "2003-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00056537",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Active Biotech AB"
      ],
      "collaborators": [],
      "interventions": [
        "CD3; 5T4FabV18-SEA/E-120; naptumomab estafenatox; Anyara",
        "ABR-217620"
      ],
      "locations": [
        "United Kingdom",
        "United States",
        "Norway"
      ],
      "enrollment": [
        44
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Pancreatic Cancer",
        "Non-Small-Cell Lung Carcinoma"
      ],
      "Start Date": [
        "2003-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03000257",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab Tesirine",
        "Budigalimab",
        "ABBV-181",
        "Venetoclax"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Austria",
        "Japan",
        "Spain",
        "United States",
        "France",
        "Taiwan",
        "Finland"
      ],
      "enrollment": [
        182
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2016-12-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05520723",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan",
        "Loperamide",
        "Neupogen",
        "Filgrastim",
        "Imodium",
        "Granulocyte Colony-Stimulating Factor"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-02-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06271837",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "T-DXd",
        "DS-8201a"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)"
      ],
      "Start Date": [
        "2024-02-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06172127",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Pertuzumab-Trastuzumab FDC SC",
        "T-DXd",
        "Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection",
        "PHESGO",
        "Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection",
        "Trastuzumab deruxtecan"
      ],
      "locations": [],
      "enrollment": [
        165
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2024-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06071871",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Columvi",
        "Glofitamab",
        "Polivy",
        "Obinutuzumab",
        "Polatuzumab vedotin",
        "Gazyvaro"
      ],
      "locations": [],
      "enrollment": [
        99
      ],
      "conditions": [
        "Large B-cell Lymphoma"
      ],
      "Start Date": [
        "2024-04-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06058988",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "T-DXd"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Leptomeningeal Metastasis",
        "Brain Cancer",
        "Glioblastoma",
        "Recurrent Glioblastoma",
        "Metastatic Cancer"
      ],
      "Start Date": [
        "2023-09-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05982678",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Netherlands Cancer Institute"
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Netherlands"
      ],
      "enrollment": [
        72
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2024-05-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05957757",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RenJi Hospital"
      ],
      "collaborators": [
        "RemeGen Co., Ltd.",
        "BeiGene"
      ],
      "interventions": [
        "Disitamab Vedotin",
        "RC48",
        "Tislelizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "HER2",
        "Non-Muscle Invasive Bladder Cancer"
      ],
      "Start Date": [
        "2023-08-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05795101",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Filipa Lynce, MD"
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Durvalumab",
        "Enhertu"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        63
      ],
      "conditions": [
        "Inflammatory Breast Cancer Stage III",
        "HER2 Low Breast Adenocarcinoma",
        "Breast Cancer",
        "Invasive Breast Cancer",
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2023-05-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05765851",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a (trastuzumab derextecan)",
        "DS-1103a",
        "T-DXd",
        "Enhertu\u00ae"
      ],
      "locations": [
        "Spain",
        "Canada",
        "United States",
        "France"
      ],
      "enrollment": [
        78
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-05-30"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05744375",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Spanish Breast Cancer Research Group"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Enhertu"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        41
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "Start Date": [
        "2023-09-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05704829",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "West German Study Group"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Chemotherapy+T+P",
        "ENHERTU",
        "Standard-of-Care"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": [
        402
      ],
      "conditions": [
        "HER2-positive Early Breast Cancer"
      ],
      "Start Date": [
        "2023-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05633979",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Valemetostat"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        37
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-02-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05246514",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "T-DXd, DS-8201a"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        72
      ],
      "conditions": [
        "HER2-mutant Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2022-07-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05034887",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "National Cancer Center Hospital East"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Trastuzumab Deruxtecan (T-DXd)",
        "DS-8201a"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        37
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": [
        "2022-01-31"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01829711",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Moxetumomab pasudotox",
        "IV Bag Protectant for Moxetumomab pasudotox"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Ireland",
        "Israel",
        "Serbia",
        "Czechia",
        "Norway",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Leukemia, Hairy Cell"
      ],
      "Start Date": [
        "2013-04-29"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04989816",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Trastuzumab Deruxtecan",
        "DS8201a; AZD4552; T-DXd"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        95
      ],
      "conditions": [
        "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "Start Date": [
        "2021-08-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04986579",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Daiichi Sankyo",
        "AstraZeneca",
        "Eisai Inc.",
        "Paxman Coolers Limited"
      ],
      "interventions": [
        "Trodelvy",
        "Paxman Scalp Cooling System",
        "Eribulin",
        "Sacituzumab govitecan",
        "Halaven",
        "Scalp Cooling Cap",
        "Trastuzumab deruxtecan",
        "DS-8201a",
        "Enhertu",
        "IMMU-132"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        120
      ],
      "conditions": [
        "Chemotherapy-induced Alopecia",
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2021-10-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04970901",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ADC Therapeutics S.A."
      ],
      "collaborators": [],
      "interventions": [
        "Polatuzumab Vedotin",
        "Mosunetuzumab",
        "Loncastuximab Tesirine",
        "Glofitamab",
        "Obinutuzumab",
        "ADCT-402",
        "ZYNLONTA"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Czechia",
        "Spain",
        "United States",
        "Italy"
      ],
      "enrollment": [
        200
      ],
      "conditions": [
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "B-Cell Non-Hodgkin Lymphoma",
        "Relapsed B-Cell Non-Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2022-06-17"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04784715",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab",
        "DS-8201a; T-DXd",
        "Placebo",
        "Trastuzumab deruxtecan",
        "Taxane",
        "Pertuzumab"
      ],
      "locations": [
        "Sweden",
        "Turkey",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Peru",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Saudi Arabia",
        "India",
        "Canada",
        "Philippines",
        "France",
        "Italy",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Hungary",
        "Romania",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        1157
      ],
      "conditions": [
        "Breast Cancer; HER2-positive; Metastatic"
      ],
      "Start Date": [
        "2021-04-26"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04752059",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Medical University of Vienna"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "Enhertu",
        "Ds8201a"
      ],
      "locations": [
        "Austria"
      ],
      "enrollment": [
        15
      ],
      "conditions": [
        "Breast Cancer Stage IV"
      ],
      "Start Date": [
        "2020-07-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04739761",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab Deruxtecan",
        "fam-trastuzumab deruxtecan-nxki"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Italy",
        "Belgium",
        "Australia",
        "Ireland",
        "Sweden",
        "Japan",
        "Portugal",
        "Spain",
        "Switzerland",
        "Germany",
        "Norway",
        "United States",
        "Netherlands",
        "Poland",
        "Denmark",
        "Finland"
      ],
      "enrollment": [
        506
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2021-06-22"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04644237",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        152
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2021-03-19"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04639219",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "DS-8201a (T-DXd)"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Korea, Republic of",
        "Japan",
        "Spain",
        "United States",
        "France",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        102
      ],
      "conditions": [
        "Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast"
      ],
      "Start Date": [
        "2020-12-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04482309",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "T-DXd",
        "DS-8201a"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Czechia",
        "Spain",
        "United States",
        "Netherlands",
        "Thailand",
        "Brazil",
        "Italy",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        468
      ],
      "conditions": [
        "Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",
        "Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer"
      ],
      "Start Date": [
        "2020-08-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04420598",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "(DS-8201a)"
      ],
      "locations": [
        "Spain",
        "Portugal"
      ],
      "enrollment": [
        41
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Leptomeningeal Metastasis",
        "Brain Metastases",
        "Advanced Breast Cancer"
      ],
      "Start Date": [
        "2020-05-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01030536",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "CAT-8015 30 mcg/kg",
        "CAT-8015 40 mcg/kg",
        "CAT-8015 20 mcg/kg",
        "CAT-8015 60 mcg/kg",
        "CAT-8015 50 mcg/kg"
      ],
      "locations": [
        "Poland",
        "United States"
      ],
      "enrollment": [
        23
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "Start Date": [
        "2010-02-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00659425",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "CAT-8015 (Moxetumomab Pasudotox)"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        57
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": [
        "2008-09"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00586924",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [
        "Cambridge Antibody Technology"
      ],
      "interventions": [
        "Moxetumomab Pasudotox (CAT 8015)",
        "CAT 8015 (Moxetumomab Pasudotox)"
      ],
      "locations": [
        "Poland",
        "United States"
      ],
      "enrollment": [
        49
      ],
      "conditions": [
        "Hairy Cell Leukemia"
      ],
      "Start Date": [
        "2007-05-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06448013",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Kura Oncology, Inc."
      ],
      "interventions": [
        "Ziftomenib",
        "GDC-0199",
        "Mylotarg",
        "ABT-199",
        "Gemtuzumab",
        "Venetoclax",
        "Gemtuzumab ozogamicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        22
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2024-11-29"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06254495",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-35C"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        170
      ],
      "conditions": [
        "Hodgkin Disease",
        "Lymphoma, T-Cell, Peripheral",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": [
        "2024-05-31"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06186986",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University Medical Center Groningen"
      ],
      "collaborators": [
        "Takeda"
      ],
      "interventions": [
        "Brentuximab vedotin",
        "89ZR-Brentuximab"
      ],
      "locations": [],
      "enrollment": [
        20
      ],
      "conditions": [
        "Diffuse Large B-cell-lymphoma"
      ],
      "Start Date": [
        "2024-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06120504",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-35T"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": [
        110
      ],
      "conditions": [
        "Lymphoma, T-Cell, Peripheral",
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, T-Cell, Cutaneous",
        "Lymphoma, Large-Cell, Anaplastic",
        "Hodgkin Disease"
      ],
      "Start Date": [
        "2024-02-29"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05442554",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        10
      ],
      "conditions": [
        "T-Cell Lymphoma"
      ],
      "Start Date": [
        "2023-07-20"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT05414500",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Alabama at Birmingham"
      ],
      "collaborators": [
        "Kyowa Kirin, Inc.",
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Mogamulizumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        10
      ],
      "conditions": [
        "Mycosis Fungoides",
        "Cutaneous T Cell Lymphoma"
      ],
      "Start Date": [
        "2023-05-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05357794",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35",
        "Adcetris"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Mycosis Fungoides"
      ],
      "Start Date": [
        "2022-10-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05316246",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Zhongshan Hospital"
      ],
      "collaborators": [
        "Takeda",
        "BeiGene"
      ],
      "interventions": [
        "Brentuximab Vedotin in Combination with Tislelizumab"
      ],
      "locations": [],
      "enrollment": [
        40
      ],
      "conditions": [
        "NK/T Cell Lymphoma Nos"
      ],
      "Start Date": [
        "2022-06-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04849910",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Vor Biopharma"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "Mylotarg",
        "VOR33"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute",
        "Myelodysplastic Syndromes"
      ],
      "Start Date": [
        "2021-12-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01156753",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Celldex Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "CDX-011",
        "\"Investigator's Choice\" chemotherapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        120
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2010-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04070768",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "John Quigley"
      ],
      "collaborators": [
        "Pfizer",
        "AbbVie"
      ],
      "interventions": [
        "Gemtuzumab Ozogamicin",
        "GO",
        "Venetoclax"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2019-09-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00704158",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "CuraGen Corporation"
      ],
      "collaborators": [],
      "interventions": [
        "CR011-vcMMAE"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        42
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2008-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03727750",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Gemtuzumab Ozogamicin"
      ],
      "locations": [
        "Canada",
        "Hungary",
        "Spain",
        "United States",
        "United Kingdom",
        "Poland"
      ],
      "enrollment": [
        51
      ],
      "conditions": [
        "Safety",
        "Pharmacokinetics",
        "ECG"
      ],
      "Start Date": [
        "2019-07-03"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT03671018",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Mosunetuzumab (IV)",
        "Rituximab",
        "BTCT4465A",
        "Tocilizumab",
        "Polatuzumab vedotin",
        "Mosunetuzumab (SC)"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Spain",
        "United States",
        "United Kingdom"
      ],
      "enrollment": [
        422
      ],
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2018-09-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03587844",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "brentuximab vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        58
      ],
      "conditions": [
        "Sezary Syndrome",
        "Mycosis Fungoides",
        "Lymphomatoid Papulosis"
      ],
      "Start Date": [
        "2018-07-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00412828",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "CuraGen Corporation"
      ],
      "collaborators": [],
      "interventions": [
        "CR011-vcMMAE"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        117
      ],
      "conditions": [
        "Unresectable Stage III or Stage IV Melanoma"
      ],
      "Start Date": [
        "2006-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03374332",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Brown University"
      ],
      "collaborators": [
        "Rhode Island Hospital",
        "Pfizer",
        "The Miriam Hospital"
      ],
      "interventions": [
        "Donor Leukocytes",
        "Gemtuzumab Ozogamicin (GO)",
        "Mylotarg"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        11
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2019-12-31"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03264131",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "CHEP",
        "Brentuximab Vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        16
      ],
      "conditions": [
        "Adult T-Cell Leukemia/Lymphoma",
        "Lymphatic Diseases",
        "Lymphoma"
      ],
      "Start Date": [
        "2018-10-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03222492",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "National Institute of Allergy and Infectious Diseases (NIAID)"
      ],
      "collaborators": [
        "Immune Tolerance Network (ITN)",
        "Rho Federal Systems Division, Inc.",
        "Seagen Inc.",
        "PPD"
      ],
      "interventions": [
        "Placebo for brentuximab vedotin",
        "Brentuximab Vedotin",
        "Placebo",
        "Adcetris\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        17
      ],
      "conditions": [
        "Scleroderma",
        "Diffuse Cutaneous Systemic Sclerosis",
        "dcSSc"
      ],
      "Start Date": [
        "2017-09-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03217643",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Imagine Institute"
      ],
      "collaborators": [
        "Takeda"
      ],
      "interventions": [
        "Brentuximab Vedotin"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        14
      ],
      "conditions": [
        "Enteropathy Associated T-cell Lymphoma"
      ],
      "Start Date": [
        "2018-02-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05834296",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Alzamend Neuro, Inc."
      ],
      "collaborators": [
        "bioRASI, LLC"
      ],
      "interventions": [
        "Placebo",
        "ALZN002 (autologous DCs pulsed with E22W mutant peptide)."
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "Start Date": [
        "2023-07-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02939014",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab Vedotin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        39
      ],
      "conditions": [
        "Hodgkin Disease",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": [
        "2016-11-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02611323",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Venetoclax"
      ],
      "locations": [
        "Australia",
        "United States",
        "Italy"
      ],
      "enrollment": [
        133
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "Start Date": [
        "2016-03-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02280785",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Samsung Medical Center"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris"
      ],
      "locations": [
        "Korea, Republic of"
      ],
      "enrollment": [
        33
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2014-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02164006",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TG Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "TGR-1202 + brentuximab vedotin",
        "brentuximab vedotin: Adcetris"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        16
      ],
      "conditions": [
        "Hodgkin's Lymphoma"
      ],
      "Start Date": [
        "2014-06-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01851200",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fondazione Michelangelo"
      ],
      "collaborators": [
        "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "SGN-35",
        "Brentuximab Vedotin",
        "Adcetris"
      ],
      "locations": [
        "Italy"
      ],
      "enrollment": [
        9
      ],
      "conditions": [
        "Germ Cell Cancer"
      ],
      "Start Date": [
        "2013-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01700751",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Washington University School of Medicine"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "Adcetris"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        17
      ],
      "conditions": [
        "Leukemia, Acute Myeloid",
        "Leukemia, Lymphoblastic,Acute",
        "Myelodysplastic Syndromes"
      ],
      "Start Date": [
        "2013-02-25"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01691898",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "DCDT2980S",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Pinatuzumab Vedotin",
        "GA101, Gazyva, Gazyvaro",
        "DCDS4501A",
        "Obinutuzumab",
        "MabThera/Rituxan"
      ],
      "locations": [
        "Canada",
        "Germany",
        "United States",
        "France",
        "Netherlands",
        "Italy"
      ],
      "enrollment": [
        231
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2012-09-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01596218",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Dana-Farber Cancer Institute"
      ],
      "interventions": [
        "SGN-35",
        "Brentuximab Vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        35
      ],
      "conditions": [
        "Graft vs. Host Disease"
      ],
      "Start Date": [
        "2012-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01578967",
      "phases": [],
      "sponsor": [
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35",
        "Adcetris",
        "ABVD"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        41
      ],
      "conditions": [
        "Hodgkin Lymphoma, Adult"
      ],
      "Start Date": [
        "2012-04"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT01508312",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "H\u00f4pitaux Universitaires Henri Mondor, France"
      ],
      "interventions": [
        "Brentuximab Vedotin (SGN-35)",
        "brentuximab vedotin (SGN-35)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        46
      ],
      "conditions": [
        "Hodgkin's Lymphoma"
      ],
      "Start Date": [
        "2012-01-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01492088",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35",
        "ADCETRIS"
      ],
      "locations": [
        "Mexico",
        "United Kingdom",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Netherlands",
        "Italy"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Relapsed or Refractory Hodgkin Lymphoma",
        "Relapsed or Refractory Anaplastic Large-cell Lymphoma"
      ],
      "Start Date": [
        "2012-04-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01352520",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        79
      ],
      "conditions": [
        "Hematologic Disorder",
        "CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma",
        "Skin Lymphoma",
        "Lymphomatoid Papulosis",
        "Cutaneous Lymphomas",
        "Mycosis Fungoides",
        "Lymphoma, Primary Cutaneous Anaplastic Large Cell",
        "Lymphoma"
      ],
      "Start Date": [
        "2011-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01290549",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Polatuzumab Vedotin",
        "Rituximab",
        "DCDS4501A"
      ],
      "locations": [
        "Canada",
        "Netherlands",
        "United States",
        "France"
      ],
      "enrollment": [
        95
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "Start Date": [
        "2011-03-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01209130",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "DCDT2980S",
        "rituximab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        91
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia"
      ],
      "Start Date": [
        "2010-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00962767",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Arm B",
        "gemtuzumab ozogamicin",
        "ATRA plus 6-MP and MTX",
        "Arm A"
      ],
      "locations": [],
      "enrollment": [
        168
      ],
      "conditions": [
        "Leukemia, Myelocytic, Acute"
      ],
      "Start Date": [
        "2002-05"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT00860639",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Nantes University Hospital"
      ],
      "collaborators": [
        "Chugai Pharmaceutical",
        "French Innovative Leukemia Organisation"
      ],
      "interventions": [
        "gemtuzumab ozogamycin (MYLOTARG \u00ae)",
        "gemtuzumab ozogamycin"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        327
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2007-10"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT00304447",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Mylotarg"
      ],
      "locations": [],
      "enrollment": [
        30
      ],
      "conditions": [
        "Infusions, Intravenous",
        "Leukemia, Myelocytic, Acute"
      ],
      "Start Date": [
        "2002-04"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT00233909",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Kanisa Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "Zosuquidar",
        "gemtuzumab ozogamicin"
      ],
      "locations": [],
      "enrollment": [
        55
      ],
      "conditions": [
        "Leukemia, Myeloid"
      ],
      "Start Date": [
        "2005-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00003673",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "chemotherapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        55
      ],
      "conditions": [
        "Leukemia"
      ],
      "Start Date": [
        "1998-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00003131",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "chemotherapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        55
      ],
      "conditions": [
        "Leukemia"
      ],
      "Start Date": [
        "1997-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00079755",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-30 (anti-CD30 mAb)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Anaplastic Large-Cell Lymphoma"
      ],
      "Start Date": [
        "2004-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00017589",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genta Incorporated"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "oblimersen sodium"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        null
      ],
      "conditions": [
        "Leukemia"
      ],
      "Start Date": [
        "2000-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00044733",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Mylotarg (gemtuzumab ozogamicin) Injection"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        38
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": [
        "2000-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00037583",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Gemtuzumab Ozogamicin"
      ],
      "locations": [],
      "enrollment": [
        69
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        null
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05687032",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "inotuzumab ozogamicin",
        "Besponsa"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        44
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": [
        "2023-02-24"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT02423928",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alden Cancer Therapy II"
      ],
      "collaborators": [
        "Norwegian Radium Hospital",
        "Haukeland University Hospital"
      ],
      "interventions": [
        "Dendritic cell based cryoimmunotherapy",
        "ipilimumab",
        "Yervoy",
        "ACT2001",
        "Cyclophosphamide",
        "Sendoxan"
      ],
      "locations": [
        "Norway"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": [
        "2015-05"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04553770",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jonsson Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd.",
        "Translational Research in Oncology-U.S"
      ],
      "interventions": [
        "Arimidex",
        "Therapeutic Conventional Surgery",
        "ICI-D1033",
        "WHO 10516",
        "ICI D1033",
        "Fam-trastuzumab Deruxtecan-nxki",
        "DS-8201",
        "DS-8201a",
        "ZD-1033",
        "Trastuzumab Deruxtecan",
        "Enhertu",
        "Anastrozole",
        "Anastrazole"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        88
      ],
      "conditions": [
        "Early-stage Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Stage II Breast Cancer",
        "Stage IIB Breast Cancer",
        "Invasive Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage III Breast Cancer"
      ],
      "Start Date": [
        "2020-10-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03983954",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "NeoTX Therapeutics Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Obinutuzumab pretreatment (Gazyva\u00ae) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)",
        "Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)"
      ],
      "locations": [
        "Israel"
      ],
      "enrollment": [
        60
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Colorectal Cancer Metastatic",
        "Renal Cell Carcinoma",
        "NSCLC",
        "Pancreatic Adenocarcinoma",
        "HER2-negative Breast Cancer",
        "Hepatocellular Carcinoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "ER+ Breast Cancer",
        "GastroEsophageal Cancer",
        "Cervical Squamous Cell Carcinoma",
        "Mesothelioma",
        "Endometrial Cancer",
        "Melanoma",
        "Urothelial Cancer",
        "NSCL2 Gene Mutation",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2019-10-10"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00346385",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN901",
        "BB-10901"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": [
        97
      ],
      "conditions": [
        "SCLC",
        "Ovarian Cancer",
        "Merkel Cell Carcinoma"
      ],
      "Start Date": [
        "2002-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00346255",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN901",
        "BB-10901"
      ],
      "locations": [
        "Argentina",
        "United States"
      ],
      "enrollment": [
        37
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2005-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00065429",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "BB-10901"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        64
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2003-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01363297",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "CMC-544",
        "Inotuzumab Ozogamicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        72
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia"
      ],
      "Start Date": [
        "2011-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00868608",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "inotuzumab ozogamicin",
        "Inotuzumab Ozogamicin (CMC-544)"
      ],
      "locations": [
        "Belgium",
        "Korea, Republic of",
        "Hungary",
        "Japan",
        "Germany",
        "Singapore",
        "Hong Kong",
        "United States",
        "Netherlands"
      ],
      "enrollment": [
        81
      ],
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": [
        "2009-07-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00717925",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Inotuzumab Ozogamicin (CMC-544)"
      ],
      "locations": [],
      "enrollment": [
        13
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": [
        "2007-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06155383",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Capecitabine",
        "Disitamab Vedotin",
        "JS001",
        "oxaliplatin",
        "Toripalimab",
        "RC48"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": [
        "2023-11-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00073749",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Inotuzumab ozogamicin [CMC-544]"
      ],
      "locations": [
        "Belgium",
        "Spain",
        "Switzerland",
        "Germany",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        79
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": [
        "2003-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05089734",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Sacituzumab Govitecan-hziy (SG)",
        "IMMU-132",
        "GS-0132",
        "Docetaxel"
      ],
      "locations": [
        "Puerto Rico",
        "Turkey",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "United States",
        "Brazil",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Mexico",
        "Australia",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Israel"
      ],
      "enrollment": [
        603
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2021-11-17"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05006794",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "GS-9716",
        "Docetaxel",
        "sacituzumab govitecan-hziy"
      ],
      "locations": [
        "Israel",
        "United States"
      ],
      "enrollment": [
        195
      ],
      "conditions": [
        "Solid Malignancies"
      ],
      "Start Date": [
        "2021-09-15"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01134575",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "interventions": [
        "CMC-544 (Inotuzumab Ozogamycin)",
        "rituxan",
        "Rituximab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": [
        "2010-06-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00867087",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "inotuzumab ozogamicin (CMC-544)",
        "rituximab",
        "cmc-544"
      ],
      "locations": [
        "Korea, Republic of",
        "Germany",
        "Singapore",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        64
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": [
        "2009-06-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00724971",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Inotuzumab Ozogamicin (CMC-544)",
        "Rituximab (Rituxan)"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        10
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": [
        "2008-07-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06221748",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "AK104, Cadonilimab Injection",
        "DV,RC48",
        "Disitamab Vedotin Injection",
        "Paclitaxel Injection",
        "Cadonilimab Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": [
        "2024-02-22"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06081244",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "West German Study Group"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Keytruda",
        "Pembrolizumab",
        "Sacituzumab govitecan",
        "Trodelvy"
      ],
      "locations": [],
      "enrollment": [
        348
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "Start Date": [
        "2024-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00299494",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "Rituximab",
        "CMC-544",
        "inotuzumab ozogamicin"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Italy",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Hong Kong",
        "Switzerland",
        "Germany",
        "United States",
        "Netherlands",
        "France",
        "Poland"
      ],
      "enrollment": [
        119
      ],
      "conditions": [
        "B-Cell Lymphoma"
      ],
      "Start Date": [
        "2006-05-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05675579",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "KEYTRUDA\u00ae",
        "Pembrolizumab",
        "(IMMU-132) Immunomedics",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-05-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05480384",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Brown University"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "OPDIVO",
        "Nivolumab",
        "ENHERTU"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "HER-2 Protein Overexpression",
        "Esophageal Adenocarcinoma",
        "Esophageal Cancer",
        "Gastroesophageal-junction Cancer"
      ],
      "Start Date": [
        "2023-07-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02590263",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Temozolomide",
        "ABT-414",
        "Mafodotin",
        "Depatuxizumab",
        "Whole Brain Radiation"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": [
        53
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma Multiforme"
      ],
      "Start Date": [
        "2015-08-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05186974",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Platinol\u00ae",
        "GS-0132",
        "Cisplatin",
        "Paraplatin\u00ae",
        "KEYTRUDA\u00ae",
        "Sacituzumab Govitecan-hziy (SG)",
        "IMMU-132",
        "Carboplatin"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Korea, Republic of",
        "Malaysia",
        "Australia",
        "Spain",
        "Hong Kong",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        193
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2022-05-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04863885",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "H. Lee Moffitt Cancer Center and Research Institute"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "Yervoy",
        "Trodelvy",
        "Opdivo",
        "Sacituzumab govitecan",
        "Nivolumab",
        "Ipilimumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        46
      ],
      "conditions": [
        "Metastatic Urothelial Carcinoma"
      ],
      "Start Date": [
        "2021-04-30"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04794699",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "IDEAYA Biosciences"
      ],
      "collaborators": [],
      "interventions": [
        "Sacituzumab govitecan",
        "Paclitaxel",
        "IDE397",
        "Docetaxel"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Taiwan"
      ],
      "enrollment": [
        180
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": [
        "2021-04-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01800695",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Temozolomide",
        "ABT-414",
        "Depatuxizumab Mafodotin",
        "Whole Brain Radiation"
      ],
      "locations": [],
      "enrollment": [
        202
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "Start Date": [
        "2013-04-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04527991",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "Vinflunine",
        "Paclitaxel",
        "Sacituzumab Govitecan-hziy",
        "Taxol\u00ae",
        "GS-0132",
        "Taxotere\u00ae",
        "Javlor \u00ae",
        "Docetaxel",
        "IMMU-132"
      ],
      "locations": [
        "Puerto Rico",
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "Hong Kong",
        "United States",
        "Georgia",
        "Canada",
        "Bulgaria",
        "Singapore",
        "France",
        "Italy",
        "Taiwan",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Austria",
        "Germany",
        "Croatia",
        "Spain",
        "Israel"
      ],
      "enrollment": [
        696
      ],
      "conditions": [
        "Locally Advanced or Metastatic Unresectable Urothelial Cancer"
      ],
      "Start Date": [
        "2021-01-13"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04468061",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Trodelvy",
        "Sacituzumab Govitecan",
        "IMMU-132",
        "Keytruda"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        110
      ],
      "conditions": [
        "PD-L1 Negative",
        "Triple Negative Breast Cancer",
        "Breast Cancer"
      ],
      "Start Date": [
        "2020-07-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04448886",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Ana C Garrido-Castro, MD"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Keytruda",
        "Pembrolizumab",
        "TRODELVY",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        110
      ],
      "conditions": [
        "Invasive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Metastatic Breast Cancer",
        "HR-Positive Breast Cancer"
      ],
      "Start Date": [
        "2020-09-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04230109",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Pembrolizumab",
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        260
      ],
      "conditions": [
        "ER-Negative Breast Cancer",
        "Triple Negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "Invasive Breast Cancer",
        "PR-Negative Breast Cancer"
      ],
      "Start Date": [
        "2020-07-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06467357",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo"
      ],
      "interventions": [
        "Agilent HercepTest\u2122 mAb pharmDx",
        "DS-8201a; T-DXd",
        "Durvalumab",
        "Ventana PD-L1 SP263 assay",
        "Rilvegostomig",
        "Trastuzumab deruxtecan",
        "Cisplatin",
        "Gemcitabine"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Korea, Republic of",
        "Austria",
        "Japan",
        "Germany",
        "Netherlands",
        "Brazil",
        "Taiwan"
      ],
      "enrollment": [
        620
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": [
        "2024-06-26"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03533283",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Polatuzumab Vedotin",
        "Glofitamab",
        "Obinutuzumab",
        "Tocilizumab",
        "Atezolizumab",
        "89Zr-Df-IAB22M2C",
        "RO7082859",
        "Actemra"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Israel",
        "Spain",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        280
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma"
      ],
      "Start Date": [
        "2018-05-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03310957",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "LV",
        "ladiratuzumab vedotin",
        "SGN-LIV1A",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Spain",
        "United States",
        "Germany",
        "Korea, Republic of"
      ],
      "enrollment": [
        186
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "Start Date": [
        "2018-02-27"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00132379",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Active Biotech AB"
      ],
      "collaborators": [],
      "interventions": [
        "docetaxel",
        "CD3; 5T4FabV18-SEA/E-120; naptumomab estafenatox; Anyara",
        "Taxotere",
        "ABR-217620"
      ],
      "locations": [
        "Denmark",
        "United States",
        "Russian Federation"
      ],
      "enrollment": [
        13
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": [
        "2005-11"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02696642",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "Moldova, Republic of",
        "France"
      ],
      "enrollment": [
        54
      ],
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": [
        "2016-04-14"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05417594",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Temozolomide",
        "Datopotamab Deruxtecan (Dato-DXd)",
        "AZD9574",
        "Trastuzumab Deruxtecan (T-DXd)",
        "[11C]AZ1419 3391"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Sweden",
        "Spain",
        "Germany",
        "United States",
        "United Kingdom"
      ],
      "enrollment": [
        490
      ],
      "conditions": [
        "Advanced Solid Malignancies"
      ],
      "Start Date": [
        "2022-08-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02610140",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [
        "ImmunoGen and MorphoSys"
      ],
      "interventions": [
        "Vinorelbine",
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Italy",
        "Belgium",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Turkey",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Poland",
        "Finland"
      ],
      "enrollment": [
        248
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "Start Date": [
        "2015-12-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04880863",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "NeoTX Therapeutics Ltd."
      ],
      "collaborators": [
        "Translational Drug Development"
      ],
      "interventions": [
        "ABR-217620",
        "NAP (Naptumomab estafenatox)",
        "Taxotere",
        "Obinutuzumab",
        "Docetaxel",
        "Gazyva",
        "Anyara"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        38
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2021-10-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04609566",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "KEYTRUDA\u00ae",
        "brentuximab vedotin",
        "ADCETRIS",
        "pembrolizumab"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        140
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "Start Date": [
        "2021-01-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04539938",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "TUKYSA, ARRY-380, ONT-380",
        "trastuzumab deruxtecan",
        "tucatinib",
        "T-DXd, Enhertu, DS-8201"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "HER2 Positive Breast Cancer"
      ],
      "Start Date": [
        "2020-12-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01609556",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "Mirvetuximab soravtansine"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        206
      ],
      "conditions": [
        "Tumors"
      ],
      "Start Date": [
        "2012-06-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02729896",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Atezolizumab [TECENTRIQ]"
      ],
      "locations": [
        "Germany",
        "Poland",
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": [
        "2016-11-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02684292",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [],
      "interventions": [
        "brentuximab vedotin",
        "MK-3475",
        "ADCETRIS\u00ae",
        "KEYTRUDA\u00ae",
        "pembrolizumab"
      ],
      "locations": [],
      "enrollment": [
        304
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2016-05-23"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02600897",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Lenalidomide",
        "Obinutuzumab",
        "Polatuzumab Vedotin",
        "Rituximab"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States"
      ],
      "enrollment": [
        114
      ],
      "conditions": [
        "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2016-03-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02581631",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab Vedotin",
        "Nivolumab"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Spain",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        145
      ],
      "conditions": [
        "Non-Hodgkin's Disease"
      ],
      "Start Date": [
        "2016-02-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05171647",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Oxaliplatin",
        "Mosunetuzumab",
        "Rituximab",
        "Tocilizumab",
        "Polatuzumab vedotin",
        "Gemcitabine"
      ],
      "locations": [
        "Canada",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "New Zealand",
        "Brazil",
        "Japan",
        "China",
        "Peru",
        "Turkey",
        "United States",
        "Thailand",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        222
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2022-04-25"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05097599",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Strata Oncology"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Pfizer",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "sacituzumab govitecan",
        "encorafenib + binimetinib",
        "lorlatinib",
        "axitinib",
        "talazoparib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        700
      ],
      "conditions": [
        "Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": [
        "2021-11-19"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02429375",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "MethylGene Inc."
      ],
      "interventions": [
        "SGN-35",
        "MGCD0103",
        "Mocetinostat Plus Brentuximab Vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        7
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2015-04-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04958785",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u00ae",
        "Abraxane",
        "Paclitaxel",
        "Sacituzumab Govitecan-hziy",
        "Taxol\u00ae",
        "GS-0132",
        "GS-4721",
        "Nab-Paclitaxel",
        "Magrolimab"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Hong Kong",
        "United States",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        92
      ],
      "conditions": [
        "Triple-Negative Breast Cancer"
      ],
      "Start Date": [
        "2021-12-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02086604",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Washington University School of Medicine"
      ],
      "collaborators": [
        "Celgene",
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Lenalidomide",
        "Revlimid\u00ae",
        "Adcetris\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        37
      ],
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": [
        "2014-09-18"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04733118",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Phesgo",
        "Trastuzumab emtansine",
        "Kadcyla",
        "Trastuzumab and Pertuzumab (FDC SC) and T-DM1"
      ],
      "locations": [
        "Bulgaria",
        "Hungary",
        "Spain",
        "Germany",
        "Italy"
      ],
      "enrollment": [
        393
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "Start Date": [
        "2021-08-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04622319",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "NSABP Foundation Inc",
        "Spanish Breast Cancer Research Group (SOLTI)",
        "German Breast Group",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab emtansine (T-DM1)",
        "T-DM1",
        "Trastuzumab deruxtecan (T-DXd)",
        "DS-8201a"
      ],
      "locations": [
        "Turkey",
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "Peru",
        "Hong Kong",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Australia",
        "Romania",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        1600
      ],
      "conditions": [
        "Residual Invasive Breast Cancer",
        "HER2-Positive Primary Breast Cancer"
      ],
      "Start Date": [
        "2020-12-04"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04404283",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin",
        "Lenalidomide",
        "Placebo",
        "Rituximab"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Italy",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Czechia",
        "Spain",
        "Switzerland",
        "Germany",
        "United States",
        "Netherlands",
        "France",
        "Poland",
        "Denmark",
        "Taiwan"
      ],
      "enrollment": [
        240
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": [
        "2020-08-20"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04182204",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Polatuzumab Vedotin",
        "Rituximab",
        "Oxaliplatin",
        "Mabthera; Rituxan",
        "Gemcitabine"
      ],
      "locations": [
        "Canada",
        "Greece",
        "Mexico",
        "United Kingdom",
        "Korea, Republic of",
        "Ireland",
        "India",
        "Turkey",
        "China",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "Italy",
        "Finland"
      ],
      "enrollment": [
        270
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2020-02-07"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03742102",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel",
        "Durvalumab",
        "Oleclumab",
        "Datopotamab deruxtecan",
        "Dato-DXd; DS-1062a",
        "Trastuzumab deruxtecan",
        "AZD5363",
        "MEDI4736",
        "MEDI9447",
        "DS-8201a",
        "Capivasertib"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "United States",
        "United Kingdom",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        240
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "Start Date": [
        "2018-12-21"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06324357",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Boehringer Ingelheim"
      ],
      "collaborators": [],
      "interventions": [
        "T-DM1; Kadcyla\u00ae",
        "Trastuzumab deruxtecan",
        "Trastuzumab emtansine",
        "T-DXd; Enhertu\u00ae",
        "Zongertinib",
        "BI 1810631"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        240
      ],
      "conditions": [
        "Metastatic Gastric Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Metastatic Breast Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": [
        "2024-05-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06313086",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "trastuzumab emtansine",
        "DP303c",
        "T -DM1"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        442
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2024-03-13"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06126640",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Jiangsu HengRui Medicine Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "SHR-A1811",
        "Trastuzumab Emtansine"
      ],
      "locations": [],
      "enrollment": [
        1200
      ],
      "conditions": [
        "HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy"
      ],
      "Start Date": [
        "2023-11"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05904106",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Technische Universit\u00e4t Dresden"
      ],
      "collaborators": [
        "University Hospital Heidelberg",
        "AbbVie"
      ],
      "interventions": [
        "Venetoclax plus Azacitidine",
        "standard of care chemotherapy plus gemtuzumab ozogamicin"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": [
        146
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2023-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05840211",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "Capecitabine",
        "Nab-paclitaxel",
        "Paclitaxel",
        "Sacituzumab Govitecan-hziy",
        "Taxol\u00ae",
        "Abraxane\u00ae",
        "GS-0132",
        "Xeloda\u00ae",
        "IMMU-132"
      ],
      "locations": [
        "Czechia",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "Hong Kong",
        "United States",
        "Brazil",
        "Canada",
        "Malaysia",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        654
      ],
      "conditions": [
        "Locally Advanced or Unresectable Metastatic Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "Start Date": [
        "2023-05-08"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05650879",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Enliven Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "Fam-Trastuzumab Deruxtecan-Nxki",
        "T-DXd",
        "Trastuzumab emtansine",
        "Kadcyla",
        "T-DM1",
        "Enhertu",
        "ELVN-002"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "France",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        198
      ],
      "conditions": [
        "HER2 Amplification",
        "HER2 Mutant Non-small Cell Lung Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Gene Mutation"
      ],
      "Start Date": [
        "2023-03-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05633654",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "NSABP Foundation Inc",
        "Alliance Foundation Trials, LLC."
      ],
      "interventions": [
        "Trodelvy\u2122",
        "Pembrolizumab",
        "Capecitabine",
        "GS-0132",
        "KEYTRUDA\u00ae",
        "IMMU-132",
        "Xeloda",
        "Sacituzumab govitecan-hziy (SG)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        1514
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "Start Date": [
        "2022-12-12"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05593094",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Suzhou Zanrong Pharma Limited"
      ],
      "collaborators": [],
      "interventions": [
        "ZN-A-1041 50mg BID",
        "ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c",
        "ZN-A-1041 200mg BID",
        "ZN-A-1041 100mg BID",
        "ZN-A-1041 400mg BID",
        "ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c",
        "ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b",
        "ZN-A-1041 600mg BID",
        "ZN-A-1041 800mg BID",
        "ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b",
        "ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c",
        "ZN-A-1041 Enteric Capsules",
        "ZN-A-1041 1000mg BID",
        "ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        210
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Advanced Solid Tumors"
      ],
      "Start Date": [
        "2020-10-15"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05415215",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Radiotherapy",
        "Investigator's Choice of Chemotherapy",
        "Kadcyla\u00ae",
        "Surgery",
        "Trastuzumab IV",
        "PHESGO\u00ae",
        "Herceptin\u00ae",
        "Perjeta\u00ae",
        "T-DM1",
        "RO5304020",
        "RO0452317",
        "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
        "Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)",
        "RO7198574",
        "RG6264",
        "Trastuzumab Emtansine",
        "Pertuzumab IV",
        "RO4368451",
        "Pertuzumab, Trastuzumab, and rHuPH20",
        "ado-trastuzumab emtansine"
      ],
      "locations": [
        "Canada",
        "Mexico",
        "South Africa",
        "Bulgaria",
        "Korea, Republic of",
        "Kenya",
        "Brazil",
        "Costa Rica",
        "Spain",
        "Singapore",
        "Croatia",
        "Peru",
        "Turkey",
        "Argentina",
        "Chile",
        "Bosnia and Herzegovina",
        "India"
      ],
      "enrollment": [
        347
      ],
      "conditions": [
        "Early Breast Cancer",
        "Inflammatory Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "Start Date": [
        "2022-07-05"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05382299",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u2122",
        "Paclitaxel",
        "Sacituzumab Govitecan-hziy",
        "Abraxane\u00ae",
        "GS-0132",
        "nab-Paclitaxel",
        "Gemcitabine",
        "IMMU-132",
        "Carboplatin"
      ],
      "locations": [
        "Puerto Rico",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "China",
        "Hong Kong",
        "United States",
        "Brazil",
        "Canada",
        "Malaysia",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel",
        "Slovakia"
      ],
      "enrollment": [
        540
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "PD-L1 Negative"
      ],
      "Start Date": [
        "2022-07-20"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05274048",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fox Chase Cancer Center"
      ],
      "collaborators": [
        "Puma Biotechnology, Inc.",
        "National Comprehensive Cancer Network"
      ],
      "interventions": [
        "Neratinib Pill",
        "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": [
        "2022-06-24"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02639091",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "Pemetrexed",
        "Cisplatin",
        "BAY 94-9343"
      ],
      "locations": [
        "Italy",
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "Medical Oncology"
      ],
      "Start Date": [
        "2016-02-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02467946",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Centre Antoine Lacassagne"
      ],
      "collaborators": [
        "Millennium: The Takeda Oncology Company"
      ],
      "interventions": [
        "Brentuximab Vedotin",
        "Bendamustine",
        "Adcetris-Levact"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        60
      ],
      "conditions": [
        "Safety",
        "Clinical Efficacy"
      ],
      "Start Date": [
        "2016-01-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04893109",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Paclitaxel",
        "Taxol",
        "Onxal",
        "Herceptin Hylecta",
        "T-DM1",
        "Kadcyla",
        "Trastuzumab SC",
        "trastuzumab-emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        500
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Breast Cancer"
      ],
      "Start Date": [
        "2021-06-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01565200",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jules Bordet Institute"
      ],
      "collaborators": [
        "Roche Pharma AG"
      ],
      "interventions": [
        "89Zr-trastuzumab",
        "Zirconium 89 labelled trastuzumab",
        "T-DM1",
        "Trastuzumab-DM1"
      ],
      "locations": [
        "Belgium",
        "Netherlands"
      ],
      "enrollment": [
        90
      ],
      "conditions": [
        "HER-2 Positive Breast Cancer"
      ],
      "Start Date": [
        "2012-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03901339",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Capecitabine",
        "Sacituzumab Govitecan-hziy",
        "Vinorelbine",
        "Eribulin",
        "GS-0132",
        "Gemcitabine",
        "IMMU-132"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Spain",
        "Germany",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ],
      "enrollment": [
        543
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2019-05-08"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03547973",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany"
      ],
      "interventions": [
        "Trodelvy\u2122",
        "Pembrolizumab",
        "Domvanalimab",
        "BAVENCIO\u00ae",
        "Sacituzumab Govitecan-hziy",
        "Avelumab",
        "Cisplatin",
        "Zimberelimab",
        "KEYTRUDA\u00ae",
        "Gemcitabine",
        "IMMU-132",
        "Carboplatin"
      ],
      "locations": [
        "Greece",
        "United Kingdom",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        643
      ],
      "conditions": [
        "Metastatic Urothelial Cancer"
      ],
      "Start Date": [
        "2018-08-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00932373",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "trastuzumab-MCC-DM1"
      ],
      "locations": [],
      "enrollment": [
        54
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2006-04"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00928330",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "GDC-0941",
        "Trastuzumab",
        "trastuzumab-MCC-DM1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        57
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2009-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03153163",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "RO5304020",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        11
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2017-06-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03102320",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [
        "MorphoSys AG",
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Gemcitabine",
        "Cisplatin",
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Singapore",
        "Switzerland",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ],
      "enrollment": [
        173
      ],
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": [
        "2017-05-26"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02999672",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Kadcyla",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "Spain",
        "Italy",
        "Slovakia",
        "Netherlands"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Bladder Cancer",
        "Cholangiocellular Carcinoma",
        "Pancreas Cancer"
      ],
      "Start Date": [
        "2016-12-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02675829",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "ado-trastuzumab emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        140
      ],
      "conditions": [
        "Lung Cancer",
        "Bladder Cancer",
        "Urinary Tract Cancers",
        "Solid Tumor Cancers"
      ],
      "Start Date": [
        "2016-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02658734",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine"
      ],
      "locations": [
        "India"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer"
      ],
      "Start Date": [
        "2016-11-01"
      ],
      "Max Phase": "4"
    },
    {
      "id": "NCT02616965",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fox Chase Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Celgene Corporation"
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Romidepsin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        16
      ],
      "conditions": [
        "Cutaneous T-cell Lymphoma (CTCL)"
      ],
      "Start Date": [
        "2017-02-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02574455",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Trodelvy\u00ae",
        "Capecitabine",
        "Vinorelbine",
        "Eribulin",
        "Sacituzumab govitecan",
        "Halaven",
        "Navelbine",
        "Gemzar",
        "Gemcitabine",
        "IMMU-132",
        "Xeloda"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Spain",
        "Germany",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        529
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2017-11-07"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02420873",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Lorvotuzumab Mertansine (IMGN901)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        9
      ],
      "conditions": [
        "Leukemia"
      ],
      "Start Date": [
        "2015-05-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02390427",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Otto Metzger, MD"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Trastuzumab",
        "Taselisib",
        "Paclitaxel",
        "Herceptin",
        "Taxol",
        "Onxal",
        "GCD-0032",
        "Trastuzumab emtansine",
        "T-DM1",
        "Kadcyla",
        "Perjeta",
        "Pertuzumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        68
      ],
      "conditions": [
        "Recurrent Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2015-04-20"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02289833",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Kadcyla, T-DM1",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "Korea, Republic of",
        "Spain",
        "Switzerland",
        "Germany",
        "United States",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        49
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2014-12-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02254018",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Boehringer Ingelheim"
      ],
      "collaborators": [],
      "interventions": [
        "bivatuzumab mertansine"
      ],
      "locations": [],
      "enrollment": [
        31
      ],
      "conditions": [
        "Head and Neck Neoplasms"
      ],
      "Start Date": [
        "2002-09-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02254005",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Boehringer Ingelheim"
      ],
      "collaborators": [],
      "interventions": [
        "bivatuzumab mertansine"
      ],
      "locations": [],
      "enrollment": [
        24
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2002-10-01"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02131064",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab",
        "Herceptin\u00ae",
        "Trastuzumab Emtansine",
        "Kadcyla\u00ae, RO5304020",
        "Perjeta\u00ae, RO4368451",
        "Docetaxel",
        "Carboplatin",
        "Pertuzumab"
      ],
      "locations": [
        "Canada",
        "Ukraine",
        "Belgium",
        "Russian Federation",
        "Korea, Republic of",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Taiwan"
      ],
      "enrollment": [
        444
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2014-06-25"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01904903",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Medstar Health Research Institute"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Pertuzumab",
        "Trastuzumab",
        "Herceptin",
        "Kadcyla",
        "Perjeta",
        "Ado Trastuzumab Emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        31
      ],
      "conditions": [
        "HER2 Positive Breast Cancer",
        "Left Ventricular Function Systolic Dysfunction"
      ],
      "Start Date": [
        "2013-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04379596",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "Capecitabine",
        "MEDI4736",
        "Drug: Capecitabine",
        "Biological: Durvalumab",
        "Volrustomig",
        "Biological: Pembrolizumab",
        "MEDI5752",
        "Drug: Fluorouracil (5-FU)",
        "Trastuzumab deruxtecan",
        "Drug: Trastuzumab deruxtecan",
        "DS-8201a",
        "AZD2936",
        "Biological: Trastuzumab",
        "Trastuzumab",
        "Oxaliplatin",
        "Durvalumab",
        "Drug: Oxaliplatin",
        "Drug: Cisplatin",
        "Rilvegostomig",
        "Cisplatin",
        "Biological: Volrustomig",
        "Biological: Rilvegostomig",
        "Fluorouracil (5-FU)"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Russian Federation",
        "Korea, Republic of",
        "Japan",
        "China",
        "Spain",
        "Germany",
        "United States",
        "Netherlands",
        "Brazil",
        "United Kingdom",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        "413",
        413
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": [
        "2020-06-03",
        "2020-05-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01772472",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "NSABP Foundation Inc",
        "German Breast Group"
      ],
      "interventions": [
        "trastuzumab emtansine",
        "trastuzumab"
      ],
      "locations": [
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Peru",
        "Hong Kong",
        "China",
        "Colombia",
        "United States",
        "Brazil",
        "Canada",
        "Serbia",
        "France",
        "Italy",
        "Taiwan",
        "Mexico",
        "Panama",
        "Ireland",
        "Austria",
        "Germany",
        "Spain",
        "Guatemala",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        1487
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2013-04-03"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01702571",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "RO5304020, T-DM1, Kadcyla",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "United Arab Emirates",
        "Sweden",
        "Slovenia",
        "Turkey",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "Peru",
        "Hong Kong",
        "China",
        "Portugal",
        "Estonia",
        "Thailand",
        "Brazil",
        "Denmark",
        "Luxembourg",
        "Canada",
        "Bulgaria",
        "Venezuela",
        "France",
        "Iceland",
        "Ecuador",
        "Italy",
        "Poland",
        "Dominican Republic",
        "Indonesia",
        "Taiwan",
        "Mexico",
        "Panama",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Australia",
        "Austria",
        "Germany",
        "Croatia",
        "Spain",
        "Guatemala",
        "Argentina",
        "Slovakia",
        "Finland"
      ],
      "enrollment": [
        2185
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2012-11-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01513083",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "trastuzumab emtansine"
      ],
      "locations": [
        "Canada",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        28
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2012-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01419197",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "T-DM1",
        "Trastuzumab emtansine",
        "Kadcyla",
        "Treatment of physician's choice"
      ],
      "locations": [
        "Czech Republic",
        "Sweden",
        "Switzerland",
        "United Kingdom",
        "Belgium",
        "Norway",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Germany",
        "Spain",
        "Israel",
        "Slovakia"
      ],
      "enrollment": [
        602
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2011-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06486441",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "GOG Foundation"
      ],
      "interventions": [
        "Sacituzumab govitecan-hziy",
        "Trodelvy\u2122",
        "Doxorubicin",
        "Paclitaxel",
        "Adriamycin",
        "GS-0132",
        "Taxol"
      ],
      "locations": [],
      "enrollment": [
        520
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2024-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01196052",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "T-DM1",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Belgium",
        "Russian Federation",
        "Korea, Republic of",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        153
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2010-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01120184",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "trastuzumab [Herceptin]",
        "paclitaxel",
        "pertuzumab",
        "pertuzumab-placebo",
        "trastuzumab emtansine",
        "docetaxel"
      ],
      "locations": [
        "Sweden",
        "Turkey",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Greece",
        "North Macedonia",
        "Belgium",
        "Bahamas",
        "Portugal",
        "Peru",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Canada",
        "Malaysia",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Bosnia and Herzegovina",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Romania",
        "New Zealand",
        "Japan",
        "Germany",
        "Spain",
        "Guatemala",
        "Argentina"
      ],
      "enrollment": [
        1095
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2010-07-31"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03552471",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Ohio State University Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Clovis Oncology, Inc.",
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Rucaparib Camsylate",
        "M9346A-sulfo-SPDB-DM4",
        "PK Study",
        "Pharmacokinetic Study",
        "IMGN853",
        "C0-338",
        "Rucaparib Phosphate",
        "PHARMACOKINETIC",
        "Laboratory Biomarker Analysis",
        "Rubraca",
        "8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt",
        "Mirvetuximab Soravtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        25
      ],
      "conditions": [
        "Recurrent Uterine Corpus Carcinoma",
        "BRCA1 Gene Mutation",
        "Recurrent Ovarian Carcinoma",
        "Folate Receptor Alpha Positive",
        "BRCA2 Gene Mutation",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Serous Carcinoma",
        "Recurrent Uterine Carcinosarcoma",
        "Platinum Resistant Ovarian Cancer",
        "Recurrent Fallopian Tube Carcinoma"
      ],
      "Start Date": [
        "2018-07-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00991562",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "huN901-DM1",
        "BB-10901",
        "IMGN901"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2009-12"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00951665",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "pertuzumab [Perjeta]",
        "paclitaxel",
        "trastuzumab emtansine [Kadcyla]"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        107
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2009-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00943670",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine [Kadcyla]",
        "trastuzumab-MCC-DM1",
        "pertuzumab",
        "PERJETA\u2122",
        "T-DM1"
      ],
      "locations": [],
      "enrollment": [
        51
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2009-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00934856",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Pertuzumab",
        "T-DM1",
        "Trastuzumab emtansine",
        "Docetaxel"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States",
        "France"
      ],
      "enrollment": [
        98
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2009-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00882102",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Eisai Inc."
      ],
      "interventions": [
        "Dacogen\u00ae",
        "Gemtuzumab ozogamicin",
        "Decitabine",
        "Mylotarg\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        43
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": [
        "2009-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00875979",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Roche Pharma AG"
      ],
      "interventions": [
        "trastuzumab-MCC-DM1",
        "Trastuzumab emtansine [Kadcyla] 3.6 mg/kg",
        "Trastuzumab emtansine [Kadcyla] 3.0 mg/kg",
        "T-DM1",
        "Perjeta",
        "Pertuzumab 420 mg",
        "trastuzumab-DM1"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        67
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2009-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03334617",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: AZD6738 (ceralasertib)",
        "AZD6738",
        "Drug: Oleclumab",
        "AZD9150",
        "AZD6738 (ceralasertib)",
        "AZD6738 (ceralasertib) (240 mg or 160 mg)",
        "Drug: trastuzumab deruxtecan",
        "Drug: AZD6738 (ceralasertib) (240 mg or 160 mg)",
        "Vistusertib",
        "Drug: AZD6738 (ceralasertib) 7 days monotherapy",
        "Olaparib",
        "Drug: Vistusertib",
        "Drug: cediranib",
        "AZD6738 (ceralasertib) 7 days monotherapy",
        "cediranib",
        "Drug: Durvalumab",
        "Durvalumab",
        "Oleclumab",
        "Drug: AZD9150",
        "Drug: Olaparib",
        "Drug: AZD6738",
        "trastuzumab deruxtecan"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Austria",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Israel"
      ],
      "enrollment": [
        531,
        "531"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2017-12-18",
        "2017-09-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00766116",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "University of California, San Diego"
      ],
      "collaborators": [
        "Pfizer",
        "Celgene Corporation"
      ],
      "interventions": [
        "Vidaz",
        "Mylotarg",
        "Gemtuzumab ozogamicin",
        "5-Azacitidine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2005-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00679341",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine [Kadcyla]",
        "Trastuzumab",
        "trastuzumab-MCC-DM1",
        "Herceptin",
        "Taxotere",
        "T-DM1",
        "Docetaxel",
        "trastuzumab-DM1"
      ],
      "locations": [],
      "enrollment": [
        137
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2008-09"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00679211",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine [Kadcyla]",
        "Trastuzumab-MCC-DM1",
        "T-DM1"
      ],
      "locations": [],
      "enrollment": [
        110
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2008-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00509769",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine [Kadcyla]",
        "T-DM1",
        "trastuzumab-DM1",
        "trastuzumab-MCC-DM1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        112
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2007-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03032107",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Trastuzumab emtansine",
        "T-DM1",
        "Keytruda"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        27
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2017-02-17"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02927769",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Opdivo",
        "brentuximab vedotin",
        "Nivolumab",
        "BMS-936558",
        "bendamustine"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Italy",
        "Ireland",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "Netherlands",
        "France",
        "Poland"
      ],
      "enrollment": [
        72
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": [
        "2017-03-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04873362",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab",
        "Tecentriq, RO5541267, MPDL3280A",
        "Trastuzumab Emtansine",
        "Kadcyla, T-DM1, RO5304020",
        "Placebo",
        "Herceptin",
        "Atezolizumab"
      ],
      "locations": [
        "Ukraine",
        "Turkey",
        "Czechia",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Kenya",
        "Portugal",
        "China",
        "Hong Kong",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "India",
        "Bulgaria",
        "Singapore",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Dominican Republic",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Uganda",
        "Hungary",
        "Australia",
        "Austria",
        "New Zealand",
        "Romania",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        1150
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2021-05-04"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04740918",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Tecentriq, RO5541267, MPDL3280A",
        "Trastuzumab Emtansine",
        "Kadcyla, T-DM1, RO5304020",
        "Placebo",
        "Atezolizumab"
      ],
      "locations": [
        "Slovenia",
        "Turkey",
        "United Kingdom",
        "Greece",
        "Norway",
        "China",
        "Portugal",
        "Colombia",
        "United States",
        "Brazil",
        "Canada",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Croatia",
        "Finland"
      ],
      "enrollment": [
        96
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2021-06-07"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05673928",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Genentech, Inc."
      ],
      "interventions": [
        "Trastuzumab-MCC-DM1",
        "ado-trastuzumab emtansine",
        "T-DM1",
        "Trastuzumab emtansine",
        "Kadcyla",
        "Tucatinib",
        "ARRY-380",
        "ONT-380"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        30
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Brain Metastases"
      ],
      "Start Date": [
        "2023-05-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02924883",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Tecentriq, RO5541267, MPDL3280A",
        "Placebo",
        "Trastuzumab emtansine",
        "Atezolizumab",
        "Kadcyla\u00ae, T-DM1, RO5304020"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        202
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2016-09-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05323955",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Carey Anders, M.D."
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Trastuzumab",
        "Tukysa",
        "Trastuzumab Emtansine (T-DM1)",
        "Herceptin",
        "Tucatinib",
        "Perjeta",
        "Pertuzumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        48
      ],
      "conditions": [
        "Brain Metastases",
        "Advanced Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast"
      ],
      "Start Date": [
        "2023-03-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02751918",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "Pegylated Liposomal Doxorubicin",
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "Spain",
        "United States",
        "Belgium",
        "Moldova, Republic of"
      ],
      "enrollment": [
        65
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "Start Date": [
        "2016-06-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT05183035",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "LLS PedAL Initiative, LLC"
      ],
      "collaborators": [
        "EuPAL",
        "Roche-Genentech",
        "Princess Maxima Center for Pediatric Oncology (European Sponsor)",
        "AbbVie"
      ],
      "interventions": [
        "Gemtuzumab Ozogamicin",
        "Fludarabine",
        "Cytarabine",
        "Azacitidine",
        "Venetoclax"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Australia",
        "Austria",
        "Sweden",
        "Israel",
        "New Zealand",
        "Czechia",
        "Portugal",
        "Spain",
        "Switzerland",
        "Norway",
        "United States",
        "Netherlands",
        "France",
        "Italy",
        "Denmark",
        "Finland"
      ],
      "enrollment": [
        98
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2022-10-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05048797",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "DS-8201a; T-DXd",
        "Pemetrexed",
        "Cisplatin",
        "Trastuzumab Deruxtecan",
        "Carboplatin"
      ],
      "locations": [
        "Turkey",
        "Netherlands",
        "Belgium",
        "China",
        "Hong Kong",
        "United States",
        "Brazil",
        "Denmark",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Austria",
        "Japan",
        "Germany",
        "Spain"
      ],
      "enrollment": [
        450
      ],
      "conditions": [
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2021-10-28"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04833114",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GWT-TUD GmbH"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Polatuzumab Vedotin",
        "Mabthera",
        "Ifosfamide",
        "Etoposide",
        "Carboplatin"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "Austria",
        "Germany"
      ],
      "enrollment": [
        334
      ],
      "conditions": [
        "Relapsed Diffuse Large B-cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2021-04-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04457596",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Alliance for Clinical Trials in Oncology"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)",
        "Seagen Inc."
      ],
      "interventions": [
        "Trastuzumab Emtansine",
        "Placebo Administration",
        "Quality-of-Life Assessment",
        "Tucatinib",
        "Questionnaire Administration"
      ],
      "locations": [
        "Canada",
        "United States",
        "Puerto Rico"
      ],
      "enrollment": [
        1031
      ],
      "conditions": [
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "HER2 Positive Breast Carcinoma",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Synchronous Bilateral Breast Carcinoma",
        "Multifocal Breast Carcinoma",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma"
      ],
      "Start Date": [
        "2021-01-06"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01976169",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Texas Southwestern Medical Center"
      ],
      "collaborators": [
        "University of Pennsylvania",
        "Pfizer"
      ],
      "interventions": [
        "KADCYLA=T-DM1",
        "Palbociclib=PD-0332991",
        "PD-0332991 and T-DM1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        29
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "Start Date": [
        "2014-01-24"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT01562990",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "The Lymphoma Academic Research Organisation"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Rituximab, CMC544, Gemcitabine and Oxaliplatine"
      ],
      "locations": [
        "Belgium",
        "France"
      ],
      "enrollment": [
        11
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2012-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06389006",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Cyclophosphamide",
        "CTX",
        "JS001",
        "Disitamab Vedotin for Injection",
        "Toripalimab",
        "RC48",
        "Epirubicin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        79
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2024-04-29"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06100705",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Dendreon"
      ],
      "interventions": [
        "Sipuleucel-T",
        "Testosterone Cypionate",
        "DEPO-Testosterone",
        "Provenge"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        26
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "Start Date": [
        "2023-12-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00781612",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Trastuzumab",
        "Tecentriq",
        "Paclitaxel",
        "Trastuzumab Emtansine",
        "Herceptin",
        "Kadcyla; T-DM1",
        "Docetaxel",
        "Atezolizumab",
        "Perjeta",
        "Pertuzumab"
      ],
      "locations": [
        "Sweden",
        "Slovenia",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "North Macedonia",
        "Belgium",
        "Norway",
        "Peru",
        "Hong Kong",
        "China",
        "Portugal",
        "United States",
        "Thailand",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "New Zealand",
        "Japan",
        "Germany",
        "Croatia",
        "Spain",
        "Guatemala",
        "Israel"
      ],
      "enrollment": [
        720
      ],
      "conditions": [
        "Neoplasm Metastasis"
      ],
      "Start Date": [
        "2008-10-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05382286",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Trodelvy\u2122",
        "Pembrolizumab",
        "Paclitaxel",
        "Sacituzumab Govitecan-hziy",
        "Taxol\u00ae",
        "Abraxane\u00ae",
        "GS-0132",
        "Gemzar",
        "nab-Paclitaxel",
        "KEYTRUDA\u00ae",
        "Gemcitabine",
        "IMMU-132",
        "Carboplatin"
      ],
      "locations": [
        "Puerto Rico",
        "Turkey",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Hong Kong",
        "United States",
        "Brazil",
        "Canada",
        "Malaysia",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Austria",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        440
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "PD-L1 Positive"
      ],
      "Start Date": [
        "2022-07-25"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02686346",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "The Lymphoma Academic Research Organisation"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "BV",
        "Carboplatine",
        "Brentuximab Vedotin",
        "Ifosfamide",
        "Etoposide",
        "SGN35"
      ],
      "locations": [
        "Belgium",
        "France"
      ],
      "enrollment": [
        53
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": [
        "2016-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00037596",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "cytarabine.",
        "Gemtuzumab Ozogamicin"
      ],
      "locations": [],
      "enrollment": [
        null
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2000-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03869190",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas"
      ],
      "interventions": [
        "Enfortumab Vedotin",
        "Tocilizumab",
        "Cisplatin",
        "Tiragolumab",
        "Atezolizumab",
        "Niraparib",
        "Gemcitabine",
        "Magrolimab (Hu5F9-G4)",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "Greece",
        "Korea, Republic of",
        "Spain",
        "United States",
        "France",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        645
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer"
      ],
      "Start Date": [
        "2019-06-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02505269",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Doxorubicin",
        "Adriamycin",
        "Adcetris",
        "DTIC",
        "Dacarbazine",
        "Brentuximab Vedotin",
        "DIC",
        "Imidazole Carboxamide",
        "DTIC-Dome\u00ae",
        "Rubex \u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        34
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2015-08-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04704934",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "T-DXd",
        "Paclitaxel",
        "Ramucirumab",
        "CYRAMZA\u00ae",
        "ENHERTU\u00ae",
        "Trastuzumab deruxtecan",
        "Drug: Trastuzumab deruxtecan",
        "DS-8201a",
        "Drug: Paclitaxel",
        "Drug: Ramucirumab"
      ],
      "locations": [
        "Ukraine",
        "Turkey",
        "United Kingdom",
        "Belgium",
        "Portugal",
        "China",
        "Hong Kong",
        "Brazil",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Romania",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel"
      ],
      "enrollment": [
        "490",
        490
      ],
      "conditions": [
        "Gastric Cancer, Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": [
        "2021-08-01",
        "2021-05-21"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04274426",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AGO Research GmbH"
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel",
        "Gemcitabine",
        "Mirvetuximab Soravtansine",
        "Carboplatin",
        "Pegylated liposomal doxorubicin (PLD)"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": [
        136
      ],
      "conditions": [
        "Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma"
      ],
      "Start Date": [
        "2021-10-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05922904",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Rubex\u00ae",
        "Brentuximab vedotin",
        "Adcetris",
        "Doxorubicin Hydrochloride",
        "Dacarbazine",
        "Adriamycin PFS\u00ae",
        "SGN-35",
        "Adriamycin RDF\u2122",
        "DTIC-Dome\u00ae",
        "Adriamycin\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2023-12-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03839446",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Robert Redner, MD"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "mitoxantrone + etoposide + gemtuzumab ozogamicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        16
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2019-02-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05633667",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Arcus Biosciences, Inc."
      ],
      "interventions": [
        "Etrumadenant (ETRUMA)",
        "Docetaxel",
        "AB154",
        "GS-0928",
        "IMMU-132",
        "Sacituzumab govitecan-hziy (SG)",
        "AB928",
        "Pemetrexed",
        "GS-0122",
        "Paclitaxel",
        "Nivolumab",
        "GS-0132",
        "AB122",
        "GS-0154",
        "Carboplatin",
        "Zimberelimab (ZIM)",
        "Nab-paclitaxel",
        "Cisplatin",
        "Domvanalimab (DOM)"
      ],
      "locations": [
        "Korea, Republic of",
        "Israel",
        "Hong Kong",
        "United States",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        397
      ],
      "conditions": [
        "Lung Cancer",
        "Resectable Non-Small-Cell Lung Cancer",
        "Advanced or Metastatic Non-Small-Cell Lung Cancer"
      ],
      "Start Date": [
        "2023-03-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05558124",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "H. Lee Moffitt Cancer Center and Research Institute"
      ],
      "collaborators": [
        "Jazz Pharmaceuticals"
      ],
      "interventions": [
        "Gemtuzumab Ozogamicin",
        "daunorubicin-cytarabine",
        "Vyxeos",
        "Mylotarg",
        "CPX-351"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        18
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2023-02-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04685616",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Takeda",
        "Australasian Leukaemia and Lymphoma Group",
        "University of Miami",
        "Seagen Inc.",
        "European Organisation for Research and Treatment of Cancer - EORTC",
        "Canadian Cancer Trials Group"
      ],
      "interventions": [
        "Involved site radiotherapy",
        "Doxorubicin",
        "Brentuximab vedotin",
        "Haematopoietic growth factor",
        "Pegfilgrastim",
        "Dacarbazine",
        "Filgrastim",
        "Bleomycin",
        "G-CSF",
        "Vinblastine"
      ],
      "locations": [
        "Belgium",
        "Australia",
        "New Zealand",
        "Spain",
        "United States",
        "United Kingdom"
      ],
      "enrollment": [
        1042
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2022-04-14"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02314481",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Alecensa",
        "Alectinib",
        "Vemurafenib",
        "MPDL3280A",
        "Trastuzumab emtansine",
        "Atezolizumab",
        "T-DM1",
        "Kadcyla",
        "Zelboraf"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2017-05-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03084939",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Lapatinib",
        "Capecitabine",
        "Kadcyla",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        351
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2017-04-24"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02979522",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Doxorubicin",
        "Adriamycin",
        "Brentuximab vedotin",
        "Adcetris",
        "Dacarbazine",
        "Vinblastine"
      ],
      "locations": [
        "Brazil",
        "Italy",
        "United States",
        "Japan"
      ],
      "enrollment": [
        59
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": [
        "2017-09-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05016947",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "AbbVie"
      ],
      "interventions": [
        "Hexadrol",
        "Dexamethasone",
        "Diodex",
        "Inotuzumab Ozogamicin",
        "Venclexta",
        "Dexasone",
        "Decadron",
        "Venetoclax",
        "Maxidex",
        "Besponsa"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        26
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia",
        "B-Cell Lymphoma",
        "ALL"
      ],
      "Start Date": [
        "2021-09-24"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04632992",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "RG7853",
        "GDC-0077",
        "RG7446",
        "Tukysa\u2122",
        "RO7499790",
        "RO5541267",
        "Inavolisib",
        "RG3502",
        "Investigator's Choice of Chemotherapy",
        "Kadcyla\u00ae",
        "Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously",
        "Entrectinib",
        "RO7092284",
        "RG6058",
        "RO5304020",
        "Alecensa\u00ae",
        "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
        "RG6268",
        "PH FDC SC",
        "RG6396",
        "RG6114",
        "Paclitaxel",
        "Tecentriq\u00ae",
        "RO7113755",
        "PHESGO\u2122",
        "RO5424802",
        "RO7102122",
        "RO5532961",
        "Ipatasertib",
        "Rozlytrek\u2122",
        "RG7440",
        "RG6264",
        "Trastuzumab Emtansine",
        "Pralsetinib",
        "GDC-0068",
        "RO7198574",
        "Alectinib",
        "MTIG7192A",
        "GAVRETO\u2122",
        "Atezolizumab",
        "Tiragolumab",
        "Tucatinib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        252
      ],
      "conditions": [
        "Advanced Unresectable or Metastatic Solid Malignancy"
      ],
      "Start Date": [
        "2021-01-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04589845",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "GDC-6036",
        "Tecentriq",
        "Camonsertib",
        "Idasanutlin",
        "Pralsetinib",
        "Rozlytrek",
        "Alecensa",
        "Entrectinib",
        "Alectinib",
        "GDC-0077",
        "Belvarafenib",
        "Trastuzumab emtansine",
        "Atezolizumab",
        "Inavolisib",
        "Kadcyla",
        "Gavreto (US)",
        "Ipatasertib"
      ],
      "locations": [
        "Puerto Rico",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "Hong Kong",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "New Zealand",
        "Japan",
        "Germany",
        "Spain",
        "Israel"
      ],
      "enrollment": [
        920
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": [
        "2021-01-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02292979",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Lymphoma Academic Research Organisation"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Doxorubicin",
        "Dacarbazine",
        "Brentuximab Vedotin",
        "Bleomycin",
        "Vinblastine"
      ],
      "locations": [
        "Belgium",
        "Croatia",
        "France",
        "Netherlands",
        "Denmark"
      ],
      "enrollment": [
        170
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2015-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04385290",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Technische Universit\u00e4t Dresden"
      ],
      "collaborators": [
        "Novartis Pharmaceuticals",
        "Pfizer"
      ],
      "interventions": [
        "Rydapt",
        "Mylotarg",
        "MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO",
        "MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO",
        "MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin",
        "MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin",
        "MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": [
        214
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2020-09-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01868451",
      "phases": [],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Stanford University",
        "Seagen Inc.",
        "City of Hope Medical Center",
        "University of Rochester"
      ],
      "interventions": [
        "Involved-Site Radiation Therapy (ISRT)",
        "Interim PET",
        "Vinblastine Sulfate",
        "Brentuximab vedotin (SGN-35)",
        "Dacarbazine",
        "Doxorubicin HCL",
        "consolidation volume RT (CVRT)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        118
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2013-05"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT02257567",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Rituximab",
        "Polatuzumab vedotin (Lyophilized)",
        "Treanda; Ribomustin; Levact",
        "DCDS4501S",
        "DCDS4501A",
        "GA101; Gazyva; Gazyvaro",
        "Obinutuzumab",
        "Polatuzumab vedotin (Liquid)",
        "Bendamustine",
        "Rituxan; MabThera"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Turkey",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "Netherlands",
        "France",
        "Italy"
      ],
      "enrollment": [
        331
      ],
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": [
        "2014-10-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01534078",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "H. Lee Moffitt Cancer Center and Research Institute",
        "Beth Israel Deaconess Medical Center",
        "Seagen Inc.",
        "Dana-Farber Cancer Institute"
      ],
      "interventions": [
        "Doxorubicin",
        "Adcetris",
        "DTIC",
        "Adriamycin, vinblastine, and dacarbazine",
        "SGN-35",
        "Brentuximab Vedotin",
        "Velban",
        "SGN35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        34
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2012-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01494662",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Puma Biotechnology, Inc.",
        "Translational Breast Cancer Research Consortium"
      ],
      "interventions": [
        "Capecitabine",
        "Biopsy",
        "Xeloda",
        "Surgical Resection",
        "Ado-Trastuzumab Emtansine",
        "T-DM1",
        "Neratinib",
        "HKI-272"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        140
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2012-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05404945",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Virginia"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Doxorubicin",
        "Adriamycin",
        "Brentuximab vedotin",
        "Dacarbazine",
        "Vinblastine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        44
      ],
      "conditions": [
        "Classical Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2022-07-26"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00829166",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab-MCC-DM1",
        "Capecitabine",
        "Tyverb",
        "Tykerb",
        "Lapatinib",
        "T-DM1",
        "Trastuzumab emtansine",
        "RO5304020",
        "Xeloda"
      ],
      "locations": [
        "Sweden",
        "Slovenia",
        "Switzerland",
        "United Kingdom",
        "Portugal",
        "Hong Kong",
        "Colombia",
        "United States",
        "Brazil",
        "Denmark",
        "India",
        "Canada",
        "Bulgaria",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "New Zealand",
        "Germany",
        "Spain",
        "Bosnia and Herzegovina",
        "Finland"
      ],
      "enrollment": [
        991
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2009-02"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05113251",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Onxol",
        "Trastuzumab",
        "Doxorubicin",
        "T-DXd",
        "Paclitaxel",
        "Neosar",
        "Adriamycin",
        "cyclophosphamide",
        "Rubex",
        "Herceptin",
        "Taxol",
        "Herzuma",
        "Cytoxan",
        "Trastuzumab Deruxtecan",
        "Enhertu",
        "Perjeta",
        "Pertuzumab"
      ],
      "locations": [
        "Canada",
        "Russian Federation",
        "Saudi Arabia",
        "Bulgaria",
        "Korea, Republic of",
        "Japan",
        "China",
        "Spain",
        "Peru",
        "Germany",
        "United States",
        "Philippines",
        "Thailand",
        "Brazil",
        "Italy",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        912
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-positive Early Breast Cancer",
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2021-10-25"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04341181",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Ulrik Lassen"
      ],
      "collaborators": [
        "Roche Pharma AG",
        "GlaxoSmithKline",
        "Pfizer"
      ],
      "interventions": [
        "Vismodegib",
        "Erivedge",
        "Herceptin plus Perjeta (combination)",
        "Tecentriq",
        "Alecensa",
        "Zelboraf plus Cotellic (combination)",
        "Bavencio",
        "Avelumab",
        "Trastuzumab emtansine",
        "Axitinib",
        "Tarceva",
        "Vemurafenib plus Cobimetinib (combination)",
        "Kadcyla",
        "Zejula",
        "Alectinib",
        "Inlyta",
        "Erlotinib",
        "Atezolizumab",
        "Niraparib",
        "Trastuzumab plus Pertuzumab (combination)"
      ],
      "locations": [
        "Denmark"
      ],
      "enrollment": [
        300
      ],
      "conditions": [
        "Neoplasms",
        "Neoplasia",
        "Cancer",
        "Tumors"
      ],
      "Start Date": [
        "2020-08-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03646123",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "nivolumab",
        "Opdivo",
        "brentuximab vedotin",
        "Adcetris",
        "pegfilgrastim",
        "filgrastim",
        "vinblastine",
        "dacarbazine",
        "SGN-35",
        "G-CSF",
        "doxorubicin"
      ],
      "locations": [
        "Australia",
        "Czechia",
        "Spain",
        "United States",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        255
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2019-01-28"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03061812",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Rova-T",
        "Topotecan",
        "Dexamethasone",
        "Rovalpituzumab tesirine"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Turkey",
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "Serbia",
        "Belarus",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Japan",
        "Latvia",
        "Germany",
        "Croatia",
        "Spain"
      ],
      "enrollment": [
        444
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2017-04-11"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT06377566",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Pembrolizumab",
        "Doxorubicin",
        "FDG-PET/CT scan",
        "Vinorelbine",
        "Brentuximab vedotin",
        "Dacarbazine",
        "Gemcitabine",
        "Vinblastine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        71
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2024-04-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04844866",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Miltenyi Biomedicine GmbH"
      ],
      "collaborators": [
        "ICON plc"
      ],
      "interventions": [
        "R-GemOx or BR plus polatuzumab vedotin",
        "MB-CART2019.1",
        "Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab"
      ],
      "locations": [
        "Belgium",
        "Austria",
        "Sweden",
        "Hungary",
        "Czechia",
        "Spain",
        "Germany",
        "Netherlands",
        "France",
        "Lithuania",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        168
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": [
        "2021-08-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03726879",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Chugai Pharmaceutical"
      ],
      "interventions": [
        "Trastuzumab",
        "Tecentriq",
        "Doxorubicin",
        "Neosar",
        "Paclitaxel",
        "Trastuzumab Emtansine",
        "Cyclophosphamide",
        "Adriamycin",
        "Placebo",
        "Herceptin",
        "Taxol",
        "Atezolizumab",
        "Kadcyla",
        "Cytoxan",
        "Perjeta",
        "Pertuzumab"
      ],
      "locations": [
        "Canada",
        "Russian Federation",
        "Korea, Republic of",
        "Japan",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "Brazil",
        "Italy",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        454
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2019-01-11"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01578499",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Methotrexate",
        "Brentuximab Vedotin",
        "SGN-35",
        "Bexarotene"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Australia",
        "Austria",
        "Spain",
        "Switzerland",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "Italy",
        "Poland"
      ],
      "enrollment": [
        131
      ],
      "conditions": [
        "Mycosis Fungoides",
        "Cutaneous T-Cell Lymphoma",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma"
      ],
      "Start Date": [
        "2012-06-11"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05498220",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Hyaluronidase",
        "Rituximab",
        "Polatuzumab vedotin (PV)",
        "Dexamethasone",
        "Cisplatin",
        "Gemcitabine",
        "GCSF"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        44
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": [
        "2023-02-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03274492",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Doxorubicin",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Cyclophosphamide",
        "DCDS4501A; anti-CD79b-VC-MMAE",
        "Vincristine",
        "Prednisone",
        "Polatuzumab vedotin Placebo",
        "Vincristine Placebo"
      ],
      "locations": [
        "Ukraine",
        "Turkey",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Belgium",
        "China",
        "Hong Kong",
        "United States",
        "Brazil",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "New Zealand",
        "Japan",
        "Germany",
        "Spain"
      ],
      "enrollment": [
        1000
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2017-11-16"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02605915",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab",
        "Doxorubicin",
        "Cyclophosphamide",
        "RO4368451",
        "Tecentriq, RO5541267",
        "Trastuzumab emtansine",
        "Atezolizumab",
        "Docetaxel",
        "RO5304020",
        "RO0452317",
        "Carboplatin",
        "Pertuzumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        98
      ],
      "conditions": [
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Locally Advanced or Early Breast Cancer"
      ],
      "Start Date": [
        "2015-12-31"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06047080",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Doxorubicin",
        "Rituximab",
        "Cyclophosphamide",
        "Glofitamab",
        "Polatuzumab vedotin",
        "Prednisone"
      ],
      "locations": [
        "Turkey",
        "Switzerland",
        "United Kingdom",
        "Belgium",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        1130
      ],
      "conditions": [
        "Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2023-09-18"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT01564784",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "cytarabine and mitoxantrone",
        "inotuzumab ozogamicin",
        "HIDAC (high dose cytarabine)",
        "FLAG (fludarabine, cytarabine and G-CSF)"
      ],
      "locations": [
        "Sweden",
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "China",
        "United States",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Finland"
      ],
      "enrollment": [
        326
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": [
        "2012-08-02"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04790903",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Doxorubicin",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Cyclophosphamide",
        "Venetoclax",
        "Prednisone"
      ],
      "locations": [
        "Spain",
        "Italy",
        "United States",
        "France"
      ],
      "enrollment": [
        50
      ],
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": [
        "2021-07-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04594798",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Rochester"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Doxorubicin",
        "Rituximab",
        "Cyclophosphamide",
        "Polatuzumab vedotin",
        "Prednisone"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        39
      ],
      "conditions": [
        "DLBCL",
        "Lymphoma, B-Cell"
      ],
      "Start Date": [
        "2021-09-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01966471",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab",
        "Doxorubicin",
        "Paclitaxel",
        "Trastuzumab Emtansine",
        "Cyclophosphamide",
        "Herceptin",
        "5-Fluorouracil",
        "Docetaxel",
        "Kadcyla",
        "Perjeta",
        "Pertuzumab",
        "Epirubicin"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Belgium",
        "Norway",
        "Peru",
        "Hong Kong",
        "Colombia",
        "United States",
        "Thailand",
        "Brazil",
        "Georgia",
        "Canada",
        "El Salvador",
        "Singapore",
        "Philippines",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Panama",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Japan",
        "Germany",
        "Spain",
        "Guatemala",
        "Bosnia and Herzegovina",
        "Israel"
      ],
      "enrollment": [
        1846
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2014-01-31"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05673785",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Cyclophosphamide",
        "Brentuximab Vedotin",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        52
      ],
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": [
        "2023-02-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05180097",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Canadian Cancer Trials Group"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Dexamethasone",
        "Brentuximab vedotin",
        "Cisplatin",
        "Gemcitabine"
      ],
      "locations": [
        "Canada"
      ],
      "enrollment": [
        84
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2022-11-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04679012",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Weill Medical College of Cornell University"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Polatuzumab Vedotin",
        "cytoxan",
        "Deltasone",
        "Paracort",
        "Cyclophosphamide",
        "Polivy",
        "Etoposide",
        "Orasone",
        "chimeric anti-CD20 monoclonal antibody",
        "Cortan",
        "Hydroxydoxorubicin Hydrochloride",
        "Rituxan",
        "etopophos",
        "VP-16",
        "Prednisone",
        "Rituximab",
        "VePesid",
        "Doxorubicin Hydrochloride",
        "Hydroxydaunomycin",
        "toposar"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        20
      ],
      "conditions": [
        "Richter Syndrome",
        "Chronic Lymphocytic Leukemia"
      ],
      "Start Date": [
        "2021-09-24"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04569032",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "cyclophosphamide",
        "brentuximab vedotin",
        "ADCETRIS",
        "prednisone",
        "doxorubicin"
      ],
      "locations": [
        "United Kingdom",
        "Czechia",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        82
      ],
      "conditions": [
        "Peripheral T-cell Lymphoma"
      ],
      "Start Date": [
        "2020-11-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01992653",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Doxorubicin",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Cyclophosphamide",
        "Prednisolone",
        "DCDS4501A",
        "Obinutuzumab",
        "MabThera/Rituxan",
        "Prednisone",
        "Gazyva/Gazyvaro"
      ],
      "locations": [
        "United States",
        "France"
      ],
      "enrollment": [
        85
      ],
      "conditions": [
        "Lymphoma, Non Hodgkin"
      ],
      "Start Date": [
        "2013-11-29"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02824042",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "Itraconazole",
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "Belgium",
        "Australia",
        "Spain",
        "United States",
        "France",
        "Netherlands"
      ],
      "enrollment": [
        63
      ],
      "conditions": [
        "Medical Oncology"
      ],
      "Start Date": [
        "2016-09-07"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02734771",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Patrick Reagan"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Deltasone",
        "Cyclophosphamide",
        "Adcetris",
        "Lyophilizedcytoxan",
        "Doxil",
        "Caelyx",
        "Orasone",
        "Cytoxan",
        "Endoxan",
        "Doxorubicin",
        "Deltacortisone",
        "Cycloblastin",
        "Prednisonum",
        "Rituxan",
        "Neosar",
        "Brentuximab vedotin",
        "Adasone",
        "Prednisone",
        "Rituximab",
        "Mabthera",
        "Adriamycin",
        "SGN-35",
        "Revimmune",
        "cAC10-vcMMAE",
        "Myocet",
        "Procytox"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": [
        "2016-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05955261",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "AbbVie"
      ],
      "interventions": [
        "Novantrone",
        "Azacitidine",
        "Mylotarg",
        "Gilteritinib",
        "Etoposide",
        "Venetoclax",
        "Mylosar",
        "Idarubicin Hydrochloride",
        "Venclextra",
        "IMI-30",
        "L-lyxo-Hexopyranoside",
        "Zavedos",
        "Neotalem",
        "Fludarabine Phosphate",
        "ABT-99",
        "Cytarabine",
        "VP-16",
        "Ara-C",
        "Cytosar-U\u00ae",
        "Vidaza",
        "Gemtuzumab Ozogamicin",
        "Pralifan",
        "FI-6339",
        "Xospata",
        "Daunorubicin Hydrochloride",
        "Mitoxantrone Hydrochloride",
        "SH T 586",
        "Vepesid\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        70
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2023-07-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03677141",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Doxorubicin",
        "Polatuzumab Vedotin",
        "Mosunetuzumab",
        "Cyclophosphamide",
        "Rituxumab",
        "Tocilizumab",
        "Vincristine",
        "Prednisone"
      ],
      "locations": [
        "Korea, Republic of",
        "Austria",
        "Spain",
        "United States",
        "France",
        "Poland"
      ],
      "enrollment": [
        117
      ],
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2019-03-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03971409",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hope Rugo, MD"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Johns Hopkins University",
        "Array BioPharma",
        "Hoosier Cancer Research Network",
        "Translational Breast Cancer Research Consortium",
        "Pfizer",
        "Breast Cancer Research Foundation"
      ],
      "interventions": [
        "PF 05082566",
        "Binimetinib",
        "Caelyx",
        "Lipodox",
        "PF-04518600",
        "Utomilumab",
        "Trodelvy",
        "MSB-0010718C",
        "Bavencio",
        "Avelumab",
        "MSB0010718C",
        "PF-05082566",
        "Sacituzumab Govitecan-hziy",
        "Anti-OX40 Antibody PF-04518600",
        "PF-2566",
        "ARRY-438162",
        "Sacituzumab Govitecan",
        "ARRY-162",
        "MEK162",
        "Liposomal Doxorubicin",
        "PF 5082566"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        150
      ],
      "conditions": [
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Breast Carcinoma",
        "Stage IIIB Breast Cancer",
        "Recurrent Breast Carcinoma",
        "Stage III Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Invasive Breast Carcinoma"
      ],
      "Start Date": [
        "2019-07-08"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01920932",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "doxorubicin",
        "quality of life assessment",
        "filgrastim",
        "radiation therapy",
        "Adcetris(R)",
        "Dacarbazine(R)",
        "irradiation",
        "radiotherapy",
        "Adriamycin(R)",
        "cyclophosphamide",
        "VP-16",
        "Cytoxan(R)",
        "radiation",
        "brentuximab vedotin",
        "prednisone",
        "SGN-35",
        "Neupogen(R)",
        "Dimethyl Triazeno Imidazole Carboximide (DTIC)",
        "Vepesid(R)",
        "etoposide",
        "prednisolone"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        77
      ],
      "conditions": [
        "Stage III Childhood Hodgkin Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Stage IV Childhood Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2013-08-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04914741",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Peter MacCallum Cancer Centre, Australia"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Doxorubicin",
        "Rituximab",
        "Cyclophosphamide",
        "Prednisolone",
        "Glofitamab",
        "CD20-TCB",
        "Vincristine",
        "RO7082859",
        "Polatuzumab vedotin"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        80
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma"
      ],
      "Start Date": [
        "2021-06-29"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04884035",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Celgene"
      ],
      "collaborators": [],
      "interventions": [
        "CC-99282",
        "Doxorubicin",
        "Rituximab",
        "BMS-986369",
        "Cyclophosphamide",
        "Prednisolone",
        "BMS-986382",
        "Vincristine",
        "Polatuzumab vedotin",
        "CC-220",
        "Prednisone",
        "Iberdomide"
      ],
      "locations": [
        "Greece",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "United States",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        174
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": [
        "2021-09-15"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03467373",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Rituximab (R)",
        "Doxorubicin",
        "Cyclophosphamide",
        "Glofitamab",
        "Obinutuzumab (G)",
        "Tocilizumab",
        "Oncovin",
        "Vincristine",
        "RO7082859",
        "Rituxan",
        "Polatuzumab vedotin",
        "Prednisone",
        "Gazyva",
        "Actemra"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        172
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "B-Cell Lymphoma"
      ],
      "Start Date": [
        "2018-03-13"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03755804",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "Teva Pharmaceuticals USA",
        "Seagen Inc."
      ],
      "interventions": [
        "Dimethyl Triazeno Imidazole Carboximide",
        "Cyclophosphamide",
        "Prednisolone",
        "Adcetris",
        "Cytoxan (R)",
        "Quality of Life Measurements",
        "TREANDA (R)",
        "Brentuximab Vedotin",
        "Velban (R)",
        "radiation therapy",
        "Etoposide",
        "Radiotherapy",
        "Oncovin (R)",
        "irradiation",
        "Doxorubicin",
        "DACARBAZINE (R)",
        "DTIC",
        "Vepeside",
        "Adriamycin (R)",
        "Vincristine",
        "bendamustine",
        "Quality of Life Measurements (QOL)",
        "Neupogen (R)",
        "VP-16",
        "Prednisone",
        "Vinblastine",
        "Blenoxane (R)",
        "Filgrastim",
        "Bleomycin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        250
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2018-12-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03424005",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Seagen Inc."
      ],
      "interventions": [
        "GDC-0077, RO7113755",
        "Abemaciclib",
        "Capecitabine",
        "Inavolisib (6 mg)",
        "Ribociclib",
        "Trastuzumab Deruxtecan",
        "Tocilizumab",
        "SGN-LIV1A",
        "Selicrelumab",
        "Atezolizumab",
        "Nab-Paclitaxel",
        "Fulvestrant",
        "Bevacizumab",
        "Inavolisib",
        "Chemotherapy (Gemcitabine + Carboplatin or Eribulin)",
        "Inavolisib (9 mg)",
        "Ipatasertib",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Israel",
        "Spain",
        "Germany",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        242
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2018-04-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01679119",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Cancer Research UK",
        "Pfizer"
      ],
      "interventions": [
        "Rituximab",
        "MabThera",
        "Cyclophosphamide",
        "Prednisolone",
        "Inotuzumab Ozogamicin",
        "Vincristine",
        "Gemcitabine"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": [
        129
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma"
      ],
      "Start Date": [
        "2013-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03991884",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "23214-92-8",
        "Genoxal",
        "14-Hydroxydaunomycin",
        "Prednilonga",
        "Way 207294",
        "Cycloblastine",
        "Cyclophosphamidum",
        "Cortancyl",
        "CTX",
        "Decortisyl",
        "Prednidib",
        "Vepesid",
        "Cyclophosphamid monohydrate",
        "Rayos",
        "Hydroxydaunomycin",
        "Cicloxal",
        "Metacortandracin",
        "Prednitone",
        "Paracort",
        "LEUROCRISTINE",
        "Cytoxan",
        "Servisone",
        "Cyclophosphane",
        "Ciclofosfamida",
        "Syklofosfamid",
        "141540",
        "VP 16",
        "VCR",
        "Delta-Dome",
        "CP monohydrate",
        "635715-01-4",
        "Cyclostine",
        "WAY-207294",
        "Ofisolona",
        "Predniment",
        "Prednisone",
        "Hydroxyldaunorubicin",
        "Genuxal",
        "Prednisone Intensol",
        "Hydroxyl Daunorubicin",
        "Revimmune",
        "CMC-544",
        "Cyclostin",
        "Ledoxina",
        "Toposar",
        "Cyclophosphamide",
        "Ciclofosfamide",
        "Mitoxan",
        "Orasone",
        "Doxorubicin",
        "Delta 1-Cortisone",
        "Promifen",
        "Prednisonum",
        "Cycloblastin",
        "Vincristine",
        "SK-Prednisone",
        "Vincrystine",
        "Prednicort",
        "VP-16",
        "Carloxan",
        "VP-16-213",
        "Besponsa",
        "22-Oxovincaleukoblastine",
        "2-Dehydrocortisone",
        "Dacortin",
        "Clafen",
        "Predicor",
        "VP 16-213",
        "DeCortin",
        "Lastet",
        "Etoposide",
        "Decorton",
        "Adriablastin",
        "Neosar",
        "VP16",
        "33419-42-0",
        "EPEG",
        "WR- 138719",
        "Inotuzumab Ozogamicin",
        "Cyclophospham",
        "Predicorten",
        "Adasone",
        "Fosfaseron",
        "Claphene",
        "Demethyl Epipodophyllotoxin Ethylidine Glucoside",
        "Cyclophosphan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        24
      ],
      "conditions": [
        "Refractory B Acute Lymphoblastic Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent B Lymphoblastic Lymphoma",
        "Refractory B Lymphoblastic Lymphoma"
      ],
      "Start Date": [
        "2019-09-24"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02243436",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Soludomerin",
        "Cytarabine",
        "ADCETRIS",
        "Brentuximab Vedotin",
        "Ara C",
        "Cisplatin",
        "Etoposide",
        "Methylprednisolone"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        67
      ],
      "conditions": [
        "CLASSICAL HODGKIN LYMPHOMA"
      ],
      "Start Date": [
        "2014-11-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05283720",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genmab"
      ],
      "collaborators": [
        "AbbVie"
      ],
      "interventions": [
        "Venclexta;",
        "CC-99282",
        "GDC-0199",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Imbruvica",
        "Cyclophosphamide",
        "Lenalidomide",
        "Ibrutinib",
        "ABT-199",
        "Doxorubicin Hydrochloride [HCl]",
        "Venetoclax",
        "Epcoritamab",
        "ABBV-GMAB-3013;",
        "Prednisone"
      ],
      "locations": [
        "Korea, Republic of",
        "Hungary",
        "Japan",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Netherlands",
        "Israel",
        "Denmark",
        "Taiwan"
      ],
      "enrollment": [
        394
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": [
        "2022-06-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04486352",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Alliance Foundation Trials, LLC."
      ],
      "collaborators": [
        "Pfizer",
        "Eli Lilly and Company",
        "Genentech, Inc.",
        "Foundation Medicine"
      ],
      "interventions": [
        "Abemaciclib",
        "GDC-0077",
        "Talzenna",
        "Inavolisib",
        "Bevacizumab",
        "Tecentriq",
        "Atezolizumab - 21 Day Cycle",
        "Trastuzumab emtansine",
        "T-DM1",
        "Avastin",
        "L01XC07",
        "Letrozole",
        "Verzenio",
        "Giredestrant",
        "GDC-9545",
        "Femara",
        "Kadcyla",
        "L01XC32",
        "Ipatasertib",
        "RG7440",
        "L01XX60",
        "Talazoparib",
        "GDC-0068",
        "Tiragolumab",
        "Atezolizumab - 28 Day Cycle"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        148
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": [
        "2021-10-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT01055496",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone",
        "CMC-544",
        "inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone"
      ],
      "locations": [
        "Canada",
        "Belgium",
        "Korea, Republic of",
        "Japan",
        "Singapore",
        "Hong Kong",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        103
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": [
        "2010-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT04307576",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Mats Heyman"
      ],
      "collaborators": [
        "Amgen",
        "The Swedish Research Council",
        "Servier",
        "Nova Laboratories Limited",
        "Direction G\u00e9n\u00e9rale de l'Offre de Soins",
        "Karolinska Institutet",
        "Aamu Pediatric Cancer Foundation",
        "NordForsk",
        "Assistance Publique - H\u00f4pitaux de Paris",
        "Danish Child Cancer Foundation",
        "Pfizer",
        "German Society for Pediatric Oncology and Hematology GPOH gGmbH",
        "The Swedish Childhood Cancer Foundation",
        "Clinical Trial Center North (CTC North GmbH & Co. KG)",
        "Grupo Portugu\u00eas De Leucemias Pedi\u00e1tricas",
        "Belgium Health Care Knowledge Centre",
        "Funda\u00e7\u00e3o Rui Os\u00f3rio de Castro",
        "The Novo Nordic Foundation",
        "Danish Cancer Society",
        "Cancer Research UK",
        "Acreditar - Associa\u00e7\u00e3o de Pais e Amigos das Crian\u00e7as com Cancro"
      ],
      "interventions": [
        "Omitted Doxorubicin",
        "Blincyto",
        "6-tioguanine+Standard Maintenance Therapy",
        "Inotuzumab Ozogamicin+Standard Maintenance Therapy",
        "Imatinib",
        "Besponsa+Maintenance Therapy",
        "Blinatumomab",
        "Omitted Vincristine+Dexamethasone pulses"
      ],
      "locations": [
        "Belgium",
        "Iceland",
        "Ireland",
        "Sweden",
        "Portugal",
        "Germany",
        "Norway",
        "Estonia",
        "France",
        "Netherlands",
        "Lithuania",
        "United Kingdom",
        "Denmark",
        "Finland"
      ],
      "enrollment": [
        6430
      ],
      "conditions": [
        "Leukemia, Acute Lymphoblastic"
      ],
      "Start Date": [
        "2020-07-13"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04931342",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "GOG Foundation"
      ],
      "interventions": [
        "Abemaciclib",
        "Cyclophosphamide",
        "Inavolisib",
        "Bevacizumab",
        "Palbociclib",
        "Luteinizing Hormone-Releasing Hormone (LHRH) Agonists",
        "RO5304020",
        "Cobimetinib",
        "Paclitaxel",
        "Letrozole",
        "Olaparib",
        "Giredestrant",
        "RO5532961",
        "Ipatasertib",
        "RO4876646, Avastin",
        "Trastuzumab Emtansine",
        "RO5541267, Tecentriq",
        "Atezolizumab",
        "RO5514041"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Turkey",
        "Czechia",
        "Spain",
        "Switzerland",
        "Germany",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        176
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "Start Date": [
        "2021-10-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03962465",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Virginia"
      ],
      "collaborators": [
        "Vanderbilt University",
        "University of Wisconsin, Madison",
        "Pfizer",
        "Virginia Commonwealth University"
      ],
      "interventions": [
        "Deltasone",
        "Trexall",
        "Rheumatrex",
        "Oncospar",
        "Daunorubicin",
        "Otrexup",
        "Pegaspargase",
        "Amethopterin",
        "daunomycin",
        "Vincristine",
        "Vincasar",
        "Methotrexate",
        "Cytarabine",
        "Ara-C",
        "Oncovin",
        "Besponsa",
        "MTX",
        "Leurocristine",
        "Rasuvo",
        "Cerubidine",
        "rubidomycin",
        "Inotuzumab ozogamicin",
        "Prednisone Pill",
        "Cytosar-U"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        36
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia"
      ],
      "Start Date": [
        "2022-07-22"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03337698",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Radiation",
        "Evolocumab",
        "Zanzalintinib",
        "Linagliptin",
        "Tocilizumab",
        "Docetaxel",
        "Bevacizumab",
        "Camonsertib",
        "Pemetrexed",
        "Cobimetinib",
        "XL092",
        "Gemcitabine",
        "Ipatasertib",
        "Carboplatin",
        "Sacituzumab Govitecan",
        "RO6958688",
        "CPI-444",
        "Atezolizumab",
        "Tiragolumab"
      ],
      "locations": [
        "Korea, Republic of",
        "Australia",
        "Israel",
        "Spain",
        "United States",
        "France",
        "United Kingdom",
        "Taiwan"
      ],
      "enrollment": [
        675
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": [
        "2018-01-02"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT03913559",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Trexall\u00ae",
        "Benadryl",
        "Methotrexate",
        "Cortisol",
        "Solu-Medrol",
        "Cytarabine",
        "Ara-C",
        "Acetaminophen",
        "Inotuzumab ozogamicin",
        "Diphenhydramine",
        "CMC-544",
        "Besponsa",
        "Hydrocortisone",
        "Tylenol",
        "Methylprednisolone"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        32
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": [
        "2019-05-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "CTIS2023-508832-68-00",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: HuMax-TF-ADC,Product Code: PRD952264,Pharmaceutical Form: SOLUTION FOR INFUSION,Other descriptive name: ,Strength: Tisotumab Vedotin 10mg,Product Code: SCP10337134,Pharmaceutical Form: ,Other descriptive name: ,Product Code: SCP6094344,Pharmaceutical Form: ,Other descriptive name: ,Product Code: SCP29096188,Pharmaceutical Form: ,Other descriptive name:"
      ],
      "locations": [
        "Belgium",
        "Ireland",
        "Czechia",
        "Spain",
        "Netherlands",
        "Italy"
      ],
      "enrollment": [
        "143"
      ],
      "conditions": [
        "Recurrent or stage IVB cervical cancer  MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "Therapeutic area: Diseases [C] - Neoplasms [C04]"
      ],
      "Start Date": [
        "2024-02-26"
      ],
      "Max Phase": "3"
    },
    {
      "id": "CTRI/2024/01/061671",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "ESIC Dental College"
      ],
      "interventions": [
        "Intervention1: Local Application of Ozone oil ( ADC INCLUSIVE DENT OZONE INDIA, OZONOINDS) at tooth extraction site.: Normal tooth extraction, ozone oil is locally applied at extraction site for 5 min and then mouth is rinsed. then patient to apply ozone oil 3 times a day locally at extraction site for 3 days. Control Intervention1: Local application of Glycerin at tooth extraction site as a placebo.: Normal tooth extraction, Glycerin is locally applied at extraction site for 5 min and then mouth is rinsed. then patient to apply glycerin 3 times a day locally at extraction site for 3 days."
      ],
      "locations": [
        "India"
      ],
      "enrollment": [
        "82"
      ],
      "conditions": [
        "Health Condition 1: K069- Disorder of gingiva and edentulousalveolar ridge, unspecified"
      ],
      "Start Date": [
        "2024-01-19"
      ],
      "Max Phase": "4"
    },
    {
      "id": "JPRN-jRCT2031230569",
      "phases": [],
      "sponsor": [
        "Hibi Kazushige"
      ],
      "interventions": [
        "Drug: AZD0901 Antibody-drug conjugate/Biologic Other Name: CMG901"
      ],
      "locations": [
        "Canada",
        "Republic of Korea",
        "United Kingdom",
        "Malaysia",
        "Australia",
        "Republic of Moldova",
        "Japan",
        "Spain",
        "Singapore",
        "Poland",
        "United States of America",
        "Georgia",
        "Taiwan"
      ],
      "enrollment": [
        "186"
      ],
      "conditions": [
        "Gastric cancer, Gastroesophageal junction cancer"
      ],
      "Start Date": [
        "2024-01-16"
      ],
      "Max Phase": null
    },
    {
      "id": "NL-OMON56595",
      "phases": [],
      "sponsor": [
        "Amsterdam UMC"
      ],
      "interventions": [
        "Supramarginal resection will be guided by ADC/FET. To make sure that the  standard treatment is always guaranteed, T1c MRI abnormalities will be included  in the surgical target."
      ],
      "locations": [
        "Netherlands"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "brain tumor  glioblastoma",
        "10009720",
        "10029211"
      ],
      "Start Date": [
        "2023-12-22"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT06178601",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanxi Province Cancer Hospital"
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: AK104"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "36"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": [
        "2023-12-12"
      ],
      "Max Phase": "2"
    },
    {
      "id": "ChiCTR2300077064",
      "phases": [],
      "sponsor": [
        "Hu'nan Cancer Hospital"
      ],
      "interventions": [
        "",
        "DWI guided DP-RT group (DWI group):The target volume GTV-DWI is defined as the area <ADC mean within the GTV. Radiation dose to GTV-DWI is escalated to 77Gy, and the fractional dose is escalated to 2.2 Gy/F.",
        "Anatomic imaging group (control group):The standard radiotherapy dose of 70.0Gy was given to the target volume PGTV, with a fractional dose of 2.0Gy/F."
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "DWI guided DP-RT group (DWI group):150;Anatomic imaging group (control group):150;"
      ],
      "conditions": [
        "head and neck squamous cell carcinoma"
      ],
      "Start Date": [
        "2023-10-27"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT06121557",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"
      ],
      "interventions": [
        "Biological: Camrelizumab",
        "Drug: Fludarabine",
        "Drug: Cyclophosphamide",
        "Biological: Interleukin-2",
        "Drug: Chemotherapeutic drug, ADC or PARP inhibitor",
        "Procedure: Surgery for harvesting tumor-draining lymph nodes",
        "Biological: Tumor-draining lymph node-derived lymphocyte (LNL)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "24"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2023-10-26"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT06112041",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Second Affiliated Hospital of Soochow University"
      ],
      "interventions": [
        "Drug: ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "29"
      ],
      "conditions": [
        "Solid Tumor",
        "Carcinoma"
      ],
      "Start Date": [
        "2023-10-23"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT06074484",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: AK104"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "36"
      ],
      "conditions": [
        "Muscle Invasive Bladder Carcinoma"
      ],
      "Start Date": [
        "2023-08-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "PER-062-22",
      "phases": [],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        " or ? Regimen 2 (participants with squamous NSCLC): Pembrolizumab 200 mg plus paclitaxel 200 mg/m2 plus carboplatin (AUC 5 or 6 mg/mL/minute) as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with pembrolizumab 200 mg monotherapy as an i.v. infusion Q3W on Day 1 of every subsequent cycle. For both regimens in the control arm, pembrolizumab must be administered first and platinum chemotherapy (carboplatin or cisplatin) last. Paclitaxel or pemetrexed must be administered after pembrolizumab, and carboplatin or cisplatin must be administered after paclitaxel or pemetrexed.",
        "Participants in the Dato-DXd in combination with durvalumab and carboplatin group will receive Dato-DXd 6.0 mg/kg plus durvalumab 1120 mg plus carboplatin AUC 5 mg/mL/minute as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with Dato-DXd 6.0 mg/kg plus durvalumab 1120 mg as i.v. infusions Q3W on Day 1 of every subsequent cycle. Dato-DXd must be administered prior to durvalumab at each cycle. Carboplatin must be administered after durvalumab at each of the first 4 cycles.  -                      Participants in the histology-specific therapy group will receive either: ? Regimen 1 (participants with non-squamous NSCLC): Pembrolizumab 200 mg plus pemetrexed 500 mg/m2 plus platinum chemotherapy (carboplatin AUC 5 mg/mL/minute or cisplatin75 mg/m2) as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with pembrolizumab 200 mg (with or without pemetrexed 500 mg/m2) as i.v. infusions Q3W on Day 1 of every subsequent cycle"
      ],
      "locations": [
        "Hungaria",
        "Sweden",
        "Turkey",
        "United Kindgdom",
        "Greece",
        "Korea South",
        "Peru",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "India",
        "Canada",
        "Bulgaria",
        "France",
        "Vietnam",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Austria",
        "Japan",
        "Germany",
        "Spain"
      ],
      "enrollment": [
        "1000"
      ],
      "conditions": [
        "C349 Bronchus or lung, unspecified  Bronchus or lung, unspecified",
        "C349"
      ],
      "Start Date": [
        "2023-08-08"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT05955209",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Peking University Cancer Hospital & Institute"
      ],
      "interventions": [
        "Drug: Disitamab Vedotin(RC48-ADC)"
      ],
      "locations": [
        ""
      ],
      "enrollment": [
        "40"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "Start Date": [
        "2023-07-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05917158",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jinling Hospital, China"
      ],
      "interventions": [
        "Drug: RC48-ADC and JS001"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "UTUC",
        "Upper Tract Urothelial Carcinoma",
        "Carcinoma"
      ],
      "Start Date": [
        "2023-06-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "ChiCTR2300071941",
      "phases": [],
      "sponsor": [
        "General Hospital of Northern Theater Command"
      ],
      "interventions": [
        "Index test:3D-T1WI sequence: gray matter volume (GMV), gray matter concentration (GMC), cortical thickness  DTI sequence: fractional anisotropy (FA), mean diffusivity (MD), apparent diffusion coefficient (ADC)  BOLD sequence: amplitude of low-frequency fluctuation (ALFF), ratio amplitude of low-frequency fluctuation (fALFF)  PET image:Standardized uptake value ratio ( SUVr)  ",
        "",
        "Gold Standard:Postoperative pathological results or stereotactic intracranial electroencephalogram (SEEG) results "
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "Target condition:30;Difficult condition:30"
      ],
      "conditions": [
        "Drug-refractory epilepsy"
      ],
      "Start Date": [
        "2023-05-30"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT05785325",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Second Affiliated Hospital, School of Medicine, Zhejiang University"
      ],
      "interventions": [
        "Drug: RC48-ADC plus Bevacizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "Start Date": [
        "2023-03-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05824325",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: TROP2 ADC",
        "Drug: SHR-A1811"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "56"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2023-05-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05749588",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: D1: TROP2 ADC",
        "Drug: A1: SHR-A1811",
        "Drug: H1: TROP2 ADC",
        "Drug: D2: TROP2 ADC with BP102",
        "Drug: G1: SHR-A1811",
        "Drug: C1: SHR-A1811",
        "Drug: B2: TROP2 ADC with Camrelizumab",
        "Drug: B1: TROP2 ADC",
        "Drug: C2: SHR-A1811 with BP102",
        "Drug: E1: SHR-A1811",
        "Drug: F1: TROP2 ADC",
        "Drug: A2: SHR-A1811 with Camrelizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "120"
      ],
      "conditions": [
        "Triple-negative Breast Cancer"
      ],
      "Start Date": [
        "2023-02-19"
      ],
      "Max Phase": "2"
    },
    {
      "id": "RBR-23dgvk8",
      "phases": [],
      "sponsor": [
        "Escuela de Osteopatia de Madri - Brasil Ltda"
      ],
      "interventions": [
        "It is a two-arm, double-blind, randomized controlled clinical trial. The selected patients will be referred by the collaborating neurologists to perform the Nuclear Magnetic Resonance (MRI) with diffusion at Centro Hospitalar Unimed Joinville (imaging department). After performing MRI with apparent diffusion coefficient (ADC) and diffusion-weighted imaging (DWI) and undergoing rehabilitation in a clinic chosen by the volunteers, all will be submitted to assessments of Basic Automatic Reactions (RAB), Functional Independence Measure (MIF), Dynamic Balance Test (Timed Up and Go  TUGt), Fugl-Meyer Scale (EFM), Barthel Index (IB) and Quality of Life Questionnaire (SF-36). For the calculated sample size (n=16), the blinding of the research will be done by the evaluation and intervention, in which researcher 1 will carry out the evaluation and researcher 2 will apply the intervention. Double blinding will be performed using the Randomizer program (www.random.org) and allocated to an experimental group (EG) and a control group (CG). The EG (n=8) will be treated with Osteopathic Manipulative Techniques. The control group (GP) (n=8) will not be treated with Osteopathic Manipulative Techniques. The EG will be undergoing treatment with the OMT proposed by the researchers in 12 (twelve) osteopathic physiotherapeutic consultations, distributed in 1 (one) weekly consultation, totaling 12 (twelve) weeks and with an estimated duration of 60 (sixty) minutes per Query. You will be interviewed via telephone weekly to complete the Barthel functional scale, sleep guidelines and ensure that they are undergoing neurofunctional rehabilitation. The CG will be interviewed weekly by telephone to complete the Barthel functional scale, sleep guidelines and ensure that they are undergoing neurofunc",
        "E02.190.599.280"
      ],
      "locations": [
        "Brazil"
      ],
      "enrollment": [
        ""
      ],
      "conditions": [
        "Ischemic Stroke",
        "C23.550.470.544"
      ],
      "Start Date": [
        "2023-01-23"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2022-002680-30-DE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Datopotamab Deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN:  Datopotamab Deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Trade Name: Pembrolizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853-91-4  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-"
      ],
      "locations": [
        "Greece",
        "Canada",
        "Belgium",
        "Italy",
        "Korea, Republic of",
        "Sweden",
        "Japan",
        "Brazil",
        "Spain",
        "China",
        "Germany",
        "United States",
        "France",
        "Argentina",
        "United Kingdom",
        "Denmark",
        "Taiwan"
      ],
      "enrollment": [
        "1075"
      ],
      "conditions": [
        "Stage I-III triple-negative breast cancer with residual invasive disease after neoadjuvant therapy.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2022-10-11"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05601401",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Peking Union Medical College Hospital"
      ],
      "interventions": [
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "10"
      ],
      "conditions": [
        "Salivary Gland Tumors"
      ],
      "Start Date": [
        "2022-10-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05594095",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: AKT inhibitor",
        "Drug: Famitinib",
        "Drug: TROP2 ADC",
        "Drug: Aromatase Inhibitors or Fulvestrant",
        "Drug: Dalpiciclib",
        "Drug: Carrelizumab",
        "Drug: Everolimus",
        "Drug: RTK Inhibitor",
        "Drug: TPC",
        "Drug: SHR-A1811",
        "Drug: Goserelin",
        "Drug: PIK3CA inhibitor",
        "Drug: Fluzoparib"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "140"
      ],
      "conditions": [
        "Breast Neoplasm",
        "Advanced Breast Cancer",
        "HER2-negative Breast Cancer",
        "Breast Cancer",
        "Hormone Receptor Positive Tumor"
      ],
      "Start Date": [
        "2022-10-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05578287",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sun Yat-sen University"
      ],
      "interventions": [
        "Drug: Anti-HER2 ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "29"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "Start Date": [
        "2022-08-10"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05571618",
      "phases": [],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "100"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2022-05-10"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT05582499",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: Goserelin",
        "Drug: Cyclophosphamide",
        "Drug: Camrelizumab",
        "Drug: Pertuzumab",
        "Drug: Trastuzumab",
        "Drug: Carboplatin",
        "Drug: Dalpiciclib",
        "Drug: Epirubicin",
        "Drug: SHR-1316",
        "Drug: HER2 ADC",
        "Drug: Letrozole",
        "Drug: Pyrotinib",
        "Drug: SHR-A1811",
        "Drug: Trophoblast cell-surface antigen 2 (TROP2) ADC",
        "Drug: Nab paclitaxel",
        "Drug: Fluzoparib"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "716"
      ],
      "conditions": [
        "Early-stage Breast Cancer",
        "Breast Neoplasm",
        "Triple-Negative Breast Cancer (TNBC)",
        "Locally Advanced Breast Cancer",
        "HER2-negative Breast Cancer",
        "Breast Tumors",
        "Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Hormone Receptor Negative Tumor",
        "HER2-positive Breast Cancer"
      ],
      "Start Date": [
        "2022-09-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "ChiCTR2200063088",
      "phases": [],
      "sponsor": [
        "Jinshazhou Hospital, Guangzhou University of Chinese Medicine"
      ],
      "interventions": [
        "standard&#32",
        "uptake&#32",
        "",
        "for&#32",
        "and&#32",
        "patients&#32",
        "D&#32",
        "Maximum&#32",
        "apparent&#32",
        "prostate&#32",
        "Syngo&#32",
        "was&#32",
        "ADC&#32",
        "PET-MR&#32",
        "PET&#32",
        "Regions&#32",
        "integrated&#32",
        "Index test:All&#32",
        "examined&#32",
        "used&#32",
        "maps,&#32",
        "in&#32",
        "(SUVmax)&#32",
        "values&#32",
        "of&#32",
        "were&#32",
        "by&#32",
        "Gold Standard:All patients met the relevant diagnostic criteria for PC in the European Society of Urogenital Radiology. All patients were diagnosed as PC by pathological puncture, and the tumor was visible and clearly displayed.",
        "diffusion&#32",
        "workstation&#32",
        "True&#32",
        "Germany.&#32",
        "with&#32",
        "minimum&#32",
        "integrate&#32",
        "(ROI)&#32",
        "machine&#32",
        "Interest&#32",
        "localized&#32",
        "to&#32",
        "lesions&#32",
        "coeffici",
        "selected.&#32",
        "Siemens&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "Target condition:212;Difficult condition:172"
      ],
      "conditions": [
        "PET-MR"
      ],
      "Start Date": [
        "2022-08-30"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2022-000776-19-PL",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Code: AZD5305 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N/A CAS Number: 2589531-76-8 Current Sponsor code: AZD5305 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-  Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Datopotamab deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Product Name: Flourouracil (5-FU) Pharmaceutical Form: Solution for injection INN or Proposed INN: fluorouracil CAS Number: 51-21-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Bevacizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Bevacizumab CAS Number: 216974-75-3 Current Sponsor code: FKB238 Other descriptive name: A recombinant, humanized IgG1 mAb specific for VEGF Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-  Product Name: Carboplatin Pharmaceutical Form: Concen"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Korea, Republic of",
        "Turkey",
        "Japan",
        "Spain",
        "Switzerland",
        "Germany",
        "China",
        "United States",
        "France",
        "United Kingdom",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        "540"
      ],
      "conditions": [
        "various Advanced/Metastatic solid tumour types  - Endometrial Cancer  - Gastric Cancer  - Ovarian Cancer - Metastatic castration-resistant prostate cancer - Colorectal cancer  MedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2022-08-29"
      ],
      "Max Phase": "3"
    },
    {
      "id": "ChiCTR2200062091",
      "phases": [],
      "sponsor": [
        "West China Hospital,Sichuan University"
      ],
      "interventions": [
        "",
        "value.",
        "fraction",
        "ADC&#32",
        "Gold Standard:Results of routine large magnetic resonance quantitative examination of liver fat",
        "Index test:Fat&#32",
        "value",
        "&#32",
        "T1&#32",
        "T2&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "Target condition:52;Difficult condition:0"
      ],
      "conditions": [
        "liver disease"
      ],
      "Start Date": [
        "2022-07-21"
      ],
      "Max Phase": null
    },
    {
      "id": "ChiCTR2200061944",
      "phases": [],
      "sponsor": [
        "The First Hospital of Jiaxing"
      ],
      "interventions": [
        "",
        "including&#32",
        "non-Gaussian&#32",
        "and&#32",
        "value),&#32",
        "(DDC&#32",
        "models&#32",
        "indicators. Indicators&#32",
        "single&#32",
        "D*,&#32",
        "a&#32",
        "f&#32",
        "multi-parameter&#32",
        "include:&#32",
        "parameters&#32",
        "stretched&#32",
        "single-exponential,&#32",
        "multi-modal&#32",
        "double&#32",
        "value),&",
        "exponential&#32",
        "Gold Standard:Histopathological diagnosis",
        "obtain&#32",
        "model&#32",
        "(D,&#32",
        "double-exponential,&#32",
        "(ADC&#32",
        "DWI&#32",
        "stretched-exponential&#32",
        "distribution&#32",
        "to&#32",
        "models,&#32",
        "Index test:Construct&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "Target condition:79;Difficult condition:0"
      ],
      "conditions": [
        "thyroid nodules"
      ],
      "Start Date": [
        "2022-07-12"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT05417230",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jiangsu Cancer Institute & Hospital"
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: Envafolimab"
      ],
      "locations": [
        ""
      ],
      "enrollment": [
        "29"
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": [
        "2022-09-06"
      ],
      "Max Phase": "2"
    },
    {
      "id": "CTRI/2022/05/042713",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline Research  Development Limited"
      ],
      "interventions": [
        "Intervention1: Single-Agent Belantamab Mafodotin (GSK2857916): GSK2857916 for injection, 100 mg, Biologic/drug (antibody-drug conjugate) ,Lyophilized powder in single-use vial for reconstitution, 100 mg/vial, IV infusion over at least 30 minutes  Intervention2: Single-Agent Belantamab Mafodotin (GSK2857916: The study has 5 arms: Arm A, a control arm (2.5 mg/kg Q3W) Intervention3: Single-Agent Belantamab Mafodotin (GSK2857916): Arms B through D, 3 arms with dosing alternatives Intervention4: Single-Agent Belantamab Mafodotin (GSK2857916): Arm E, a fifth exploratory arm to evaluate the feasibility of dosing 1.9 mg/kg every 6 weeks (Q6W) based on ocular symptoms (patient-reported symptoms using the OSDI), visual acuity assessments (Snellen chart or equivalent), and corneal findings (KVA scale). Control Intervention1: There is no comparator agent in the study and this monotherapy study.: There is no comparator agent in the study and this monotherapy study."
      ],
      "locations": [
        "Canada",
        "Greece",
        "Republic of Korea",
        "United Kingdom",
        "Russian Federation",
        "Australia",
        "Ireland",
        "Brazil",
        "Germany",
        "Spain",
        "France",
        "Thailand",
        "Argentina",
        "Italy",
        "United States of America",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        "288"
      ],
      "conditions": [
        "Health Condition 1: -  Health Condition 2: D758- Other specified diseases of bloodand blood-forming organs Health Condition 3: D758- Other specified diseases of bloodand blood-forming organs"
      ],
      "Start Date": [
        "2022-05-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05403242",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Chinese PLA General Hospital"
      ],
      "interventions": [
        "Drug: S-1",
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "42"
      ],
      "conditions": [
        "Advanced Gastroesophageal Adenocarcinoma"
      ],
      "Start Date": [
        "2022-06-05"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05349383",
      "phases": [],
      "sponsor": [
        "Central South University"
      ],
      "interventions": [
        "Drug: Antibody-Drug Conjugate",
        "Drug: Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "24618"
      ],
      "conditions": [
        "Agranulocytosis",
        "Sepsis (SMQ)",
        "Opportunistic Infections"
      ],
      "Start Date": [
        "2022-04-21"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT05356351",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Tianjin Medical University Cancer Institute and Hospital"
      ],
      "interventions": [
        "Drug: RC48- ADC"
      ],
      "locations": [
        ""
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance"
      ],
      "Start Date": [
        "2022-04-18"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT05331326",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
      ],
      "interventions": [
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "64"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2022-08-04"
      ],
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2021-005223-21-IT",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "ASTRAZENECA AB"
      ],
      "interventions": [
        "Trade Name: Carbo-Cell 10 mg/ml concentrate for solution for infusion Product Name: Carboplatin Product Code: [Carboplatin] Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CARBOPLATINO CAS Number: 41575-94-4 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Product Name: Eribulin mesylate Product Code: [Eribulin mesylate] Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: ERIBULINA CAS Number: 441045-17-6 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-  Product Name: Nab-paclitaxel Product Code: [Nab-paclitaxel] Pharmaceutical Form: Powder for suspension for injection INN or Proposed INN: PACLITAXEL ALBUMINA CAS Number: 153212-75-1 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Glucocorticoids Product Code: [Glucocorticoids] Pharmaceutical Form: Powder and solvent for solution for injection Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Abraxane 5 mg/ml powder for dispersion for infusion Product Name: Nab-paclitaxel Product Code: [Nab-paclitaxel] Pharmaceutical Form: Dispersion for infusion INN or Proposed INN: PACLITAXEL ALBUMINA CAS Number: 153212-75-1 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: HALAVEN 0.44 mg/ml solution for injection Product Name: Eribulin mesylate Product Code: [Eribulin mesylate] Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: ERIBULINA CAS Number: 441045-17-6 Current Sponsor code: n/a Concentr"
      ],
      "locations": [
        "Turkey",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "China",
        "United States",
        "Thailand",
        "Brazil",
        "India",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Hungary",
        "Japan",
        "Spain",
        "Germany",
        "Argentina"
      ],
      "enrollment": [
        "600"
      ],
      "conditions": [
        "Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2022-03-24"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05320380",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Children's Oncology Group"
      ],
      "interventions": [
        "Drug: Fludarabine Phosphate",
        "Drug: Methotrexate",
        "Drug: Anti-CD123 ADC IMGN632",
        "Drug: Liposome-encapsulated Daunorubicin-Cytarabine",
        "Procedure: Bone Marrow Aspiration and Biopsy",
        "Drug: Cytarabine",
        "Drug: Prednisolone",
        "Drug: Hydrocortisone Sodium Succinate"
      ],
      "locations": [
        ""
      ],
      "enrollment": [
        "0"
      ],
      "conditions": [
        "Refractory Acute Myeloid Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Refractory T Acute Lymphoblastic Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia"
      ],
      "Start Date": [
        "2022-03-22"
      ],
      "Max Phase": "2"
    },
    {
      "id": "ACTRN12622000080729",
      "phases": [],
      "sponsor": [
        "St. Vincent's Private Hospital"
      ],
      "interventions": [
        " \tDynamic Contrast Enhanced imaging (DCE) with automatically-delivered IV gadolinium DTPA bolus 10ml at 3ml/ second followed by rapid sequences with temporal resolution of between 4-7 seconds between scans",
        " \tDetailed quantitative analysis of DCEI imaging using K-trans colour maps and curve analysis according to PIRADS DCEI analytic guidelines",
        "  \tNo use of Endo-rectal coils or MR Spectroscopy as per current guidelines \tDedicated MRI physicists present for all scans to optimise protocols \tApproximate scan time 30minutes.",
        " \tT2-weighted imaging in 3 planes with sagittal, coronal, axial and TSE images",
        "Multi-parametric MRI scans will be performed as per standard of care for patients on active surveillance and assessed as per this protocol at Baseline, 1 year, 2 years and 3 years including follow-up up to 7 years consistent with the highest standards of prostate MRI: \t3-Tesla magnet field strength \t32-channel system with 14-channel spine coil and 18-channel pelvic phased array coil arrangement \tT1-weighted gradient spine echo sequence to identify biopsy haemorrhage artifact \tT2-weighted, high spatial resolution, anatomical imaging to identify and precisely localise areas of suspicion, and direct MRI-guided biopsy where performed",
        " \t Diffusion-Weighted Imaging with software derived Apparent Diffusion Co-efficient (ADC) quantitative analysis maps, and multiple B-values (0, 400, 800, 1400)"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        "300"
      ],
      "conditions": [
        "Cancer - Prostate",
        "  Prostate Cancer",
        "Prostate Cancer"
      ],
      "Start Date": [
        "2022-01-21"
      ],
      "Max Phase": null
    },
    {
      "id": "ChiCTR2200055827",
      "phases": [],
      "sponsor": [
        "Department of Biotherapy, Tumor Center, West China Hospital, Sichuan University"
      ],
      "interventions": [
        "",
        "Experimental group:Videsetuzumab for injection (RC48-ADC)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "Experimental group:66;"
      ],
      "conditions": [
        "HER2-expressing locally advanced or metastatic malignant solid tumor"
      ],
      "Start Date": [
        "2022-01-20"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2021-005873-25-ES",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "SOTIO Biotech a.s."
      ],
      "interventions": [
        "Product Name: SOT102 Product Code: SOT102 Pharmaceutical Form: Solution for infusion INN or Proposed INN: antibody-drug conjugate of an anti-CLDN18.2 mAb and the cytotoxic drug PNU159682, coupled by a Gly2-EDA linker Current Sponsor code: SOT102 Other descriptive name: SOT102 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Czechia",
        "Spain",
        "United States",
        "France"
      ],
      "enrollment": [
        "269"
      ],
      "conditions": [
        "Gastric and pancreatic adenocarcinoma  MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 100000004864   MedDRA version: 21.1 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2022-01-17"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05115500",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Second Affiliated Hospital of Soochow University"
      ],
      "interventions": [
        "Drug: ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "55"
      ],
      "conditions": [
        "Solid Tumor",
        "Carcinoma"
      ],
      "Start Date": [
        "2021-04-11"
      ],
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2020-005620-12-ES",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Datopotamab deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Eribulin mesylate Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Eribulin mesylate CAS Number: 441045-17-6 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.44-  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9  Product Name: Gemcitabine Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Gemcitabine CAS Number: 95058-81-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 38-  Product Name: Vinorelbine Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Vinorelbine CAS Number: 71486-22-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Netherlands",
        "United Kingdom",
        "South Africa",
        "Belgium",
        "China",
        "United States",
        "Brazil",
        "India",
        "Canada",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Hungary",
        "Japan",
        "Spain",
        "Germany",
        "Argentina"
      ],
      "enrollment": [
        "700"
      ],
      "conditions": [
        "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy  MedDRA version: 23.0 Level: PT Classification code 10083232 Term: HER2 negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2021-06-10"
      ],
      "Max Phase": "3"
    },
    {
      "id": "CTRI/2021/08/035674",
      "phases": [],
      "sponsor": [
        "Tata Memorial Hospital"
      ],
      "interventions": [
        "Intervention1: Adc b 4000: Additional mri sequence to be taken along with adc b 0 and b1000"
      ],
      "locations": [
        "India"
      ],
      "enrollment": [
        "245"
      ],
      "conditions": [
        "Health Condition 1: C718- Malignant neoplasm of overlappingsites of brain"
      ],
      "Start Date": [
        "2021-08-16"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT05016973",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: Triplizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "25"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "Start Date": [
        "2021-07-25"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04983121",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shengjing Hospital"
      ],
      "interventions": [
        "Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": [
        "2021-09-07"
      ],
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2019-004531-22-PL",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: paclitaxel CAS Number: 33069-62-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6-  Product Name: Pertuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: pertuzumab CAS Number: 380610-27-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "United Kingdom",
        "Turkiye",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        "450"
      ],
      "conditions": [
        "HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2021-06-28"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04928846",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "interventions": [
        "Biological: Telisotuzumab Vedotin",
        "Drug: Docetaxel"
      ],
      "locations": [
        "Ukraine",
        "Sweden",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "South Africa",
        "Belgium",
        "Portugal",
        "China",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Bulgaria",
        "France",
        "Italy",
        "Poland",
        "Chile",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Austria",
        "Romania",
        "Hungary",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Israel",
        "Slovakia"
      ],
      "enrollment": [
        "698"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "Start Date": [
        "2021-06-14"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT05160714",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University Hospital Tuebingen"
      ],
      "interventions": [
        "Radiation: Real-time ADC-guided response adaptive Boost in HNC"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": [
        "24"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "Start Date": [
        "2021-01-06"
      ],
      "Max Phase": "1"
    },
    {
      "id": "CTRI/2021/03/032107",
      "phases": [],
      "sponsor": [
        "Pacific dental college and hospital"
      ],
      "interventions": [
        "Intervention1: Use of ozone as irrigant in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India used without activation Control Intervention1: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India activated by manual agitation Control Intervention2: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone Ozonator by ADC India activated by ultra-sonic agitation Control Intervention3: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India activated by pro agitator tips system (PATS)"
      ],
      "locations": [
        "India"
      ],
      "enrollment": [
        "120"
      ],
      "conditions": [
        "Health Condition 1: K041- Necrosis of pulp"
      ],
      "Start Date": [
        "2021-03-18"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2020-001574-29-BE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Russian Federation",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Czechia",
        "Spain",
        "United States",
        "Netherlands",
        "Thailand",
        "Brazil",
        "United Kingdom",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        "280"
      ],
      "conditions": [
        "Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2021-03-16"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04814758",
      "phases": [],
      "sponsor": [
        "Federal Research Institute of Pediatric Hematology, Oncology and Immunology"
      ],
      "interventions": [
        "Diagnostic Test: MRI DWI sequence (ADC values)"
      ],
      "locations": [
        "Russian Federation"
      ],
      "enrollment": [
        "230"
      ],
      "conditions": [
        "Nephroblastoma (Wilms Tumour)"
      ],
      "Start Date": [
        "2021-04-03"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2020-003427-42-NL",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo, Inc."
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan for injection 100 mg Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Spain",
        "United States",
        "France",
        "Netherlands",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        "150"
      ],
      "conditions": [
        "HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2021-03-03"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04697628",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "interventions": [
        "Drug: gemcitabine",
        "Drug: vinorelbine",
        "Drug: topotecan",
        "Drug: pemetrexed",
        "Drug: tisotumab vedotin",
        "Drug: irinotecan"
      ],
      "locations": [
        "Sweden",
        "Czechia",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "Norway",
        "China",
        "Peru",
        "United States",
        "Brazil",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Hungary",
        "Japan",
        "Germany",
        "Spain",
        "Argentina",
        "Finland"
      ],
      "enrollment": [
        "568"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": [
        "2021-04-01"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2020-003427-42-FR",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo, Inc."
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan for injection 100 mg Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "Australia",
        "Japan",
        "Spain",
        "United States",
        "Netherlands",
        "France",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        "150"
      ],
      "conditions": [
        "HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2020-12-24"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2020-005182-14-FR",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Alligator Bioscience AB"
      ],
      "interventions": [
        "Product Name: mitazalimab Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: mitazalimab  Other descriptive name: ADC-1013, JNJ-64457107 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Oxaliplatin Product Code: Eloxatine  Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Leucovorin Product Code: Calcium Folinate Zentiva  Pharmaceutical Form: Solution for injection/infusion  Product Name: Irinotecan Product Code: Campto  Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Flurouracil Product Code: Flurouracil Teva Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Gemcitabine Product Code: Gemcitabine Accord Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Abraxane Product Code: Abraxane Pharmaceutical Form: Powder for solution for injection/infusion"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        "80"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma  MedDRA version: 20.0 Level: PT Classification code 10073364 Term: Ductal adenocarcinoma of pancreas System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2020-12-23"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-004531-22-FR",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: paclitaxel CAS Number: 33069-62-4  Product Name: Pertuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: pertuzumab CAS Number: 380610-27-5"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Turkey",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "United Kingdom",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        "350"
      ],
      "conditions": [
        "HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2020-12-22"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04656652",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Drug: DS-1062a",
        "Drug: Docetaxel"
      ],
      "locations": [
        "Puerto Rico",
        "Czechia",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Belgium",
        "China",
        "Hong Kong",
        "United States",
        "Brazil",
        "Canada",
        "Singapore",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Mexico",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Romania",
        "Japan",
        "Germany",
        "Spain",
        "Argentina"
      ],
      "enrollment": [
        "590"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2020-11-19"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2020-001574-29-PL",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Russian Federation",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Czechia",
        "Spain",
        "United States",
        "Netherlands",
        "Thailand",
        "Brazil",
        "United Kingdom",
        "Poland",
        "Taiwan",
        "India"
      ],
      "enrollment": [
        "280"
      ],
      "conditions": [
        "Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2020-11-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04506333",
      "phases": [],
      "sponsor": [
        "University of Louisiana Monroe"
      ],
      "interventions": [
        "Device: ADC 740-N Manual Sphygmomanometer",
        "Device: A&D UA-651 Blood Pressure Monitor"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        "50"
      ],
      "conditions": [
        "Blood Pressure"
      ],
      "Start Date": [
        "2020-06-08"
      ],
      "Max Phase": null
    },
    {
      "id": "ACTRN12620000773932",
      "phases": [],
      "sponsor": [
        "Arterica, Inc."
      ],
      "interventions": [
        "The device used is the Arterica Closure Device (ACD). The ACD is a medical device used to close large-bore vascular access sites following endovascular or interventional procedures. It is a handheld device operated by a trained clinician or doctor. The device has a handle and a nose with an extended tip. The tip of the device is inserted into the access site where it brings together the surrounding tissue and closes the wound.   The investigational procedure will be performed in an operation room or catherization lab, by an experienced and trained device operator.    The ADC procedure will take approximately 30 minutes.   The device must be used per the Instructions for Use. The sponsor will ensure all device operators are trained."
      ],
      "locations": [
        "New Zealand"
      ],
      "enrollment": [
        "21"
      ],
      "conditions": [
        "large-bore common femoral access site",
        "Surgery - Other surgery",
        "  large-bore common femoral access site"
      ],
      "Start Date": [
        "2020-07-28"
      ],
      "Max Phase": null
    },
    {
      "id": "ACTRN12620000757910",
      "phases": [],
      "sponsor": [
        "Dr Myo Min"
      ],
      "interventions": [
        "This study will evaluate the feasibility of a diffusion-weighted magnetic resonance imaging (DW-MRI) guided radiotherapy boost for locally advanced rectal cancer.   Patients will undergo pre-treatment MRI in the fortnight prior to commencing radiotherapy (+/- chemotherapy). Boost volume will be defined quantitatively according to intratumoural apparent diffusion coefficient (ADC) value. This volume will be targeted for a single-fraction 5-10Gy boost 3-5 days prior to commencing standard radiotherapy (50Gy delivered in 25 fractions).   Treatment will be administered by the Radiation Oncology department at Sunshine Coast University Hospital (SCUH), Birtinya. Each treatment takes approximately 15 minutes per day. Patients will be reviewed once per week by radiation oncology medical staff as per normal practice. Patients will also be asked to complete a quality of life questionnaire at several timepoints prior to, during and following completion of the treatment course, which will take an additional 5-10 minutes on each occasion."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "Cancer - Bowel - Back passage (rectum) or large bowel (colon)",
        "Rectal cancer",
        "  Rectal cancer"
      ],
      "Start Date": [
        "2020-07-23"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT04484142",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Drug: DS-1062a"
      ],
      "locations": [
        "Korea, Republic of",
        "Hungary",
        "Japan",
        "Germany",
        "Spain",
        "United States",
        "France",
        "Netherlands",
        "Italy",
        "Taiwan"
      ],
      "enrollment": [
        "137"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2020-07-20"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT04431739",
      "phases": [],
      "sponsor": [
        "Mohamed Ibrahim Abbas"
      ],
      "interventions": [
        "Device: MRI including conventional MRI, DWI with multiple ADC values"
      ],
      "locations": [
        ""
      ],
      "enrollment": [
        "50"
      ],
      "conditions": [
        "Vertebral Lesion"
      ],
      "Start Date": [
        "2020-11-06"
      ],
      "Max Phase": null
    },
    {
      "id": "ACTRN12620000592943",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Conjugate Light (Australia) Pty Ltd"
      ],
      "interventions": [
        "The name of the drug being administered is GQ1001. GQ1001 is an Antibody-Drug Conjugate used to treat patients with HER2-positive advanced solid tumors. GQ1001 will be administered by the licensed medical staff at the clinical site as a single intravenous dose on Day 1 of a 21-day treatment cycle. Patient medical records, routine safety lab tests and other necessary medical monitoring will be conducted by the investigators and site medical staff during the study.  Eligible patients will be enrolled into one specific dose cohort following the study progress. Intra-patient dose escalation will not be allowed. Dose cohorts planned for the dose escalation are 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg, and 6.0 mg/kg. Eight cycles treatment was planned for each enrolled patient. The safety review by the Safety Review Committee (SRC) will occur on a continual basis through the duration of the study. The SCR will monitor the safety and provide decisions as to dose escalations and exploring intermediate or higher doses. Patients may stay on the study treatment longer, until disease progression occurs, unacceptable toxicity occurs, or voluntarily withdraw the consent."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        "13"
      ],
      "conditions": [
        "  HER2-Positive Advanced Solid Tumors",
        "HER2-Positive Advanced Solid Tumors",
        "Cancer - Any cancer"
      ],
      "Start Date": [
        "2020-05-21"
      ],
      "Max Phase": "1"
    },
    {
      "id": "ACTRN12620000534987",
      "phases": [],
      "sponsor": [
        "Dr Myo Min"
      ],
      "interventions": [
        "This study aims to assess the feasibility of diffusion weighted magnetic resonance imaging (DW-MRI) guided radiation therapy dose escalation in head and neck cancer (HNC). Participants will need to attend an MRI scan at the Sunshine Coast University Hospital within one week prior to their standard radiotherapy planning CT. This scan will be performed with the participant lying in the radiation therapy treatment position with a custom fit immobilisation mask in place and may take up to an hour to perform.   Based on the quantitative information from this scan, a high-risk volume within the tumour will be identified. A boost dose of 5-7Gy in one fraction will be delivered to this tumour subvolume defined by an area of low apparent diffusion coefficient (ADC) value, representative of increased cellular density. This is followed by a 3-5 day break then the standard fractionated radiation therapy schedule of 66-70Gy over 6-7 weeks is delivered. Each individual treatment takes approximately 15 minutes.  The study will be conducted by the Radiation Oncology department at the Sunshine Coast University Hospital in Birtinya, Queensland. The participant will be asked to complete quality of life questionnaires at 5 different timepoints before, during and after the treatment period. These questionnaires may take up to 5mins to complete each time. Patients will be monitored closely by the treating team for any acute or late treatment side effects."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "Cancer - Head and neck",
        "  Head and Neck Cancer",
        "Head and Neck Cancer"
      ],
      "Start Date": [
        "2020-04-30"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT04264936",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Beijing Cancer Hospital"
      ],
      "interventions": [
        "Drug: RC48-ADC and JS001"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "36"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": [
        "2020-01-15"
      ],
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2019-001655-39-ES",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab Vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Tisotumab Vedotin CAS Number: 1418731-10-8 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Gemcitabine 1000 mg, powder for solution for infusion Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: GEMCITABINE CAS Number: 95058-81-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-  Trade Name: Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: IRINOTECAN CAS Number: 97682-44-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Trade Name: Potactasol (Topotecan Actavis)4 mg Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TOPOTECAN CAS Number: 123948-87-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4-  Trade Name: Vinorelbin Aurobindo 10 mg/ml Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: VINORELBINE CAS Number: 71486-22-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Ukraine",
        "Czech Republic",
        "Sweden",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "Norway",
        "United States",
        "Estonia",
        "Brazil",
        "Denmark",
        "Canada",
        "Singapore",
        "France",
        "Lithuania",
        "Italy",
        "Taiwan",
        "Korea, Republic of",
        "Ireland",
        "Austria",
        "Hungary",
        "Japan",
        "Spain",
        "Croatia",
        "Germany",
        "Argentina",
        "Israel",
        "Finland"
      ],
      "enrollment": [
        "482"
      ],
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Second- or Third-Line Recurrent or Metastatic Cervical Cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": [
        "2019-12-20"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT04146610",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
      ],
      "interventions": [
        "Drug: an antibody drug conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": [
        "2019-10-28"
      ],
      "Max Phase": "1"
    },
    {
      "id": "EUCTR2019-001219-22-IE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Seagen, Inc."
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Tistotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-"
      ],
      "locations": [
        "Belgium",
        "Ireland",
        "Spain",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        "222"
      ],
      "conditions": [
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)  MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10080244 Term: Peritoneal cancer index System Organ Class: 10022891 - Investigations ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2019-10-22"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-002991-15-ES",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "SOLTI"
      ],
      "interventions": [
        "Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201A Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": [
        "180"
      ],
      "conditions": [
        "Her2-positive, unresectable and/or metastatic breast cancer.",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2019-04-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-001219-22-ES",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Seattle Genetics, Inc."
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin                 Product Code: HuMax-TF-ADC                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: TISOTUMAB VEDOTIN                 CAS Number: 1418628-81-5                 Other descriptive name: HuMax-TF-ADC                 Concentration unit: mg/kg milligram(s)/kilogram                 Concentration type: equal                 Concentration number: 90-                  Product Name: Tisotumab vedotin                 Product Code: HuMax-TF-ADC                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: TISOTUMAB VEDOTIN                 CAS Number: 1418628-81-5                 Other descriptive name: HuMax-TF-ADC                 Concentration unit: mg/kg milligram(s)/kilogram                 Concentration type: equal                 Concentration number: 200-"
      ],
      "locations": [
        "Belgium",
        "Ireland",
        "Spain",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        "142"
      ],
      "conditions": [
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)                   MedDRA version: 20.0                 Level: PT                 Classification code 10033128                 Term: Ovarian cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10016180                 Term: Fallopian tube cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10080244                 Term: Peritoneal cancer index                 System Organ Class: 10022891 - Investigations             ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2019-04-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-001512-34-BE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Inc."
      ],
      "interventions": [
        "Product Name: DS-8201a Product Code: DS-8201a Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan  Current Sponsor code: DS-8201A Other descriptive name:  Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Belgium",
        "Italy",
        "Spain",
        "United States",
        "United Kingdom"
      ],
      "enrollment": [
        "72"
      ],
      "conditions": [
        "Unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumab-containing regimen     MedDRA version: 21.1 Level: LLT Classification code 10071114 Term: Metastatic gastric adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2019-08-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03859752",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Open Innovation Partners, Inc."
      ],
      "interventions": [
        "Biological: TR1801-ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        "15"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "Start Date": [
        "2019-02-26"
      ],
      "Max Phase": "1"
    },
    {
      "id": "EUCTR2018-002816-29-DE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline Research & Development Ltd"
      ],
      "interventions": [
        "Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: belantamab mafodotin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: Pembrolizumab Product Code: MK-3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: MK-3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-"
      ],
      "locations": [
        "Spain",
        "Canada",
        "United States",
        "Germany"
      ],
      "enrollment": [
        "40"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2019-02-25"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000764-29-PL",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: MEDI9447 CAS Number: NA Current Sponsor code: MEDI9447 Other descriptive name: MEDI9447 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 160-200  Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab Deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 Antibody-Drug Conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Datopotamab deruxtecan Product Code: Dato-DXd Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Korea, Republic of",
        "United States",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        "320"
      ],
      "conditions": [
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-12-19"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03763370",
      "phases": [],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Drug: Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate"
      ],
      "locations": [
        ""
      ],
      "enrollment": [
        ""
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": [
        "2018-11-30"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2017-004758-40-DK",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Keytruda Product Name: Pembrolizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: Keytruda Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-  Trade Name: Carboplatin Product Name: Carboplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Carboplatin Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Avastin Product Name: Avastin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BEVACIZUMAB CAS Number: 216974-75-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-"
      ],
      "locations": [
        "Belgium",
        "Italy",
        "Ireland",
        "Czech Republic",
        "Czechia",
        "Turkey",
        "Germany",
        "United States",
        "Netherlands",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        "140"
      ],
      "conditions": [
        "recurrent or stage IVB cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-11-16"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000764-29-GB",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: MEDI9447 CAS Number: NA Current Sponsor code: MEDI9447 Other descriptive name: MEDI9447 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 80-200  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 160-200  Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab Deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 Antibody-Drug Conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Korea, Republic of",
        "United States",
        "United Kingdom",
        "Poland",
        "Taiwan"
      ],
      "enrollment": [
        "191"
      ],
      "conditions": [
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-10-15"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-001772-38-IE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie Deutschland GmbH & Co. KG"
      ],
      "interventions": [
        "Product Name: Telisotuzumab Vedotin Product Code: ABBV-399 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Telisotuzumab Vedotin Current Sponsor code: ABBV-399 Other descriptive name: ABT-700-vcMMAE ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-"
      ],
      "locations": [
        "Czech Republic",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "China",
        "United States",
        "Canada",
        "Bulgaria",
        "France",
        "Poland",
        "Italy",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Romania",
        "Hungary",
        "Australia",
        "Japan",
        "Israel"
      ],
      "enrollment": [
        "270"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-11-10"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-001772-38-HU",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie Deutschland GmbH & Co. KG"
      ],
      "interventions": [
        "Product Name: Telisotuzumab Vedotin Product Code: ABBV-399 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Telisotuzumab Vedotin Current Sponsor code: ABBV-399 Other descriptive name: ABT-700-vcMMAE ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-"
      ],
      "locations": [
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "China",
        "United States",
        "Canada",
        "Bulgaria",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Ireland",
        "Hungary",
        "Australia",
        "New Zealand",
        "Japan",
        "Israel"
      ],
      "enrollment": [
        "310"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-09-10"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000221-31-CZ",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Inc."
      ],
      "interventions": [
        "Product Name: trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: Herceptin Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab CAS Number: 180288-69-1 Other descriptive name: trastuzumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Tyverb Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lapatinib CAS Number: 231277-92-2 Other descriptive name: lapatinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Capecitabine Accord Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-  Trade Name: Capecitabine Dr. Reddy's Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade"
      ],
      "locations": [
        "Greece",
        "Belgium",
        "Italy",
        "Korea, Republic of",
        "Czech Republic",
        "Israel",
        "Australia",
        "Japan",
        "Turkey",
        "Spain",
        "Germany",
        "United States",
        "France",
        "Brazil",
        "United Kingdom"
      ],
      "enrollment": [
        "600"
      ],
      "conditions": [
        "Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-09-13"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000221-31-BE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Inc."
      ],
      "interventions": [
        "Product Name: trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: Herceptin Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab CAS Number: 180288-69-1 Other descriptive name: trastuzumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Tyverb Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lapatinib CAS Number: 231277-92-2 Other descriptive name: lapatinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Capecitabine Accord Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-  Trade Name: Capecitabine Dr. Reddy's Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade"
      ],
      "locations": [
        "Greece",
        "United Kingdom",
        "Italy",
        "Belgium",
        "Korea, Republic of",
        "Czech Republic",
        "Australia",
        "Turkey",
        "Czechia",
        "Spain",
        "Germany",
        "Japan",
        "United States",
        "France",
        "Netherlands",
        "Brazil",
        "Israel"
      ],
      "enrollment": [
        "600"
      ],
      "conditions": [
        "Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-11-09"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03539536",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "interventions": [
        "Drug: Telisotuzumab vedotin"
      ],
      "locations": [
        "Puerto Rico",
        "Czechia",
        "Turkey",
        "Switzerland",
        "Netherlands",
        "United Kingdom",
        "Greece",
        "Belgium",
        "China",
        "United States",
        "Canada",
        "Bulgaria",
        "France",
        "Italy",
        "Poland",
        "Taiwan",
        "Russian Federation",
        "Korea, Republic of",
        "Australia",
        "Hungary",
        "Ireland",
        "Romania",
        "Japan",
        "Germany",
        "Spain",
        "Israel"
      ],
      "enrollment": [
        "270"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": [
        "2018-05-17"
      ],
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2017-004810-25-DE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline Research & Development Ltd"
      ],
      "interventions": [
        "Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate  CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 for Injection, 100mg Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Australia",
        "Spain",
        "Germany",
        "United States",
        "France",
        "United Kingdom"
      ],
      "enrollment": [
        "230"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-05-14"
      ],
      "Max Phase": "3"
    },
    {
      "id": "JPRN-jRCT2080223860",
      "phases": [],
      "sponsor": [
        "DAIICHI SANKYO Co.,Ltd."
      ],
      "interventions": [
        "investigational material(s) Generic name etc : DS-8201a INN of investigational material : trastuzumab deruxtecan Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Intravenous  control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code :  Dosage and Administration for Investigational material : -"
      ],
      "locations": [
        "Europe",
        "North America",
        "Japan"
      ],
      "enrollment": [
        "170"
      ],
      "conditions": [
        "HER2-over-expressing or HER2-mutated unresectable and/or metastatic non-squamous NSCLC"
      ],
      "Start Date": [
        "2018-09-04"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2017-003413-25-IT",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Czech Republic",
        "Sweden",
        "Spain",
        "Germany",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        "100"
      ],
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-03-13"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT03485209",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "interventions": [
        "Drug: pembrolizumab",
        "Drug: carboplatin",
        "Drug: cisplatin",
        "Drug: tisotumab vedotin"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Puerto Rico",
        "Germany",
        "Spain",
        "United States",
        "France",
        "Italy"
      ],
      "enrollment": [
        "692"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Colorectal Neoplasms",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Exocrine Pancreatic Cancer"
      ],
      "Start Date": [
        "2018-08-03"
      ],
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2017-003413-25-DE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Czech Republic",
        "Sweden",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        "100"
      ],
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-01-03"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2017-003413-25-DK",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Czech Republic",
        "Sweden",
        "Czechia",
        "Spain",
        "Germany",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        "100"
      ],
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-02-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2017-003413-25-CZ",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Czech Republic",
        "Sweden",
        "Spain",
        "Germany",
        "United States",
        "Italy",
        "Denmark"
      ],
      "enrollment": [
        "100"
      ],
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2018-02-27"
      ],
      "Max Phase": "3"
    },
    {
      "id": "ChiCTR-DND-17012404",
      "phases": [],
      "sponsor": [
        "Central Hospital of Minhang District,Shanghai"
      ],
      "interventions": [
        "TERT&#32",
        "gene,&#32",
        "",
        "K-trans,&#32",
        "DCE,&#32",
        "ADC,&#32",
        "BRAF&#32",
        "Index test:T1WI,&#32",
        "T2WI,&#32",
        "DWI,&#32",
        "mapping,&#32",
        "gene",
        "Gold Standard:Pathological diagnosis",
        "T2&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "Target condition:0;Difficult condition:0"
      ],
      "conditions": [
        "Papillary thyroid carcinoma"
      ],
      "Start Date": [
        "2017-08-18"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT03243331",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Kathy Miller"
      ],
      "interventions": [
        "Drug: PTK7-ADC",
        "Drug: Gedatolisib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        "18"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": [
        "2017-03-08"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT03192501",
      "phases": [],
      "sponsor": [
        "Second Affiliated Hospital of Guangzhou Medical University"
      ],
      "interventions": [
        "Drug: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group."
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "250"
      ],
      "conditions": [
        "Lung Cancer",
        "Cancer",
        "Gene Abnormality",
        "Gene Product Sequence Variation"
      ],
      "Start Date": [
        "2017-06-15"
      ],
      "Max Phase": null
    },
    {
      "id": "ChiCTR-DDD-17010744",
      "phases": [],
      "sponsor": [
        "Jinling Hospital"
      ],
      "interventions": [
        "",
        "f,&#32",
        "Gold Standard:Use long-term clinical follow-up results or pathology as gold standard. Within 12 weeks after concurrent chemoradiotherapy was completed, the progress of disease can be diagnosed as following: A.There is new enhancement outside of the radiation field",
        "CBF",
        "Index test:Ktrans,&#32",
        "D,&#32",
        "ADC,&#32",
        " B. histologically proven disease.",
        "Vp,&#32",
        "Ve,&#32",
        "FA,&#32",
        "D*,&#32",
        "MK,&#32",
        "Kep,&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": [
        "Target condition:74;Difficult condition:222"
      ],
      "conditions": [
        "Glioma"
      ],
      "Start Date": [
        "2017-02-27"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2016-004743-37-BE",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin                 Product Code: IgG1-1015-011-1006                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: tisotumab vedotin                 CAS Number: 1418731-10-1                 Current Sponsor code: IgG1-1015-011-1006                 Other descriptive name: HUMAX-TF-ADC                 Concentration unit: mg/ml milligram(s)/millilitre                 Concentration type: equal                 Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Hungary",
        "Sweden",
        "United States",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        "25"
      ],
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castrationresistant prostate cancer [CRPC]), esophagus, lung (non-small cell lung cancer [NSCLC]), and Squamous cell carcinoma of the head and neck (SCCHN)                   MedDRA version: 20.0                 Level: PT                 Classification code 10060862                 Term: Prostate cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: HLT                 Classification code 10014742                 Term: Endometrial neoplasms malignant                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10008342                 Term: Cervix carcinoma                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10023774                 Term: Large cell lung cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10062878                 Term: Gastrooesophageal cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10005003                 Term: Bladder cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: SOC        "
      ],
      "Start Date": [
        "2017-01-30"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02738424",
      "phases": [],
      "sponsor": [
        "Centre Hospitalier Universitaire de Saint Etienne"
      ],
      "interventions": [
        "Other: Calculate the ADC scores"
      ],
      "locations": [
        "France"
      ],
      "enrollment": [
        "98"
      ],
      "conditions": [
        "Low Back Pain"
      ],
      "Start Date": [
        "2016-11-04"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2015-001120-29-DK",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: HuMax-TF-ADC Product Code: IgG1-1015-011-1006 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Hungary",
        "United States",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        "44"
      ],
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), esophagus or lung (non-small cell lung cancer [NSCLC])  MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": [
        "2015-07-15"
      ],
      "Max Phase": "3"
    },
    {
      "id": "NCT02379741",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alligator Bioscience AB"
      ],
      "interventions": [
        "Biological: ADC-1013"
      ],
      "locations": [
        "Sweden",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        "24"
      ],
      "conditions": [
        "Neoplasms",
        "Solid Tumors"
      ],
      "Start Date": [
        "2015-02-16"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT02341625",
      "phases": [
        "Phase 2",
        "Phase 1"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "Drug: BMS-986148",
        "Biological: Nivolumab"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "Korea, Republic of",
        "Australia",
        "Hong Kong",
        "United States",
        "Netherlands",
        "Italy"
      ],
      "enrollment": [
        "126"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "Start Date": [
        "2015-01-14"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT02312037",
      "phases": [],
      "sponsor": [
        "Pfizer"
      ],
      "interventions": [
        "Biological: Antibody Drug Conjugate Chemotherapeutic"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": [
        ""
      ],
      "conditions": [
        "CD33 Positive Acute Myelogenous Leukemia"
      ],
      "Start Date": [
        "2014-04-12"
      ],
      "Max Phase": null
    },
    {
      "id": "ISRCTN68413407",
      "phases": [],
      "sponsor": [
        "Wellcome Trust/DBT India Alliance (India)"
      ],
      "interventions": [
        " total 48 tablets).                 2. Distribution of therapeutic IFA (20 mg/day) 20 tablets/month to the mother/care giver of all anemic children for a total duration of 5 months meant for consumption by the anemic child (total 100 tablets).                 3. Monthly education and counselling of mothers of anemic children by the LHW trained for delivery of this intervention covering the following topics regarding:                 3.1. Symptoms and signs of anemia                 3.2. Treatment with IFA and its side effects                 3.3. Education regarding IFA compliance and its monitoring                 3.4. Information about local iron rich foods and dietary diversification                 3.5. Information about personal hygiene and deworming                 The education and counselling with occur either at the ADC or at the mother?s home at the discretion of the LHW.                 4. Ensuring that all children attend the village ADC for retesting at the end of 6 months.                  Control arm (treatment as usual or CA):                 T",
        "Current interventions as of 31/10/2014:                 Cluster definition:                 A cluster in this study is defined as a village in the geographic area of this trial that is randomly allocated to one of the study arms, its ADC or one of its ADCs, the LHW in charge of the selected ADC, all children aged 12 ? 59 months registered in the ADC and the mothers/care givers of these children.                  In particular, the following activities will take place in the intervention group:                 1. Distribution of supplementary IFA (20 mg, 1 tablet taken biweekly) to the mother/care giver of all non anemic children (supplied at 8 tablets/month, for a duration of 6 months of the trial"
      ],
      "locations": [
        "India"
      ],
      "enrollment": [
        "2520"
      ],
      "conditions": [
        "Anemia  Haematological Disorders  Anaemia, unspecified"
      ],
      "Start Date": [
        "2013-12-17"
      ],
      "Max Phase": null
    },
    {
      "id": "ISRCTN77650947",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Birmingham (UK)"
      ],
      "interventions": [
        "Brentuximab vedotin: Antibody-drug conjugate                 30 patients will be recruited from hospitals across the UK and will receive a maximum of 16 doses over 48 weeks."
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": [
        "30"
      ],
      "conditions": [
        "Topic: National Cancer Research Network",
        " Disease: Lymphoma (Hodgkin's)  Cancer  Hodgkin lymphoma",
        " Subtopic: Lymphoma"
      ],
      "Start Date": [
        "2013-10-16"
      ],
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2013-001074-15-GB",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: HuMax-TF-ADC Product Code: IgG1-1015-011-1006 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: HuMax-TF-ADC CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Sweden",
        "United States",
        "United Kingdom",
        "Denmark"
      ],
      "enrollment": [
        "217"
      ],
      "conditions": [
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (non-small cell lung cancer [NSCLC]  MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2013-07-24"
      ],
      "Max Phase": "3"
    },
    {
      "id": "RBR-3vwfjs",
      "phases": [],
      "sponsor": [
        "Universidade Federal do Tocantins"
      ],
      "interventions": [
        "HP3.073.433.101",
        "Drug",
        "This is a double blind study. Subjects: We wil select individuals with crack cocaine addiction diagnosis, males, and with minimum age of 18 years, and maximum age 50 years old, and capable of consenting. The intervention will be held for 12 weeks. Study groups: 20 individuals who make use of topiramate and 20 individuals who make use of placebo. Randomization: The sample will be randomized by permuted block technique. The total sample will have 40 participants. Patients will be randomly selected from the Psychosocial Care Center of Palmas, Brazil. Randomization will be performed according to a computer generated random list by the method exchanged in blocks. The first five participants will be allocated in the group who use the medication topiramate. The next five in grup that use placebo. Following five in the second group topiramate and so on until the total number of 40 individuals. Medications that will be used: 25 to 200 mg of topiramate (increased at doses every 7 days 25mg) for 12 weeks. Placebo for 12 weeks single capsule. Urine test to confirm the negative use of the drug: Be quantified for each group (arm) the number of individuals testing negative urine after 12 weeks of intervention. The urine test for cocaine is an immunoassay based on the competitive binding between the antibody drug conjugate immobilized on the membrane and the drug or its metabolites which may be present in the urine sample. The test strip has immobilized drug conjugate in the area of test and antibodies conjugated to gold colloidal conjugate to the membrane. During the examination, a urine sample migrates by capillary action. The benzoylecgonine, if the sample Urine below 300 ng / ml did not saturate the binding sites of antibodies conjugated to gold in the test strip. Antibodies conjug",
        "D27.505.954.427.080"
      ],
      "locations": [
        "Brazil"
      ],
      "enrollment": [
        ""
      ],
      "conditions": [
        "D02.145.074.722.388.250",
        "F01.145.527.100.120",
        "Cocaine crack addiction."
      ],
      "Start Date": [
        "2013-06-13"
      ],
      "Max Phase": null
    },
    {
      "id": "DRKS00002954",
      "phases": [],
      "sponsor": [
        "Universitatsklinikum Freiburg"
      ],
      "interventions": [
        "Group 1: Study protocol MRI (3.0 Tesla): 1. Localizer sequence to plan scan orientations 2. high-resolution T2-weighted images in sagittal, coronal and axial orientation 3. diffusion-weighted (DWI) images with different diffusion weighting, to determine apparent diffusion coefficient (ADC) 4. T2-weighted images with different echo times in the axial orientation in order to determine the relaxation time T2. 5. T2 *-weighted images with different echo times in the axial orientation in order to determine the relaxation time T2 *. 6. T1-weighted MR images with different T1-weighted image in order to determine the relaxation time T1 7. Time series (dynamic) T1-weighted MR images before, during and after contrast agent administration in order to evaluate the tissue-perfusion (dynamic contrast-enhancement, DCE)"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": [
        "20"
      ],
      "conditions": [
        "C61",
        "Malignant neoplasm of prostate"
      ],
      "Start Date": [
        "2012-09-05"
      ],
      "Max Phase": null
    },
    {
      "id": "EUCTR2010-020729-42-PL",
      "phases": [
        "Phase 2",
        "Phase 3",
        "Phase 1"
      ],
      "sponsor": [
        "Helix BioPharma Corp"
      ],
      "interventions": [
        "Product Name: Lyophilised L-DOS47 Product Code:  L-DOS47 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Lyophilised L-DOS47 Current Sponsor code: L-DOS47 Other descriptive name: AFAIKL2-urease immunoconjugate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1.7-"
      ],
      "locations": [
        "Poland"
      ],
      "enrollment": [
        "74"
      ],
      "conditions": [
        "Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer  MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": [
        "2011-07-19"
      ],
      "Max Phase": "3"
    },
    {
      "id": "ACTRN12608000462381",
      "phases": [],
      "sponsor": [
        "The Royal Childrens' Hospital Mebourne"
      ],
      "interventions": [
        "The randomised cross over trial will aim to determine if additional priming of a haemofilter circuit with 5 u/ml heparinised 4% albumin increases circuit life (compared to only 5 u/ml heparinised saline).  This additional priming will be performed before the circuit is connected to the patient. The study will also determine if there is a difference between regional citrate and global heparinised anticoagulation on circuit life.  The dose of citrate (in the form of ADC-A) will be titrated with a calcium chloride infusion to maintain circuit calciums of less than 0.3 mmol/L and a patient calcium of 1.0-1.3 mmol/L. Upon recruitment all participants will be randomly assigned to one of 8 sequences of varying anticoagulation and priming methods as recommended for a four period crossover design with 2 factorial treatments.  Their first 4 circuits will consist of two heparin and two citrate circuits, one of each will be primed with heparinised saline and the other with an additional heparinised albumin prime, with the order of the treatments determined by their pre-assigned randomised sequence. As hemofiltration is necessary to maintain these patients there will be no intentional \"wash out\" period as with holding treatment may be detrimental to the patient. Each circuit will run until TMP (Transmembrane Pressure) reaches 280mmHg, treatment needs to be interrupted for longer than two hours or a significant adverse event occured.  The participant will be in the trial for a maximum of eight circuits."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": [
        "100"
      ],
      "conditions": [
        "Acute renal failure",
        "Renal and Urogenital - Kidney disease",
        "  Acute renal failure"
      ],
      "Start Date": [
        "2008-09-16"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT00077493",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "interventions": [
        "Procedure: antibody-drug conjugate therapy",
        "Procedure: immunotoxin therapy",
        "Drug: BL22 immunotoxin",
        "Procedure: monoclonal antibody therapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        "95"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "Start Date": [
        "2004-10-02"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00051584",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seattle Genetics, Inc."
      ],
      "interventions": [
        "Drug: SGN-15 (cBR96-Doxorubicin Immunoconjugate)",
        "Drug: Gemzar (Gemcitabine)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        "60"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "Start Date": [
        "2003-01-13"
      ],
      "Max Phase": "2"
    },
    {
      "id": "NCT00028483",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seattle Genetics, Inc."
      ],
      "interventions": [
        "Drug: docetaxel",
        "Drug: cBR96-doxorubicin immunoconjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        ""
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": [
        "2002-04-01"
      ],
      "Max Phase": "2"
    },
    {
      "id": "ISRCTN17161961",
      "phases": [],
      "sponsor": [
        "Cardiff University (UK)"
      ],
      "interventions": [
        "1. (R1) Patients with acute promyelocytic leukemia (APL) will be randomised to receive oral retinoic acid together with either MRC H-DAT chemotherapy or the Spanish Intermittent Idarubicin. Following confirmation of remission, patients will continue with the MRC (DAT:MACE:MIDAC) or Spanish chemotherapy but will be randomised to receive CMA-676/Myelotarg (Immunoconjugate) on day 1 of course 3 or not. (Patients will be monitered molecularly by Reverse Transcription (RT) and real time Polymerase Chain Reaction (PCR) to predict relapse. Three quality of life assessments will be made at 3, 6 and 9 months and resource use information will be collected for cost benefit analysis.)                 2. (R2) Non-APL patients will be randomised to receive induction cources 1 and 2 with H-Dat (Daunorbicin:Ara-C, Thioguanine) or FLA_G IDA (Fludarabine, Ara C, G-CSF, Idarubicin) and to receive CMA-676 (Myelotarg) on day 1 of course 1 or not.                 3. Following the first course of chemotherapy the risk profile of each patient will be determined (based on cytogenetics, blast clearance after course 1). Good risk patients (15%) will leave AML15 and will enter the MRC AML High Risk Trial.                 4. (R3)(R4) Patients who have completed course 2 and are allocated to the chemotherapy comparisons will be randomised to receive CMA-676 (Myelotarg) on day 1 of course 3.                 5. (R5) All patients allocated to allogenic transplant up to 35 years will receive standard conditioning (Cyclophosphamide/TBI) with stem cells obtained from peripheral blood or bone marrow as course 3. For patients 36-50 investigators may choose a conventional transplant or a non-ablative transplant. Patients over 50 years will receive a non-ablative transplant. The non-ablative"
      ],
      "locations": [
        "United Kingdom",
        "Wales"
      ],
      "enrollment": [
        "3000"
      ],
      "conditions": [
        "Leukaemia  Cancer  Leukaemia"
      ],
      "Start Date": [
        "2001-02-05"
      ],
      "Max Phase": null
    },
    {
      "id": "NCT00004858",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Parker Hughes Cancer Center"
      ],
      "interventions": [
        "Biological: B43-genistein immunoconjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": [
        ""
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "Start Date": [
        "2000-07-03"
      ],
      "Max Phase": "1"
    },
    {
      "id": "NCT00002163",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Glaxo Wellcome"
      ],
      "interventions": [
        "Drug: Abacavir sulfate"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": [
        ""
      ],
      "conditions": [
        "AIDS Dementia Complex",
        "HIV Infections"
      ],
      "Start Date": [
        "1999-02-11"
      ],
      "Max Phase": "3"
    }
  ]
}